EAU19 | BARCELONA
15-19 March 2019
Cutting-edge Science at Europe’s largest Urology Congress

European Association of Urology
### Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

**Urology beyond Europe**

**Friday 15 March**
**08:45 - 12:15**

**Location:** Green Area, Room 11

**Chairs:**
- C.R. Chapple, Sheffield (GB)
- J. Gutierrez, Winston Salem (US)

**Aims and objectives of this session**
- Focus on hot topics in renal, prostate and bladder cancer
- Contemporary update on urethral surgery
- Practical tips on andrology, the management of the buried penis, female LUTS and the small renal stone

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 08:50</td>
<td>Welcome and introduction</td>
<td>C.R. Chapple, Sheffield (GB)</td>
<td>Green Area, Room 11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Gutierrez, Winston Salem (US)</td>
<td></td>
</tr>
<tr>
<td>08:50 - 09:10</td>
<td>Does MRI prevent the need of prostate biopsy?</td>
<td>J. Walz, Marseille (FR)</td>
<td></td>
</tr>
<tr>
<td>09:10 - 09:30</td>
<td>Lymphadenectomy for prostate cancer: When and for who?</td>
<td>R. Sanchez-Salas, Paris (FR)</td>
<td></td>
</tr>
<tr>
<td>09:30 - 09:50</td>
<td>Management of BCG refractory NIM bladder cancer</td>
<td>M. Babjuk, Prague (CZ)</td>
<td></td>
</tr>
<tr>
<td>09:50 - 10:10</td>
<td>Robotic renal transplant</td>
<td>A. Breda, Barcelona (ES)</td>
<td></td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td>Surgical treatment of buried penis: Practical hints</td>
<td>R. Virasoro, Virginia Beach (US)</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:50</td>
<td>Urethral trauma: An update</td>
<td>C.R. Chapple, Sheffield (GB)</td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td>Prostate enucleation; Holmium or green light laser?</td>
<td>F. Gomez Sanchez, Madrid (ES)</td>
<td></td>
</tr>
<tr>
<td>11:10 - 11:30</td>
<td>Andrology for urologists: Update 2019</td>
<td>N. Sofikitis, Ioannina (GR)</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:50</td>
<td>1 to 2 cm renal stones: What is the best treatment alternative?</td>
<td>M.D. Baptistussi, Ribeirao Preto (BR)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Presenters</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------</td>
<td>------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>12:10 - 12:15</td>
<td>Closing remarks</td>
<td>C.R. Chapple, Sheffield (GB)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Gutierrez, Winston Salem (US)</td>
<td></td>
</tr>
</tbody>
</table>
The future is bright: Basic research in spinal cord injury

Poster Session 01

**Location:** Red Area, eURO Auditorium 2

**Chairs:**
- L. Birder, Pittsburgh (US)
- B.F.M. Blok, Rotterdam (NL)
- M.P. Schneider, Steffisburg (CH)

**Friday 15 March**

**09:00 - 10:30**

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

1

**Effect of early sacral neuromodulation on bladder function in a rat model of incomplete spinal cord injury due to focal contusion**

By: Jeong S.J. 1, Yoon C.Y. 1, Lee Y.J. 1, Kim J.H. 2, Song S.H. 1, Ryu H.Y. 1

1Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, Korea, South

2Kangwon National University School of Medicine, Dept. of Urology, Chuncheon, Korea, South

---

*3

**Barrington’s nucleus CRH neurons conditionally drive bladder contraction: A multi-unit optogenetic recording study in mice**

By: Ito H., Sales A., Tench B., Drake M.J., Pickering A.E.

University of Bristol, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom

---

4

**Therapeutic effects of p38 MAP kinase inhibitor in storage and voiding dysfunction in mice with spinal cord injury (SCI)**


1Kindai University, Dept. of Urology, Faculty of Medicine, Osaka-Sayama, Japan

2Hamamatsu University school of Medicine, Dept. of Urology, Hamamatsu, Japan

3University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America

4Kindai University Nara Hospital, Dept. of Urology, ikoma, Japan

5University of Pittsburgh, Dept. of Medicine, Pittsburgh, United States of America

6University of Pittsburgh, Dept. of Pharmacology and Chemical Biology, Pittsburgh, United States of America

---

5

**Improvement of bladder and urethral dysfunction by the early intervention with anti-BDNF antibody after spinal cord injury in mice**

By: Wada N.W. 1, Suzuki T. 2, Tyagi P. 2, Tsuchida M. 1, Banjo H. 1, Yoshimura N. 2, Kakizaki H. 1
1Asahikawa Medical University, Dept. of Renal and Urologic Surgery, Asahikawa, Japan, 2University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America

* 6 High field single subject brain mapping of pelvic floor motor control. A 7-Tesla fMRI study
By: Groenendijk I.M.1, Luijten S.1, Van Der Zwaag W.2, Holstege J.C3, Scheepe J.1, De Zeeuw C.4, Blok B.1
1Erasmus Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, 2Spinoza Center for Neuroimaging, Dept. of Neuroimaging, Amsterdam, Netherlands, The, 3Erasmus Medical Center, Dept. of Neuroscience, Rotterdam, Netherlands, The, 4Netherlands Institute for Neuroscience, Dept. of Neuroscience, Amsterdam, Netherlands, The

7 Muscarinic receptor expression in spinal cord transected rats with early anticholinergic treatment
By: Loutochin G.1, Przydacz M.1, Cammisotto P.2, Biardeau X.1, Campeau L.2, Corcos J.1
1Jewish General Hospital, Dept. of Urology, Montreal, Canada, 2Lady Davis Institute, Dept. of Urology, Montreal, Canada

8 Urinary TIMP-2 is significantly associated with poor bladder compliance and upper urinary tract damage in adult patients with spina bifida
By: Peyronnet B.1, Richard C.1, Bendavid C.2, Naudet F.3, Hascoet J.1, Brochard C.4, Alimi Q.1, Khene Z.1, Siproudhis L.5, Bouguen G.6, Kerdraon J.7, Manunta A.1, Gamé X.8
1Rennes University Hospital, Dept. of Urology, Rennes, France, 2Rennes University Hospital, Dept. of Biochemistry, Rennes, France, 3University of Rennes, Inserm CIC, Rennes, France, 4Rennes University Hospital, Dept. of Gastroenterology, Rennes, France, 5Rennes University Hospital, Dept. of Gastroenterology, Rennes, France, 6Rennes university Hospital, Dept. of Gastroenterology, Rennes, France, 7Centre de Rééducation de Kerpape, Dept. of Rehabilitation, Ploemeur, France, 8Toulouse University Hospital, Dept. of Urology, Toulouse, France

9 Nerve growth factor-mediated Na+ channel plasticity of bladder afferent neurons in mice with spinal cord injury
By: Gu B.J.1, Ni J.S.1, Yoshimura N.2
1Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Dept. of Urology, Shanghai, China, 2University of Pittsburgh, School of Medicine, Dept. of Urology, Pittsburgh, United States of America

10 Physiopathology of neurogenic detrusor overactivity: Role of neurotrophins, inflammation and extracellular matrix according to the neurological disease
By: Richard C.1, Bendavid C.1, Hascoet J.1, Alimi Q.1, Khene Z-E.1, Kerdraon J.1, Manunta A.1, Gamé X.2, Peyronnet B.1
11

Bladder primary afferent pathways to the spinal cord in mice

By: Takezawa K., Ueda N., Sekii Y., Inagaki Y., Fukuhara S., Kiuchi H., Kondo M., Shimada S., Nonomura N.

1Osaka University Medical School, Dept. of Urology, Suita, Japan, 2Osaka University Medical School, Dept. of Neuroscience and Cell Biology, Suita, Japan

12

Injecting RNA interference lentiviruses targeting the muscarinic 3 receptor gene into the bladder wall inhibits neurogenic detrusor overactivity in rats with spinal cord injury

By: Shang Z., Ou T.
Xuanwu Hospital Capital Medical University, Dept. of Urology, Beijing, China

10:15 - 10:22

The bladder, the spinal cord and the brain

To be confirmed
Stones: It is all about endourology
Poster Session 02

Friday 15 March
09:00 - 10:30

Location: Green Area, Room 2
Chairs: G. Bozzini, Busto Arsizio (IT)
T.Y. Lee, Seoul (KR)
G.H Zeng, Guangzhou (CN)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

13
Safety and efficacy of different calyx accesses in percutaneous nephrolithotomy
By: Değer M., İzol V., Ok F., Sukur I.H., Bayazit Y., Aridogan I.A.
University of Çukurova, Dept. of Urology, Faculty of Medicine, Adana, Turkey

15
Safety and efficacy of superior calyceal access versus inferior calyceal access for pelvic and lower calyceal stones – prospective observational comparative study
By: Chawla A.K., Mohan A.
Kasturba Medical College, Manipal University. India, Urology and Renal Transplant, MANIPAL, India

16
First experience with vacuum-assisted mini percutaneous nephrolithotomy (vmPCNL): Preliminary results
Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico; Department of Clinical Sciences and Community Health, University of Milan, Dept. of Urology, Milan, Italy

20
Trends and predictors of 30 day readmissions following percutaneous nephrolithotomy in kidney stones formers and implications for readmissions-based quality metrics
By: Tully K.\(^1\), Harmouch S.S.\(^1\), Cole A.P.\(^1\), Nguyen D.\(^1\), Ramaswamy A.\(^1\), Lipsitz S.R.\(^2\), Trinh Q-D.\(^1\), Bhojani N.\(^3\)
\(^1\)Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, \(^2\)Brigham and Women's Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, United States of America, \(^3\)Centre Hospitalier de l'Université de Montréal, faculté de médecine de l'Université de Montréal, Division of Urologic Surgery, Montreal, Canada
Development of a simple and practical nomogram for predicting stone-free rate after flexible ureteroscopy or percutaneous nephrolithotomy for solitary medium sized renal stones in adults

By: Micali S.,1 Di Pietro C.,1 Elsherbiny A.,2 Bevilacqua L.,1 Eissa A.,2 Fidanza F.,1 Mofferdin A.,1 Zoeir A.,2 Kaleci S.,3 Puliatti S.,1 Sighinolfi M.C.,1 Bianchi G.,1 Rocco B.1
1University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, 2Faculty of Medicine, Tanta University, Dept. of Urology, Tanta, Egypt, 3University of Modena and Reggio Emilia, Dept. of Diagnostic Medicine, Modena, Italy

Impact of preoperative ureteral stenting on ureteroscopic findings: A propensity score matching analysis

By: Hamamoto S.,1 Sugino T.,1 Hasebe K.,1 Isogai M.,1 Taguchi K.,1 Ando R.,1 Inoue T.,2 Okada S.,3 Okada A.,1 Matsuda T.,2 Yasui T.1
1Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, 2Kansai Medical University Medical Center, Dept. of Urology, Osaka, Japan, 3Gyotoku general Hospital, Dept. of Urology, Chiba, Japan

Awareness reduces radiation exposure during flexible ureteroscopy – A prospective multicenter evaluation

By: Hein S.,1 Wilhelm K.,1 Miernik A.,1 Salem J.,2 Karapanos L.,2 Netsch C.,3 Becker B.,3 Secker A.,4 Veser J.,5 Neisius A.,6 Fritsche H-M.,7 Schnabel M.J.,8
1Medical Center, University of Freiburg, Dept. of Urology, Division of Urotechnology, Freiburg, Germany, 2University Hospital Cologne, Dept. of Urology, Cologne, Germany, 3Asklepios Hospital Barmbek, Dept. of Urology, Hamburg, Germany, 4Westfälische Wilhelms-Universität, Dept. of Urology, Münster, Germany, 5Medical University, General Hospital Vienna, Dept. of Urology, Vienna, Austria, 6Barmherzige Brüder Hospital Trier, Dept. of Urology, Trier, Germany, 7Surgical Clinic Munich-Bogenhausen, Dept. of Urology, Munich, Germany, 8University of Regensburg, Caritas St. Josef Medical Centre, Dept. of Urology, Regensburg, Germany

Practice-level variation in postoperative pain management after ureteroscopy (URS): Lessons from a statewide collaborative quality initiative

By: Dauw C., Swarna K., Qi J., Kim T., Telang J., Ambani S., Roberts W.R., Ghani K.R., Hollingsworth J.M.
University of Michigan, Dept. of Urology, Ann Arbor, United States of America
Infectious diseases: Lower urinary tract infections
Poster Session 03

Friday 15 March
09:00 - 10:30

Location: Green Area, Room 4
Chairs: To be confirmed
L.O. Pinto, Belém (BR)
N. Stepanova, Kyiv (UA)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

29
Evaluation of knowledge and perception of antibiotic use, resistance and strategies toward antimicrobial stewardships in urology
Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain

32
Comparative study of 1-day versus multiple-day administration of antimicrobial prophylaxis in radical cystectomy
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Dept. of Genitourinary Oncology, Tokyo, Japan

33
Impact of a long-term antibiotic prophylaxis on the bladder colonisation by E. coli in clean intermittent self-catheterisation patients
By: Vallée M., 1 Mowbray C., 2 Fisher H., 2 Ming Zhi Tan A., Harding C., 3 Hall J., 1 Aldridge P., 1
1Newcastle University, Institute for Cell & Molecular Bio Sciences, Newcastle upon Tyne, United Kingdom, 2Institute of Health and Society, Dept. of Microbiology Department, Newcastle upon Tyne, United Kingdom, 3Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom

35
Do not use antimicrobial prophylaxis (AMP) before routine Transurethral Resection of the Bladder tumor (TURB)!
By: Verzotti E., 1 Rizzo M., 1 Di Cosmo G., 1 Morreale C., 1 Marchesin A., 1 Pavan N., 1 Cai T., 2 Cocci A., 3 Umari P., 4 Usai S., 5 Liguori G., 1 Trombetta C., 1
1Università degli Studi di Trieste, Dept. of Urology, Trieste, Italy, 2Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, 3Università degli Studi di Firenze, Dept. of Urology, Firenze, Italy, 4Università degli Studi del Piemonte Orientale, Dept. of Urology,
36 Prospective randomized controlled trial comparing the effect of fulguration versus fulguration and hydrodistension in Interstitial Cystitis/Bladder Pain Syndrome

By: Son H.S.¹, Yoon H.², Kim J.H.¹
¹Yonsei University College of Medicine, Dept. of Urology, Seoul, Korea, South, ²Ewha Womans University, College of Medicine, Dept. of Urology, Seoul, Korea, South

37 Clinical pharmacokinetics of beta-lactam and quinolone antibiotics in prostate tissue, and dosing considerations for prostatitis based on site-specific pharmacodynamics

By: Nakamura K.¹, Ikawa K.², Nishikawa G.¹, Kobayashi I.¹, Sugie M.¹, Muramatsu H.¹, Morinaga S.¹, Kajikawa K.¹, Watanabe M.¹, Kanao K.¹, Morikawa N.²
¹Aichi Medical University, School of Medicine, Dept. of Urology, Nagakute, Japan, ²Hiroshima University, Dept. of Clinical Pharmacotherapy, Hiroshima, Japan

38 Individual, DNA-guided, antibacterial prophylaxis prior to transrectal prostate biopsy based on results of next generation sequencing (NGS) of rectal swabs can be considered as a promising targeted approach to prevent severe urinary tract infection

By: Mouraviev V.¹, Dixon M.², Stefi M.², Skinner C.³, Mcdonald M.⁴, Vourganti S.⁵, Albala D.⁶, Wagenlehner F.⁷, Naber K.⁸, Bjerklund Johansen T.⁹, Crawford E.¹⁰
¹Central Florida Cancer Institute, Dept. of Urology, Davenport, United States of America, ²University of East Anglia, Norwich Medical School, Norwich, United Kingdom, ³University of Central Florida, College of Medicine, Orlando, United States of America, ⁴Florida Hospital Celebration Health, Urology Centre of Central Florida, Celebration, United States of America, ⁵Rush University Medical Center, Division of Urology, Chicago, United States of America, ⁶Associated Medical Professionals of New York, Dept. of Urology, New York City, United States of America, ⁷Justus-Liebig University Giessen, Dept. of Urology, Pediatric Urology, and Andrology, Giessen, Germany, ⁸Technical University of Munich, Medical Faculty, Munich, Germany, ⁹Oslo University Hospital, Dept. of Urology, Oslo, Norway, ¹⁰University of Colorado Anschutz Medical Center, Dept. of Urologic Oncology and Radiation Oncology, Aurora, United States of America

39 Rectal swab cultures prior to transrectal prostate biopsy: Among Gram-negative isolates, in 42% of samples non-E.coli species are present

By: Hajdinjak T.¹, Wergner A-N.², Prammer W.³, Rigler-Hohenwarter K.³, Pelzer A.E.¹
¹Klinikum Wels-Grieskirchen, Dept. of Urology, Wels, Austria, ²Medical University, Graz, Austria, ³Klinikum Wels-Grieskirchen, Dept. of Microbiology and Immunology, Wels, Austria

41 Is urine dipstick testing still useful in evaluating the presence of bacteriuria in a post antibiotic era?
Diversity of the microbial flora in healthy male genitourinary tract

By: Cao M., Xu H., Hui Z., Li Q.
the Second Chengdu Hospital Affiliated to Chongqing Medical University, Dept. of Urology, Chengdu, China
**Novel regulators of cellular events in prostate cancer tissue and stroma**

**Poster Session 04**

Location: Green Area, Room 5

Chairs: To be confirmed

M. Puhr, Innsbruck (AT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**43**

The bone microenvironment drives upregulation of the pentose phosphate pathway in prostate cancer, improving antioxidant properties

By: Whitburn J.¹, Rao S.R.¹, Tabata S², Hirayama A.², Soga T.², Hamdy F.C.¹, Edwards C.M.¹

¹University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, ²Keio University, Institute for Advanced Biosciences, Tsuruoka, Japan

---

**44**

Xenobiotic metabolism of abiraterone acetate and glucocorticoids by the gut microbiota

By: Abdur-Rashid K.¹, Nair S.², Chanyi R.¹, Chin J.², Burton J.¹

¹University of Western Ontario, Dept. of Microbiology and Immunology, London, Canada, ²London Health Sciences Centre, Division of Urology, London, Canada

---

**45**

A preclinical model to assess the interaction between patient-derived 3D microtumors and tumor infiltrating immune cells in prostate cancer

By: Erne E.¹, Stahl R.¹, Bodenhoefer M.², Anderle N.², Yuez S.², Stenzl A.¹, Schmees C.², Todenhoefer T.¹

¹University Hospital Tuebingen, Dept. of Urology, Tuebingen, Germany, ²Natural and Medical Science Institute, University of Tuebingen, Dept. of Tumorbiology, Reutlingen, Germany

---

**46**

Loss of miR-21 delays Myc-driven prostate cancer progression in the Hi-Myc transgenic mouse model

By: Zennami K.¹, Rafiqi F.², Liao R.², Sealover K.², Simons B.², Sumitomo M.¹, Shiroki R.¹, Lupold S.E.²

¹Fujita Medical University, Dept. of Urology, Toyoake, Japan, ²Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America

---

**47**

HSP70/STUB1 complex regulates androgen receptor variants through proteostasis and confers enzalutamide and abiraterone resistance in lethal prostate cancer
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>The role of SPOP &amp; BRCA-1 in the regulation of estrogenic activity in prostate stem cells</td>
<td>By: Xu C., Peng G., Ruihui X., Ming H., Qianghua Z., Jingtong Z., Jian H., Tianxin L. Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China</td>
</tr>
<tr>
<td>51</td>
<td>Tumor suppressor REIC/Dkk-3 and its co-chaperone SGTA: Their interaction and role to control castration-resistant prostate cancer by the release from androgen independence and malignancy</td>
<td>By: Greenwald D., Hu D-P., Hu W-Y., Prins G.S. University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America</td>
</tr>
<tr>
<td>54</td>
<td>Follicle-stimulating hormone is responsible for androgen deprivation therapy associated atherosclerosis by exaggerating endothelial inflammation</td>
<td>By: Wang Q.¹, Zhou J.², Yao W.², Xu T.¹ ¹Peking University People’s Hospital, Dept. of Urology, Beijing, China, ²Peking University, Dept. of Physiology and Pathophysiology, Beijing, China</td>
</tr>
<tr>
<td>55</td>
<td>GPRC5A facilitates cell proliferation and bone metastasis of prostate cancer</td>
<td>By: Sawada Y.¹, Kikugawa T.¹, Iio H.¹, Yanagihara Y.², Saeki N.³, Sakakibara I.⁴, Győrffy B.⁵, Kishida T.⁶, Miyagi Y.⁷, Saika T.¹, Imai Y.³ ¹Ehime University Graduate School of Medicine, Dept. of Urology, Toon, Japan, ²Ehime University, Division of Laboratory Animal Research, Advanced Research Support Center, Toon, Japan, ³Ehime University, Division of Integrative Pathophysiology, Proto-Science Center, Toon, Japan, ⁴The University of Tokyo, Research Center for Advanced Science and Technology, Tokyo, Japan, ⁵Hungarian Academy of Sciences, MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Budapest, Hungary, ⁶Kanagawa Cancer Center, Division of Urology, Kanagawa, Japan, ⁷Kanagawa Cancer Center Research Institute, Molecular Pathology and Genetics Division, Kanagawa, Japan</td>
</tr>
<tr>
<td>56</td>
<td>Generation of prostate basal stem cell lines from transgenic mice - proof of principle of inducible ex vivo gene deletion</td>
<td>By: Höfner T.¹, Klein C.², Medyouf H.³, Sprick M.², Haferkamp A.¹</td>
</tr>
<tr>
<td>57</td>
<td>Fibroblast-secreted exosomes in prostate cancer</td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>-----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>By: Kessler J., Theobald L., Baumgart S., Stöckle M., Junker K., Linxweiler J.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Saarland University, Dept. of Urology, Homburg, Germany</td>
<td></td>
</tr>
</tbody>
</table>
New techniques in functional and reconstructive urology

Video Session 01

Location: Green Area, Room 10
Chairs: C. Introini, Genova (IT)
       B. Peyronnet, Rennes (FR)
       F. Van Der Aa, Leuven (BE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V02
First robot-assisted laparoscopic pyeloplasty utilizing the da Vinci SP system
By: Agarwal D.K., Viers B.R., Chow G.K., Frank I., Tollefson M.K., Gettman M.
Mayo Clinic, Dept. of Urology, Rochester, United States of America

V03
Integral perineal sacrocolpopexy, a whole non invasive technique to restore perineal descent and concomitant pelvic prolapse
Hospital Universitario Ramon y Cajal, Dept. of Urology, Madrid, Spain

V04
Robot-assisted supratrigonal cystectomy and augmentation cystoplasty (RASCAC) with total intracorporeal reconstruction in neuro-urological patients: Technique description and preliminary results
By: Grilo N., Chartier-Kastler E., Grande P., Rouprêt M., Parra J., Phé V.
Médecine Sorbonne Université, Pitié-Salpêtrière, Academic Hospital, Dept. of Urology, Paris, France

V05
Robot-assisted implantation of artificial urinary sphincter in women: A standardized surgical technique
By: Peyronnet B.¹, Capon G.², Belas O.³, Manunta A.¹, Cardot V.⁴, Dubois F.⁵, Hascoet J.¹, Vidart A.⁶, Game X.⁷, Descazeaud A.⁸, Fournier G.⁹
¹Rennes University Hospital, Dept. of Urology, Rennes, France, ²Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ³Pole Santé Sud, Dept. of Urology, Le Mans, France, ⁴Pitié Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, ⁵Saint Grégoire Private Hospital, Dept. of Urology, Rennes, France, ⁶Foch Hospital, Dept. of Urology, Suresnes, France, ⁷Toulouse University Hospital, Dept. of Urology, Toulouse, France, ⁸Limoges University Hospital, Dept. of Urology, Limoges, France, ⁹Brest University Hospital, Dept. of Urology, Brest, France
Intraoperative adjustable non obstructive bulbourethral suspension

By: Wyss Y., Randazzo M., John H.
Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

Superficial transverse perineal muscle interposition for vesicorectal fistula after radical prostatectomy

By: Rioja Zuazu J.P. 1, Rioja C. 2, Baltanas P. 3, Solano J. 4, Oliva J. 5, Rodriguez-Vela L. 6, Mallen E. 6, Galve V. 7, Corbatón D. 6, Capapé V. 1, Valle J. 1, Blasco B. 1
1University Clinic Hospital, Dept. of Urology, Zaragoza, Spain, 2Montecanal Clinic, Dept. of Urology, Zaragoza, Spain, 3University Clinic Hospital, Dept. of Anesthesiology, Zaragoza, Spain, 4Quiron Clinic, Dept. of Surgery, Zaragoza, Spain, 5Royo Villanova Hospital, Dept. of Urology, Zaragoza, Spain, 6University Hospital, Dept. of Urology, Zaragoza, Spain, 7University Hospital, Dept. of Urology, Zaragoza, Spain
Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma


1University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, 2Cleveland Clinic, Dept. of Internal Medicine, Cleveland, United States of America, 3University of Texas Southwestern Medical Center, Dept. of Internal Medicine, Dallas, United States of America, 4University of Texas Southwestern Medical Center, Dept. of Bioinformatics, Dallas, United States of America, 5University of Texas Southwestern Medical Center, Dept. of Biostatistics, Dallas, United States of America, 6University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America

Comprehensive investigation of the molecular underpinnings of translocation renal cell carcinoma

By: Marcon J. 1, Sanchez A. 1, Gupta S. 2, Di Natale R.G. 1, Sandhu A. 3, Mano R. 1, Silagy A.W. 1, Blum K.A. 1, Nassau D.E. 1, Motzer R.J. 4, Coleman J.A. 1, Russo P. 1, Reuter V.E. 2, Hakimi A.A. 1, Reznik E. 3

1Memorial Sloan-Kettering Cancer Center, Dept. of Surgery, Urology Service, New York, United States of America, 2Memorial Sloan-Kettering Cancer Center, Dept. of Pathology, New York, United States of America, 3Memorial Sloan-Kettering Cancer Center, Computational Biology Center, Center for Molecular Oncology, New York, United States of America, 4Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, Dept. of Medicine, New York, United States of America

The concordant analysis of target gene sequencing data showing the tumor heterogeneity in triplet-paired metastatic tumor tissues in metastatic renal cell carcinoma

By: Kim S.H. 1, Park W.S. 2, Chung J. 3
Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients

By: Singla N. ¹, Woolford L. ², Stevens C. ², Tcheuyap V. ², Onabolu O. ², Xie Z. ³, Mckay R. ², Wang T. ³, Christie A. ⁴, Gahan J. ¹, Bagrodia A. ¹, Raj G. ¹, Sagalowsky A. ¹, Lotan Y. ¹, Cadeddu J. ¹, Margulis V. ¹, Kapur P. ⁵, Brugarolas J. ²

¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ²University of Texas Southwestern Medical Center, Dept. of Internal Medicine, Dallas, United States of America, ³University of Texas Southwestern Medical Center, Dept. of Bioinformatics, Dallas, United States of America, ⁴University of Texas Southwestern Medical Center, Dept. of Biostatistics, Dallas, United States of America, ⁵University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America

Feasibility of establishing renal cancer patient-specific ‘tumouroids’ as personalised treatment screening tools

By: Stamati K. ¹, Neves J.B. ¹, De Albuquerque Garcia Redondo P. ¹, Presneau N. ², Azimi T. ², Mohammad Hadi L. ¹, Brew-Graves C. ³, Williams N.R. ³, Grierson J. ³, Tran M.G.B. ¹, Cheema U. ⁴, Loizidou M. ¹, Emberton M. ⁵

¹UCL, Research Department of Surgical Biotechnology, Division of Surgery and Interventional Science, London, United Kingdom, ²University of Westminster, Cancer Research Group, London, United Kingdom, ³UCL, Surgical and Interventional Trials Unit, Division of Surgery and Interventional Science, London, United Kingdom, ⁴UCL, Research Department of Orthopaedics and Musculoskeletal Science, Division of Surgery and Interventional Science, London, United Kingdom, ⁵UCL, Faculty of Medical Science, London, United Kingdom

Improving the definition of high-risk patients for tumor recurrence from clear-cell renal cell carcinoma – The U-CISS classification

By: Lebacle C. ¹, Kroeger N. ², Pooli A. ³, Liu S.T. ⁴, Chami K. ³, Belldegrun A.S. ³, Shuch A.S. ³, Drakaki A. ⁵, Pantuck A.J. ³

¹Institute of Urologic Oncology (Iuo), David Geffen School of Medicine at UCLA, Los Angeles, CA - Department of Urology, University Hospital Bicetre, APHP, University Paris-Saclay, Dept. of Urology, Le Kremlin Bicetre, France, ²University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, ³Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Dept. of Urology, Los Angeles, United States of America, ⁴David Geffen School of Medicine at UCLA, Dept. of Hematology and Oncology, Los Angeles, United States of America, ⁵Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Dept. of Hematology and Oncology, Los Angeles, United States of America
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>64</td>
<td>Tumor-infiltrating regulatory T lymphocytes orchestrate oncogenic PAK1-conferred immune evasion in clear-cell renal cell carcinoma</td>
<td>Qu Y.1, Liu L.1, Bai Q.1, Xu J.2, Guo J.1</td>
<td>Zhongshan Hospital, Fudan University, Dept. of Urology, Shanghai, China, Fudan University, Dept. of Biochemistry and Molecular Biology, Shanghai, China</td>
</tr>
<tr>
<td>65</td>
<td>Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal cell carcinoma patients</td>
<td>Xiong Y., Liu L., Bai Q., Xia Y., Wang J., Guo J.</td>
<td>Zhongshan Hospital, Fudan University, Dept. of Urology, Shanghai, China</td>
</tr>
<tr>
<td>66</td>
<td>Identification of a microRNA profile in urine with diagnostic and prognostic value for clear cell renal cell carcinoma</td>
<td>Oto J.1, Solmoirago M.J.1, Pérez-Ardavin J.2, Sánchez-González J.V.2, Plana E.3, Hervás D.4, Fernández-Pardo A.1, Yelo M.1, Vera C.D.2, Martínez-Sarmiento M.2, España F.1, Navarro S.1, Medina P.1</td>
<td>Medical Research Institute Hospital La Fe, Dept. of Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Valencia, Spain, La Fe University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, La Fe University and Polytechnic Hospital, Dept. of Angiology and Vascular Surgery Service, Valencia, Spain, Medical Research Institute of Hospital La Fe, Biostatistics Unit, Valencia, Spain</td>
</tr>
<tr>
<td>67</td>
<td>Real world data of how next-generation sequencing changes treatment strategy and identify hereditary diseases in urology cancers</td>
<td>Wang H-K., Yao Z., Ye D.W.</td>
<td>Shanghai Cancer Center, Dept. of Urology, Shanghai, China</td>
</tr>
<tr>
<td>*69</td>
<td>The UCLA histo-genetic risk classification (U-HGRC) to stratify prognosis of localized clear-cell renal cell carcinoma</td>
<td>Lebacle C.1, Pooli A.2, Rao N.3, Wood E.L.4, Kroeger N.5, Kim G.6, Faiena I.2, Liu S.T.7, Chami K.2, Beldegrun A.S.2, Shuch B.2, Drakaki A.8, Pantuck A.J.2</td>
<td>Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, CA - Department of Urology, University Hospital Bicetre, APHP, University Paris-Saclay, Dept. of Urology, Le Kremlin Bicetre, France, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Dept. of Urology, Los Angeles, United States of America, David Geffen School of Medicine at UCLA, Dept. of Pathology and Cytogenetic lab, Los Angeles, United States of America, David Geffen School of Medicine at UCLA, Dept. of Urology, Los Angeles, United States of America, University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, Fielding School of Public Health at UCLA, Los Angeles, CA - Department of Radiological Science, David Geffen School of Medicine at University of California, Dept. of Biostatistics, Los Angeles, United States of America, David Geffen School of Medicine at UCLA, Dept. of Hematology and Oncology, Los Angeles, United States of America, Institute of Urologic Oncology (IUO),</td>
</tr>
</tbody>
</table>
Genomic categorization of high-grade unclassified renal cell carcinoma to refine prognostication and therapeutic approach


1Memorial Sloan-Kettering Cancer Center, Urology Service, Dept. of Surgery, New York, United States of America, 2Memorial Sloan-Kettering Cancer Center, Dept. of Pathology, New York, United States of America, 3Memorial Sloan-Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States of America, 4Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, Dept. of Medicine, New York, United States of America

Circulating tumor cells in renal cancer

By: Klézl P., Sonsky J., Grill R., Pospisilova E., Kolostova K., Bobek V.

1University Hospital Kralovske Vinohrady, Dept. of Urology, Prague, Czech Republic, 2University Hospital Kralovske Vinohrady, Dept. of Laboratory Diagnostics, Lab. Genetics, Prague, Czech Republic
## Joint Session of the European Association of Urology (EAU) and Russian Society of Urology (RSU)

**Urology beyond Europe**

**Friday 15 March**

**09:30 - 12:15**

**Location:** Green Area, Room 13

**Chairs:**
- W. Artibani, Verona (IT)
- I. Korneyev, St. Petersburg (RU)

### Aims and objectives of this session

This session aims to involve Russian urologists into active discussion of hot urological topics with EAU opinion leaders. Current opinion in BPH/LUTS treatment, reconstructive urology and urolithiasis will be presented by both sides followed by interactive discussion of clinical cases and approaches to solve the patients’ problems. The simultaneous translation of both languages will be provided.

### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 - 09:35</td>
<td>Welcome and introduction</td>
<td>W. Artibani, Verona (IT) I. Korneyev, St. Petersburg (RU)</td>
</tr>
<tr>
<td>09:35 - 10:25</td>
<td>Current trends in BPH/LUTS treatment</td>
<td>To be confirmed M.I. Kogan, Rostov On Don (RU) A.Z. Vinarov, Moscow (RU)</td>
</tr>
<tr>
<td>09:35 - 09:50</td>
<td>Is urodynamic evaluation needed to plan BPO surgery?</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>09:50 - 10:05</td>
<td>A single-centre comparative study on the efficacy of different endoscopic prostatic enucleation techniques</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>10:05 - 10:25</td>
<td>Case presentations</td>
<td>M.I. Kogan, Rostov On Don (RU) J.P.F.A. Heesakkers, Nijmegen (NL)</td>
</tr>
<tr>
<td>10:25 - 11:15</td>
<td>Reconstructive urology</td>
<td>To be confirmed D. Pushkar, Moscow (RU)</td>
</tr>
<tr>
<td>10:25 - 10:40</td>
<td>When and how to use meshes in Pelvic Organ Prolapse (POP) surgery</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>10:40 - 10:55</td>
<td>Detailed Pelvic Organ Prolapse (POP) evaluation: Would it improve further treatment results?</td>
<td>Y.A. Kupriyanov, Moscow (RU)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speakers</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>10:55 - 11:15</td>
<td>Case presentations</td>
<td>B. Komyakov, St. Petersburg (RU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V.A. Ochelenko, St. Petersburg (RU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E.C Costantini, Perugia (IT)</td>
</tr>
<tr>
<td>11:15 - 12:05</td>
<td>Urolithiasis</td>
<td>A.G. Martov, Moscow (RU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zyrianov, Tyumen (RU)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Technological advances in endourology</td>
<td>G. Giusti, Milan (IT)</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Urolithiasis: A look at aspects of metaphylaxis</td>
<td>V. Pavlov, Ufa (RU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Pushkarev, Ufa (RU)</td>
</tr>
<tr>
<td>11:45 - 12:05</td>
<td>Case presentations</td>
<td>A.G. Martov, Moscow (RU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G. Giusti, Milan (IT)</td>
</tr>
<tr>
<td>12:05 - 12:15</td>
<td>Closing remarks</td>
<td>W. Artibani, Verona (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I. Korneyev, St. Petersburg (RU)</td>
</tr>
</tbody>
</table>
### Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)

**Urology beyond Europe**

**Friday 15 March**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45 - 12:15</td>
<td><strong>Welcome and introduction</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> M. Eissa, Cairo (EG)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>09:50 - 10:25</td>
<td><strong>Uro-oncology</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> M. Colombel, Lyon (FR)</td>
</tr>
<tr>
<td></td>
<td>R. Azhar, Jeddah (SA)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>09:50 - 10:05</td>
<td><strong>Neoadjuvant chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Current status and outcome</strong></td>
</tr>
<tr>
<td></td>
<td>J.A. Witjes, Nijmegen (NL)</td>
</tr>
<tr>
<td>10:05 - 10:20</td>
<td><strong>Prostate Specific Antigen (PSA) relapse following radical prostatectomy: What and when to do?</strong></td>
</tr>
<tr>
<td></td>
<td>M. Bulbul, Riad El Solh - Beirut (LB)</td>
</tr>
<tr>
<td>10:25 - 11:00</td>
<td><strong>Stones and endourology</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> O. Angerri Feu, Barcelona (ES)</td>
</tr>
<tr>
<td></td>
<td>H. Kouicem, Sétif (DZ)</td>
</tr>
<tr>
<td></td>
<td>M. Mustafa, Nablus (PA)</td>
</tr>
<tr>
<td>10:25 - 10:40</td>
<td><strong>Residual stones after Percutaneous nephrolithotomy (PCNL): Significance and outcome</strong></td>
</tr>
<tr>
<td></td>
<td>E. Liatsikos, Patras (GR)</td>
</tr>
</tbody>
</table>

**Location:** Green Area, Room 3

**Chairs:**
- H. Abol-Enein, Mansoura (EG)
- J. Palou, Barcelona (ES)

**Aims and objectives of this session**

This session aims to open a channel between European urology and the urologists in the Arab world. The chosen topics include future developments of urinary stone treatment and reconstructive urology and different situations in Urology-oncology and European and Arab approaches to solve these problems. Thus all participants will be able to learn from alternatives from Europe and Arab countries. It is expected to have interaction and exchange of concepts in order to improve urology all over the world.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40 - 10:55</td>
<td>Complications of Ureteroscopy (URS): How to avoid and tricks of treatment</td>
<td>Y. Farahat</td>
<td>Dubai (AE)</td>
</tr>
<tr>
<td>10:55 - 11:00</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:35</td>
<td>Lower urinary tract disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderators: T.R.W. Herrmann, Frauenfeld (CH)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M.S.A. Al-Marhoon, Muscat (OM)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N. Alfgih, Tripoli (LY)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Failure of prostatectomy to cure in Lower Urinary Tract Symptoms (LUTS): Case selection and technique of choice</td>
<td>E. Chartier-Kastler</td>
<td>Paris (FR)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Overactive Bladder (OAB): What to do when medical therapy fails</td>
<td>Y. Nouira</td>
<td>Tunis (TN)</td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35 - 12:10</td>
<td>Reconstructive urology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderators: A.N. Al Shunaigat, Amman (JO)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Sarikaya, Ankara (TR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N. Ramadan, Khartoum (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35 - 11:50</td>
<td>Pyeloplasty: Open, laparoscopic or robotic tricks and outcome</td>
<td>A. Minervini</td>
<td>Florence (IT)</td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td>Stress urinary incontinence in female: The optimal procedure for the best outcome</td>
<td>F. Farag</td>
<td>Portstewart (GB)</td>
</tr>
<tr>
<td>12:05 - 12:10</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:10 - 12:15</td>
<td>Closing remarks</td>
<td>H. Abol-Enein</td>
<td>Mansoura (EG)</td>
</tr>
<tr>
<td></td>
<td>J. Palou, Barcelona</td>
<td></td>
<td>Barcelona (ES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Joint Session of the European Association of Urology (EAU) and the
Maghreb Union Countries
Urology beyond Europe

Friday 15 March
09:45 - 12:15

Location: Green Area, Room 20

Chairs: M. Harouni, Oran (DZ)
        To be confirmed

09:45 - 09:48 Welcome and introduction
        M. Harouni, Oran (DZ)
        To be confirmed

09:48 - 10:33 Bladder cancer
        Moderators: M. Harouni, Oran (DZ)
                    R. El Kamel, Kairouan (TN)
                    M.J. Ribal, Barcelona (ES)

09:48 - 10:03 En-bloc resection of bladder tumours: Indications, advantages, pitfalls
        To be confirmed

10:03 - 10:08 European perspective Management of pT1 high-grade bladder tumours
        S. Shariat, Vienna (AT)

10:08 - 10:28 Maghreb Union perspective Management of pT1 high-grade bladder tumours
        N. Bekki, Djasr Kassentina (DZ)
        A. Hidoussi, Sousse (TN)
        S.K Kerroumi, Sig (DZ)
        I. Sarf, Marrakech (MA)

10:28 - 10:33 Discussion

10:33 - 11:13 Stone management
        Moderators: To be confirmed
                    To be confirmed
                    E. Liatsikos, Patras (GR)

10:33 - 11:03 Maghreb - Complex stones: Which therapeutic approach?
        S. Bouras, (DZ)
        To be confirmed
        I. Ziouziou, Rabat (MA)

11:03 - 11:13 The management of large kidney stones: PCNL versus RIRS
        S. Choong, London (GB)

11:13 - 12:13 Prostate cancer
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:13 - 11:23</td>
<td>European perspective</td>
<td>The management of locally advanced prostate cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Stief, Munich (DE)</td>
</tr>
<tr>
<td>11:23 - 11:43</td>
<td>Maghreb Union perspective</td>
<td>The management of locally advanced prostate cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M.M. Atoui, Annaba (DZ)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Berhouma, Bab Saadoune (TN)</td>
</tr>
<tr>
<td>11:43 - 11:53</td>
<td>European perspective</td>
<td>Update on the management of Castration Resistant Prostate Cancer (CRPC)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Verze, Naples (IT)</td>
</tr>
<tr>
<td>11:53 - 12:13</td>
<td>Maghreb Union perspective</td>
<td>Update on the management of Castration Resistant Prostate Cancer (CRPC)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>K. Benakila, Alger (DZ)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Y. El Harrech, paris (FR)</td>
</tr>
<tr>
<td>12:13 - 12:15</td>
<td>Closing remarks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Moderators:**
- R. El Kamel, Kairouan (TN)
- To be confirmed
- To be confirmed
- To be confirmed
### Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

**Urology beyond Europe**

- **Location:** Green Area, Room 17
- **Chairs:** C.C.M. Lei, Kuching (MY)  
  J. Rassweiler, Heilbronn (DE)

#### Friday 15 March  09:45 - 12:15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45 - 09:50</td>
<td>Welcome and introduction</td>
<td>C.C.M. Lei</td>
<td>Kuching (MY)</td>
</tr>
<tr>
<td>09:50 - 10:30</td>
<td>Paediatric urology</td>
<td>I. Wahyudi</td>
<td>Jakarta (ID)</td>
</tr>
<tr>
<td>09:50 - 10:00</td>
<td>DSD, Development Sexual Dysfunction</td>
<td>I. Wahyudi</td>
<td>Jakarta (ID)</td>
</tr>
<tr>
<td>10:00 - 10:10</td>
<td>Hypospadias in Indonesia</td>
<td>G.W.K. Duarsa</td>
<td>Denpasar (ID)</td>
</tr>
<tr>
<td>10:10 - 10:20</td>
<td>Diagnosis and treatment of testicular torsion: A multicenter clinical study in Thailand</td>
<td>P. Mahawong</td>
<td>Chiang Mai (TH)</td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>How to avoid complications of circumcision</td>
<td>G. Bogaert</td>
<td>Leuven (BE)</td>
</tr>
<tr>
<td>10:30 - 11:10</td>
<td>Reconstructive urology</td>
<td>S. Sothilingam</td>
<td>Kuala Lumpur (MY)</td>
</tr>
<tr>
<td>10:30 - 10:40</td>
<td>Urethroplasty in Malaysia: Past, present and future</td>
<td>P. Myint</td>
<td>Yangon Myanmar (MM)</td>
</tr>
<tr>
<td>10:40 - 10:50</td>
<td>Challenges in management of penile paraffinoma</td>
<td>T. Lwin</td>
<td>Yangon (MM)</td>
</tr>
<tr>
<td>10:50 - 11:00</td>
<td>Management of uro-genital fistula: Asian perspective</td>
<td>M. Fisch</td>
<td>Hamburg (DE)</td>
</tr>
<tr>
<td>11:00 - 11:10</td>
<td>How to manage complicated cases of hypospadias</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:10 - 11:40</td>
<td>Kidney transplantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:10 - 11:20</td>
<td>Standardised surgical technique of laparoscopic donor nephrectomy: Experience from a single high-volume center in Asia</td>
<td>K Kijvikai</td>
<td>Bangkok (TH)</td>
</tr>
</tbody>
</table>

**Aims and objectives of this session**

This session continues the excellent collaboration between the major countries included in the FAUA and the EAU. Focusing on four important fields in urology, experts from Asia and Europe will present and discuss new developments.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:20 - 11:30| Laparoscopic right donor nephrectomy: Philippines’ experience and technique  
E. Gerial Jr, Quezon City (PH) |
| 11:30 - 11:40| Robot-assisted kidney transplantation – the new way to go?  
A. Breda, Barcelona (ES) |
| 11:40 - 12:10| Minimally invasive surgery in Asia                                      |
| 11:40 - 11:50| Evolution of Percutaneous nephrolithotomy (PCNL) in the Philippines  
S.V. Yrastorza, Quezon City (PH) |
| 11:50 - 12:00| Robot assisted laparoscopy radical cystectomy – the real world  
V.L. Chuyen, Ho Chi Minh City (VN) |
| 12:00 - 12:10| MRI targeted prostate biopsy  
To be confirmed |
| 12:10 - 12:15| Closing remarks  
J. Rassweiler, Heilbronn (DE) |
### Genital urinary reconstruction

**Expert-Guided Poster Tour 01**

**Location:** Green Area, Room A (Expert-Guided Poster Tours)

**Chairs:** J.P.F.A. Heesakkers, Nijmegen (NL)
F. Liedberg, Malmö (SE)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

---

**Introduction**  
F. Liedberg, Malmö (SE)

**PT001**  
**Excision and primary anastomosis for strictures at the anastomosis between the fixed and phallic part of the urethra in female-to-male transsexuals**

By: Verla W., Hoebeke P., Spinoit A-F., Waterloos M., Lumen N.
Ghent University Hospital, Dept. of Urology, Ghent, Belgium

**PT002**  
**Penile prosthesis insertion after female to male phalloplasty: Our experience**

By: Stojanovic B., Bizic M., Kojovic V., Pusica S., Bencic M., Djordjevic M.
School of Medicine, University of Belgrade, Dept. of Urology, Belgrade, Serbia

**PT004**  
**Correction of isolated congenital penile curvature in young adults**

By: Roizman S., Chertin B., Zisman A., Shenfeld O.Z.
1 Shaare Zedek Medical Center, Center for Reconstructive and Functional Urology, Jerusalem, Israel, 2 Shaare Zedek Medical Center, Dept. of Urology, Jerusalem, Israel, 3 Shamir (Asaf Harofeh) Medical Center, Dept. of Urology, Zerifin, Israel

**PT006**  
**Australian trends in urinary diversion over the past 20 years**

By: Best O., Patel M.I.
1 Westmead Hospital, Dept. of Surgery, Westmead, Australia, 2 Westmead Hospital, Dept. of Urology, Westmead, Australia

**PT009**  
**Surgical outcomes of transvaginal neobladder-vaginal fistula repair after radical cystectomy with ileal orthotopic neobladder in women**

By: Song W., Jeong J.Y., Kim T.H., Yoon H.S., Kim K.H., Yoon H., Chung W.S., Sim B.S., Lee D.H.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT011</td>
<td>Long term functional outcomes and complications of Studer orthotopic neobladder</td>
<td>By: Chan E.P., Hetou K., Nair S., Stephenson E., Izawa J., Chin J.L.</td>
<td>Ewha Womans University School of Medicine, Dept. of Urology, Seoul, Korea, South; Kangbuk Samsung Hospital, Dept. of Urology, Seoul, Korea, South; CHA Bundang Medical Center, Dept. of Urology, Seongnam, Korea, South</td>
</tr>
<tr>
<td>PT012</td>
<td>Subject specific bladder morphology and correspondent 3D mold lattice structure for organ reconstruction</td>
<td>By: Monteiro V., Gasser C.T., Moerman K.</td>
<td>MIT, Media Lab, Cambridge, United States of America; The Royal Institute of Technology, Dept. of Solid Mechanics, Stockholm, Sweden; NUI Galway, Galway, Ireland</td>
</tr>
<tr>
<td>PT014</td>
<td>Risk factors of recurrence and de novo incontinence following endoscopic treatment of vesico-urethral anastomotic stenosis</td>
<td>By: Rosenbaum C.M., Reiss P., Vetterlein M., Fisch M., Kranz J., Steffens J., Salomon G., Worst T., Pfalzgraf D.</td>
<td>University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany; St. Antonius Hospital, Dept. of Urology and Pediatric Urology, Eschweiler, Germany; University Medical Center Hamburg-Eppendorf, Martini Klinik Prostate Cancer Center, Hamburg, Germany; Medical Faculty Mannheim, University of Heidelberg, Dept. of Urology, Mannheim, Germany</td>
</tr>
<tr>
<td>PT015</td>
<td>Depression, anxiety and erectile function after successful urethroplasty: A short-term follow up study</td>
<td>By: Kogan M.I., Mitusov V.V., Amirbekov B.G.</td>
<td>Rostov State Medical University, Dept. of Urology and Human Reproductive Health, Rostov-on-Don, Russia</td>
</tr>
<tr>
<td>PT016</td>
<td>Augmentation urethral reconstruction using tissue-engineered oral mucosa graft MukoCell®</td>
<td>By: Karapanos L., Akbarov I., Zugor V., Eich C., Heidenreich A.</td>
<td>University Hospital of Cologne, Dept. of Urology, Uro-Oncology and robot-assisted Surgery, Cologne, Germany</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Authors</td>
<td>Institution</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>PT017</td>
<td>The application of 3D printed Poly-L-lactide nanofiber membrane in substitutional urethroplasty</td>
<td>Qiang F.</td>
<td>Shanghai 6th Hospital, Dept. of Urology, Shanghai, China</td>
</tr>
<tr>
<td>PT022</td>
<td>Retrospective comparison between thermo-expandable urethral stent and self-expandable polymer coated urethral stent for temporary stent placement in patients with traumatic bulbar urethral stricture</td>
<td>Kim S.W. , Ahn S.T. , Lee D.H. , Kim J.W. , Oh M.M. , Park H.S. , Moon D.G.</td>
<td>Korea University, College of Medicine, Dept. of Urology, Seoul, Korea, South</td>
</tr>
<tr>
<td>PT023</td>
<td>The sexual and continence outcome of patients with post anastomotic (end to end) urethroplasty for pelvic fracture posterior urethral distraction defects</td>
<td>Abdel-Aziz O. , Ghoneima W. , Abdel-Rassoul M. , Abdelwahab M. , Elkady A. , El Ghoneimy M. , Amrlotfi M.</td>
<td>Kasr Al Ainy Teaching Hospital, Dept. of Urology, Cairo, Egypt</td>
</tr>
<tr>
<td>PT024</td>
<td>Transvaginal repair of anterior and apical prolapse using OPUR 6-strap mesh: Five years of experience</td>
<td>Snurmitsyna O. , Enikeev M. , Glybochko P. , Rapoport L. , Nikitin A. , Lobanov M. , Abdusalamov A.</td>
<td>Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, Spasocucotskogo Hospital, Dept. of Gynecology, Moscow, Russia</td>
</tr>
<tr>
<td>PT025</td>
<td>The Management And Outcomes Of Urethral Complications Of Mid Urethral Tapes For Stress Urinary Incontinence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT026</th>
<th>Comparison of surgical outcomes of laparoscopic versus robotic assisted repair of vesicovaginal fistula: Initial experience from northwest China</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Zhu G.D., Wu D.P., Song W.B., Yang Z.S., He D.L.</td>
<td>The First Affiliated Hospital of Xi’an Jiaotong University, Dept. of Urology, Xi’an, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT027</th>
<th>Surgical outcomes of vesicovaginal fistula in the radiotherapy field</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PT028</th>
<th>Outcomes of recto-urethral fistula repair using a York-Mason procedure – Return to full normal continuity of urinary and bowel function</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Kowalik U.¹, Sexton S.¹, Inouye B.¹, Gilmore B.², Kahokehr A.³, Peterson A.¹, Mantyh C.², Migaly J.²</td>
<td>¹Duke University Medical Center, Dept. of Urology, Durham, United States of America, ²Duke University Medical Center, Dept. of Surgery, Durham, United States of America, ³University of Adelaide, Division of Surgical Specialties &amp; Anaesthetics, Adelaide, Australia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT029</th>
<th>Results of the York Mason procedure with or without concomitant graciloplasty to treat iatrogenic rectourethral fistulas</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Van Der Doelen M.J.¹, Fransen Van De Putte E.E.², Martens F.M.J.¹, Horenblas S.², Heesakkers J.P.F.A.¹</td>
<td>¹Radboud University Medical Center, Dept. of Urology, Nijmegen, Netherlands, The, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>09:45 - 09:55</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>09:55 - 10:45</td>
<td>Management of clinical Benign Prostatic Hyperplasia (BPH)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>09:55 - 10:10</td>
<td>Developments in treatment of clinical BPH</td>
</tr>
<tr>
<td>10:25 - 10:45</td>
<td>Questions and answers</td>
</tr>
<tr>
<td>10:45 - 11:35</td>
<td>Vesicovaginal fistula (VVF)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>How to achieve best outcomes in treatment of vesicovaginal fistula</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Evolution in surgical management of VVF in Pakistan</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:35</td>
<td>Questions and answers</td>
</tr>
<tr>
<td>11:35 - 12:05</td>
<td>EAU-PAUS case discussion</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>11:35 - 11:50</td>
<td><strong>Male Lower Urinary Tract Symptoms (LUTS)</strong></td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td><strong>VVF</strong></td>
</tr>
<tr>
<td>11:55 - 12:05</td>
<td><strong>Case 3: To be confirmed</strong></td>
</tr>
<tr>
<td>12:05 - 12:15</td>
<td><strong>Closing remarks</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Aims and objectives of this session**
To discuss challenges in urolithiasis and male infertility through case presentations and present newer modalities for treatment of benign prostatic hyperplasia. Key note lectures will include difficult cases and tissue engineering in urethral reconstruction as well as new dimensions of flexible ureteroscopy and miniaturisation in percutaneous endourology. Leading experts from the Urological Society of India and European Association of Urology will give the case presentations and lectures followed by panel discussion led by key opinion leaders.

**09:45 - 09:50**
Welcome and introduction  
M.S. Agrawal, Agra (IN)  
J.O.R. Sønksen, Herlev (DK)

**09:50 - 10:25**
Panel discussion: Challenges in urolithiasis  
*Panel:* To be confirmed  
T. Knoll, Sindelfingen (DE)  
To be confirmed

**09:50 - 09:57**
Case 1  
J. Desai, Ahmedabad (IN)

**09:57 - 10:04**
Case 2  
P. Maheshwari, Mumbai (IN)

**10:04 - 10:11**
Case 3  
O. Traxer, Paris (FR)

**10:11 - 10:18**
Case 4  
S.K. Pal, Delhi (IN)

**10:18 - 10:25**
Discussion

**10:25 - 11:00**
Symposium: Newer modalities for Benign prostatic hyperplasia (BPH)  
*Moderators:* A. Elhence, Meerut (IN)  
M.M. Fode, Herlev (DK)

**10:25 - 10:32**
Plasma enucleation  
M. Chiruvella, Hyderabad (IN)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:32 - 10:39</td>
<td>Uro-Lift</td>
<td>O. Kayes, Leeds (GB)</td>
</tr>
<tr>
<td>10:39 - 10:46</td>
<td>Aquablation</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>10:46 - 10:53</td>
<td>Stents in BPH</td>
<td>R.P. Kulkarni, Chertsey (GB)</td>
</tr>
<tr>
<td>10:53 - 11:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:35</td>
<td>Panel discussion: Challenges in male infertility</td>
<td>A.K. Chawla, Manipal (IN)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Dinkelman-Smit, Rotterdam (NL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R. Sood, New Delhi (IN)</td>
</tr>
<tr>
<td>11:00 - 11:07</td>
<td>Case 1: Antioxidant treatment</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:07 - 11:14</td>
<td>Case 2: Varicoceles</td>
<td>R. Kumar, New Delhi (IN)</td>
</tr>
<tr>
<td>11:21 - 11:28</td>
<td>Case 4: Hypogonadism</td>
<td>R. TP, Bangalore (IN)</td>
</tr>
<tr>
<td>11:28 - 11:35</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:35 - 12:10</td>
<td>Key note lectures</td>
<td>C.R. Chapple, Sheffield (GB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Seth, New Delhi (IN)</td>
</tr>
<tr>
<td>11:35 - 11:42</td>
<td>Miniaturisation in percutaneous endourology: How small is small enough</td>
<td>M.S. Agrawal, Agra (IN)</td>
</tr>
<tr>
<td>11:49 - 11:56</td>
<td>Difficult cases in urethral reconstruction</td>
<td>S. Kulkarni, Pune (IN)</td>
</tr>
<tr>
<td>11:56 - 12:03</td>
<td>Tissue engineering in urethral reconstruction: Where are we today?</td>
<td>F. Castiglione, London (GB)</td>
</tr>
<tr>
<td>12:03 - 12:10</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:10 - 12:15</td>
<td>Closing remarks</td>
<td>M.S. Agrawal, Agra (IN)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J.O.R. Sønksen, Herlev (DK)</td>
</tr>
</tbody>
</table>
Regional meetings session - Best Poster presenters and first prize winners Young Urologist Competition

**Location:** Green Area, Room 21

**Friday 15 March**

**10:00 - 12:00**

Poster viewing of 20 minutes. Introduction by the chairs
Poster presentations:
• 2 min. presentation
• 2 min. discussion
Video presentations:
• Max 8 min. video presentation
• 4 min discussion
First prize winners Young Urologist Competition presentation:
• Max 7 min. presentation
• 3 min. discussion

Best posters presented at the time of the 5th Baltic Meeting in conjunction with the EAU

**Chairs:** To be confirmed
To be confirmed
J.L. Vásquez, Copenhagen (DK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 10:20 - 10:30 | **BALTIC1** Laparoscopic pyeloplasty combined with flexible nephroscopy (video)  
M. Cerskute, Vilnius (LT) |
| 10:30 - 10:34 | **BALTIC2** Blood-circulating androgen receptor variants as markers for progression and response to treatment in prostate cancer patients  
A. Bakavicius, Vilnius (LT) |
| 10:34 - 10:38 | **BALTIC3** Epigenetic markers to overcome limitations in prostate cancer diagnostics  
A. Bakavicius, Vilnius (LT) |
| 10:38 - 10:42 | **BALTIC4** Prostate resection speed in TURP – how determining is this for patients and how appropriate as a measure for assessing trainees?  
J.F. Donati-Bourne, Wolverhampton (GB) |
| 10:42 - 10:52 | **BALTIC5** Laparoscopic left adrenalectomy. Adrenal ganglioneuroma (video)  
To be confirmed |
| 10:52 - 10:56 | **BALTIC6** The influence of specific urinary incontinence type on the quality of life of incontinent women  
Z. Pilsetniece, Riga (LV) |
| 10:00 - 12:00 | Best posters presented at the time of the 18th EAU Central European Meeting in conjunction with the national congress of the Romanian Association of Urology |
### Scientific Programme - EAU19 Barcelona

**Chairs:** To be confirmed  
I. Sinescu, Bucharest (RO)  
J.L. Vásquez, Copenhagen (DK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:56 - 11:00 | **CEM1** Perineal urethrostomy – a last resort in the treatment of difficult urethral conditions  
A. Andresanu, Sector 3, Bucharest (RO) |
| 11:00 - 11:04 | **CEM2** A novel surgical technique to reduce lymphocele formation following pelvic lymph node dissection  
A. Magyar, Budapest (HU) |
| 11:04 - 11:08 | **CEM3** Cystic tumours of the kidney - our experiences in treatment and diagnostics  
T. Pitra, Plzeň (CZ) |
| 11:08 - 11:12 | **CEM4** Lymphopenia can help to predict response to targeted 1st-line therapy in patients with metastatic renal cell carcinoma  
M. Seles, Graz (AT) |
| 11:12 - 11:16 | **CEM5** Single-use cystoscopy - assessment of quality  
A. Ostrowski, Bydgoszcz (PL) |
| 11:16 - 11:20 | **CEM6** Musculocutaneous latissimus dorsi free flap as an option for phallic reconstruction in transmen  
V. Kojovic, Belgrade (RS) |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:00 - 12:00 | **Best posters presented at the time of the 13th South Eastern European Meeting in conjunction with the EAU**  
**Chairs:**  
D. Basic, Nis (RS)  
A. Vuksanovic, Belgrade (RS)  
J.L. Vásquez, Copenhagen (DK) |
| 11:20 - 11:24 | **SEEM1** Low-intensity shockwave therapy (LiST) for erectile dysfunction: A randomized clinical trial assessing the impact of energy flux density (EFD) and frequency of sessions  
I. Mykoniatis, Thessaloniki (GR) |
| 11:24 - 11:28 | **SEEM2** Late functional and psychosexual complications of primary hypospadias repaired in childhood  
B. Stojanovic, Belgrade (RS) |
| 11:28 - 11:32 | **SEEM3** Buccal one-stage mucosal graft urethroplasty for urethral stricture: Results of 10 years of experience  
G. Galiqi, Shkoder (AL) |
| 10:00 - 12:00 | **First prize winners Young Urologist Competition**  
**Chairs:**  
J. Gómez Rivas, Algete (ES)  
J.L. Vásquez, Copenhagen (DK) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker/Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:32 - 11:42</td>
<td>Upper Tract Urothelial Carcinome: Is it possible to save the kidney?</td>
<td>T. Põdramägi, Tartu (EE)</td>
</tr>
<tr>
<td>11:42 - 11:52</td>
<td>Invasive nodal staging in intermediate and high risk cN0 penile cancer. Dynamic sentinel lymph node biopsy or modified lymph node dissection?</td>
<td>I. Trávníček, Plzeň (CZ)</td>
</tr>
<tr>
<td>11:52 - 12:02</td>
<td>The biocompatibility profile of urogynecology synthetic grafts and the underlying mechanism of action</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
Parameters for detrusor underactivity in women: Predictive value towards ineffective voiding in a large cohort of women with urinary incontinence

By: Rosier P.
University Medical Center Utrecht, Dept. of Urology, Utrecht, Netherlands, The Netherlands

Development of mathematical formulas for the prediction of outflow obstruction on an individual basis: a post-hoc analysis of the flow resistive forces index (QRF) study.

By: Spyropoulos E. 1, Spyropoulos K. 2
1Private practice, Dept. of Urology, Paleo Faliro, Greece, 2University of Athens, School of Dentistry, Athens, Greece

Sensitivity and specificity of neurotrophins as biomarkers of a neurogenic detrusor overactivity in multiple sclerosis patients

By: Philippova E.S. 1, Bazhenov I. 2, Zryyanov A. 2, Bazarny V. 3, Sazonov S. 4, Volkova L. 5
1Ural State Medical University, Dept. of Urology, Ekaterinburg, Russia, 2Ural State Medical University, Dept. of Urology, Ekaterinburg, Russia, 3Ural State Medical University, Dept. of Laboratory Diagnosis, Ekaterinburg, Russia, 4Ural State Medical University, Dept. of Histology, Cytology and Embriology, Ekaterinburg, Russia, 5Ural State Medical University, Dept. of Neurology, Ekaterinburg, Russia

Detecting differences with magnetoencephalography (MEG)-urodynamics study of somatosensory processing normal desire to void and maximum desire to void sensation

By: Kitta T. 1, Shiraishi H. 2, Yagyu K. 2, Shimojo A. 2, Egawa K. 2, Kanno Y. 1, Ouchi M. 1, Higuchi M. 1, Togo M. 1, Takahashi Y. 1, Tsukiyama M. 1, Moriya K. 1, Ariga T. 2, Shinohara N. 1
79

Possible roles of urethral C-fiber afferents in storage/voiding dysfunction in female patients

By: Ichiyanagi O.¹, Nishimoto K-I.², Nagaoka A.³, Naito S.⁴, Yagi M.⁴, Ushijima M.⁴, Kajinuma A.¹, Kato T.⁴, Tsuchiya N.⁴
¹Yamagata Prefectural Kahoku Hospital, Dept. of Urology, Kahoku, Japan,
²Seichokai Fuchu Hospital, Dept. of Urology, Izumi, Japan,
³Yonezawa City Hospital, Dept. of Urology, Yonezawa, Japan,
⁴Yamagata University Faculty of Medicine, Dept. of Urology, Yamagata, Japan

80

Lower urinary tract symptoms amongst adult patients with genetically-confirmed mitochondrial disease

By: Sachdeva A., Feeney C., Gorman G., Turnbull D.M., Harding C.
¹Newcastle University, Wellcome Centre for Mitochondrial Research, Newcastle upon Tyne, United Kingdom,
²Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom

81

Therapeutic effects of PDE9 inhibitor on lower urinary tract dysfunction (LUTD) in mice with spinal cord injury (SCI)

¹Kindai University Faculty of Medicine, Dept. of Urology, Osaka-Sayama, Japan,
²University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America,
³Kindai University Nara Hospital, Faculty of Medicine, Dept. of Urology, Ikoma, Japan,
⁴University of Pittsburgh, Dept. of Medicine, Pittsburgh, United States of America,
⁵University of Pittsburgh, Dept. of Pharmacology and Chemical Biology, Pittsburgh, United States of America

83

Three-dimensional model of MRI prostate in bladder outlet obstruction of male LUTS/BPH patients

By: Sheng X., Jie S.
Renji Hospital, Dept. of Urology, Shanghai, China

84

The role of prostatic apex shape in voiding symptom and urine flow: A development and validation study

Yonsei University College of Medicine, Dept. of Urology, Seoul, Korea, South

12:04 - 12:09

Can imaging differentiate function from dysfunction?
To be confirmed
6th ESO Prostate Cancer Observatory: Innovations and care in the next 12 months
Specialty Session

Friday 15 March
10:45 - 12:30

Location: Green Area, Room 2
Chairs: To be confirmed
R.J.A. Van Moorselaar, Amsterdam (NL)

Aims and objectives of this session
ESO Observatories are high-level sessions organised during major international congresses with the aim of providing the audience with updated and unbiased information on a given topic. An ESO Observatory lasts about one hour and concentrates on a forecast given by a panel of experts of what it is expected to happen in their own field in the coming 12 months. The Panel includes distinguished clinicians and/or scientists and a patient advocate.

The forecast by each Panel Member is given in the form of concise take-home messages with 8-minute slide presentation followed by 2 minutes of discussion for each topic. The forecast will be discussed by the panel.

10:45 - 10:50
Introduction and looking back at the 2018 predictions
To be confirmed
R.J.A. Van Moorselaar, Amsterdam (NL)

10:50 - 11:00
The urologist's perspective on focal therapy
R. Ganzer, Bad Tölz (DE)

11:00 - 11:10
The urologist's perspective on surgery
M. Graefen, Hamburg (DE)

11:10 - 11:20
The urologist's perspective on active surveillance
R.C.N. Van Den Bergh, Amsterdam (NL)

11:20 - 11:30
The imaging specialist's perspective on MRI
O. Rouviere, Lyon (FR)

11:30 - 11:40
The pathologist's perspective
F. Algaba, Barcelona (ES)

11:40 - 11:50
The radiation oncologist's perspective
A. Bossi, Villejuif (FR)

11:50 - 12:00
The medical oncologist's perspective
S. Gillessen Sommer, St. Gallen (CH)

12:00 - 12:10
The andrologist's perspective
M. Albersen, Leuven (BE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10 - 12:25</td>
<td>The patient's perspective</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>12:25 - 12:30</td>
<td>Discussion and take-home messages</td>
<td>To be confirmed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R.J.A. Van Moorselaar, Amsterdam (NL)</td>
</tr>
</tbody>
</table>
Infectious diseases: Prostate and bladder
Poster Session 07

Friday 15 March
10:45 - 12:15

Location: Green Area, Room 4
Chairs: A. Chkhotua, Tbilisi (GE)
S. Malde, London (GB)
F.M.E. Wagenlehner, Giessen (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

85

Chronological trends of resistant Escherichia coli isolated from community-acquired urinary tract infections

By: Nasu Y.\(^1\), Kosaka N.\(^2\), Tanaka D.\(^1\), Sugimoto M.\(^1\), Takamoto A.\(^1\)
\(^1\)Okayama Rosai Hospital, Dept. of Urology, Okayama, Japan, \(^2\)Okayama Rosai Hospital, Dept. of Clinical Laboratory, Okayama, Japan

86

Outcomes of an observational protocol to prevent healthcare-associated Infections (HAIs) in a urology ward

By: Medina-Polo J.\(^1\), Justo-Quintas J.\(^1\), Gil-Moradillo J.\(^1\), Garcia-Rojo E.\(^1\), González-Padilla D.A.\(^1\), Abad-López P.\(^1\), González-Díaz A.\(^1\), Santos-De La Blanca R.\(^1\), Hernández-Arroyo M.\(^1\), Peña-Vallejo H.\(^1\), Teigell-Tobar J.\(^1\), López-Medrano F.\(^2\), Tejido-Sánchez Á.\(^1\)
\(^1\)Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, \(^2\)Hospital Universitario 12 de Octubre, Dept. of Infectious Diseases, Madrid, Spain

87

The effects of intervention by a dedicated urology team on reduction of catheter associated urinary tract infections, morbidity and mortality in hospitalized patients

By: Sadeh O.\(^1\), Shabataev V.\(^1\), Ram S.\(^2\), Paul M.\(^3\), Amiel G.E.\(^1\)
\(^1\)Rambam Health Care Campus, Dept. of Urology, Haifa, Israel, \(^2\)Technion- Israel Institute of Technology, Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, \(^3\)Rambam Health Care Campus, Dept. of Infectious Diseases, Haifa, Israel

88

Intra-vesical gentamicin (IVG) installations improve QoL, reduces the frequency of UTIs and reduce micro-organism resistance in patients with intractable recurrent UTIs

By: Hamed A.H.\(^1\), Mcphee S.\(^1\), Jones J.\(^1\), Altmeyer U.\(^2\), Weddings R.N.\(^1\), Bekarma H.\(^1\)
\(^1\)University Hospital Ayr, Dept. of Urology, Ayr, United Kingdom, \(^2\)University Hospital Crosshouse, Dept. of Microbiology, Kilmarnock, United Kingdom
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>89</td>
<td>Efficacy of prophylactic administration of prurifloxacin vs. cefixime in patients undergoing ultrasound guided prostate biopsy: A prospective randomized study</td>
<td>Samarinas M. ¹, Skriapas K. ¹, Karatzas A. ², Gravas S. ², Tzortzis V. ²</td>
<td>¹General Hospital of Larissa, Dept. of Urology, Larissa, Greece, ²University Hospital of Larissa, Dept. of Urology, Larissa, Greece</td>
</tr>
<tr>
<td>91</td>
<td>Is adjuvant amikacin to oral levoflaxcine effective for prevention of febrile complications following transrectal prostate biopsy in patients with fluoroquinolone-resistant E. coli in the rectal flora?</td>
<td>Nasu Y. ¹, Kosaka N. ², Tanaka D. ¹, Murata T. ¹</td>
<td>¹Okayama Rosai Hospital, Dept. of Urology, Okayama, Japan, ²Okayama Rosai Hospital, Dept. of Clinical Laboratory, Okayama, Japan</td>
</tr>
<tr>
<td>93</td>
<td>The role of next generation sequencing of semen samples in the diagnosis and treatment of chronic bacterial prostatitis</td>
<td>Mouraviev V.</td>
<td>CFCl, Dept. of Urology, Davenport, United States of America</td>
</tr>
<tr>
<td>94</td>
<td>Improving the management of recurrent urinary tract infections in women under 30 – does conservative treatment really work?</td>
<td>Hamed A.H., Cameron L., Mcphee S., Granger L., Bell A., Crombie E., Larkin K., Clark R., Bekarma H.</td>
<td>Health Care - NHS, Dept. of Urology, Ayr, United Kingdom</td>
</tr>
<tr>
<td>95</td>
<td>Minimally invasive combined surgical treatment for postcoital cystitis</td>
<td>Snurmitsyna O. ¹, Enikeev M. ², Rapoport L. ¹, Lobanov M. ¹, Abdusalamov A. ¹, Malinina O. ³</td>
<td>¹Sechenov University, Dept. of Urology and Reproductive Health, Moscow, Russia, ²Sechenov University, Dept. of Urology and Reproductive Health, Moscow, Russia, ³Bauman Hospital, Dept. of Urology, Moscow, Russia</td>
</tr>
<tr>
<td>96</td>
<td>Prevalence and antibiotic susceptibility of bacterial uropathogens in obstetric patients of Moscow region</td>
<td>Lokshin K. ¹, Shirshov V. ², Popko A. ², Demidko Y. ³, Luchenkova N. ⁴</td>
<td>¹GMS Clinics and Hospitals, Dept. of Urology, Moscow, Russia, ²Clinical Hospital Lapino, Mother and Child Group of Companies, Dept. of Urology, Moscow, Russia, ³Clinic of Urology, Sechenov University, Dept. of Urology, Moscow, Russia, ⁴Clinical Hospital Lapino, Mother and Child Group of Companies, Dept. of Obstetrics, Moscow, Russia</td>
</tr>
<tr>
<td>97</td>
<td>Analysis of mixed growth urine cultures in patients undergoing endoscopic urological procedures at an Australian tertiary hospital</td>
<td>Bhoopathy V. ¹, Weerakoon M. ¹, Wang A. ¹, Watts M. ²</td>
<td></td>
</tr>
</tbody>
</table>
Urine culture test: Is the sample collected satisfactorily?

By: Maheshwari P. ¹, Chaurasia A. ¹, Okwi N. ², Mukasa N.V. ³
¹Fortis Hospital Mulund, Dept. of Urology, Mumbai, India, ²Faculty of Health Sciences, Busitema University, Dept. of Surgery, Busitema, Uganda, ³Mulago National Referral Hospital, Dept. of Surgery, Kampala, Uganda
Novel biomarkers to improve prostate cancer predictions: The research continues
Poster Session 08

Location: Green Area, Room 5
Chairs: G. Giannarini, Udine (IT)
J.A. Schalken, Nijmegen (NL)
G. Zhu, Beijing (CN)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

100

Use of the PHI assay as a first line triaging test in an image-guided prostate cancer diagnostic pathway. The phi in refining MRI (PRIM) study

By: Gnanapragasam V.J. 1, Barret T. 2, Starling L. 3, George A. 3, Burling K. 4, Saeb-Parsy K. 5, Kastner C. 5, Lamb B. 5, Kim L 6
1University of Cambridge, Academic Urology Group, Cambridge, United Kingdom,
2University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom, 3University of Cambridge, Dept. of Urology Translational Research and Clinical Trials, Cambridge, United Kingdom, 4University of Cambridge, Dept. of Core Biochemistry and Analytical Laboratory, Cambridge, United Kingdom, 5Cambridge University Hospitals Trust, Dept. of Urology, Cambridge, United Kingdom, 6University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom

101

External validation of SelectMDx (v1) in an opportunistic screening cohort in first TRUS-guided biopsy without MRI imaging

By: Rubio Briones J. 1, Borque A. 2, Esteban L.M. 3, Mascarós J.M. 4, Collado A. 1, Ramírez-Backhaus M. 1, Casanova J. 1, Gómez-Ferrer A. 1, Mir M.C. 1, Wong A. 1, Iborra I. 1, Domínguez-Escrig J. 1
1Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, 2Hospital Miguel Servet, Dept. of Urology, Zaragoza, Spain, 3Escuela Universitaria Politécnica La Almunia, Universidad de Zaragoza, Dept. of Biostatistics, Zaragoza, Spain, 4Instituto Valenciano de Oncología, Dept. of Statistics, Valencia, Spain

102

Percent genome alteration predicts adverse oncologic outcomes after radical prostatectomy in African American men: A profile of cancer genomics by racial ancestry

By: Faisal F. 1, Tomlins S. 2, Lotan T. 3, Schaeffer E. 4
1Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, 2University of Michigan, Dept. of Urology and Pathology, Ann Arbor, United States of America, 3Johns Hopkins University School of Medicine, Dept. of Urology
Pooled analysis of >1000 patients enrolled in two independent prospective validation studies show consistent performance of a urine exosome gene expression assay to rule-out benign and low-grade prostate cancer at initial biopsy


1 Exosome Diagnostics GmbH, Martinsried, Germany, 2 Columbia University Medical Center, Dept. of Urology, New York, United States of America, 3 Icahn School of Medicine at Mt. Sinai, Dept. of Pathology, New York, United States of America, 4 Johns Hopkins Hospital, Dept. of Urology, Baltimore, United States of America, 5 Delaware Valley Urology, Voorhees, United States of America, 6 Urology Center of Englewood, Englewood, United States of America, 7 Exosome Diagnostics, Waltham, United States of America, 8 Atlantic Urology Clinics, Myrtle Beach, United States of America, 9 Washington University, Dept. of Surgery, Saint Louis, United States of America, 10 UT Health Science Center, San Antonio, United States of America, 11 University of California, Dept. of Urology, San Francisco, United States of America

Prostate cancer (PCa) incidence and severity in 823 hypogonadal men with and without testosterone therapy (TTh) in a controlled, observational registry study over up to 14 years

By: Haider A., Haider K.S.

Praxis Dr. Haider, Dept. of Urology, Bremerhaven, Germany

Low free testosterone is an independent risk factor for high grade prostate cancer

By: Towe M., Huynh L.M., El-Khatib F.M., Osman M., Yafi F., Ahlering T.

University of California, Irvine, Dept. of Urology, Orange, United States of America

International comparison in the risk calculator-based age-standardized incidence rate of prostate cancer between Japan and the Netherlands


1 Kurosawa Hospital, Institute for Preventive Medicine, Takasaki, Japan, 2 Gunma University Hospital, Dept. of Urology, Maebashi, Japan, 3 Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan, 4 Erasmus Medical Center, Dept. of Urology, Rotterdam, Netherlands, The

Clinical significant prostate cancer diagnostic performance of LacdiNAc-prostate-specific antigen glycoisomer assay at initial prostate biopsy: Retrospective multi-institutional study

By: Yoneyama T., Tobisawa Y., Kaneko T., Kaya T., Hatakeyama S., Mitsuzuka K., Duivenvoorden W., Pinthus J., Hashimoto Y., Ito A., Koie T.
111

The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study

By: Loubersac T.¹, Nguile-Makao M.², Pouliot F.², Fradet V.², Toren P.²
¹CHU Nantes, Urology Unit, Nantes, France, ²Centre Hospitalier Universitaire (CHU) de Québec Research Centre, Urology Unit, Quebec City, Canada

112

Prognostic significance of serum γ-glutamyltransferase in patients with castration-resistant prostate cancer treated with enzalutamide

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan

12:00 - 12:08

How to develop a clinically relevant biomarker
To be confirmed
V09  Comprehensive clinical study of SuperPulse™ fiber laser for treatment of stone disease

By: Traxer O.¹, Dymov A.M.², Rapoport L.M.², Enikeev D.V.², Tsarichenko D.G.², Sorokin N.I.², Proskura A.V.², Akopyan G.N.², Ali S.K.H.², Lekarev V.Y.², Klimov R.E.², Korolev D.O.²

¹Tenon Hospital, Dept. of Urology, Paris, France, ²Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

V11  Simultaneous bilateral endoscopic surgery (SBES): A new technique for the treatment of bilateral renal stones

By: Proietti S.¹, Rodriguez Socarras M.E.¹, Eisner B.², Saitta G.¹, De Coninck V.¹, Mantica G.¹, De Marchi D.¹, Bellinzoni P.¹, Gaboardi F.¹, Giusti G.¹

¹San Raffaele Hospital, Ville Turro Division, Dept. of Urology, Milan, Italy, ²Harvard Medical School, Massachusetts General Hospital, Dept. of Urology, Boston, United States of America

V12  The management of urinary stones in pediatrics: Overcoming traditional challenges with Moses technology

By: Tasian G.
The Children's Hospital of Philadelphia, Dept. of Urology, Philadelphia, United States of America

V13  High-power holmium laser with Moses Technology: Our initial experience

By: Angerri Feu O.¹, Sabiote L., Mayordomo O., Mosquera L., Flores L.D., Emiliani E., Kanashiro A., Sánchez-Martín F., Millán F., Palou J.
Fundació Puigvert, Dept. of Urology, Barcelona, Spain

V14  One-surgeon basketing technique in flexible ureteroscopy

By: Okada S.¹, Hamamoto S.², Inoue T.³, Minagawa S.¹, Morikawa H.¹, Matsuda T.⁴, Miura H.⁵
V15

Non-biological 3d printed simulator for percutaneous nephrolithotripsy

By: Ali S.H. 1, Sirota S.E. 1, Ali K.M. 1, Sukhanov B.R. 1, Vocvdenko V.S. 1, Plett A. 2, Evgenii A.B. 1

1 Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia,
2 Ludwig-Maximilians University, Dept. of Internal Medicine, Munich, Germany

V16

Endoscopic renal parenchyma tunnel cauterization for the management of hemorrhage during percutaneous renal surgery

By: Lezrek M. 1, Tazi H. 2, El Yazami O. 2, Alami M. 1, Ammani A. 1

1 Military Hospital Moulay Ismail, Dept. of Urology, Meknes, Morocco,
2 Al Ghassani Hospital, Dept. of Urology, Fes, Morocco
Update on diagnosis and prognosis in renal cancer

Poster Session 09

Friday 15 March 10:45 - 12:15

Location: Green Area, Room 12

Chairs: F.D.J. Birkhäuser, Luzern (CH)
        S. Dabestani, Malmö (SE)
        N. Nonomura, Osaka (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

113

Utility of the modified MAP score for predicting adherent perinephric fat in robot-assisted partial nephrectomy

By: Shiozaki K. 1, Sasaki Y. 1, Nakanishi R. 1, Izaki H. 1, Kanda K. 1, Kawanishi Y. 2, Yamanaka M. 2, Izumi K. 2, Kanayama H. 3

1Tokushima Prefectural Central Hospital, Dept. of Urology, Tokushima, Japan,
2Takamatsu Red Cross Hospital, Dept. of Urology, Tokushima, Japan,
3Tokushima University Hospital, Dept. of Urology, Tokushima, Japan

114

Association between adherent perinephric fat assessed using MAP score and PnFSD and perioperative outcomes at the time of partial nephrectomy for localized renal mass. A single high-volume referral center experience

By: Di Maida F. 1, Campi R. 1, Tellini R. 1, Sforza S. 1, Cocci A. 1, Corti F. 1, Viola L. 1, Bertelli E. 2, Lucarini S. 2, Agostini S. 2, Siena G. 1, Masieri L. 1, Carini M. 1, Mari A. 1, Minervini A. 1

1University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy,
2University of Florence, Careggi Hospital, Dept. of Radiology, Florence, Italy

117

Refining American joint committee on cancer prognostic groups for renal cell carcinoma: A more precise prediction of survival

By: Ning S., Qu Y., Wan F., Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

118

Topographic distribution of lymphatic oligometastases in patients with renal cancer

By: Kuusk T. 1, Zondervan P. 2, Lagerveld B. 3, Rosenzweig B. 4, Raman A. 5, Bex A. 1

1Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The,
2Academic Medical Center, Dept. of Urology, Amsterdam, Netherlands, The,
3OLVG, Dept. of Urology, Amsterdam, Netherlands, The,
4The Chaim Sheba Medical Center, Dept. of Urology, Ramat Gan, Israel,
5John Hunter Hospital, Dept. of Urology, Newcastle, Australia
Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients

By: Wen-Hao X., Qu Y-Y.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Summary -
S. Dabestani, Malmö (SE)
Active surveillance in prostate cancer
Expert-Guided Poster Tour 02

Friday 15 March
11:45 - 13:45

Location: Green Area, Room A (Expert-Guided Poster Tours)
Chairs: C.H. Bangma, Rotterdam (NL)
To be confirmed

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

- Introduction
  To be confirmed
  C.H. Bangma, Rotterdam (NL)

PT030
Withdrawn
To be confirmed

PT031
NCCN favourable intermediate-risk prostate cancer patients: Do all of them have a good prognosis?
By: Ono A., Hirasawa Y., Matsubara S., Tokuyama N., Hashimoto T., Satake N., Nakagami Y., Namiki K., Nakashima J., Ohno Y.
1Tokyo Medical University, Dept. of Urology, Tokyo, Japan, 2Sanno Hospital, Dept. of Urology, Tokyo, Japan

PT032
Thirty-year nationwide population-based follow-up of men on active surveillance for prostate cancer: Who benefits the most? A state-transition analysis
By: Ventimiglia E., Van Hemelrijck M., Lindhagen L., Stattin P., Garmo H.
1IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2King’s College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, United Kingdom, 3Uppsala Clinical Research Center, Dept. of Statistics, Uppsala, Sweden, 4Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

PT033
Active surveillance vs. radical prostatectomy in favourable-risk localised prostate cancer
1Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, 2Herlev Hospital, Dept. of Urology, Copenhagen, Denmark, 3Aalborg University Hospital, Dept. of Urology, Aalborg,
A novel predictor of clinical progression in patients on active surveillance for prostate cancer

University Health Network, Division of Urology, Toronto, Canada

Eight year patient reported outcome data of the first 150 Dutch men on active surveillance in the Prostate cancer Research International Active Surveillance study (PRIAS)

By: Venderbos L.D.F., Van Den Bergh R.C.N., Bangma C.H., Roobol M.J.
1Erasmus University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, 2St. Antonius Hospital, Dept. of Urology, Nieuwegein, Netherlands, The

Reclassification due to upgrading during active surveillance protocols in low risk prostatic cancer: The role of number of repeat biopsies in the long terms

1Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Unit, Milan, Italy, 2Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Prostate Cancer Unit, Milan, Italy, 3Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Program, Milan, Italy, 4Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Therapy, Milan, Italy, 5Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Pathology, Milan, Italy, 6Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Therapy, Prostate Cancer Unit, Milan, Italy

Do number of biopsies and PSA doubling time at 3 and 5 years in active surveillance protocols associate with upgrading reclassification?

1Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Prostate Cancer Unit, Milan, Italy, 2Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Unit, Milan, Italy, 3Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Program, Milan, Italy, 4Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiation Therapy, Milan, Italy, 5Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Pathology, Milan, Italy, 6Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 7Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiation Therapy, Prostate Program, Prostate Cancer Unit, Milan, Italy
PT038  
**Do we really need detailed biopsy assessment of patients with low-risk prostate cancer candidate to active surveillance? A prospective validation of the ISUP recommendations**

By: Bandini M.¹, Suardi N.², Scarcella S.², Nocera L.², Gandaglia G.², Fossati N.², Cucchiara V.², Zaffuto E.², Shariat S.³, Longo N.⁴, Mirone V.⁴, Scuderi S.², Larcher A.², Robesti D.², Karakiewicz P.⁵, Rizzo A.², Cannoletta D.², Pellegrino A.², Barletta F.², Montorsi F.², Briganti A.²

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴University of Naples Federico II, Dept. of Urology, Napoli, Italy, ⁵University of Montreal Health Center, Montreal, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada

---

PT039  
**Active surveillance in men with low to intermediate risk localized prostate cancer: A prospective multiple cohort study**

By: Rakauskas A.¹, Lucca I.¹, Burruni R.¹, Tawadros T.¹, Herrera F.², Bourhis J.², La Rosa S.³, Meuwly J.⁴, Jichlinski P.¹, Berthold D.⁵, Valerio M.¹

¹Lausanne University Hospital, Dept. of Urology, Lausanne, Switzerland, ²Lausanne University Hospital, Dept. of Radiotherapy, Lausanne, Switzerland, ³Lausanne University Hospital, Inst. of Pathology, Lausanne, Switzerland, ⁴Lausanne University Hospital, Dept. of Radiology, Lausanne, Switzerland, ⁵Lausanne University Hospital, Dept. of Oncology, Lausanne, Switzerland

---

PT040  
**Examining the limits of as eligibility: Validation of a Swedish national prostate cancer register (NPCR) observational study**

By: Chadrasekar T., Leong J.Y., Teplitsky S., Mann M., Trabulsi E., Lallas C., Gomella L., Mark J.R.

Thomas Jefferson University, Sidney Kimmel Cancer Center, Dept. of Urology, Philadelphia, United States of America

---

PT041  
**Does time spent on active surveillance adversely affect the pathologic and oncologic outcomes in patients undergoing delayed radical prostatectomy?**

By: Ahmad A.¹, Richard P.², Leao R.³, Timilshina N.⁴, Martin L.⁴, Komisarenko M.⁴, Oliaei A.⁴, Jain K.⁴, Salem S.⁴, Alhunaidi O.⁴, Horyn I.⁴, Finelli A.⁴

¹Princess Margaret Cancer Centre, University Health Network, University of Toronto, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada, ²Centre Hospitalier Universitaire de Sherbrooke, Centre de Recherche du CHUS, Université de Sherbrooke, Division of Urology, Dept. of Surgery, Sherbrooke, Canada, ³Hospital De Braga, Faculty of Medicine, University of Coimbra, CUF Dept. of Urology, Braga, Portugal, ⁴Princess Margaret Cancer Centre, University Health Network, University of Toronto, Division of Urology, Dept. of Surgery, Toronto, Canada

---

PT042  
**Do small tumor foci at biopsy predict the occurrence of adverse pathology in active surveillance patients?**
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT043</td>
<td>Active surveillance of men younger than 60: Assessment of differences in discontinuation and treatment choice in the Movember GAP3 Consortium</td>
<td>Al-Kailani Z.T.F., Niklas C., Siemer S., Stöckle M., Saar M. (Universitätsklinikum des Saarlandes, Dept. of Urology, Homburg, Germany)</td>
</tr>
<tr>
<td>PT045</td>
<td>Comparative analysis of cryoablation, brachytherapy, HIFU and Active surveillance: Oncological outcomes in low-risk prostate cancer</td>
<td>Remmers S., Helleman J., Nieboer D., Bangma C.H., Roobol M.J. (Erasmus University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The Netherlands)</td>
</tr>
<tr>
<td>PT047</td>
<td>Active surveillance for low risk prostate cancer among men with high risk genetic predisposition</td>
<td>Halstuch D., Sela S., Ber Y., Kedar D., Baniel J., Margel D. (Rabin Medical Center, Dept. of Urology, Petah-Tikva, Israel)</td>
</tr>
<tr>
<td>PT050</td>
<td>Magnetic resonance imaging and ultrasound fusion biopsy in follow-up of patients in active surveillance protocol. Can PSA density discriminate patients at higher risk of reclassification?</td>
<td>Roscigno M., Stabile A., Lughezzani G., Pepe P., Dell’atti L., Nicolai M., La Croce G., Manica M., Naselli A., Guazzoni G., Balzarini L., Montorsi F., Briganti A., Sironi S., Da Pozzo L. (ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy; Urological Research Institute, IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, Milan, Italy; Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy; Cannizzaro Hospital, Dept. of Urology, Catania, Italy; University Hospital, Dept. of Urology, Ancona, Italy; Ospedale San Giuseppe, Gruppo Multimedica, Dept. of Urology, Milan, Italy; Humanitas Clinical and Research Center, Humanities University, Dept. of Urology, Rozzano, Italy; Humanitas Clinical and Research Center, Dept. of Radiology, Rozzano, Italy; Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute University, Unit of Urology/Division of Oncology, Milan, Italy; Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute University, Unit of Urology, Division of Oncology, Milan, Italy; School of Medicine, University of Milano-Bicocca, H. Papa Giovanni XXIII, Dept. of Radiology, Bergamo, Italy)</td>
</tr>
<tr>
<td>PT051</td>
<td>Danish nationwide results for active surveillance for localised prostate cancer</td>
<td>Thomsen F.B., Jakobsen H., Langkilde N.C., Borre M., Jakobsen E.B., Frey A., Lund L., Lunden D., Dahl C., Helgstrand J.T., Brasso K. (Rigshospitalet, Dept. of Urology, Copenhagen, Denmark; Herlev Hospital, Dept. of Urology, Copenhagen, Denmark; Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark)</td>
</tr>
</tbody>
</table>
PT052

**Molecular markers of grade progression in longitudinally tracked prostate cancer foci during active surveillance of low risk disease**

By: Tosoian J.¹, Salami S.¹, Nallandhighal S.¹, Jones Jr T.², Plouffe K.³, Elkhoury F.², Morgan T.¹, Liu C.³, Kunju L.³, Montgomery J.¹, Natarajan S.², Sisk Jr A.⁴, Tomlins S.³, Palapattu G.¹, Marks L.²

¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America,
²University of California, Dept. of Urology, Los Angeles, United States of America,
³University of Michigan, Dept. of Pathology, Ann Arbor, United States of America,
⁴University of California, Dept. of Pathology, Los Angeles, United States of America

PT053

**Magnetic resonance imaging alone should not be considered as a stand-alone test for disease reclassification of men in active surveillance**

By: Roscigno M.¹, Stabile A.², Lughezzani G.³, Pepe P.⁴, Galosi A.B.⁵, Nicolai M.¹, La Croce G.¹, Manica M.¹, Naselli A.⁶, Guazzoni G.⁷, Briganti A.⁸, Balzarini L.⁹, Montorsi F.¹⁰, Sironi S.¹¹, Da Pozzo L.F.¹²

¹ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy,
²Urological Research Institute, IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, Milan, Italy,
³Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy,
⁴Cannizzaro Hospital, Dept. of Urology, Catania, Italy,
⁵Polytechnic University of Marche Region, Dept. of Urology, Ancona, Italy,
⁶Ospedale San Giuseppe, Gruppo Multimedica., Dept. of Urology, Milan, Italy,
⁷Humanitas Clinical and Research Center, Dept. of Urology, Milan, Italy,
⁸Urological Research Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Oncology, Milan, Italy,
⁹Humanitas Clinical and Research Center, Dept. of Radiology, Rozzano, Italy,
¹⁰Urological Research Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Oncology, Milan, Italy,
¹¹School of Medicine, University of Milano-Bicocca, Osp. Papa Giovanni XXIII, Dept. of Radiology, Bergamo, Italy,
¹²School of Medicine, University of Milano-Bicocca, Osp. Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy

PT054

**Upgrading in men with serial MRIs on active surveillance for low-risk prostate cancer: Are confirmatory biopsies still necessary?**

By: Osses D.F.¹, Drost F-K.H.¹, Verbeek J.F.M.², Luiting H.B.², Roobol M.J.², Schoots I.G.³

¹Erasmus University Medical Center, Dept. of Urology, Dept. of Nuclear Medicine, Rotterdam, Netherlands, The,
²Erasmus University Medical Center, Dept. of Radiology, Rotterdam, Netherlands, The,
³Erasmus University Medical Center, Dept. of Radiology, Dept. of Nuclear Medicine, Rotterdam, Netherlands, The

PT055

**Incremental utility of mp-MRI performed before confirmatory biopsy in reducing the risk of progression during active surveillance for men with low risk prostate cancer:**


Is imaging always useful?

1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milano, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 3Vienna General Hospital, Unit of Urology, Vienna, Austria, 4University of Naples Federico II, Unit of Urology, Napoli, Italy, 5University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montréal, Canada

PT056

Is a confirmatory biopsy still necessary in men considering active surveillance for low-risk prostate cancer in the multiparametric MRI era?

By: Fishelevitz A., Haskiya H., Kogan T., Buchler A., Keizman D., Dresler H., Leibovitch I., Sternberg I.
1Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, 2Meir Medical Center, Dept. of Radiology, Kfar Saba, Israel, 3Meir Medical Center, Dept. of Pathology, Kfar Saba, Israel, 4Meir Medical Center, Dept. of Oncology, Kfar Saba, Israel

PT057

Is multiparametric MRI really helpful to predict upgrading and upstaging in active surveillance?

By: Kim H., Pak S., Kim M., Jeong I.G., Song C., Hong J.H., Kim C.S., Ahn H.
Asan Medical Center, Dept. of Urology, Seoul, Korea, South
In females with overactive bladder, an alternative injection paradigm for onabotulinumtoxina is associated with low clean intermittent catheterisation use

By: Macdiarmid S. 1, Glazier D. 2, Shapiro A. 3, McCammon K. 4, McCrery R. 5, Jamagin B. 6, Boroujerdi A. 7, Bai Z. 8, Gao G. 9, Patel A. 10

1Alliance Urology Specialists, Dept. of Urology, Greensboro, United States of America, 2Virginia Urology, Dept. of Urology, Emporia, United States of America, 3Chesapeake Urology, Dept. of Urology, Owings Mills, United States of America, 4Eastern Virginia Medical School, Dept. of Urology, Virginia Beach, United States of America, 5Adult Pediatric Urology, Dept. of Urology, Omaha, United States of America, 6Center for Pelvic Health, Female Pelvic Medicine & Reconstructive Surgery, Franklin, United States of America, 7Allergan plc, Dept. of Urology, Irvine, United States of America, 8Allergan plc, Biostatistics, Madison, United States of America, 9Allergan plc, Medical Safety, Madison, United States of America, 10Allergan plc, Medical Affairs (Neurology and Urology), Marlow, United Kingdom

Intradetrusor botulinum toxin administration under local anaesthesia: A prospective, randomized trial comparing two different anaesthesia protocols

By: Borges Da Ponte C., Pereira E. Silva R.M., Pinto Pe Leve P.J., Sousa Guimarães De Castro A., Palma Dos Reis J.M., Matos Lopes T.M.

Centro Hospitalar Lisboa Norte, Dept. of Urology, Lisbon, Portugal

Delivery of intravesical botulinum toxin A using low energy shock waves in treatment of overactive bladder: A phase II self-controlled feasibility study

By: Nageib M., El-Hefnawy A.S., Zahran M.H., El-Tabey N.A., Sheir K.Z., Shokeir A.A.

Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt

Randomized prospective trial comparing uni- and bilateral sacral neuromodulation tests in the treatment of refractory idiopathic overactive bladder

By: Wagner L. 1, Alonso S. 2, Lenormand L. 3, Faix A. 4, Game X. 5, Cornu J.N. 6
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>130</td>
<td>Sacral neuromodulation: A comparison of office test stimulation vs. staged implant</td>
<td>By: Badin Castro J.¹, Abello A.², Das A.K.¹ ¹Beth Israel Deaconess Medical Center, Dept. of Surgery and Urology, Boston, United States of America, ²Yale School of Medicine, Dept. of Urology, New Haven, United States of America</td>
</tr>
<tr>
<td>*131</td>
<td>InterStim™ Sacral Neuromodulation for intractable urinary voiding dysfunctions (SOUNDS): Results of clinical effectiveness, quality of life, patient-reported outcomes and safety in a French multicenter observational study</td>
<td>By: Chartier-Kastler E.¹, Ruffion A.², Le Normand L.³, Cornu J-N.⁴, Abouihia A.⁵, Melotti A.⁵, Keller D.U.J⁵ ¹Academic Hospital Pitié-Salpêtrière Paris, Dept. of Urology, Paris, France, ²CH Lyon Sud, Dept. of Urology, Lyon, France, ³CHU de Nantes - Hôtel Dieu, Dept. of Urology, Nantes, France, ⁴CHU de Rouen – Hôpital Charles Nicolle, Dept. of Urology, Rouen, France, ⁵Medtronic Intl Sàrl, Dept. of Clinical RTG implantable therapies, Tolochenaz, Switzerland</td>
</tr>
<tr>
<td>132</td>
<td>Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: A prospective single blinded randomized trial</td>
<td>By: Abdelbaset M., Taha D., H Zahran M., Ezzat O., Elhefnawy A.S., Elkenawy M., Shokier A.A. Urology and Nephrology center, Dept. of Urology, Mansoura, Egypt</td>
</tr>
<tr>
<td>133</td>
<td>Patient satisfaction with sacral neuromodulation therapy for lower urinary tract dysfunction and factors affecting therapy satisfaction: A single-center survey</td>
<td>By: Banakhar M.¹, Hassouna M.² ¹King Abdulaziz University Hospital, Dept. of Urology, Jeddah, Saudi Arabia, ²Toronto Western Hospital, Dept. of Urology, Toronto, Canada</td>
</tr>
<tr>
<td>134</td>
<td>Is botulinum toxin A an effective treatment in patients following radiotherapy?</td>
<td>By: Toia B., Pakzad M., Hamid R., Greenwell T., Ockrim J. University College Hospital London, Dept. of Urology, London, United Kingdom</td>
</tr>
<tr>
<td>135</td>
<td>10-year follow-up study on long-term intravesical botulinum toxin A injections efficacy for overactive bladder treatment</td>
<td></td>
</tr>
</tbody>
</table>

**Scientific Programme - EAU19 Barcelona**
Treatment outcomes of patients with overactive bladder with or without uninhibited bladder contraction following selective bladder denervation

By: Brière R. 1, Richard P. 2, Gratton M. 3, Tu L.M 2
1Laval University, Quebec, Canada, 2Sherbrooke University, Dept. of Urology, Sherbrooke, Canada, 3Laval University, Dept. of Urology, Quebec, Canada

A multinational real-world study of OnabotulinumtoxinA in patients with overactive bladder demonstrates reduction in urinary symptoms and an improvement in quality of life along with a reduction in reliance on incontinence products

By: Hamid R. 1, Lorenzo-Gomez M-F. 2, Schulte-Baukloh H. 3, Boroujerdi A. 4, Patel A. 5, Farrelly E. 6
1University College London Hospitals, Dept. of Urology, London, United Kingdom, 2University Hospital of Salamanca, Dept. of Urology, Salamanca, Spain, 3St. Hedwig-Krankenhaus, Dept. of Urology, Berlin, Germany, 4Allergan plc, Dept. of Urology, Irvine, CA, United States of America, 5Allergan plc, Dept. of Medical Affairs, Neurology and Urology, Marlow, United Kingdom, 6Södersjukhuset, Stockholm South General Hospital, Dept. of Urology, Stockholm, Sweden

Botox versus SNM: The verdict
To be confirmed
### Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

**Urology beyond Europe**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Title</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| Friday 15 March 12:30 - 15:45 | Welcome and introduction | A. Stenzl, Tübingen (DE)  
K-S. Lee, Seoul (KR) |                                                             |
R. Seiler, Bern (CH)                                                  |
|               | 12:45 - 12:50 | Questions and answers                             |                                                                       |
|               | 12:50 - 13:00 | Molecular markers: Where is the clinical application? | R. Seiler, Bern (CH)                                                  |
|               | 13:00 - 13:05 | Questions and answers                             |                                                                       |
|               | 13:15 - 13:20 | Questions and answers                             |                                                                       |
|               | 13:20 - 14:20 | Benign Prostatic Hyperplasia (BPH) - current alternatives | Moderators: S. Gravas, Larissa (GR)  
K-S. Lee, Seoul (KR)                                                  |
|               | 13:20 - 13:30 | Current EAU guidelines on BPH                      | S. Gravas, Larissa (GR)                                               |

**Aims and objectives of this session**

With the help of specialists and key opinion leaders an up to date approach to "urothelial cancer", "benign prostatic enlargement", imaging in prostate cancer, and the role of cytoreductive nephrectomy will be outlined for both regions. Common approaches as well as regional differences will discussed with state of the art lectures, and panel and case based discussions to understand their reasoning.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 13:35</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>13:45 - 13:50</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Anatomical endoscopic enucleation of prostate</td>
<td>C.M. Scoffone, Turin (IT)</td>
</tr>
<tr>
<td>14:00 - 14:05</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>Postoperative management of enucleation procedures of prostate</td>
<td>S.Y. Cho, Seoul (KR)</td>
</tr>
<tr>
<td>14:15 - 14:20</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>14:20 - 14:50</td>
<td>Imaging in prostate cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderators: J. Cheon, Seoul (KR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Walz, Marseille (FR)</td>
</tr>
<tr>
<td>14:20 - 14:30</td>
<td>Does negative MRI really means no cancer?</td>
<td>S.K. Hong, Sungnam (KR)</td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>14:35 - 14:45</td>
<td>Prostate imaging: Ultra-sensitive ultrasound versus mp MRI</td>
<td>J. Walz, Marseille (FR)</td>
</tr>
<tr>
<td>14:45 - 14:50</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>Past, present and future of PI-RADS in prostate cancer</td>
<td>S.H. Choi, Daegu (KR)</td>
</tr>
<tr>
<td>15:00 - 15:05</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>15:05 - 15:25</td>
<td>Case discussion: MR Fusion biopsy in real practice</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-S. Byun, Seongnam (KR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J.H. Hong, Seoul (KR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Kastner, Cambridge (GB)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D.D. Kwon, Gwangju (KR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. Walz, Marseille (FR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Case presenter: H.K. Ha, Busan (KR)</td>
<td></td>
</tr>
<tr>
<td>15:25 - 15:45</td>
<td>Debate: Role of cytoreductive nephrectomy in the era of immunotherapy in Renal Cell Carcinoma (RCC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderators: A. Bex, Amsterdam (NL)</td>
<td></td>
</tr>
</tbody>
</table>
Scientific Programme - EAU19 Barcelona

G.T. Sung, Busan (KR)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>City</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:25 - 15:30</td>
<td><strong>Pro</strong></td>
<td>A. Bex, Amsterdam (NL)</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:35</td>
<td><strong>Con</strong></td>
<td>S.I. Seo, Seoul (KR)</td>
<td></td>
</tr>
<tr>
<td>15:35 - 15:45</td>
<td><strong>Questions and answers</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Stones: Conservative management and stents
Poster Session 11

Friday 15 March
12:30 - 14:00

Location: Green Area, Room 4
Chairs: N. Atassi, Sindelfingen (DE)
To be confirmed
A. Skolarikos, Athens (GR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

139
Urinary stone disease in Germany – Trends from federal hospital episode statistics
By: Heers H.¹, Stay D.², Hofmann R.¹, Hegele A.¹, Keil C.¹, Wiesmann T.²
¹Philipps-Universität Marburg, Dept. of Urology and Paediatric Urology, Marburg, Germany, ²Philipps-Universität Marburg, Dept. of Anaesthesiology and Intensive Care Medicine, Marburg, Germany

140
Factors predicting the failure of spontaneous passage by patients of small ureteric stones ≤3 mm
Chungbuk National University, Dept. of Urology, Cheongju, Korea, South

141
Renal colic during pregnancy: Predictors of ureteral stones
By: Lourenco D., Partezani A.D., Amaral B.S., Teles S.B., Barbosa A.R., Kayano P.P., Korkes F.
Hospital Israelita Albert Einstein, Dept. of Urology, Sao Paulo, Brazil

142
Can hyperoxaluria cause kidney damage in women with recurrent pyelonephritis?
By: Stepanova N., Kolesnyk M., Driianska V., Korol L.
Institute of Nephrology of the National Academy of Medical Sciences, Nephrology and Dialysis, Kyiv, Ukraine

143
Reducing delay in care for patients with obstructing stones: Results from an accelerated pathway
By: Matanhelia M., Simmons L., Jelski J., Albuheissi S., Timoney A., Philip J.
Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom

144
Percutaneous nephrostomy vs ureteral stent for hydronephrosis secondary to ureteric calculi: Impact on spontaneous stone passage and health-related quality of life – A prospective study
145 Efficacy and safety of complete intra-ureteral stent placement versus conventional stent placement in relieving ureteral stent-related symptoms: A randomized, prospective, single-blinded, multicenter clinical trial

By: Yoshida T., Inoue T., Taguchi M., Matsuzaki T., Muruta T., Kinoshita H., Matsuda T.
Kansai medical university, Dept. of Urology, Osaka, Japan

146 Randomized clinical trial on urinary pH monitoring and nutraceutical intervention in the prevention of ureteral stent calcification

1 Bellvitge University Hospital, Dept. of Urology, Barcelona, Spain, 2 La Paz University Hospital, Dept. of Urology, Madrid, Spain, 3 Rio Hortega University Hospital, Dept. of Urology, Valladolid, Spain, 4 Puigvert Foundation, Dept. of Urology, Barcelona, Spain, 5 San Cecilio University Hospital, Dept. of Urology, Granada, Spain, 6 Valse University Hospital, Dept. of Urology, Sevilla, Spain, 7 Álvaro Cunqueiro Hospital, Dept. of Urology, Vigo, Spain, 8 La Fe University Hospital and Polytechnic, Dept. of Urology, Valencia, Spain, 9 University Hospital of Santiago of Compostela, Dept. of Urology, Santiago of Compostela, Spain, 10 Devicare SL, Scientific director, Barcelona, Spain

147 Efficacy of a novel, single-use digital flexible cystoscope for double J removal: A multicentric study

By: Oderda M., Fasolis G., Doizi S., Gontero P.
1 Città della Salute e della Scienza, Dept. of Urology, Turin, Italy, 2 Alba Hospital, Dept. of Urology, Alba, Italy, 3 Tenon Hospital, Dept. of Urology, Paris, France

148 New persistent opioid use after ureteroscopy for stone treatment

By: Tam C., Yan P., Raisky J., Gunaseelan V., Kim T., Leavitt D., Dauw C., Hollingsworth J.M.
1 University of Michigan Medical School, Dept. of Urology, Ann Arbor, United States of America, 2 Henry Ford Health System, Dept. of Urology, Detroit, United States of America

149 Effects of silicone hydrocoated double loop ureteral stent (dj) on symptoms and quality of life in patients undergoing f-urs for kidney stone: Final results of a prospective randomized multicentre clinical study

By: Traxer O., Letendre J., Cloutier J., Daudon M., Kleinclauss F., Doizi S., Wiseman O.
Comparison of 4.8 Fr and 6 Fr ureteral stents on stent related symptoms following ureterorenoscopy: A prospective randomized controlled trial

By: Cubuk A., Yanaral F., Ozgor F., Savun M., Ozdemir H., Erbin A., Yuksel B., Sarilar O.

1Kartal Dr. Lütfi Kırdar Training and Research Hospital, Dept. of Urology, ISTANBUL, Turkey
2Haseki Training and Research Hospital, Dept. of Urology, Istanbul, Turkey
3Esenler Maternity and Children Hospital, Obstetrics and Gynecology, Istanbul, Turkey

Development and validation of a disease specific renal stone patient reported outcome measure (PROM)

By: Ragab M., Collie J., Baldin N., Tran M., Armitage J., Al Hayek S., Wiseman O.

1Salisbury District Hospital, Dept. of Urology, Salisbury, United Kingdom
2Cambridge University Hospital, Dept. of Urology, Cambridge, United Kingdom
3University of Cambridge, Dept. of Pure Mathematics and Mathematical Statistics, Cambridge, United Kingdom
4Royal Free Hospital, Dept. of Urology, London, United Kingdom

Effect of payer status and index care setting on 30-day revisit following elective surgery for nephroureterolithiasis

By: Friedlander D.F., Krimphove M.J., Cole A.P., Marchese M., Ortega G., Trinh Q-D.

Brigham and Women's Hospital, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America
Individualising prostate cancer treatment decision-making
Poster Session 12

Friday 15 March
12:30 - 14:00

Location: Green Area, Room 5
Chairs: To be confirmed
To be confirmed
S. Loeb, New York (US)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

153

Added value of concomitant systematic biopsies in predicting upgrading in patients with localized prostate cancer diagnosed by MRI-targeted biopsy: Implications for treatment selection

By: Gandaglia G. 1, Ploussard G. 2, Valerio M. 3, Mattei A. 4, Fiori C. 5, Fossati N. 1, Stabile A. 1, Beauval J. 6, Malavaud B. 6, Roumigué M. 6, Robesti D. 7, Dell’Oglio P. 1, Dehò F. 1, Capitanio U. 1, Moschini M. 4, Zamboni S. 4, Rakauskas A. 3, De Cobelli F. 8, Porpiglia F. 5, Montorsi F. 1, Briganti A. 1

1IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, Milan, Italy, 2Saint Jean Languedoc/La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, 3Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, 4Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 5San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, 6CHU Rangueil, Dept. of Urology, Andrology and Renal Transplantation, Toulouse, France, 7IRCCS Ospedale San Raffaele, Unit of Urology: Division of Oncology, Milan, Italy, 8IRCCS Ospedale San Raffaele, Unit of Clinical Research in Radiology, Experimental Imaging Center, Milan, Italy

154

Impact of introducing pre-biopsy multi-parametric MRI on presenting grade group and prognostic categories of newly diagnosed prostate cancers


1University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, 2Cambridge University Hospitals Trust, Dept. of Urology, Cambridge, United Kingdom, 3Cambridge University Hospitals Trust, Dept. of Radiology, Cambridge, United Kingdom, 4Cambridge University Hospitals Trust, Dept. of Pathology, Cambridge, United Kingdom, 5Oxford University Hospitals NHS Foundation Trust, Dept. of Urology, Oxford, United Kingdom, 6Oxford University Hospitals NHS Foundation Trust, Dept. of Radiology, Oxford, United Kingdom, 7University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom, 8University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom
Changes in Gleason score misclassification between diagnostic biopsies and radical prostatectomy specimens – A nationwide analysis

By: Helgstrand J.T.¹, Røder M.A.¹, Klemann N.¹, Kawa S.M.¹, Toft B.G.², Brasso K.¹

¹Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, ²Copenhagen University Hospital, Rigshospitalet, Dept. of Pathology, Copenhagen, Denmark

Using machine learning tools to predict prostate cancer upgrading after robotic radical prostatectomy

By: Panfilo D.¹, De Nunzio C.², Pastore A.L.³, Saccani S.⁴, Boudewijn A.⁴, Tortella P.⁴, Mattioli M.⁵, Lombardo R.⁵, Carbone A.³, Fuschi A.⁵, Dutto L.⁶, Witt J.H.⁷, Medvet E.¹, Tubaro A.²

¹Università degli studi di Trieste, Dept. of Urology, Trieste, Italy, ²Ospedale Sant Andrea, University La Sapienza, Dept. of Urology, Rome, Italy, ³Ospedale di Latina, Dept. of Urology, Rome, Italy, ⁴Aindo EU, s.r.l.s., Dept. of Urology, Trieste, Italy, ⁵Sant’Andrea Hospital-, Dept. of Urology, Rome, Italy, ⁶Queen Elisabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, ⁷St Antonius Hospital, Urology, Dept. of Urology, Pediatric Urology and Urological Oncology, Gronau, Germany

Hybrid PSMA PET/MRI for primary staging in presumed localised prostate cancer: A contemporary, tertiary hospital series

By: Mehawed G.¹, Saadat P.², Ong M.², Joshi A.², Roberts M.², Perera M.², Rhee H.², Yeates A.², Mckenzie I.², Munj J.², Malone G.², Chung E.², Heathcote P.², Preston J.², Lawson M.², Wood S.², Gustafson S.², Ngai S.², Miles K.³, Vela I.²

¹University of Queensland, School of Medicine, Brisbane, Australia, ²Princess Alexandra Hospital, Dept. of Urology, Brisbane, Australia, ³Princess Alexandra Hospital, Dept. of Radiology, Brisbane, Australia

Diagnostic efficacy of 18F-rhPSMA7 positron emission tomography for lymph node staging in patients with high-risk primary prostate cancer

By: Maurer T.¹, Kroenke M.², Wurzer A.³, Schwamborn K.⁴, Ulrich L.², Jooß L.², Horn T.⁵, Haller B.⁶, Weber W.², Wester H-J.³, Eiber M.²

¹Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Martini Klinik, Hamburg, Germany, ²TUM, Dept. of Nuclear Medicine, Munich, Germany, ³TUM, Dept. of Radiopharmacy, Munich, Germany, ⁴TUM, Dept. of Pathology, Munich, Germany, ⁵TUM, Dept. of Urology, Munich, Germany, ⁶TUM, Dept. of Medical Statistics and Epidemiology, Munich, Germany

The AJCC 8th edition no longer substages pT2 prostate cancer: Does extent of tumor involvement not matter?

By: Pompe R.S.¹, Preisser F.², Leyh-Bannurah S.³, Gild P.³, Salomon G.¹, Graefen M.¹, Fisch M.³, Huland H.¹, Tilki D.¹

¹University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center,
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>162</td>
<td>Rare histological variants of prostate adenocarcinoma (PCa): A National Cancer Database (NCDB) analysis</td>
<td>Arora S., Sood A., Deepansh D., Keeley J., Borchert A., Baumgarten L., Rogers C.G., Peabody J.O., Menon M., Abdollah F.</td>
<td>Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America</td>
</tr>
<tr>
<td>163</td>
<td>Tumor locations in the prostate gland affect the incidence, clinicopathological features and prognosis of prostate cancer</td>
<td>Akatsuka J., Kimura G., Obayashi K., Mikami H., Sano M., Yanagi M., Takeda H., Matsuzawa I., Suzuki Y., Hamasaki T., Yamamoto Y., Kondo Y.</td>
<td>Nippon Medical School Hospital, Dept. of Urology, Tokyo, Japan, RIKEN Center for Advanced Intelligence Project, Pathology Informatics Team, Tokyo, Japan</td>
</tr>
<tr>
<td>164</td>
<td>External validation of the PREDICT Prostate tool for prognostication in non-metastatic prostate cancer: A study in 69,206 men from prostate cancer data base Sweden</td>
<td>Thurtle D., Bratt O., Stattn P., Pharoah P.D., Gnanapragasam V.J.</td>
<td>University of Cambridge, Dept. of Surgery, Cambridge, United Kingdom, Gothenburg University, Sahlgrenska Academy, Dept. of Urology, Gothenburg, Sweden, Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, University of Cambridge, Dept. of Cancer Epidemiology, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>165</td>
<td>Understanding of prognosis in non-metastatic prostate cancer: A randomised comparative study of clinician estimates measured against the PREDICT prostate tool</td>
<td>Thurtle D., Jenkins V., Pharoah P.D., Gnanapragasam V.J.</td>
<td>University of Cambridge, Academic Urology Group, Dept. of Surgery, Cambridge, United Kingdom, University of Sussex, Sussex Health Outcomes Research in Cancer, Brighton, United Kingdom, University of Cambridge, Dept. of Cancer Epidemiology, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>166</td>
<td>A multilayer perceptron artificial neural network model for predicting survival of patients with prostate cancer according to initial treatment strategy: Development of a web-based clinical decision support system</td>
<td>Koo K.C., Min G.R., Kim J., Park J.S., Kim J.W., Ahn H.K., Min M., Kim J., Chung B.H.</td>
<td>Yonsei University College of Medicine, Dept. of Urology, Seoul, Korea, Selvas Artificial Intelligence, ML Research Team, Seoul, Korea, South</td>
</tr>
<tr>
<td>167</td>
<td>Development and external validation of a novel risk score to predict long-term clinical recurrence after radical prostatectomy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Scientific Programme - EAU19 Barcelona**
By: *Mazzone E.*¹, Gandaglia G.², Knipper S.³, Graefen M.³, Tilki D.³, Rosiello G.², Fallara G.², Bandini M.², Stabile A.², Bravi C.A², Dell'oglio P.², Fossati N.², Montorsi F.², Briganti A.²

¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology URI, Milan, Italy,
²IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy,
³Martini Klinik, University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
Urothelial cancer and bladder reconstruction

Video Session 03

Friday 15 March
12:30 - 14:00

Location: Green Area, Room 10

Chairs: To be confirmed
To be confirmed
J.D. Kelly, London (GB)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V17

High resolution micro-ultrasound imaging for bladder cancer: A gender and stage-oriented assessment

By: Saita A.R. 1, Hurle R. 1, Buffi N. 1, Lughezzani G. 1, Nava L. 2, Colombo P. 3, Elefante M.G 3, Fasulo V. 1, Paciotti M. 1, Domanico L. 1, Lazzeri M. 1, Guazzoni G.F 1, Casale P. 1

1Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, MI, Italy,
2Humanitas San Pio X Hospital, Dept. of Urology, Milano, MI, Italy,
3Humanitas Clinical and Research Center, Dept. of Pathology, Rozzano, MI, Italy

V18

Total retroperitoneoscopic nephroureterectomy with modified pluck technique: Initial experience

By: Izumi K. 1, Kawanishi Y. 1, Yamanaka M. 1, Kawanishi S. 2, Fukawa T. 3, Kanayama H. 3

1Takamatsu Red Cross Hospital, Dept. of Urology, Takamatsu, Japan,
2Goshikidai Clinic, Dept. of Psychiatry, Takamatsu, Japan,
3Tokushima University, Dept. of Urology, Tokushima, Japan

V19

Ten commandments of intracorporeal ileal conduit during robot assisted radical cystectomy

By: Narain T.A., Mavuduru R., Bora G., Tyagi S., Mandal A.K.
Post Graduate Institute of Medical Education and Research, Dept. of Urology, Chandigarh, India

V21

Sex-sparing vs standard robot-assisted radical cystectomy with intracorporeal Padua ileal neobladder in female: Step-by-step surgical technique, perioperative, oncological and functional outcomes

By: Tuderti G., Mastroianni R., Flammia R.S., Guaglianone S., Minisola F., Anceschi U., brassetti A., Ferriero M., Gallucci M., Simone G.
Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy
V22 Robotic radical cystectomy with “en bloc” extended lymphadenectomy and intracorporeal orthotopic neo bladder: An innovative and reproducible technique

By: Fakhfakh S., Hoepffner J.L., Brillac N.B., Piechaud T., Gaston R.P.
Saint Augustin Clinic, Dept. of Urology, Bordeaux, France

V23 Robot-assisted radical cystectomy and hybrid neobladder reconstruction with the aid of GelPOINT device: Technical nuances and preliminary results

By: Vignolini G. 1, Pili A. 2, Sebastianelli A. 1, Campi R. 1, Sessa F. 1, Greco I. 1, Presutti M. 1, Mormile N. 1, Spatafora P. 1, Gacci M. 1, Serni S. 1
1AOUC Azienda Ospedaliero-Universitaria Careggi, Dept. of Urology, Florence, Italy,
2Aou Careggi, Dept. of Urology, Firenze, Italy
**Novel technology and techniques in urothelial cancer diagnosis**

**Poster Session 13**

**Location:** Green Area, Room 11

**Chairs:** Y. Fujii, Tokyo (JP)  
M. Kramer, Lübeck (DE)  
M. Moschini, Luzern (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**168**

**Ex vivo fluorescence confocal microscopy in the assessment of urothelial carcinoma grading in bladder and ureter: Our preliminary experience**

By: Puliatti S.¹, Eissa A.², Bevilacqua L.¹, Pellacani G.³, Sighinolfi M.C.¹, Azzoni P.⁴, Bertoni L.⁴, Reggiani Bonetti L.⁵, Elsherbiny A.², Micali S.⁶, Patel V.⁷, Rocco B.¹, Bianchi G.¹

¹University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ²Tanta University, Dept. of Medicine, Tanta, Egypt,
³University of Modena and Reggio Emilia, Dept. of Dermatology, Modena, Italy, ⁴University of Modena and Reggio Emilia, Dept. of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, Modena, Italy,
⁵University of Modena and Reggio Emilia, Dept. of Pathology, Modena, Italy, ⁶University of Modena & Reggio Emilia, Dept. of Urology, Modena, Italy,
⁷Global Robotics Institute, Florida Hospital-Celebration Health Celebration, Dept. of Urology, Florida, United States of America

---

**169**

**Stepwise transfer learning in convolutional neural networks for the cystoscopic diagnosis of bladder cancer using gastroscopic images**

By: Ikeda A.¹, Nosato H.², Kojima T.¹, Kawai K.¹, Kochi Y.², Sakanashi H.², Murakawa M.², Tada T.³, Nishiyama H.¹

¹University of Tsukuba, Dept. of Urology, Faculty of Medicine, Tsukuba, Japan, ²National Institute of Advanced Industrial Science and Technology, Artificial Intelligence Research Center, Tsukuba, Japan,
³Tada Tomohiro Institute of Gastroenterology and Proctology, Dept. of Gastroenterology and Proctology, Saitama, Japan

---

**170**

**IDENTIFY: The Investigation and DETection of urological Neoplasia in paTients reFerred with suspected urinarY tract cancer: A multicentre analysis**

By: Khadhouri S.¹, Gallagher K.M.², Mackenzie K.R.³, Shah T.T.⁴, Gao C.⁵, Moore S.⁶, Zimmermann E.⁷, Edison E.⁸, Jefferies M.⁹, Nambiar A.³, Mcgrath J.S.¹⁰, Kasivisvananthan V.¹¹

¹Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, ²Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ³Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ⁴Charing Cross Hospital, Imperial College
Scientific Programme - EAU19 Barcelona

Healthcare NHS Trust, Dept. of Surgery and Cancer, London, United Kingdom,  
5Peterborough City Hospital, Dept. of Urology, Peterborough, United Kingdom,  
6Wrexham Maelor Hospital, Dept. of Urology, Wrexham, United Kingdom,  
7Weston General Hospital, Dept. of Urology, Weston-super-Mare, United Kingdom,  
8North Middlesex Hospital, Dept. of Urology, London, United Kingdom,  
9Morriston Hospital, Dept. of Urology, Swansea, United Kingdom,  
10University of Exeter Medical School, Dept. of Urology, Exeter, United Kingdom,  
11West Hertfordshire NHS Trust, Dept. of Urology, London, United Kingdom

172

Clinical study on circulating tumor cells for diagnosis and prognosis of patients with bladder cancer

The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, Jiangsu, China

173

The pathological and clinical response of molecular subtype of muscleinvasive bladder cancer to neoadjuvant chemotherapy

By: Zhang R., Chen H., Huang Y., Xue W., Li C., Zhuang G., Allory Y., Radvanyi F.  
1Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China,  
2Institute of Biophysics, Chinese Academy of Sciences, Laboratory Animal Center, Protein Science core facility center, Beijing, China,  
3Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Shanghai, China,  
4Hôpitaux Universitaires Henri-Mondor, Dept. of Pathology, Créteil, France,  
5Institut Curie, Centre de Recherche, CNRS, Paris, France

174

Predictive value and potentials for co-targeted therapy of STAT1 signaling in gemcitabine/cisplatin resistant bladder cancer

1Hiroshima University, Dept. of Urology, Hiroshima, Japan,  
2Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

176

Survival differences between men and women with bladder cancer depend strongly on time since diagnosis

1Netherlands Comprehensive Cancer Organisation, Dept. of Research, Utrecht, Netherlands, The,  
2Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden,  
3Radboud University Medical Center, Dept. of Urology, Nijmegen, Netherlands, The,  
4Radboud University Medical Center, Dept. for Health Evidence, Dept. of Urology, Nijmegen, Netherlands, The,  
5Radboud Institute for Health Sciences, Nijmegen, The Netherlands; Netherlands Comprehensive Cancer Organisation, Dept. of Research, Utrecht, Netherlands, The
177 The pathological diagnostic convenience and accuracy of En-bloc TUR specimen: Analysis of 10 pathologists

By: Yanagiswawa T. 1, Yorozu T. 2, Sano T. 1, Otsuka T. 1, Enei Y. 1, Iwatani K. 1, Kobayashi D. 1, Tanaka S. 1, Obayashi K. 1, Sato S. 2, Kimura T. 3, Takahashi H. 2, Egawa S. 3
1Jikei University Kashiwa Hospital, Dept. of Urology, Kashiwa, Japan, 2Jikei University School of Medicine, Dept. of Pathology, Tokyo, Japan, 3Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan

178 Multimodal fiber optic spectroscopy can successfully and rapidly discriminate between high and low grade urothelial cancer and provide valid tumor stage information

By: Morselli S. 1, Sebastianelli A. 1, Fantechi R. 1, Di Camillo M. 1, Baria E. 2, Cicchi R. 2, Pavone F.S. 2, Serni S. 1, Gacci M. 1
1University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, 2University of Florence, Department of Physics, European Laboratory for Non-Linear Spectroscopy, Sesto Fiorentino, Florence, Italy

179 Prediction of muscle invasive bladder cancer using the Vesical Imaging-Reporting and Data System and apparent diffusion coefficient values (VI-RADS/ADC)

By: Sakamoto K., Ito M., Nakanishi Y., Kataoka M., Suzuki H., Takemura K., Tobisu K., Koga F.
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan

180 Assessing the proposed confocal laser endomicroscopy criteria for grading of upper tract urothelial carcinoma

By: Freund J.E. 1, Liem E.I.M.L. 1, Savci-Heijink D. 2, Baard J. 1, Kamphuis G.M. 1, De La Rosette J.J.M.C.H. 3, De Bruin M. 4
1Amsterdam UMC, University of Amsterdam, Dept. of Urology, Amsterdam, Netherlands, The, 2Amsterdam UMC, University of Amsterdam, Dept. of Pathology, Amsterdam, Netherlands, The, 3Istanbul Medipol University, Dept. of Urology, Istanbul, Turkey, 4Amsterdam UMC, University of Amsterdam, Dept. of Biomedical Engineering & Physics and Dept. of Urology, Amsterdam, Netherlands, The

181 A randomized controlled trial of a modified cystoscopy technique to decrease patient's pain and anxiety

By: Hetou K., Li Gan A.M., Izawa J., Chin J.L., Power N.E.
University of Western Ontario, Dept. of Urology, London, Canada

182 Development and external validation of the haematuria cancer risk score to identify patient at risk of harbouring cancer

By: Tan W.S. 1, Ahmad A. 2, Feber A. 1, Mostafid H. 3, Cresswell J. 4, Fankhauser C. 5
Hermanns T. 6, Waisbrod S. 6, Sasieni P. 7, Kelly J. 1
1University College London, Dept. of Urology, London, Afghanistan, 2Cancer Research UK, Cancer Intelligence, London, United Kingdom, 3Royal Surrey County Hospital, Dept. of Urology, Surrey, United Kingdom, 4James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom, 5University Hospital Zurich, Dept. of Urology, Zurich, United Kingdom, 6University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, 7Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, Guys Cancer Centre, London, United Kingdom
Meeting of the Young Academic Urologists (YAU)
Specialty Session

**Location:** Green Area, Room 12

**Chairs:** To be confirmed
To be confirmed
To be confirmed

**Aims and objectives of this session**
The Young Academic Urologists (YAU) is a group of talented and already renowned European young urologists. We aim to promote high-quality studies in order to provide strong evidence for the best urological practice. In this session both scientific and educational context will be discussed among the members of YAU and the leaders of European Urology.

**12:30 - 13:10**
*EAU Young Academic Urologists (YAU) and improving science*

*Moderators:* To be confirmed
To be confirmed
To be confirmed

**12:30 - 12:40**
*Young Academic Urologists: Overview of the scientific activities and future perspectives*
To be confirmed

**12:40 - 12:50**
*Overview of the Non-Oncology groups achievements*
To be confirmed

**12:50 - 13:00**
*Overview of the Oncology and Technology groups achievements*
To be confirmed

**13:00 - 13:10**
*EAU Scientific Office and scientific contribution of YAU members in EAU meetings*
To be confirmed

**13:10 - 13:20**
*YAU Awards*

**13:10 - 13:20**
*Best paper published in 2018 by a YAU group*

**13:10 - 13:20**
*Best poster presented at EAU 2019 by a YAU group*

**13:10 - 13:20**
*Reviewer of the year from YAU*

**13:20 - 14:20**
*Step by step: How do I get funded for my research?*

*Moderators:* To be confirmed
To be confirmed
To be confirmed
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:20 - 13:30</td>
<td>How I developed a research which was funded by EAU Research Foundation</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>13:40 - 13:50</td>
<td>Criticism of the research project of YAU-RCC group</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
| 13:50 - 14:00 | Research Proposal by YAU-Men’s Health group: Li-SWT for penile rehabilitation after radical prostatectomy: a prospective, multi-center, randomized, sham-controlled study | P. Capogrosso, Milan (IT)  
P. Verze, Naples (IT) |
| 14:10 - 14:20 | How to conduct a prospective collaborative research? Examples from BURST                          | To be confirmed                                                                          |
| 14:20 - 15:20 | Challenge the expert                                                                               | Moderators:  
To be confirmed  
To be confirmed  
To be confirmed |
| 14:40 - 15:00 | Slings vs. Artificial urinary sphincter for urinary incontinence after radical prostatectomy       |                                                                                           |
| 15:00 - 15:20 | Primary urethral realignment vs. Suprapubic catheter for posterior urethral (traumatic) injuries   |                                                                                           |
| 14:20 - 14:40 | Ejaculation-sparing approaches in LUTS-BPH surgery: from 'laser' to 'water'                      |                                                                                           |
| 15:20 - 16:20 | Key studies of the year                                                                            | Moderators:  
To be confirmed  
To be confirmed  
To be confirmed |
| 15:20 - 15:40 | Impact of Surgical Factors on Robotic Partial Nephrectomy Outcomes: Comprehensive Systematic Review and Meta-Analysis |                                                                                           |
| 15:40 - 16:00 | Local treatment in oligometastatic disease (STAMPEDE and HORRAD trials)                           |                                                                                           |
| 16:00 - 16:20 | Development and validation of a risk-prediction nomogram for patients with ureteral calculi associated with urosepsis: A retrospective analysis |                                                                                           |
Joint Session of the European Association of Urology (EAU) and the Urological Society of Australia and New Zealand (USANZ)

Urology beyond Europe

Friday 15 March
12:30 - 15:15

Location: Green Area, Room 19

Chairs: P. Heathcote, Sydney (AU)
M. Wirth, Dresden (DE)

Aims and objectives of this session
In this Joint Session of the European Association of Urology and the Urological Society of Australia and New Zealand Practice patterns in the different regions of the world will be presented and discussed. The session itself includes different urological topics starting with gender reassignment surgery in Australia and treatment of iatrogenic ureteric fistulas today. LUTS and treatment of benign prostate hyperplasia is another topic which will be currently discussed. News in medical and surgery treatment modalities will be presented. Modern Stone treatment and the limits of Mini-PNL is another important topic in a country like Australia with a quite hot temperature. The session will be concluded by topics in prostate cancer regarding especially new imaging techniques and diagnosis of the local tumour and in metastasis.

12:30 - 12:35
Welcome and introduction
P. Heathcote, Sydney (AU)
M. Wirth, Dresden (DE)

12:35 - 12:50
Practice patterns of female urologists in Australia and New Zealand: Do we need to know?
Johns Putra, Ballarat (AU)

12:50 - 12:55
Discussion

12:55 - 13:10
Female to male gender reassignment surgery Australia: Early experience and outcome
H. Goossen, Upper Mount Gravatt (AU)

13:10 - 13:15
Discussion

13:15 - 13:30
Nightmare of urology: Iatrogenic ureteric fistulas – what is the best management of care?
SP Propping, Dresden (DE)

13:30 - 13:35
Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:35 - 13:50</td>
<td><strong>Ejaculatory dysfunction and treatment for BPH/LUTS</strong> To be confirmed</td>
</tr>
<tr>
<td>13:50 - 13:55</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:55 - 14:10</td>
<td><strong>Modern surgical management of benign prostate hyperplasia: Which technique is the best for whom?</strong> J. Rassweiler, Heilbronn (DE)</td>
</tr>
<tr>
<td>14:10 - 14:15</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td><strong>Mini PNL: It is getting small and tiny - the challenge of minimal invasive approach in modern stone treatment</strong> T. Knoll, Sindelfingen (DE)</td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:35 - 14:50</td>
<td><strong>Prostate biopsy: Is multiparametric MRI the decision maker?</strong> A. Briganti, Milan (IT)</td>
</tr>
<tr>
<td>14:50 - 14:55</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:55 - 15:10</td>
<td><strong>PSMA PET Imaging has shifted the goalposts of advanced prostate cancer</strong> D. Murphy, Melbourne (AU)</td>
</tr>
<tr>
<td>15:10 - 15:15</td>
<td><strong>Discussion</strong></td>
</tr>
</tbody>
</table>
### Aims and objectives of this session

The aim of this session is to provide the audience a deep insight on specific topics of current clinical practice in urology. The selected themes are renal cell cancer, reconstructive surgery and prostate cancer. For each topic, the discussion will follow two pathways: on one hand a synthesis of the most recent scientific evidence will be examined, on the other hand, complex surgical scenarios will be discussed by top-class experts. The audience will learn how to face complex clinical decision-making in case of metastatic or locally advanced kidney cancer, challenging scenarios of congenital hydronephrosis and reconstructive surgery and local and systemic management of metastatic prostate cancer.

### Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
</table>
| 12:30 - 12:35 | Welcome and introduction | F. Montorsi, Milan (IT)  
Y. Tomita, Niigata (JP) |
| 12:35 - 13:20 | Renal cell cancer | G. De Naeyer, Aalst (BE)  
Y. Tomita, Niigata (JP) |
| 12:45 - 12:55 | Robot-assisted radical nephrectomy with IVC thrombosis | M. Gallucci, Rome (IT) |
| 12:55 - 13:20 | Panel discussion on renal cell cancer: How do you treat this patient? | |
| 13:20 - 14:05 | Congenital hydronephrosis/reconstructive surgery | A. Gallina, Milan (IT)  
A. Kawauchi, Otsu (JP) |
<p>| 13:30 - 13:40 | Complex robot-assisted pyeloplasty | A. De La Taille, Créteil (FR) |
| 13:40 - 14:05 | Panel discussion on congenital hydronephrosis: How to manage this situation? | |
| 14:05 - 14:50 | Prostate cancer | |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:05 - 14:15</td>
<td>Local therapy for patients with oligo-metastasis</td>
</tr>
<tr>
<td></td>
<td>A. Mattei, Luzern (CH)</td>
</tr>
<tr>
<td>14:15 - 14:25</td>
<td>Differential management of drug therapy in specific clinical situation</td>
</tr>
<tr>
<td></td>
<td>S. Akamatsu, Kyoto (JP)</td>
</tr>
<tr>
<td>14:25 - 14:50</td>
<td>Panel discussion on prostate cancer: What is your choice of treatment?</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>Closing remarks</td>
</tr>
<tr>
<td></td>
<td>M. Fujisawa, Kobe (JP)</td>
</tr>
</tbody>
</table>

*Moderators:* A. De La Taille, Créteil (FR)  
H. Matsuyama, Ube (JP)
Joint Session of the European Association of Urology (EAU) and the Société Internationale d’Urologie (SIU)

Urology beyond Europe

Friday 15 March
12:30 - 15:00

Location: Green Area, Room 17

Chairs: S. Tanguay, Montreal (CA)
        H.P.A.M. Van Poppel, Leuven (BE)

Aims and objectives of this session

- Attendees will be able to develop an understanding of the key controversial issues in urologic oncology
- Attendees will be able to identify and utilise best practices and current technology and methods of management of complex urologic problems

12:30 - 12:35
Welcome and introduction
S. Tanguay, Montreal (CA)
H.P.A.M. Van Poppel, Leuven (BE)

12:35 - 13:40
Prostate cancer
Moderators: L.H. Klotz, Toronto (CA)
            H.P.A.M. Van Poppel, Leuven (BE)

12:35 - 12:45
Debate Prostate cancer diagnosis after mpMRI: Only target biopsies should be performed
C. Moore, London (GB)

12:45 - 12:55
Debate Prostate cancer diagnosis after mpMRI: Random and target biopsies should be performed
M.V. Khochikar, Miraj (IN)

12:55 - 13:10
Is active surveillance appropriate for Gleason 7 prostate cancer?
L.H. Klotz, Toronto (CA)

13:10 - 13:25
Optimal management of castration sensitive metastatic prostate cancer
N. Mottet, Saint-Étienne (FR)

13:25 - 13:40
Castration resistant prostate cancer: How to select optimal initial treatment
F. Saad, Montréal (CA)

13:40 - 13:45
Renal cancer
Moderators: A. Bex, Amsterdam (NL)
            S. Tanguay, Montreal (CA)

13:40 - 13:55
Is there a role for cytoreductive nephrectomy in 2019?
A. Bex, Amsterdam (NL)

13:55 - 14:10
Optimal use of check point inhibition in metastatic Renal Cell Carcinoma (RCC)
J.J. Ischia, Heidelberg (AU)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:10 - 14:55| **Urothelial carcinoma**  
**Moderators:**  
S. Tanguay, Montreal (CA)  
H.P.A.M. Van Poppel, Leuven (BE) |
| 14:10 - 14:25| **Check point inhibition in the treatment of non-invasive bladder cancer**  
A. Necchi, Milan (IT) |
| 14:25 - 14:40| **Robotic cystectomy: Surgical tips and prevention of complications**  
N.P. Wiklund, Stockholm (SE) |
| 14:40 - 14:55| **Optimal timing of peri-operative chemotherapy in Urinary Tract Urothelial Carcinoma (UTUC)**  
P. Gontero, Turin (IT) |
| 14:55 - 15:00| **Closing remarks**  
S. Tanguay, Montreal (CA)  
H.P.A.M. Van Poppel, Leuven (BE) |
Joint Meeting of the European Association of Urology (EAU) and the Caucasus/Central Asian countries

Urology beyond Europe

**Location:** Green Area, Room 18

**Chairs:** D. Nikoleishvili, Tbilisi (GE)
J.P.M. Sedelaar, Nijmegen (NL)

**Aims and objectives of this session**
Integration Caucasus and Central Asia regional urological societies under the EAU umbrella. Find out new promising urologist from this countries and involving EAU activities. Spread EAU and international standardize statements through this regional urological associations.

**Friday 15 March**
**12:30 - 15:45**

### 12:30 - 12:35
**Welcome and introduction**
D. Nikoleishvili, Tbilisi (GE)
J.P.M. Sedelaar, Nijmegen (NL)

### 12:35 - 13:35
**Bladder cancer: Radical cystectomy**

**Moderators:**
- F. Akilov, Tashkent (UZ)
- F. Guliyev, Baku (AZ)
- E. Xylinas, Paris (FR)

**12:35 - 12:45**
Immediate radical cystectomy for high-risk non-muscle invasive bladder cancer
E. Xylinas, Paris (FR)

**12:45 - 12:50**
Discussion

**12:50 - 13:00**
Development of the surgical treatment of invasive bladder cancer in Georgia
A. Chkhotua, Tbilisi (GE)

**13:00 - 13:05**
Discussion

**13:05 - 13:15**
10 years of experience of radical cystectomy with orthotopic diversion in Azerbaijan
T. Musayev, Baku (AZ)

**13:15 - 13:20**
Discussion

**13:20 - 13:30**
Extraperitoneal radical cystectomy with and without the extraperitonealization of the orthotopic neobladder: A retrospective study
K.G. Kiknavelidze, Kutaisi (GE)

**13:30 - 13:35**
Discussion

**13:35 - 14:35**
**Endo-urology: Part 1**

**Moderators:**
- Z. Khakimkhodzhaev, Bishkek (KG)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:35 - 13:45</td>
<td><strong>Optimal treatment of lower pole 1-2 cm renal stones</strong>&lt;br&gt;E. Emiliani, Barcelona (ES)</td>
</tr>
<tr>
<td>13:45 - 13:50</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td><strong>Uroolithiasis: Experience from the National Hospital in Kyrgyzstan</strong>&lt;br&gt;N. Monolov, Bishkek (KG)</td>
</tr>
<tr>
<td>14:00 - 14:05</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td><strong>Multiple and staghorn stones – difficulties of endoscopic approach</strong>&lt;br&gt;S. Mukhtarov, Tashkent (UZ)</td>
</tr>
<tr>
<td>14:15 - 14:20</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:20 - 14:30</td>
<td><strong>Survival and quality of life of patients following radical cystectomy</strong>&lt;br&gt;A. Tsaturyan, Yerevan (AM)</td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:35 - 15:35</td>
<td><strong>Endo-urology: Part 2</strong>&lt;br&gt;<strong>Moderators:</strong> S.V. Fanarjyan, Yerevan (AM)&lt;br&gt;P. Kallidonis, Patras (GR)&lt;br&gt;D. Nikoleishvili, Tbilisi (GE)</td>
</tr>
<tr>
<td>14:35 - 14:45</td>
<td><strong>Papillary approach for percutaneous nephrolithotomy. Is it a dogma?</strong>&lt;br&gt;P. Kallidonis, Patras (GR)</td>
</tr>
<tr>
<td>14:45 - 14:50</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td><strong>Evaluation of complication during laparoscopic surgery in urology</strong>&lt;br&gt;B. Ayubov, Tashkent (UZ)</td>
</tr>
<tr>
<td>15:00 - 15:05</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>15:05 - 15:15</td>
<td><strong>Case from practice: Augmentation - dorsal urethroplasty using buccal mucosa graft into the female patient with distal urethral stricture</strong>&lt;br&gt;B. Kasymov, Astana (KZ)</td>
</tr>
<tr>
<td>15:15 - 15:20</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>15:20 - 15:30</td>
<td><strong>Features of the methods of reconstruction of post-traumatic stricture of the posterior urethra</strong>&lt;br&gt;I. Rofiev, Dushanbe (TJ)</td>
</tr>
<tr>
<td>15:30 - 15:35</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>15:35 - 15:45</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>
**EAU History Office: Spanish contributions to urology**

**Specialty Session**

**Friday 15 March**

**12:30 - 15:00**

**Location:** Green Area, Room 14

**Chairs:** L.A. Fariña-Pérez, Vigo (ES)  
             P. Van Kerrebroeck, Maastricht (NL)

### Aims and objectives of this session

Each European country has made unique contributions to the field of urology, be it through early technical breakthroughs, medical insights or by visionary surgeons who pushed the boundaries of their field. The EAU History Office has prepared a programme featuring four prominent speakers who each highlight a different facet of uniquely Spanish urology. We go back to the 16th century for the earliest developments in Spanish urology, to the former Spanish Empire for a profile of one of Cuba's most celebrated urologists and his time in Spain, and we examine a key Spanish-language publication and the development of ureteroscopy in the modern treatment of stones.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 12:30 - 12:35 | **Welcome word**  
                P. Van Kerrebroeck, Maastricht (NL)                                             |
| 12:35 - 13:05 | **The birth of urology in renaissance Europe (XVI century): The Hispanic contribution**  
                R. Vela Navarrete, Madrid (ES)                                                      |
| 13:05 - 13:10 | **Discussion**                                                                                |
| 13:10 - 13:40 | **Joaquín María Albarrán (1860-1912): The Spanish influence in his life, work and professional links**  
                J. Angulo Cuesta, Getafe (ES)                                                      |
| 13:40 - 13:45 | **Discussion**                                                                                |
| 13:45 - 14:15 | **Salvador Gil Vernet 's “Patologia Urogenital” (1944) and medical illustration in urology**  
                J.M. Gil-Vernet Sedo, Barcelona (ES)                                               |
| 14:15 - 14:20 | **Discussion**                                                                                |
| 14:20 - 14:50 | **Ureteroscopy in the modern treatment of urinary stones**  
                E. Perez-Castro Ellendt, Madrid (ES)                                               |
<p>| 14:50 - 14:55 | <strong>Discussion</strong>                                                                                |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:55 - 15:00</td>
<td>Closing remarks</td>
<td>P. Van Kerrebroeck, Maastricht (NL)</td>
</tr>
</tbody>
</table>
# Common problems in muscle-invasive and advanced bladder cancer: Evidence based debates

**Specialty Session**

**Friday 15 March**
**12:45 - 15:45**

**Location:** Green Area, Room 2

**Chairs:**
- A.M. Kamat, Houston (US)
- To be confirmed
- A. Stenzl, Tübingen (DE)
- A. Stenzl, Tübingen (DE)

**Aims and objectives of this session**
- Using case based discussions, allow the presenters an opportunity to discuss nuances of common dilemmas facing urologic oncology patients and providers
- Use evidence based debates to provide clear, rationale guidance on the management of difficult situations in bladder cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 - 12:48</td>
<td>Welcome and introduction</td>
<td>A.M. Kamat, Houston (US)</td>
</tr>
<tr>
<td>12:48 - 13:10</td>
<td>Case-based debate: Role of radical cystectomy in metastatic disease, (N+ and/or M+)</td>
<td>B.A. Inman, Durham (US)</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>Discussants</td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:03</td>
<td>Summary</td>
<td>A.M. Kamat, Houston (US)</td>
</tr>
<tr>
<td>13:03 - 13:10</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>13:10 - 13:32</td>
<td>Case-based debate: Can I avoid radical cystectomy in a patient who is cT0 after neoadjuvant chemotherapy?</td>
<td>A.M. Kamat, Houston (US)</td>
</tr>
<tr>
<td>13:10 - 13:12</td>
<td>Case presenter</td>
<td></td>
</tr>
<tr>
<td>13:12 - 13:22</td>
<td>Discussants</td>
<td>A.M. Kamat, Houston (US)</td>
</tr>
<tr>
<td>13:22 - 13:25</td>
<td>Summary</td>
<td>A.M. Kamat, Houston (US)</td>
</tr>
<tr>
<td>13:25 - 13:32</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>13:32 - 13:54</td>
<td>Case-based debate: Ileal conduit or continent diversion: Which is a better choice for most patients?</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:32 - 13:34</td>
<td><strong>Case presenter</strong>&lt;br&gt;M. Rouprêt, Paris (FR)</td>
</tr>
<tr>
<td>13:34 - 13:39</td>
<td><strong>Discussant - Conduit</strong>&lt;br&gt;J. Taylor, Kansas City (US)</td>
</tr>
<tr>
<td>13:44 - 13:47</td>
<td><strong>Summary</strong>&lt;br&gt;M. Rouprêt, Paris (FR)</td>
</tr>
<tr>
<td>13:47 - 13:54</td>
<td><strong>Questions and answers</strong></td>
</tr>
<tr>
<td>13:54 - 13:56</td>
<td><strong>Case-based debate: Who lives better - quality of life after bladder-preserving therapy (Trimodal Therapy) vs radical cystectomy</strong></td>
</tr>
<tr>
<td>13:56 - 14:01</td>
<td><strong>Case presenter</strong>&lt;br&gt;A. Stenzl, Tübingen (DE)</td>
</tr>
<tr>
<td>13:56 - 14:01</td>
<td><strong>Discussant - Radical cystectomy</strong>&lt;br&gt;J.W.F. Catto, Sheffield (GB)</td>
</tr>
<tr>
<td>14:01 - 14:06</td>
<td><strong>Discussant - Trimodal therapy</strong>&lt;br&gt;N. James, Birmingham (GB)</td>
</tr>
<tr>
<td>14:06 - 14:09</td>
<td><strong>Summary</strong>&lt;br&gt;A. Stenzl, Tübingen (DE)</td>
</tr>
<tr>
<td>14:09 - 14:16</td>
<td><strong>Questions and answers</strong></td>
</tr>
<tr>
<td>14:16 - 14:38</td>
<td><strong>Case-based debate: In a patient who is pure UC, T2 disease; good GFR, should I go straight to radical cystectomy without neoadjuvant chemotherapy?</strong></td>
</tr>
<tr>
<td>14:16 - 14:18</td>
<td><strong>Case presenter</strong>&lt;br&gt;M. Babjuk, Prague (CZ)</td>
</tr>
<tr>
<td>14:18 - 14:23</td>
<td><strong>Discussant - Yes (no NAC)</strong>&lt;br&gt;W. Kassouf, Montreal (CA)</td>
</tr>
<tr>
<td>14:23 - 14:28</td>
<td><strong>Discussant - No (NAC)</strong>&lt;br&gt;P. Grivas, Seattle (US)</td>
</tr>
<tr>
<td>14:28 - 14:31</td>
<td><strong>Summary</strong>&lt;br&gt;M. Babjuk, Prague (CZ)</td>
</tr>
<tr>
<td>14:31 - 14:38</td>
<td><strong>Questions and answers</strong></td>
</tr>
<tr>
<td>14:38 - 15:00</td>
<td><strong>Case-based debate: 1 year after cystectomy, a patient develops a 2 cm PET avid lung nodule, only site of disease. The best management is: (what if lone site: liver or RP node?)</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 14:38 - 14:40 | **Case presenters**  
J.W.F. Catto, Sheffield (GB) |
| 14:40 - 14:45 | **Discussant - Systemic therapy**  
F.C. Maluf, Criciúma - SC (BR) |
| 14:45 - 14:50 | **Discussant - Metastasectomy**  
B.A. Inman, Durham (US) |
| 14:50 - 14:53 | **Summary**  
J.W.F. Catto, Sheffield (GB) |
| 14:53 - 15:00 | **Questions and answers** |
| 15:00 - 15:22 | **Case based debate: Healthy male patient wants radical cystectomy, undecided on diversion. Open or robotic?** |
| 15:00 - 15:02 | **Case presenters**  
J. Palou, Barcelona (ES) |
| 15:02 - 15:07 | **Discussant - Open RC better**  
S. Lerner, Houston (US) |
| 15:07 - 15:12 | **Discussant - Robot RC better**  
P. Agarwal, Bethesda (US) |
| 15:12 - 15:15 | **Summary**  
J. Palou, Barcelona (ES) |
| 15:15 - 15:22 | **Questions and answers** |
| 15:22 - 15:44 | **Case based debate: In a PDL1 + ve patient, good PS and renal function, with lung metastases, should I use IO (anti PDL1 therapy) as initial therapy instead of chemotherapy?** |
| 15:22 - 15:24 | **Case presenter**  
W. Kassouf, Montreal (CA) |
| 15:24 - 15:29 | **Discussant - No, chemotherapy first**  
J. Bedke, Tübingen (DE) |
| 15:29 - 15:34 | **Discussant - Yes, IO first**  
P. Grivas, Seattle (US) |
| 15:34 - 15:37 | **Summary**  
W. Kassouf, Montreal (CA) |
| 15:37 - 15:44 | **Questions and answers** |
| 15:44 - 15:45 | **Closing remarks**  
A. Stenzl, Tübingen (DE) |
New technologies
Expert-Guided Poster Tour 03

**Location:** Green Area, Room A (Expert-Guided Poster Tours)

**Chairs:** To be confirmed
D. Veneziano, Reggio Calabria (IT)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

**Introduction**
To be confirmed
D. Veneziano, Reggio Calabria (IT)

---

**PT058**

**Novel modalities for real-time optical imaging in urological neoplasm: A systematic review**

By: Brunckhorst O., Ong Q.J., Elson D., Mayer E.

1St Mary's Hospital Campus, Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom,
2Imperial College London, Hamlyn Centre for Robotic Surgery, Institute of Global Health Innovation, London, United Kingdom

**PT059**

**Utilizing semantic segmentation method with convolutional neural net to model a partial nephrectomy simulator for 3D printing**

By: Kyung Y.S., Lim B., Choi S.Y., Han J.H., Lee W., Jeong I.G., Kim N., Kim C.-S.

1Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Health Screening and Promotion Center, Seoul, Korea, South,
2Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, Korea, South,
3Asan Medical Center, University of Ulsan College of Medicine, Dept. of Convergence Medicine, Seoul, Korea, South

**PT060**

**Safety, feasibility and oncologic efficacy of treatment for small renal masses using an innovative liquid nitrogen-based cryogenic device**

By: Shprits S., Sachner R., Croitoru S., Dorfman K., Avitan O., Bahouth Z., Zisman A., Nativ O.

1Bnai Zion Medical Center, Dept. of Urology, Haifa, Israel,
2Bnai Zion Medical Center, Dept. of Radiology, Haifa, Israel,
3Assaf Harofeh Medical Center, Dept. of Urology, Be’er Ya’akov, Israel
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT061</td>
<td>An experimental study of the use of sodium fumarate as a nephroprotective method under warm ischemia of the kidney</td>
<td>Popov S., Guseinov R., Orlov I., Katunin A. City Hospital Saint Luka, Dept. of Urology, Saint Petersburg, Russia</td>
</tr>
<tr>
<td>PT064</td>
<td>Efficacy and safety of ultrasonic longitudinal-axis vibration for the reduction of ureteral access sheath insertion force: A randomized controlled trial in a porcine model</td>
<td>Koo K.C., Lee K.S., Kim J., Ahn H.K., Min G.R., Lim B.J., Kim J.S., Park N., Kim D.W., Chung B.H. 1 Yonsei University College of Medicine, Dept. of Urology, Seoul, Korea, South 2 Yonsei University College of Medicine, Dept. of Pathology, Seoul, Korea, South 3 Yonsei University College of Medicine, School of Mechanical Engineering, Seoul, Korea, South</td>
</tr>
<tr>
<td>PT066</td>
<td>Impact of SuperPulse Thulium Fiber Laser settings and curve diameter on optical fiber fracture during intracorporeal lithotripsy</td>
<td>Chiron P.H.L., Doizi S., De Coninck V., Keller E.X., Berthe L., Traxer O. 1 HIA Bégin, Dept. of Urology, Saint-Mandé, France 2 Tenon Hospital, Dept. of Urology, Paris, France 3 Ecole Nationale Supérieure des Arts et Métiers, PIMM Laboratory, Paris, France</td>
</tr>
<tr>
<td>PT067</td>
<td>Dusting efficiency comparison between Moses technology of Ho: YAG laser and superpulse thulium fiber laser</td>
<td>De Coninck V.M.J., Keller E.X., Kovalenko A., Vinnichenko V., Traxer O. 1 AZ Klina, Dept. of Urology, Brasschaat, Belgium 2 Tenon Hospital, Assistance-Publique Hôpitaux de Paris. Pierre et Marie Curie University, Dept. of Urology, Paris, France 3 National Research Nuclear University MEPhI, Dept. of Engineering, Moscow, Russia</td>
</tr>
<tr>
<td>PT068</td>
<td>Effect of fiber tip to tissue distance on resulting damage pattern: An in vitro study of four laser systems</td>
<td>Taratkin M., Enikeev D., Glybochko P., Netsch C., Becker B., Gross A.J., Rapoport L. 1 Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia 2 Asklepios Hospital Barmbek, Dept. of Urology, Hamburg, Germany</td>
</tr>
<tr>
<td>PT069</td>
<td>Methylene blue-conjugated gold nanoparticles enhanced photoimmunotherapy for bladder cancer in T24 cell line</td>
<td>Hsu C-W., Chiu Y-C., Cheng N-C., Liao M-Y., Huang C-C. 1 Division of Urology, Department of Surgery, Zhongxiao Branch Taipei City Hospital, Dept. of Surgery, Taipei, Taiwan 2 Center for Micro/Nano Science and Technology and Advanced Optoelectronic Technology Center, National Cheng Kung University, Dept. of Photonics, Tainan, Taiwan 3 National Pingtung University, Dept. of Applied Chemistry, Pingtung, Taiwan</td>
</tr>
</tbody>
</table>
PT070  Directed differentiation of feeder-free human induced pluripotent stem cells into stratified bladder urothelium

By: Suzuki K. ¹, Koyanagi-Aoi M.K-A ², Uehara K.U. ³, Hinata N.H. ¹, Fujisawa M.F. ¹, Aoi T.A. ²
¹Kobe University Graduate school of Medicine, Division of Urology, Kobe, Japan, ²Kobe University Graduate School of Science, Technology and Innovation, Division of Advanced Medical Science, Kobe, Japan, ³Kobe University Graduate school of Medicine, Division of Pathology, Kobe, Japan

PT071  Reducing perioperative anxiety in patients undergoing transurethral resection of bladder tumor by acupuncture treatment: A prospective randomized controlled study

By: Shprits S. ¹, Meyer G. ¹, Halachmi S. ¹, Stoppelman N. ¹, Avshalomov D. ¹, Biton K. ¹, Attias S. ², Schif E. ², Nativ O. ¹
¹Bnai Zion Medical Center, Dept. of Urology, Haifa, Israel, ²Bnai Zion Medical Center, Dept. of Internal Medicine, Haifa, Israel

PT074  A prospective randomized trial of paper versus digital PROMS follow-up in prostate cancer patients after radiation therapy: Acceptance of digital follow-up by patients

By: Myllykangas M. ¹, Bergroth R.H.J. ², Tenhunen H. ³, Hiltunen A. ³, Siilander K. ³, Kouri M. ¹, Rannikko A. ⁴
¹Helsinki University Hospital, Dept. of Oncology, Helsinki, Finland, ²Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ³Aalto University, Dept. of Industrial Engineering and Management, Espoo, Finland, ⁴University of Helsinki, Dept. of Urology, Helsinki, Finland

PT075  A tethered laparoscopic gamma probe for radioguided surgery in prostate cancer – usability and technical feasibility evaluation in a pelvic phantom and porcine model

By: Adshead J. ¹, Oldfield F. ², Hadaschik B. ³, Everaerts W. ⁴, Mestre-Fusco A. ⁵, Newbery M. ⁶, Elson D. ⁷, Grootendorst M. ⁸, Vyas K. ², Fumado L. ⁹, Harke N.N. ³
¹The Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ²Lightpoint Medical Ltd., Dept of. Product Development, Chesham, United Kingdom, ³University Hospital Essen, Dept. of Urology, Essen, Germany, ⁴KU Leuven, Dept. of Urology, Leuven, Belgium, ⁵Hospital Del Mar, Dept. of Nuclear Medicine, Barcelona, Spain, ⁶Inspired Usability, Dept. of Product Development and Usability, Knaresborough, United Kingdom, ⁷Imperial College London, Dept. of Surgery & Cancer, London, United Kingdom, ⁸Lightpoint Medical Ltd., Dept. of Clinical Research, Chesham, United Kingdom, ⁹Hospital Del Mar, Dept. of Urology, Barcelona, Spain

PT076  GMP-Verification processes of the final product in a clinical stem cell trial to treat Stress Urinary Incontinence

By: Prange J.A. ¹, Mohr-Haralampieva D. ¹, Alves De Sousa R.A. ¹, Schmid F. ², Eberli D. ²
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT077</td>
<td>Organ culture of seminiferous tubules using a modified soft agar culture system</td>
<td>Pourmand G.¹, Gholami K.², Koruji M.³, Ashouri S.², Abbasi M.²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Tehran University of Medical Sciences, Urology Research Center, Tehran, Iran, ²Tehran University of Medical Sciences, Dept. of Anatomy, School of Medicine, Tehran, Iran, ³Iran University of Medical Sciences, Cellular and Molecular Research Center &amp; Department of Anatomical Sciences, Tehran, Iran</td>
</tr>
<tr>
<td>PT079</td>
<td>A novel machine-learning augmented audio-uroflowmetry – comparison with standard uroflowmetry</td>
<td>Aslim E.J.¹, B T B. T. B.², Ng Y.S.L.¹, Kuo T.L.C.¹, Chen J.S.², Chen J.², Ng L.G.¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²Singapore University of Technology and Design, Information Systems Technology and Design, Singapore, Singapore</td>
</tr>
<tr>
<td>PT081</td>
<td>New biomaterials alternative to small intestinal submucosa (SIS) for urethral stricture repair</td>
<td>Vulpi M.¹, Gallo N.², Salvatore L.², Vitarelli A.¹, Sallustio F.³, Curci C.³, Divella C.³, Gallone A.³, Gervaso F.⁴, Ditonno P.¹, Sannino A.²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹University of Bari, Dept. of Urology and Andrology Unit, Department of Emergency and Organ Transplantation, Bari, Italy, ²University of Salento, Dept. of Engineering for Innovation, Lecce, Italy, ³University of Bari, Dept. of Basic Medical Sciences, Neuroscience and Sense Organs, Bari, Italy, ⁴CNR Nanotech, Institute of Nanotechnology, Lecce, Italy</td>
</tr>
<tr>
<td>PT082</td>
<td>A new urethral catheterisation device for safe urethral catheterisation in difficult cases</td>
<td>Flückiger S.C., John H. Kantonspital Winterthur, Dept. of Urology, Winterthur, Switzerland</td>
</tr>
<tr>
<td>PT083</td>
<td>A novel urinary catheter for use in haematuria</td>
<td>Kesavan A.¹, Pha M.T.N.²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹National University Health System, Dept. of Urology, Singapore, Singapore, ²National University of Singapore, Dept. of Industrial Design, Singapore, Singapore</td>
</tr>
<tr>
<td>PT084</td>
<td>The screening of deep venous thrombosis in patients undergoing urological surgery</td>
<td>Tatarano S., Enokida H., Yonemori M., Eura R., Yoshino H., Nishimura H., Yamada Y., Nakagawa M. Kagoshima University, Dept. of Urology, Kagoshima, Japan</td>
</tr>
<tr>
<td>PT085</td>
<td>A simple novel surgical technique for penile elongation: Compensation for tunical plication in Peyronie’s disease</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>By: <a href="#">Lee D.H.</a>, Kim S.W., Ahn S.T., Kim J.W., Moon D.G.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Korea University, College of Medicine, Dept. of Urology, Seoul, Korea, South</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT086</th>
<th>Transgender and adolescence: Is online information accurate or misleading?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Dunford C., <a href="#">Gresty H.</a>, Takhar M., Morley R., Rashid T.</td>
</tr>
<tr>
<td></td>
<td>Imperial College Healthcare NHS Trust, Dept. of Urology, London, United Kingdom</td>
</tr>
</tbody>
</table>
New insights in LUTS/BPH pathophysiology and medical treatment
Poster Session 14

Location: Red Area, eURO Auditorium 2
Chairs: To be confirmed
G.I. Russo, Catania (IT)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

183 
5α-Reductase inhibitors and risk of prostate cancer death
By: Bonde Miranda T. 1, Garmo H. 2, Stattin P. 3, Robinson D. 1
1Ryhov Hospital, Dept. of Urology, Jonkoping, Sweden, 2Uppsala University Hospital, Regional Cancer Centre, Uppsala, Sweden, 3Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

184 
Dutasteride may change renal morphology?
By: Da Silva M., Sampaio F., De Souza D.
Rio de Janeiro State University, Urogenital Research Unit, Rio de Janeiro, Brazil

187 
Long-term effects of tadalafil on storage and voiding function for male patients with detrusor underactivity induced by benign prostatic hyperplasia
By: Matsukawa Y., Takai S., Kanada Y., Ishida S., Majima T., Funahashi Y., Yamamoto T., Gotoh M.
Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan

188 
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of overactive bladder associated with benign prostatic hyperplasia (CONTACT Study)
By: Yamanishi T. 1, Kaga K. 2, Sakata K. 3, Yokoyama T. 4, Fuse M. 2, Kaga M. 2, Tokunaga S. 5
1, Afghanistan, 2Continence Centre, Dokkyo Medical University, Dept. of Urology, Tochigi, Japan, 3Imaichi Hospital, Dept. of Urology, Imaichi, Japan, 4Yokoyama Urological Clinic, Dept. of Urology, Okayama, Japan, 5Kyushu University Hospital, Medical Information Center, Fukuoka, Japan

189 
Mild-to-moderate benign prostatic hyperplasia symptoms: Filling the gap. Efficacy and safety of Afalaza in men with benign prostatic hyperplasia at risk of progression: A multicenter, double-blind, placebo-controlled, randomized clinical trial
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>190</td>
<td>Correlation of alpha blocker with dementia in patients with benign prostate hyperplasia: A nationwide population-based study using the National Health Insurance Service database</td>
<td>Vinarov A.Z.¹, Pushkar D.², Spivak L.¹</td>
<td>Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, Moscow State University of Medicine and Dentistry, Clinic of Urology, Moscow, Russia</td>
</tr>
<tr>
<td>192</td>
<td>Ghrelin-mediated promotion of prostate growth and prostate smooth muscle contraction: Evidence from functional, in vivo, and genomic approaches</td>
<td>Tae B.S.¹, Jeon B.J.¹, Choi H.¹, Park J.Y.¹, Cheon J.², Lee J.G.², Bae J.H.¹</td>
<td>Korea University Ansan Hospital, Dep. of Urology, Ansan, Korea, South, Korea University Ansan Hospital, Dep. of Urology, Seoul, Korea, South</td>
</tr>
<tr>
<td>193</td>
<td>Inhibition of prostate smooth muscle contraction by NAV2729: Evidence for a role of ADP ribosylation factor 6 (ARF6) for prostate smooth muscle contraction</td>
<td>Wang X.¹, Wang Y.¹, Gratzke C.¹, Li B.¹, Yu Q.¹, Strittmatter F.¹, Stief C.¹, Liu C.², Hennenberg M.¹</td>
<td>Ludwig-Maximilians University, Dept. of Urology, Munich, Germany, Southern Medical University, Dept. of Urology, Guangzhou, China</td>
</tr>
<tr>
<td>194</td>
<td>Withdrewed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>196</td>
<td>Estrogen receptor alpha (ERα) antagonist improves benign prostatic hyperplasia (BPH) in high fat induced obesity rat model</td>
<td>Yamanaka N., Mori K., Mizoguchi S., Shin T., Mimata H.</td>
<td>Oita University, Dept. of Urology, Oita, Japan</td>
</tr>
</tbody>
</table>
Stones: Research and metabolics
Poster Session 15

Location: Green Area, Room 4
Chairs: To be confirmed
P.M. Ferraro, Rome (IT)
K. Taguchi, Nagoya (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

198
Vitamin D3 promotes renal CaOx crystals formation/adhesion via increasing plasma/urinary oxalate through altering a novel VDR/miR-125b/Slc26a6 axis

By: Haoran L., Kun T., Tao Y., Xifeng S., Xiaoqi Y., Zhangqun Y.
Tongji Hospital, Dept. of Urology, Wuhan, China

199
β3 Stimulant contributes to the prevention of renal crystal formation via differentiation of beige adipocytes

1Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan,
2JA Mie Komono Kosei Hospital, Dept. of Urology, Komono, Japan,
3College of Life and Health Sciences, Chubu University, Dept. of Biomedical Sciences, Kasugai, Japan

200
Estrogen can reduce incidence of kidney stones by enhancing intestinal excretion of oxalate

By: Gong J., Jiang H., Gao X., Liu J.
1Tongji Hospital, Dept. of Urology, Wuhan, China,
2Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

201
Preclinical study using in vivo mouse models to target the androgen receptor/miR-182/TXNRD1/GLRX2 axis with antiandrogen or miR-182 antagonist suppressed the high-dose vitamin C-induced nephrocalcinosis

By: Haoran L., Kun T., Kehua J., Tao Y., Xiaoqi Y., Zhangqun Y.
Tongji Hospital, Dept. of Urology, Wuhan, China

202
Identification of aberrant glycosylation of osteopontin in urinary stone former patients as a urolithiasis biomarker

By: Anan G., Yoneyama T., Tobisawa Y., Hatakeyama S., Yoneyama M.
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>203</td>
<td><strong>Discovery of fatty acid binding protein 4 as an essential molecule for the development of kidney stones: A new understanding of the relationship between obesity and nephrolithiasis</strong></td>
<td>Iwamura H. , Ito J. , Kaiho Y. , Yamamoto H. , Imai A. , Yoneyama T. , Hashimoto Y. , Sato M. , Ohyama C.</td>
<td>1Tohoku Medical and Pharmaceutical University, Dept. of Urology, Sendai, Japan, 2Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, 3Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 4Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan</td>
</tr>
<tr>
<td>204</td>
<td><strong>Association between metabolic syndrome (MetS) and kidney stone disease recurrence: Outcomes from a retrospective cohort study with a mean follow-up of 18-years</strong></td>
<td>Taguchi K. , Chen L. , Usawachintachit M. , Hamamoto S. , Kang M. , Unno R. , Tzou D. , Sherer B. , Yasui T. , Ho S. , Stoller M. , Chi T.</td>
<td>1University of California, Dept. of Urology, San Francisco, United States of America, 2Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, 3Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan</td>
</tr>
<tr>
<td>205</td>
<td><strong>High concentration of calcium promotes mineralization and apoptosis via an NADPH oxidase/Nox4-MAPK pathway-dependent mechanism</strong></td>
<td>Xun Y. , Wang Q. , Li C. , Wu Y. , Qin BL. , Wang S.</td>
<td>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of urology, Hubei Wuhan, China</td>
</tr>
<tr>
<td>206</td>
<td><strong>LncRNA H19 sponges miR-21 to promote kidney CaOx crystals deposition via activation of HMGB1/TLR4/NF-κB pathway</strong></td>
<td>Haoran L. , Kun T. , Tao Y. , Xifeng S. , Xiaoqi Y. , Zhangqun Y.</td>
<td>Tongji Hospital, Dept. of Urology, Wuhan, China</td>
</tr>
<tr>
<td>207</td>
<td><strong>Low bone mineral density is associated with the onset of symptoms during follow-up: The relationship between bone mineral density and clinical outcomes in urolithiasis patients</strong></td>
<td>Taguchi K. , Sugino T. , Okada A. , Hamamoto S. , Tanaka Y. , Unno R. , Ando R. , Tozawa K. , Kohri K. , Yasui T.</td>
<td>Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan</td>
</tr>
</tbody>
</table>
208 The role of gut microbiome and short chain fatty acids in renal calcium oxalate stones formation

By: Liu Y. 1, Chen Z. 1, Jiang Q. 1, Cheng L. 1, Zhou L. 1, Li Y. 2, Sun Q. 3, Wang K. 1, Li H. 1

1 West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China, 2 University of Michigan, Dept. of Kidney Epidemiology and Cost Center, School of Public Health, Ann Arbor, United States of America, 3 Sichuan University, Dept. of Life Sciences, Chengdu, China

210 A new approach to the dietary stereotypes study in urolithiasis patients

By: Anokhin N.A. 1, Prosiannikov M. 1, Konstantinova O. 1, Voytko D. 1, Golovanov S. 1, Apolihin O. 2, Sivkov A. 3

1 N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiocentre of the Ministry of Health of Russian Federation, Dept. of Urolithiasis, Moscow, Russia, 2 N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiocentre of the Ministry of Health of Russian Federation, Dept. of Administration, Moscow, Russia, 3 N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiocentre of the Ministry of Health of Russian Federation, Dept. of Administration, Moscow, Russia

211 Nephrolithiasis predicts ischemic stroke: A longitudinal follow-up study using a national sample cohort

By: Bang W. 1, Ko K.T. 2, Shim M.S. 1, Oh C.Y. 1, Lee Y.S. 1, Cho J.S. 1

1 Hallym Sacred Heart Hospital, Dept. of Urology, Anyang, Korea, South, 2 Kangdong Sacred Heart Hospital, Dept. of Urology, Seoul, Korea, South
Improving outcomes from radical prostatectomy: The influence of big data
Poster Session 16

Friday 15 March
14:15 - 15:45

Location: Green Area, Room 5
Chairs: G. Carrieri, Bari (IT)
X. Cathelineau, Paris (FR)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 213

18-year prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer

By: Herlemann A., Cowan J.E., Washington 3rd S.L., Broering J.M., Carroll P.R., Cooperberg M.R.
University of California, Dept. of Urology, San Francisco, United States of America

215

Oncologic outcomes after radical prostatectomy for high risk prostate cancer: Impact of various definitions on cancer-specific and overall mortality

By: Knipper S., Karakiewicz P., Steuber T., Huland H., Graefen M., Tilki D.
1Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany,
2University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montréal, Germany

216

Which patients with clinically node positive prostate cancer should be considered as candidates for radical prostatectomy as part of a multimodal treatment? The impact of nodal burden

1IRCCS Ospedale San Raffaele, Division of Oncology Unit of Urology URI, Milan, Italy,
2Mayo Clinic, Dept. of Urology, Rochester (MN), United States of America,
3University Hospitals Leuven, Dept. of Urology, Leuven, Belgium,
4IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, URI, Milan, Italy,
5IRCCS Ospedale San Raffaele, Unit of Urology: Division of Oncology, URI, Milan, Italy

217

Impact of bilateral neurovascular bundle preservation on oncological outcomes in non-organ confined prostate cancer patients
219  Dehydrated human amnion/chorion membrane accelerates the return to continence and potency recovery after a nerve-sparing robotic-assisted radical prostatectomy

By: Govorov A., Kolontarev K., Dyakov V., Rasner P., Pushkar D.
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia

220  The impact of surgical experience on the risk of surgical margins and biochemical recurrence after robot-assisted radical prostatectomy: A learning-curve study

IRCCS San Raffaele Hospital, Division of Oncology, Unit of Urology, Milan, Italy, Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America

221  Gleason pattern 4 or 5 at a positive surgical margin predicts early biochemical recurrence (<12 months) after robotic radical prostatectomy

By: Planas Morin J., Celma A., Regis L., Cuadras M., Placer J., Salvador C., Lorente D., Trilla E., Morote J.
Hospital Vall d’Hebrón, Dept. of Urology, Barcelona, Spain

222  Variation in positive surgical margin status following radical prostatectomy for pT2 prostate cancer

Imperial College Healthcare, Dept. of Urology, London, United Kingdom, Brigham and Women’s Hospital, Dept. of Urology, Boston, United States of America, Brigham and Women’s Hospital, Center for Surgery and Public Health, Boston, United States of America, Marien Hospital Herne, Dept. of Urology, Herne, Germany, Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, United States of America, University College London Hospitals, Dept. of Urology, London, United Kingdom

223  Atlas of ex vivo prostate tissue and cancer images using confocal laser endomicroscopy: A project for intraoperative positive surgical margins detection during radical prostatectomy
224  
Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence

By: Preißer F. ¹, Busto Castanon L. ², Haese A. ², Pompe R.S. ³, Graefen M. ², Tilki D. ²
¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²University Hospital Hamburg-Eppendorf, Martini-Klinik, Hamburg, Germany, ³University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

225  
Inductive androgen deprivation and radical prostatectomy in T4 prostate cancer: Consecutive assessment of perioperative outcomes and long-term follow up

By: Saar M. ¹, Niklas C. ¹, Hajili T. ¹, Ohlmann C-H. ², Linxweiler J. ³, Siemer S. ¹, Stöckle M. ¹
¹Saarland University, Dept. of Urology, Hamburg/Saar, Germany, ²Saarland University, Malteser Hospital Bonn/Rhein-Sieg, Dept. of Urology, Homburg/Saar, Bonn, Germany, ³Saarland University, Dept. of Urology, Hamburg/Saarr, Germany

226  
Comparison of outcomes in salvage robot-assisted laparoscopic prostatectomy for post-primary radiation vs. ablation therapies

By: Önoğlu F. ⁴, Bhat S. ¹, Rogers T. ¹, Ganapathi H. ¹, Jenson C. ¹, Rocco B. ², Patel V. ¹
¹Florida Hospital Global Robotics Institute, Dept. of Urology, Celebration, United States of America, ²University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy
### Complex kidney and adrenal surgery

**Video Session 04**

**Friday 15 March**

**14:15 - 15:45**

| Location: | Green Area, Room 10 |
| Chairs: | To be confirmed M. Musquera Felip, () To be confirmed |

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

---

**V24**

**Removal of the tumor thrombus from the right atrium without extracorporeal circulation: Emphasis on the displacement of the tumor apex**

By: Shchukin D.¹, Lesoyov V.¹, Khareba G.¹, Harahatyi A.¹, Polyakov M.¹, Stetsyshyn R.², Mozzhakov P.¹

¹Kharkiv National Medical University, Dept. of Urology, Nephrology and Andrology, Kharkiv, Ukraine, ²Kharkiv Medical Academy of Postgraduate Education, Dept. of General, Pediatric and Oncological Urology, Kharkiv, Ukraine

---

**V25**

**En bloc removal of left renal cell carcinoma and cavo-atrial thrombosis with an intra-abdominal approach using liver transplantation techniques**

By: Urbani L.¹, Roffi N.¹, Baldesi R.², Tesi L.², Signori S.¹, Selli C.²

¹Pisa Hospitals, Dept. of Surgery, Section of Liver Metastasis Parenchyma-Sparing Surgery, Pisa, Italy, ²University of Pisa, Dept. of Translational Research, Section of Urology, Pisa, Italy

---

**V26**

**Indocyanine green guided robot assisted radical nephrectomy and level III inferior vena cava tumor thrombectomy**


Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

---

**V27**

**Latrogenic complications during robotic surgery: Lessons learnt**

By: Mandal A.K.¹, Mavuduru R.S.¹, Bora G.S.¹, Jain V.², Singh S.K.¹

¹PGIMER Chandigarh, Dept. of Urology, Chandigarh, India, ²PGIMER Chandigarh, Dept. of Gynaecology, Chandigarh, India

---

**V28**

**3D laparoscopic cavoraphy solutions for controlling vena cava during the surgical treatment of T3b renal tumors**

By: Petru? B.¹, Bujoreanu E.C.¹, Hârdo V.V.¹, Mari? C.V.¹, Munteanu V.C.¹, Schi?cu V.H.¹, Maghiar T.²
Robot Assisted Retroperitoneal lymphadenectomy in patient with type 1 papillary renal cancer recurrence after 5 years of follow-up

By: Al Salhi Y.¹, Pastore A.L.¹, Fuschi A.¹, Velotti G.¹, Capone L.¹, Martoccia A.¹, Artibani W.², Carbone A.¹

¹Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Latina, Italy, ²University of Verona, Dept. of Urology, Verona, Italy
227

**Mix methods approach to determine patients’ perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy for bladder cancer surveillance**

By: Tan W.S. 1, Teo C.H. 2, Chan D. 2, Heinrich M. 3, Feber A. 1, Sarpong R. 1, Allan J. 1, Williams N. 1, Brew-Graves C. 1, Ng C.J. 2, Kelly J. 1

1University College London, Dept. of Urology, London, United Kingdom, 2University of Malaya, Dept. of Primary Care Medicine, Kuala Lumpur, Malaysia, 3University College London, Health Behaviour Research Centre, Department of Epidemiology and Public Health, London, United Kingdom

228

**A urine assay to triage patients with hematuria for cystoscopy**


1Erasmus University Medical Center, Dept. of Pathology, Rotterdam, Netherlands, The, 2Erasmus University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, 3Haga Teaching Hospital, Dept. of Urology, The Hague, Netherlands, The, 4Harbour Hospital, Dept. of Urology, Rotterdam, Netherlands, The, 5Franciscus Hospital, Dept. of Urology, Rotterdam, Netherlands, The, 6Amphia Hospital, Dept. of Urology, Breda, Netherlands, The, 7IJselland Hospital, Dept. of Urology, Rotterdam, Netherlands, The, 8MDxHealth, Dept. of R&D, Irvine, United States of America, 9Erasmus University Medical Center, Dept. of Public Health, Rotterdam, Netherlands, The, 10University of Ghent, Faculty of Biosciences, Ghent, Belgium

229

**Prediction of tumor recurrence in patients in follow up for bladder cancer with suspicious urinary cytology using molecular and cytogenetic approaches**

By: Montalbo R. 1, Ingelmo-Torres M. 1, Izquierdo L. 1, Montadas J. 1, Sole M. 2, Franco A. 1, Ribal M.J. 1, Alcaraz A. 1, Mengual L. 1

1Hospital Clinic / IDIBAPS, Dept. of Urology, Barcelona, Spain, 2Hospital Clinic / IDIBAPS, Dept. of Pathology, Barcelona, Spain
Xpert bladder cancer monitor in the follow up of patients affected by non muscle invasive bladder cancer (NMIBC): An update

By: D'Elia C. 1, Trenti E. 1, Pycha A. 2, Mian C. 3, Schwienbacher C. 3, Hanspeter E. 3, Pycha A. 1

1Central Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, 2Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 3Central Hospital of Bolzano, Dept. of Pathology, Bolzano, Italy

TOF-MS based urine DNA methylation classifier: A fast and effective technique for non-invasive diagnosis and monitoring of bladder cancer

By: Xu C. 1, Jian-Bing F. 2, Darryl Luke I. 3, Ming H. 1, Chanjuan W. 4, Zeyu J. 2, Meng Y. 2, Jingtong Z. 1, Xia L. 2, Yu Z. 3, Tianxin L. 5

1Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China, 2AnchorDx Medical Co., Ltd., Guangzhou, China, 3Agena Bioscience, Inc., San Diego, United States of America, 4Southern Medical University, School of Basic Medical Sciences, Guangzhou, China, 5Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China

Performance of FDA/EMA approved PD-L1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab


1University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Pathology, Erlangen, Germany, 2Ruprecht-Karls-Universität Heidelberg, Dept. of Urology, Medical Faculty Mannheim, Mannheim, Germany, 3Ruprecht-Karls-Universität Heidelberg, Institute of Pathology, Medical Faculty Mannheim, Mannheim, Germany, 4STRATIFYER Molecular Pathology, Cologne, Germany, 5University Hospital, Friedrich-Alexander Universität Erlangen-Nürnberg, Dept. of Urology and Paediatric Urology, Erlangen, Germany, 6University Hospital, University of Regensburg, Dept. of Urology, Regensburg, Germany, 7TU Munich, Institute of Pathology, Munich, Germany, 8University Hospital, University of Ulm, Dept. of Urology, Ulm, Germany

High diagnostic efficacy of 5-aminolevulinic acid induced fluorescence urine cytology for urothelial carcinoma

By: Yamamichi G. 1, Nakata W. 1, Tani M. 1, Tsujimura G. 1, Tsujimoto Y. 1, Nin M. 1, Mimura A. 2, Miwa H. 3, Tsujihata M. 1

1Osaka Rosai Hospital, Dept. of Urology, Sakai, Japan, 2Osaka Rosai Hospital, Laboratory Medicine, Sakai, Japan, 3Osaka Rosai Hospital, Dept. of Pathology, Sakai, Japan

mRNAs detection in urinary extracellular vesicles as diagnostic markers of non-muscle invasive bladder cancer
235 Low coverage copy number profiling of urinary sediments DNAs for bladder cancer molecular diagnostics


1Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China, 2Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Cellular & Molecular Diagnostics Center, Guangzhou, China, 3Yikon Genomics, Dept. of Clinical Research, Shanghai, China

236 A non-invasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade


1University of Zurich, Dept. of Urology, Zurich, Switzerland, 2Sinai Health System, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, 3University of Florence, Dept. of Urology, Florence, Italy, 4University Health Network, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada, 5University Health Network, Dept. of Biostatistics, Toronto, Canada, 6Sinai Health System, Dept. of Surgery, Division of Urology, Toronto, Canada, 7University of Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland, 8Capital District Health Authority, Dept. of Urology, Halifax, Canada, 9University Hospital of Liege, Dept. of Urology, Liege, Belgium, 10University Health Network, Dept. of Pathology, Toronto, Canada, 11Sinai Health System, Dept. of Surgery, Division of Urology, Toronto, Canada

237 Digital holography can differentiate between bladder cancer grades

By: Haifler M., Yogev A., Goldstein O., Zisman A., Shaked N.

1Shamir Medical Center, Dept. of Urology, Beer Yaakov, Israel, 2Tel Aviv University, Biomedical Engineering, Tel Aviv, Israel

238 Photonic sensor-based detection of urinary volatile organic compounds (VOCs) bladder cancer biomarkers: A prospective study

By: Zhu S., Nabi G.

University of Dundee, School of Medicine, Dundee, United Kingdom

239 Proximity to oil refineries and risk of bladder cancer: A population-based analysis

By: Ray-Zack M., Kerr P., Shan Y., Baillargeon J., Kuo Y-F., Mehta H.
Androgen receptor mRNA expression in urothelial carcinoma of the bladder: A retrospective analysis of two independent cohorts


Friedrich-Alexander University Erlangen-Nürnberg, Dept. of Urology and Pediatric Urology, Erlangen, Germany, STRATIFYER Molecular Pathology GmbH, Dept. of Molecular Pathology, Cologne, Germany, Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, Medical Faculty Mannheim, University of Heidelberg, Dept. of Urology, Mannheim, Germany, University Hospital Ulm, Dept. of Urology and Pediatric Urology, Ulm, Germany, University of Regensburg, Dept. of Urology, Regensburg, Germany, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Dept. of Genetics, Chapel Hill, United States of America, Baylor College of Medicine, Dept. of Urology, Houston, United States of America, Friedrich-Alexander University Erlangen-Nürnberg, Dept. of Pathology, Erlangen, Germany
Networking Reception

Friday 15 March 19:30 - 21:00

Location: Red Area, eURO Auditorium 1
**Bladder cancer in the young patient: Unique aspects**

**Plenary 1**

**Saturday 16 March**

**08:15 - 10:00**

**Location:** Red Area, eURO Auditorium 1

**Chairs:**
- F.C. Burkhard, Bern (CH)
- M. Rouprêt, Paris (FR)

**Aims and objectives of this session**

In young patients with bladder cancer the physician is faced with unique aspects associated with younger age. This session focuses on special challenges such as preserving fertility and the problems of pregnancy and delivery after urinary diversion and also addresses the role of developing diagnostic and therapeutic options in the younger patient. Specific molecular aspects and pathways and perspectives in the use of systemic immunotherapy in that setting will also be discussed extensively.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 08:15 - 08:40 | Fertility in the young female patient with bladder cancer | **Setting the stage**
F.C. Burkhard, Bern (CH) |
<p>| 08:15 - 08:20 | <strong>Setting the stage</strong>                                                       | F.C. Burkhard, Bern (CH)                   |
| 08:20 - 08:30 | <strong>Surgical aspects</strong>                                                         | J. Cresswell, Middlesbrough (GB)          |
| 08:30 - 08:40 | <strong>Pregnancy and delivery: What do you need to know</strong>                         | E. Chartier-Kastler, Paris (FR)            |
| 08:40 - 09:10 | <strong>Immunotherapy in localised disease</strong>                                       |                                             |
| 08:40 - 08:55 | <strong>Beyond BCG in non-muscle invasive bladder cancer</strong>                         | A.M. Kamat, Houston (US)                   |
| 08:55 - 09:10 | <strong>Perioperative systemic immunotherapy in Muscle Invasive Bladder Cancer (MIBC): Where are we heading?</strong> | A. Necchi, Milan (IT)                       |
| 09:10 - 09:25 | <strong>Molecular aspects in young patients</strong>                                       | R. Seiler, Bern (CH)                       |
| 09:25 - 10:00 | <strong>Case-based debate</strong> No evidence of disease after neoadjuvant chemotherapy for MIBC: What next?** | M. Brausi, Modena (IT)                     |
| 09:25 - 09:30 | <strong>Case presentation</strong>                                                         | M. Brausi, Modena (IT)                     |
| 09:30 - 09:38 | <strong>Cystectomy</strong>                                                               | V. Hernández Cañas, Madrid (ES)           |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:38 - 09:46</td>
<td>Chemoradiation</td>
<td>J. Efstathiou</td>
<td>Boston (US)</td>
</tr>
<tr>
<td>09:46 - 09:54</td>
<td>Active surveillance</td>
<td>E. Solsona</td>
<td>Valencia (ES)</td>
</tr>
<tr>
<td>09:54 - 09:59</td>
<td>What can we expect from imaging?</td>
<td>V. Panebianco</td>
<td>Rome (IT)</td>
</tr>
<tr>
<td>09:59 - 10:00</td>
<td>Summary</td>
<td>M. Brausi</td>
<td>Modena (IT)</td>
</tr>
</tbody>
</table>
**Nightmare session: Stones**

**Plenary 2**

**Saturday 16 March**
**08:15 - 10:00**

**Location:** Red Area, eURO Auditorium 2

**Chairs:**
- T. Knoll, Sindelfingen (DE)
- T.S. O’Brien, London (GB)

**Aims and objectives of this session**
Stones are everywhere. No urology unit can afford not to treat stones. Treatment has become a minimally-invasive daily business with low morbidity. However, pitfalls are everywhere and complications where nobody expects them are disappointing for urologists and patients. We will discuss some routine procedures leading to significant issues to identify risk factors and preventive strategies.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 - 08:50</td>
<td><strong>Case-based debate</strong> The forgotten stent</td>
</tr>
<tr>
<td>08:15 - 08:20</td>
<td><strong>Case presentation</strong></td>
</tr>
<tr>
<td></td>
<td>Davidoff, Sofia (BG)</td>
</tr>
<tr>
<td>08:20 - 08:30</td>
<td><strong>Evidence</strong></td>
</tr>
<tr>
<td></td>
<td>P.J.S. Osther, Fredericia (DK)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td><strong>Cross examination</strong></td>
</tr>
<tr>
<td></td>
<td>B. Leigh, London (GB)</td>
</tr>
<tr>
<td>08:45 - 08:50</td>
<td><strong>Case solution</strong></td>
</tr>
<tr>
<td></td>
<td>Davidoff, Sofia (BG)</td>
</tr>
<tr>
<td>08:50 - 09:25</td>
<td><strong>Case-based debate</strong> Severe sepsis following ureteroscopy</td>
</tr>
<tr>
<td>08:50 - 08:55</td>
<td><strong>Case presentation</strong></td>
</tr>
<tr>
<td></td>
<td>M. Fiedler, Heilbronn (DE)</td>
</tr>
<tr>
<td>08:55 - 09:05</td>
<td><strong>Evidence</strong></td>
</tr>
<tr>
<td></td>
<td>J. Denstedt, London, Ontario (CA)</td>
</tr>
<tr>
<td>09:05 - 09:20</td>
<td><strong>Cross examination</strong></td>
</tr>
<tr>
<td></td>
<td>B. Leigh, London (GB)</td>
</tr>
<tr>
<td>09:20 - 09:25</td>
<td><strong>Case solution</strong></td>
</tr>
<tr>
<td></td>
<td>M. Fiedler, Heilbronn (DE)</td>
</tr>
<tr>
<td>09:25 - 10:00</td>
<td><strong>Case-based debate</strong> Bowel injury following percutaneous nephrolithotomy</td>
</tr>
<tr>
<td>09:25 - 09:30</td>
<td><strong>Case presentation</strong></td>
</tr>
<tr>
<td></td>
<td>L.B. Dragoș, Timisoara (RO)</td>
</tr>
<tr>
<td>09:30 - 09:40</td>
<td><strong>Evidence</strong></td>
</tr>
<tr>
<td></td>
<td>C.C. Seitz, Vienna (AT)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>09:40 - 09:55</td>
<td>Cross examination</td>
</tr>
<tr>
<td>09:55 - 10:00</td>
<td>Case solution</td>
</tr>
</tbody>
</table>
Aims and objectives of this session
The ESU Course on testicular cancer will cover all important issues in the diagnosis and treatment of patients with germ cell cancer. There will be time for discussion during and after the presentations. Case reports will be discussed to highlight special situations of controversy. In addition, short video clips will be presented to demonstrate surgical techniques in retroperitoneal residual tumour resection.

In brief, following items will be presented and discussed:
- EAU Guideline recommended staging procedures an classifications like IGCCCG.
- Stage-by-stage treatment of low stage disease including TIN.
- Chemotherapy and indication of post chemotherapy surgery according to EAU guidelines.
- Recommended follow-up investigations, long-term toxicities, 2nd malignancies.

Testicular cancer
ESU Course 04

Location: Green Area, Room 13
Chair: P. Albers, Düsseldorf (DE)

Testis cancer - Early stages
N.W. Clarke, Manchester (GB)

Testis cancer - Case discussion
N.W. Clarke, Manchester (GB)

Testis cancer - Advanced stages
P. Albers, Düsseldorf (DE)

Testis cancer - Case discussion
P. Albers, Düsseldorf (DE)
Aims and objectives of this session
• The course aims to address the multiplicity of treatment options for small renal masses.
• Essential concepts to guide the clinical decision making process will be interactively discussed with the help of clinical cases.
• Practical tips for a safe and effective treatment delivery will be provided on the current standard of ablative therapies and minimally invasive surgery.
• Attendees should become familiar on when and how to propose active surveillance in their daily clinical practice.

Introduction
P. Gontero, Turin (IT)

Active surveillance and ablative therapies: When and how
P. Gontero, Turin (IT)

Minimally invasive surgery: Tips and tricks
F. Keeley, Bristol (GB)

How to choose the best treatment for SRM: A clinical case based approach
P. Gontero, Turin (IT)
F. Keeley, Bristol (GB)
### Renal transplantation: Technical aspects, diagnosis and management of early and late urological complications

**ESU Course 02**

**Location:** Green Area, Room 15

**Chair:** F.J. Burgos Revilla, Madrid (ES)

**Aims and objectives of this session**
Renal transplant is an essential part of urology. The aims of the course are:

- To show surgical techniques of organ procurement in deceased and living donation settings.
- To establish the basic principles for evaluation of candidates to donation and recipients of kidney graft.
- To show the different approaches and surgical details of kidney transplant in conventional and complex recipients.
- To review the algorithms for diagnosis and treatment of medical and surgical complications after kidney transplantation.

---

**Selection and urological preparation of transplant recipients. Surgical aspects of deceased donor nephrectomy**
A.J. Figueiredo, Coimbra (PT)

**Living donor nephrectomy: Technical alternatives and controversies**
F.J. Burgos Revilla, Madrid (ES)

**Renal transplantation. Surgical options: Tips and tricks**
A.J. Figueiredo, Coimbra (PT)

**How to diagnose and manage postoperative and long-term complications following renal transplantation**
F.J. Burgos Revilla, Madrid (ES)
Aims and objectives of this session
Understand how to construct a well written introduction and methods section for your manuscript. Learn how to work through examples of good and bad practices, and understand key points when writing. Obtain insight from editors on what they expect to see.

- To understand what makes good introduction.
- To understand what makes a good methods section.
- To understand about systematic reviews and meta-analysis.
- To learn from experienced editors.

Welcome
J.W.F. Catto, Sheffield (GB)

Writing the introduction
M.R. Cooperberg, San Francisco (US)

How to write the methods section
M. Albersen, Leuven (BE)

Key features for a systematic review
G. Novara, Padova (IT)

What to look for in the statistics section
To be confirmed
Aims and objectives of this session
Urolithiasis is an increasingly prevalent worldwide disease with recurrence rates up to 50% over 5 years. Metabolic assessment to identify predisposing factors and prevention therefore play an important role in patient management. This course will address common findings on dietary and metabolic workup and highlight medical and non-medical treatment options for these metabolic abnormalities in the prevention of stone recurrence.

The goal of the course is for participants to be able to
• identify patients that would benefit from metabolic workup.
• interpret standard metabolic workup, including dietary and medical history and biochemical analyses.
• understand what the guidelines say on targeted medical treatment for prevention of urinary stone disease.
• understand the influence of dietary changes on metabolic urinary values and provide dietary counseling.
Prosthetic surgery in urology
ESU Course 06

Location: Green Area, Room 22
Chair: A. Muneer, London (GB)

Aims and objectives of this session
An increasing number of urological surgeons are developing a surgical practice which involves prosthetic surgery. This course will aim to cover the key areas of prosthetic surgery in urology with the aid of a video based platform. The course is aimed at urological trainees as well as established urologists wishing to develop a practice or gain an update and surgical tips in this area.

Surgical techniques with the aid of semi-live surgery will be a key focus of this course. At the end of the course participants should have a good understanding of:

• Minimising the risk of prosthesis infection and understand the role of biofilms
• Theatre preparation and set up for prosthetic surgery
• Patient selection and prosthetic surgery for male and female urinary incontinence including artificial urinary sphincters and sacral neuromodulation
• Penile prosthesis surgery – surgical techniques, avoiding complications and revision surgery

Introduction to biofilms and prosthetic infections
A. Muneer, London (GB)

Theatre set up and preparation of patients
A. Muneer, London (GB)

Prosthetic surgery for male urinary incontinence - Male slings and AUS
S. Malde, London (GB)

Prosthetic surgery for female urinary incontinence
S. Malde, London (GB)

Penile prosthesis surgery – surgical technique and avoiding complications
A. Muneer, London (GB)

Dealing with intraoperative complications and penile prosthesis revision surgery
A. Muneer, London (GB)
Aims and objectives of this session

• Provide an update on recent imaging techniques like TRUS, Elastography, Histoscanning, multiparametric magnetic resonance imaging (mpMRI) and nuclear imaging techniques for prostate cancer diagnosis.
• Explain standard reporting systems for ultrasound and mpMRI like PI-RADS.
• Discuss different prostate biopsy techniques.
• Tips and Tricks to reduce morbidity of prostate biopsies.

Indications for TRUS and biopsy
P. Hammerer, Braunschweig (DE)

Practical aspects of TRUS and TRUS-guided biopsies
P. Hammerer, Braunschweig (DE)

Indications for rebiopsy
C. Moore, London (GB)

Update on new technical developments
C. Moore, London (GB)
<table>
<thead>
<tr>
<th><strong>ESU/ESFFU Hands-on Training Course in Urodynamics</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saturday 16 March</strong></td>
<td><strong>Location:</strong> Green Area, Room 7</td>
</tr>
<tr>
<td><strong>09:30 - 12:30</strong></td>
<td><strong>Chair:</strong> To be confirmed</td>
</tr>
<tr>
<td><strong>Chair:</strong> To be confirmed</td>
<td><strong>Tutor:</strong> To be confirmed</td>
</tr>
</tbody>
</table>
**Aims and objectives of this session**

In this session we introduce the European Society of Residents in Urology (ESRU) and the Young Urology Office (YUO). The main aim of this session is to offer talks tailored to residents' educational needs. We present the traditional surgical tips and tricks with all you need to know about certain surgical procedures. Furthermore, we show what residents need to know on the most recent oncological studies. Modern surgical practice requires technical and non-technical skills, as a new feature this year, we present the “soft skills session” together with the Young Endourological society. We will finish with the great finale of the EAU Guidelines Cup, a competition between the three finalists of the Cup and also the audience.

**10:00 - 10:10**

**Welcome and introduction**

J. Gómez Rivas, Madrid (ES)
J.P.M. Sedelaar, Nijmegen (NL)

**10:10 - 10:55**

**European Urology Scholarship Programme (EUSP)**

*Moderators:* F. Esperto, Sheffield (GB)
To be confirmed

**10:10 - 10:20**

**EUSP Programme; does it deserve your attention?**
M.J. Ribal, Barcelona (ES)

**10:20 - 10:28**

**EUSP Scholarship: Science in practice**
J.A. Schalken, Nijmegen (NL)

**10:28 - 10:36**

**EUSP Scholarship: Practice makes perfection**
G. Patruno, Rome (IT)

**10:36 - 10:41**

**Why it is worth to have a visiting Professor in your centre?**
To be confirmed

**10:41 - 10:45**

**Announcing the Best Scholar award winners**
To be confirmed

**10:45 - 10:48**

**Presentation Best Scholar award winner clinical research**
V.M.J. De Coninck, Paris (FR)

**10:48 - 10:51**

**Presentation Best Scholar award winner basic research**
M.D. Vartolomei, Targu Mures (RO)

**10:51 - 10:55**

**Questions and answers**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55 - 11:20</td>
<td>EAU session</td>
<td>S. Nikles, Zagreb (HR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J.L. Vásquez, Herlev (DK)</td>
</tr>
<tr>
<td>10:55 - 11:05</td>
<td>What can the EAU do for you?</td>
<td>J.P.M. Sedelaar, Nijmegen (NL)</td>
</tr>
<tr>
<td>11:05 - 11:15</td>
<td>European Board of Urology</td>
<td>A.J. Figueiredo, Coimbra (PT)</td>
</tr>
<tr>
<td>11:15 - 11:20</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>11:20 - 12:20</td>
<td>What do the residents need to know about...</td>
<td>P.B. Ostergren, Herlev (DK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Gómez Rivas, Madrid (ES)</td>
</tr>
<tr>
<td>11:20 - 11:35</td>
<td>CPRC M0. Prosper and Spartan trials</td>
<td>M. Rouprêt, Paris (FR)</td>
</tr>
<tr>
<td>11:35 - 11:50</td>
<td>M+ Renal carcinoma. CARMENA trial</td>
<td>U. Capitanio, Milan (IT)</td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td>MRI in prostate cancer. PRECISION trial</td>
<td>V. Kasivisvanathan, London (GB)</td>
</tr>
<tr>
<td>12:05 - 12:20</td>
<td>Upper Tract Carcinoma. POUT trial</td>
<td>S. Shariat, Vienna (AT)</td>
</tr>
<tr>
<td>12:20 - 13:30</td>
<td>Surgery tips and tricks</td>
<td>D. Duijvesz, Nijmegen (NL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T. Ucar, Istanbul (TR)</td>
</tr>
<tr>
<td>12:20 - 12:35</td>
<td>Basic penile surgery</td>
<td>M. Fisch, Hamburg (DE)</td>
</tr>
<tr>
<td>12:35 - 12:50</td>
<td>Prepubic approach to urethrectomy</td>
<td>H.P.A.M. Van Poppel, Leuven (BE)</td>
</tr>
<tr>
<td>13:05 - 13:20</td>
<td>Urgent urinary diversions</td>
<td>S. Proietti, Milan (IT)</td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td>The European School of Urology</td>
<td>J. Palou, Barcelona (ES)</td>
</tr>
<tr>
<td>13:30 - 14:25</td>
<td>Joint session with the young endourological society</td>
<td>M.E. Rodríguez Socarrás, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T. Tailly, Ghent (BE)</td>
</tr>
<tr>
<td>13:30 - 13:35</td>
<td>Introduction</td>
<td>T. Tailly, Ghent (BE)</td>
</tr>
</tbody>
</table>
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:35 - 13:45</td>
<td>Organising urological research by the young academic network: YAU</td>
<td>E. Xylinas, Paris (FR)</td>
<td></td>
</tr>
<tr>
<td>13:55 - 14:10</td>
<td>Fellowship: the perfect transition from resident to an academic position</td>
<td>P. Kallidonis, Patras (GR)</td>
<td></td>
</tr>
<tr>
<td>14:10 - 14:25</td>
<td>Dealing with stress starting your career: Stay cool and work smart</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>14:25 - 14:55</td>
<td>Challenging clinical cases</td>
<td>G. Mantica, Genoa (IT)</td>
<td>M. Taskovska, Ljubljana (SI)</td>
</tr>
<tr>
<td>14:25 - 14:45</td>
<td>Penile trauma</td>
<td>A. Van Der Merwe, Cape Town (ZA)</td>
<td></td>
</tr>
<tr>
<td>14:45 - 15:05</td>
<td>Urinary fistulas</td>
<td>N.I. Osman, Sheffield (GB)</td>
<td></td>
</tr>
<tr>
<td>15:05 - 15:50</td>
<td>New paradigms in urology</td>
<td>D.M. Carrion, Madrid (ES)</td>
<td>D Karsza, Budapest (HU)</td>
</tr>
<tr>
<td>15:05 - 15:20</td>
<td>New diagnostic imaging in Upper Tract Urothelial Carcinoma (UTUC)</td>
<td>J. Baard, Amsterdam (NL)</td>
<td></td>
</tr>
<tr>
<td>15:20 - 15:35</td>
<td>Robotic renal transplant</td>
<td>A. Breda, Barcelona (ES)</td>
<td></td>
</tr>
<tr>
<td>15:35 - 15:50</td>
<td>New robots</td>
<td>D. Veneziano, Reggio Calabria (IT)</td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:50</td>
<td>Guidelines cup</td>
<td>G. Dosin, Bruxelles (BE)</td>
<td>J.L. Vásquez, Herlev (DK)</td>
</tr>
<tr>
<td>15:50 - 16:50</td>
<td>Guideline masters</td>
<td>M. Albersen, Leuven (BE)</td>
<td>T.A.T. Marcelissen, Maastricht (NL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M.J. Ribal, Barcelona (ES)</td>
<td></td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td>Prices and awards</td>
<td>J. Gómez Rivas, Madrid (ES)</td>
<td>J.P.M. Sedelaar, Nijmegen (NL)</td>
</tr>
</tbody>
</table>
New medical and surgical options in andrological treatment: From molecular biology to surgery and from philosophy to ethics
Meeting of the EAU Section of Andrological Urology (ESAU)

Saturday 16 March
10:00 - 14:00

Location: Green Area, Room 3
Chair: N. Sofikitis, Ioannina (GR)

Aims and objectives of this session
The main objective of the meeting of the EAU Section of the European Section of andrological urology is to provide the latest information on several controversial issues and unanswered questions in the fields of male infertility, male endocrinology, and sexual medicine. Video presentations will assist the participants to pick up the tips and tricks of several surgical procedures in the male genital tract as take home-messages. Time-lapse cinematography of embryological development will raise an important role for the male gamete-DNA beyond fertilisation susceptible to philosophical considerations. Emphasis will be given to the molecular biology- basis of several andrological pathophysiologies. Novel surgical techniques, ethical barriers, and physiological consequences of disputable and criticised procedures such as penile elongation/penile enlargement and gender reassignment surgery will be discussed. The role of the andrologist in the oncological clinics will be promoted. In addition this meeting will provide compelling evidence for the unique role of testosterone as a source of youth for the male. Discussion of interesting case reports will give the opportunity for an active interaction between the faculty members and the participants.

10:00 - 10:01 Welcome and introduction
N. Sofikitis, Ioannina (GR)

10:01 - 10:10 State-of-the-art lecture Penile rehabilitation after radical prostatectomy: Where we are today?
Moderators: J. Rassweiler, Heilbronn (DE)
J.I. Martínez Salamanca, Majadahonda (ES)
Speaker: F. Montorsi, Milan (IT)

10:10 - 10:28 Debate Penile elongation and enlargement surgery: Should we do it?
Moderators: O. Apolikhin, Moscow (RU)
M.M. Fode, Herlev (DK)
Pro: D.J. Ralph, London (GB)
Con: C. Bettocchi, Bari (IT)

10:28 - 10:55 Challenges in andrology
Moderators: S. Pahernik, Nuremberg (DE)
J.O.R. Sønksen, Herlev (DK)

10:28 - 10:37 Early or delayed penile implant insertion in low flow priapism
P.A.S. Vendeira, Matosinhos (PT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Location</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:37 - 10:46</td>
<td>Can male infertility serve as an indicator of male health status?</td>
<td>A. Salonia, Milan</td>
<td>(IT)</td>
</tr>
<tr>
<td>10:46 - 10:55</td>
<td>Asymptomatic infections in the male reproductive tract: Consequences</td>
<td>S. Kliesch, Münster</td>
<td>(DE)</td>
</tr>
<tr>
<td></td>
<td>on male fertility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:55 - 11:16</td>
<td>Surgery in motion: Sexual medicine</td>
<td>O. Apolikhin, Moscow</td>
<td>(RU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M.F. Usta, Antalya</td>
<td>(TR)</td>
</tr>
<tr>
<td>10:55 - 11:03</td>
<td>Video presentation Prevention and treatment of the infected penile</td>
<td>E. Ruiz-Castañé,</td>
<td>Barcelona (ES)</td>
</tr>
<tr>
<td></td>
<td>prosthesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:03 - 11:11</td>
<td>Video presentation Advances in reconstructive surgery in Peyronie's</td>
<td>A. Kadioglu,</td>
<td>Istanbul (TR)</td>
</tr>
<tr>
<td></td>
<td>disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:11 - 11:16</td>
<td>Video presentation The difficult penile implant</td>
<td>P. Egydio, Sao Paulo</td>
<td>(BR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Takenaka, Yonago</td>
<td>(JP)</td>
</tr>
<tr>
<td>11:16 - 11:26</td>
<td>Urethral reconstruction and sexual function</td>
<td>R. Wang, San Antonio</td>
<td>(US)</td>
</tr>
<tr>
<td>11:26 - 11:36</td>
<td>Stem cell therapies in erectile dysfunction: Is it too early or too</td>
<td>M. Albersen,</td>
<td>Leuven (BE)</td>
</tr>
<tr>
<td></td>
<td>risky?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:36 - 11:54</td>
<td>Testosterone as a source of youth for the male</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Verze, Naples</td>
<td>(IT)</td>
</tr>
<tr>
<td>11:36 - 11:45</td>
<td>Controversies of the effects of testosterone treatment on</td>
<td>A. Giwercman,</td>
<td>Malmö (SE)</td>
</tr>
<tr>
<td></td>
<td>cardiovascular events</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45 - 11:54</td>
<td>How much evidence is available for the treatment of late-onset male</td>
<td>G.R. Dohle,</td>
<td>Rotterdam (NL)</td>
</tr>
<tr>
<td></td>
<td>hypogonadism?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:54 - 12:30</td>
<td>Surgery of the testis and male infertility</td>
<td>C-C. Abbou, Créteil</td>
<td>(FR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.S. Minhas, London</td>
<td>(GB)</td>
</tr>
<tr>
<td>11:54 - 12:03</td>
<td>Do we need robotic surgery in andrology?</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>12:03 - 12:12</td>
<td>Are there any indications for varicocele repair beyond the EAU</td>
<td>S.S. Minhas,</td>
<td>(GB)</td>
</tr>
<tr>
<td></td>
<td>Guidelines?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
12:12 - 12:21
Is there a role for salvage testicular sperm extraction in the setting of a negative sperm retrieval?
M. Dinkelman-Smit, Rotterdam (NL)

12:21 - 12:30
Onco-testicular sperm extraction (onco-TESE): Indications, outcomes, and effects on testicular endocrine function
F. Fusco, Naples (IT)

12:30 - 12:48
Surgery in motion: Male infertility
Moderators: T. Diemer, Giessen (DE) F. Dimitriadis, Kalamaria, Thessaloniki (GR)

12:30 - 12:38
Video presentation Microdissection TESE, TESA, and MESA: How do I do it?
W. Huang, Taipei (TW)

12:38 - 12:43
Video presentation Real-time observation of varicocele-induced effects on early embryonic development by lapse cinematography
N. Sofikitis, Ioannina (GR)

12:43 - 12:48
Video presentation Tips and tricks in the identification of the testicular artery during varicocele repair
S. Çayan, Mersin (TR)

12:48 - 13:06
Debate Varicocelectomy prior to Assisted Reproductive Technology (ART)
Moderators: M. Fujisawa, Kobe (JP) F. Fusco, Naples (IT)
Pro: T. Diemer, Giessen (DE)
Con: Z. Kopa, Budapest (HU)

13:06 - 13:24
Gender reassignment surgery: Complications and outcomes
Moderators: D.J. Ralph, London (GB) O. Yaman, Ankara (TR)

13:06 - 13:15
Vaginoplasty: Tips and tricks for aesthetic outcome
To be confirmed

13:15 - 13:24
Phalloplasty: Which is the patient’s preferred technique?
R. Djinovic, Belgrade (RS)

13:24 - 13:42
Debate Collagenase for the treatment of Peyronie’s disease
Moderators: D. Hatzichristou, Thessaloniki (GR) A. Muneer, London (GB)
Pro: D.J. Ralph, London (GB)
Con: I. Moncada, Madrid (ES)

13:42 - 13:59
My most challenging andrological case
Panel: P. Egydio, Sao Paulo (BR) A. Kadioglu, Istanbul (TR) M.F. Usta, Antalya (TR) R. Wang, San Antonio (US)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:42 - 13:45</td>
<td>Case presentation 1</td>
<td>R. Wang</td>
<td>San Antonio (US)</td>
</tr>
<tr>
<td>13:45 - 13:48</td>
<td>Case presentation 2</td>
<td>M.F. Usta</td>
<td>Antalya (TR)</td>
</tr>
<tr>
<td>13:48 - 13:51</td>
<td>Case presentation 3</td>
<td>P. Egydio</td>
<td>Sao Paulo (BR)</td>
</tr>
<tr>
<td>13:51 - 13:59</td>
<td>Panel discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:59 - 14:00</td>
<td>Closing remarks</td>
<td>N. Sofikitis</td>
<td>Ioannina (GR)</td>
</tr>
</tbody>
</table>
### Management of urinary stones: Where are we in 2019?

**Meeting of the EAU Section of Urolithiasis (EULIS)**

**Location:** Green Area, Room 5  
**Chair:** K. Sarica, Istanbul (TR)

**Aims and objectives of this session**

Treatment concepts in the contemporary management of stone disease have considerably changed in the last two decades in the light of the remarkable technological advances, coupled with increased experience in both adults and children. Clinical introduction of new treatment methods along with the effective use of disposable instruments led us to change our existing treatment policies in order to ease the procedures with acceptable "stone free" rates and limited or no complications. Management of stones in certain patient populations requiring special expertise will be demonstrated and discussed during semi-live video presentations by experienced surgeons. Thus, in this EULIS session we will take a close look at the recent developments, particularly new minimally invasive stone treatment procedures in complex cases. Additionally, we will try to focus on the importance of experience with tips and tricks from the experts to increase stone-free rates and limit well-known complications. The possible introduction of new treatment concepts and/or new future treatment modalities that can further minimize the invasiveness and increase patient acceptance will also be discussed in detail.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:00 - 10:05      | Welcome and introduction  
K. Sarica, Istanbul (TR)  |
| 10:05 - 10:45      | Pathophysiology and non-surgical management of stones: What’s new?  
**Moderators:**  
G. Gambaro, Rome (IT)  
J.P. Haymann, Paris (FR)  
D.J. Kok, Oegstgeest (NL)  
R.J. Unwin, London (GB)  |
| 10:05 - 10:15      | The renal papilla and kidney stone formation: Where are we in 2019?  
D. Lange, Vancouver (CA)  |
| 10:15 - 10:25      | Urolithiasis as a systemic disorder: What are the hypotheses?  
K. Sarica, Istanbul (TR)  |
| 10:25 - 10:35      | Dietary management of urinary stones: Tips and tricks based on stone composition  
P.M. Ferraro, Rome (IT)  |
| 10:35 - 10:45      | Herbal treatments for renal stones: Myth or fact  
S. Al-Hayek, Cambridge (GB)  |
| 10:45 - 11:33      | Video session 1: Percutaneous management of 1-2 cm renal stones – How I do it  
**Moderators:**  
M. Cepeda, Valladolid (ES)  
P.A. Geavlete, Bucharest (RO)  
A. Papatsoris, Athens (GR)  
A. Szendröi, Budapest (HU)  |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 10:57</td>
<td>Video presentation <strong>Mini-PNL</strong></td>
<td>S. Lahme, Pforzheim (DE)</td>
</tr>
<tr>
<td>10:57 - 11:09</td>
<td>Video presentation <strong>Ultra-mini PNL</strong></td>
<td>U. Nagele, Hall in Tirol (AT)</td>
</tr>
<tr>
<td>11:09 - 11:21</td>
<td>Video presentation <strong>Super-mini PNL</strong></td>
<td>G.H Zeng, Guangzhou (CN)</td>
</tr>
<tr>
<td>11:21 - 11:33</td>
<td>Video presentation <strong>Flexible URS</strong></td>
<td>T. Knoll, Sindelfingen (DE)</td>
</tr>
<tr>
<td>11:33 - 11:43</td>
<td><strong>Late breaking news TISU: A randomised trial of ESWL vs URS</strong></td>
<td>S. McClinton, Aberdeen (GB)</td>
</tr>
<tr>
<td>11:43 - 12:03</td>
<td><strong>Lasers for stones: What is new?</strong></td>
<td>E. Cicerello, Treviso (IT)</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong></td>
<td>C.C. Seitz, Vienna (AT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.P. Zanetti, Milan (IT)</td>
</tr>
<tr>
<td>11:43 - 11:53</td>
<td><strong>Impact of laser settings on lithotripsy performance</strong></td>
<td>A. Miernik, Freiburg (DE)</td>
</tr>
<tr>
<td>11:53 - 12:03</td>
<td><strong>New lasers for stone treatment in 2020: What can we expect?</strong></td>
<td>O. Traxer, Paris (FR)</td>
</tr>
<tr>
<td>12:03 - 12:15</td>
<td>Video presentation <strong>Paediatric lower calyceal stone – Micro PNL</strong></td>
<td>M. Straub, Munich (DE)</td>
</tr>
<tr>
<td>12:15 - 12:27</td>
<td>Video presentation <strong>Large and complex renal stone: Upper pole approach in supine position</strong></td>
<td>M.I. Gökce, Ankara (TR)</td>
</tr>
<tr>
<td>12:27 - 12:39</td>
<td>Video presentation <strong>Large renal pelvic stone ( &gt;20 mm): FURS without access sheath</strong></td>
<td>R. Cansino, Madrid (ES)</td>
</tr>
<tr>
<td>12:39 - 12:51</td>
<td>Video presentation <strong>Pediatric large renal stone ( &gt;15 mm): Standard PNL</strong></td>
<td>B. Önal, Istanbul (TR)</td>
</tr>
<tr>
<td>12:51 - 13:11</td>
<td><strong>Sepsis after endourologic management of stones: How to minimise the risk</strong></td>
<td>J.P. Caballero Romeu, Alicante (ES)</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong></td>
<td>L. Villa, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. Prezioso, Naples (IT)</td>
</tr>
<tr>
<td>12:51 - 13:01</td>
<td><strong>Pre-, intra- and post-op work-up in infections in stones</strong></td>
<td>E. Montanari, Milan (IT)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 13:01 - 13:11 | Intra-renal pressure during retrograde and percutaneous stone treatment: The effect of miniaturisation  
A. Hoznek, Creteil (FR) |
*Moderators:* J. Galán-Llopis, Alicante (ES)  
F. Sanguedolce, Barcelona (ES)  
C. Türk, Vienna (AT)  
G. Wendt-Nordahl, Sindelfingen (DE) |
| 13:11 - 13:21 | Disposable URS: Suitable for stones?  
A. Budía Alba, Valencia (ES) |
| 13:11 - 13:21 | Which role does anatomy play for PNL?  
To be confirmed |
| 13:21 - 13:31 | A unique tool in order to intraoperatively tailor the best procedure on the patient with stone disease for a maximally safe and effective treatment  
C.M. Scoffone, Turin (IT) |
S. Hruby, Zell am See (AT) |
| 13:46 - 13:56 | Development of a training curriculum for percutaneous renal surgery  
K. Ahmed, London (GB) |
| 13:56 - 14:00 | Closing remarks  
K. Sarica, Istanbul (TR) |
Prepare for the future: Prevent, detect, strike back!
Joint meeting of the EAU Section of Infections in Urology (ESIU) and the EAU Section of Urological Imaging (ESUI)

Saturday 16 March
10:00 - 14:00
Location: Green Area, Room 10
Chairs: G. Salomon, Hamburg (DE)
        F.M.E. Wagenlehner, Giessen (DE)

Aims and objectives of this session
Get prepared for the future: This joined session of ESIU and ESUI will handle the dilemma of increasing antibiotic resistance, what to expect and what to do. The impact of increasing antibiotic resistance on infectious complications after prostate biopsies will be highlighted. If or how imaging can help to avoid prostatic biopsies, and if imaging can in anyway help in chronic systemic infections. In addition the hottest topics in imaging (PIRADS v3 and radioguided surgery) will be presented followed by the antimicrobial stewardship course, which will be finalised with a certificate following an online exam. During the session, the prize giving ceremony for the 2019 ESUI vision award will be held, followed by the presentation of the awarded study.

10:00 - 10:05
Welcome and introduction
G. Salomon, Hamburg (DE)
F.M.E. Wagenlehner, Giessen (DE)

10:05 - 10:50
The dilemma of increasing antibiotic resistance in the prostate
Moderators: T.E. Bjerklund Johansen, Oslo (NO)
            V. Scattoni, Milan (IT)

10:05 - 10:20
Increasing prevalence of biopsy-related complications and increasing incidence of antibiotic resistance
To be confirmed

10:20 - 10:35
Rectal preparations: Evidence and clinical practice
A. Pilatz, Giessen (DE)

10:35 - 10:50
Targeted prophylaxis: What you need to know
T. Cai, Trento (IT)

10:50 - 12:20
Decreasing the risk of biopsy-related complications by imaging
Moderators: M. Ritter, Mannheim (DE)
            A. Villers, Lille (FR)

10:50 - 11:05
Does the mpMRI help avoid unnecessary biopsies?
A. Villers, Lille (FR)

11:05 - 11:20
Will sophisticated ultrasound be the future?
J. Walz, Marseille (FR)

11:20 - 11:35
Better go transperineal?
V. Mouraviev, Davenport (US)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:35 - 11:50</td>
<td>Time for transrectal biopsy is NOT over!</td>
<td>V. Scattoni, Milan (IT)</td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td>Better be prepared! Standards and recommendations for antibiotic prophylaxis in transrectal prostate biopsy</td>
<td>G. Bonkat, Basel (CH)</td>
</tr>
<tr>
<td>12:05 - 12:20</td>
<td>What to do if acute systemic infection results after prostate biopsy?</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>12:20 - 12:50</td>
<td>ESUI Hot topics</td>
<td>L. Budäus, Hamburg (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M.C. Kriegmair, Mannheim (DE)</td>
</tr>
<tr>
<td>12:35 - 12:50</td>
<td>Will radio-guided surgery will become state of the art?</td>
<td>T. Maurer, Hamburg (DE)</td>
</tr>
<tr>
<td>12:50 - 13:05</td>
<td>ESUI Vision Award</td>
<td>G. Salomon, Hamburg (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Mischi, Eindhoven (NL)</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>Title To be confirmed</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>13:00 - 13:05</td>
<td>Award</td>
<td></td>
</tr>
<tr>
<td>13:05 - 13:35</td>
<td>Antimicrobial stewardship course (ABS): An ABS update (ABS certificates)</td>
<td>T. Perepanova, Moscow (RU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Wullt, Helsingborg (SE)</td>
</tr>
<tr>
<td>13:05 - 13:20</td>
<td>How to reduce antibiotic administrations</td>
<td>R. Bartoletti, Pisa (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Kulchavenya, Novosibirsk (RU)</td>
</tr>
<tr>
<td>13:45 - 13:55</td>
<td>What is the best management</td>
<td>J. Medina-Polo, Madrid (ES)</td>
</tr>
<tr>
<td>13:55 - 14:00</td>
<td>Closing remarks</td>
<td>G. Salomon, Hamburg (DE)</td>
</tr>
</tbody>
</table>
Scientific Programme - EAU19 Barcelona

F.M.E. Wagenlehner, Giessen (DE)
| Location:  | Green Area, Room 8 |
| Chair:     | To be confirmed   |
New modalities in diagnosis and treatment in oncology

Joint meeting of the EAU Section of Oncological Urology (ESOU), the EAU Robotic Urology Section (ERUS), the EAU Section of Uro-Technology (ESUT) and with the ECCO, EORTC GUCG, ESMO, ESSO, ESTRO and EUOG

**Aims and objectives of this session**
To give an update on diagnosis and treatment of urological malignancies. The importance of new technologies and training facilities for young European urologists will be illustrated together. Basic science advancements in oncurology will be also presented and discussed with the audience.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 - 10:20</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td></td>
<td>M. Brausi, Modena (IT)</td>
</tr>
<tr>
<td></td>
<td>E. Liatsikos, Patras (GR)</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>10:20 - 10:35</td>
<td>The European Uro-Oncology Group (EUOG)</td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>Genetics in bladder cancer</td>
</tr>
<tr>
<td></td>
<td>S. Osanto, Leiden (NL)</td>
</tr>
<tr>
<td>10:30 - 10:35</td>
<td>Discussion</td>
</tr>
<tr>
<td>10:35 - 10:50</td>
<td>The European Cancer Organisation (ECCO)</td>
</tr>
<tr>
<td>10:35 - 10:45</td>
<td>The essential requirements of quality cancer care</td>
</tr>
<tr>
<td></td>
<td>I. Banks, Spa (IE)</td>
</tr>
<tr>
<td>10:45 - 10:50</td>
<td>Discussion</td>
</tr>
<tr>
<td>10:50 - 11:05</td>
<td>The European Society for Radiotherapy &amp; Oncology (ESTRO)</td>
</tr>
<tr>
<td>10:50 - 11:00</td>
<td>Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer</td>
</tr>
<tr>
<td></td>
<td>P. Hoskin, Northwood (GB)</td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:05 - 11:20</td>
<td>The European Society for Medical Oncology (ESMO)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:05 - 11:15</td>
<td><strong>Neo-adjuvant chemotherapy and checkpoint inhibitors in muscle-invasive bladder cancer</strong>&lt;br&gt;A. Bamias, Athens (GR)</td>
</tr>
<tr>
<td>11:15 - 11:20</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>11:20 - 11:30</td>
<td><strong>New therapeutic strategies in the treatment of renal cancer</strong>&lt;br&gt;A. Bex, Amsterdam (NL)</td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>11:35 - 11:50</td>
<td><strong>The European Society of Surgical Oncology (ESSO)</strong></td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td><strong>Multidisciplinary surgical team (GS, U, Gy, RO, VS) in advanced pelvic tumours</strong>&lt;br&gt;To be confirmed</td>
</tr>
<tr>
<td>11:45 - 11:50</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>11:50 - 11:50</td>
<td><strong>ESOU-ESUR-ESUT: Advances in diagnosis and treatment of cancer</strong></td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td><strong>Training in surgery in 2018: How we can improve it?</strong>&lt;br&gt;J.W. Collins, Stockholm (SE)</td>
</tr>
<tr>
<td>12:05 - 12:10</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>12:10 - 12:25</td>
<td><strong>The role of mpMRI in prostate cancer patients eligible for active surveillance</strong>&lt;br&gt;C. Moore, London (GB)</td>
</tr>
<tr>
<td>12:25 - 12:30</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>12:30 - 12:55</td>
<td><strong>Debate</strong> <strong>Focal therapy in intermediate risk patients</strong></td>
</tr>
<tr>
<td>12:30 - 12:40</td>
<td><strong>Pro</strong>&lt;br&gt;M. Emberton, London (GB)</td>
</tr>
<tr>
<td>12:40 - 12:50</td>
<td><strong>Con</strong>&lt;br&gt;A. Heidenreich, Cologne (DE)</td>
</tr>
<tr>
<td>12:50 - 12:55</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>12:55 - 13:05</td>
<td><strong>Radical prostatectomy (open vs robotic) in oligometastatic prostate cancer</strong>&lt;br&gt;F. Montorsi, Milan (IT)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>13:05 - 13:10</td>
<td>Discussion</td>
</tr>
<tr>
<td>13:10 - 13:20</td>
<td>Robotic radical cystectomy</td>
</tr>
<tr>
<td></td>
<td>with intracorporeal diversion</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>13:20 - 13:25</td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td>preservation in muscle-invasive</td>
</tr>
<tr>
<td></td>
<td>bladder cancer</td>
</tr>
<tr>
<td>13:35 - 13:40</td>
<td>Discussion</td>
</tr>
<tr>
<td>13:40 - 14:05</td>
<td>Debate</td>
</tr>
<tr>
<td>13:40 - 13:50</td>
<td>Pro</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Con</td>
</tr>
<tr>
<td>14:00 - 14:05</td>
<td>Discussion</td>
</tr>
<tr>
<td>14:05 - 14:25</td>
<td>Debate</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>Yes</td>
</tr>
<tr>
<td>14:15 - 14:25</td>
<td>No</td>
</tr>
<tr>
<td>14:25 - 14:30</td>
<td>Discussion</td>
</tr>
<tr>
<td>14:30 - 14:55</td>
<td>Debate</td>
</tr>
<tr>
<td>14:30 - 14:40</td>
<td>Yes</td>
</tr>
<tr>
<td>14:40 - 14:50</td>
<td>No</td>
</tr>
<tr>
<td>14:50 - 14:55</td>
<td>Discussion</td>
</tr>
<tr>
<td>14:55 - 15:00</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>
Innovative surgical procedures in functional urology
Meeting of the EAU Section of Female and Functional Urology (ESFFU)

Saturday 16 March  
10:15 - 14:00

Location: Green Area, Room 1

Chair: F. Cruz, Porto (PT)

Aims and objectives of this session
Functional urology requires expertise in a large number of complex surgeries on the lower urinary tract. Along the years, many of these surgeries incorporated numerous technical advances initially applied in other fields of urology or the result of the search for minimally-invasive procedures. The main objective of this session is to review some of the surgical innovations introduced in functional urology and discuss some of the present controversies related to the minimally-invasive treatment of female stress urinary incontinence.

10:15 - 10:20
Welcome and introduction
F. Cruz, Porto (PT)

10:20 - 11:20
Robotics is arriving to functional urology
Moderators: F.C. Burkhard, Bern (CH)  
E. Chartier-Kastler, Paris (FR)

10:20 - 10:32
Colposuspension
P. Dasgupta, London (GB)

10:32 - 10:35
Discussion

10:35 - 10:47
Sacrocolpopexy and Pelvic Organ Prolapse (POP)
E.C Costantini, Perugia (IT)

10:47 - 10:50
Discussion

10:50 - 11:02
Vesicovaginal fistula repair
To be confirmed

11:02 - 11:05
Discussion

11:05 - 11:17
Benign Prostatic Hyperplasia (BPH) prostatectomy
H. John, Winterthur (CH)

11:17 - 11:20
Discussion

11:20 - 12:20
Minimally-invasive surgery in prostate
Moderators: H. Hashim, Bristol (GB)  
F. Van Der Aa, Leuven (BE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 - 11:32</td>
<td>I prefer uro-lift</td>
</tr>
<tr>
<td></td>
<td>K-D. Sievert, Detmold (DE)</td>
</tr>
<tr>
<td>11:32 - 11:35</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:35 - 11:47</td>
<td>I prefer prostate embolisation</td>
</tr>
<tr>
<td></td>
<td>D. Abt, St. Gallen (CH)</td>
</tr>
<tr>
<td>11:47 - 11:50</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:50 - 12:02</td>
<td>I prefer aquablation</td>
</tr>
<tr>
<td></td>
<td>N. Barber, Camberley (GB)</td>
</tr>
<tr>
<td>12:02 - 12:05</td>
<td>Discussion</td>
</tr>
<tr>
<td>12:05 - 12:17</td>
<td>TURP is still the gold standard</td>
</tr>
<tr>
<td></td>
<td>S. Madersbacher, Vienna (AT)</td>
</tr>
<tr>
<td>12:17 - 12:20</td>
<td>Discussion</td>
</tr>
<tr>
<td>12:20 - 13:20</td>
<td>ESFFU meets with other societies</td>
</tr>
<tr>
<td></td>
<td>Moderators: R. Hamid, London (GB)</td>
</tr>
<tr>
<td></td>
<td>T.M. Kessler, Zurich (CH)</td>
</tr>
<tr>
<td>12:20 - 12:35</td>
<td>International Continence Society (ICS) lecture: Are synthetic slings for female Stress Urinary Incontinence (SUI) coming to an end?</td>
</tr>
<tr>
<td></td>
<td>D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)</td>
</tr>
<tr>
<td>12:35 - 12:50</td>
<td>Sociedad Iberoamericana de Neuropatología y Uroginecología (SINUG) lecture: Are bulking agents ready for prime time in female SUI?</td>
</tr>
<tr>
<td></td>
<td>S. Arlandis Guzman, Valencia (ES)</td>
</tr>
<tr>
<td>12:50 - 13:05</td>
<td>Japanese Continence Society (JCS) lecture: Can we improve the bladder diary?</td>
</tr>
<tr>
<td></td>
<td>S. Takahashi, Tokyo (JP)</td>
</tr>
<tr>
<td>13:05 - 13:20</td>
<td>Prize winner 7th International Neuro-Urology Meeting</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>13:20 - 13:50</td>
<td>Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC)</td>
</tr>
<tr>
<td></td>
<td>Moderators: S. Charalampous, Limassol (CY)</td>
</tr>
<tr>
<td></td>
<td>M. Drake, Bristol (GB)</td>
</tr>
<tr>
<td>13:20 - 13:32</td>
<td>Why phenotyping patients may be so important in BPS/IC</td>
</tr>
<tr>
<td></td>
<td>D.S. Engeler, St. Gallen (CH)</td>
</tr>
<tr>
<td>13:32 - 13:35</td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td>J.P.F.A. Heesakers, Nijmegen (NL)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>13:47 - 13:50</td>
<td>Discussion</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>

F. Cruz, Porto (PT)
### Current aspects of advanced tumour therapy: From bedside to bench

Joint meeting of the EAU Section of Uropathology (ESUP) and the EAU Section of Urological Research (ESUR)

**Saturday 16 March**
**10:15 - 13:35**

**Location:** Green Area, Room 4

**Chairs:** K. Junker, Homburg (DE)  
R. Montironi, Ancona (IT)

#### Aims and objectives of this session

Treatment options in metastatic patients are currently changing. More effective systemic therapies are available for prostate, bladder and kidney tumour patients. In this regard, the role of primary tumour surgery in the metastatic situation has to be discussed based on new clinical trial data. On the other hand, the impact of primary tumour on formation and therapy response of metastases has to be considered. In the first part of the session clinicians and researcher will present the current knowledge in this field and will also discuss the rationale of primary tumour surgery in metastatic bladder, prostate and kidney cancer. In the second part, challenges and prerequisites of immune checkpoint inhibition will be discussed including development of predictive markers.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:15 - 10:20 | Welcome and introduction  
K. Junker, Homburg (DE) |
| 10:20 - 12:25 | The role of the primary tumour for metastatic disease  
**Moderators:** R. Montironi, Ancona (IT)  
K. Junker, Homburg (DE)  
H.Y. Leung, Glasgow (GB) |
| 10:20 - 10:35 | Premetastatic niche formation  
To be confirmed |
| 10:35 - 10:50 | Cytoreductive primary tumour surgery in metastatic disease - Prostate cancer: In?  
M. Stöckle, Homburg (DE) |
| 10:50 - 11:05 | Cytoreductive primary tumour surgery in metastatic disease - Kidney cancer: Out?  
A. Mejean, Paris (FR) |
| 11:05 - 11:20 | Cytoreductive primary tumour surgery in metastatic disease - Bladder cancer: Never ever?  
G.N. Thalmann, Berne (CH) |
| 11:20 - 11:35 | Role of exosomes for priming metastasis  
H. Peinado, Madrid (ES) |
| 11:35 - 11:55 | Reasonability of inductive therapy in urologic metastatic patients  
A. Necchi, Milan (IT) |
<p>| 11:55 - 12:25 | Panel discussion |
| 12:25 - 13:15 | Checkpoint inhibitors: The best for all patients? |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:25 - 12:40</td>
<td>Do we understand checkpoint inhibition?</td>
<td>E. Nossner, Munich (DE)</td>
</tr>
<tr>
<td>12:40 - 13:00</td>
<td>The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>13:00 - 13:15</td>
<td>PD-1, PD-L1...: What are the best predictive markers? Standardisation of marker analysis</td>
<td>T. Gevaert, Kluisbergen (BE)</td>
</tr>
<tr>
<td>13:15 - 13:40</td>
<td>Chopin award lecture: A translational approach to prostate cancer</td>
<td>A.S. Bjartell, Malmö (SE)</td>
</tr>
<tr>
<td>13:40 - 13:45</td>
<td>Closing remarks</td>
<td>R. Montironi, Ancona (IT)</td>
</tr>
</tbody>
</table>
Aims and objectives of this session
Again another comprehensive programme of genitourinary reconstruction designed to give both the general urologist and the reconstructive surgeon an update on the management of common and complex pathologies. The first session is on urethral stricture disease: From basic urethrotomy to simple and then complex urethroplasty with the final session on BXO. An update on penile augmentation, penile cancer and revascularisation is followed by a session on female reconstruction and surgery for male incontinence. Peyronie's disease will be fully covered with new insights into its medical and surgical management. The programme is completed with talks on urinary diversion and bladder reconstruction. This is a state of the art programme which will be informative to all.

10:15 - 10:20
Welcome and introduction
R. Djinovic, Belgrade (RS)

10:20 - 11:15
Urethral reconstruction - I
Moderators: M. Fisch, Hamburg (DE)
A. Mundy, London (GB)

10:20 - 10:30
Spongiosum-sparing bulbar urethroplasty techniques: Single graft, double graft, TT muco-mucosa
E. Palminteri, Arezzo (IT)

10:30 - 10:40
Early urethral reconstruction after urethral trauma: When and for whom?
N. Lumen, Ghent (BE)

10:40 - 10:50
Primary versus redo-urethroplasty: What are the differences?
W. Verla, Ghent (BE)

10:50 - 11:00
Spiral preputial graft for very long, non-BXO urethroplasties modification of technique
P. Anderson, Dudley (GB)

11:00 - 11:15
Complex posterior urethroplasty
S. Kulkarni, Pune (IN)

11:15 - 12:00
Urethral reconstruction - II
Moderators: E. Lledó García, Madrid (ES)
A. Zhivov, Moscow (RU)

11:15 - 11:30
Reconstructive urology in the European reference networks: Workstream 2 of eUROGEN
M. Fisch, Hamburg (DE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:35</td>
<td><strong>The role of internal urethrotomy in selected urethral strictures</strong></td>
<td>S. Sansalone</td>
<td>Rome (IT)</td>
</tr>
<tr>
<td>11:35 - 11:42</td>
<td><strong>BXO: Diagnosis and medical treatment</strong></td>
<td>J.I. Martínez Salamanca</td>
<td>Majadahonda (ES)</td>
</tr>
<tr>
<td>11:42 - 11:50</td>
<td><strong>BXO: Surgical management of glans disease</strong></td>
<td>J. Romero Otero</td>
<td>Madrid (ES)</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td><strong>BXO: Surgical management of pendular and pan-urethral disease</strong></td>
<td>D.E. Andrich</td>
<td>London (GB)</td>
</tr>
<tr>
<td>12:00 - 12:40</td>
<td><strong>Penile and Sex Reassignment Surgery (SRS)</strong></td>
<td><strong>Moderators:</strong></td>
<td>To be confirmed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Shamsodini Takhtei</td>
<td>Doha (QA)</td>
</tr>
<tr>
<td>12:00 - 12:10</td>
<td><strong>Penis enlargement surgery</strong></td>
<td>F. Colombo</td>
<td>Bologna (IT)</td>
</tr>
<tr>
<td>12:10 - 12:20</td>
<td><strong>Penile cancer – organ sparing</strong></td>
<td>A. Muneer</td>
<td>London (GB)</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td><strong>Video presentation Microsurgical penile revascularization</strong></td>
<td>C. Trombetta</td>
<td>Trieste (IT)</td>
</tr>
<tr>
<td>12:30 - 12:40</td>
<td><strong>Video presentation Vaginoplasty; when skin is not enough (alternatives to penile inversion skin flaps)</strong></td>
<td>E. Kocjancic</td>
<td>Chicago (US)</td>
</tr>
<tr>
<td>12:40 - 13:10</td>
<td><strong>Female reconstruction</strong></td>
<td><strong>Moderators:</strong></td>
<td>E. Kocjancic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O. Shenfeld</td>
<td>Jerusalem (IL)</td>
</tr>
<tr>
<td>12:40 - 12:50</td>
<td><strong>Female urethroplasty options</strong></td>
<td>S. Shah</td>
<td>Ahmedabad (IN)</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td><strong>The use of buccal mucosa in vaginal reconstruction</strong></td>
<td>D.N. Wood</td>
<td>London (GB)</td>
</tr>
<tr>
<td>13:00 - 13:10</td>
<td><strong>Urethral diverticulum in women</strong></td>
<td>T.J. Greenwell</td>
<td>London (GB)</td>
</tr>
<tr>
<td>13:10 - 13:50</td>
<td><strong>Peyronie's disease in the era of Clostridium Histolyticum (CH)</strong></td>
<td><strong>Moderators:</strong></td>
<td>D.J. Ralph</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N. Tomada</td>
<td>Porto (PT)</td>
</tr>
<tr>
<td>13:17 - 13:25</td>
<td><strong>Results of Peyronie treatment with CH</strong></td>
<td>J. Romero Otero</td>
<td>Madrid (ES)</td>
</tr>
<tr>
<td>13:25 - 13:32</td>
<td><strong>Differences in the protocol of CH</strong></td>
<td>G. Garaffa</td>
<td>London (GB)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker(s)</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
<td></td>
</tr>
<tr>
<td>13:32 - 13:40</td>
<td>Has the patient we brought to the operating room changed?</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>13:40 - 13:50</td>
<td>Do I find differences when operating?</td>
<td>I. Moncada, Madrid (ES)</td>
<td></td>
</tr>
<tr>
<td>13:50 - 14:35</td>
<td>Penile implant and Peyronie's surgery</td>
<td>C. Bettocchi, Bari (IT)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>R. Olianas, Luneburg (DE)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>13:50 - 14:05</td>
<td>Diverse using of penile implant: Peyronie's disease, penile enlargement, neofallus..</td>
<td>J. Romero Otero, Madrid (ES)</td>
<td></td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>SIS-Corporoplasty: Long term results</td>
<td>R. Dahlem, Hamburg (DE)</td>
<td></td>
</tr>
<tr>
<td>14:25 - 14:35</td>
<td>Tips and tricks in Peyronie’s IPP surgery</td>
<td>P. Egydio, Sao Paulo (BR)</td>
<td></td>
</tr>
<tr>
<td>14:35 - 14:55</td>
<td>Incontinence surgery</td>
<td>E. Kocjancic, Chicago (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>V. Pansadoro, Rome (IT)</td>
<td></td>
</tr>
<tr>
<td>14:35 - 14:45</td>
<td>De novo incontinence after sphincter or sling</td>
<td>O. Shenfeld, Jerusalem (IL)</td>
<td></td>
</tr>
<tr>
<td>14:45 - 14:55</td>
<td>Expertise and complications arising and evaluations in Artificial Urinary Sphincter (AUS) surgery and what is new?</td>
<td>O.R. Sedigh, Turin (IT)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Deger, Ostfildern (DE)</td>
<td></td>
</tr>
<tr>
<td>14:55 - 15:05</td>
<td>Different kinds of urinary diversion in adult patients after ureterosigmoidostomy in childhood</td>
<td>S. Darenkov, Moscow (RU)</td>
<td></td>
</tr>
<tr>
<td>15:05 - 15:15</td>
<td>Video presentation The serous-lined continent outlet</td>
<td>H. Abol-Enein, Mansoura (EG)</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:25</td>
<td>Complications after Mitrofanoff procedure and their treatment</td>
<td>C. Konstantinidis, Ilion (GR)</td>
<td></td>
</tr>
<tr>
<td>15:25 - 15:35</td>
<td>The Tübinger i-Pouch in modification</td>
<td>K-D. Sievert, Detmold (DE)</td>
<td></td>
</tr>
<tr>
<td>15:35 - 15:45</td>
<td>Summary and closing remarks</td>
<td>R. Djinovic, Belgrade (RS)</td>
<td></td>
</tr>
</tbody>
</table>
Uro-genital infections: What is important in the urologic office?
Joint Meeting of the EAU Section of Infections in Urology (ESIU) and of the EAU Section of Urologists in Office (ESUO)

Saturday 16 March
10:15 - 14:00

Location: Green Area, Room 12
Chairs: A. Dobrowolski, Myslowice (PL)
H. Haas, Heppenheim (DE)
To be confirmed
P. Tenke, Budapest (HU)

Aims and objectives of this session
This joint meeting of the EAU sections for Urologists in Office (ESUO) and Infections in Urology (ESIU) will deal with the topic of treatment of Urinary Tract Infections (UTI) in the urologic office. Diagnostics and treatment of these infections are a core task in everyday urologic practice. Guided by cases and supported by an interactive discussion with the audience, ESUO members will present characteristic cases and elucidate their way of treatment regarding the infrastructure of urologic office. ESIU members will present scientific information about diagnostics and treatment of UTI in general, but also related to the cases presented. Key information will be given about the diagnostics necessary and the rational selection of antibiotics according to the extent of disease, the situation of antibiotic resistances in different European countries, the demands of antibiotic stewardship, and the decision which patients should be treated in the urologic office and which in hospital. The audience will learn in a systematic way what to consider when treating patients for UTI in the urologic office and make wise decisions.

10:15 - 10:20
Welcome and introduction
H. Haas, Heppenheim (DE)

10:20 - 11:05
Severe Urinary Tract Infection (UTI): When can they be managed in the office, when to be transferred to the clinic?
Moderators: H. Brenneis, Pirmasens (DE)
P. Tenke, Budapest (HU)

10:20 - 10:35
Case presentation and keynote speech
S.M. Haensel, Rotterdam (NL)

10:35 - 10:55
What can we learn from science?
To be confirmed

10:55 - 11:05
Discussion

11:05 - 11:50
HPV vaccination in men: To whom and when?
Moderators: H.M. Çek, Edirne (TR)
F. Dimitriadis, Kalamaria, Thessaloniki (GR)

11:05 - 11:20
Case presentation and keynote speech
A. Dobrowolski, Myslowice (PL)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 - 11:40</td>
<td><strong>What do we learn from science</strong></td>
<td></td>
<td>T. Cai, Trento (IT)</td>
</tr>
<tr>
<td>11:40 - 11:50</td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:35</td>
<td><strong>When to treat a UTI: The differences between asymptomatic bacteriuria and symptomatic UTI. Treatment in patients with urinary diversion</strong></td>
<td></td>
<td>Moderators: S.M. Haensel, Rotterdam (NL); K. Naber, Straubing (DE)</td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td><strong>Case presentation and keynote speech</strong></td>
<td></td>
<td>F. Dimitriadis, Kalamaria, Thessaloniki (GR)</td>
</tr>
<tr>
<td>12:05 - 12:25</td>
<td><strong>What do we learn from science</strong></td>
<td></td>
<td>B. Wullt, Lund (SE)</td>
</tr>
<tr>
<td>12:25 - 12:35</td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:35 - 13:20</td>
<td><strong>Urogenital tuberculosis and BCGitis: How to diagnose, how to manage</strong></td>
<td></td>
<td>Moderators: T.E. Bjerklund Johansen, Oslo (NO); A. Zachariou, Volos (GR)</td>
</tr>
<tr>
<td>12:35 - 12:50</td>
<td><strong>Case presentation and keynote speech</strong></td>
<td></td>
<td>H. Brenneis, Pirmasens (DE)</td>
</tr>
<tr>
<td>12:50 - 13:10</td>
<td><strong>What do we learn from science</strong></td>
<td></td>
<td>E. Kulchavenya, Novosibirsk (RU)</td>
</tr>
<tr>
<td>13:10 - 13:20</td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:20 - 13:55</td>
<td><strong>Recent developments of new antibiotics</strong></td>
<td></td>
<td>Moderators: A. Dobrowolski, Myslowice (PL); P. Tenke, Budapest (HU)</td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td><strong>Case presentation and keynote speech</strong></td>
<td></td>
<td>T.H. Kuru, Köln (DE)</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td><strong>What do we learn from science</strong></td>
<td></td>
<td>K. Naber, Straubing (DE)</td>
</tr>
<tr>
<td>13:45 - 13:55</td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:55 - 14:00</td>
<td><strong>Closing remarks</strong></td>
<td></td>
<td>H. Haas, Heppenheim (DE)</td>
</tr>
</tbody>
</table>
Sexual dysfunction and andrological issues in end stage renal disease and kidney transplant patients
Joint meeting of the EAU Section of Transplantation Urology (ESTU) and the EAU Section of Andrological Urology (ESAU)

Saturday 16 March 10:15 - 14:00

Location: Green Area, Room 20
Chairs: E. Lledó García, Madrid (ES)  N. Sofikitis, Ioannina (GR)

Aims and objectives of this session
The main objective of the joint meeting of the EAU Section of Transplantation Urology and the EAU Section of Andrological Urology is to elucidate the molecular, biochemical, hormonal, and cytological alterations in men with end-stage renal disease resulting in testicular deficiency and sexual dysfunction, as well. Pharmaceutical treatment of defects in testicular function, low sexual desire, and erectile dysfunction will be discussed. The role of penile surgery for obtaining adequate erections in men with end-stage renal disease will be emphasized.

10:15 - 10:20 Welcome and introduction
E. Lledo Garcia, Madrid (ES)
N. Sofikitis, Ioannina (GR)

10:20 - 10:50 Effects of End-Stage Renal Disease (ESRD) and KT on testicular testosterone production. The role of supplementation.
Moderators: T. Diemer, Giessen (DE)
To be confirmed

10:20 - 10:35 Physiopathology
A. Giwercman, Malmö (SE)

10:35 - 10:50 Treatment
R. Boissier, Marseille (FR)

10:50 - 11:20 Physiopathological effect of ESRD, kidney transplant and immunosuppressors on spermatogenesis: Therapeutical possibilities
Moderators: To be confirmed
S.S. Minhas, London (GB)
Speaker: N. Sofikitis, Ioannina (GR)

11:20 - 12:00 Round table discussion on sexual dysfunction and ESRD: Therapeutic options and effects of kidney transplantation - libido, erection and ejaculatory disorders
Moderators: Z. Kopa, Budapest (HU)
E. Lledó Garcia, Madrid (ES)

11:20 - 11:30 Therapeutics before transplantation: PDE5I
V. Tugcu, Istanbul (TR)
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:40</td>
<td>Therapeutics before transplantation: Others</td>
<td>A. Salonia, Milan (IT)</td>
</tr>
<tr>
<td>11:40 - 11:50</td>
<td>Therapeutics after the transplant: Surgical</td>
<td>J.I. Martínez Salamanca, Majadahonda (ES)</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>Therapeutics after the transplant: Pharmacological</td>
<td>A. Kadioglu, Istanbul (TR)</td>
</tr>
<tr>
<td>12:00 - 12:40</td>
<td>Round table discussion: Lower Urinary Tract Symptoms (LUTS) in patients before and after the transplant. When and how to treat. Pharmaceutical approaches and surgical options.</td>
<td>To be confirmed</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> To be confirmed</td>
<td>C. Hernández Fernández, Madrid (ES)</td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>Before</td>
<td>J.D.J.M. Branchereau, Nantes (FR)</td>
</tr>
<tr>
<td>12:20 - 12:40</td>
<td>After</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>12:40 - 12:55</td>
<td>Rene Küss Award 2019</td>
<td>F.J. Burgos Revilla, Madrid (ES)</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> To be confirmed</td>
<td>A.J. Figueiredo, Coimbra (PT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Lledó García, Madrid (ES)</td>
</tr>
<tr>
<td>12:40 - 12:55</td>
<td>To be confirmed</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>12:55 - 13:10</td>
<td>Presentation of results: ESTU research project 2018</td>
<td>V. Gomez Dos Santos, Madrid (ES)</td>
</tr>
<tr>
<td>13:10 - 13:25</td>
<td>Presentation of 2019 awarded research project</td>
<td>E. Lledó García, Madrid (ES)</td>
</tr>
<tr>
<td>13:10 - 13:25</td>
<td>To be confirmed</td>
<td>To be confirmed</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> To be confirmed</td>
<td>L. Peri Cusi, Barcelona (ES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speaker:</strong> To be confirmed</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Closing remarks</td>
<td>E. Lledó García, Madrid (ES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N. Sofikitis, Ioannina (GR)</td>
</tr>
</tbody>
</table>
Technology development never ends!
Meeting of the EAU Section of Uro-Technology (ESUT), in cooperation with the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS)

Saturday 16 March
10:30 - 18:00

Location: Red Area, eURO Auditorium 1
Chair: E. Liatsikos, Patras (GR)

Aims and objectives of this session
Following a more than 10-year tradition of live-surgery sessions, the EAU Section of Uro-Technology (ESUT) presents an ambitious programme focussing on novel techniques and technologies in endourological, laparoscopic and robotic-assisted procedures. This year, we want to focus on novel technology improving the performance of video-assisted surgery and diagnostics in all fields of Endourology. This session is conducted in collaboration with the the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS).

In the laparoscopic and robot-assisted cases, we will focus on the developments of imaging as well as on new instruments and devices that improve its ergonomics. The latest digital developments for flexible endoscopy of the upper urinary tract for diagnosis and treatment of tumours and calculi will also be demonstrated. ESUT faculty consists of internationally well-known experts serving as surgeons and moderators. The different surgical procedures will be transmitted from Fundacio Puigvert Hospital, Barcelona in high definition and 3D quality. Traditionally, the format of ESUT Live Surgery will allow all delegates to directly communicate with the surgeons to ask questions and to discuss every aspect of the procedure. In addition, the ESUT session will also be available online.

- Live broadcasts from Fundacio Puigvert Hospital, Barcelona (ES)
- Coordinators in the eURO Auditorium

10:30 - 18:00
Coordinator at the Fundacio Puigvert hospital, Barcelona (ES)

10:30 - 10:35
Welcome and introduction
E. Liatsikos, Patras (GR)

10:35 - 10:40
Ethics of Live-Surgery – Cases from last year
B. Kromann-Andersen, Herlev (DK)

10:40 - 12:33
Live surgery - Part I
Moderators: F. Gomez Sancha, Madrid (ES)
P. Kallidonis, Patras (GR)
S. Micali, Baggiovara (IT)
C. Schwentner, Stuttgart (DE)
P. Tenke, Budapest (HU)
O. Wiseman, Cambridge (GB)
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40 - 11:10</td>
<td>3D Laparoscopic partial nephrectomy</td>
<td>A. Alcaraz, Barcelona (ES)</td>
</tr>
<tr>
<td>11:10 - 11:29</td>
<td>Prone percutaneous nephrolithotripsy</td>
<td>J-T. Klein, Ulm (DE)</td>
</tr>
<tr>
<td>11:29 - 11:47</td>
<td>En-bloc bipolar bladder tumour resection</td>
<td>A. Breda, Barcelona (ES)</td>
</tr>
<tr>
<td>11:47 - 12:17</td>
<td>Complex robot-assisted partial nephrectomy</td>
<td>A. Mottrie, Aalst (BE)</td>
</tr>
<tr>
<td>12:17 - 12:25</td>
<td>Pre-recorded video GreenLight advanced technique</td>
<td>E. Rijo, Barcelona (ES)</td>
</tr>
<tr>
<td>12:25 - 12:33</td>
<td>Pre-recorded video Bladder tumour resection with PDD</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>12:33 - 14:29</td>
<td>Live surgery - Part II</td>
<td>Moderators: A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Barret, Paris (FR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O.R. Durutovic, Belgrade (RS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Netsch, Hamburg (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I.Y. Ozgok, Ankara (TR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R. Sanchez-Salas, Paris (FR)</td>
</tr>
<tr>
<td>12:33 - 12:43</td>
<td>Pre-recorded video Robot-assisted radical cystectomy</td>
<td>C.J. Wijburg, Arnhem (NL)</td>
</tr>
<tr>
<td>12:43 - 12:51</td>
<td>Pre-recorded video MOSES Laser enucleation (MOLEP)</td>
<td>K. Lehrich, Berlin (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C.M. Scoffone, Turin (IT)</td>
</tr>
<tr>
<td>13:51 - 14:02</td>
<td>'Lithovue' Single use ureteroscopic lithotripsy</td>
<td>E. Emiliani, Barcelona (ES)</td>
</tr>
<tr>
<td>14:02 - 14:13</td>
<td>Flexible ureteroscopic lithotripsy</td>
<td>M. Straub, Munich (DE)</td>
</tr>
<tr>
<td>14:13 - 14:21</td>
<td>Pre-recorded video Bipolar enucleation of prostate</td>
<td>J. Rassler, Leipzig (DE)</td>
</tr>
<tr>
<td>14:21 - 14:29</td>
<td>Pre-recorded video Holmium prostate enucleation</td>
<td>A. Miernik, Freiburg (DE)</td>
</tr>
<tr>
<td>14:29 - 16:18</td>
<td>Live surgery - Part III</td>
<td>Moderators: D. Enikeev, Moscow (RU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A.S. Gözen, Heilbronn (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>L. Lusuardi, Salzburg (AT)</td>
</tr>
</tbody>
</table>

---
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:12 - 15:42</td>
<td>Prone endoscopic combined intrarenal surgery</td>
<td>L. Ajayi, London (GB) E. Liatsikos, Patras (GR)</td>
</tr>
<tr>
<td>14:29 - 14:37</td>
<td>Pre-recorded video Bladder stone lithotripsy</td>
<td>M. Lipkin, Durham (US)</td>
</tr>
<tr>
<td>14:37 - 14:45</td>
<td>Pre-recorded video NBI-assisted resection of bladder tumour</td>
<td>B. Malavaud, Toulouse (FR)</td>
</tr>
<tr>
<td>14:45 - 14:53</td>
<td>Pre-recorded video Enucleation of prostate using hemera pulsed thulium laser with updated settings</td>
<td>J.B. Roche, Bordeaux (FR)</td>
</tr>
<tr>
<td>14:53 - 15:01</td>
<td>Pre-recorded video Bipolar Enucleation of the prostate</td>
<td>T.R.W. Herrmann, Frauenfeld (CH)</td>
</tr>
<tr>
<td>15:01 - 15:12</td>
<td>Flexible Ureteroscopic Lithotripsy</td>
<td>O. Traxer, Paris (FR)</td>
</tr>
<tr>
<td>15:42 - 16:00</td>
<td>Percutaneous nephrolithotripsy</td>
<td>D.A. Pérez Fentes, Santiago de Compostela (ES)</td>
</tr>
<tr>
<td>16:00 - 16:18</td>
<td>MIP L with Calculase III</td>
<td>T. Knoll, Sindelfingen (DE)</td>
</tr>
<tr>
<td>16:18 - 18:00</td>
<td>Live surgery - Part IV</td>
<td></td>
</tr>
<tr>
<td>16:18 - 16:26</td>
<td>Pre-recorded video Rezūm™ for prostate treatment</td>
<td>R. Hindley, Hook (GB)</td>
</tr>
<tr>
<td>16:26 - 16:34</td>
<td>Pre-recorded video Aquablation</td>
<td>T. Bach, Hamburg (DE)</td>
</tr>
<tr>
<td>16:34 - 16:42</td>
<td>Pre-recorded video UTUC ablation – Comparison of Thulium and Holmium</td>
<td>G. Giusti, Milan (IT)</td>
</tr>
<tr>
<td>16:42 - 16:50</td>
<td>Pre-recorded video TOOKAD Vascular focal therapy with non-thermal L-light for unilateral low-risk prostate cancer</td>
<td>F. Montorsi, Milan (IT)</td>
</tr>
<tr>
<td>16:50 - 17:01</td>
<td>Flexible single-use ureteroscopic lithotripsy</td>
<td>B. Somani, Southampton (GB)</td>
</tr>
<tr>
<td>17:01 - 17:12</td>
<td>Flexible ureteroscopic lithotripsy</td>
<td>T. Tailly, Ghent (BE)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 17:12 - 17:30| **Mini percutaneous nephrolithotripsy**  
O. Angerri Feu, Barcelona (ES)                                                                 |
| 17:30 - 18:00| **Robot-assisted radical prostatectomy with nerve sparing**  
M. Graefen, Hamburg (DE)                                                                       |
Aims and objectives of this session
To teach all about the adrenal gland minimal invasive approach; starting with the correct indications for surgery and preoperative medical preparation. The different approaches and new equipment will be shown including special instructions. The operations will be given step by step in high quality videos in detail with tips and tricks. The complication videos and intraoperative management will be discussed interactively with the experts.

Introduction
A.S. Gözen, Heilbronn (DE)

Indications and patient preparation (medical and surgical)
J.F. Langenhuisen, Nijmegen (NL)

Surgical anatomy of adrenals
F. Porpiglia, Turin (IT)

How I do it; step by step operative procedure, technical tips and tricks

- Transperitoneal
  J.F. Langenhuisen, Nijmegen (NL)

- Retroperitoneal and prone
  A.S. Gözen, Heilbronn (DE)

- Mini-laparoscopic
  F. Porpiglia, Turin (IT)

Partial adrenalectomy and challenging cases in adrenalectomy
J.F. Langenhuisen, Nijmegen (NL)

Complications and management
A.S. Gözen, Heilbronn (DE)

Discussion and interaction
A.S. Gözen, Heilbronn (DE)
J.F. Langenhuisen, Nijmegen (NL)
F. Porpiglia, Turin (IT)
Aims and objectives of this session
The course objective is to explain the surgical technique of radical prostatectomy performed through robotic-assisted laparoscopy for the treatment of prostatic carcinoma. The outline of this course will give a detailed reminder of anatomical basic principles of radical prostatectomy. General principles regarding ports placement will be also reminded considering the different possible options and the different types of robotic systems used. Then each teacher will make a presentation of his surgical technique using a video of 20 minutes explaining all the steps of the surgery in details. Other options of anatomical approach will be also introduced (posterior approach, lateral approach). Finally, the course will present the possible intraoperative risks of complications and the functional and oncological results of this surgery.

Introduction
P-T. Piéchaud, Bordeaux (FR)

General principles of robotic radical prostatectomy, patient position, ports placement, ways of access
W. Artibani, Verona (IT)
P. Dasgupta, London (GB)

Anatomical and oncological supports of radical prostatectomy:

- Bladder neck preservation: Useful? Dangerous?
P-T. Piéchaud, Bordeaux (FR)

- Neurovascular bundle dissection: Anatomical reminders of the peri-prostatic fascia and space of dissection
P. Dasgupta, London (GB)

Step by step operative procedure: How I do it?
W. Artibani, Verona (IT)
P. Dasgupta, London (GB)
P-T. Piéchaud, Bordeaux (FR)

Technical alternatives:

Posterior approach: Bocciardi technique
W. Artibani, Verona (IT)

Lateral approach: Gaston technique
P-T. Piéchaud, Bordeaux (FR)
Lymphadenectomy: Technical principles
W. Artibani, Verona (IT)

Operative and postoperative complications
P. Dasgupta, London (GB)

Oncological and functional results
W. Artibani, Verona (IT)

Conclusion
P-T. Piéchaud, Bordeaux (FR)
Paediatric urology for the adult urologist. Congenital disorders of the external genitalia, DSD and longterm outcome
ESU Course 10

**Location:** Green Area, Room 14

**Chair:** G. Bogaert, Leuven (BE)

**Aims and objectives of this session**
Congenital anomalies of the external genitalia are an important topic for the urologist and paediatric urologist. A child born with a disorder of sexual differentiation is a physical and psychological emergency. It requires the knowledge of the pathophysiology of the most frequent causes and the subsequent diagnostic and treatment decision tree. Together with a team of paediatricians, psychologists, geneticists, the (paediatric) urologist must be able to explain the condition to the parents in a way that they can choose the best option for their child. The external genitalia of a child will evolve from a social and voiding tool to an erotic and reproduction tool during puberty and adolescence. Again, the (paediatric) urologist should be aware of possible problems and accompany the child and their parents during that process.

After this course, the attendant will be able:
• to identify the most common causes of sexual differentiation (DSD) and know how to handle in the neonatal period.
• to diagnose and how to treat the most common congenital and acquired problems of the external genitalia.
• the normal development of the sexual function and fertility during puberty and adolescence, as well as possible problems due to congenital or acquired pathology.

**Disorders of sex development**
C. Radmayr, Innsbruck (AT)

**Congenital malformations of the external genitalia: What do we need to know regarding sexual function and fertility in adolescence and adulthood?**
G. Bogaert, Leuven (BE)

**Congenital and acquired pathology of the external genitalia**
B. Burgu, Ankara (TR)

**Discussion**
## Non-oncology guidelines: Incontinence; bladder/paediatric stones; male LUTS

**ESU Course 12**

**Location:** Green Area, Room 22

**Chairs:**
- A.K. Nambiar, Newcastle-upon-Tyne (GB)
- To be confirmed

---

**TBC**
- J-N.L. Cornu, Rouen (FR)

---

**TBC**
- J. Donaldson, Aberdeen (GB)
EBU Session: European standards for assessment, accreditation and certification
Specialty Session

Saturday 16 March
12:00 - 13:00

Location: Green Area, Room 19
Chairs: A.J. Figueiredo, Coimbra (PT)
        R.J.A. Van Moorselaar, Amsterdam (NL)

Aims and objectives of this session
The common purpose of all urologists is the best care for the patient. The EBU in collaboration with the EAU and national urological organisations is concerned with the standards of training and education for urologists of the present and the future. The aim of this session is to explore current and future needs.

12:00 - 12:05
Welcome and introduction
A.J. Figueiredo, Coimbra (PT)

12:05 - 12:15
CME/CPD in Europe
K.A. German, Birkirkara (MT)

12:15 - 12:25
EBU exams
S. Tekgül, Sihhiye, Ankara (TR)

12:25 - 12:35
Medbook PRO
To be confirmed

12:35 - 12:55
Do we need certification for onco-urology?

12:35 - 12:45
EBU perspective
A.J. Figueiredo, Coimbra (PT)

12:45 - 12:55
EAU perspective
To be confirmed

12:55 - 13:00
Closing remarks
A.J. Figueiredo, Coimbra (PT)
How to write results and discussion
ESU Course 08

Location: Green Area, Room 16
Chair: J.W.F. Catto, Sheffield (GB)

Aims and objectives of this session
Learn the best way to draft the results and discussion section of a scientific paper. Understand how to work through examples of good and bad practices, to find the key points of the manuscript. Obtain insight from editors on what they expect to see.

• To understand what makes good results section and how best to present your data.
• To understand what makes a good discussion.
• To learn from experienced editors.

Welcome
J.W.F. Catto, Sheffield (GB)

Choosing and presenting your statistical analysis
To be confirmed

How to write the results section
R. Lee, New York (US)

Writing the discussion section
P.L. Nguyen, Boston (US)

What the editor looks for when reviewing the results and discussion
L. Albigeres, Villejuif (FR)
<table>
<thead>
<tr>
<th>Location:</th>
<th>Green Area, Room 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair:</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
Prostate cancer diagnosis
Expert-Guided Poster Tour 04

Saturday 16 March 13:30 - 15:30
Location: Green Area, Room A (Expert-Guided Poster Tours)
Chairs: To be confirmed
M. Valerio, Lausanne (CH)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

- 

Introduction
M. Valerio, Lausanne (CH)
To be confirmed

PT088

Trends in prostate biopsy criteria and outcomes from 2010 to present: The Columbia experience

By: Haas C.R. ¹, Caputo J.M. ², Sebesta E.M. ¹, Wang V.M. ¹, Siddiqui S. ¹, Hyams E. ¹, Wenske S. ¹
¹New York-Presbyterian Columbia University Medical Center, Dept. of Urology, New York, United States of America, ²New York-Presbyterian Columbia University Medical Center, Dept. of Urology, New York, United States of America

PT089

Which cancers are still diagnosed by standard prostate biopsy without an upfront multiparametric MRI? Results from a tertiary care, high volume centre

By: Stabile A.¹, Dell’ Oglio P. ¹, Zaffuto E. ¹, De Cobelli F. ², Gandaglia G. ¹, Rosiello G. ¹, Fossati N. ¹, Galosi A.B. ³, Scarcella S. ¹, Scattoni V. ¹, Gallina A. ¹, Suardi N. ¹, Roupret M. ⁴, Esposito A. ², Montorsi F. ¹, Briganti A. ¹
¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, ³Ospedali riuniti University Hospital, Dept. of Urology, Ancona, Italy, ⁴Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, Sorbonne Université, Dept. of Urology, Paris, France

PT091

Role of PI-RADS version 2 for prediction of incidental prostate cancer after radical cystoprostatectomy

By: Song W.¹, Jeong J.Y. ², Kim T.H. ³, Yoon H.S. ¹, Kim K.H. ¹, Yoon H. ¹, Chung W.S. ¹, Sim B.S. ¹, Lee D.H. ¹
¹Ewha Womans University School of Medicine, Dept. of Urology, Seoul, Korea, South, ²Kangbuk Samsung Hospital, Dept. of Urology, Seoul, Korea, South, ³CHA Bundang Medical Center, Dept. of Urology, Seongnam, Korea, South
Quantitative analysis between multiparametric MRI parameters and prostate cancer Gleason score with whole-mount histopathology

By: Gao J., Zhang Q., Zhang C., Guo H.
Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China

Periprocedural and diagnostic outcomes of transrectal versus transperineal US/MRI guided fusion prostate biopsy: Multi-institutional propensity score matched pair analysis

1 Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2 University of Turin, Dept. of Surgical Sciences, Urology, Turin, Italy, 3 Sapienza University, Dept. of Radiological, Oncological and Anatomical-Pathological Sciences, Rome, Italy, 4 Institut Jules Bordet, Universite Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, 5 Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, 6 Humanitas Gradenigo Hospital, Dept. of Urology, Turin, Italy, 7 Pitie Salpetriere Hospital, Assistance Publique-Hopitaux de Paris, Universites Paris Sorbonne, Dept. of Urology, Paris, France, 8 Clinique Saint Augustin, Dept. of Urology, Bordeaux, France

How to prevent patients with a false positive overall score of PI-RADS 4

By: Von Beyme Cortés C., Ullrich T., Quentin M., Laqua N., Rabenalt R., Antoch G., Schimmöller L., Albers P., Arsov C.
1 University of Dusseldorf, Dept. of Urology, Dusseldorf, Germany, 2 University of Dusseldorf, Dept. of Diagnostic and Interventional Radiology, Dusseldorf, Germany

Does size matter? A comparison of Gleason score concordance rate between 23 Belgian centres

By: Soenens C., Dekuyper P., Van Cleynenbreugel B., Quackels T., Roumeguère T., Van Damme N., De Coster G., Van Eycken L., Joniau S., Ameye F.
1 AZ Maria Middelaars, Dept. of Urology, Ghent, Belgium, 2 University Hospital Leuven, Dept. of Urology, Leuven, Belgium, 3 Erasmus Hospital, Dept. of Urology, Brussels, Belgium, 4 Belgian Cancer Registry, Brussels, Belgium

Is one targeted biopsy core of the index lesion sufficient to accurately detect clinically significant prostate cancer across all PI-RADS scores?

1 IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 2 Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3 Groupe Hospitalier Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie
### PT100

**Fusion US/MRI prostate biopsy using a computer aided diagnostic (CAD) system**

By: Ferriero M.C.¹, Flammia R.S.¹, Zeccolini G.², De Concilio B.², Tuderti G.¹, Anceschi U.¹, Brasseti A.¹, Mastroianni R.¹, Celia A.², Gallucci M.¹, Simone G.¹

¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²San Bassiano Hospital, Dept. of Urology, Bassano del Grappa, Italy

### PT101

**Predictors of adverse pathology on radical prostatectomy: Development of a prognostic nomogram incorporating transperineal biopsy and mpMRI**

By: Kalapara A.¹, Sathianathen N.², Frydenberg M.¹, Grummet J.P.¹

¹Monash University, Dept. of Surgery, Melbourne, Australia, ²University of Minnesota, Dept. of Urology, Minneapolis, United States of America

### PT102

**Clinical impact of male BRCA2 germline pathogenic mutation: Preliminary results from a National Clinical Research Hospital**

By: Buffi N.¹, Saita A.², Zuradelli M.², Casale P.², Hurle R.², Lughezzani G.², Pasini L.², Fasulo V.², Paciotti M.², Domanico L.², Bevilacqua G.², Barile M.³, Ripamonti C.B.³, Lazzeri M.², Guazzoni G.¹

¹Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Humanitas University, Dept. of Urology, Rozzano, Italy, ²Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, ³Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Laboratory Unit, Rozzano, Italy

### PT103

**Descriptive analysis of BRCA-associated cancer family history among Japanese prostate cancer patients**

By: Ishiyama Y.¹, Shimbo M.², Deshpande G.³, Iizuka J.¹, Tanabe K.¹, Hattori K.²

¹Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan, ²St. Luke's International Hospital, Dept. of Urology, Tokyo, Japan, ³St. Luke's International Hospital, Dept. of General Internal Medicine, Tokyo, Japan

### PT104

**Genetic testing for hereditary prostate cancer among men in Israel**

By: Golan S.¹, Sela S.¹, Frumer M.¹, Kedar I.², Ber Y.¹, Kedar D.¹, Margel D.¹

¹Rabin Medical Center, Dept. of Urology, Petah-Tikva, Israel, ²Rabin Medical Center, Dept of Genetics, Petah-Tikva, Israel

### PT105

**Bioelectric impedance analysis (BIA) for non-invasive prostate carcinoma (PCa) diagnosis using a novel “finger” probe tool: Results from a cross-sectional, hospital-based study**

By: Bartoletti R.¹, Neri G.¹, Greco A.², Di Vico T.¹, Durante J.¹, Tognarelli A.¹, Talluri T.³, Valenza G.²

¹University of Pisa, Dept. of Translational Research and New Technologies, Pisa, Italy, ²Scientific Programme - EAU19 Barcelona
<table>
<thead>
<tr>
<th>PT106</th>
<th>Prognostic value of prostate specific antigen in primary neuroendocrine prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Wang J., Yao Z., Dingwei Y.</td>
</tr>
<tr>
<td></td>
<td>Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT107</th>
<th>Circulating tumor cells may improve PSA ability to predict positive prostate biopsy in patients with total serum prostate-specific antigen levels of 4–10 ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Wang B., Ma L.</td>
</tr>
<tr>
<td></td>
<td>Peking University Third Hospital, Dept. of Urology, Beijing, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT108</th>
<th>Effects of metabolic syndrome on the prevalence of prostate cancer: Historical cohort study using the national health insurance service database</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Park J.¹, Yoo S.¹, Cho S.Y.¹, Cho M.C.¹, Paick J-S.², Son H.¹, Jeong H.¹</td>
</tr>
<tr>
<td></td>
<td>¹Boramae Medical Center, Dept. of Urology, Seoul, Korea, South, ²Mediplex Sejong Hospital, Dept. of Urology, Incheon, Korea, South</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT110</th>
<th>Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Siltari A.¹, Murtola T.J.¹, Talala K.², Taari K.³, Tammela T.L.J.¹, Auvinen A.⁴</td>
</tr>
<tr>
<td></td>
<td>¹University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland, ²Finnish Cancer Registry, Finnish Cancer Registry, Helsinki, Finland, ³Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁴University of Tampere, School of Health Sciences, Tampere, Finland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT111</th>
<th>Association between chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Beckmann K.¹, Russell B.¹, Josephs D.², Garmo H.¹, Haggstrom C.³, Holmberg L.¹, Stattin P.⁴, Van Hemelrick M.¹, Aldofsson J.⁵</td>
</tr>
<tr>
<td></td>
<td>¹Kings College London, School of Cancer and Pharmaceutical Studies, London, United Kingdom, ²Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Oncology, London, United Kingdom, ³Umea, Dept. of Biobanking Research, Umea, Sweden, ⁴Uppsala University Hospital, Regional Cancer Centre Uppsala, Uppsala, Sweden, ⁵Karolinska Institute, CLINTEC-Department, Stockholm, Sweden</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT112</th>
<th>Negative Predictive Value of multi-parametric MRI in detection of clinically significant prostate cancer: A systematic review and meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Sathianathen N.¹, Omer A.², Kasvisvanathan V.³, Punwani S.³, Moore C.³, Kastner C.⁴, Barrett T.⁴, Van Den Bergh R.⁵, Gleeson F.², Macpherson R.², Bryant R.J.², Macpherson R.², Murphy D.G.⁶, Hamdy F.C.², Lamb A.D.²</td>
</tr>
</tbody>
</table>

¹University of Pisa, Dept. of Information Engineering & Bioengineering and Robotics Research Center, Pisa, Italy, ²Akern Srl, Dept. of Development and Research, Pontassieve, Italy
PT114

**Robot-assisted radical prostatectomy (RARP) versus volumetric modulated arc therapy (VMAT) in cT1-4N0M0 prostate cancer**

By: Taguchi S.¹, Shiraishi K.², Fujimura T.³, Naito A.⁴, Kawai T.⁴, Nakagawa K.⁵, Igawa Y.⁴, Abe O.⁵, Kume H.⁴, Fukuhara H.¹

¹Kyorin University Faculty of Medicine, Dept. of Urology, Tokyo, Japan, ²Teikyo University School of Medicine, Dept. of Radiology, Tokyo, Japan, ³Jichi Medical University, Dept. of Urology, Tochigi, Japan, ⁴Graduate School of Medicine, The University of Tokyo, Dept. of Urology, Tokyo, Japan, ⁵Graduate School of Medicine, The University of Tokyo, Dept. of Radiology, Tokyo, Japan

PT115

**Withdrawn**

To be confirmed
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

Introduction
A.S. Bjartell, Malmö (SE)
M. De Santis, Berlin (DE)

Baseline features and treatment-decision making in patients with prostate cancer enrolled in the United in Fighting prOstate (UFO) cancer registry


1Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, 2Kindai University Faculty of Medicine, Dept. of Urology, Osaka, Japan, 3West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China, 4National University Hospital, National University Health System, Dept. of Urology, Singapore, Singapore, 5Hiroaki University Graduate School of Medicine, Dept. of Urology, Hiroaki Aomori, Japan, 6Chulalongkorn University, Dept. of Surgery, Bangkok, Thailand, 7Institute Urology and Nephrology, Hospital Kuala Lumpur, Dept. of Urology, Kuala Lumpur, Malaysia, 8Gangnam Severance Hospital, Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, Korea, South, 9Rajeev Gandhi Cancer Institutes & Research Centre, Uro Oncology Services , New Delhi, India, 10National Taiwan University Hospital, Dept. of Urology , Taipei, Taiwan, 11National Cancer Centre, Division of Medical Oncology, Singapore, Singapore, 12Faculty of Medicine, University of Malaya, Dept. of Surgery, Kuala Lumpur, Malaysia, 13Faculty of Medicine, Prince of Songkla University, Dept. of Surgery, Songkhla, Thailand, 14Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, Korea, South, 15Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, 16Janssen Research & Development, LLC, Epidemiology, Raritan, United States of America, 17Janssen (China) Research & Development Center, SDS China Dept, Shanghai, China, 18Janssen, GCDO-MAO, Selangor, Malaysia, 19Janssen Asia-Pacific, Medical Affairs, Sydney, Australia, 20Janssen Research & Development, Epidemiology, Singapore, Singapore
PT118  
Design of phase 1b/2 study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration and androgen blocking agent resistant prostate cancer

By: Getzenberg R. 1, Markowski M.C. 2, Eisenberger M.A. 2, Antonarakis E.S. 2, Yu E.Y. 3, Barnette G. 4, Rodriguez D. 4, Steiner M.S. 4
1Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, FL, United States of America, 2Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States of America, 3University of Washington, Dept. of Oncology, Seattle, WA, United States of America, 4Veru Inc, Veru, Miami, FL, United States of America

PT119  
A phase 2, dose finding, placebo-controlled, study of zuclomiphene citrate to alleviate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer

By: Getzenberg R. 1, Rodriguez D. 2, Hancock M. 3, Fisch H. 2, Steiner M. 2
1Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, FL, United States of America, 2Veru Inc, Clinical Operations, Miami, FL, United States of America, 3Hancock Consulting, Biostatistics, Memphis, TN, United States of America

PT122  
Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (SOAP) surgery for benign prostate obstruction: A multicentre randomized controlled trial

1Clinique Pasteur, Dept. of Urology, Toulouse, France, 2University Hospital Tours, Dept. of Urology, Tours, France, 3University Hospital Rennes, Dept. of Urology, Rennes, France, 4University Hospital Grenoble, Dept. of Urology, Grenoble, France, 5University Hospital Limoges, Dept. of Urology, Limoges, France, 6Cochin Hospital, Dept. of Urology, Paris, France, 7Private Hospital of Cotes d’Armor, Dept. of Urology, Plerin, France, 8Conception Hospital, Dept. of Urology, Marseille, France, 9Private Hospital of Louviere, Dept. of Urology, Lille, France, 10University Hospital Angers, Dept. of Urology, Angers, France, 11University Hospital Brest, Dept. of Urology, Brest, France, 12Clinique Pasteur, Dept. of Cardiovascular Medicine, Toulouse, France, 13University Grenoble-Alpes, University Hospital, Dept. of Anaesthesiology and Intensive Care Medicine, Grenoble, France, 14Assistance Publique-Hôpitaux de Paris, Cochin University Hospital, Dept. of Anaesthesiology and Intensive Care, Paris, France, 15University Hospital of Toulouse Rangueil, Dept. of Haematology, Toulouse, France, 16Clinique Pasteur, Dept. of Anaesthesiology and Intensive Care, Toulouse, France

PT123  
The effects of sequential mitomycin and bacillus Calmette-Guérin treatment versus bacillus Calmette-Guérin monotherapy in patients with high risk non-muscle invasive bladder cancer: Mito-bcg (EudraCT-2017-004540-37)
PT124

A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT


1Radboud University Medical Centre, Dept. of Urology, Nijmegen, Netherlands, The, 2Technical University of Munich, Dept. of Urology, Munich, Germany, 3Fundació Puigvert, Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, 4University of California, San Francisco, Dept. of Urology, San Francisco, United States of America, 5Vanderbilt University School of Medicine, Dept. of Urologic Surgery, Nashville, United States of America, 6Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, 7University of Minnesota, Dept. of Urology, Minneapolis, United States of America, 8The University of Chicago Medicine, Dept. of Surgery, Chicago, United States of America, 9University of Tsukuba, Dept. of Urology, Tsukuba, Japan, 10University of Kansas Medical Center, Dept. of Urology, Kansas City, United States of America, 11Bristol-Myers Squibb, Princeton, United States of America, 12Bristol-Myers Squibb, Dept. of Clinical Biostatistics, Princeton, United States of America, 13Bristol-Myers Squibb, Dept. of Clinical Pharmacology and Pharmcometrics, Princeton, United States of America, 14Bristol-Myers Squibb, Dept. of Translational Medicine, Princeton, United States of America, 15Bristol-Myers Squibb, Dept. of Clinical Protocol, Princeton, United States of America, 16Bristol-Myers Squibb, Dept. of Clinical Operations, Princeton, United States of America, 17Bristol-Myers Squibb, Dept. of Clinical Trials, Bladder Cancer Program, Princeton, United States of America, 18Bristol-Myers Squibb, Dept. of Clinical Trials, Princeton, United States of America, 19Bristol-Myers Squibb, Dept. of Development, Princeton, United States of America, 20Johns Hopkins University School of Medicine, Departments of Oncology and Urology, Baltimore, United States of America

PT125

PURE-02: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (Pembro), preceding radical nephroureterectomy (RNU), for patients with localized high-risk urothelial carcinoma of the upper urinary tract (UTUC)

By: Necchi A. 1, Raggi D. 1, Gust K. 2, D'andrea D. 2, Briganti A. 3, Capitanio U. 3, Colecchia M. 1, Chung J. 4, Ali S. 4, Ross J. 4, Montorsi F. 3, Shariat S. 2

1Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Medical University of Vienna, Dept. of Urology, Vienna, Austria, 3Vita Salute San Raffaele University, Urological Research Institute (URI), Milan, Italy, 4Foundation Medicine, Foundation Medicine, Cambridge, United States of America
PT127

**ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma**


¹Hospital Del Mar, Dept. of Genitourinary Cancer Unit, Barcelona, Spain, ²Studienpraxis Urologie, Dept. of Urologic Oncology, Nurtingen, Germany, ³Gustave Roussy Cancer Campus, Dept. of Cancer Medicine, Villejuif, France, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, ⁵Huntsman Cancer Institute, University of Utah, Dept. of Genitourinary Oncology Program, Salt Lake City, United States of America, ⁶Guy’s and St. Thomas’ NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, ⁷Stanford University School of Medicine, Dept. of Urologic Oncology Clinic, Stanford, United States of America, ⁸University of Iowa and Holden Comprehensive Cancer Center, Dept. of Division of Hematology, Iowa City, United States of America, ⁹Clovis Oncology, Inc., Dept. of Clinical Science, Boulder, United States of America, ¹⁰Clovis Oncology, Inc., Dept. of Biostatistics, Boulder, United States of America, ¹¹Clovis Oncology, Inc., Dept. of Clinical Operations, Boulder, United States of America, ¹²Clovis Oncology, Inc., Dept. of Translational Medicine, Boulder, United States of America, ¹³University of Washington, Dept. of Medicine, Division of Oncology, Seattle, United States of America, ¹⁴Guy’s and St Thomas’ NHS Foundation Trust and Sarah Cannon Research Institute, Dept. of Medical Oncology, London, United Kingdom

PT128

**Post-nephrectomy adjuvant therapy for localized renal cell carcinoma (RCC): The phase III randomized, placebo-controlled CheckMate 914 study of nivolumab plus ipilimumab in patients at high risk of relapse**

By: Bex A.,² Russo P.,³ Tomita Y.,³ Grunwald V.,⁴ Ramirez L.M.,⁵ McHenry M.B.,⁶ Motzer R.J.⁷

¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, ²Memorial Sloan Kettering Cancer Center, Dept. of Surgery, New York, United States of America, ³Niigata University Graduate School of Medical and Dental Sciences, Dept. of Molecular Oncology, Niigata, Japan, ⁴Hannover Medical School, Dept. of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover, Germany, ⁵Bristol-Myers Squibb, Dept. of Research & Development Oncology, Princeton, United States of America, ⁶Bristol-Myers Squibb, Dept. of Global Biometric Sciences, Princeton, United States of America, ⁷Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America

PT129

**Real world evidence in renal cell carcinoma: A national, prospective, non-interventional study of nivolumab in patients with advanced renal cell carcinoma after prior therapy (NORA)**

By: Grimm M-O.,¹ Grünwald V.,² Müller-Huesmann H.,³ Schostak M.,⁴ Schultze-Seemann W.,⁵ Bedke J.⁶

¹Jena University Hospital, Dept. of Urology, Jena, Germany, ²University Hospital Essen, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Essen, Germany, ³Brüderkrankenhaus St. Josef, Dept. of Internal Medicine, Hematology and Oncology,
<table>
<thead>
<tr>
<th>PT130</th>
<th>Pilot results from the laparoscopic entry technique in renal surgery: A randomised controlled trial comparing open (Hasson) versus closed (Veress) techniques (LAPRES)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tullaght University Hospital, Dept. of Urology, Dublin, Ireland, Independent scholar, Dept. of Statistics, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT131</th>
<th>The iROC trial: An RCT comparing intracorporeal robot-assisted vs open radical cystectomy for bladder cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>University College London, Dept. of Urology, London, United Kingdom, University College London, Surgical and Interventional Trials Unit, London, United Kingdom, University College London, Dept. of Statistical Science, London, United Kingdom, Guy's Hospital, Dept. of Urology, London, United Kingdom, University College London Hospital, Dept. of Anaesthetics, London, United Kingdom, University College London, Division of Surgical &amp; Interventional Sciences, London, United Kingdom, University of Sheffield, Dept. of Health Economics and Decision Science, Sheffield, United Kingdom, Lister Hospital, Stevenage, Dept. of Urology, Stevenage, United Kingdom, University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, Royal Devonshire and Exeter NHS Trust, Dept. of Urology, Exeter, United Kingdom, Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, University College London Hospital, Dept. of Urology, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT133</th>
<th>NeuroSAFE PROOF: A multi-centre feasibility study to evaluate the ability to randomize men with prostate cancer into an RCT comparing NeuroSAFE robotic-assisted radical prostatectomy (RARP) to standard RARP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>University College London, Dept. of Surgery and Interventional Sciences, London, United Kingdom, University College Hospital London, Dept. of Histopathology, London, United Kingdom, University College Hospital London, Dept. of Radiology, London, United Kingdom, University College Hospital London, Dept. of Uro-Oncology, London, United Kingdom, Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom</td>
</tr>
<tr>
<td>374</td>
<td>Evolve: Designing a model of meaningful patient involvement in guideline development</td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
ESU/ESUT/ESUI Hands-on Training in Fusion biopsy

HOT 10

Saturday 16 March
14:00 - 16:00

Location: Green Area, Room 8

Chair: To be confirmed
Male infertility and reproductive health: Translating new techniques into clinical application

Poster Session 18

Saturday 16 March
14:15 - 15:45

Location: Green Area, Room 3

Chairs: M. Dinkelman-Smit, Rotterdam (NL)
S.S. Minhas, London (GB)
E. Ventimiglia, Milan (IT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 244

Impact of human papilloma virus infection on the success of ART in infertile couples: A prospective cohort study

By: Monforte M. ¹, Sotto A. ², Rougier-Maillard N. ³, Hamamah S. ⁴, Huberlant S. ⁵, Boule N. ⁶, Anahory T. ⁷, Fabbro-Perray P. ⁸, Costa P. ⁹, Droupy S. ⁹
¹CHU de Montpellier, Dept. of Gynaecology and Reproductive Medicine, Montpellier, France, ²CHU de Nîmes, Dept. of Infectiology, Nîmes, France, ³CHU de Nîmes, Dept. of Reproductive Medicine, Nîmes, France, ⁴CHU de Montpellier, Dept. of Reproductive Medicine, Montpellier, France, ⁵CHU de Nîmes, Dept. of Gynaecology, Nîmes, France, ⁶CHU de Montpellier, Dept. of Infectiology, Montpellier, France, ⁷CHU de Montpellier, Dept. of Gynaecology and Reproductive Medicine, Montpellier, France, ⁸CHU de Nîmes, Dept. of Methodology, Nîmes, France, ⁹CHU de Nîmes, Dept. of Urology and Andrology, Nîmes, France

245

High-risk human papillomavirus in semen is associated with poor sperm progressive motility and a high sperm DNA fragmentation index in infertile men

By: Boeri L. ¹, Capogrosso P. ¹, Ventimiglia E. ¹, Cazzaniga W. ¹, Pederzoli F. ¹, Chierigo F. ¹, Pozzi E. ¹, Gaboardi F. ¹, Montanari E. ², Montorsi F. ¹, Salonia A. ²
¹IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology, Milan, Italy, ²IRCCS Fondazione Ca’ Granda - Maggiore Policlinico Hospital, Dept. of Urology, Milan, Italy

246

Prevalence of positive semen cultures in infertile men without leukocytospermia: A cross sectional study

By: Cazzaniga W. ¹, Capogrosso P. ², Ventimiglia E. ², Boeri L. ³, Pozzi E. ¹, Chierigo F. ¹, Schifano N. ¹, Belladelli F. ¹, Zuabi R. ¹, Abbate C. ¹, Dehò F. ¹, Mirone V. ⁴, Gaboardi F. ¹, Montorsi F. ¹, Salonia A. ¹
¹IRCCS Ospedale San Raffaele, Dept. of Urology, Division of Experimental Oncology, Milan, Italy, ²Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale
Evidence that testicular sperm in infertile men has improved DNA integrity compared to ejaculated sperm

By: Vyas L.¹, Tharakan T.¹, Lewis S.², Minhas S.¹, Ramsay J.¹, Jayasena C.¹
¹Imperial University Hospitals trust, Dept. of Urology, London, United Kingdom, ²Examen labs, Dept. of Pathology, London, United Kingdom

Outcome of microdissection testicular sperm extraction in hypogonadotropic hypogonadal azoospermia after failure of gonadotropin therapy

By: Chen Y.K., Chen W.J., Huang E.Y., Huang W.J. 
Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan

Serum albumin levels are associated with sex steroids hormones and sperm concentration impairment in primary infertile men – Results of a cross-sectional study

By: Boeri L.¹, Capogrosso P.,² Ventimiglia E.,² Cazzaniga W.,² Pozzi E.,³ Schifano N.,³ Chierigo F.,³ Abbate C.,² Dehò F.,² Mirone V.,⁴ Gaboardi F.,² Montanari E.¹, Montorsi F.², Salonia A.²
¹IRCCS Fondazione Ca’ Granda – Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Unit of Urology, URI, Milan, Italy, ³Università Vita-Salute San Raffaele, Dept. of Urology, Urological Research Institute (URI), Milan, Italy, ⁴Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples “Federico II”, Dept. of Urology, Naples, Italy

More prevalent prescription of testosterone in men from couples undergoing intracytoplasmic sperm injection (ICSI)

By: Elenkov A., Al-Jebari Y., Lundberg Giwercman Y., Giwercman A.
Lund University, Dept. of Translational Medicine, Malmo, Sweden

Success rate of bilateral onco-testicular semen extraction (oncoTESE) in azoospermic men with testicular germ cell tumor (TGCT)

By: Van Moolenbroek G.,¹ Boellaard W.,² Dinkelman-Smit M.,²
¹Erasmus MC, University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, ²Erasmus MC, University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The

Randomized, single-blind, controlled clinical trial to evaluate the effect of intraoperative flushing of vas deferens with sterile water and nitrofurazone on the semen of post-vasectomy control
Post vasectomy semen analysis can be performed at 8 weeks without compromising clearance rates: A single centre retrospective study

Forth Valley Royal Hospital, Dept. of Urology, Larbert, United Kingdom

Epididymovasostomy: Patency, pregnancy rate and predictive factors for success in 109 patients over a decade

By: Chiriacò G., Modgil V., Assiri H.M, Blecher G.A., Alnajjar H., Sangster P., Ralph D.J.
University College London Hospital (UCLH), Dept. of Andrology, London, United Kingdom
Usefulness of novel tumour models in studies on oncogenes and tumor suppressors
Poster Session 19

Saturday 16 March
14:15 - 15:45

Location: Green Area, Room 4
Chairs: To be confirmed
S.K. Hong, Sungnam (KR)
M. Nevalainen, Milwaukee (US)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

256

Luteolin regulates AR-V7 expression via miRNA recruitment in castration-resistant prostate cancer

By: Naiki T. ¹, Naiki-Ito A. ², Etani T. ¹, Iida K. ¹, Ando R. ¹, Nagai T. ¹, Kawai N. ¹, Takahashi S. ², Yasui T. ¹
¹Nagoya City University Graduate School of Medicine, Dept. of Nephro-Urology, Nagoya City, Japan, ²Nagoya City University Graduate School of Medicine, Dept. of Experimental Pathology and Tumor Biology, Nagoya City, Japan

259

The role of fibroblasts in local progression and metastatic spread of prostate cancer: Examinations in an orthotopic xenograft model

By: Linxweiler J. ¹, Körbel C. ², Stöckle M. ¹, Menger M.D. ², Junker K. ¹, Saar M. ¹
¹Saarland University, Dept. of Urology, Homburg Saar, Germany, ²Saarland University, Institute for Clinical-Experimental Surgery, Homburg Saar, Germany

260

PCDH9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients

By: Sekino Y. ¹, Goto K. ¹, Sakamoto N. ¹, Oue N. ², Sentani K. ², Hayashi T. ¹, Teishima J. ¹, Yasui A. ², Matsubara A. ¹
¹Hiroshima University Graduate School of Biomedical and Health Sciences, Dept. of Urology, Hiroshima, Japan, ²Hiroshima University Graduate School of Biomedical and Health Sciences, Dept. of Molecular Pathology, Hiroshima, Japan

261

Profiling of the immune microenvironment in prostate cancer at single cell level

By: Lazzeri M. ¹, Saita A. ¹, Casale P. ¹, Buffi N.M. ², Hurle R. ¹, Lughezzani G. ¹, Fasulo V. ¹, Paciotti M. ¹, Maffei D. ¹, Domanico L. ¹, Bevilacqua G. ¹, Colombo P. ³, Elefante G.M. ³, Peano C. ⁴, Kunderfranco P. ⁴, Cibella J. ⁴, Guazzoni G. ¹, Di Mitri D. ⁵
¹Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, ²Istituto Clinico Humanitas IRCCS, Humanitas University, Dept. of
**Activation of IRAK1 by uropathogenic E.coli and its overexpression in prostate cancer is regulated by DNA methylation**

By: Breiding V., Loose M., Steger K., Luedecke G., Wagenlehner F., Schagdarsurengin U., Dansranjavin T.

Justus Liebig University, Clinic of Urology, Pediatric Urology and Andrology, Giessen, Germany

**Investigation of TRPM4 and store-operated calcium entry in prostate cancer cell systems and a primary prostate cancer stem cell model**

By: Borgstroem A., Kiener M., Kappel S., Hauert B., Delalande C., Zoni E., Reymond J., Thalmann G.N., Peinelt C., Kruithof-De Julio M.

1University of Bern, Institute of Biochemistry and Molecular Medicine, Bern, Switzerland,
2University of Bern, Dept. of Urology and BioMedical Research, Bern, Switzerland,
3University of Bern, Dept. of Biochemistry and Chemistry, Bern, Switzerland
4University Hospital of Bern, Dept. of Urology, Bern, Switzerland

**Cancer-associated fibroblasts induce epithelial-mesenchymal transition in prostate cancer cells through HGF/Met/Fra1/SOX9 signaling**

By: Qin H., Qiu X., Jiang B., Chen W., Diao W., Zhao X., Guo H.

Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Nanjing, China

**Role of ER-generated redox and calcium signals in the modulation of prostate cancer progression**


1Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland
2Università Vita-Salute San Raffaele, Urological Research Institute (URI), Dept. of Urology, Milan, Italy
3Università Vita-Salute San Raffaele, Istituto di Ricovero e Cura a Carattere Scientifico, Protein Transport and Secretion Unit, Division of Genetics and Cell Biology, Milan, Italy
4IRCCS Ospedale San Raffaele, Urological Research Institute (URI), Dept. of Urology, Milan, Italy
5Università Vita-Salute San Raffaele, Istituto di Ricovero e Cura a Carattere Scientifico, Protein Transport and Secretion Unit, Division of Genetics and Cell Biology, Milan, Italy

**Development and characterisation of a spontaneously metastatic patient-derived xenograft (PDX) model of human prostate cancer (PCa)**

By: Lange T., Oh-Hohenhorst S., Joosse S., Hahn O., Gosau T., Feldhaus S.
270

**Withdrawn**

To be confirmed
## Stones: Extracorporeal shock wave lithotripsy

**Poster Session 20**

**Saturday 16 March**
14:15 - 15:45

**Location:** Green Area, Room 5

**Chairs:**
- M. Hanna, London (GB)
- Hernandez Porras, Tijuana (MX)
- A. Petřík, Hluboka nad Vltavou (CZ)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

### 271

**Predictive model for one-session success rate of shock wave lithotripsy using variation coefficient of stone density ratio**

By: Lee J.Y.\(^1\), Kim J.W.\(^1\), Kang D.H.\(^2\), Jung H.D.\(^1\), Cho K.S.\(^1\), Choi Y.D.\(^1\)

\(^1\)Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, Korea, South, \(^2\)Inha University School of Medicine, Dept. of Urology, Incheon, Korea, South

### 272

**Evaluation of a neural network model with machine learning for predicting optimal shockwave lithotripsy treatment protocols: Alignment with known successful treatments**

By: Seltzer R.\(^1\), Hamilton B.D.\(^2\), Klett D.E.\(^2\), Chen Z.\(^3\), Nakada S.Y.\(^4\), Gerber G.S.\(^5\)

\(^1\)Translational Analytics and Statistics, Dept. of Research, Tucson, United States of America, \(^2\)University of Utah, Dept. of Urology, Salt Lake City, United States of America, \(^3\)University of Arizona, Dept. of Statistics, Tucson, United States of America, \(^4\)University of Wisconsin, Dept. of Urology, Madison, United States of America, \(^5\)University of Chicago, Dept. of Urology, Chicago, United States of America

### 273

**Algorithm-based tools to improve shockwave lithotripsy outcomes in urology practice: Results of implementing interactive, real-time tools**

By: Hamilton B.D.\(^1\), Seltz R.G.N.\(^2\), Klett D.E.\(^1\), Chen Z.\(^3\), Nakada S.Y.\(^4\), Gerber G.S.\(^5\)

\(^1\)University of Utah, Dept. of Urology, Salt Lake City, United States of America, \(^2\)Translational Analytics and Statistics, Dept. of Research, Tucson, United States of America, \(^3\)University of Arizona, Dept. of Statistics, Tucson, United States of America, \(^4\)University of Wisconsin, Dept. of Urology, Madison, United States of America, \(^5\)University of Chicago, Dept. of Urology, Chicago, United States of America

### 274

**Ureteral wall volume at ureteral stone site is a critical predictor for shock wave lithotripsy outcome: Comparison with ureteral wall thickness and area**

By: Yamashita S., Kohjimoto Y., Higuchi M., Iguchi T., Nishizawa S., Kikkawa K., Hara
I. Wakayama Medical University, Dept. of Urology, Wakayama, Japan

275 A clinical observational study of a solid conductive interface for improving treatment efficacy in extracorporeal shock wave lithotripsy

By: Chen W-C.¹, Liou W-C², Yang Y-H², Lin Y.³, Cheng K-T.⁴
¹St. Joseph Hospital, Dept. of Urology, Kaohsiung, Taiwan, ²St. Joseph Hospital, Medicine, Kaohsiung, Taiwan, ³National Kaohsiung Normal University, Grad. Inst. Human Res. and Knowledge Management, Kaohsiung, Taiwan, ⁴CleanWave Medical Co., LTD, Research and Development, Kaohsiung, Taiwan

276 The effect of focus size on stone fragmentation in SWL

By: Veser J., Jahrreis V., Seitz C., Özsoy M.
Medical University Vienna, Dept. of Urology, Vienna, Austria

277 To investigate the effect of voltage escalation on treatment outcome in extracorporeal shockwave lithotripsy of renal calculi – Final analysis

By: Ng C.F.¹, Yee C.H.¹, Teoh J.Y.C.¹, Leung S.C.H.¹, Lau B.¹, Wong K.T.², Chu W.C.W.²
¹The Chinese University of Hong Kong, SH Ho Urology Centre, Hong Kong, Hong Kong, ²The Chinese University of Hong Kong, Dept. of Imaging and Interventional Radiology, Hong Kong, Hong Kong

278 Emergency extracorporeal shockwave lithotripsy: Reducing morbidity and enhancing stone free rates for obstructing ureteric stones

By: Matanhelia M., Lee S-M., Timoney A., Philip J.
Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom

279 KIM-1: A novel serum & urinary biomarker to predict acute/tubular injury following ESWL

By: Ilyas R., Young J.G., Chow K.
Central Manchester NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom

281 Optimal non-invasive treatment of 1-2.5 cm radiolucent renal stones: Oral dissolution therapy (ODT), shock wave lithotripsy (SWL) or combined treatment: A randomized controlled trial

By: Abdelbaset M.¹, Hashem A.¹, Eraky A.², Ezzat O.¹, Sharaf M.¹, El-Assmy A.¹, Sheir K.¹, Shokeir A.¹
¹Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt, ²Mediclin Murtitz Hospital, Dept. of Urology, Waren (Müritz), Germany
Comparing extracorporeal shock wave lithotripsy and ureteroscopic laser lithotripsy for treatment of urinary stones smaller than 2 cm: A cost-utility analysis


1Hospital Universitario y Politécnico La Fe, Dept. of Urology, Valencia, Spain,
2Universidad Politécnica de Valencia, Research centre for health economics and management, Valencia, Spain

Shockwave lithotripsy and ureteroscopy for the treatment of lower pole stones: Results from a statewide clinical registry

By: Ghani K., Stockall E., Swarna K., Telang J., Kim T., Hollingsworth J., Dauw C.

1University of Michigan, Dept. of Urology, Ann Arbor, MI, United States of America,
2Capital Urology Associates, Dept. of Urology, Lansing, MI, United States of America

Efficacy of pethidine, ketorolac and lidocaine gel as analgesics for pain control in shockwave lithotripsy


Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt
What is new in Percutaneous Nephrolithotomy (PCNL)?

**Video Session 05**

### Saturday 16 March

**14:15 - 15:45**

**Location:** Green Area, Room 10

**Chairs:**

- F.J. Burgos Revilla, Madrid (ES)
- M. Lezrek, Meknes (MA)
- To be confirmed

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

---

**V31**

**Miniper: Yes, please!**

By: Rodríguez Socarrás M.E., Proietti S., Saitta G., De Coninck V., Mantica G., De Marchi D., Bellinzoni P., Gaboardi F., Giusti G.

Ospedale San Raffaele, Turro, Dept. of Urology, Milan, Italy

---

**V32**

**Semi-closed circuit vacuum-assisted mini-percutaneous nephrolithotomy with holmium laser lithotripsy**


Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

---

**V33**

**NAID: A novel percutaneous navigation system**

By: Patena Forte J.P., Baltazar P.M., Fernandes F., Falcão G., Campos-Pinheiro L.

Centro Hospitalar e Universitário de Lisboa Central, Dept. of Urology, Lisbon, Portugal

---

**V35**

**Techniques for fluoroscopic access in PNL: An ESUT educational video**

By: Berdempes M., Kyriazis I., Lazarou L., Markopoulos T., Kallidonis P., Liatsikos E., Skolarikos A.

1. Sismanoglio General Hospital, Dept. of Urology, Athens, Greece
2. General University Hospital of Patras, Dept. of Urology, Patras, Greece

---

**V36**

**Thulium SuperPulse Fiber Laser (TSPFL) for micro-PCNL**

By: Martov A.G., Andronov A., Dutov S., Traxer O.

1. Federal Medical-Biological Agency of Russian Federation State Institute of Continuous Medical Education, Dept. of Urology, Moscow, Russia
2. Pletnev’s Clinical Hospital, Dept. of Urology, Moscow, Russia
3. Sorbonne Université, GRC n°20, Hôpital Tenon, Dept. of Urology, Paris, France

---
Homemade on the spot improvised baskets for PCNL

By: Lezrek M.¹, Tazi H.², Mawfik H.², El Yazami O.², Slimani A.¹, Alami M.¹, Ammani A.¹

¹Military Hospital Moulay Ismail, Dept. of Urology, Meknes, Morocco, ²Al Ghassani Hospital, Dept. of Urology, Fes, Morocco
Infectious diseases: New basic insights
Poster Session 21

Location: Green Area, Room 12
Chairs: G. Bonkat, Basel (CH)
        T. Cai, Trento (IT)
        To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

286
Long-term efficacy of antibiotics prophylaxis for preventing recurrent uncomplicated urinary tract infections: A systematic review and network meta-analysis

By: Salahia S. 1, Riffai M. 1, Shehata M. 2, Salahia H. 1, Dall’antonia M. 3, Hammadeh M. 4
1Ain Shams University, Faculty of Medicine, Cairo, Egypt, 2Zagazig University, Faculty of Medicine, Zagazig, Egypt, 3Queen Elizabeth Hospital, Consultant Microbiologist, Department of Microbiology, London, United Kingdom, 4Queen Elizabeth Hospital, Consultant Urological Surgeon & Honorary Senior Lecturer, London, United Kingdom

287
Identifying barriers for non-adherence to guidelines on urinary tract infections

By: Schneidewind L. 1, Schlager D. 2, Mühlstädt S. 3, Kranz J. 4
1University Medicine Greifswald, Dept. of Haematology/Oncology, Greifswald, Germany, 2University of Freiburg Medical Center, Dept. of Urology, Freiburg (Brsgr.), Germany, 3University of Halle (Saale) Medical Center, Dept. of Urology, Halle (Saale), Germany, 4St.-Antonius-Hospital Eschweiler, Dept. Of Urology and Paediatric Urology, Eschweiler, Germany

289
Adapted bacteriophages for treating urinary tract infections

By: Leitner L. 1, Ujmaurjdze A. 2, Chanishvili N. 3, Goderdzishvili M. 3, Mehnert U. 1, Chkhotua A. 2, Sybesma W. 1, Kessler T.M. 1
1University Hospital Balgrist, Dept. of Neuro-Urology, Zürich, Switzerland, 2The Alexander Tsulukidze National Center of Urology, Dept. of Urology, Tbilisi, Georgia, 3The George Eliava Institute of Bacteriophage, Dept. of Microbiology and Virology, Tbilisi, Georgia

290
Anti-virulence treatment: The solution to antimicrobial resistance?

By: Magistro G. 1, Stief C.G. 1, Schubert S. 2
1Ludwig-Maximilians-University of Munich, Dept. of Urology, Munich, Germany, 2Ludwig-Maximilians-University of Munich, Max von Pettenkofer-Institute for Hygiene and Medical Microbiology, Munich, Germany
Prevalence of recurrent extended-spectrum beta-lactamase (ESBL) urinary tract infections (UTIs) in patients within a urology service. Introducing the concept of faecal Microbiota transplantation (FMT) as a treatment modality.

By: Ghani R. 1, Gan C. 2, Mullish B. 3, Ferizoli V. 2, Davies F. 1, Thursz M. 3, Marchesi J. 4, Dasgupta R. 2, Minhas S. 2

1 Imperial College Healthcare NHS Trust, Dept. of Microbiology, London, United Kingdom, 2 Imperial College Healthcare NHS Trust, Dept. of Urology, London, United Kingdom, 3 Imperial College Healthcare NHS Trust, Dept. of Gastroenterology, London, United Kingdom, 4 Imperial College London, Dept. of Digestive Diseases, London, United Kingdom

A new bacterial resistant polymer catheter coating to reduce catheter associated urinary tract infection (CAUTI): A first-in-man pilot study

By: Jeffery N. 1, Kalenderski K. 2, Dubern J. 2, Lomiteng A. 1, Dragova M. 1, Frost A. 1, Macrae B. 3, Mundy A. 1, Alexander M. 4, Williams P. 2, Andrich D. 1

1 University College London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 2 University Nottingham, Centre for Biomolecular Sciences & School of Life Sciences, Nottingham, United Kingdom, 3 University College London NHS Foundation Trust, Dept. of Microbiology, London, United Kingdom, 4 University of Central Florida, Dept. of Statistics, Orlando, United States of America

Comparative value of chronic urinary tract infection (UTI) diagnosis between standard culture sensitivity and next generation sequence (NGS) in urine samples

By: Dixon M. 1, Stefil M. 1, Skinner C. 2, Coba G. 3, Zaman S. 3, Koo T. 3, Ni L. 4, McDonald M. 5, Mouraviev V. 6

1 University of East Anglia, Norwich Medical School, Norwich, United Kingdom, 2 University of Central Florida, College of Medicine, Orlando, United States of America, 3 University of South Florida, Morsani College of Medicine, Tampa, United States of America, 4 University of Central Florida, Dept of Statistics, Orlando, United States of America, 5 Florida Hospital Celebration Health, Urology Centre of Central Florida, Celebration, United States of America, 6 Central Florida Cancer Institute, Dept. Of Urology, Davenport, United States of America

Rapid detection of extended-spectrum β-lactamases in uropathogenic Escherichia coli in urinary tract infections: A new alternative for empirical treatment

By: Ortega M. 1, Hernandez HCR 2, Martinez MAC 1, Cantellano COM 1, Morales MMG 1, Fernandez FNG 1, Cortes PCR 1, Hernandez HMA 1, Calvo CVI 1, Pacheco PGC 1

1 Hospital General Dr. Manuel Gea Gonzalez, Dept. of Urology, MEXICO CITY, Mexico, 2 Hospital General Dr. Manuel Gea Gonzalez, Dept. of Research, MEXICO CITY, Mexico

Targeting IL-11 in the treatment of BK virus associated hemorrhagic cystitis – A promising new approach

By: Schneidewind L. 1, Neumann T. 1, Weigel M. 1, Plis A. 1, Brückmann S. 2, Krüger W. 1, Schmidt C.A. 1
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| 296  | Bacteriological diagnosis with volatile organic compounds – First experiences with an electronic nose | By: Heers H. 1, Heinig J. 1, Von Stauffenberg F. 1, Hegele A. 1, Hofmann R. 1, Böselt T. 2, Koczulla A.R. 2  
1University Medicine Greifswald, Dept. of Haematology and Oncology, Greifswald, Germany,  
2University Medicine Greifswald, Dept. of Pathology, Greifswald, Germany                                                                                     |
| 297  | Can E. coli 10^3 CFU/ml cause the development of acute bacterial prostatitis? Experimental study | By: Kogan M.I. 1, Naboka Y.L. 2, Pasechnik D.G. 1, Ismailov R.S. 1, Popov I.V. 1, Slyusarenko N.V. 1  
1Rostov State Medical University, Dept. of Urology and Human Reproductive Health, Rostov-on-Don, Russia,  
2Rostov State Medical University, Dept. of Microbiology and Virology, Rostov-on-Don, Russia                                                                 |
1Washington University School of Medicine, Obstetrics and Gynaecology, Saint Louis, United States of America,  
2Loyola University Chicago, Microbiology and Immunology, Chicago, United States of America,  
3Washington University School of Medicine, Molecular Microbiology, Saint Louis, United States of America |
| 300  | Aortic calcification is the risk factor of severe acute kidney injury development in patients with urological sepsis | By: Fujita N. 1, Momota M. 1, Tobisawa Y. 1, Yoneyama T. 1, Yamamoto H. 1, Imai A. 1, Hatakeyama S. 1, Ito H. 2, Yoneyama T. 1, Hashimoto Y. 1, Yoshikawa K. 3, Ohyama C. 1  
1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,  
2Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan,  
3Mutsu General Hospital, Dept. of Urology, Mutsu, Japan                                                                                                          |
Is vitamin B6 supplementation needed for cystinuric patients taking penicillamine?

By: Farrah N.¹, Ross L.², Wells H.², Game D.³, Thomas K.¹, Bultitude M.¹

¹Guy's and St. Thomas' NHS Foundation Trust, Urology Centre, London, United Kingdom,
²Guy's and St. Thomas' NHS Foundation Trust, Dept. of Pharmacy, London, United Kingdom,
³Guy's and St. Thomas' NHS Foundation Trust, Dept. of Nephrology, London, United Kingdom

Assessment of health-related quality of life in a UK cystinuric population

By: Shahrjerdi P.¹, Vijay A.¹, Game D.², Thomas K.¹, Bultitude M.¹

¹Guy's and St. Thomas' NHS Foundation Trust, Urology Centre, London, United Kingdom,
²Guy's and St. Thomas' NHS Foundation Trust, Dept. of Nephrology, London, United Kingdom

Identification of novel susceptibility loci for tuberous sclerosis complex (TSC) in the Japanese population

By: Uemura M.¹, Yamamoto Y.¹, Ishizuya Y.¹, Katayama K.², Yamaguchi R.³, Miyano S.³, Kaneda M.⁴, Matsuda K.⁵, Inagaki Y.¹, Fukuhara S.¹, Fiujita K.¹, Imamura R.¹, Nonomura N.¹

¹Osaka University, Graduate School of Medicine, Dept. of Urology, Suita, Japan,
²The University of Tokyo, The institute of of medical science, Human genome center, Laboratory of Sequence analysis, Tokyo, Japan,
³The University of Tokyo, The Institute of of medical science, Human genome Center, Laboratory of DNA information analysis, Tokyo, Japan,
⁴Osaka University, Graduate School of Medicine, Dept. of Dermatology, Suita, Japan,
⁵The University of Tokyo, The Institute of of medical science, Human genome center, Dept. of Computational Biology and Medical Sciences, Laboratory of Clinical Genome Sequencing, Tokyo, Japan

Presurgical targeted therapy with Everolimus for angiomyolipoma associated with tuberous sclerosis complex
307 Prognostic analysis of extramammary Paget's disease in scrotum
By: Xiao W., Zhu Y., Qu Y., Zhu Y., Su H., Wang J., Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

308 Prognosis of early stage small cell bladder cancer is not always dismal
By: Lim JH, Al-Izzi S., Santhanam S.
Nottingham University Hospitals NHS Trust, Dept. of Clinical Oncology, Nottingham, United Kingdom

309 Fifteen years of experience in emphysematous cystitis: Findings in a rare disease
Ramon y Cajal Hospital, IRYCIS Institute, University of Alcalá, Dept. of Urology, Madrid, Spain

310 Differential expression of PD-L1 between sporadic and VHL-associated hereditary clear cell renal cell carcinoma and its correlation with clinicopathological features
By: Hong B., Ma K., Zhou J., Zhang J., Xie H., Zhang K., Li L., Gong K.
Peking University First Hospital, Dept. of Urology, Beijing, China

311 Intra-familial phenotypic heterogeneity in von Hippel-Lindau disease: Implications for personalized surveillance plan
By: Wang J.Y., Gong K.
Institute Of Urology, Peking University, Peking University First Hospital, Dept. of Urology, Beijing, China

312 Follow-up of MiT family translocation RCC in young adults
By: Zhang S., Ma L.L., Zhang F.
Peking University Third Hospital, Dept. of Urology, Beijing, China

313 Sexuality and pregnancy education among transitional spina bifida women: A patient-based survey
By: Bujons Tur A., Lang Motta G., Garat J.M., Palou J.
Fundació Puigvert, Dept. of Urology, Barcelona, Spain

By: Brenton T.¹, Sharma D.², Moran C.³
¹St Georges Hospital, Dept. of Urology, London, United Kingdom, ²St Georges Hospital,
Sperm retrieval rates in non-mosaic Klinefelter patients undergoing microsurgical testicular sperm extraction: What expectations do we have in the real-life setting?

By: Boeri L.¹, Preto M.², Sibona M.², Palmisano F.¹, Capogrosso P.³, Ventimiglia E.³, Lo Russo V.¹, Serrago M.¹, Falcone M.², Timpano M.², Ceruti C.², Gadda F.¹, Salonia A.³, Rolle L.², Gontero P.², Montanari E.¹

¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ²A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Dept. of Urology, Turin, Italy, ³IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology; URI, Milan, Italy
Paediatric Urology: Upper urinary tract
Poster Session 23

Saturday 16 March
14:15 - 15:45

Location: Green Area, Room 20
Chairs: B. Burgu, Ankara (TR)
M. Eissa, Cairo (EG)
B. Haid, Linz (AT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 316

Anatomical aspects of the kidney surface in human fetuses during the second gestational trimester

By: Lobo M.L.P., Favorito L.A., Sampaio F.
State University of Rio de Janeiro, Urogenital Research Unit, Rio de Janeiro, Brazil

317

Isolated bilateral low grade antenatal hydronephrosis: Clinical outcome

1Prince Sultan Military Medical City, Dept. of Urology, Riyadh, Saudi Arabia, 2King Fahad Specialist Hospital, Dept. of Urology, Dammam, Saudi Arabia

318

Complex renal cysts: Examining the applicability of modified Bosniak classification for children

By: Frumer M., Shenhar C., Konen O., Shpira-Rootman M., Livne P.M., Ben Meir D.
1Schneider Childrens Medical Center of Israel, Dept. of Paediatric Radiology, Petach Tikva, Israel, 2Schneider Childrens Medical Center of Israel, Dept. of Urology, Petach Tikva, Israel, 3Schneider Childrens Medical Center of Israel, Dept. of Urology, Petach Tikva, Israel

319

Laparoscopic and robotic-assisted repair of retrocaval ureter in children: A multi-institutional comparative study with open repair

By: Esposito C., Masieri L., Valla J., Lopez P.J., Tokar B., Mushtaq I., Sforza S., Venturini S., Escolino M.
1Federico II University of Naples, Dept. of Pediatric Surgery, Naples, Italy, 2University of Florence, Dept. of Urology, Florence, Italy, 3CHU Lellay, Dept. of Pediatric Urology, Nice, France, 4Hospital Exequiel Gonzalez Cortes & Clinica Alemana, Dept. of Pediatric Urology, Santiago, Chile, 5Eskisehir Osmangazi University, Dept. of Pediatric Urology,
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>320</td>
<td>Robot-assisted laparoscopic pyeloplasty (RALP) in children with horseshoe kidneys: Results of a multicentric study</td>
<td>Esposito C.¹, Masieri L.², Blanc T.³, Manzoni G.⁴, Silay S.⁵, Cerulo M.¹, Venturini S.², Escolino M.¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Federico II University of Naples, Dept. of Pediatric Urology, Naples, Italy, ²University of Florence, Meyer Children's Hospital, Dept. of Pediatric Urology, Florence, Italy, ³Hopital Necker-Enfants Malades, Dept. of Pediatric Urology, Paris, France, ⁴Ospedale Maggiore Policlinico, Dept. of Pediatric Urology, Milan, Italy, ⁵Istanbul Medeniyet University, Dept. of Pediatric Urology, Istanbul, Turkey</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Florence, Dept. of Urology, Florence, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kasr Alainy Hospital, Cairo University, Dept. of Urology, Cairo, Egypt</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Habib Thameur Hospital, Dept. of pediatric surgery, Tunis, Tunisia</td>
</tr>
<tr>
<td>324</td>
<td>Surgical outcome of robot-assisted laparoscopy pyeloplasty in children with no drainage placement for ureteropelvic junction obstruction</td>
<td>Venturini S., Cini C., Longo M., Cito G., Morselli S., Minervini A., Carini M., Masieri L.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Florence, Dept. of Urology, Florence, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Burjeel Hospital, Dept. of Urology, Abu Dhabi, United Arab Emirates, ²Al-Azhar University Hospital, Dept. of Urology, Cairo, Egypt, ³Suez Canal University, Dept. of Pediatrics, Ismailia, Egypt, ⁴Burjeel Hospital, Dept. of Pediatric Surgery, Abu Dhabi, United Arab Emirates</td>
</tr>
</tbody>
</table>
Ureterocele size predicts surgical management and outcome: Data from 20 years experience with long follow-up

By: Haid B.¹, Kerling M.², Stredele R.², Oswald J.¹, Waidelich R.², Riccabona M.²
¹Hospital of the Sisiters of Charity, Dept. of Pediatric Urology, Linz, Austria, ²Ludwig Maximilians University, Dept. of Urology, Munich, Germany

Mini-laparotomy in-situ pyeloplasty for repair of the uretroplevic junction obstruction: outcome of 150 cases

By: El-Moghazy H.¹, Eissa M.²
¹Sohag university, Dept. of Urology, Sohag, Egypt, ²Cairo University, Dept. of Urology, Cairo, Egypt
Aims and objectives of this session
Trauma is a leading cause of death and morbidity in civilian populations. All Urologists will have to manage trauma patients and need to understand basic principles. The EAU Guidelines Group prepare guidelines in order to assist in the management of urological trauma and these principles will be followed for the specific organ systems and in the context of polytrauma.

- Urological trauma is usually associated with other injuries. The role of the urologist in polytrauma is important to understand.
- Modern diagnostic imaging and interventional radiology techniques has resulted in a greater understanding of organ injury and treatment.
- Increasing use is made of non-operative or delayed surgical intervention with a resulting higher rate of organ preservation.
- Minimising long term morbidity is an important role for injuries that are usually not life threatening.

Introduction and trauma management principles
N. Kitrey, Ramat Gan (IL)

Renal trauma
D.M. Sharma, London (GB)

Renal trauma case
N. Kitrey, Ramat Gan (IL)
N. Lumen, Ghent (BE)
D.M. Sharma, London (GB)

Ureteral trauma
N. Lumen, Ghent (BE)

Bladder trauma
N. Kitrey, Ramat Gan (IL)

Urethral trauma
N. Lumen, Ghent (BE)

Urethral trauma case
N. Kitrey, Ramat Gan (IL)
N. Lumen, Ghent (BE)

Genital trauma
D.M. Sharma, London (GB)
Dealing with the challenge of infection in urology
ESU Course 15
Saturday 16 March
14:30 - 17:30

Location: Green Area, Room 14
Chair: F.M.E. Wagenlehner, Giessen (DE)

Aims and objectives of this session
This ESU course on infection diseases provides a broad, up to date coverage of the most important and recent problems of infectious diseases in urology. Antimicrobial resistance is one of the biggest worldwide challenges in medicine and gains increasing importance in urology. The management of infections in general and of urogenital tract infections especially, has been compromised by this rapid and continuous increase of antimicrobial resistance. Basic biologic principles and strategies to treat urogenital tract infections from benign infections to life threatening infections will be discussed in this workshop:

- Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis.
- Diagnosis, treatment and prophylaxis strategies of urogenital tract infections.
- Uncomplicated and recurrent cystitis.
- Complicated urinary tract infections.
- Urosepsis and Fournier gangrene.
- Male genital tract infections.

Introduction
F.M.E. Wagenlehner, Giessen (DE)

Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis
Z. Tandoğdu, Newcastle Upon Tyne (GB)

Low grade and recurrent UTI
F.M.E. Wagenlehner, Giessen (DE)

Male genital infections: Prostatitis, epididymitis and urethritis
B. Köves, Budapest (HU)

Hospital acquired UTI and antibiotic resistance
Z. Tandoğdu, Newcastle Upon Tyne (GB)

Perioperative prophylaxis with special focus on prostate biopsies, stone surgery and prosthesis implantation
B. Köves, Budapest (HU)

Sepsis and Fournier’s gangrene
F.M.E. Wagenlehner, Giessen (DE)
Paediatric urology for the adult urologist. Congenital problems of the urinary tract: Obstruction and reflux and longterm outcome
ESU Course 14

Saturday 16 March
14:30 - 17:30

Location: Green Area, Room 15
Chair: J.M. Nijman, Groningen (NL)

Aims and objectives of this session
Many children with congenital anomalies will present to the adult urologist with long-term sequellae. It is important to know what has been done in terms of surgical procedures so that the adult urologist knows what he can do in the future. It is also important to know how the urological follow-up of these patients should be done. The most common paediatric conditions will be reviewed, while long-term complications will be explored by short interactive case presentations.

• Many children born with hydronephrosis may not require surgical intervention, but need close follow-up until after puberty.
• Penile and urethral reconstruction, such as hypospadias may have serious implications for transurethral procedures in the future.
• The clinical presentation of congenital anomalies of the urinary tract is changing but some of these may still present in the adult patient.
• Obstructive uropathy and VUR are not always surgical anomalies, but may be functional in nature: The treatment modalities and long-term outcomes depend on the pathophysiology.

Prenatal hydronephrosis / prenatal intervention and postnatal management
J.M. Nijman, Groningen (NL)

Vesico-ureteral reflux: Longterm outcome and complications
S. Tekgül, Sihhiye, Ankara (TR)

Obstructive uropathy: Megaureter, posterior urethral valves and the valve bladder. A life-long dilemma
D.N. Wood, London (GB)

Discussion
Aims and objectives of this session
• Prostate cancer is a global public health concern. While large randomized trials have shown a reduction in prostate cancer mortality with regular prostate-specific antigen (PSA) screening, there is potential for negative effects from over-diagnosis and treatment, making screening a controversial topic. This course will provide an overview of the evidence of both benefits and harm from the randomized trials as well as data from epidemiological studies illustrating the global incidence and mortality trends.
• Today’s challenges include the age when to start screening, screening intervals and the optimal use of "smarter screening". This course will cover the EAU-ESTRO-SIOG guidelines and other risk-stratified approaches to screening based on age, health and PSA-values, family history, ethnicity and genetic risk.
• Active surveillance (AS) is now widely accepted as a management strategy for low risk prostate cancer with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Several AS studies have consistently shown a low rate of progression to metastatic disease or death from prostate cancer with AS, with the majority of patients remaining free from definitive therapy for many years.
• Clinical and pathological factors influencing the risk of disease progression in patients with low risk prostate cancer under AS, surveillance strategy, role of repeat biopsy, inclusion criteria, and the use of MRI will be discussed.
• The course will be interactive and include illustrative and practical clinical case discussions.

Who, when, and how often to screen and when to stop? An illustrated risk-adapted strategy
S. Carlsson, New York (US)

Active surveillance
A.R. Zlotta, Toronto (CA)
Aims and objectives of this session
In many parts of Europe, open retropubic radical prostatectomy is still the gold standard for treating localised prostate cancer. The competition with radiotherapy and novel techniques like cryosurgery and HIFU, should encourage urologists to optimally perform the surgical resection. This teaching course is a must for the elder resident and the younger urologist but well trained urologists who do not treat many patients with localised prostate cancer, will benefit.

Introduction
O. Hakenberg, Rostock (DE)

Surgical anatomy
O. Hakenberg, Rostock (DE)

Step by step radical retropubic prostatectomy
G.N. Thalmann, Berne (CH)

Tips, tricks and pitfalls
O. Hakenberg, Rostock (DE)

Treatment of complications
G.N. Thalmann, Berne (CH)

Discussion and interaction
Aims and objectives of this session
This course was made more practical in 2016 with more cases, many video’s regarding TUR techniques and problems, to obtain optimal interaction with the audience. Both the 2016 and 2017 evaluation were very positive by the participants. Therefore, we chose to keep the subjects unchanged in 2018 with obvious updates where needed.

After discussing diagnostic opportunities of NMIBC, we will spent considerable time on the technique of TUR, including tips, potential problems, En bloc resection, TUR in difficult situations and TUR with enhanced imaging. We will illustrate this with video’s and discuss pitfalls with the audience. Additional risk adapted intravesical treatment including new modalities, including limitations of these recommendations, will be discussed next.

After that, we will discuss daily problems with regard to complications during and after intravesical therapy and how to prevent and treat that. Finally a topic that remains a clinical problem remains on the program: how to deal with abnormal cytology including locations outside the bladder. Since we try to keep the course as practical in interactive as possible we experienced lively discussions and interaction in Copenhagen in 2018. This might imply that we might not cover all topics as planned in the program. Our goal is that attendees will have updated their guideline knowledge, but also know what (not) to do in exceptional or complicated cases, and what alternatives could be.

Introduction
J.A. Witjes, Nijmegen (NL)

Diagnosis, markers and innovations, no video’s on PDD, NBI etc.
J. Palou, Barcelona (ES)

TUR technique: Tips and tricks; problems; En bloc resection; TUR and the location, including diverticula, ureteral meatus; Re-TUR; PDD, SPIES, NBI etc.: With several cases and video’s
M. Babjuk, Prague (CZ)

Complications during surgery and what to do: Obturator nerve contraction, intra and extraperitoneal perforation, bleeding etc.
J. Palou, Barcelona (ES)

Risk groups and guideline treatment: What is clearly established
J.A. Witjes, Nijmegen (NL)
<table>
<thead>
<tr>
<th>Title</th>
<th>Presenter, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comments on guideline treatment including BCG shortage and new treatment modalities</td>
<td>M. Babjuk, Prague (CZ)</td>
</tr>
<tr>
<td>Complications of intravesical therapy, including case</td>
<td>J.A. Witjes, Nijmegen (NL)</td>
</tr>
<tr>
<td>How to deal with abnormal cytology including locations outside the bladder (UUT and urethra) and its limitations</td>
<td>J. Palou, Barcelona (ES)</td>
</tr>
</tbody>
</table>
Lymphadenectomy in urological malignancies
ESU Course 19

Saturday 16 March
14:30 - 17:30

Location: Green Area, Room 23
Chair: A. Mattei, Luzern (CH)

Aims and objectives of this session
Mostly, in case of tumour surgery, a loco-regional lymph node (LND) dissection is also indicated.
With the introduction of minimal invasive surgery the LND often seems to have lost the attention of the surgeons and has been practiced in less cases and/or less extensively.
Throughout our presentation we will corroborate the indications when a LND has to be performed, the templates, the techniques using different approaches, and the oncological as well as functional outcomes.

After attending this course, participants should be able to:
• Know the indication when to perform LND during surgery for urological malignancies.
• Apply the most modern imaging concepts for the preoperative lymph node staging.
• Have solid knowledge about the templates that have to be removed.
• Be informed concerning the oncological and functional results of lymph node dissection as well as complications.

Renal cancer
U. Capitanio, Milan (IT)

Urothelial cancer
A. Mattei, Luzern (CH)

Prostate cancer
A. Mattei, Luzern (CH)

Testicular cancer
J. Sheinfeld, New York (US)

Penile cancer
U. Capitanio, Milan (IT)
Prostate cancer imaging from diagnosis to monitoring
Expert-Guided Poster Tour 06

Saturday 16 March
15:30 - 17:30

Location: Green Area, Room A (Expert-Guided Poster Tours)
Chairs: To be confirmed
A. Villers, Lille (FR)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

- Introduction
  To be confirmed
  A. Villers, Lille (FR)

PT136

Does cancer grade impact MRI accuracy in estimating lesion size for prostate focal therapy?

By: Aslim E.J. 1, Law T.Y.X. 1, Chen K. 1, Lee L.S. 1, Ho H.S.S. 1, Lau W.K.O. 1, Yuen J.S.P. 1, Cheng C.W.S. 1, Ngo N. 2, Law Y.M. 3, Tay K.J. 1

1 Singapore General Hospital, Dept. of Urology, Singapore, Singapore,
2 Singapore General Hospital, Dept. of Anatomical Pathology, Singapore, Singapore,
3 Singapore General Hospital, Dept. of Diagnostic Radiology, Singapore, Singapore

PT137

Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation

By: Blazevski A. 1, Scheltema M.J. 2, Yuen B. 1, Masand N. 2, Cusick T. 2, Haynes A. 2, Shnier R. 3, Stricker P.D. 1

1 St. Vincent's Prostate Cancer Centre, Dept. of Urology, Sydney, Australia,
2 Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Sydney, Australia,
3 Southern Radiology, Neuroscience Research Australia, Sydney, Australia

PT139

Evaluating the predictive role of automated bone scan index in selecting newly diagnosed metastatic prostate cancer patients for prostate radiotherapy: A STAMPEDE trial exploratory analysis

By: Ali A. 1, Hoyle A.P. 1, Parker C.C. 2, James N.D. 3, Brawley C.C. 4, Parmar M.K. 4, Sydes M.R. 4, Clarke N.W. 1

1 University of Manchester, Genito-Urinary Cancer Research Group, Manchester, United Kingdom,
2 Royal Marsden Hospital, Dept. of Academic Urology, London, United Kingdom,
3 University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham,
PT140 Clinical utility of prebiopsy PSMA PET CT in patients suspected of carcinoma prostate

By: Jain H., Sood R., Goel H.K., Sharma U., Kumar A.
PGIMER & Dr RML Hospital, Dept Of Urology & Renal Transplant, New Delhi, India

PT141 Potentials of 68Ga-prostate specific membrane antigen PET/CT for primary diagnosis of prostate cancer

By: Lopci E.¹, Saita A.², Lughezzani G.², Castello A.¹, Colombo P.³, Buffi N.², Hurle R.², Marzo K.¹, Leonardi L.¹, Benetti A.², Casale P.², Fasulo V.², Paciotti M.², Domanico L.², Maffei D.², Bevilacqua G.², Balzarini L.⁴, Chiti A.¹, Guazzoni G.², Lazzeri M.²
¹Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Nuclear-Medicine, Rozzano, Italy,
²Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy,
³Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Pathology, Rozzano, Italy,
⁴Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Radiology, Rozzano, Italy

PT142 The effect of androgen deprivation therapy on PSMA expression evaluated with 68Ga-PSMA-11 PET/ MRI - A prospective, registered clinical trial

By: Ettala O.¹, Malaspina S.², Tuokkola T.², Boström P.J.¹, Kemppainen J.³
¹Turku University Hospital, Dept. of Urology, Turku, Finland,
²University of Turku, Turku PET Centre, Turku, Finland,
³Turku University Hospital, Dept. of Clinical Physiology and Nuclear Medicine, Turku, Finland

PT143 Apparent diffusion coefficient ratio between tumor and nontumor as a potential imaging biomarker for prostate cancer

By: Matsuoka Y.¹, Tanaka H.², Kimura T.², Moriyama S.¹, Uehara S.¹, Yasuda Y.¹, Kijima T.¹, Yoshida S.¹, Yokoyama M.¹, Ishioka J.¹, Saito K.¹, Fujii Y.¹
¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan,
²Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan

PT144 Quantitative analysis between apparent diffusion coefficients on MRI and cellularity metrics of prostate cancer with whole-mount pathology

By: Gao J., Zhang Q., Zhang C., Guo H.
Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China

PT145 Clinical evaluation of dispersion MRI for prostate cancer localization: A multicenter study

By: Turco S.¹, Lavini C.², Heijmink S.³, Barentsz J.⁴, Wijkstra H.⁵, Mischi M.¹
¹Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven,
PT146

Likert vs. PI-RADS v2: A comparison of two radiological scoring systems for detection of clinically significant prostate cancer


1 Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom
2 Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom
3 Imperial College Healthcare NHS Trust, Dept. of Imperial Urology, London, United Kingdom
4 Imperial College Healthcare NHS Trust, Dept. of Imperial Urology, London, United Kingdom
5 Imperial College London, Dept. of Imperial Epidemiology and Biostatistics, London, United Kingdom
6 Imperial College Healthcare NHS Trust, Dept. of Imperial Radiology, London, United Kingdom

PT147

Risk stratification of high-risk prostate cancer based on MR prostate imaging for clinical practice and implementation in computer-aided software systems


1 University Hospital Essen, Dept. of Diagnostic and Interventional Radiology and Neuroradiology, Essen, Germany
2 Hirslanden Klinik Zürich, Dept. of Urology, Prostate Cancer Center Hirslanden, Zürich, Switzerland
3 Klinik Hirslanden Zürich, Dept. of Radiology, Zürich, Switzerland
4 University Hospital Essen, Dept. of Urology, Essen, Germany

PT148

Should we rely on multiparametric MRI of the prostate performed at non-academic centres? Implications for optimized target biopsy approaches


1 IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy
2 IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy

PT149

Improved interdisciplinary communication – the impact of structured reporting of prostate magnetic resonance imaging


1 University Hospital Basel, Dept. of Urology, Basel, Switzerland
2 University Hospital Basel, Clinic of Radiology and Nuclear Medicine, Basel, Switzerland
<table>
<thead>
<tr>
<th>PT150</th>
<th>3D multiparametric contrast ultrasound predicts the histopathological outcome of systematic biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Wildeboer R.R. 1, Van Sloun R.J.G. 1, Huang P. 2, Wijkstra H. 3, Mischi M. 1</td>
<td></td>
</tr>
<tr>
<td>1Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, Netherlands, The, 2Second Affiliated Hospital of Zhejiang University, Ultrasound, Hangzhou, China, 3Amsterdam UMC/AMC, Dept. of Urology, Amsterdam, Netherlands, The</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT151</th>
<th>A biparametric MRI based risk model for improved risk stratification and selection of biopsy-naïve men for prostate biopsies</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Boesen L. 1, Thomsen F.B. 1, Nørgaard N. 1, Løgager V. 2, Balslev I. 3, Bisbjerg R. 1, Thomsen H.S. 2, Jakobsen H. 1</td>
<td></td>
</tr>
<tr>
<td>1Herlev Gentofte University Hospital, Dept. of Urology, Herlev, Denmark, 2Herlev Gentofte University Hospital, Dept. of Radiology, Herlev, Denmark, 3Herlev Gentofte University Hospital, Dept. of Pathology, Herlev, Denmark</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT152</th>
<th>Do the performance characteristics of pre-biopsy mpMRI in detecting “clinically significant” prostate cancer vary according to age?</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Bryant R.J. 1, Brewster S.F. 1, Hobbs C.P. 1, Eyre K.S. 1, Davies L.C. 2, Sullivan M.E. 1, Shields W. 1, Sooriakumaran P. 3, Verrill C.L. 4, El-Sheikha J. 5, Hamdy F.C. 1, Macpherson R. 5, Gleeson F.V. 5</td>
<td></td>
</tr>
<tr>
<td>1Oxford University Hospitals NHS Foundation Trust, Dept. of Urology, Oxford, United Kingdom, 2University of Oxford, Nuffield Dept. of Population Health, Oxford, United Kingdom, 3University College London Hospital NHS Foundation Trust, Dept. of Uro-Oncology, London, United Kingdom, 4Oxford University Hospitals NHS Foundation Trust, Dept. of Pathology, Oxford, United Kingdom, 5Oxford University Hospitals NHS Foundation Trust, Dept. of Radiology, Oxford, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT153</th>
<th>Analysis of clinical and oncological follow-up after negative MRI-TRUS fusion biopsy of the prostate.</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Von Landenberg N., Noldus J., Hanske J., Berg S., Brock M.</td>
<td></td>
</tr>
<tr>
<td>Marien Hospital Herne, Ruhr University Bochum, Dept. of Urology, Herne, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT157</th>
<th>How important are prostate MRI reading skills to urologists?</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Sternberg I. 1, Fishelevitz A. 1, Kogan T. 2, Sagy I. 1, Buchler A. 1, Keizman D. 3, Dresler H. 3, Leibovitch I. 1</td>
<td></td>
</tr>
<tr>
<td>1Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, 2Meir Medical Center, Dept. of Pathology, Kfar Saba, Israel, 3Meir Medical Center, Dept. of Oncology, Kfar Saba, Israel</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT159</th>
<th>Automatic segmentation of the prostate in transrectal ultrasound images using deep learning for application in MRI-TRUS fusion</th>
</tr>
</thead>
</table>
PT160

Multivariable retrospective lesion based analyses of number of MRI ultrasound fusion targeted biopsy cores needed for prostate cancer detection in patients treated with radical prostatectomy

By: Leyh-Bannurah S-R. ¹, Kachanov M. ², Beyersdorff D. ³, Pompe R. ¹, Preisser F. ⁴, Tian Z. ⁵, Karakiewicz P. ⁵, Fisch M. ¹, Maurer T. ², Graefen M. ², Budäus L. ²

¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Martini-Klinik Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³University Medical Center Hamburg-Eppendorf, Dept. of Radiology, Hamburg, Germany, ⁴University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany, ⁵University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada

PT161

Assessing the diagnostic accuracy of micro-ultrasound for the detection of clinically significant prostate cancer: Results from a single-institutional experience

By: Lughezzani G. ¹, Maffei D. ¹, Paciotti M. ¹, Lazzeri M. ¹, Colombo P. ², Fasulo V. ¹, Domanico L. ¹, Casale P. ¹, Saita A. ¹, Hurle R. ¹, Buffi N. ¹, Guazzoni G.F. ¹

¹Humanitas Clinical and Research Hospital, Dept. of Urology, Milan, Italy, ²Humanitas Clinical and Research Center, Dept. of Pathology, Milan, Italy

PT163

Who gains additional benefits from systematic biopsy concurrently performed with MRI-ultrasound fusion targeted biopsy in the detection of significant prostate cancer?

By: Matsuoka Y. ¹, Uehara S. ¹, Yoshida S. ¹, Tanabe K. ¹, Tanaka H. ², Kimura T. ², Moriyama S. ¹, Yasuda Y. ¹, Kijima T. ¹, Yokoyama M. ¹, Ishioka J. ¹, Saito K. ¹, Fujiy Y. ¹

¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan
Benign prostatic enlargement management
Expert-Guided Poster Tour 07

Saturday 16 March
15:30 - 17:30

Location: Green Area, Room B (Expert-Guided Poster Tours)
Chairs: J-N.L. Cornu, Rouen (FR)
         S.M. Haensel, Rotterdam (NL)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

Introduction
S.M. Haensel, Rotterdam (NL)

PT164
Benign prostatic hyperplasia increases the risk of colon cancer: A population-based study

By: Lai C.H. ¹, Shih H-J. ¹, Huang C-J. ²
¹Wan Fang Hospital, Dept. of Urology, Taipei, Taiwan, ²Wan Fang Hospital, Dept. of Anesthesiology, Taipei, Taiwan

PT165
Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to severe symptoms: Results from clinical trial simulations using individual IPSS trajectories

By: Della Pasqua O. ¹, D’agate S. ², Adalig B. ³, Wilson T. ⁴, Chavan C. ⁵, Manyak M. ⁶, Palacios-Moreno J.M. ⁷, Oelke M. ⁸, Roehrborn C. ⁹
¹GlaxoSmithKline, Dept. of Urology, London, United Kingdom, ²University College London, Clinical Pharmacology and Therapeutics Group, London, United Kingdom, ³GlaxoSmithKline, Dept. of Urology, Istanbul, Turkey, ⁴PAREXEL International, Dept. of Statistics, Durham, United States of America, ⁵GlaxoSmithKline, Dept. of Urology, Mumbai, India, ⁶GlaxoSmithKline, Dept. of Urology, Washington, United States of America, ⁷GlaxoSmithKline, Dept. of Urology, Madrid, Spain, ⁸St. Antonius Hospital, Dept. of Urology, Gronau, Germany, ⁹University of Texas Southwestern Medical Center, Dept. of Urology, Texas, United States of America

PT166
Management of urinary retention in patients with benign prostatic obstruction: A systematic review and meta-analysis

By: Karavitakis M. ¹, Kyriazis I. ², Omar M.I. ³, Gravas S. ⁴, Cornu J-N. ⁵, Drake M.J. ⁶, Gacci M. ⁷, Gratzeke C. ⁸, Herrmann T.R.W ⁹, Madersbacher S. ¹⁰, Rieken M. ¹¹, Speakman M.J. ¹², Tikkinen K.A. ¹³, Yuan Y. ¹⁴, Mamoulakis C. ¹⁵
¹Athens Medical Center, Dept. of Minimally Invasive Urology, Athens, Greece, ²University
PT167

**Detrusor wall thickness does not predict a successful trial without catheter after acute urinary retention in patients on medical treatment for benign prostatic hyperplasia**

By: De Nunzio C.¹, Tema G.¹, Cindolo L.², Bada M.¹, Lombardo R.¹, Cicione A.¹, Nacchia A.¹, Cancrini F.¹, Schips L.², Gacci M.³, Milanesi M.³, Cito G.³, Semis S.³, Tubaro A.¹

¹Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ²S.Pio da Pietrelcina Hospital, Dept. of Urology, Vasto, Italy, ³University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy

PT168

**The outcomes of male patients with acute urinary retention with concomitant post-obstructive diuresis**

By: Fishelevitz A., Leibovitch I., Vainrib M.

Meir Medical Center, Dept. of Urology, Kfar Saba, Israel

PT169

**Is it clinically useful to screen all patients with LUTS for erectile dysfunction?**

By: Capogrosso P.¹, Ventimiglia E.¹, Boeri L.¹, Pozzi E.², Schifano N.¹, Chierigo F.¹, Belladelli F.², Cazzaniga W.¹, Abbate C.¹, Dehò F.¹, Mirone V.³, Gaboardi F.⁴, Montorsi F.¹, Salonia A.¹

¹IRCCS Ospedale San Raffaele, Unit of Urology, URI, Milan, Italy, ²Università Vita-Salute San Raffaele, Unit of Urology, URI, Milan, Italy, ³University of Naples “Federico II”, Department of Neurosciences, Sciences of Reproduction and Odontostomatlogy, Urology Unit, Naples, Italy, ⁴IRCCS Ospedale San Raffaele Turro, Unit of Urology, URI, Milan, Italy

PT171

**A high preoperative PSA level is not accurate to predict incidental prostate cancer detection in patient underwent endoscopic enucleation of the prostate for large glands**

By: Misrai V.¹, Peyronnet B.², Pradere B.³, Bordier B.¹, Guillotreau J.¹, Gryn A.¹,
PT172

Postoperative PSA levels after holmium laser enucleation of the prostate: Enucleation ratio matters rather than preoperative prostate volume

By: Kimura S., Ohara E., Aoki H., Ishidoya S.
Sendai City Hospital, Dept. of Urology, Sendai, Japan

PT173

Diagnosing incidental prostate cancer (pT1a/b): Is the game worth the candle in times of changing health economics?

AZ Maria Middelares, Dept. of Urology, Gent, Belgium

PT174

How should we screen out prostate cancer from benign prostate hyperplasia patients? Analysis of 764 cases treated with Holmium laser enucleation of the prostate in a tertiary institution

By: Kimura S., Ohara E., Aoki H., Shibuya R., Naganuma H., Ishidoya S.
1Sendai City Hospital, Dept. of Urology, Sendai, Japan, 2Sendai City Hospital, Dept. of Pathology, Sendai, Japan

PT175

Preoperative pelvic floor muscle exercise for early continence after holmium laser enucleation of the prostate: A randomized controlled study

By: Anan G., Iwamura H., Ito J., Kaiho Y., Sato M.
Tohoku Medical and Pharmaceutical University, Dept. of Urology, Sendai, Japan

PT176

Holmium laser enucleation of the prostate (HoLEP): Evaluation of the first thousand patients

Vall d’Hebron University Hospital, Dept. of Urology, Barcelona, Spain

PT177

Track and teach: Simplified endoscope tracking in prostate enucleation reveals differing motion patterns dependent on surgeon experience

By: Dressler F.F., Gratzke C., Miernik A., Schöb D.S.
University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany

PT179

Holmium laser transurethral enucleation of the prostate 100 W vs 120 W: 12-month retrospective data from a single surgeon experience

By: Franco M., Sanchez Macias J., Mercader C., Pardo A., Camacho Rovira D., Calaf O., D’anna M., Rifa Lapienza L., Alcaraz A.
<table>
<thead>
<tr>
<th>PT180</th>
<th>The influences of preoperative acute urinary retention to holmium laser enucleation of prostate: Multicenter analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Bae S.(^1), Park B.H.(^1), Chung H.(^2), Lee Y.S.(^1), Kim H.S.(^2), Kang S.H.(^1), Han C.H.(^1)</td>
</tr>
<tr>
<td></td>
<td>(^1)The Catholic University of Korea, Uijeongbu St.Mary’s Hospital, Dept. of Urology, Gyeonggi-do, Korea, South, (^2)Konkuk University Chungju Hospital, Dept. of Urology, Chungcheongbuk-do, Korea, South</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT182</th>
<th>Initial results of a prospective randomized trial on the learning curve of three endoscopic enucleation techniques (HoLEP, ThuFLEP and MEP) for BPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Taratkin M.(^1), Enikeev D.(^1), Rapoport L.(^1), Enikeev M.(^1), Glybochko P.(^1) Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT183</th>
<th>Vaporesection of the prostate with Tm:YAG laser: The oyster technique</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Kotsiris D.(^1), Kallidonis P.(^1), Adamou K.(^1), Kyriazis J.(^1), Ntasiotis P.(^1), Saki Z.(^1), Liatsikos E.(^1) University of Patras, Dept. of Urology, Patras, Greece</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT184</th>
<th>Energy impact on voiding symptoms after thulium enucleation of prostate: A large multi institutional analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Nazzani S.(^1), Motta G.(^1), Blezien O.(^1), Vizziello D.(^1), Signorini C.(^1), Maruccia S.(^2), Casellato S.(^3), Acquati P.(^1), Stubinski R.(^1), Carmignani L.F.(^1)</td>
</tr>
<tr>
<td></td>
<td>(^1)IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, (^2)Istituti Clinici Zucchi, Dept. of Urology, Monza, Italy, (^3)Istituti Clinici Zucchi, Dept. of Urology, Milan, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT185</th>
<th>Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia: A single centre 3-year comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Lombardo R.(^1), Gentile B.C.(^2), Mirabile G.(^2), Albanesi L.(^2), Tariciotti P.(^2), Tema G.(^1), Aloisi P.(^2), Davilla L.(^2), Bellangino M.(^2), Rizzo G.(^2), Lopes Mendes A.L.(^2), Giulianelli R.(^2)</td>
</tr>
<tr>
<td></td>
<td>(^1)Sapienza University of Roma, Dept. of Urology, Rome, Italy, (^2)Nuova Villa Claudia, Dept. of Urology, Rome, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT186</th>
<th>Aquablation for treating benign prostatic obstruction in small to medium-size glands: 6 months-outcomes of the first French registry</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Misrai V.(^1), Barry Delongchamps N.(^2), Descazeaud A.(^3)</td>
</tr>
<tr>
<td></td>
<td>(^1)Clinique Pasteur, Dept. of Urology, Toulouse, France, (^2)Cochin Hospital, Dept. of Urology, Paris, France, (^3)Dupuytren Hospital, Dept. of Urology, Limoges, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT187</th>
<th>Aquablation of the prostate. Real-life data from 180 consecutive patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Bach T.(^1), Giannakis I.(^2), Karimi M.(^1), Rijo E.(^3)</td>
</tr>
<tr>
<td></td>
<td>(^1)Hospital Clinic, Dept. of Urology, Barcelona, Spain, (^2)Laseralia, C.E.O., Barcelona, Spain, (^3)Hospital Germans Trias, Dept. of Urology, Barcelona, Spain</td>
</tr>
</tbody>
</table>
### Scientific Programme - EAU19 Barcelona

1Asklepios Hospital Harburg, Dept. of Urology, Hamburg, Germany, 2Kantonspital Frauenfeld, Dept. of Urology, Frauenfeld, Switzerland, 3Hospital Quirón Barcelona, Dept. of Urology, Hamburg, Germany

| PT188 | Withdrawn  
To be confirmed |
| --- | --- |
| **PT189** | Inferior tissue ablation after 120W greenlight laser vaporization does not result into inferior clinical outcome compared to conventional TURP: Update of a prospective 3D ultrasound volumetry study after 5 years  
By: Kranzbühler B., Gross O., Fankhauser C., Wettstein M., Grossmann N., Keller E., Eberli D., Sulser T., Poyet C., Hermanns T.  
University Hospital Zürich, Dept. of Urology, Zurich, Switzerland |
| **PT190** | Anticoagulants continued during PVP does not impact the risk of postoperative hemorrhagic complications: A multicentric prospective study  
By: Pradere B. 1, Naspro R. 2, Peyronnet B. 3, Guillotreau J. 4, Bordier B. 4, Misrai V. 4  
1CHRU Tours, Dept. of Urology, Tours, France, 2ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, France, 3CHU Rennes, Dept. of Urology, Rennes, France, 4Clinique Pasteur, Dept. of Urology, Toulouse, France |
| **PT191** | Clinical comparison of holmium laser enucleation of the prostate (HoLEP) and bipolar transurethral enucleation of the prostate (BTUEP) in patients under either anticoagulation or antiplatelet therapy  
By: Boeri L. 1, Capogrosso P. 1, Ventimiglia E. 1, Fontana M. 2, Sampogna G. 2, Zanetti S.P. 2, Pozzi E. 1, Schifano N. 1, Zuabi R. 1, Chierigo F. 1, Scattoni V. 1, Longo F. 2, Gadda F. 2, Dell’orto P.G. 2, Montorsi F. 1, Montanari E. 2, Salonia A. 1  
1IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology; URI, Milan, Italy, 2IRCCS Fondazione Ca’ Granda - Maggiore Policlinico Hospital, Dept. of Urology, Milan, Italy |
| **PT192** | A prospective, randomized controlled trial (RCT) regarding antimicrobial prophylaxis in transurethral resection of the prostate (TURP): An interim analysis of the prophylaxis001-trial  
By: Baten E. 1, Ariis I. 2, Goethuys H. 3, Vandecandelaere M. 4, Cartuyvels R. 5, Van Der Aa F. 1, Van Renterghem K. 6  
1UZLeuven, Dept. of Urology, Leuven, Belgium, 2UHasselt, Dept. of Biomedical Sciences, Hasselt, Belgium, 3ZOL Genk, Dept. of Urology, Genk, Belgium, 4KUILeuv, Dept. of Educational Sciences, Leuven, Belgium, 5Jessa Ziekenhuis, Dept. of Microbiology, Hasselt, Belgium, 6Jessa Ziekenhuis, Dept. of Urology, Hasselt, Belgium |
**A prospective multicenter evaluation of predictive factors for positive surgical margins after partial nephrectomy for renal cell carcinoma: The RECORD2 project**

By: Mari A.¹, Di Maida F.¹, Schiavina R.², Amparore D.³, Antonelli A.⁴, Barale M.⁵, Borghesi M.², Bove P.⁶, Brunocilla E.², Capitanio U.⁷, Da Pozzo L.⁸, Gontero P.⁵, Larcher A.⁷, Longo N.⁹, Montanari E.¹⁰, Porpiglia F.³, Sermi S.¹, Simeone C.⁴, Siracusano S.¹¹, Trombetta C.¹², Volpe A.¹³, Ficarra V.¹⁴, Carini M.¹, Minervini A.¹

¹University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ²University of Bologna, Dept. of Urology, Bologna, Italy, ³San Luigi Gonzaga Hospital, Dept. of Oncology, Division of Urology, Orbassano, Italy, ⁴University of Brescia, Spedali Civili Hospital, Dept. of Urology, Brescia, Italy, ⁵University of Studies of Torino, San Giovanni Battista Hospital, Dept. of Surgical Sciences, Turin, Italy, ⁶University Hospital of Tor Vergata, Dept. of Urology, Rome, Italy, ⁷URI-Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁸Papa Giovanni XXIII Hospital, Dept. of Urology, Bergamo, Italy, ⁹University Federico II of Naples, Dept. of Urology, Naples, Italy, ¹⁰Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Policlinico, University of Milan, Dept. of Urology, Milan, Italy, ¹¹Azienda Ospedaliera Universitaria Integrata (A.O.U.I.) of Verona, Dept. of Urology, Verona, Italy, ¹²University of Trieste, Dept. of Urology, Trieste, Italy, ¹³Maggiore della Carità Hospital, Dept. of Urology, Novara, Italy, ¹⁴University of Messina, Dept. of Human and Paediatric Pathology Gaetano Barresi, Urologic Section, Messina, Italy

**Predictors of positive surgical margins after partial nephrectomy for localized renal masses: Results of a prospective multicentre study (Surface-Intermediate-Base Project)**


¹University of Florence, Dept. of Urology, Florence, Italy, ²Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, United States of America, ³European Institute of Oncology (IEO), University of Milan, Dept. of Urology, Milan, Italy, ⁴Southmead Hospital,
Assessment of clinicopathological predictors of local recurrence on tumor resection bed in patients treated with partial nephrectomy for localized renal cell carcinoma (the RECORd 1 project)

By: Mari A. 1, Tellini R. 1, Amparore D. 2, Antonelli A. 3, Bianchi G. 4, Fiori C. 5, Furlan M. 6, Longo N. 7, Mirone V. 7, Morgia G. 8, Novara G. 9, Porpiglia F. 5, Schiavina R. 10, Di Maida F. 1, Campi R. 1, Presutti M. 1, Simeone C. 6, Terrone C. 11, Carini M. 1, Minervini A. 1

1University of Florence, Dept. of Urology, University of Florence, Careggi Hospital, Florence, Italy, 2Università di Torino, Divisione di Urologia, Ospedale San Luigi Gonzaga, Orbassano, Torino, Orbassano, Torino, Italy, 3Azienda AO Spedali Civili di Brescia, Unità Operativa di Urologia, Brescia, Italy, 4Università di Modena, Clinica Urologica, Policlinico di Modena, Modena, Italy, 5Università di Torino, Ospedale San Luigi Gonzaga, Orbassano, Torino, Orbassano, Torino, Italy, 6Azienda AO Spedali Civili di Brescia, Unità Operativa di Urologia Dipartimento di NefroUrologia, Brescia, Italy, 7Università di Napoli, Policlinico Federico II, Napoli, Italy, 8University of Catania, Dept. of Urology, Catania, Italy, 9Università di Padova, Clinica Urologica, Padova, Italy, 10Università di Bologna, Dipartimento di Urologia, Bologna, Italy, 11Azienda Ospedaliera Maggiore della Carità, Dipartimento di Urologia, Novara, Italy

A novel trifecta to simplify the assessment of perioperative outcomes after robot assisted partial nephrectomy for cT1 renal masses: Results of a multicenter series

By: Anceschi U. 1, Bertolo R. 2, Brassetti A. 1, Tuderti G. 1, Guaglianone S. 1, Garisto J. 3, Kaouk J. 2, Mottrie A. 4, Dell’oglio P. 4, Veccia A. 5, Antonelli A. 5, Capitanio U. 6, Montorsì F. 6, Larcher A. 6, Minervini A. 7, Porpiglia F. 8, Aron M. 9, Ithaar D. 10, Autorino R. 11, Swavely N. 11, Eun D. 12, Ferriero M. 1, Gallucci M. 1

1Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, 3Cleveland Clinic, Dept. of 
337

A preoperative nomogram to predict major complications after robot assisted partial nephrectomy

By: Khene Z-E. 1, Peyronnet B. 1, Bernhard J. 2, Kocher N. 3, Vaessen C. 4, Doumerc N. 5, Pradere B. 6, Seisen T. 4, Beauval J. 5, Verhoest G. 1, Roumiguie M. 5, De La Taille A. 7, Bruyere F. 6, Roupret M. 4, Méjean A. 8, Mathieu R. 1, Shariat S. 9, Raman J. 3, Bensalah K. 1

1University of Rennes, Dept. of Urology, Rennes, France, 2University of Bordeaux, Dept. of Urology, Bordeaux, France, 3Penn State Health Milton S. Hershey Medical Center, Dept. of Urology, Hershey, United States of America, 4La Pitié Salpêtrière Hospital, Dept. of Urology, Paris, France, 5University of Toulouse, Dept. of Urology, Toulouse, France, 6University of Tours, Dept. of Urology, Tours, France, 7Mondor Hospital, Dept. of Urology, Créteil, France, 8University of Paris Descartes, Dept. of Urology, Paris, France, 9Medical University Vienna, Dept. of Urology, Vienna, Austria

339

Clinicopathologic factors that influence the occurrence of symptomatic pseudoaneurysm after partial nephrectomy and the influence of selective arterial embolization on postoperative renal function

By: Lee C.H. 1, Seo W.I. 1, Ku J.Y. 2, Chung J.I. 1, Park Y.J. 3, Ha H.K. 2, Choi S.H. 4

1Inje University Busan Paik Hospital, Dept. of Urology, Busan, Korea, South, 2Pusan National University Hospital, Dept. of Urology, Busan, Korea, South, 3Pusan National University Hospital, Dept. of Internal Medicine, Busan, Korea, South, 4Kyungpook National University Hospital, Dept. of Urology, Daegu, Korea, South

340

Clinical and surgical predictors of medical and surgical postoperative complications in patients with limited life expectancy treated with partial nephrectomy for renal tumors: Insight from the RECORD2 project

By: Mari A. 1, Tellini R. 1, Gontero P. 2, Amparore D. 3, Antonelli A. 4, Barale M. 5, Bertini R. 6, Bove P. 7, Brunocilla E. 8, Capitanio U. 6, Da Pozzo L. 9, Miron V. 10, Montanari E. 11, Pisano F. 12, Pompiglia F. 13, Schiavina R. 8, Seri S. 14, Simeone C. 4, Trombetta C. 15, Volpe A. 16, Artibani W. 17, Ficarra V. 18, Carini M. 1, Minervini A. 1

1University of Florence, Dept. of Urology, University of Florence, Careggi Hospital, Florence, Italy, Florence, Italy, 2University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, San Giovanni Battista Hospital, Turin, Italy, 3San Luigi Gonzaga Hospital, Division of Urology, Dept. of Oncology, San Luigi Gonzaga Hospital, School of Medicine, Orbassano, Turin, Italy, 4University of Brescia, Dept. of Urology, Spedali Civili Hospital, Brescia, Italy, 5University of Turin., Division of Urology, Dept. of Surgical Sciences, San Giovanni Battista Hospital, Torino, Italy, 6Vita-Salute San Raffaele
Scientific Programme - EAU19 Barcelona

341

Retrospective comparative study between robot-assisted partial nephrectomy and open partial nephrectomy for the treatment of highly complex renal tumors with RENAL nephrometry score ≥8

By: Kim J.J., Lee D.H., Hong S.K., Byun S-S.
Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, Korea, South

342

Perioperative complications after partial nephrectomy for complex (PADUA score ≥10) renal tumors: A prospective multicenter observational study (the RECORD2 Project)

1University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, 2San Luigi Gonzaga Hospital, School of Medicine, Division of Urology, Dept. of Oncology, Orbassano, Turin, Italy, 3Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, 4San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Dept. of Oncology, Turin, Italy, 5University Hospital of Tor Vergata, Dept. of Urology, Rome, Italy, 6University of Bologna, Dept. of Urology, Bologna, Italy, 7Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Division of Urology, Dept. of Oncology, Milan, Italy, 8Papa Giovanni XXIII Hospital, Dept. of Urology, Bergamo, Italy, 9San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Dept. of Oncology, Turin, Italy, 10University Federico II of Naples, Dept. of Urology, Naples, Italy, 11Foundation IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Policlinico, University of Milan, Dept. of Urology, Milan, Italy, 12Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Unit of Urology, Division of Experimental Oncology, Milan, Italy, 13University of Trieste, Dept. of Urology, Trieste, Italy, 14Maggiore della Carità Hospital, Dept. of Urology, Novara, Italy, 15Azienda Ospedaliera Universitaria Integrata (A.O.U.I.), Dept. of Urology, Verona, Italy, 16University of Messina, Dept. of Urology, Messina, Italy
Head to head impact of MIC vs a novel TRIFECTA score on oncologic and functional outcomes after robotic assisted partial nephrectomy: Results of a multicentric series

By: Anceschi U. 1, Bertolo R. 2, Brassetti A. 1, Tuderti G. 1, Capitanio U. 3, Nandanan N. 4, Ferriero M.C. 1, Larcher A. 5, Veccia A. 6, Guaglianone S. 1, Garisto J. 2, Mottrie A. 7, Antonelli A. 6, Minervini A. 8, Dell'oglio P. 7, Amparore D. 9, Mari A. 10, Derweesh I. 11, Porpiglia F. 9, Montorsi F. 5, Koauk J. 2, Autorino R. 4, Gallucci M. 1, Simone G. 1

1 Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2 Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, 3 San Raffaele, Dept. of Urology, Milan, Italy, 4 VCU, Dept. of Urology, Virginia, United States of America, 5 San Raffaele, Dept. of Urology, Milan, Italy, 6 University of Brescia, Dept. of Urology, Brescia, Italy, 7 OLV Aalst, Dept. of Urology, Aalst, Belgium, 8 University of Florence, Dept. of Urology, Florence, Italy, 9 San Luigi Orbassano, Dept. of Urology, Orbassano, Italy, 10 University of Florence, Dept. of Urology, Florence, Italy, 11 UCSD Health System La Jolla, Dept. of Urology, San Diego, United States of America
**345**

**Postoperative vacuum therapy following AMS™ LGX 700® inflatable penile prosthesis placement: Penile dimension outcomes and overall satisfaction**

By: Antonini G.¹, Busetto G.M.¹, Del Giudice F.¹, Gross M.S.², Perito P.E.³, De Berardinis E.¹

¹Sapienza Rome University Policlinico Umberto I, Dept. of Urology, Rome, Italy,
²Dartmouth-Hitchcock Medical Center, Dept. of Urology, Lebanon, United States of America,
³Coral Gables Hospital, Dept. of Urology, Coral Gables, United States of America

**346**

* **Adherence to the AUA penile prosthesis antibiotic prophylaxis guidelines in diabetic patients is associated with significantly higher risks of device infection**

By: Towe M.¹, Osman M.¹, Huynh L.¹, El-Khatib F.M.¹, Diabetes and Infection Prosthesis Group D.¹, Yafi F.¹

University of California, Irvine, Dept. of Urology, Orange, United States of America

**347**

**Which patient may benefit the most from penile prosthesis implantation?**

By: Deho F.¹, Capogrosso P.², Bettocchi C.³, Colombo F.⁴, Liguori G.⁴, Fiordelise S.³, Vitarelli A.³, Silvani M.³, Mondaini N.⁴, Paradiso M.⁴, Ceruti C.³, Utizi L.⁴, Varvello F.⁴, Palumbo F.⁴, Avolio A.³, Antonini G.⁴, Pozza D.⁴, Franco G.³, Bitelli M.³, Conti E.⁴, Caraceni E.⁴, Pescatori E.⁴, Palmieri A.⁴

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ³Società Italiana di Andrologia SIA, Dept. of Urology Andrology, Roma, Italy, ⁴Società Italiana di Andrologia SIA, Dept. of Urology Andrology, Roma, Italy

**348**

**Outcomes of 764 inflatable penile prostheses in 547 female-to-male transsexuals undergoing phalloplasty**

By: Christopher A.N.¹, Garaffa G.¹, Ralph D.J¹

University College London Hospital, Dept. of Urology, London, United Kingdom
349  Larger malleable rod diameter is associated with more complications and less patient satisfaction

By: Habous M.E., Teloken P., Abdelwahab O., Tealab A., Kamil U., Mulhall J., Bettocchi C., Ralph D.

1 Elaj Medical Centers, Dept. of Urology, Jeddah, Saudi Arabia, 2 Gold Cost University Hospital, Dept. of Urology, Queensland, Australia, 3 MSKCC, Dept. of Sexual Medicine and Infertility, New York, United States of America, 4 Bari University, Dept. of Urology, Bari, Italy, 5 UCLH, Dept. of Andrology, London, United Kingdom

350  Comparison of long term results and couples' satisfaction with penile implant types and brands: Lessons learned from 883 patients with erectile dysfunction who underwent penile prosthesis implantation

By: Çayan S., Aşcı R., Efesoy O., Bolat M.S., Akbay E., Yaman Ö.

1 University of Mersin, School of Medicine, Dept. of Urology, Mersin, Turkey, 2 Ondokuz Mayis University, School of Medicine, Dept. of Urology, Samsun, Turkey, 3 Ankara University, School of Medicine, Dept. of Urology, Ankara, Turkey

351  Predictors of 30-day revisit and associated costs following penile prosthesis surgery

By: Friedlander D.F., Berger A.J., Trinh Q-D.

Brigham and Women's Hospital, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America

352  Immediate preoperative blood glucose and Hemoglobin A1c levels are not predictive of post-operative infections in diabetic men undergoing penile prosthesis placement

By: Osman M., Huynh L., El-Khatib F.M., Towe M., Yafi F.

University of California, Irvine, School of Medicine, Dept. of Urology, Orange, United States of America

354  Fasting blood sugar at the time of penile prosthesis surgery is not correlated with the outcome of surgery

By: Habous M.E., Teloken P., Binsaleh S., Mulhall J., Abdelwahab O., Ralph D.

1 Elaj medical center, Dept. of Urology, Jeddah, Saudi Arabia, 2 Gold Cost University Hospital, Dept. of Urology, Queensland, Australia, 3 King Saud University, Dept. of Urology, Riyadh, Saudi Arabia, 4 MSKCC, Dept. of Sexual Medicine and Infertility, New York, United States of America, 5 Benha University, Dept. of Urology, Benha, Egypt, 6 St. Peter Institute of Andrology, UCLH, Dept. of Andrology, London, United Kingdom

355  20-Year follow-up after penile prosthesis implantation – functional and quality of life outcomes

By: Chierigo F., Capogrosso P., Dehò F., Ventimiglia E., Cazzaniga W., Boeri
Neurogenic bladder is an independent risk factor for complications associated with inflatable penile prosthesis placement

By: Dave C., Khalaf A., Trock B., Burnett A.
Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America

How can we optimise the penile implant surgery?
To be confirmed
Genomic biomarkers for diagnosis and prognosis of prostate cancer

Location: Green Area, Room 4
Chairs: R. Flanigan, Maywood (US)
       G. Jenster, Rotterdam (NL)
       K.A. Tasken, Oslo (NO)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

358

Molecular phenotypes in DNA repair deficiency correlate with specific clinical outcomes subtypes and genetic background

By: Cussenot O.¹, Perrot E.², Brureau L.², Blanchet P.², Diedhiou A.³, Comperat E.¹, ilie D.⁴, Pruss D.⁴, Timms K.M.⁴, Cancel-Tassin G.⁵
¹Sorbonne Universite, GRC n°5, ONCOTYPE-URO, AP-HP, Tenon Hospital, Paris, France, ²CHU Pointe-a-Pitre/Abymes, Dept. of Urology, Pointe a Pitre, Guadeloupe, ³CHU Pointe-a-Pitre/Abymes, Dept. of Pathology, Pointe a Pitre, Guadeloupe, ⁴Myriad Genetics Inc, Salt Lake City, United States of America, ⁵CeRePP, Paris, France

359

Mitochondrial dysfunction correlates directly with progression and poor long-term prognosis in prostate cancer

By: Sachdeva A.¹, Hart C.A.², Carey C.³, Lawless C.¹, Brown M.D.², Greaves L.¹, Heer R.⁴, Turnbull D.M.¹, Clarke N.W.²
¹Newcastle University, Wellcome Centre for Mitochondrial Research, Newcastle-upon-Tyne, United Kingdom, ²University of Manchester, Genito-Urinary Cancer Research Group, Manchester, United Kingdom, ³Newcastle University, Dept. of Molecular Pathology Node, Newcastle-upon-Tyne, United Kingdom, ⁴Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom

360

INSM1 expression discriminates neuroendocrine differentiation from Paneth cell-like change in prostate cancer and predicts castration-resistance progression

By: Xin Z., Zhu Y., Pan J., Dong B., Xue W.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China

361

5hmC levels predict biochemical failure following radical prostatectomy in prostate cancer patients with ERG negative tumors

By: Kristensen¹, Strand S.H², Røder M.A¹, Berg K.D¹, Toft B.G³, Høyer S.⁴, Borre M.⁵, Sørensen K.D², Brasso K.¹
¹Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center,
Genomic profiling of patients with metastatic castration-resistant prostate cancer (mCRPC) for the evaluation of rucaparib: Next-generation sequencing (NGS) of tumour tissue and cell-free DNA (cfDNA)


1Instituto Catalan de Oncologia, Dept. of Medical Oncology, Barcelona, Spain, 2Memorial Sloan Kettering Cancer Center, Dept. of Genitourinary Oncology, New York, United States of America, 3Adelaide and Meath Hospital (Incorporating the National Children’s Hospital), Dept. of Genito-Urinary Oncology, Dublin, Ireland, 4 Cabrini Hospital, Dept. of Medical Oncology, Malvern, Australia, 5Mount Vernon Cancer Centre, Dept. of Clinical Oncology, Northwood, United Kingdom, 6The Ottawa Hospital Centre, Dept. of Medical Oncology, Ottawa, Canada, 7Veje Sygehus, Dept. of Oncology, Vejle, Denmark, 8Royal Hobart Hospital, Dept. of Medical Oncology, Hobart, Australia, 9University of Maryland Greenebaum Cancer Center, Dept. of Medicine, Baltimore, United States of America, 10Urology Associates Clinical Research, Dept. of Oncology, Nashville, United States of America, 11University Hospital Geelong (Barwon Health), Dept. of Medical Oncology, Geelong, Australia, 12Rocky Mountain Cancer Centers – USOR, Dept. of Medical Oncology, Hematology, Aurora, United States of America, 13Centre Eugène Marquis, Dept. of Medical Oncology, Rennes, France, 14Royal Marsden Hospital, Dept. of Medical Oncology, London, United Kingdom, 15Clinique Victor Hugo Centre Jean Bernard, Dept. of Medical Oncology, Le Mans, France, 16Centre Hospitalier Universitaire Dr-Georges-L.-Dumont, Dept. of Medical Oncology, Moncton, Canada, 17Centre d’Oncologie de Gentilly, Dept. of Medical Oncology, Nancy, France, 18Premier Medical Group of the Hudson Valley, Dept. of Urology, Poughkeepsie, United States of America, 19Frimley Health NHS Foundation Trust, Dept. of Medical Oncology, Slough, United Kingdom, 20Clovis Oncology, Inc., Dept. of Translational Medicine, Boulder, United States of America, 21Clovis Oncology, Inc., Clinical Development, Boulder, United States of America, 22Clovis Oncology, Inc., Clinical Science, Boulder, United States of America, 23University of Minnesota, Dept. of Medicine, Minneapolis, United States of America, 24Guy’s Hospital and Sarah Cannon Research Institute, Dept. of Medical Oncology, London, United Kingdom

Ductal adenocarcinoma of the prostate: Exploring its genetic landscape

By: Chow K. 1, Wong L-M. 2, Bedo J. 3, Papenfuss A.T. 3, Peters J.S. 4, Costello A.J. 4, Hovens C.M. 1, Corcoran N.M. 1

1University of Melbourne, Dept. of Surgery, Melbourne, Australia, 2St Vincent's Hospital, Dept. of Urology, Melbourne, Australia, 3Walter and Eliza Hall Institute of Medical
364 Tumor-metastasis crosstalk in prostate cancer: Examining the effects of cytoreductive primary tumor removal in an orthotopic xenograft model

By: Linxweiler J.¹, Hajili T.¹, Körbel C.², Zeuschner P.¹, Menger M.D.², Stöckle M.¹, Junker K.¹, Saar M.¹
¹Saarland University, Dept. of Urology, Homburg Saar, Germany, ²Saarland University, Institute for Clinical-Experimental Surgery, Homburg Saar, Germany

365 The cluster of differentiation 44 variant 8-10 messenger RNA contained in exosomes is a potential marker for docetaxel resistance among prostate cancer patients

By: Kato T.¹, Mizutani K.¹, Horie K.¹, Kawakami K.², Fujita Y.², Ito M.², Koie T.¹
¹Gifu University Graduate School of Medicine, Dept. of Urology, Gifu, Japan, ²Tokyo Metropolitan Institute of Gerontology, Research Team for Mechanism of Aging, Tokyo, Japan

366 Natural killer cell activity: An innovative biomarker predicting prostate cancer severity

By: Kuo M-C.¹, Huang C-Y.¹, Kung H-N.², Lu Y-C.¹
¹National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan, ²National Taiwan University, Dept. of Anatomy and Cell Biology, Taipei City, Taiwan

367 Capturing circulating tumor cells from a large blood volume: A pilot study using diagnostic leukapheresis

Johns Hopkins Hospital, Dept. of Urology, Baltimore, United States of America

368 Circulating tumor DNA targeted sequencing predicts the prognosis of mCRPC patients

By: Dong B.¹, Fan L.¹, Yang B.², Wu K.³, Zhang F.⁴, Chen W.⁵, Huihua C.⁶, Pan J.¹, Zhu Y.¹, Luo C.⁷, Yang Y.⁷, Zhao G.⁷, Wang C.⁷, Li L.⁸, Yao X.², Wei X.¹
¹Renji hospital, Dept. of Urology, Shanghai, China, ²Shanghai Tenth People’s Hospital affiliated to Tongji University, Dept. of Urology, Shanghai, China, ³The First Affiliated Hospital of Xi’an Jiaotong University, Dept. of Urology, Xi’an, China, ⁴Beijing Friendship Hospital affiliated to Capital Medical University, Dept. of Urology, Shanghai, China, ⁵The First Affiliated Hospital of Wenzhou Medical University, Dept. of Urology, Wenzhou, China, ⁶Fuzhou General Hospital, Dept. of Oncology, Fuzhou, China, ⁷Shanghai Rendong Clinical Laboratory, Clinical Laboratory, Shanghai, China, ⁸The First Affiliated hospital of Xi’an Jiaotong University, Dept. of Urology, Xi’an, China

369 Tissue specific NNX3.1 positive circulating tumor cells isolated by ISET in prostatic cancer patients
A modified bioinformatics approach of detecting low-frequency mutations in cell-free DNA to achieve precision medicine for advanced prostate cancer

By: Mizuno K., Fujimoto A., Sumiyoshi T., Goto T., Kobayashi T., Yamasaki T., Inoue T., Ogawa O., Akamatsu S., Nakagawa H.

1Kyoto University Graduate School of Medicine, Dept. of Urology, Kyoto, Japan, 2Kyoto University Graduate School of Medicine, Dept. of Drug Discovery Medicine, Kyoto, Japan, 3RIKEN Center for Integrative Medical Sciences, Laboratory for Genome Sequencing Analysis, Yokohama, Japan

Comparative proteome analysis identified NAMPT as a potential serum marker for the prediction of docetaxel-resistance in prostate cancer


1Semmelweis University, Dept. of Urology, Budapest, Hungary, 2Ruhr University Bochum, Medizinisches Proteom-Center, Bochum, Germany, 3Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, 4Donauphital, Dept. of Urology, Vienna, Austria, 5Medical University of Vienna, Dept. of Urology, Vienna, Austria
Stones: Is it all about lasers?
Poster Session 27

Saturday 16 March
16:00 - 17:30

Location: Green Area, Room 5
Chairs: D. Abt, St. Gallen (CH)
F. Keeley, Bristol (GB)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

373
The impact of millimetric residual stones after endourological procedures for treatment of kidney calculi: A retrospective analysis
By: De Sousa Morais N.A. ¹, Ribeiro C. ², Mota P. ², Torres J. ¹, Anacleto S. ¹, Rodrigues R. ¹, Carvalho-Dias E. ², Oliveira C. ¹, Alves M. ¹, Lima E. ¹
¹Hospital de Braga, Dept. of Urology, Braga, Portugal,
²University of Minho, School of Medicine, Braga, Portugal

374
What is the exact definition of stone dust? An in vitro evaluation
By: Keller E.X. ¹, De Coninck V. ², Doizi S. ³, Daudon M. ⁴, Traxer O. ³
¹University Hospital Zurich, University of Zurich, Dept. of Urology, Zurich, Switzerland,
²AZ Klina, Dept. of Urology, Brasschaat, Belgium,
³Sorbonne Université, Hôpital Tenon, Dept. of Urology, Paris, France,
⁴Sorbonne Université, Hôpital Tenon, CRISTAL Laboratory, Paris, France

375
High frequency for dusting during holmium laser lithotripsy: Does it matter?
By: Ghani K. ¹, Black K.M. ¹, Aldoukhi A. ¹, Hall T. ², Roberts W. ¹
¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America,
²University of Michigan, Dept. of Engineering, Ann Arbor, United States of America

376
Impact of variable pulse width and pulse modulation on dusting effect for holmium laser lithotripsy: In vitro evaluation with calcium oxalate monohydrate stones
By: Ghani K.R., Black K.M., Aldoukhi A.H., Roberts W.W.
University of Michigan, Dept. of Urology, Ann Arbor, United States of America

377
Prospective randomized study of fixed laser settings vs variable laser settings for a better stone free rate
By: Vaddi C.M. ¹, Siddalingaswamy P. ¹, Ramakrishna P. ¹, Manoj Kumar Y. ¹, Gopi P. ¹, Roopa P. ¹, Agarwal M. ², Panda A. ³
¹Preeti Urology and Kidney Hospital, Dept. of Urology, Hyderabad, India,
²Ramesh
Scientific Programme - EAU19 Barcelona

Hospital, Dept. of Urology, Guntur, India, 3KIMS Hospital, Dept. of Urology, Hyderabad, India

378

Ho:YAG laser lithotripsy in non-contact mode: Optimization of fiber to stone working distance to improve ablation efficiency

By: De Coninck V.M.J. 1, Keller E. 2, Chiron P. 2, Dragos L. 3, Doizi S. 4, Berthe L. 5, Traxer O. 2

1AZ Klina, Dept. of Urology, Brasschaat, Belgium, 2Tenon Hospital, Assistance-Publique Hôpitaux de Paris. Pierre et Marie Curie University, Dept. of Urology, Paris, France, 3University of Medicine and Pharmacy “Victor Babes” Timişoara, Dept. of Urology, Timişoara, Romania, 4Tenon Hospital, Assistance-Publique Hôpitaux de Paris. Pierre et Marie Curie University., Dept. of Urology, Paris, France, 5Laboratoire PIMM, Dept. of Engineering, Paris, France

379

High power laser machines – a game changer in the field of endourology? The impact of stone density on laser time using Lumenis laser p120 compared to standard 20w laser

By: Mekayten M. 1, Lorber A. 1, Katafigiotis I. 1, Leotsakos I. 1, Sfougaristos S. 1, Heifetz E.M. 2, Abu Sbeih B. 1, Yutkin V. 1, Latke A. 1, Gofrit O.N. 1, Duvdevani M.D. 1

1Hadassah Hebrew University Medical Center, Dept. of Urology, Jerusalem, Israel, 2Jerusalem College of Technology, Dept. of Health Informatics, Jerusalem, Israel

383

Prospective clinical study on superpulse thulium fiber laser: Initial analysis of optimal laser settings


Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

385

Thermal effects of Ho: YAG laser lithotripsy – Real-time evaluation in an ex vivo porcine kidney model


Medical Center, University of Freiburg, Dept. of Urology, Division of Urotechnology, Freiburg, Germany

387

Comparison of three different energy modalities in the treatment of large bladder calculi over 3cm

By: Choi J.Y., Ko Y.H., Song P.H., Moon K.H., Jung H.C.

Yeungnam University Medical Center, Dept. of Urology, Daegu, Korea, South
Innovative solutions in urological surgery

Video Session 06

Saturday 16 March
16:00 - 17:30

Location: Green Area, Room 10

Chairs: Y. Ahallal, Meknes (MA)
A. Carbone, Latina (IT)
To be confirmed

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V39

Feasibility of virtual partial nephrectomy imaging for T1b and complex T1a tumors

By: Izumi K.¹, Kawanishi Y.¹, Yamanak M.¹, Kawanishi S.², Fukawa T.³, Kanayama H.³
¹Takamatsu Red Cross Hospital, Dept. of Urology, Takamatsu, Japan,
²Goshikidai, Clinic, Takamatsu, Japan,
³Tokushima University, Dept. of Urology, Tokushima, Japan

V40

Needle in a haystack: Prevention and management of needle loss during robotic surgery

By: Mallya A.¹, Zafar F.A.¹, Nataraj S.A.¹, Wadhwa P.¹, Ahlawat R.K.¹
Medanta, The Medicity, Dept. of Urology and Robotic Surgery, Gurugram, India

V42

New technologies for old procedures: When Firefly improves robotic bladder diverticulectomy

By: Vedovo F.¹, De Concilio B.², Zeccolini G.², Celia A.²
¹Azienda Sanitaria Universitaria Integrata di Trieste, Dept. of Urology, Trieste, Italy,
²San Bassano Hospital, ULSS 7 Pedemontana, Dept. of Urology, Bassano del Grappa, Italy

V43

Robot-assisted embryological remnant resection in a 1 year old boy with a difference of sexual development

By: Waterschoot M.¹, De Groote R.¹, De Bleser E.¹, Cools M.², Van Laecke E.¹,
Hoebekes P.¹, Spinoit A.-F.¹
¹Ghent University Hospital, Dept. of Pediatric Urology, Ghent, Belgium,
²Ghent University Hospital, Dept. of Pediatric Endocrinology, Ghent, Belgium

V44

Robot-assisted kidney transplantation from deceased donors: Step-by-step technique

By: Vignolini G.¹, Campi R.¹, Sessa F.¹, Greco I.¹, Larti A.², Giancane S.¹,
Sebastianelli A.¹, Gacci M.¹, Peris A.³, Li Marzi V.¹, Breda A.⁴, Siena G.¹, Serni S.¹
V45

Robot-assisted laparoscopic retroperitoneal lymph node dissection with concomitant IVC thrombectomy for metastatic mixed testicular germ cell cancer

By: Zhu G., Zhang K., Portillo F.J.M., Li H.
Beijing United Family Hospital, Dept. of Urology, Beijing, China
Reconstruction of the urethra and external genitalia
Poster Session 28

Location: Green Area, Room 11
Chairs: J.L.H.R. Bosch, Berkel en Rodenrijs (NL)
D. Eberli, Zurich (CH)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

389
Patient reported outcomes from a 6 year prospective study on satisfaction following penile curvature surgery
By: Akiboye R.D., Patel P., Campbell A.A.E., Watkin N.
Epsom & St Helier University Hospitals NHS Trust, Dept. of Urology, London, United Kingdom

390
Development and Content Validation of the Urethroplasty Training and Assessment Tools (UTAT)
1Kings College London, Dept. of Urology, London, United Kingdom, 2Kings College Hospital, Dept. of Urology, London, United Kingdom, 3Sindh Institute of Urology and Transplantation, Dept. of Urology, Karachi, Pakistan, 4Russells Hall Hospital, Dept. of Urology, Dudley, United Kingdom, 5Centro Chirurgico Toscano, Dept. of Urology, Arezzo, Italy

391
The effect of annual hospital volume on perioperative outcomes after urethroplasty
1Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, 2Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, 3Fundeni Clinical Institute, Center for Uro nephrology and Renal Transplant, Bucharest, Romania, 4Christian Medical College and Hospital, Dept. of Urology, Vellore, India, 5NU Hospitals, Dept. of Urology, Bangalore, India, 6University of Tor Vergata, Dept. of Experimental Medicine and Surgery, Roma, Italy, 7Centre Hospitalier de l'Université de Montréal (CHUM), Centre de recherche (CR), Montréal, Canada
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>394</td>
<td>Stricture etiology, characteristics, recurrence, and patient-reported outcomes after penile one-stage dorsal inlay buccal mucosal graft urethroplasty according to Asopa</td>
<td>Zumstein V.¹, Dahlem R.¹, Rosenbaum C.¹, Maurer V.¹, Kluth L.², Fisch M.¹, Vetterlein M.W.¹ ¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²University Medical Center Frankfurt, Dept. of Urology, Frankfurt (Main), Germany</td>
</tr>
<tr>
<td>395</td>
<td>Independent risk factors for failure after anterior urethroplasty: A prospective, multivariate analysis</td>
<td>Verla W., Waterloos M., Spinoit A-F., Oosterlinck W., Lumen N. Ghent University Hospital, Dept. of Urology, Ghent, Belgium</td>
</tr>
<tr>
<td>397</td>
<td>The reasonable procedure for pelvic fracture urethral distraction defects: Transperineal end-to-end anastomosis</td>
<td>Sa, Chongrui J., Yuemin X., Sanbao J., Qiang F. Shanghai Jiaotong University Affiliated Sixth People’s Hospital, Dept. of Urology, Shanghai, China</td>
</tr>
<tr>
<td>398</td>
<td>Augmented anastomotic urethroplasty for ultra-short pendulous urethral stricture: Short-term outcome</td>
<td>Reyad A.M.¹, Elkassaby A.² ¹Sohag University Hospital, Dept. of Urology, Sohag, Egypt, ²Ain Shams University Hospital, Dept. of Urology, Cairo, Egypt</td>
</tr>
<tr>
<td>399</td>
<td>Surgical treatment for recurrent bulbar urethral stricture: A randomised open label superiority trial of open urethroplasty versus endoscopic urethrotomy (The OPEN Trial)</td>
<td>Goulao B.¹, Carnell S.², Shen J.², Maclennan G.³, Norrie J.³, Cook J.⁴, Mccoll E.⁵, Breckons M.⁵, Vale L.⁵, Forbes R.², Currer S.², Forrest M.⁶, Wilkinson J.², Andrich D.⁷, Barclay S.⁸, Munday A.⁷, N’dow J.⁹, Payne S.¹⁰, Watkin N.¹¹, Pickard R.¹² ¹University of Aberdeen, Health Services Research Unit, Aberdeen, United Kingdom, ²Newcastle University, Newcastle Clinical Trials Unit, Newcastle, United Kingdom, ³University of Aberdeen, Health Services Research Unit &amp; Centre for Healthcare Randomised Trials (CHaRT), Aberdeen, United Kingdom, ⁴Oxford University, Surgical Intervention Trials Unit, Oxford, United Kingdom, ⁵Newcastle University, Institute of Health and Society, Newcastle, United Kingdom, ⁶Newcastle University, Health Services Research Unit &amp; Centre for Healthcare Randomised Trials (CHaRT), Newcastle, United Kingdom, ⁷University College Hospital NHS Trust, Dept. of Urology, London, United Kingdom, ⁸Patient Representative, Newcastle University Teaching Hospital, Newcastle, United Kingdom, ⁹University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ¹⁰Central Manchester Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, ¹¹St George’s University Hospital, Dept. of Urology, United Kingdom, ¹²University of York, Health Services Research Unit, York, United Kingdom</td>
</tr>
</tbody>
</table>
Comparative analysis of successful outcome after substitution urethroplasty with “Buccal Mucosa Graft versus Inner Preputial Skin Graft” for anterior urethral stricture disease

By: Parmar K., Tyagi S., Singh S.K., Kumar S., Mete U., Mohan R., Dewana S., Bora G., Sharma A.
PGIMER, Dept. of Urology, Chandigarh, India
Infectious diseases: Upper urinary tract infections and sepsis

Poster Session 29

Saturday 16 March
16:00 - 17:30

Location: Green Area, Room 12

Chairs: R. Bartoletti, Pisa (IT)
T.E. Bjerklund Johansen, Stavanger (NO)
T.W. Khor, Kuala Lumpur (MY)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

402

Perioperative infectious risk in urology: Management of preoperative polymicrobial urine culture - a systematic review

By: Vallée M.¹, Cattoir V.², Malavaud S.³, Sotto A.⁴, Cariou G.⁵, Arnaud P.⁶, Bugel H.⁷, Coloby P.⁸, Chartier-Kastler E.⁹, Bruyère F.¹⁰
¹Nantes Hôtel Dieu University Hospital, Dept. of Urology, Nantes, France, ²Rennes University Hospital, Dept. of Microbiology, Rennes, France, ³Toulouse-Rangueil University Hospital, Dept. of Epidemiology, Toulouse, France, ⁴Nîmes University Hospital, Dept. of Infectious disease, Nîmes, France, ⁵Cabinet office, Dept. of Urology, Paris, France, ⁶Notre-Dame de la Misericorde Hospital, Dept. of Urology, Ajaccio, France, ⁷Charles-Nicolle University Hospital, Dept. of Urology, Rouen, France, ⁸René-Dubos Hospital, Dept. of Urology, Cergy Pontoise, France, ⁹Academic Hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux, Dept. of Urology, Paris, France, ¹⁰Bretonneau University Hospital, Dept. of Urology, Tours, France

403

The impact of acute kidney injury on cardiovascular disease and renal impairment in patients with urological sepsis

By: Fujita N.¹, Momota M.¹, Tobisawa Y.¹, Yoneyama T.¹, Yamamoto H.¹, Imai A.¹, Hatakeyama S.¹, Ito H.², Yoneyama T.¹, Hashimoto Y.¹, Yoshikawa K.³, Ohyama C.¹
¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, ³Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

404

Evaluation of the impact of seric procalcitonin in the management of obstructive acute pyelonephritis

Aix-Marseille University, La Conception Academic Hospital, Dept. of Urology, APHM, Marseille, France
Fever in patients with upper ureteral stone: How many days of antibiotic treatment are sufficient to proceed with URSL?

By: Cheng P-Y., Wu W.C , Chung S.D
Far Eastern Memorial Hospital, Dept. of Surgery, New Taipei City, Taiwan

Comparing pre-operative and intra-operative bacteriuria during ureteroscopy with laser lithotripsy: A prospective cohort study

By: Churchill J ., Yao J. , Wines M.
Royal North Shore Hospital, Dept. of Urology, St Leonards, Australia

The significance of intraoperative renal pelvic urine and stone culture for patients at high risk of post-ureteroscopy systemic inflammatory response syndrome

By: Yoshida S ., Takazawa R. , Waseda Y. , Tsujii T.
Tokyo Metropolitan Ohtsuka Hospital, Kidney Stone Center, Dept. of Urology, Tokyo, Japan

Clinical and microbiological characteristics in men with non-obstructive acute pyelonephritis

By: Lee J.W. 1 , Park M.G. 2 , Kwon S.Y. 3 , Choi H. 4 , Cho S.Y. 5
1Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Dept. of Urology, Goyang, Korea, South, 2Seoul Paik Hospital, Inje University College of Medicine, Dept. of Urology, Seoul, Korea, South, 3Dongguk University Gyeongju Hospital, Dongguk University College of Medicine, Dept. of Urology, Gyeongju, Korea, South, 4Korea University Ansan Hospital, Korea University College of Medicine, Dept. of Urology, Ansan, Korea, South, 5Ilsan Paik Hospital, Inje University College of Medicine, Dept. of Urology, Goyang, Korea, South

Urine culture vs. lithiasis culture: Which is the best?

Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain

How many pathogens in stone patients are misidentified without an intraoperative stone culture?

By: De Lorenzis E. 1 , Fontana M. 1 , Boeri L. 1 , Gallioli A. 1 , Piccoli M. 1 , Arghittu M. 2 , Colombo R. 3 , Sampogna G. 1 , Sabatini I. 1 , Luzzago S. 1 , Zanetti S.P. 1 , Longo F. 1 , Montanari E. 1 , Albo G. 1
1Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico Department of Clinical Sciences and Community Health, University of Milan, Dept. of Urology, Milan, Italy, 2Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Dept. of Microbiology and Virology, Milan, Italy, 3Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Dept. of Microbiology and Virology, Milan, Italy
Cross-resistance and the mechanisms of cephalosporine-resistant urinary tract infection (UTI)-causative bacteria isolated in Indonesia

By: Shigemura K., Kitagawa K., Shirakawa T., Fujisawa M.
Kobe University, Dept. of Urology, Kobe, Japan

Genetic analysis of extended spectrum beta-lactamase (ESBL)-producing Klebsiella pneumonia isolated urinary tract infection (UTI) patients in Indonesia

By: Shigemura K.1, Yamasaki S.2, Osawa K.2, Fujisawa M.1
1Kobe University, Dept. of Urology, Kobe, Japan, 2Kobe University, Dept. of Health Science, Kobe, Japan

Impact of Lactobacillus probiotics on biofilm formed by Pseudomonas aeruginosa

By: Matsuo S., Wada K., Sadahira T., Mitsuhata R., Yamamoto M., Ishii A., Watanabe T., Nasu Y.
Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan

Comparison of molecular characteristics of carbapenem-resistant urinary tract infection-causing pathogens between Japan, Taiwan and Indonesia

By: Shigemura K.1, Nishimoto K.2, Osawa K.2, Kuntaman K.3, Sung S.4, Chen K.5, Kitagawa K.1, Huang T.6, Shirakawa T.1, Fujisawa M.1
1Kobe University, Dept. of Urology, Kobe, Japan, 2Kobe University, Dept. of Health Science, Kobe, Japan, 3Airlangga University, Dept. of Microbiology, Surabaya, Indonesia, 4Taipei Medical University, The Ph.D. Program for Translational Medicine, Taipei, Taiwan, 5Taipei Medical University, Dept. of Urology, Taipei, Taiwan, 6Taipei Medical University, Dept. of Microbiology, Taipei, Taiwan

Surgical hand hygiene does not influence the onset of surgical site infection in an endourological surgery

Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan
Paediatric urology: Complex urological conditions

Location: Green Area, Room 19

Chairs: A. Abdel Aziz Elderwy, Assiut (EG)
J. Hosseini, Tehran (IR)
To be confirmed
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

417

Do EAU/ESPU guidelines recommendations fit to patients? Results of a survey on awareness of spina bifida patients

By: Dogan H.S. ¹, Stein R. ², 't Hoen L.A. ³, Bogaert G. ⁴, Nijman R.J.M. ⁵, Tekgul S. ¹, Quaedackers J. ⁶, Silay M.S. ⁷, Radmayr C. ⁸
¹Hacettepe University Faculty of Medicine, Dept. of Urology, Ankara, Turkey,
²Universitätsmedizin Mannheim, Dept. of Urology, Mannheim, Germany,
³Erasmus Medical Center, Dept. of Urology, Rotterdam, Netherlands, The,
⁴University Hospitals of the KU Leuven., Dept. of Urology, Leuven, Belgium,
⁵Rijks Universiteit Groningen, Dept. of Urology, Groningen, Netherlands, The,
⁶Universiteit Groningen, Dept. of Urology, Groningen, Netherlands, The,
⁷Istanbul Medeniyet University, Dept. of Urology, Istanbul, Turkey,
⁸Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria

419

Repeated detrusor injection of botulinum toxin A for neurogenic bladder overactivity in children: A long term option?

By: Madec F-X.R. ¹, Suply E. ², Forin V. ¹, Chamond O. ¹, Irtan S. ¹, Audry G. ¹, Lallemant P ¹
¹Children Hospital Armand Trousseau - APHP, Sorbonne Medicine University, Dept. of Paediatric Surgery, Paris, France,
²Lille Catholic hospitals, Dept. of Paediatric Surgery, Paris, France

421

Urologic status and sexuality in a transitional spina bifida population: A patient-based survey

By: Bujons Tur A., Lang Motta G., Garat J.M., Palou J.
Fundació Puigvert, Dept. of Urology, Barcelona, Spain

424

Virilized females with congenital adrenal hyperplasia and persistent urogenital sinus, early versus delayed intervention, single center experience

By: Al Otay A. ¹, El Helaly A.A. ¹, Al Ghanbar M.S. ¹, Al Harbi F. ¹, Al Hagbani F. ¹, Nakshabandi Z. M. ¹, Sarhan O.M. ²
1Prince Sultan Military Medical City, Dept. of Urology, Riyadh, Saudi Arabia, 2King Fahad Specialist Hospital, Dept. of Urology, Dammam, Saudi Arabia

425
Sigmoid vaginoplasty in patients with vaginal agenesis: Technique and outcomes

By: Bizic M. 1, Stojanovic B. 1, Benic M. 1, Korac G. 2, Djordjevic M. 1
1School of Medicine, University of Belgrade, Dept. of Urology, Belgrade, Serbia, 2School of Medicine, University of Belgrade, Dept. of Anesthesiology, Belgrade, Serbia

426
Is continent urinary diversion the gold standard in failed initial childhood repair of bladder extrophy? – Experience of the developing world

By: Perera N.D., Weerasinghe N.L., Willaraarachchi W.A.M.A.
The National Hospital of Sri Lanka, Dept. of Urology, Ward 65, Colombo, Sri Lanka

427
Management of the bladder extrophy an 18-yr experience

Habib Thameur Hospital, Dept. of Pediatric Surgery, Tunis, Tunisia

428
Augmentation enterocystoplasty with continent diversion in children: Short- and long-term complications

Bachir Hamza Children Hospital, Dept. of Pediatric Surgery, Tunis, Tunisia

429
Abdominal leak point pressure - A simple way to predict urinary incontinence following surgical treatment of unilateral ectopic ureter in girls

By: Mani A., Yadav P., Ansari M.S.
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dept. of Urology and Renal Transplantation, Lucknow, India

430
A new evaluation method for children with bladder bowel dysfunction: Pelvic floor muscle activity (PFMA)

By: Pekbay Y. 1, Topuz B. 2, Sarikaya S. 2, Irkilata Y. 3, Irkilata H.C. 4, Dayanc M.M. 1
1Prof. Dr. Murat Dayanc Private Pediatric Urology Clinic, Dept. of Pediatric Urology, Ankara, Turkey, 2Gulhane Research and Training Hospital, Dept. of Urology, Ankara, Turkey, 3Prof.Dr.Murat Dayanc Private Pediatric Urology Clinic, Dept. of Pediatric Urology, Ankara, Turkey, 4Private Davraz Yasam Hospital, Dept. of Urology, Isparta, Turkey

431
Fate of micropenis and constitutional small penis: Does it grow to be normal after puberty?

By: Han J.H. 1, Lee J. 2, Jun J.B. 2, Song S.H. 2, Kim K.S. 2
1Asan Medical Center, Dept. of Urology, Seoul, Korea, South, 2Asan Medical Center, Dept. of Urology, Seoul, Korea, South
### Paediatric urology: Stone management in children

**Poster Session 31**

**Location:** Green Area, Room 20  
**Chairs:** To be confirmed  
M.S. Silay, Istanbul (TR)  
A-F. Spinoit, Ghent (BE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>437</td>
<td>Mini-Perc for renal calculi in pediatric patients: Does size matter? A prospective randomised study</td>
<td>Mani A., Yadav P., Sureka S., Ansari M.</td>
<td>Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dept. of Urology and Renal Transplantation, Lucknow, India</td>
</tr>
<tr>
<td>439</td>
<td>Closed-circuit vacuum-assisted MiniPerc system for kidney stones in children: Our initial experience</td>
<td>Sampogna G., Zanetti S.P., Berrettini A., Gnech M., Manzoni G., Montanari E.</td>
<td>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Pediatric Urology, Milan, Italy</td>
</tr>
<tr>
<td>440</td>
<td>Comparing micro-percutaneous nephrolithotomy and flexible ureteroscopic lithotripsy in treating 1-2 cm solitary renal stones in infants</td>
<td>Wenying W., Li J.</td>
<td>Beijing Friendship Hospital, Capital Medical University, Dept. of Urology, Beijing, China</td>
</tr>
<tr>
<td>441</td>
<td>Withdrawn</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>442</td>
<td>Outcomes of ureteroscopy (URS) for stone disease in the paediatric population: Results of over 100 URS procedures from a UK tertiary centre</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Mutational analysis of HOGA1 in Chinese pediatric patients with primary hyperoxaluria type 3

By: Wenying W. 1, Li J. 2
1Beijing Friendship Hospital, Capital Medical University, Dept. of Urology, Beijing, China,
2Beijing Friendship Hospital, Capital Medical University, Dept. of urology, Beijing, China

Brushite calculi: Review of a pediatric cohort

By: Vila Reyes H., Llorens De Knecht E., Quiroz Madarriaga Y., Lang Motta G., Kanashiro K., Bujons Tur A., Palou Redorta J.
Fundacio Puigvert, Dept. of Urology, Barcelona, Spain
Imaging in prostate cancer: Is it time to change paradigms?

Plenary 3

Sunday 17 March
08:00 - 10:23

Location: Red Area, eURO Auditorium 1

Chairs: F. Montorsi, Milan (IT)
J. Walz, Marseille (FR)

08:00 - 08:30
Debate Is MRI-targeted biopsy enough?
Moderator: A. Alberts, Rotterdam (NL)

08:00 - 08:05
Setting the stage / voting
A. Alberts, Rotterdam (NL)

08:05 - 08:10
Pro I
V. Kasivisvanathan, London (GB)

08:10 - 08:15
Con I
G. Ploussard, Toulouse (FR)

08:15 - 08:20
Pro II
F. Porpiglia, Turin (IT)

08:20 - 08:25
Con II
C. Arsov, Düsseldorf (DE)

08:25 - 08:30
Conclusion / voting

08:30 - 08:55
Debate Critical assessment of image-guided therapy of prostate cancer
Moderator: C. Surcel, Bucharest (RO)

08:30 - 08:35
Setting the stage / voting
C. Surcel, Bucharest (RO)

08:35 - 08:42
Pro focal therapy
R. Sanchez-Salas, Paris (FR)

08:42 - 08:49
Con focal therapy
D. Murphy, Melbourne (AU)

08:49 - 08:55
Discussion / voting

08:55 - 09:10
Urological Association of Asia (UAA) lecture The future of prostate fusion biopsies
To be confirmed

09:10 - 09:25
Fusion biopsy devices: A true improvement or only marketing?
H. Van Melick, Nieuwegein (NL)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
</table>
| 09:25 - 10:08 | Debate  **PET imaging in prostate cancer: Improvement or waste of money?**  
**Moderator:** H.G. Van Der Poel, Amsterdam (NL) |                          |                |
| 09:25 - 09:30 | **Setting the stage**                                                  | H.G. Van Der Poel, Amsterdam (NL) |                |
| 09:30 - 09:37 | **Pro initial regional staging**                                      | T. Maurer, Hamburg (DE)   |                |
| 09:37 - 09:44 | **Con initial regional staging**                                      | S. Joniau, Leuven (BE)   |                |
| 09:44 - 09:49 | **Discussion**                                                        |                          |                |
| 09:49 - 09:56 | **Pro recurrent disease**                                             | P. Ost, Ghent (BE)       |                |
| 09:56 - 10:03 | **Con recurrent disease**                                             | N. Suardi, Milan (IT)    |                |
| 10:03 - 10:08 | **Discussion**                                                        |                          |                |
| 10:08 - 10:23 | **European Association of Nuclear Medicine (EANM) lecture**  **Theranostics: The future of functional imaging** | S. Fanti, Bologna (IT)   |                |
Renal Cell Carcinoma (RCC)

Sunday 17 March
08:00 - 10:15

Location: Red Area, eURO Auditorium 2
Chairs: M-O. Grimm, Jena (DE)
H.P.A.M. Van Poppel, Leuven (BE)

Aims and objectives of this session
The majority of renal tumours are nowadays diagnosed as small renal mass. During this session the pros and cons of various surgical approaches and alternative treatments will be discussed by distinguished experts. In locally advanced and metastatic RCC the timing and role of tumour nephrectomy is under debate. This session will summarise recent data and ongoing clinical trials and discuss their impact on current treatment algorithms.

08:00 - 08:30
Minimally-invasive partial nephrectomy

08:00 - 08:15
An operation without limits?
A. Mottrie, Aalst (BE)

08:15 - 08:30
There are limits
M. Kuczyk, Hanover (DE)

08:30 - 09:10
Case-based debate Small renal mass in the young and obese: Knife, needle or nothing?
Moderator: P.F.A. Mulders, Nijmegen (NL)

08:30 - 08:35
Case presentation
P.F.A. Mulders, Nijmegen (NL)

08:35 - 08:45
Partial
C.K. Bensalah, Rennes (FR)

08:45 - 08:55
Needle
U. Capitanio, Milan (IT)

08:55 - 09:05
Surveillance
A. Finelli, Toronto (CA)

09:05 - 09:10
Discussion

09:10 - 09:25
Neoadjuvant therapy in localised disease - who is going to benefit?
M.C. Mir Maresma, Valencia (ES)

09:25 - 10:00
Debate Cytoreductive nephrectomy: Does CARMENA change everything?
Moderator: M. Kuczyk, Hanover (DE)

09:25 - 09:35
Yes
A. Mejean, Paris (FR)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:35 - 09:40</td>
<td>Rebuttal</td>
<td></td>
</tr>
<tr>
<td>09:40 - 09:50</td>
<td>Maybe</td>
<td>A. Bex, Amsterdam (NL)</td>
</tr>
<tr>
<td>09:50 - 09:55</td>
<td>Rebuttal</td>
<td></td>
</tr>
<tr>
<td>09:55 - 10:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Update on systemic therapy</td>
<td>J. Bedke, Tübingen (DE)</td>
</tr>
</tbody>
</table>
### Advanced course on laparoscopic renal surgery

**ESU Course 23**

**Sunday 17 March 08:30 - 11:30**

**Location:** Green Area, Room 13

**Chair:** V. Pansadoro, Rome (IT)

### Aims and objectives of this session

Minimally invasive surgery has steadily improved over the last years. Today one can approach with confidence new, difficult and challenging situations. The course is structured to evaluate and explore the increasing indications and possible complications of laparoscopic and robotic kidney surgery. This course will focus upon common and uncommon complications and how to manage and prevent them. In addition, special situations such as single port inguinal approach, zero ischemia time, cava thrombus, accidental splenectomy and living donor nephrectomy will be presented.

### Introduction

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

### Transperitoneal approach

V. Pansadoro, Rome (IT)

### Retroperitoneal approach

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

### Single port inguinal approach

R. Bollens, Lomme (FR)

### Intraoperative complications

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

### Difficult nephrectomies

R. Bollens, Lomme (FR)

### Partial nephrectomy

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

### Special cases

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)
**Metastatic prostate cancer**

**ESU Course 22**

**Sunday 17 March**
**08:30 - 11:30**

**Location:** Green Area, Room 14

**Chair:** K. Pummer, Graz (AT)

**Aims and objectives of this session**
The three lectures of ESU course 22 will provide comprehensive state-of-the-art information about currently available therapies for hormone-naïve and castration resistant prostate cancer, such as various forms of primary androgen deprivation, immunotherapy, chemotherapy, and therapies approved for CRPC. After the course, attendees should be able to adequately treat patients with metastatic prostate cancer at all disease stages.

---

**Treatment of kastration-sensitive metastatic prostate cancer**
C.P. Evans, Sacramento (US)

**What is the role of chemotherapy and immunotherapy in patients with CRPC?**
G. Mickisch, Bremen (DE)

**Treatment of mCRPC – Sequence or combination?**
K. Pummer, Graz (AT)

**Case discussion**
G. Mickisch, Bremen (DE)
C.P. Evans, Sacramento (US)
K. Pummer, Graz (AT)
Aims and objectives of this session
The previously devastating burden of urinary tract urolithiasis has been reduced by modern stone therapy. Complex branched stones are rare, and therapy has moved largely to the outpatient setting. Nevertheless, successful management requires competence in all aspects of stone management. After a brief review of new developments in present treatment strategies, these will be further explored by interactive case presentations.

- Stone disease aetiology is multi-factorial, relating in large part to genetics, diet (salt, calorie and protein intake), hydration status factors and ageing.
- The clinical presentation is changing with a growing base of elderly and obese patient cohorts in developed nations.
- Today’s challenge is employing the ideal initial and salvage approaches for specific situations - individuals, including judicious selection of prevention strategies.
- Patients should be given choices and counselled about the risk benefits and potential outcomes of all appropriate reasonable approaches.

Introduction
A. Patel, London (GB)

Medical aspects of urinary stones
M. Straub, Munich (DE)

SWL
M. Straub, Munich (DE)

Uretero-Renoscopy
E.K. Bres-Niewada, Warsaw (PL)

Percutaneous nephrolithotomy and questions and answers
A. Patel, London (GB)

Interactive case discussion
A. Patel, London (GB)
Aims and objectives of this session
Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is to employ scientific principles, published information and clinical experience to describe and position newly developed techniques in current management of urinary incontinence. Special attention will be given to new techniques that use synthetics tapes in SUI surgery. This course will also cover the management of complications of surgery for stress incontinence and mesh complications. Treatment of recurrent urinary incontinence and incontinence with mixed symptoms also will be under discussion. Management of vesicovaginal fistulae, urethral diverticula and some rare conditions will be shown both during podium and video presentations. An interactive course means active participation by the audience and participants are encouraged to prepare and present interesting and challenging clinical cases for consultation by the faculty. After this course, participants should know how to apply the newest technique in patients with stress incontinence, urethral loss and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those who are just starting their careers and for advanced surgeons.

Introduction: Female Urology – Improving functional outcome
D. Pushkar, Moscow (RU)

Stress urinary incontinence – Approaching patients' expectations
T.J. Greenwell, London (GB)

Obstructive slings: What to do?
D. Pushkar, Moscow (RU)
K-D. Sievert, Detmold (DE)

Autologous sling in 2018
T.J. Greenwell, London (GB)

Management of mesh complications
T.J. Greenwell, London (GB)
D. Pushkar, Moscow (RU)
K-D. Sievert, Detmold (DE)

Urethral diverticulae surgery – Tips and tricks
T.J. Greenwell, London (GB)

Urethral loss in females
D. Pushkar, Moscow (RU)
Vesico-vaginal fistulae repair from simple to complicated
D. Pushkar, Moscow (RU)

New slings for SUI – Do you need one?
T.J. Greenwell, London (GB)
K-D. Sievert, Detmold (DE)

Conclusions
Surgery or radiotherapy for localised and locally advanced prostate cancer
ESU Course 24

Sunday 17 March
08:30 - 11:30

Location: Green Area, Room 21
Chair: R.J.A. Van Moorselaar, Amsterdam (NL)

Aims and objectives of this session
This course will summarize the decision process and indications for patients with localized and locally advanced disease and will help to select the optimal treatment including active surveillance based on most recent oncological and functional data.

After this course participants have updated their knowledge on:
• Surgical and radiotherapeutic treatment modalities
• The optimal indication for which treatment option
• Oncological and functional results
• New options for adjuvant treatment

08:30 - 11:30

Introduction
R.J.A. Van Moorselaar, Amsterdam (NL)

- Localised prostate cancer

- Treatment options in localised prostate cancer
  J.P.M. Sedelaar, Nijmegen (NL)

- Oncological and functional results of radiation therapy
  A. Bossi, Villejuif (FR)

- Oncological and functional results of radical prostatectomy
  R.J.A. Van Moorselaar, Amsterdam (NL)

- Advanced prostate cancer

- Radiotherapy with or without hormonal treatment in advanced PCA
  A. Bossi, Villejuif (FR)

- Adjuvant therapies following radical prostatectomy
  R.J.A. Van Moorselaar, Amsterdam (NL)

- Results of radical prostatectomy for T3 disease
  J.P.M. Sedelaar, Nijmegen (NL)

08:30 - 11:30
Take home messages
Chronic pelvic pain in men and women
ESU Course 25

Location: Green Area, Room 22

Chair: E.J. Messelink, Groningen (NL)

Aims and objectives of this session
The urologist is often dealing with patients having Chronic Pelvic Pain. This course will offer the urologist practical guidance in treating these patients. In the case discussion the participants will have the opportunity to help outlining the problem. In the lectures theoretical knowledge will be translated into daily guidelines for diagnostics and treatment of patients with pelvic pain. At the end of this course the participant will
• Know the basic principles of treating patients with chronic pelvic pain.
• Know how to rule out well known causes.
• Have knowledge of the myofascial and psychological aspects.
• Be able to refer patients at the right time to the right team.

Chronic pelvic pain, the basics: Mechanisms and terminology
E.J. Messelink, Groningen (NL)

Chronic pelvic pain in men: Case presentation and discussion
D.S. Engeler, St. Gallen (CH)

Chronic pelvic pain in men: Practical guidelines on diagnostics and treatment
D.S. Engeler, St. Gallen (CH)

Chronic pelvic pain in women: Case presentation and discussion
E.J. Messelink, Groningen (NL)

Chronic pelvic pain in women: Practical guidelines on diagnostics and treatment
E.J. Messelink, Groningen (NL)

The interdisciplinary approach: Team members and organisation
D.S. Engeler, St. Gallen (CH)
Surgical anatomy for laparoscopic and robotic assisted radical prostatectomy and cystectomy

ESU Course 26

Sunday 17 March
08:30 - 11:30

Location: Green Area, Room 23

Chair: J-U. Stolzenburg, Leipzig (DE)

Aims and objectives of this session
This course addresses comprehensively important anatomical considerations for minimally invasive pelvic surgery. Based on the anatomy key technical aspects of laparoscopic and robotic-assisted radical prostatectomy and radical cystectomy such access, port placement, robotic docking and each step of the procedures will be discussed. Additionally different techniques of nerve-sparing surgery such as interfascial and intrafascial will be discussed and intensively explained by video presentations.

Introduction
J-U. Stolzenburg, Leipzig (DE)

Pelvic and surgical anatomy for laparoscopic/robotic radical prostatectomy (RPE)
H.A.R. Qazi, London (GB)
J-U. Stolzenburg, Leipzig (DE)

Surgical anatomy for laparoscopic/robotic assisted radical cystectomy
J. Cresswell, Middlesbrough (GB)

Port placement and robot docking-principles for pelvic laparoscopy
J. Cresswell, Middlesbrough (GB)
H.A.R. Qazi, London (GB)
J-U. Stolzenburg, Leipzig (DE)

Prostate, bladder and urethral sphincter anatomy. How to preserve urinary continence
H.A.R. Qazi, London (GB)
J-U. Stolzenburg, Leipzig (DE)

Surgical anatomy for nerve sparing surgery. How to perform nerve sparing surgery
J-U. Stolzenburg, Leipzig (DE)

Boundaries and technique of pelvic lymph node dissection for radical prostatectomy (standard, extended PLNA, risk stratified access) and radical cystectomy
J. Cresswell, Middlesbrough (GB)
H.A.R. Qazi, London (GB)

Summary and take home messages
J. Cresswell, Middlesbrough (GB)
Quiz
J. Cresswell, Middlesbrough (GB)
H.A.R. Qazi, London (GB)
J-U. Stolzenburg, Leipzig (DE)
**Novel treatment strategies in Benign Prostatic Obstruction (BPO): A video-based course on the procedural essentials**  
Specialty Session - European Urology

<table>
<thead>
<tr>
<th>Sunday 17 March</th>
<th>Location: Red Area, eURO Auditorium 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:30</td>
<td>Chairs: A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td></td>
<td>J.W.F. Catto, Sheffield (GB)</td>
</tr>
<tr>
<td></td>
<td>A. Mottrie, Aalst (BE)</td>
</tr>
<tr>
<td></td>
<td>P. Schatteman, Dilbeek (BE)</td>
</tr>
</tbody>
</table>

**Aims and objectives of this session**
The Surgery-in-Motion session is dedicated to novel treatment strategies in BPO. Experts in the field will provide explanations and video demonstrations of various surgical techniques and discuss why they do it “their way.” Questions from the audience are welcome.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:40</td>
<td>Welcome and introduction</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Schatteman, Aalst (BE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J.W.F. Catto, Sheffield (GB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Mottrie, Aalst (BE)</td>
</tr>
<tr>
<td>10:40 - 10:48</td>
<td>Natural history of Benign prostatic hyperplasia (BPH) and prostate conditions for surgery</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td>10:48 - 11:28</td>
<td>Enucleation techniques</td>
<td>Moderator: A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td>10:48 - 10:58</td>
<td>HoLEP</td>
<td>P. Schatteman, Aalst (BE)</td>
</tr>
<tr>
<td>10:58 - 11:08</td>
<td>ThuLEP</td>
<td>A. J. Gross, Hamburg (DE)</td>
</tr>
<tr>
<td>11:08 - 11:18</td>
<td>Green-LEP</td>
<td>F. Gomez Sancha, Madrid (ES)</td>
</tr>
<tr>
<td>11:18 - 11:28</td>
<td>Bipolar enucleation</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:28 - 11:52</td>
<td>Vaporisation techniques</td>
<td>Moderator: P. Schatteman, Aalst (BE)</td>
</tr>
<tr>
<td>11:28 - 11:36</td>
<td>Greenlight Laser</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td>11:36 - 11:44</td>
<td>REZUM</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>11:44 - 11:52</td>
<td>Bipolar Plasmavaporisation ('Button' or Mushroom)</td>
<td>B. Geavlete, Bucharest (RO)</td>
</tr>
<tr>
<td>11:52 - 12:00</td>
<td>New immediate ablative techniques: Aqua-ablation</td>
<td>P. Schatteman, Aalst (BE)</td>
</tr>
<tr>
<td>12:00 - 12:16</td>
<td>Mechanically deobstructing techniques and others</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td>12:00 - 12:08</td>
<td>Urolift</td>
<td>H. Woo, Sydney (AU)</td>
</tr>
<tr>
<td>12:08 - 12:16</td>
<td>Temporary implantable Nitinol Device (iTIND),</td>
<td>F. Porpiglia, Turin (IT)</td>
</tr>
<tr>
<td>12:16 - 12:21</td>
<td>Closing remarks</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
</tbody>
</table>
Aims and objectives of this session
Immunotherapy has become a standard of care for the treatment of urothelial and renal cell cancer. The field is rapidly evolving and includes research on biomarkers, the tumour microenvironment, tumour mutational burden and genetic alterations. Clinical trials are evaluating combination therapies, sequencing of treatments and new indications like prostate cancer.

Also we need to learn how to best manage patients on immune checkpoint inhibitors and how to deal with specific side effects. This session will cover these major aspects of immunotherapy in GU cancers and summarise research and tips and tricks for daily practice.

10:30 - 10:45
Immunotherapy in prostate cancer - review and outlook
N. Shore, Myrtle Beach (US)

10:45 - 11:00
What is behind the microbiota?
L. Albiges, Villejuif (FR)

11:00 - 11:15
Immunotherapy and genomics
M.S. Van Der Heijden, Amsterdam (NL)

11:15 - 11:40
Case-based debate Checkpoint inhibitors: Safety and management in daily practice
Case presenter: M. Retz, Munich (DE)
Panel: L. Albiges, Villejuif (FR)
To be confirmed
N. Shore, Myrtle Beach (US)
M.S. Van Der Heijden, Amsterdam (NL)

11:40 - 12:00
Urothelial and renal cell cancer - is monotherapy out?
I. Duran, Santander (ES)
Focal therapy
Thematic 02

Sunday 17 March
10:30 - 12:00

Location: Green Area, Room 2
Chairs: C.H. Bangma, Rotterdam (NL)
A. Villers, Lille (FR)

Aims and objectives of this session
This session on focal therapy for intermediate-risk prostate cancer addresses the methods for selection, treating and monitoring in the developing field of imaging and targeted biopsies. The background for the setting will be presented, including guidelines and available oncological and functional outcomes.
À la carte selection of type of energies according to tumour characteristics, location and results are highlighted. Afterwards, the session participants will be able to make a decision when and how to include the individual patient with intermediate risk cancer in focal therapy.

10:30 - 10:50
Point-counterpoint session  Focal therapy in which setting?

10:30 - 10:40
Focal therapy ready for which recommendations in the guidelines?
O. Yossepowitch, Tel Aviv (IL)

10:40 - 10:50
Yes focal therapy is of benefit for patients
H.U. Ahmed, London (GB)

10:50 - 11:30
Case-based debate  Are there best treatments?
Moderator: C.H. Bangma, Rotterdam (NL)

10:50 - 10:55
Case presentation
C.H. Bangma, Rotterdam (NL)

10:55 - 11:19
Discussion  Does my energy fit this patient (HIFU, VTP, CRYO, NanoKnife-IEP)?

11:19 - 11:25
Failed first focal treatment: What now?
R. Ganzer, Bad Tölz (DE)

11:25 - 11:30
Concluding remarks
C.H. Bangma, Rotterdam (NL)

11:30 - 11:45
How reliable is MRI for monitoring?
M. Valerio, Lausanne (CH)

11:45 - 12:00
Solving the unmet needs on patient selection
To be confirmed
Limited pelvic lymph node involvement in otherwise localised disease
Thematic 03

Sunday 17 March
10:30 - 12:00

**Location:** Green Area, Room 3

**Chairs:** T.S. O'Brien, London (GB)
To be confirmed

10:30 - 10:45
**Biology of lymphatic dissemination**
G. Palapattu, Ann Arbor (US)

10:45 - 11:00
**European Society of Urogenital Radiology (ESUR) lecture** Which imaging technique is reliable for lymph node detection?
To be confirmed

11:00 - 11:30
**Case 1** PCa cN1 cM0

11:00 - 11:05
**Clinical case presentation**
M. Moschini, Luzern (CH)

11:05 - 11:15
**Additional local therapy**
P. Nyirády, Budapest (HU)

11:15 - 11:25
**Systemic therapy only**
N. Mottet, Saint-Étienne (FR)

11:25 - 11:30
**Summary**
M. Moschini, Luzern (CH)

11:30 - 12:00
**Case 2** MIBC cN1 cM0

11:30 - 11:35
**Clinical case presentation**
A. Masson-Lecomte, Paris (FR)

11:35 - 11:45
**Induction chemotherapy**
S. Bracarda, Terni (IT)

11:45 - 11:55
**Upfront radical cystectomy**
J.E. Gschwend, Munich (DE)

11:55 - 12:00
**Summary**
A. Masson-Lecomte, Paris (FR)
Penile cancer

Aims and objectives of this session
In the Western world, penile cancer is diagnosed in only 1/100,000-1,000,000 men, which makes it a rare cancer. The rarity of the disease, especially in countries where routine circumcision has been adopted, makes it a challenging diagnosis for many urologists. In this session we will discuss controversies and new developments in penile cancer: should we vaccinate boys against HPV? How to diagnose and manage premalignant diseases? What is the best staging for high risk patients without palpable lymph nodes, and what will the future look like in terms of novel systemic agents? Last, the role of the European Reference Network eUROGEN in penile cancer treatment will be highlighted.

10:30 - 10:45
The role of HPV in penile cancer pathogenesis: An opportunity to start vaccination in boys?
M. Burger, Regensburg (DE)

10:45 - 11:00
Premalignant lesions: What should the urologist know?
C. Bunker, London (GB)

11:00 - 11:30
Case-based debate High-risk cN0 patient

11:00 - 11:05
Case presentation
C. Protzel, Schwerin (DE)

11:05 - 11:15
DSNB is still the way to go for staging of high-risk N0 disease
N. Watkin, London (GB)

11:15 - 11:25
Robot-assisted and/or video-endoscopic inguinal management is the future in high-risk cN0 staging
C.A. Pettaway, Houston (US)

11:25 - 11:30
Concluding remarks
C. Protzel, Schwerin (DE)

11:30 - 11:45
Novel targeted therapies on the horizon?
P. Spiess, Tampa (US)

11:45 - 12:00
Centralisation of penile cancer care and eUROGEN: Are we improving outcomes?
V. Sangar, Manchester (GB)
Complications of laparoscopy due to technique
Thematic 05

Aims and objectives of this session
Even in the era of robotics, laparoscopy represents a very important technique which has to be mastered by all urologic surgeons. In this context, the management of the main complications of this procedure is of utmost importance. We are happy to present a distinguished faculty with extraordinary experience with laparoscopy and retroperitoneoscopy. The audience is invited to actively participate during discussion of the different complications, their management and prevention.

10:30 - 10:45
Prevention of complications during laparoscopic access and exit
B. Petrut, Cluj Napoca (RO)

10:45 - 11:00
Intraoperative management of: Vascular and nerve injuries
M. Georgiev, Sofia (BG)

11:00 - 11:15
Intraoperative management of: Bowel injuries
P.L. Chlosta, Cracow (PL)

11:15 - 11:30
Intraoperative management of: Ureter injuries
A.S. Gözen, Heilbronn (DE)

11:30 - 11:45
Decision-making on early re-exploration
R. Autorino, Richmond (US)

11:45 - 12:00
Management and prevention of lymphoceles
J-U. Stolzenburg, Leipzig (DE)
# Semi-live surgery: Percutaneous stone removal

**Thematic 08**

**Location:** Green Area, Room 10  
**Chairs:** E. Liatsikos, Patras (GR)  
M. Monga, Chagrin Falls (US)  
**Panel:** M.S. Michel, Mannheim (DE)  
E. Montanari, Milan (IT)  
M. Sofer, Tel-Aviv (IL)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Surgical video presentation <em>Percutaneous nephrolitholapaxy in difficult cases</em> M.R. Desai, Naidad (IN)</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Panel discussion</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Surgical video presentation <em>Combined percutaneous and transureteral stone removal</em> M. Özsoy, Vienna (AT)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Panel discussion</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Surgical video presentation <em>Complications of percutaneous stone removal - dislocation, perforation, bleeding</em> T. Tailly, Ghent (BE)</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Panel discussion</td>
</tr>
</tbody>
</table>
Aims and objectives of this session
The mainstay of OAB treatment is medical management. Since decades a search is going on to find the ideal drug for OAB treatment. A drug should be effective, should not have many and severe side events and should be safe. So far the ideal drug has not been found. This implies that other options like the combination of drugs, also qualify for treatment. This session explores the feasibility of drug combination for OAB.

10:30 - 10:45
OAB drugs: What's new from the bench?
M.C. Michel, Mainz (DE)

10:45 - 11:00
Role of drug combination therapy for OAB management
F. Van Der Aa, Leuven (BE)

11:00 - 11:15
Case presentation faculty:
S. Charalampous, Limassol (CY)
E. Finazzi Agrò, Rome (IT)
T.A.T. Marcelissen, Maastricht (NL)
M.I.A. Wyndaele, Utrecht (NL)

11:00 - 11:03
Case presentation

11:03 - 11:06
Prefers an anticholinergic
To be confirmed

11:06 - 11:09
Prefers mirabegron
To be confirmed

11:09 - 11:12
No drugs - prefers PTNS
To be confirmed

11:12 - 11:15
Something else
To be confirmed

11:15 - 11:30
Case 2  Man, 50 years old, with OAB after Benign Prostatic Obstruction (BPO) relief

11:15 - 11:18
Case presentation
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:18 - 11:21</td>
<td>Prefers an anticholinergic</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:21 - 11:24</td>
<td>Prefers mirabegron</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:24 - 11:27</td>
<td>No drugs - prefers PTNS</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:27 - 11:30</td>
<td>Something else</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Case 3 Man, 60 years old, Parkinson disease, presenting with OAB</td>
</tr>
<tr>
<td>11:30 - 11:33</td>
<td>Case presentation</td>
</tr>
<tr>
<td>11:33 - 11:36</td>
<td>Prefers an anticholinergic</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:36 - 11:39</td>
<td>Prefers mirabegron</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:39 - 11:42</td>
<td>No drugs - prefers PTNS</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:42 - 11:45</td>
<td>Something else</td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Associated abstract presentations</td>
</tr>
<tr>
<td>125</td>
<td>In females with overactive bladder, an alternative injection paradigm for onabotulinumtoxina is associated with low clean intermittent catheterisation use</td>
</tr>
<tr>
<td></td>
<td>By: Macdiarmid S. ¹, Glazier D. ², Shapiro A. ³, McCammon K. ⁴, McCrery R. ⁵, Jarnagin B. ⁶, Boroujerdi A. ⁷, Bai Z. ⁸, Gao G. ⁹, Patel A. ¹⁰</td>
</tr>
<tr>
<td></td>
<td>¹Alliance Urology Specialists, Dept. of Urology, Greensboro, United States of America, ²Virginia Urology, Dept. of Urology, Emporia, United States of America, ³Chesapeake Urology, Dept. of Urology, Owings Mills, United States of America, ⁴Eastern Virginia Medical School, Dept. of Urology, Virginia Beach, United States of America, ⁵Adult Pediatric Urology, Dept. of Urology, Omaha, United States of America, ⁶Center for Pelvic Health, Female Pelvic Medicine &amp; Reconstructive Surgery, Franklin, United States of America, ⁷Allergan plc, Dept. of Urology, Irvine, United States of America, ⁸Allergan plc, Biostatistics, Madison, United States of America, ⁹Allergan plc, Medical Safety, Madison, United States of America, ¹⁰Allergan plc, Medical Affairs (Neurology and Urology), Marlow, United Kingdom</td>
</tr>
<tr>
<td>PT235</td>
<td>Exploration of litoxetine (LTX): A potential novel treatment for mixed urinary incontinence (MUI)</td>
</tr>
<tr>
<td></td>
<td>By: Haab F.</td>
</tr>
<tr>
<td></td>
<td>Hopital Tenon, Dept. of Urology, Paris, France</td>
</tr>
</tbody>
</table>
### How much do you know about modern imaging: Test yourself!

**Thematic 07**

**Sunday 17 March**

**10:30 - 12:00**

**Location:** Green Area, Room 12

**Chair:** J. Walz, Marseille (FR)

**Panel:**
- J.W.F. Catto, Sheffield (GB)
- N. Fossati, Milan (IT)
- S. Fanti, Bologna (IT)
- S. Shariat, Vienna (AT)
- G. Villeirs, Ghent (BE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Case</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:49</td>
<td>Case 1</td>
<td><strong>UPJ obstruction with limited renal function</strong></td>
</tr>
<tr>
<td>10:30 - 10:35</td>
<td>Case presentation</td>
<td>J. Walz, Marseille (FR)</td>
</tr>
<tr>
<td>10:35 - 10:49</td>
<td>Interactive test and discussion</td>
<td></td>
</tr>
<tr>
<td>10:49 - 11:08</td>
<td>Case 2</td>
<td><strong>PET in prostate cancer initial/relapse staging and treatment</strong></td>
</tr>
<tr>
<td>10:49 - 10:54</td>
<td>Case presentation</td>
<td>J. Walz, Marseille (FR)</td>
</tr>
<tr>
<td>10:54 - 11:08</td>
<td>Interactive test and discussion</td>
<td></td>
</tr>
<tr>
<td>11:08 - 11:27</td>
<td>Case 3</td>
<td><strong>The use of FDG-PET in newly-diagnosed bladder cancer</strong></td>
</tr>
<tr>
<td>11:08 - 11:13</td>
<td>Case presentation</td>
<td>J. Walz, Marseille (FR)</td>
</tr>
<tr>
<td>11:13 - 11:27</td>
<td>Interactive test and discussion</td>
<td></td>
</tr>
<tr>
<td>11:27 - 11:46</td>
<td>Case 4</td>
<td><strong>The use of mpMRI in newly-diagnosed bladder cancer</strong></td>
</tr>
<tr>
<td>11:27 - 11:32</td>
<td>Case presentation</td>
<td>J. Walz, Marseille (FR)</td>
</tr>
<tr>
<td>11:32 - 11:46</td>
<td>Interactive test and discussion</td>
<td></td>
</tr>
</tbody>
</table>
### Aims and objectives of this session

This session aims to provide you with the latest information and state of the art of different aspects for the care of your pediatric patients with a congenital urogenital anomaly or urological problem and long term outcome related to daily practice. The objectives are to inform urologists, residents in urology, researchers in pediatric urology and pediatric urologists and all interested in the recent developments on different subjects in the field of pediatric urology and the consequences for lifelong urological care.

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Long-term follow-up and quality of life of Spina Bifida patients</td>
<td>A. Bujons Tur, Barcelona (ES)</td>
<td>Green Area, Room 19</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Complicated stones in children and safe solutions</td>
<td>M.S. Silay, Istanbul (TR)</td>
<td>Green Area, Room 19</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Management of vesico-ureteral reflux and complication solutions</td>
<td>B. Haid, Linz (AT)</td>
<td>Green Area, Room 19</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Testicular development and adolescent varicocele: Diagnosis, treatment and outcome</td>
<td>G. De Win, Antwerpen (BE)</td>
<td>Green Area, Room 19</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Bladder extrophy care into adulthood</td>
<td>A. Baird, Liverpool (GB)</td>
<td>Green Area, Room 19</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Regenerative medicine technologies in the urinary tract</td>
<td>G. Pellegrini, Baggiovara (IT)</td>
<td>Green Area, Room 19</td>
</tr>
</tbody>
</table>
Testis cancer: Surgery is back again

Thematic 09

Sunday 17 March
10:30 - 12:00

Location: Green Area, Room 20

Chairs: P. Albers, Düsseldorf (DE)
J.L. Boormans, Rotterdam (NL)

Aims and objectives of this session
This session will provide you with up-to-date knowledge on the pathogenesis of germ cell tumors followed by a debate on a still controversial issue of primary RPLND for staging and treatment in patients with high risk clinical stage I non-seminoma. In a state-of-the-art latest data on one of the most dangerous histological transformations will be presented: Somatic malignancies in teratoma. The session will conclude with evidence-based recommendations for follow-up and two of the best abstracts on epidemiology and quality of care in testicular cancer.

10:30 - 10:42
The cause of everything: The testicular dysgenesis syndrome
D. Nettersheim, Düsseldorf (DE)

10:42 - 10:45
Discussion

10:45 - 11:15
Debate  Surgery for non-seminoma clinical stage I "high risk"

10:45 - 10:57
Pro surgery
S. Daneshmand, Los Angeles (US)

10:57 - 11:09
Con surgery
D.L. Nicol, London (GB)

11:09 - 11:15
Discussion

11:15 - 11:27
Surgical management for Somatic Malignant-transformed teratoma (SM)
N.W. Clarke, Manchester (GB)

11:27 - 11:30
Discussion

11:30 - 11:42
Challenging the guidelines  Risk-based follow-up schedules for testis cancer
R. Cathomas, Chur (CH)

11:42 - 11:45
Discussion

11:45 - 11:59
Associated abstract presentations
1239  Non-guideline concordant treatment of testicular cancer patients is associated with a significantly reduced event-free survival

By: Paffenholz P., Osterholt T., Nestler T., Pfister D., Heidenreich A. University Hospital Cologne, Dept. of Urology, Cologne, Germany

1240  Contemporary assessment of survival rates in stage I testicular seminoma: A population-based comparison between surveillance and active treatment after initial orchiectomy

By: Mistretta F.A.¹, Mazzone E.¹, Palumbo C.¹, Knipper S.¹, Tian Z.¹, Nazzani S.¹, Lattouf J-B.², Musi G.³, Perrotte P.², Montanari E.⁴, Shariat S.F.⁵, Montorsi F.⁶, Saad F.⁷, De Cobelli O.³, Karakiewicz P.I.¹

¹University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, ²University of Montreal Health Center, Dept. of Urology, Montreal, Canada, ³European Institute of Oncology, Dept. of Urology, Milan, Italy, ⁴IRCCS Fondazione Ca’ Granda-Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, ⁵Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁶IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Dept. of Oncology, Unit of Urology, URI, Milan, Italy, ⁷University of Montreal Hospital Center, Dept. of Urology, Montreal, Canada
Basic penile scrotal surgery and first steps in endourology
ESU Course 30

Sunday 17 March
12:00 - 14:00

Location: Green Area, Room 13
Chair: L. Henningsohn, Huddinge (SE)

Aims and objectives of this session
The course is designed to introduce the application of basic surgical knowledge and principles for the 1st and 2nd year residents. The course will provide the learners with basic knowledge and skills in developing a safe and methodological approach to their initial application of surgical knowledge. The course includes case discussions and learner activity.

Intended learning outcomes.
After this course you will be able to:
• Discuss the basic principles, indications and techniques in basic urological surgery of the scrotum and penis and basic endourology.
• Reason and plan for basic urological procedures based on the anatomy and the individual previous medical history.
• Choose the most appropriate surgical technique in common basic urological conditions.
• Discuss and understand the most common surgical risks in basic urological surgery and endoscopy.

Physical examination of the genitourinary tract
L. Henningsohn, Stockholm (SE)
R. Sanchez-Salas, Paris (FR)

Penile surgery
L. Henningsohn, Stockholm (SE)

Scrotal surgery
R. Sanchez-Salas, Paris (FR)

Basic endoscopic procedures (urethral catheterization, cystoscopy, nephrostomy)
L. Henningsohn, Stockholm (SE)
R. Sanchez-Salas, Paris (FR)
Laparoscopy for beginners
ESU Course 29

Aims and objectives of this session
With the large widespread of mini-invasive surgery, improving knowledge of practical aspects of laparoscopy is mandatory. Knowledge of:
• Indications and contra-indications of laparoscopic approach.
• How to choose and use the instrumentation, in order to optimize the procedure and minimize adverse effects.
• Air insufflations parameters and optimal access in laparoscopic urology.
• How to prevent, recognize and manage complications.

This course aims to provide all this knowledge in an interactive and practical way (video clip, open discussion), in order to assist beginners in laparoscopy shortening their learning curve and optimizing the success of their laparoscopic procedures.
• Laparoscopic surgery: For which patients and which procedures?
• Masterize the armentarium.
• Tips and tricks to optimize the procedure.
• New potential and future evolutions.

Indications for laparoscopy
B.S.E.P. Van Cleynenbreugel, Leuven (BE)

Instrumentation and haemostatis
X. Cathelineau, Paris (FR)

Peritoneal access and effects of pneumoperitoneum
B.S.E.P. Van Cleynenbreugel, Leuven (BE)

Avoiding complications
X. Cathelineau, Paris (FR)
New perspectives in the management of upper tract tumours
ESU Course 28

**Location:** Green Area, Room 15

**Chair:** S. Shariat, Vienna (AT)

**Aims and objectives of this session**
This course will address contemporary concepts and controversies in UTUC such as:
- Accurate staging and its role in clinical decision making/risk stratification.
- Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery.
- Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy.
- Systemic therapy for high-risk and metastatic patients.

**Epidemiology, diagnosis, evaluation**
M. Rouprêt, Paris (FR)

**Prognostic and predictive factors, pathology**
S. Shariat, Vienna (AT)

**Treatment of low risk cancer (high grade Ta, T1 and CIS)**
M. Rouprêt, Paris (FR)

**Treatment of localized high risk (invasive) and metastatic cancer**
S. Shariat, Vienna (AT)
Aims and objectives of this session
• Provide an introduction to working definition(s), background, and biology of oligometastatic prostate cancer.
• Update the current molecular imaging to provide such a diagnosis.
• Review the potential roles of surgery and/or radiation as metastasis directed therapy.
• Understand opportunities and challenges in individualizing care of the oligometastatic prostate cancer patient.

Introductions; Oligometastatic prostate cancer as a diagnosis
R.J. Karnes, Rochester (US)

Surgery for recurrent nodal metastasis with updates on molecular/PET imaging
A. Briganti, Milan (IT)

Radiation in oligometastatic prostate cancer (primary and recurrent) and clinical trial updates
P. Ost, Ghent (BE)

Surgery of primary oligometastatic prostate cancer (N1/M1)
R.J. Karnes, Rochester (US)

Further cases (case illustrations throughout)
A. Briganti, Milan (IT)
R.J. Karnes, Rochester (US)
P. Ost, Ghent (BE)

Questions audience
**Aims and objectives of this session**
The course aims to introduce the basic principles of the diagnostic work-up and management of the common micturition dysfunctions in neurological disease. The early introduction of correct management contributes to the patient’s quality of life and prevents potential complications for neurological patients.

The main aims are:
- To refresh the pathophysiology and the key points of the management of neurogenic bladder dysfunction.
- To apply those principles in specific cases which illustrate the most common problems seen in the clinical practice.
- To discuss with the help of real life clinical cases pharmacological and surgical options available for the management of neuro-urological patients.

**Introduction**
F. Cruz, Porto (PT)

**Pathophysiology and key points of the investigation of neurogenic bladder dysfunction**
M. Drake, Bristol (GB)

**Management of neurogenic bladder dysfunction: Key principles**
F. Cruz, Porto (PT)

**Patient with cerebral vascular accident**
M. Drake, Bristol (GB)

**Conclusion**
F. Cruz, Porto (PT)
M. Drake, Bristol (GB)
Aims and objectives of this session
MIBC is a multifaceted entity where one size no longer fits all, supporting the development of personalized and, in selected cases, organ-preserving strategies. Are the advances in imaging, molecular biology, conservative surgery; medical oncology and radiotherapy strong enough to shift the current pre-eminence of the ablative approach toward a more integrated and conservative perspective? If yes, what are the ideal candidates?

- One size does not fit all and urologists are central to the development of personalized treatment in MIBC.
- Patients selection is critical and based on advances in imaging, resection techniques and pathology.
- Organ preservation is feasible in a significant proportion of patients.
- Radical cystectomy and pre-emptive chemotherapy are essential to optimize results in aggressive conditions.

Introduction
B. Malavaud, Toulouse (FR)

Cystectomy in the management of bladder invasive and locally-advanced bladder cancer
M. Burger, Regensburg (DE)

Elements for a multidimensional approach to MIBC
B. Malavaud, Toulouse (FR)

Bladder-sparing approaches to muscle invasive bladder cancer
B. Malavaud, Toulouse (FR)

Overview of systemic treatments in metastatic bladder cancer
B. Malavaud, Toulouse (FR)

Concluding remarks
To be confirmed
Aims and objectives of this session
This course is aimed at critically reviewing key manuscripts published during the previous 12 months and devoted to the management of prostate cancer patients with a particular focus on basic research, screening, diagnosis, staging, and local and systemic therapies. Practice-changing manuscripts published in peer-reviewed journals between April 2018 and March 2019 will be identified and discussed for each topic. For every paper a clear take home message applicable to the every-day clinical practice will be identified and discussed. The main objective of the course is to inform participants on the latest and most significant novelties related to the contemporary management of prostate cancer patients.

Clinical implications of basic research
F. Montorsi, Milan (IT)

Screening: Novel biomarkers
M. Graefen, Hamburg (DE)

Diagnosis: Multiparametric magnetic resonance imaging (mpMRI) and MRI-targeted biopsies
F. Montorsi, Milan (IT)

Staging: Imaging and predictive models
M. Graefen, Hamburg (DE)

Treatment of localized prostate cancer: Active surveillance
F. Montorsi, Milan (IT)

Treatment of localized prostate cancer: Radical prostatectomy
M. Graefen, Hamburg (DE)

Treatment of localized prostate cancer: External beam radiotherapy and brachytherapy
M. Graefen, Hamburg (DE)

Treatment of localized prostate cancer: Focal therapy
F. Montorsi, Milan (IT)

Management of recurrence after treatment with curative intent
F. Montorsi, Milan (IT)
Management of hormone sensitive metastatic prostate cancer
F. Montorsi, Milan (IT)

Management of castration-resistant prostate cancer
M. Graefen, Hamburg (DE)
Updates on partial nephrectomy techniques

Video Session 07

Sunday 17 March
12:15 - 13:45

Location: Red Area, eURO Auditorium 1
Chairs: C-C. Abbou, Vincennes (FR)
        A. Minervini, Florence (IT)
        A. Mottrie, Aalst (BE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V46
Laparoscopic resection of intraparenchymal kidney neoplasm in condition of warm ischemia

By: Popov S., Guseinov R., Orlov I., Katunin A.
City Hospital Saint Luka, Dept. of Urology, Saint Petersburg, Russia

V47
Bilateral kidney tumor: Management and feasibility

By: Sforza S., Campi R., Mari A., Di Maida F., Tellini R., Vanacore D., Grosso A.,
Barzaghi P., Siena G., Masieri L., Carini M., Minervini A.
University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy

V48
Robot-assisted partial nephrectomy: Techniques and outcomes from the Transatlantic Robotic Nephron-sparing Surgery (TRoNeS) study group

By: Casale P., Lughezzani G., Buffi N., Maffei D., Dell'oglio P., Paciotti M.,
Fasulo V., Domanico L., Bevilacqua G., Saita A., Lazzeri M., Hurle R.,
Guazzoni G.F., Porter J., Mottrie A.
1Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, MI, Italy,
2Onze-Lieve-Vrouw Hospital, Dept. of Urology, Aalst, Belgium,
3Swedish Medical Center, Dept. of Urology, Seattle, WA, United States of America

V49
Non-ischemic partial nephrectomy with the hydrojet resection technique

By: Gakis G., Schubert T., Hassan F., Sokolakis I., Olschlager M., Hatzichristodoulou G., Kübler H.
University Hospital of Würzburg, Julius Maximilians University, Dept. of Urology and Pediatric Urology, Wurzburg, Germany

V50
Image-guided robot-assisted partial nephrectomy (IGRAPN): Combining 3 imaging techniques to perform an anatomical zero ischemia hemi-nephrectomy

By: Gury L., Grande P., Bernhard J-C.
CHU Pellegrin, Dept. of Urology, Bordeaux, France
V51  Robot-assisted partial nephrectomy for complex (PADUA score ≥10) tumors: Results from a multicenter experience at four high-volume centers

By: Buffi N.1, Lughezzani G.1, Maffei D.1, Dell'oglio P.2, Casale P.1, Saita A.1, Guazzoni G.F.1, Porter J.3, Porpiglia F.4, Fiori C.4, Amparore D.5, Mottrie A.2

1Humanitas Clinical and Research Center, Dept. of Urology, Milan, Italy, 2Onze-Lieve-Vrouw Hospital, Dept. of Urology, Aalst, Belgium, 3Swedish Urology Group, Dept. of Urology, Seattle, United States of America, 4San Luigi Gonzaga Hospital, Division of Urology, Dept. of Oncology, Turin, Italy, 5San Luigi Gonzaga Hospital, Division of Urology, Department of Oncology, Turin, Italy

V52  Robot-assisted partial nephrectomy in a patient with multiple tumor lesions in an s-shaped kidney: Superselective arterial clamping guided by the use of 3D images generated by a dedicated software

By: Annino F.1, Fuschi A.2, Pastore A.L.2, Carbone A.3, Al Salhi Y.2, De Angelis M.1, Asimakopoulos A.1

1San Donato Hospital, Dept. of Urology, Arezzo, Italy, 2Sapienza University of Rome, Medico-Surgical Sciences and Biotechnologies, Latina, Italy, 3Sapienza University of Rome, Medico-Surgical Sciences and Biotechnologies, Latina, Italy
Preclinical immunotherapy approaches in urothelium cancer

Poster Session 32

Sunday 17 March
12:15 - 13:45

Location: Green Area, Room 1
Chairs: K. W. Mouw, Boston (US)
G. Pignot, Montreuil (FR)
T.W. Todenhöfer, Tübingen (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 447

Mitomycin C triggers immunogenic cell death in bladder cancer cells

By: Oresta B. 1, Pozzi C. 1, Hurle R. 2, Lazzeri M. 2, Faccani C. 1, Colombo P. 3, Elefante G. 3, Casale P. 2, Guazzoni G. 4, Rescigno M. 5
1Humanitas Clinical and Research Center, Laboratory of Mucosal Immunology and Microbiota, Rozzano, Italy, 2Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, 3Humanitas Clinical and Research Center, Dept. of Pathology, Rozzano, Italy, 4Humanitas Clinical and Research Center\ Humanitas University, Dept. of Urology, Rozzano, Italy, 5Humanitas Clinical and Research Center\ Humanitas University, Laboratory of Mucosal Immunology and Microbiota, Rozzano, Italy

448

Cytotoxic T cell related gene expression signature predicts improved outcome in muscle-invasive urothelial bladder cancer patients following radical cystectomy and adjuvant chemotherapy

By: Eckstein M. 1, Wirtz R. 2, Strissel P. 3, Pfannstiel C. 1, Wullweber A. 1, Lange F. 1, Erben P. 4, Stoehr R. 1, Bertz S. 1, Geppert C. 1, Fuhrich N. 1, Weyerer V. 1, Taubert H. 5, Erlmeier F. 6, Breyer J. 7, Otto W. 7, Keck B. 5, Wach S. 5, Kunath F. 5, Strick R. 3, Hartmann A. 1, Wullich B. 5, Sikic D. 5
1University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Pathology, Erlangen, Germany, 2STRATIFYER Molecular Pathology, STRATIFYER Molecular Pathology, Cologne, Germany, 3University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Dept. of Gynecology and Obstetrics, Erlangen, Germany, 4Medical Faculty Mannheim, Ruprecht-Karls-Universität Heidelberg, Dept. of Urology Mannheim, Mannheim, Germany, 5University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Dept. of Urology and Pediatric Urology, Erlangen, Germany, 6TU Munich, Institute of Pathology, Munich, Germany, 7University Hospital, University of Regensburg, Dept. of Urology, Regensburg, Germany

449

The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 overcomes cisplatin resistance in cisplatin-resistant bladder cancer cells
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>451</td>
<td>Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment</td>
<td>By: Isono M., Okubo K., Asano T., Sato A. National Defense Medical College, Dept. of Urology, Tokorozawa, Japan</td>
<td></td>
</tr>
</tbody>
</table>
| 455| Standard anticancer agents increase the sensitivity of human Vγ9Vδ2T cell mediated cytotoxicity through NKG2D ligands in urinary bladder cancer | By: Umezu D.1, Okada N.2, Sakoda Y.2, Adachi K.2, Eto M.1, Tamada K.2  
1 Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan, 2 Graduate School of Medicine, Yamaguchi University, Dept. of Immunology, Ube, Japan |
| 456| Cobicistat, a potent CYP3A4 inhibitor, acts synergistically with oprozomib to cause endoplasmic reticulum stress in bladder cancer cells | By: Sato A., Asano T., Isono M., Okubo K. National Defense Medical College, Dept. of Urology, Tokorozawa, Japan |
| 457| Tumor targeting hyaluronic acid nanoparticles with combined phototherapy and hypoxia-activated chemotherapy for bladder preservation in MIBC | By: Lin T. Nanjing Drum Tower Hospital, Medical school of Nanjing University, Dept. of Urology, Nanjing, China |
| 458| Systematic chemical screening identifies disulfiram as a repositionable drug that enhances sensitivity to cisplatin in bladder cancer: A summary of preclinical studies | By: Kita Y.1, Kobayashi T.1, Teramoto Y.2, Tanaka R.3, Hamada A.1, Matsumoto K.1, Murakami K.1, Saito R.1, Nakayama K.1, Takano K.4, Akamatsu S.1, Yamasaki T.1, Inoue T.1, Tabata Y.3, Okuno Y.5, Ogawa O.1  
1 Kyoto University, Dept. of Urology, Kyoto, Japan, 2 Kyoto University, Dept. of Clinical Pathology, Kyoto, Japan, 3 Kyoto University, Dept. of Regeneration Science and Engineering, Kyoto, Japan, 4 Hokkaido Institute of Public Health, Dept. of Environmental and Health Sciences, Hokkaido, Japan, 5 Kyoto University, Dept. of Clinical System Onco-Informatics, Kyoto, Japan |
| 459| Aberrant error-prone DNA damage repair as a potential therapeutic target for chemo-radiation resistant urothelial carcinoma | By: |
| 13:34 - 13:41 | **Summary**  
|              | To be confirmed |

By: Komura K., Inamoto T., Uehara H., Ibuki N., Minami K., Tsujino T., Azuma H.  
Osaka Medical College, Dept. of Urology, Takatsuki city, Japan
Active surveillance vs focal therapy in prostate cancer?

Poster Session 33

Sunday 17 March 12:15 - 13:45

Location: Green Area, Room 2

Chairs: V.J. Gnanapragasam, Cambridge (GB)
P. Rischmann, Toulouse (FR)
F. Saad, Brossard (CA)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

460 Discontinuation of active surveillance of men with GG2 PCa: Assessment of 14 centres in 8 countries in the Movember GAP3 consortium

By: Helleman J., Remmers S., Nieboer D., Bangma C.H., Roobol M.J.
Erasmus MC, Dept. of Urology, Rotterdam, Netherlands, The

462 Using prognosis to guide inclusion criteria, stratify follow up and define standardized end-points in active surveillance for prostate cancer

By: Gnanapragasam V.J. 1, Barret T. 2, Thankapannair V. 3, Bratt O. 4, Stattin P. 5, Muir K. 6, Lophatananon A. 6
1University of Cambridge, Academic Urology Group, Cambridge, United Kingdom,
2University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom, 3Cambridge University Hospitals Trust, Dept. of Urology, Cambridge, United Kingdom, 4Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Gothenberg, Sweden, 5Uppsala University Hospital, Surgical Sciences, Uppsala, Sweden, 6University of Manchester, Dept. of Population Health, Manchester, United Kingdom

463 Multiparametric magnetic resonance of the prostate during active surveillance for low-risk prostate cancer: Time to reduce the number of follow-up biopsies?

By: Luzzago S. 1, Catellani M. 1, Mistretta F.A. 1, Conti A. 1, Di Trapani E. 1, Bianchi R. 1, Cozzi G. 1, Pricolo P. 2, Alessi S. 2, Ferro M. 1, Cordima G. 1, Matei D. 1, Petralia G. 2, Musi G. 1, De Cobelli O. 1
1IEO, European Institute of Oncology, Dept of. Urology, Milan, Italy, 2IEO, European Institute of Oncology, Dept. of Radiology, Milan, Italy

464 Natural history of prostate cancer on active surveillance: Stratification by MRI using the PRECISE recommendations in a UK cohort over 11 years

By: Giganti F. 1, Stabile A. 1, Stavrinides V. 1, Retter A. 1, Orczyk C. 1, Panebianco V. 2, Freeman A. 3, Jameson C. 3, Punwani S. 4, Allen C. 4, Kirkham A. 4, Emberton M. 5, Moore C.M. 6
1University College London, Division of Surgical and Interventional Sciences, London,
Young men with low risk prostate cancer can be safely candidate to active surveillance regardless of the extent of biopsy involvement: Results from a single center series with pathological confirmation

By: Bandini M. 1, Scarcella S. 2, Suardi N. 1, Nocera L. 1, Gandaglia G. 1, Fossati N. 1, Stabile A. 1, Dell’Oglio P. 1, Shariat S. 3, Longo N. 4, Mirone V. 4, Scuderi S. 1, Karakiewicz P. 5, Roberti D. 1, Rizzo A. 1, Cannoletta D. 1, Barletta F. 1, Pellegrino A. 1, Montorsi F. 6, Briganti A. 6

1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 3Vienna General Hospital, Dept. of Urology, Vienna, Austria, 4University of Naples Federico II, Dept. of Urology, Napoli, Italy, 5University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada

Development of novel criteria for active surveillance based on multiparametric MRI alone in men with Gleason 3+4 prostate cancer: Use of imaging to safely expand the eligibility for active surveillance

By: Gandaglia G. 1, Ploussard G. 2, Valerio M. 3, Mattei A. 4, Fiori C. 5, Fossati N. 6, Stabile A. 6, Beauval J. 7, Malavaud B. 7, Roumigué M. 7, Dell’Oglio P. 6, Suardi N. 6, Moschini M. 4, Zamboni S. 4, Rakauskas A. 3, Mirone V. 8, De Cobelli F. 9, Porpiglia F. 5, Montorsi F. 6, Briganti A. 6

1IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2Saint Jean Languedoc, La Croix du Sud Hospital, Toulouse, France, 3Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, 4Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 5San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, 6IRCCS Ospedale San Raffaele, Dept. of Oncology, UIR, Milan, Italy, 7CHU Rangueil, Dept. of Urology, Andrology and Renal Transplantation, Toulouse, France, 8University of Naples Federico II, Dept. of Urology, Naples, Italy, 9IRCCS Ospedale San Raffaele, Unit of Clinical Research in Radiology, Experimental Imaging Center, Milan, Italy

A longitudinal study of patients undergoing active surveillance for low grade prostate cancer diagnosed at Transperineal Template Prostate Mapping

By: Kailavasan M., Walton T.J., Ravindra P., Trecarten S., Voss J., Sherwood B.T., Pal R.P., Nottingham City Hospital, Dept. of Urology, Nottingham, United Kingdom

Multiparametric MRI can exclude prostate cancer progression in patients under active surveillance

By: Von Beyme Cortés C. 1, Ullrich T. 2, Quentin M. 2, Mones F. 2, Rabenalt R. 1,
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| 469  | Update on 12-month biopsy proven oncological and functional outcomes of primary irreversible electroporation for localised prostate cancer | Antoch G. ², Schimmöller L. ², Albers P. ¹, Arsov C. ¹  
¹University of Dusseldorf, Dept. of Urology, Dusseldorf, Germany, ²University of Dusseldorf, Dept. of Diagnostic and Interventional Radiology, Dusseldorf, Germany |
| 470  | 10-Year experience of primary cryotherapy for localized prostate cancer treatment: Oncologic and functional outcomes | Blazevski A. ¹, Scheltema M. ², Yuen B. ¹, Masand N. ², Cusick T. ², Haynes A. ², Stricker P. ¹  
¹St. Vincent's Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, ²Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Sydney, Australia |
| 471  | Medium term oncological outcomes in a large cohort of men treated with either focal- or hemi-ablation with HIFU for primary localized prostate cancer | Mercader Barrull C. ¹, Musquera M. ¹, Roldán F.L. ¹, Franco A. ¹, Fernández C. ², Alcaraz A. ¹, Ribal M.J. ¹  
¹Clinic Hospital, Dept. of Urology, Barcelona, Spain, ²Sant Joan de Déu Hospital, Dept. of Urology, Manresa, Spain |
| 473  | Menon-precision prostatectomy (MPP): An idea, development, exploration, assessment, long-term follow-up (IDEAL) stage 1 study | Abdollah F., Jeong W., Dalela D., Palma-Zamora I., Sood A., Menon M.  
Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America |
University Hospital Center of Angers, Dept. of Urology, Angers, France |
Staging bladder urothelial cancer in the era of molecular imaging and pathology

Poster Session 34

Sunday 17 March
12:15 - 13:45

Location: Green Area, Room 3

Chairs: To be confirmed
L-M. Krabbe, Münster (DE)
T. Seisen, Boston (US)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*475

Prognostic value of the 1973 and 2004/2016 WHO grading systems in primary Ta/T1 non-muscle invasive urothelial carcinoma of the bladder: A multicenter EAU NMIBC guidelines panel study

By: Van Rhijn B.W.G. 1, Burger M. 2, Comperat E. 3, Babjuk M. 4, Sylvester R. 5
1Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Surgical Oncology (Urology), Amsterdam, Netherlands, The, 2Caritas St Joseph Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, 3Hôpital Tenon, Sorbonne University, Dept. of Pathology, Paris, France, 4Hospital Motol, Second Faculty of Medicine - Charles University, Dept. of Urology, Prague, Czech Republic, 5European Association of Urology Guidelines Office, Dept. of Statistics, Brussels, Belgium

476

Vesical imaging-reporting and data system (VI-RADS) for bladder cancer staging with multiparametric MRI

By: Yoshida S. 1, Tanaka H. 2, Kijima T. 1, Yokoyama M. 1, Ishioka J. 1, Matsuoka Y. 1, Saito K. 1, Fujiy Y. 1
1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan

*477

Molecular characterization of neuroendocrine-like bladder cancer

1University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 2GenomeDX Biosciences, Dept. of R&D, Vancouver, Canada, 3Johns Hopkins Medical Institution, Dept. of Urology, Baltimore, United States of America, 4University of British Columbia, Dept. of Urology, Vancouver, Canada, 5Massachusetts General Hospital,
Co-expression of stem cell and epithelial mesenchymal transition markers in circulating tumor cells of bladder cancer patients

By: Zhang R., Chen H., Huang Y., Xue W.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China

Independent multicenter validation of the prognostic significance of histopathologic tumor regression grade after neoadjuvant chemotherapy in bladder cancer

1Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, Netherlands, The, 2Vancouver Prostate Centre - University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 3University of Bern, Dept. of Pathology, Bern, Switzerland, 4Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Pathology, Amsterdam, Netherlands, The, 5Instituto Oncológico FALP, Dept. of Urology, Santiago, Chile, 6Instituto Oncológico FALP, Dept. of Pathology, Santiago, Chile, 7Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 8Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 9Cochin Hospital, Paris Descartes University, Dept. of Pathology, Paris, France, 10Sorbonne Université, Hôpital Pitié-Salpêtrière, Dept. of Urology, Paris, France, 11Sorbonne Université, Hôpital Pitié-Salpêtrière, Dept. of Pathology, Paris, France, 12University Hospital Zurich, Institute of Pathology and Molecular Pathology, Zurich, Switzerland, 13Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Pathology, Amsterdam, Netherlands, The, 14University of Oregon, Dept. of Urology, Portland, United States of America, 15University of Minnesota, Dept. of Urology, Minneapolis, United States of America
**481**

**Associations between genetic pathways and radiomic metrics in muscle-invasive bladder cancer**

By: Lerner S.¹, Duddalwar V.², Huang E.³, Varghese B.², King K.G.², Cen S.Y.⁴, Hwang D.², Altun E.⁵, Bathala T.⁶, Kennish S.⁷, Ibarra J.¹, Lucchesi F.⁸, Muglia V.F.⁹, Thomas S.¹⁰, Vikram R.⁶, Kirby J.¹¹, Jaffe C.¹², Freymann J.¹¹

¹Baylor College of Medicine, Dept. of Urology, Houston, United States of America, ²Keck School of Medicine of USC, Dept. of Radiology, Los Angeles, United States of America, ³NIH/NCI, Dept. of Research Informatics, Durham, United States of America, ⁴Keck School of Medicine of USC, Dept. of Neurology, Los Angeles, United States of America, ⁵University of North Carolina, Dept. of Radiology, Chapel Hill, United States of America, ⁶MD Anderson Cancer Center, Dept. of Radiology, HOUSTON, United States of America, ⁷University of Sheffield, Dept. of Radiology, Sheffield, United Kingdom, ⁸Barretos Cancer Hospital, Dept. of Radiology, Barretos, Brazil, ⁹Ribeirao Preto School of Medicine, Dept. of Radiology, Sao Paulo, Brazil, ¹⁰University of Chicago, Dept. of Radiology, Chicago, United States of America, ¹¹NIH/NCI, Dept. of Computer Imaging Program, Bethesda, United States of America, ¹²TCIA, Dept. of Radiology, Boston, United States of America

**482**

**Prognostic significance of controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients**

By: Suzuki H., Takemura K., Ito M., Nakanishi Y., Kataoka M., Sakamoto K., Tobisu K., Koga F.

Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Dept. of Urology, Tokyo, Japan

**483**

**Histological characterization of lymph nodes metastasis in mixed urothelial-squamous histological variant at radical cystectomy**


ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy

**484**

**Mixed urothelial-squamous histological variant and its percentage on survival outcomes after radical cystectomy for bladder cancer in patients with lymph node invasion**


ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy

**485**

**Prognosis of rare pathological primary urethral carcinoma**


Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
Expert pathology review and the impact on clinical management in high-risk bladder cancer patients

By: van Doeveren T.¹, Berendsen S.A.¹, Van Leenders G.J.L.H.², Boormans J.L.¹
¹Erasmus MC, Dept. of Urology, Rotterdam, Netherlands, The, ²Erasmus MC, Dept. of Pathology, Rotterdam, Netherlands, The
Penile cancer: Has quality of care already improved through regionalisation?

Poster Session 35

**Sunday 17 March**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 - 13:45</td>
<td>Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.</td>
</tr>
</tbody>
</table>

**Location:** Green Area, Room 4

**Chairs:** To be confirmed

C. Protzel, Schwerin (DE)

V. Sangar, Manchester (GB)

---

### Outcomes of penile cancer patients with micro-metastases in dynamic sentinel lymph node biopsy specimens: An eurogen collaboration

*488*

By: Khaw R.A.¹, Van Thoor J. ², Albersen M. ², Oliveira P. ³, Elliott T. ³, Sangar V. ³, Lau M. ³, Parnham A. ³

¹University of Manchester, Faculty of Biology, Medicine and Health, Manchester, United Kingdom,

²Universitair Ziekenhuis Leuven, Dept. of Urology, Leuven, Belgium,

³The Christie Foundation NHS Trust, Dept. of Urology, Manchester, United Kingdom

---

### Radiotherapy plus chemotherapy versus chemotherapy alone in penile cancer patients with extracapsular nodal extension after inguinal lymph node surgery: A multi-institutional study

489

By: Li Z.¹, Zhou F. ², Han H. ², Wang B. ³, Tang Y. ⁴, Liu N. ⁵, Chen P. ⁶, Liao H. ⁷, Li X. ⁸, Ornellas A.A. ⁹, Mi Q. ¹⁰

¹Shenzhen People’s Hospital, Dept. of Urology, Shenzhen, China,

²Sun Yat-sen University Cancer Cente, Dept. of Urology, Guangzhou, China,

³Cancer Center of Guangzhou Medical University, Dept. of Urology, Guangzhou, China,

⁴Tumor Hospital of GuangXi Medical College, Dept. of Urology, Nanning, China,

⁵ChongQing Cancer Hospital & Institute, Dept. of Urology, ChongQing, China,

⁶Affiliated Tumor Hospital of Xinjiang Medical University, Dept. of Urology, Urumchi, China,

⁷SiChuang Cancer Hospital & Institute, Dept. of Urology, ChengDu, China,

⁸West China Hospital, Dept. of Urology, Chengdu, China,

⁹Brazilian National Cancer Institute, Dept. of Urology, Rio de Janeiro, Brazil,

¹⁰Dong Guan People’s Hospital, Dept. of Urology, Dongguan, China

---

### Treatment outcomes of penile intraepithelial neoplasia (PeIN) related to P16 status

490

By: Ashley S. ¹, Cleaveland P. ¹, Oliveira P. ¹, Clarke N. ¹, Parr N. ², Lucky M. ³, Lau M. ¹, Parnham A. ¹, Sangar V. ¹

¹The Christie NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom,

²Wirral University Hospitals NHS Foundation Trust, Dept. of Urology, Wirral, United Kingdom
Predicting overall survival (OS) in patients (pts) with penile squamous cell carcinoma (PSCC) undergoing regional lymph node dissection (LND) ± multimodal therapy

By: Necchi A. 1, Mariani L. 1, Zhu Y. 2, Ye D-W. 3, Ornellas A. 4, Watkin N. 5, Ager M. 5, Lo Vullo S. 1, Hakenberg O. 6, Heidenreich A. 7, Raggi D. 1, Catanzaro M. 1, Salvioni R. 1, Chipollini J. 8, Azizi M. 8, Spiess P. 8

1 Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy
2 Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
3 Fudan University Shanghai Cancer Center, Dept. of Urology, Shangai, China
4 Hospital Mário Kröeff and Brazilian Cancer Institute, Dept. of Urology, Rio de Janeiro, Brazil
5 St. George’s University Hospitals, Dept. of Urology, London, United Kingdom
6 University Hospital Rostock, Dept. of Urology, Rostock, Germany
7 Universitätssklinikum Köln, Dept. of Urology, Cologne, Germany
8 Moffitt Cancer Center and Research Institute, Dept. of Urology, Tampa, United States of America

Results of a 10 year multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis (SCCP)

By: Ager M. 1, Njoku K. 2, Serra M. 3, Pickering L. 4, Afshar M. 4, Beesley S. 5, Robinson A. 6, Crellin P. 7, Vyas L. 8, Kayes O. 8, Elmamoun M. 8, Eardley I. 9, Ayres B. 1, Henry A. 2, Tree A. 3, Watkin N. 1

1 St George’s University Hospital NHS Trust, Dept. of Urology, London, United Kingdom
2 Leeds Teaching Hospital NHS Trust, Dept. of Oncology, Leeds, United Kingdom
3 Royal Marsden NHS Trust, Dept. of Oncology, London, United Kingdom
4 St George’s University Hospital NHS Trust, Dept. of Oncology, London, United Kingdom
5 Maidstone and Tunbridge Well NHS Trust, Dept. of Oncology, Maidstone, United Kingdom
6 Brighton and Sussex University Hospital NHS Trust, Dept. of Oncology, Brighton, United Kingdom
7 Poole NHS Foundation Trust, Dept. of Oncology, Poole, United Kingdom
8 Leeds Teaching Hospital NHS Trust, Dept. of Urology, Leeds, United Kingdom
9 Leeds Teaching Hospital NHS Trust, Dept. of Urology, Leeds, United Kingdom

The SentiPen trial from eUROGEN & The NCRI (UK): Concordance of Sienna+/Sentimag with Standard 99mTc labeled nanocolloid technique for the detection of inguinal sentinel lymph nodes in patients with cN0 penile cancer

By: Cleaveland P., Oliveira P., Hambrock T., Bell J., Najran P., Clarke N., Murby B., Parr N., Parham A., Lau M., Sangar V.
Christie NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom

Trends in surgical treatment for penile cancer in Germany from 2006 to 2015: Rising case numbers and moderate centralization

By: Groeben C. 1, Koch R. 2, Baunacke M. 1, Borkowetz A. 1, Thomas C. 1, Huber J. 1

1 Medical Faculty Carl Gustav Carus, TU Dresden, Dept. of Urology, Dresden, Germany
Surveillance algorithm for node positive squamous cell carcinoma of the penis

By: Ager M.¹, Manjunath A.¹, Yan S.¹, Corbishley C.², Tinwell B.², Afshar M.³, Tree A.⁴, Ayres B.¹, Watkin N.¹

¹St George's University Hospital NHS Trust, Dept. of Urology, London, United Kingdom,
²St George's University Hospital NHS Trust, Dept. of Pathology, London, United Kingdom,
³St George's University Hospital NHS Trust, Dept. of Clinical Oncology, London, United Kingdom,
⁴Royal Marsden NHS Trust, Dept. of Clinical Oncology, London, United Kingdom

Summary
To be confirmed
### How technology will change your practice in the next decade - The appealing image of new experimental technologies

**Poster Session 36**

**Sunday 17 March**  
**12:15 - 13:45**

**Location:** Green Area, Room 5

**Chairs:** P.M. Kronenberg, Lisbon (PT)  
U. Nagele, Vienna (AT)  
E. Nemr, Achrafieh - Beirut (LB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>499</td>
<td>Transcription and protein phenotyping with 3D pathology: Light-sheet microscopy overlooks cellular malignancy of intact tumour volumes</td>
<td>Tanaka N.¹, Kanatani S.², Kaczynska D.², Louhivuori L.², Oya M.¹, Miyakawa A.³, Uhlén P.²</td>
<td>¹Keio University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Karolinska Institutet, Dept. of Medical Biochemistry and Biophysics, Stockholm, Sweden, ³Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden</td>
</tr>
<tr>
<td>500</td>
<td>Characterization of bladder organoid cultures from healthy and cancer tissues</td>
<td>Patard P.M.¹, Rubio A.², Tostivint V.³, Rouget C.⁴, Lluel P.⁴, Vergnolle N.², Gamé X.¹</td>
<td>¹Rangueil University Hospital, Dept. of Urology, Andrology and Kidney Transplantation, Toulouse, France, ²Inserm, Institut de Recherche en Santé Digestive, Inserm, U1220, Toulouse, France, ³University of Toulouse, CHU Rangueil, Dept. of Urology, Andrology and Kidney Transplantation, Toulouse, France, ⁴Urosphere, Dept. of Urology, Andrology and Kidney Transplantation, Toulouse, France</td>
</tr>
<tr>
<td>501</td>
<td>Holographic surgical planning of partial nephrectomy using a wearable mixed reality computer</td>
<td>Yoshida S.¹, Fukuda S.¹, Moriya S.¹, Yokoyama M.¹, Taniguchi N.², Shinjo K.², Sugimoto M.², Saito K.¹, Fujii Y.¹</td>
<td>¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Holoeys Inc., Dept. of Urology, Tokyo, Japan</td>
</tr>
<tr>
<td>502</td>
<td>Biodistribution and toxicity of gold nanoparticle-based photo-immuno-nanotherapy for bladder cancer</td>
<td>Barton G.¹, Liu Y.², Maccarini P.², Palmer G.³, Etienne W.¹, Tan W.P¹, Vo-Dinh T.², Inman B.¹</td>
<td>¹Duke University Medical Center, Dept. of Urology, Durham, United States of America, ²Harvard Medical School, Dept. of Urology, Boston, United States of America, ³University of California, San Francisco, Dept. of Urology, San Francisco, United States of America, ⁴Georgia State University, Dept. of Urology, Atlanta, United States of America</td>
</tr>
</tbody>
</table>
Remarkable difference between 3D and 2D cultures of bladder cancer cells in response to drugs: A concrete example for importance of 3D culture

By: Yoshida T.¹, Kates M.², Liu X.², Joice G.², Sopko N.², Mcconkey D.², Bivalacqua T.²

¹Hyogo Prefectural Nishinomiya Hospital, Dept. of Urology, Nishinomiya, Japan, ²The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America

Cerenkov luminescence imaging for intraoperative specimen analysis: A pre-clinical evaluation

By: Olde Heuvel J.¹, De Wit - Van Der Veen L.¹, Stokkel M.P.M.¹, Van Der Poel H.P.², Tuch D.S.³, Grootendorst M.R.³, Vyas K.N.³, Slump C.H.⁴

¹Netherlands Cancer Institute, Antoni van Leeuwenhoek, Dept. of Nuclear Medicine, Amsterdam, Netherlands, The, ²Netherlands Cancer Institute, Antoni van Leeuwenhoek, Dept. of Urology, Amsterdam, Netherlands, The, ³Lightpoint Medical Ltd, Chesham, United Kingdom, ⁴University of Twente, MIRA Institute for Biomedical Technology and Technical Medicine, Enschede, Netherlands, The

Implementation of grayscale values of hypoechoic lesions in transrectal ultrasound-guided biopsy for predicting prostate cancer and clinically significant prostate cancer: A validating confirmatory study

By: Park J.S., Koo K.C., Chung B.H., Lee K.S.

Yonsei University College of Medicine, Dept. of Urology, Seoul, Korea, South

Real-time high resolution diagnostic imaging for prostatic tissue with ex vivo fluorescence confocal microscopy: Our preliminary experience

By: Puliatti S.¹, Bertoni L.², Pirola G.M.¹, Azzoni P.², Bevilacqua L.¹, Eissa A.³, Elsherbiny A.³, Sighinolfi M.C.¹, Chester J.², Rocco B.¹, Micali S.¹, Bagni L.⁴, Reggiani Bonetti L.⁴, Maioran A.⁴, Malvehy J.⁶, Longo C.⁶, Montironi R.⁷, Patel V.⁸, Pellacani G.⁶, Bianchi G.¹

¹University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ²University of Modena and Reggio Emilia, Dept. of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, Modena, Italy, ³Faculty of Medicine, Tanta University, Dept. of Urology, Tanta, Egypt, ⁴University of Modena and Reggio Emilia, Dept. of Pathology, Modena, Italy, ⁵Hospital Clinic Barcelona, Dept. of Dermatology, Melanoma Unit, Barcelona, Spain, ⁶University of Modena and Reggio Emilia, Dept. of Dermatology, Modena, Italy, ⁷Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Dept. of Pathological Anatomy, Ancona, Italy, ⁸Global Robotics Institute, Florida Hospital-Celebration Health Celebration, Dept. of Urology, Orlando, United States of America
510 Utilisation of the HoloLens mixed-reality device in minimally invasive surgery

By: Al Janabi H.F. 1, Aydin A. 1, Palaneer S. 1, Macchione N. 2, Al-Jabir A. 1, Khan M.S 3, Dasgupta P. 3, Ahmed K. 3

1 King’s College London, MRC Centre for Transplantation, London, United Kingdom, 2 Università degli Studi di Milano, ASST Santi Paolo e Carlo, Milan, Italy, 3 Guy’s and St. Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom

511 Electrophysiological differences between typical and dense benign prostatic hyperplasia tissues retrieved after holmium laser enucleation of the prostate


1 Pusan National University Hospital, Dept. of Urology, Busan, Korea, South, 2 BHS Hansong Hospital, Dept. of Urology, Busan, Korea, South, 3 Kosin University College of Medicine, Dept. of Urology, Busan, Korea, South, 4 Dong-A University Hospital, Dept. of Urology, Busan, Korea, South, 5 Inje University Busan Paik Hospital, Dept. of Urology, Busan, Korea, South, 6 Samsung Changwon Hospital, Dept. of Urology, Changwon, Korea, South, 7 Ulsan-Jeil Hospital, Dept. of Urology, Ulsan, Korea, South, 8 Gwangju Institute of Science and Technology, Biomedical Science and Engineering, Gwangju, Korea, South

512 Electric stimulation hyperthermia relieves inflammation via toll-like receptor 4 (TLR-4) suppressor of cytokine signaling (SOCS) pathway in chronic prostatitis/chronic pelvic pain syndrome


Seoul St. Mary’s Hospital, Catholic University of Korea, Dept. of Urology, Seoul, Korea, South
New modalities for staging of recurrent prostate cancer

Poster Session 37

Sunday 17 March
12:15 - 13:45

Location: Green Area, Room 10
Chairs: W.C. Loidl, Linz (AT)
N. Suardi, Milan (IT)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

513

Follow-up after robot-assisted radical prostatectomy with sentinel node biopsy and lymph node dissection: Analysis of biochemical recurrences with PSMA-PET/CT

By: Brouwer O.R. 1, Wit E. 1, Van Leeuwen P.J. 1, Van Leeuwen F.W.B. 2, Van Der Poel H.G. 1
1The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The, 2Leiden University Medical Center, Dept. of Interventional Molecular Imaging, Leiden, Netherlands, The

514

18F-rhPSMA7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy

1Martini-Klinik, Dept. of Urology, UKE, Hamburg, Germany, 2TUM, Dept. of Nuclear Medicine, Munich, Germany, 3TUM, Dept. of Radiochemistry, Munich, Germany, 4TUM, Dept. of Urology, Munich, Germany, 5TUM, Dept. of Medical Statistics and Epidemiology, Munich, Germany

516

Validation of strategies for selective bone scan staging in australian men with newly diagnosed prostate cancer

By: Hiwase M. 1, Vincent A. 2, O’callaghan M. 3
1University of Adelaide, Adelaide Medical School, Adelaide, Australia, 2University of Adelaide, Freemasons Centre for Men’s Health, Adelaide, Australia, 3Flinders Medical Centre, Dept. of Urology, Adelaide, Australia

517

Pitfalls of PSMA imaging for nodal recurrences after radical prostatectomy: Comparison of PET/CT results with histopathology and PSMA immunostaining

By: Linxweiler J. 1, Sprenk J. 1, Hölters S. 1, Pryalukhin A. 2, Ezziddin S. 3, Bohle R.M. 4, Ohlmann C.H. 5, Stöckle M. 1, Saar M. 1, Junker K. 1
1Saarland University, Dept. of Urology, Homburg Saar, Germany, 2Bonn University, Dept. of Pathology, Bonn, Germany, 3Saarland University, Dept. of Nuclear Medicine, Homburg
The value of 99mTc-PSMA SPECT/CT guided surgery for recurrent prostate cancer patients

By: Su H., Ye D., Zhu Y.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Clinical impact of "true whole-body" Ga-68-PSMA I&T PET/CT: Lesion frequency and added benefit in lower extremities

By: Stolzenbach L.F., Maurer T., Budäus L., Steuber T., Graefen M., Sauer M., Kobayashi Y., Apostolova I., Berliner C.
1University Medical Center Hamburg-Eppendorf, Martini Klinik, Hamburg, Hamburg, Germany, 2University Medical Center Hamburg-Eppendorf, Department for Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg, Hamburg, Germany

Quantitative whole-body magnetic resonance imaging to predict prognosis in patients with metastatic prostate cancer: A prospective study

By: Iwamura H., Kaiho Y., Ito J., Anan G., Sato M.
1Tohoku Medical and Pharmaceutical University, Dept. of Urology, Sendai, Japan, 2Tohoku Medical and Pharmaceutical University Hospital, Dept. of Urology, Sendai, Japan

Raman spectral signature of serum for prostate cancer bone metastases screening

By: Shao S., Pan J.H.P., Zhu Y.J.Z., Dong B.J.D., Wang Y., Xue W.X.
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China

Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging

1University of Duisburg-Essen and German Cancer Consortium (DKTK), partner site University Hospital Essen, Dept. of Urology, Essen, Germany, 2University of Duisburg-Essen and German Cancer Consortium (DKTK), partner site University Hospital Essen, Dept. of Nuclear Medicine, Essen, Germany, 3Peter MacCallum Cancer Centre, Dept. of Cancer Imaging, Melbourne, Australia, 4University of California Los Angeles, Dept. of Molecular and Medical Pharmacology, Los Angeles, United States of America, 5LMU, Dept. of Nuclear Medicine, Munich, Germany, 6Université de Montréal, Centre Hospitalier de l'Université de Montréal, Montréal, Canada, 7University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America, 8Massachusetts General Hospital Cancer Center and Harvard Medical School,
524  
Metastasis-directed therapy for oligoprogressive castration refractory prostate cancer

By: Berghen C. 1, Joniau S. 2, Ost P. 3, Poels K. 1, Everaerts W. 2, Haustermans K. 1, De Meerleer G. 1
1UZLeuven, Dept. of Radiation Oncology, Leuven, Belgium, 2UZLeuven, Dept. of Urology, Leuven, Belgium, 3UZ Ghent, Dept. of Radiation Oncology, Ghent, Belgium

525  
Loco-regional radiotherapy targeting oligo-progressive lesions in castration-resistant prostate cancer patients: Intra-pelvic localized progressive lesions are the good targets

By: Yoshida S. 1, Takahara T. 2, Ishii C. 3, Nakagawa K. 4, Toda K. 4, Arita Y. 5, Kijima T. 1, Yokoyama M. 1, Ishioka J. 1, Matsuoka Y. 1, Saito K. 1, Yoshimura R. 4, Fujii Y. 1
1Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, 2Tokai University School of Engineering, Dept. of Biomedical Engineering, Kanagawa, Japan, 3AIC Yaesu Clinic, Dept. of Radiology, Tokyo, Japan, 4Tokyo Medical and Dental University Graduate School, Dept. of Radiation Therapeutics and Oncology, Tokyo, Japan, 5Keio University School of Medicine, Dept. of Diagnostic Radiology, Tokyo, Japan

526  
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration resistant prostate cancer

By: Grubmüller B. 1, Senn D. 2, Kramer G. 1, Baltzer P. 3, D’andrea D. 1, Eidherr H. 2, Haug A. 2, Wadsak W. 2, Pfaff S. 2, Hacker M. 2, Shariat S.F. 1, Hartenbach M. 2
1Medical University of Vienna, Dept. of Urology, Vienna, Austria, 2Medical University of Vienna, Dept. of Biomedical Imaging and Image guided Therapy, Division of Nuclear Medicine, Vienna, Austria, 3Medical University of Vienna, Dept. of Biomedical Imaging and Image guided Therapy, Division of General and Pediatric Radiology, Vienna, Austria

17:04 - 17:11  
Summary
To be confirmed
Understanding how the bladder works: News from the bench
Poster Session 38

Sunday 17 March
12:15 - 13:45

Location: Green Area, Room 11
Chairs: To be confirmed
M. Gotoh, Nagoya (JP)
K. Monastyrskaya, Bern (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

527

Urothelial ATP is implicated in the appearance of detrusor underactivity (DU) early after bladder outlet obstruction (BOO) and in the recovery of detrusor function after obstruction relief

By: Pedrosa Do Vale L.1, Charrua A. 2, Cavaleiro H. 2, Avelino A. 2, Lopes T. 3, Birder L.A. 4, Cruz F. 3
1Faculdade de Medicina da Universidade do Porto, Dept. of Biomedicine, Porto, Portugal,
2Faculdade de Medicina da Universidade do Porto, Dept. of Biomedical Science, Porto, Portugal,
3Faculdade de Medicina da Universidade do Porto, Dept. of Urology, Porto, Portugal,
4University of Pittsburgh School of Medicine, Dept. of Medicine and Pharmacology-Chemical Biology, Porto, Portugal

528

Reduced apoptosis of bladder cells for the improved bladder underactivity after transplantation of HGF over-expressing mesenchymal stem cell

By: Song Y.S. 1, Lee H.J. 2, Song E.S. 3, Kim J.H. 1, Doo S.W. 1, Yang W.J. 1, Yun J.H. 4, Lee S.J. 5
1Soonchunhyang University College of Medicine, Dept. of Urology, Seoul, Korea, South,
2Chungbuk National University College of Medicine, Medical Research Institute, Cheongju, Korea, South,
3Gwangjin-Gu Health Center, Medical Treatment Division, Seoul, Korea, South,
4Soonchunhyang University College of Medicine, Dept. of Urology, Gumi, Korea, South,
5Kyungh ee University Hospital, Dept. of Urology, Seoul, Korea, South

529

Development of chronic bladder ischemia rat model for reproducing the detrusor underactivity

By: Ryu C-M. 1, Yu H.Y.1, Kim M. 1, Shin J.H 1, Shin D-M 2, Choo M.S 1
1Asan Medical Center, Dept. of Urology, Seoul, Korea, South,
2Asan Medical Center, Dept. of Biomedical Sciences, Seoul, Korea, South

530

The nicotine-induced alterations in oxidative stress parameters in the rat bladder

By: Tsounapi P. 1, Honda M. 1, Teraoka S. 1, Kimura Y. 1, Hikita K. 1, Zachariou A. 2, Sofikitis N. 2, Saito M. 3, Takenaka A. 1
Role of corticotropin-releasing factor on bladder function in rats with psychological stress

By: Seki M., Zha X-M., Ito H., Aoki Y., Matsuta Y., Taga M., Inamura S., Yokoyama O. School of Medical Science, University of Fukui, Dept. of Urology, Fukui, Japan

MicroRNA-126 transferred by extracellular vesicles of human adipose-derived stem cells enhances regenerated bladder angiogenesis via SDF-1α/CXCR4 pathway

By: Xiao D., Lu M., Yan H., Lv X.G., Zhang M. Shanghai Renji Hospital, Dept. of Urology and Andrology, Shanghai, China

Inhibition of detrusor contractions by the LIM kinase inhibitors, SR7826 and LIMKi3: A new anti-contractile strategy and implications for a role of LIM kinases in the control of detrusor muscle

By: Yu Q., Hennenberg M., Wang R., Wang X., Li B., Duan X., Zeng G. 1 1The First Affiliated Hospital Of Guangzhou Medical University, Dept. of Urology, Guangzhou, China, 2Ludwig Maximilian University of Munich, Dept. of Urology, Munich, Germany

Dysregulation of phospholamban and beta 3-adrenergic receptor expression might lead to bladder detrusor overactivity via SERCA inhibition

By: Monastyrskaya K., Besic M., Hashemi Gheinani A., Burkhard F.C. 1 1University of Bern, Urology Research Laboratory, Dept. of BioMedical Research, Bern, Switzerland, 2University Hospital Bern, Inselspital, Dept. of Urology, Bern, Switzerland

Large-conductance voltage- and calcium-activated potassium channels regulate contraction function of human bladder smooth muscle cells under hydrostatic pressure

By: Wang K.J., He Q., Luo D., Ai J., Jin X., Gong L., Xiao K., Hong L. West China Hospital, Sichuan University, Dept. of Urology, Laboratory of Reconstructive Urology, Chengdu, China

Partial inhibition of activin receptor-like kinase 4 alleviates bladder fibrosis caused by bladder outlet obstruction

By: Wang N., Shen H., Qi J. Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

Urinary miRNA profiles discriminate between BPO patients and healthy controls

By: Kueffer M., Besic M., Hashemi Gheinani A., Vassella E., Schneider M.
The circadian rhythm of bladder clock genes in spontaneously hypertensive rat

By: Kimura Y. 1, Honda M. 1, Sasaki R. 2, Panagiota T. 1, Morizane S. 1, Hikita K. 1, Osaki M. 2, Okada F. 2, Takenaka A. 1

1 Tottori University, Division of Urology, Faculty of Medicine, Yonago, Japan, 2 Tottori University, Division of Pathological Biochemistry, Yonago, Japan

Molecular characterization of bladder pain syndrome identifies functional mRNA-microRNA regulatory modules

By: Hashemi Gheinani A. 1, Burkhard F. 2, Rehrauer H. 3, Aquino Fournier C. 3, Rémi B. 4, Monastyrskaya K. 1

1 University of Bern, Urology Research Laboratory, Dept. of BioMedical Research, Bern, Switzerland, 2 University Hospital, Dept. of Urology, Bern, Switzerland, 3 ETH Zurich, Functional Genomics Center, Zurich, Switzerland, 4 University Hospital, Interfaculty Bioinformatics Unit, Bern, Switzerland

What factors affect both urethral and rectal function in a female rat model?

By: Kitta T., Ouchi M., Kanno Y., Higuchi M., Togo M., Takahashi Y., Moriya K., Shinohara N.

Hokkaido University, Dept. of Urology, Sapporo, Japan
Is mp MRI enough (IMRIE) in prostate cancer diagnosis?
¹King’s College Hospital, Dept. of Urology, London, United Kingdom, ²Guy’s Hospital, Dept. of Urology, London, United Kingdom, ³Canterbury Centre for Robotic Urological Surgery, Dept. of Urology, Eastbourne, United Kingdom, ⁴Glasgow Royal Infirmary, Dept. of Urology, Glasgow, United Kingdom, ⁵Southmead Hospital, Dept. of Urology, Bristol, United Kingdom, ⁶Brighton and Sussex University Hospital, Dept. of Urology, Brighton, United Kingdom, ⁷Ashford and St. Peter’s Hospital, Dept. of Urology, Ashford, United Kingdom, ⁸Princess Alexandra Hospital, Dept. of Urology, Harlow, United Kingdom, ⁹Imperial College London, Dept. of Urology, London, United Kingdom, ¹⁰University College London Hospitals (UCLH), Dept. of Urology, London, United Kingdom

Do performance characteristics of multi-parametric MRI of the prostate change according to patient age? Clinical implications for age-tailored biopsy approaches
By: Stabile A. ¹, Dell’Oglio P. ¹, Solili M. ², De Cobelli F. ³, Gandaglia G. ¹, Zaffuto E. ¹, Fallara G. ¹, Fossati N. ¹, Boeri L. ², Scuderi S. ¹, Deho’ F. ¹, Esposito A. ³, Del Maschio A. ³, Karnes J. ², Montorsi F. ¹, Briganti A. ¹
¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy

Artificial Intelligence for automated Gleason Grading in prostate cancer biopsies
By: Marginean F-E. ¹, Krzyzanowska A. ¹, Arvidsson I. ², Simoulis A. ³, Sjöblom E. ⁴, Lundström C. ⁴, Overgaard N.C. ², Ehrnström R. ³, Åström K. ⁵, Heyden A. ², Bjartell A. ¹
¹Lund University, Faculty of Medicine, Division of Urological Cancers, Malmö, Sweden, ²Lund University, Centre for Mathematical Sciences, Lund, Sweden, ³Skåne University
External validation and comparison of multivariable prostate cancer risk calculators incorporating multiparametric magnetic resonance imaging

By: Saba K.¹, Wettstein M.S.¹, Lieger L.¹, Märzendorfer O.¹, Hötker A.M.², Donati O.F.², Poyet C.¹, Sulser T.¹, Eberli D.¹, Mortezaei A.¹
¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital Zurich, Institute of Diagnostic and Interventional Radiology, Zurich, Switzerland

Radiogenomic characterization of multifocal prostate cancer

By: Salami S.¹, Kaplan J.², Nallandhighal S.¹, Takhar M.³, Tosioian J.¹, Lee M.¹, Yoon J.⁴, Hovelson D.⁵, Plouffe K.², Kaffenberger S.¹, George A.¹, Montgomery J.¹, Davenport M.⁶, You S.⁴, Tomlins S.², Curci N.⁶, Kim H.⁷, Spratt D.⁸, Udager A.², Palapattu G.¹
¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³GenomeDx Biosciences Inc., Clinical Laboratory, San Diego, United States of America, ⁴Cedars-Sinai Medical Center, Dept. of Biomedical Sciences, Los Angeles, United States of America, ⁵Strata Oncology, Clinical Laboratory, Ann Arbor, United States of America, ⁶University of Michigan, Dept. of Radiology, Ann Arbor, United States of America, ⁷Cedars-Sinai Medical Center, Dept. of Surgery, Los Angeles, United States of America, ⁸University of Michigan, Dept. of Radiation Oncology, Ann Arbor, United States of America

Prostate MRI, with or without targeted biopsy and standard biopsy for detecting prostate cancer: A Cochrane systematic review and meta-analysis

By: Drost F.J.¹, Osses D.F.¹, Nieboer D.², Bangma C.H.², Steyerberg E.W.³, Roobol M.J.², Schoots I.G.⁴
¹Erasmus University Medical Center, Dept. of Radiology & Nuclear Medicine and Dept. of Urology, Rotterdam, Netherlands, The, ²Erasmus University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, ³Erasmus MC University Medical Center, Dept. of Public Health, Rotterdam, Netherlands, The, ⁴Erasmus University Medical Center, Dept. of Radiology & Nuclear Medicine, Rotterdam, Netherlands, The

Pathological findings at radical prostatectomy of biopsy naïve men submitted to MRI-Targeted biopsy alone without standard systematic sampling

By: Luzzago S.¹, Catellani M.¹, Mistretta F.A.¹, Conti A.¹, Di Trapani E.¹, Brescia A.¹, Pricolo P.², Alessi S.², Verweij F.¹, Ferro M.¹, Matei D.¹, Renne G.³, Petralia G.², Musi G.¹, De Cobelli O.¹
¹IEO, European Institute of Oncology, Dept. of Urology, Milan, Italy, ²IEO, European Institute of Oncology, Dept. of Radiology, Milan, Italy, ³IEO, European Institute of Oncology, Dept. of Pathology, Milan, Italy
Diagnostic accuracy of targeted prostate biopsies: Results from a prospective trial comparing micro-ultrasound with multiparametric MRI for the detection of prostate cancer

By: Maffei D.¹, Paciotti M.¹, Lazzeri M.¹, Colombo P.², Gasulo V.¹, Domanico L.¹, Casale P.¹, Saita A.¹, Hurle R.¹, Buffi N.¹, Guazzoni G.F.¹, Lughezzani G.¹
¹Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, ²Humanitas Clinical and Research Center, Dept. of Pathology, Rozzano, Italy

There is no way to avoid concomitant systematic prostate biopsies in addition to mp-MRI targeted sampling in men with positive imaging

By: Dell'Oglio P.¹, Stabile A.¹, Soligo M.², Zaffuto E.¹, Boeri L.², De Cobelli F.³, Brembilla G.³, Cannoletta D.¹, Gandaglia G.¹, Fossati N.¹, Esposito A.³, Del Maschio A.³, Suardi N.¹, Karnes J.², Montorsi F.¹, Briganti A.¹
¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy

Fusion biopsy improves prostate cancer detection in the first set biopsy: Development of a clinical nomogram

By: De Nunzio C.¹, Simone G.², Ferriero M.², Papalia R.³, Ludovico G.M.⁴, Giacobbe A.⁵, Oderda M.⁵, Muto G.⁵, Gallucci M.², Sica A.¹, Scarcia M.⁶, Lombardo R.¹, Tubaro A.¹
¹Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ²IFO, Istituto Nazionale Tumori Regina Elena Hospital, Dept. of Urology, Rome, Italy, ³Campus Bio-Medico University Hospital, Dept. of Urology, Rome, Italy, ⁴Ospedale F. Miulli, Dept. of Urology, Acquaviva delle Fonti, Italy, ⁵Humanitas Gradenigo, Dept. of Urology, Gradenigo, Italy, ⁶Humanitas Gradenigo, Dept. of Urology, Rome, Italy

Outcomes of transperineal prostate biopsy using local anesthesia by trainee urologists during learning curve: Comparison with those of senior urologists

By: Ito M., Madoka K., Takemura K., Suzuki H., Sakamoto K., Nakanishi Y., Tobisu K., Koga F.
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Dept. of Urology, Tokyo, Japan

A multi-institutional randomized controlled trial comparing novel first generation high-resolution micro-ultrasound with conventional frequency ultrasound for transrectal prostate biopsy

By: Pavlovich C.¹, Hyndman M.E.², Eure G.³, Ghai S.⁴, Fradet V.⁵
¹Johns Hopkins University Brady Urological Institute, Dept. of Urology, Baltimore, United States of America, ²University of Calgary, Prostate Centre Calgary, Calgary, Canada, ³Urology Of Virginia, Dept. of Urology, Virginia Beach, United States of America, ⁴University Health Network, University of Toronto, Joint Dept. of Medical Imaging, Toronto, Canada, ⁵CHU de Québec-Laval University, Dept. of Surgery, Quebec, Canada
Could 68Ga-PSMA PET/CT play a role in primary prostate cancer localisation? A single institution comparative analysis of 68Ga PSMA PET/CT, multiparametric MRI and prostate biopsy

Royal Brisbane and Women's Hospital, Dept. of Urology, Brisbane, Australia

Contrast enhanced ultrasound for the localization of prostate cancer – correlation with radical prostatectomy specimens

1 Jeroen Bosch Hospital, Dept. of Urology, ’s-Hertogenbosch, Netherlands, The,
2 Amsterdam University Medical Centers, Dept. of Urology, Amsterdam, Netherlands, The,
3 Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, Netherlands, The

Transperineal systematic prostate biopsy under local anaesthesia using brachytherapy grid with accurate localization of biopsy cores on 3D ultrasound mapping

By: Chiu P.K. 1, Teoh J.Y. 1, Yee C.H. 1, Li S.Y. 1, Kwok S.W. 1, Chan C.K. 1, Hou S.M. 1, Ng C.F. 2
1 The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong,
2 SH Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong
Paediatric urology: Penile and hypospadias reconstruction
Poster Session 40
Sunday 17 March
12:15 - 13:45
Location: Green Area, Room 19
Chairs: A. Bujons Tur, Barcelona (ES)
        To be confirmed
        D.J. Summerton, Leicester (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

556
Hypospadias complexity score (HCS): A new tool for predicting operating time and complications in hypospadias surgery
By: Bandini M.¹, Sekulovic S.², Stanojevic N.², Slavkovic M.², Spiridonescu B.³, Dangi A.D.⁴, Krishnappa P.⁵, Pasic V.², Briganti A.¹, Salonia A.¹, Montorsi F.¹, Djinovic R.²
¹Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, ²Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, ³Fundeni Clinical Institute, Center for Urophrology and Renal Transplantation, Bucharest, Romania, ⁴Christian Medical College and Hospital, Dept. of Urology, Vellore, Tamil Nadu, India, ⁵NU Hospitals, Dept. of Urology, Bangalore, India

557
Genetic variants related to sex hormone biosynthesis, genital tubercle, and urethral development as a predictive marker for hypospadias
By: Han J.H.¹, Song S.H.², Choi J.², Kim K.S.²
¹Asan Medical Center, Dept. of Urology, Seoul, Afghanistan, ²Asan Medical Center, Dept. of Urology, Seoul, Korea, South

559
How to make the best choice of hypospadias repair: A 10-year data analysis
By: Jiang X., Ye W.
Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Dept. of Urology, Shanghai, China

561
Proximal hypospadias repair with the Koyanagi urethroplasty: Results as a two-stage procedure and complications easily managed
By: Madec F-X.R.¹, Desplanches M.¹, Chaubaud M.¹, Irtan S.¹, Suply E.², Audry G.¹
¹Children Hospital Armand Trousseau - APHP, Sorbonne medicine University, Dept. of Paediatric Surgery, Paris, France, ²Lille Catholic hospitals, Dept. of Paediatric Surgery, Lille, France
Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in proximal hypospadias: A feasibility, safety and protocol compliance assessment study

By: Bandini M.¹, Sekulovic S.², Spiridonescu B.³, Dangi A.D.⁴, Krishnappa P.⁵, Stanojevic N.², Pesic V.², Slavkovic M.², Briganti A.¹, Salonia A.¹, Montorsi F.¹, Djinovic R.²
¹Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, ²Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, ³Fundeni Clinical Institute, Center for Urology and Urotransplantation, Bucharest, Romania, ⁴Christian Medical College and Hospital, Dept. of Urology, Vellore, India, ⁵NU Hospitals, Dept. of Urology, Bangalore, India

Montage procedure: One-stage repair using an inner preputial graft with prepuce flap for penoscrotal hypospadias with severe chordee

By: Ye W., Jiang X.
Renji Hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China

Covering the skin tube and urethral anastomosis by spongiosum to prevent fistula at the anastomotic site in inner preputial flap repair

By: Bhat A.L.¹, Bhat M.², Khandelwal N.³, Bhat A.³
¹Jaipur National University Institute for Medical Sciences and Research Centre, Dept. of Urology, Jaipur, India, ²NIIMS, Dept. of Urology, Jaipur, India, ³S.P. Medical College Bikaner, Dept. of Surgery, Bikaner, India

Real prevalence and severity of penile curvature in different types of hypospadias

By: Sekulović S.¹, Bandini M.², Spiridonescu B.³, Stanojevic N.¹, Slavkovic M.⁴, Deep Dangi A.⁵, Krishnappa P.⁶, Pesic V.⁷, Montorsi F.², Djinovic R.¹
¹Sava Perovic Foundation, Center for Urology and Urotransplantation, Belgrade, Serbia, ²San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Urological Research Institute (URI), Milan, Italy, ³Fundeni Clinical Institute, Center for Urology and Urotransplantation, Bucharest, Romania, ⁴University Children's Hospital Tirsova, Dept. of Urology, Belgrade, Serbia, ⁵Christian Medical College and Hospital, Dept. of Urology, Vellore, India, ⁶NU Hospitals, Dept. of Urology, Bangalore, India, ⁷Clinical Center Dr Dragisa Misovic-Dedinje, Dept. of Urology, Belgrade, Serbia

Corporeal penile curvature (CPC) and surgical complications in hypospadias repairs: Associations and outcomes

By: Bandini M.¹, Sekulović S.², Dangi A.D.³, Krishnappa P.⁴, Stanojevic N.², Pesic V.², Slavkovic M.², Spiridonescu B.⁵, Briganti A.¹, Salonia A.¹, Montorsi F.¹, Djinovic R.²
¹Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, ²Sava Perovic Foundation, Center for Genito-
Risk factors of concomitant undescended testis in patients with hypospadias

By: Hirata Y., Moriya K., Nakamura M., Kon M., Nishimura Y., Shinohara N. Hokkaido University Graduate School of Medicine, Dept. of Renal and Genitourinary Surgery, Sapporo, Japan

Prevalence and surgical management of pubic hypertrophy in hypospadias patients: Results from a high-volume surgeon


1Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, 2Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Unit of Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, 3Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Unit of Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, 4Fundeni Clinical Institute, Center for Uro nephrology and Renal Transplantation, Bucharest, Romania, 5Christian Medical College and Hospital, Dept. of Urology, Tamil Nadu, India, 6NU Hospitals, Dept. of Urology, Bangalore, India

Cowper’s gland syringoceles: A multicentre analysis

By: Waterschoot M., Floyd Jr M.S., Hermans B., Ackaert K., Goeman L., Joniau S.

1University of Leuven, Dept. of Urology, Leuven, Belgium, 2AZ Turnhout, Dept. of Urology, Turnhout, Belgium, 3AZ Delta, Dept. of Urology, Roeselare, Belgium

Urethral reconstruction for pelvic fracture urethral distraction defects in boys: A 10-year experience

By: Sa, Lin W., Chongrui J.

1Shanghai Jiaotong University Affiliated Sixth People's Hospital, Dept. of Urology, Shanghai, China, 2Shanghai Children's Hospital, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China
Modern management of non-muscle invasive bladder cancer: Towards precision medicine and immunotherapy

Poster Session 41

Sunday 17 March
12:15 - 13:45

Location: Green Area, Room 20

Chairs: P.S-K. Chu, Hong Kong (HK)
L. Izquierdo Reyes, Barcelona (ES)
Y. Neuzillet, Suresnes (FR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 571

**Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study**

By: Boormans J.L.¹, Balar A.V.², De Wit R.¹, Kamat A.³, Uchio E.⁴, Mourey L.⁵, Krieger L.⁶, Singer E.A.⁷, Bajorin D.⁸, Grivas P.⁹, Seo H.K.¹⁰, Nishiyama H.¹¹, Konyet L.¹², Nam K.¹³, Kapadia E.¹⁴, Frenkl T.¹⁴, Kulkarini G.S.¹⁵

¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The,
²Perlmutter Cancer Center at NYU Langone Health, Genitorurinary Medical Oncology, New York, United States of America,
³The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America,
⁴UC Irvine Health, Dept. of Urology, Orange, United States of America,
⁵University Institute Cancer Toulouse Oncopole, Dept. of Medical Oncology, Toulouse, France,
⁶Royal North Shore Hospital, Northern Cancer Institute, St. Leonards, Australia,
⁷Rutgers Cancer Institute of New Jersey, Dept. of Urologic Oncology, New Brunswick, United States of America,
⁸Memorial Sloan Kettering Cancer Center, Dept. of Medical Oncology, New York, United States of America,
⁹University of Washington, Dept. of Medical Oncology, Seattle, United States of America,
¹⁰National Cancer Center, Dept. of Urology, Goyang, Korea, South,
¹¹University of Tsukuba, Dept. of Urology, Tsukuba, Japan,
¹²University of Minnesota, Dept. of Urology, Minneapolis, United States of America,
¹³Merck & Co., Inc., Dept. of Medical Oncology, Kenilworth, United States of America,
¹⁴Merck & Co., Inc., Dept. of Medical Oncology, Kenilworth, United States of America,
¹⁵University of Toronto, UHN Princess Margaret Cancer Center, Toronto, Canada

572

**Reducing recurrence in non-muscle invasive bladder cancer by systematically implementing guideline-based recommendations: Outcome of a prospective intervention effort in primary bladder cancer patients**

By: Sörenby A.K.¹, Baseckas G.¹, Bendahl P-O.², Brändstedt J.¹, Håkansson U.¹, Nilsson S.¹, Patschan O.¹, Tinzl M.¹, Wokander M.¹, Liedberg F.¹, Guðjónsson S.³

¹Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ²Lund University, Medicon
Bipolar en bloc tumor resection versus standard monopolar TURBT in non-muscle invasive bladder cancer – a medium-term, prospective, randomized-controlled comparison

By: Geavlete B. , Multescu R. , Georgescu D. , Moldoveanu C. , Ene C. , Bulai C. , Balan G. , Ene A. , Geavlete P.
Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania

12 month results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk (LR) non-muscle invasive bladder cancer (NMIBC)

1Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, 2Institute of Cancer Research, ICR-CTSU, London, United Kingdom, 3James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom, 4University Hospitals of Leicester NHS Trust, Clinical Sciences Unit, Leicester, United Kingdom, 5University College London Hospital, Dept. of Oncology, London, United Kingdom, 6University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, 7Gloucestershire Hospitals NHS Foundation Trust, Dept. of Urology, Cheltenham, United Kingdom, 8Royal Devon and Exeter NHS Foundation Trust, Exeter Surgical Health Services Research Unit, Exeter, United Kingdom, 9The Royal Wolverhampton Hospitals NHS Trust, Dept. of Urology, Wolverhampton, United Kingdom, 10Medway NHS Trust, Dept. of Urology, Gillingham, United Kingdom, 11University College London, UCL Cancer Institute, London, United Kingdom, 12St James's University Hospital, Leeds Institute of Cancer and Pathology, Leeds, United Kingdom, 13Patient Representative, Hampshire, United Kingdom

The use of selenium and vitamin E supplementation to prevent recurrence of non-muscle-invasive bladder cancer: results of the SELENIB trial

1University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, 2University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom, 3The Royal Wolverhampton NHS Trust, Dept. of Urology, Wolverhampton, United Kingdom, 4The Royal Orthopaedic Hospital NHS Foundation Trust, Research, Audit and Development, Birmingham, United Kingdom, 5University of Birmingham, Birmingham Clinical Trials Unit, Birmingham, United Kingdom, 6University of Birmingham, Institute for Mental Health, Birmingham, United Kingdom, 7University of Birmingham, Human Biomaterials Resource Centre, Birmingham, United Kingdom, 8University Hospitals Birmingham NHS Foundation Trust, Dept. of Urology, Birmingham, United Kingdom, 9University Hospitals Birmingham NHS Foundation Trust, Dept. of
577  Development and validation of a simulator-based test in transurethral resection of bladder tumors (TURB) establishing pass/fail standards

By: Bube S.H. 1, Hansen R.B. 2, Dahl C. 1, Konge L. 3, Azawi N. 1
1Zealand University Hospital, Dept. of Urology, Roskilde, Denmark, 2Herlev/Gentofte Hospital, Dept. of Urology, Herlev, Denmark, 3Rigshospitalet, Copenhagen Academy for Medical Education and Simulation, Copenhagen, Denmark

578  HIVEC HR: Chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a randomized controlled trial

By: González Padilla D.A. 1, González Díaz A. 1, Miranda-Utrera N. 1, De La Rosa Kehrmann F. 1, Villacampa-Aubá F. 2, Guerrero-Ramos F. 1
1Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain, 2Clinica Universidad de Navarra, Dept. of Urology, Madrid, Spain

579  A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC)

By: Purshouse K. 1, Woodcock V.K. 1, Butcher C. 2, Haddon C. 1, Verrall G. 3, Elhussein L. 4, Salio M. 5, Middleton M.R. 1, Cerundolo V. 6, Kwok J. 1, Blagden S. 1, Protheroe A.S. 1, Crew J. 3
1University of Oxford, Dept. of Oncology, Oxford, United Kingdom, 2Oncology Clinical Trials Office, Dept. of Oncology, Oxford, United Kingdom, 3Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, 4Centre for Statistics in Medicine, Dept. of Statistics, Oxford, United Kingdom, 5MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Immunology, Oxford, United Kingdom, 6MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Dept. of Immunology, Oxford, United Kingdom

580  A prospective, randomized controlled trial regarding antimicrobial prophylaxis in transurethral resection of the bladder tumor (TURB): An interim analysis of the prophylaxis001-trial

By: Baten E. 1, Arijs I. 2, Goethuys H. 3, Vandecandelaere M. 4, Cartuyvels R. 5, Van Der Aa F. 1, Van Renterghem K. 6
1UZLeuven, Dept. of Urology, Leuven, Belgium, 2UHasselt, Dept. of Biomedical Sciences, Hasselt, Belgium, 3ZOL Genk, Dept. of Urology, Genk, Belgium, 4KULeuven, Dept. of Educational Sciences, Leuven, Belgium, 5Jessa Ziekenhuis, Dept. of Microbiology, Hasselt, Belgium, 6Jessa Ziekenhuis, Dept. of Urology, Leuven, Belgium

581  Comparing prognosis of photodynamic diagnosis with 5-aminolaevulinic Acid or hexylaminolevulinate and narrow band imaging versus white light cystoscopy for non-muscle invasive bladder cancer
583

Neoadjuvant short-term intensive chemoresection vs. standard adjuvant intravesical instillations in NMIBC: Preliminary results on tolerability and adverse events

By: Skydt Lindgren M., Dyrskjøt Andersen L., Bue P., Bjerggaard Jensen J.
1 Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, 2 Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, 3 Regional Hospital West Jutland, Dept. of Urology, Holstebro, Denmark
<table>
<thead>
<tr>
<th>Date</th>
<th>Location</th>
<th>Chair</th>
<th>Tutors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday 17 March</td>
<td>Green Area, Room 7</td>
<td>H. Hashim, Bristol (GB)</td>
<td>E. Chartier-Kastler, Paris (FR)</td>
</tr>
<tr>
<td>13:00 - 15:00</td>
<td></td>
<td>To be confirmed</td>
<td>D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Musco, Florence (IT)</td>
<td>S. Arlandis Guzman, Valencia (ES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>L. Thomas, Bristol (GB)</td>
<td>L. Thomas, Bristol (GB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Van Kerrebroeck, Maastricht (NL)</td>
<td></td>
</tr>
</tbody>
</table>

**Aims and objectives of this session**

A practical hands-on workshop that will allow the participants to practice on models the different steps of performing sacral neuromodulation including primary percutaneous nerve evaluation, tined lead and battery implantation and programming and also troubleshooting.

- Understand the indications for SNM
- Be able to perform the different steps of the procedure in a standardized format
- Be able to troubleshoot problems with SNM
ESU/ESUT/ESUI Hands-on Training in Prostate MRI reading for urologists

HOT 22

<table>
<thead>
<tr>
<th>Location</th>
<th>Green Area, Room 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>Tutors</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>Tutors</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

**Introduction**
R. Schiavina, Bologna (IT)
T. Loch, Flensburg (DE)

PT193
Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusion-weighted MRI

By: Kaneko K.¹, Yoshida S.¹, Arita Y.², Yamamoto K.³, Kijima T.¹, Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Saito K.¹, Fujii Y.¹
¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan,
²Keio University, Dept. of Diagnostic Radiology, Tokyo, Japan,
³Tokyo Medical and Dental University, Dept. of Pathology, Tokyo, Japan

PT194
Characterization of complex renal cystic masses: Comparison among CT, MRI and CEUS in the same series of patients

By: Verzotti E.¹, Sachs C.², Campo I.², Boltri M.¹, Currò I.², Cavallaro M.², Cova M.A.², Bertolotto M.², Liguori G.¹, Trombetta C.¹
¹Università degli Studi di Trieste, Dept. of Urology, Trieste, Italy,
²Università degli Studi di Trieste, Dept. of Radiology, Trieste, Italy

PT195
Usefulness of numerical imaging analysis for distinguishing pathologic features in small renal masses: A development and validation study

Yonsei University College of Medicine, Dept. of Urology, Seoul, Korea, South

PT196
Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT

By: Meyer A.R.¹, Rowe S.², Carducci M.³, Denmeade S.³, Markowski M.³, Pomper
PT198
Could computed tomography volumetric scanning-split renal volume of the live-donor affects donor side selection?

By: Zahran M.H. 1, Galal A. 1, Refaie H. 2, Fakhreldin I. 1, Harraz A. 1, Osman Y. 1, Ali-El-Dein B. 1
1Urology and Nephrology Center, Mansoura University, Dept. of urology, Mansoura, Egypt, 2Urology and Nephrology Center, Mansoura University, Dept. of Radiology, Mansoura, Egypt

PT199
Evaluation of renal volume and adipose tissue distribution as predictors of renal function after radical nephrectomy

By: Olivero A. 1, Basso L. 2, Barabino E. 2, Milintenda P. 1, Testino N. 1, Pacchetti A. 1, Neumair C.E. 3, Terrone C. 1
1San Martino Policlinico Hospital, IRCCS for Oncology, Dept. of Urology, Genoa, Italy, 2Department of Health science (DISSAL), University of Genoa, Dept. of Radiology, Genoa, Italy, 3San Martino Policlinico Hospital, IRCCS for Oncology, Genoa, Italy, Diagnostic imaging and senology, Genoa, Italy

PT200
Diagnostic and staging performance of mpMRI-US fusion prostate biopsy: Prospective analysis on consecutive radical prostatectomy specimens from a multicentre series

By: Ferriero M.C. 1, Flammia R.S. 1, Tuderti G. 1, Anceschi U. 1, Brassetti A. 1, Oderda M. 2, Peltier A. 3, Kumar P. 4, Roche J. 5, Piechaud T. 5, Descotes J.L. 6, Mastroianni R. 1, Giacobbe A. 7, Puglisi M. 8, Malossini G. 8, Papalia R. 9, Guaglianone S. 1, Muto G. 7, Gontero P. 2, Gallucci M. 1, Simone G. 1
1Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2University of Turin, Dept. of Surgical Sciences, Urology, Turin, Italy, 3Institut Jules Bordet, Université Libre de Bruxelles, Dept. of Urology, Bruxelles, Belgium, 4Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, 5Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, 6Centre Hospitalier Universitaire de Grenoble, Dept. of Urology, Grenoble, France, 7Humanitas Gradenigo Hospital, Dept. of Urology, Turin, Italy, 8Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, 9Campus Bio Medico University, Dept. of Urology, Rome, Italy

PT202
Added value of mpMRI, MRI-targeted and systematic biopsy in the prediction of adverse pathologic features in contemporary prostate cancer patients undergoing radical prostatectomy

By: Gandaglia G. 1, Ploussard G. 2, Valerio M. 3, Mattei A. 4, Fiori C. 5, Fossati N. 1, Stabile A. 1, Beauval J. 6, Malavaud B. 6, Roumigué M. 6, Robesti D. 1, Dell’Oglio P. 1, Moschini M. 4, Zamboni S. 4, Rakauskas A. 3, Dehò F. 1, Gallina A. 1, De Cobelli F. 7
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| PT203       | Extracapsular extension on multiparametric MRI better predicts pT3 disease at radical prostatectomy compared to perineural invasion on biopsy | Griffiths L., Kotamarti S., Mikhail D., Villani R., Vira M., Hall S., Schwarz M., Richstone L.  
Arthur Smith Institute for Urology at Northwell Health, Dept. of Urology, New Hyde Park, United States of America |
| PT204       | Multiparametric MRI outperforms the Partin tables, Memorial Sloan Kettering Cancer Center nomogram, and CAPRA score in predicting extraprostatic cancer in patients undergoing radical prostatectomy | Giannarini G., Girometti R., Crestani A., Rossanese M., Calandriello M., Zuiani C., Valotto C., Ficarra V.  
1Academic Medical Centre Santa Maria della Misericordia, Dept. of Urology, Udine, Italy,  
2University of Udine, Dept. of Medicine, Urology Unit, Udine, Italy,  
3University of Messina, Dept. of Human and Paediatric Pathology “Gaetano Barresi”, Urology Section, Messina, Italy,  
4University of Udine, Dept. of Medicine, Radiology Unit, Udine, Italy |
| PT205       | Contrast media kinetics in multiparametric MRI before radical prostatectomy predicts probability of postoperative incontinence | Schmid F.A., Wettstein M.S., Kessler T.M., Boss A., Eberli D.  
1University Hospital Zurich, Dept. of Urology, Zurich, Switzerland,  
2Balgrist University Hospital, Dept. of Neuro-Urology, Zurich, Switzerland,  
3University Hospital Zurich, Dept. of Radiology, Zurich, Switzerland |
| PT206       | Validation of Gallium-68 PSMA-PET/CT for primary lymph node staging in prostate cancer patients | Van Kalmthout L., Van Melick H., Lavalaye J., Kooistra A., De Klerk J., Meijer R., De Keizer B., Lam M.  
1UMC Utrecht, Nuclear Medicine,Dept. of Urology, Utrecht, Netherlands, The,  
2St. Antonius Ziekenhuis, Dept. of Urology, Nieuwegein, Netherlands, The,  
3St. Antonius Ziekenhuis, Nuclear Medicine, Nieuwegein, Netherlands, The,  
4Meander Medisch Centrum, Dept. of Urology, Amersfoort, Netherlands, The,  
5Meander Medisch Centrum, Nuclear Medicine, Amersfoort, Netherlands, The,  
6UMC Utrecht, Dept. of Urology, Utrecht, Netherlands, The,  
7UMC Utrecht, Nuclear Medicine, Utrecht, Netherlands, The |
PT207

Impact of 18F-DCFPyL PET scanning in patients undergoing post prostatectomy radiotherapy (IMPPORT) – preliminary results of a prospective multi-site trial

By: Koschel S.¹, Sutherland T.², Wong L.¹, Taubman K.³, Yap K.³, Schlicht S.³, Ng M.⁴
¹St Vincent's Hospital Melbourne, Dept. of Urology, Melbourne, Australia, ²St Vincent's Hospital Melbourne, Medical Imaging, Melbourne, Australia, ³St Vincent's Hospital Melbourne, Nuclear Medicine, Melbourne, Australia, ⁴Genesis Care St Vincent's Melbourne, Radiation Oncology, Melbourne, Australia

PT208

Radioactive tracer guided metastasectomy of 68Ga-PSMA-PET/CT positive lesions in patients with rising prostatic-specific antigen after definitive treatment of prostate cancer

By: Rahnama'i M.S.¹, Von Mallek D.², Lehnhardt M.¹, Heinzel A.², Mottaghy F.², Heinzel A.², Bach C.¹
¹Uniklinik RWTH Aachen, Dept. of Urology, Aachen, Germany, ²Uniklinik RWTH Aachen, Dept. of Nuclear Medicine, Aachen, Germany

PT209

External validation of the CHAARTED and LATITUDE criteria in patients with hormone-naive metastatic prostate cancer: A multi-institutional study in Japan

By: Kodama H.¹, Hatakeyama S.¹, Takahashi M.², Narita S.³, Sakurai T.⁴, Kawamura S.⁵, Hoshi S.⁶, Ishida M.⁷, Kawaguchi T.⁸, Ishidoya S.⁹, Shimoda J.¹⁰, Sato H.², Mitsuzuka K.², Tochigi T.⁵, Tsuchiya N.⁴, Arai Y.², Habuchi T.³, Ohyama C.¹
¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan, ³Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁴Yamagata University Graduate School of Medicine, Dept. of Urology, Yamagata, Japan, ⁵Miyagi Cancer Center, Dept. of Urology, Natori, Japan, ⁶Yamagata Prefectural Central Hospital, Dept. of Urology, Yamagata, Japan, ⁷Iwate Prefectural Isawa Hospital, Dept. of Urology, Oshu, Japan, ⁸Aomori Prefectural Central Hospital, Dept. of Urology, Aomori, Japan, ⁹Sendai City Hospital, Dept. of Urology, Sendai, Japan

PT210

Impact of patient’s real-time visualization of flexible cystoscopy finding on pain in a randomized controlled trial

By: Prasanchaimontri P., Tritipwanit S., Prachapinyo T.
Ratchaburi Hospital, Dept. of Surgery, Ratchaburi, Thailand

PT211

Application of narrow-band imaging flexible ureteroscopy in the treatment of upper urinary tract transitional carcinomas

By: Hao Y.
Peking University Third Hospital, Dept. of Urology, Beijing, China

PT212

Narrow Band Imaging reduces persistence of cancer in patients with pT1 high grade bladder cancer
PT213

Development of a rodent model for preclinical evaluation of multiple contrast agents and real-time multispectral imaging in bladder cancer

By: Günes C. 1, Meessen S. 1, Rother J. 2, Kriegmair M.C. 3, Zheng X. 1, Hernandez D. 2, Grychtol B. 2, Deliolanis N. 2, Bolenz C. 1

1University of Ulm, Dept. of Urology, Ulm, Germany, 2University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany, 3University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany

PT215

Preoperative FDG-PET/CT predicts non-organ-confined disease and disease recurrence in patients with upper urinary tract urothelial carcinoma

By: Asai S. 1, Nishida K. 1, Watanabe R. 2, Koyama K. 2, Sawada Y. 2, Noda T. 2, Fukumoto T. 2, Miura N. 2, Yanagihara Y. 2, Miyauchi Y. 2, Miyagawa M. 3, Kikugawa T. 2, Saika T. 2

1Ehime Prefectural Central Hospital, Dept. of Urology, Matsuyama, Japan, 2Ehime University School of Medicine, Dept. of Urology, Toon, Japan, 3Ehime University School of Medicine, Dept. of Radiology, Toon, Japan

PT216

Defining better cut-off value for peak systolic velocity and resistance index under Penile Doppler ultrasound for patient with erectile dysfunction in correlation with computed tomography, pelvic angiography and angioplasty


1National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, 2National Taiwan University Hospital, Dept. of Cardiology, Taipei, Taiwan, 3National Taiwan University Hospital, Dept. of Radiology, Taipei, Taiwan

PT217

Color-coded contrast enhanced voiding urosonography (CE-VUS/ADI): Implementation into pediatric urologic routine by non-radiologists

By: Steinkellner L. 1, Haid B. 2, Oswald J. 2

1Hospital of the Sisters of Charity, Dept. of Pediatric Urology, Linz, Austria, 2Hospital of the Sisters of Charity, Dept. of Pediatric Urology, Linz, Austria

PT218

Level of knowledge on radiation and compliance to protective equipment: Where do urologists stand? An ESUT/EULIS survey

By: Tzelves L. 1, Somani B. 2, Knoll T. 3, Kamphuis G. 4, Sarica K. 5, Skolarikos A. 1

1National and Kapodistrian University of Athens, 2nd Department of Urology, Sismanoglio Hospital, Dept. of Urology, Athens, Greece, 2University Hospital Southampton NHS Trust,
Fluoroscopy-use during ureterorenoscopy: Are urologists concerned about radiation exposure?

By: Henderickx M.M.E.L., Baard J., Beerlage H.P., Kamphuis G.M.
Amsterdam UMC, Dept. of Urology, Amsterdam, Netherlands, The
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

Introduction
F.C. Burkhard, Bern (CH)
A.G. Giannantoni, Perugia (IT)

PT220
Longitudinal intravital imaging of transplanted mesenchymal stem cells elucidates their functional integration and therapeutic potency in an animal model of interstitial cystitis/bladder pain syndrome

By: Ryu C-M. 1, Shin J.H. 1, Yu H.Y. 1, Lee J. 1, Shin D-M. 2, Choo M-S. 1
1Asan Medical Center, Dept. of Urology, Seoul, Korea, South
2Asan Medical Center, Dept. of Biomedical Sciences, Seoul, Korea, South

PT221
Bladder pain induced by chronic stress is mediated by a systemic increase of nerve growth factor involving the activation of adrenoceptors

By: Dias B. 1, Cruz F. 1, Charrua A. 2
1Faculty of Medicine of University of Porto, Dept. of Urology, Porto, Portugal
2Faculty of Medicine of University of Porto, Dept. of Biomedicine, Porto, Portugal

PT222
Anti-inflammatory mechanism of indoleamine 2,3-dioxygenase inhibition in the chronic prostatic inflammation

By: Ohira S. 1, Nishishita N. 2, Tone S. 3, Hara R. 1, Fujii T. 1, Miyaji Y. 1, Nagai A. 1
1Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan
2Graduate School of Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan
3Graduate School of Tokyo Denki University, Dept. of Life Science and Engineering, Hiki-gun, Saitama, Japan

PT224
Palmitoylethanolamide/polydatin as add-on therapy in pain resistant patients with interstitial cystitis/bladder painful syndrome

By: Gubbiotti M. 1, Illiano E. 2, Costantini E. 2, Giannantoni A. 3
<table>
<thead>
<tr>
<th>PT225</th>
<th>Intravesical therapy for interstitial cystitis/bladder pain syndrome: A systematic review and network meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Yeh T-C., Chen P-C., Chang H-C., Tu Y-K. 1 2 3 4</td>
<td></td>
</tr>
<tr>
<td>1National Taiwan University Hospital Hsin-Chu Branch, Dept. of Urology, Hsinchu City, Taiwan, 2En Chu Kong Hospital, Dept. of Urology, New Taipei City, Taiwan, 3National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan, 4National Taiwan University, Institute of Epidemiology and Preventive Medicine, Taipei City, Taiwan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT226</th>
<th>Factors affecting the period between the first and second hydrodistension in females with painful bladder syndrome and interstitial cystitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Kim H.W., Shin D.G., Yoon C.S., Choi S., Cho W.Y., Min K.S., Oh T.H., Lee W., Lee S.D., Lee J.Z. 1 2 3 4 5 6 7 8</td>
<td></td>
</tr>
<tr>
<td>1Pusan National University Hospital, Dept. of Urology, Busan, Korea, South, 2BHS Hanséo Hospital, Dept. of Urology, Busan, Korea, South, 3Kosin University College of Medicine, Dept. of Urology, Busan, Korea, South, 4Dong-A University Hospital, Dept. of Urology, Busan, Korea, South, 5Inje University Busan Paik Hospital, Dept. of Urology, Busan, Korea, South, 6Samsung Changwon Hospital, Dept. of Urology, Busan, Korea, South, 7Ulsan-Jeil Hospital, Dept. of Urology, Ulsan, Korea, South, 8Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan, Korea, South</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT227</th>
<th>Botulin toxin type A injections during chronic pelvic pain syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Khelaia A. 1</td>
<td></td>
</tr>
<tr>
<td>National Center of Urology, Dept. of Urology, Tbilisi, Georgia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT228</th>
<th>Long-term follow-up after cystectomy for bladder pain syndrome: Pain status, sexual function and quality of life</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Mateu Arrom L., Gutierrez Ruiz C., Mayordomo O., Martinez V., Palou J., Errando C. 1 2 3 4 5 6</td>
<td></td>
</tr>
<tr>
<td>1Fundació Puigvert, Dept. of Functional Urology and Urodynamics, Barcelona, Spain, 2Fundació Puigvert, Dept. of Urology, Barcelona, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT229</th>
<th>Therapeutic effect of tadalafil in the chronic prostatitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Nishishita N., Ohira S., Tone S., Hara R., Fujii T., Uehara S., Miyaji Y., Nagai A. 1 2 3 4 5 6 7 8</td>
<td></td>
</tr>
<tr>
<td>1Graduate School of Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan, 2Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan, 3Graduate School of Tokyo Denki University, Dept. of Life Science and Engineering, Hiki-gun, Saitama, Japan</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>PT232</td>
<td>Effect of salt reduction on nocturia persistent after administration of mirabegron for overactive bladder</td>
</tr>
<tr>
<td>PT233</td>
<td>Efficacy of the novel β3 adrenergic receptor agonist vibegron for the treatment of nocturia in patients with overactive bladder: A post hoc analysis of phase 3 study</td>
</tr>
<tr>
<td>PT234</td>
<td>Salt intake reduction as a treatment option for overactive bladder</td>
</tr>
<tr>
<td>PT236</td>
<td>Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in Caucasian patients with overactive bladder</td>
</tr>
<tr>
<td>PT237</td>
<td>Chance of OAB patients to become symptom-free upon anti-muscarinic treatment depends on age and gender</td>
</tr>
</tbody>
</table>
PT238  
**Combination of alpha blocker and phosphodiesterase 5 inhibitors versus alpha blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: A systematic review and meta-analysis**

By: Chen P-C.¹, Yeh T-C.²

¹En Chu Kong Hospital, Dept. of Urology, New Taipei City, Taiwan, ²National Taiwan University Hospital Hsin-Chu Branch, Dept. of Urology, Hsin-Chu, Taiwan

PT239  
**Is the combination of alpha-blocker and phosphodiesterase-5 inhibitor better in improving the lower urinary tract symptoms and erectile dysfunction in comparison to monotherapy? A systematic review and meta-analysis**

By: Adamou C.¹, Kallidonis P.¹, Kotsiris D.¹, Ntasiotis P.¹, Verze P.², Athanasopoulos A.¹

¹University hospital of Patras, Dept. of Urology, Patra, Greece, ²University of Naples, Dept. of Urology, Naples, Italy

PT240  
**Benefit-risk evaluation of approved pharmacotherapies for the treatment of overactive bladder: A sensitivity analysis of benefits versus safety for individual OAB symptoms using multi-criteria decision analysis modelling**

By: Mironska E.¹, Phillips L.², Castro-Diaz D.³, Chartier-Kastler E.⁴, De Ridder D.⁵, Kölbl H.⁶, Milsom I.⁷, Pushkar D.⁸, Tubaro A.⁹, Wagg A.¹⁰, Chapple C.¹

¹University of Sheffield, Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, ²London School of Economics, Dept. of Management, London, United Kingdom, ³Universidad de la Laguna, Dept. of Urology, Santa Cruz de Tenerife, Spain, ⁴Sorbonne Université, Dept. of Urology, Paris, France, ⁵Leuven University, Dept. of Development and Regeneration, Leuven, Belgium, ⁶Medical University of Vienna, Dept. of Obstetrics and Gynaecology, Vienna, Italy, ⁷Gothenburg University, Dept. of Obstetrics and Gynaecology, Gothenburg, Sweden, ⁸Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, ⁹Sapienza University, Dept. of Urology, Rome, Italy, ¹₀University of Alberta, Dept. of Medicine, Alberta, Canada

PT241  
**Multi-criteria decision analysis modelling to help physicians optimise treatment in patients diagnosed with overactive bladder**

By: Mironska E.¹, Phillips L.², Castro-Diaz D.³, Chartier-Kastler E.⁴, De Ridder D.⁵, Kölbl H.⁶, Milsom I.⁷, Pushkar D.⁸, Tubaro A.⁹, Wagg A.¹⁰, Chapple C.¹

¹University of Sheffield, Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, ²London School of Economics, Dept. of Management, London, United Kingdom, ³Universidad de la Laguna, Dept. of Urology, Santa Cruz de Tenerife, Spain, ⁴Sorbonne Université, Dept. of Urology, Paris, France, ⁵Leuven University, Dept. of Development and Regeneration, Leuven, Belgium, ⁶Medical University of Vienna, Dept. of Obstetrics and Gynaecology, Vienna, Italy, ⁷Gothenburg University, Dept. of Obstetrics and Gynaecology, Gothenburg, Sweden, ⁸Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, ⁹Sapienza University, Dept. of Urology, Rome, Italy, ¹₀University of Alberta, Dept. of Medicine, Alberta, Canada
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| PT242   | Urinary function improves in hypogonadal men receiving long-term treatment with testosterone compared to a hypogonadal control group: 6471 Patient-years of clinical experience | Haider K.S.¹, Haider A.¹, Doros G.², Traish A.³  
¹Praxis Dr. Haider, Dept. of Urology, Bremerhaven, Germany, ²Boston University School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America, ³Boston University School of Medicine, Dept. of Biochemistry and Dept. of Urology, Boston, United States of America |
| PT243   | Different types of catheters for intermittent self-catheterization: A systematic review and network meta-analysis | Ye D., Chen Y.T., Jian Z.Y., Li H., Wang K.J.  
West China Hospital, Sichuan University, Dept. of Urology, Laboratory of Reconstructive Urology, Chengdu, China |
| PT245   | PTNS: Still going strong or an ever ending story?                     | Te Dorsthorst M., Van Balken M.R.  
Rijnstate, Dept. of Urology, Arnhem, Netherlands, The |
| PT246   | Percutaneous tibial nerve stimulation is effective in the treatment of neurogenic overactive bladder in multiple sclerosis patients: A controlled study | Pacini P.¹, Iacovelli V.¹, Petta F.¹, D'Ippolito G.¹, Ragaglini R.², Pletto S.¹, Carilli M.¹, Finazzi Agrò E.¹  
¹Policlinico Tor Vergata Roma, Dept. of Urology, Rome, Italy, ²Fondazione Santa Lucia, Dept. of Neuro-Urology, Rome, Italy |
Sunday 17 March
14:00 - 15:30

Location: Red Area, eURO Auditorium 1

Chairs: To be confirmed
A. Messas, Paris (FR)
B. Rocco, Modena (IT)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

**V54**
The crush carving technique using a soft coagulation device - A simple method for successful laparoscopic hemi-nephrectomy without hilar clamping

Cancer Institute Hospital of Japanese Foundation for Cancer Research, Dept. of Genitourinary Oncology, Tokyo, Japan

**V55**
The use and applications of near infrared fluorescence using Indocyanine Green in robotic urology

By: Ahallal Y., Jeglinschi S., Chevallier D., Tibi B., Durand M., Messas A.
1CHU Nice, Dept. of Urology, Nice, France, 2Turin Urology Hospital, Dept. of Urology, Paris, France

**V57**
Exploring the parameters affecting stone retropulsion in holmium laser lithotripsy: A video analysis

By: Black K.M., Aldoukhi A.H., Roberts W.W., Hall T., Ghani K.R.
1University of Michigan, Dept. of Urology, Ann Arbor, United States of America, 2University of Michigan, Dept. of Engineering, Ann Arbor, United States of America

**V58**
Renal cell carcinoma with inferior vena cava thrombus: 3D laparoscopic approach

By: Martos Calvo R., Peri L., D'anna M., Ribal M.J., Alcaraz A.
Hospital Clinic, Dept. of Urology, Barcelona, Spain
Improving outcome from radical prostatectomy: Imaging and different approaches
Poster Session 42

Sunday 17 March
14:00 - 15:30

Location: Green Area, Room 2
Chairs: N. Fossati, Milan (IT)
S. Joniau, Leuven (BE)
R. Shiroki, Aichi (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

585
Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI

By: Doo Yong C.¹, Hyun Ho H.¹, In Rae C.², Young Sig K.³, Joong Shik L.⁴, Dong Hoon L.⁵, Hyeok Jun G.¹, Jinu K.¹, Young Deuk C.¹
¹Yonsei University College of Medicine, Urological Science Institute, Dept. of Urology, Seoul, Korea, South,
²Inje University College of Medicine, Dept. of Urology, Gimhae, Korea, South,
³National Health Insurance Corporation Ilsan Hospital, Dept. of Urology, Goyang, Korea, South,
⁴Cheil General Hospital, Women's Healthcare Center, Dept. of Urology, Seoul, Korea, South,
⁵Chosun University College of Medicine, Dept. of Urology, Gwangju, Korea, South

586
PI-RADSv2 score <5 associates with a very low risk of pelvic lymph node invasion in prostate cancer, even among high-risk population

By: Song G., Huang C.
Peking University First Hospital, Dept. of Urology, Beijing, China

587
Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer

By: Doo Yong C.¹, In Rae C.², Young Sig K.³, Joong Shik L.⁴, Dong Hoon L.⁵, Jinu K.⁶, Hyeok Jun G.⁶, Ji Eun H.⁶, Won Sik J.⁶, Young Deuk C.⁶
¹Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, Korea, South,
²Inje University College of Medicine, Dept. of Urology, Gimhae, Korea, South,
³National Health Insurance Corporation Ilsan Hospital, Dept. of Urology, Goyang, Korea, South,
⁴Cheil General Hospital & Women's Healthcare Center, Dept. of Urology, Seoul, Korea, South,
⁵Chosun university college of medicine, Dept. of Urology, Gwangju, Korea, South,
⁶Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, Korea, South
Use of intraoperative $^{68}$Gallium-PSMA Cerenkov luminescence imaging for surgical margins in radical prostatectomy – A feasibility study

By: Darr C.¹, Hadaschik B.A.¹, Grootendorst M.², Herrmann K.³, Binse I.³, Fragoso Costa P.³, Harke N.¹
¹University Hospital Essen, Dept. of Urology and Urological Oncology, Essen, Germany, ²Lightpoint Medical Ltd., Clinical Research, Chesham, United Kingdom, ³University Hospital Essen, Dept. of Nuclear Medicine, Essen, Germany

Which positive surgical margins features impact on the risk of prostate cancer specific mortality? A disease-tailored, competing-risk, long-term analysis

By: Suardi N.¹, Gandaglia G.¹, Robesti D.¹, Scuderi S.¹, Barletta F.¹, Dell’Oglio P.¹, Mazzone E.¹, Bandini M.¹, Freschi M.², Stabile A.¹, Zaffuto E.¹, Mirone V.³, Longo N.³, Shariat S.F.⁴, Soria F.⁴, D’Andrea D.⁴, Luciano’ R.⁵, Capitanio U.¹, Fossati N.¹, Montorsi F.¹, Briganti A.¹
¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology URI, Milan, Italy, ²IRCCS Ospedale San Raffaele, Unit of Pathology, Milan, Italy, ³University of Naples Federico II, Dept. of Urology, Naples, Italy, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵IRCCS Ospedale San Raffaele, Division of Pathology, Milan, Italy

Sentinel lymph node biopsy in prostate cancer patients: Results from a modified injection technique targeting the index lesion in the prostate gland

By: Fumado Ciutat L.¹, Abascal J.M.¹, Mestre T.², Costa M.¹, Reixach L.³, Juanpere N.⁴, Aguilar G.⁵, Lloreta J.⁴, Cecchini L.¹
¹Hospital del Mar, Dept. of Urology, Barcelona, Spain, ²Hospital del Mar, Dept. of Nuclear Medicine, Barcelona, Spain, ³University Pompeu Fabra, Fellowship Dept. of Urology, Barcelona, Spain, ⁴Hospital del Mar, Dept. of Pathology, Barcelona, Spain, ⁵Hospital del Mar, Dept. of Radiology, Barcelona, Spain

Implication of missed posterolateral tumour on mpMRI for nerve-sparing during radical prostatectomy

By: Kalapara A., Pan H., Frydenberg M., Grummet J. P.
Monash University, Dept. of Surgery, Melbourne, Australia

Predictive factors of postoperative quality of life, erectile function and continence after robot-assisted radical prostatectomy: A multicentre study

By: Devlies W.¹, De Coster G.², Van Damme N.², Roumeguère T.³, Quackels T.³, Van Cleynenbreugel B.¹, Dekuypcr P.⁴, Ameye F.⁴, Everaerts W.¹, Joniau S.¹
¹KU Leuven, University of Leuven, Dept. of Urology, Leuven, Belgium, ²Belgian Cancer Registry, Belgian Cancer Registry, Brussels, Belgium, ³Université Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, ⁴Maria Middelares Hospital, Dept. of Urology, Ghent, Belgium
595

Are we improving functional outcomes of prostate cancer patients treated with robot-assisted radical prostatectomy? A 10-year analysis in men treated at two high volume, tertiary referral centers

By: Mazzone E.\textsuperscript{1}, Gandaglia G.\textsuperscript{1}, Knipper S.\textsuperscript{2}, Graefen M.\textsuperscript{2}, Tilki D.\textsuperscript{2}, Suardi N.\textsuperscript{1}, Gallina A.\textsuperscript{1}, Nocera L.\textsuperscript{1}, Scarcella S.\textsuperscript{1}, Pellegrino A.\textsuperscript{1}, Bravi C.A.\textsuperscript{1}, Bianchi M.\textsuperscript{1}, Fossati N.\textsuperscript{1}, Montorsi F.\textsuperscript{1}, Briganti A.\textsuperscript{1}

\textsuperscript{1}IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, URI, Milan, Italy, \textsuperscript{2}University Hospital Hamburg-Eppendorf, Dept. of Urology, Martini Klinik, Hamburg, Germany

596

Pelvic anatomical features after Retzius-sparing robotic-assisted radical prostatectomy intended for early recovery of urinary continence

By: Hamamoto S.\textsuperscript{1}, Ota Y.\textsuperscript{1}, Naiki T.\textsuperscript{1}, Ando R.\textsuperscript{1}, Nakane A.\textsuperscript{1}, Okada A.\textsuperscript{1}, Kawai N.\textsuperscript{1}, Towaza K.\textsuperscript{1}, Yasui T.\textsuperscript{1}
Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan

597

Superiority of Retzius-sparing robot assisted radical prostatectomy in continence result compared to conventional method: Single surgeon experience with propensity score matching total of 1218 patients

By: Lee J.S.\textsuperscript{1}, Almujalhem A.\textsuperscript{1}, Raheem A.\textsuperscript{2}, Chung, D.Y.\textsuperscript{1}, Kim J.\textsuperscript{1}, Chang K.\textsuperscript{3}, Kim J.H.\textsuperscript{1}, Hong S.J.\textsuperscript{1}, Chung B.H.\textsuperscript{1}, Choi Y.D.\textsuperscript{1}, Rha K.H.\textsuperscript{1}

\textsuperscript{1}Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, Korea, South, \textsuperscript{2}Tanta University College of Medicine, Dept. of Urology, Tanta, Egypt, \textsuperscript{3}Yonsei University Wonju College of Medicine, Dept. of Urology, Wonju, Korea, South

598

Retzius-sparing radical prostatectomy for surgeons in the learning curve: A propensity score-matching analysis

By: Olivero A.\textsuperscript{1}, Galfano A.\textsuperscript{2}, Secco S.\textsuperscript{2}, Piccinelli M.\textsuperscript{2}, Panarello D.\textsuperscript{1}, Di Trapani D.\textsuperscript{2}, Petralia G.\textsuperscript{2}, Strada E.\textsuperscript{2}, Barbieri M.\textsuperscript{2}, Napoli G.\textsuperscript{2}, Bocciardi A.M.\textsuperscript{2}

\textsuperscript{1}San Martino Policlinico Hospital, IRCCS for Oncology, Dept. of Urology, Genoa, Italy, \textsuperscript{2}Niguarda Hospital, Dept. of Urology, Milan, Italy
Improving the oncological outcomes of cystectomy

Poster Session 43

Location: Green Area, Room 3
Chairs: P. Gontero, Turin (IT)
Y. Lotan, Dallas (US)
M.S. Michel, Mannheim (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

600

The natural history of untreated muscle-invasive bladder cancer

By: Martini A. 1, Renström-Koskela L. 2, Mortezavi A. 2, Hosseini A. 2, Mehrazin R. 1, Galsky M. 1, Sfakianos J. 1, Steineck G. 3, Wiklund N. 1
1Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America,
2Karolinska Institutet, Dept. of Molecular Medicine and Surgery, section of Urology, Stockholm, Sweden,
3University of Göteborg, Sahlgrenska Academy Clinical Sciences, Stockholm, Sweden

601

Population-based survival outcomes and treatment costs comparing radical cystectomy with trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer

By: Williams S. 1, Shan Y. 1, Kerr P. 1, Kosarek C. 1, Hudgins H. 1, Jazzaar U. 1, Ray-Zack M. 1, Kaul S. 2, Kamat A. 3, Tyler D. 4, Swanson T. 5, Mehta H. 4
1The University of Texas Medical Branch, Dept. of Surgery, Division of Urology, Galveston, United States of America,
2The University of Texas Medical Branch, Dept. of Preventive Medicine and Community Health, Galveston, United States of America,
3The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America,
4The University of Texas Medical Branch, Dept. of Surgery, Galveston, United States of America,
5The University of Texas Medical Branch, Dept. of Radiation Oncology, Galveston, United States of America

602

Survival outcomes and salvage treatments for local bladder cancer recurrences following radical cystectomy

By: Soligo M. 1, Colicchia M. 1, Morlacco A. 1, Boeri L. 2, Sharma V. 2, Frank I. 2, Boorjian S. 2, Karnes R.J. 2
1University of Padua, Dept. of Urology, Padua, Italy,
2Mayo Clinic, Dept. of Urology, Rochester, United States of America

603

Risk factors of urethral recurrence in men after radical cystectomy with orthotopic urinary diversion for urothelial carcinoma

Scientific Programme - EAU19 Barcelona
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>604</td>
<td>Clinical outcomes of tetra-modality bladdersparing therapy incorporating consolidative partial cystectomy in muscle-invasive bladder cancer patients with hydrenephrosis</td>
<td>By: Song W. ¹, Jeong J.Y. ², Kim T.H. ³, Yoon H.S. ¹, Kim K.H. ¹, Yoon H. ¹, Chung W.S. ¹, Sim B.S. ¹, Lee D.H. ¹</td>
<td>¹Ewha Womans University School of Medicine, Dept. of Urology, Seoul, Korea, South, ²Kangbuk Samsung Hospital, Dept. of Urology, Seoul, Korea, South, ³CHA Bundang Medical Center, Dept. of Urology, Seongnam, Korea, South</td>
</tr>
<tr>
<td>605</td>
<td>A novel nomogram to identify patients with lymph node metastases in the extended lymph node dissection area at radical cystectomy</td>
<td>By: Moschini M. ¹, Zamboni S. ², Mattei A. ², Baumeister P. ², Burgio G. ³, Shariat S.F. ⁴, Dell'Oglio P. ³, Zaffuto E. ¹, Salonia A. ¹, Montorsi F. ¹, Briganti A. ¹, Colombo R. ¹, Gallina A. ¹</td>
<td>¹IRCCS Ospedale San Raffaele; URI, Unit of Urology, Division of Oncology, Milan, Italy, ²Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ³IRCCS Ospedale San Raffaele; URI, Unit of Urology, Division of Oncology, Milan, Italy, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria</td>
</tr>
<tr>
<td>606</td>
<td>Standard vs extended pelvic lymph node dissection: Peri-operative complications and survival outcomes following radical cystectomy</td>
<td>By: Soligo M. ¹, Morlacco A. ¹, Colicchia M. ¹, Boeri L. ², Sharma V. ², Frank I. ², Boorjian S. ², Karnes R.J. ²</td>
<td>¹University of Padua, Dept. of Urology, Padua, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America</td>
</tr>
<tr>
<td>607</td>
<td>Attributable fraction for the risk of death in patients with clinically localized muscle-invasive bladder cancer</td>
<td>By: Audenet F. ¹, Ferket B.S. ², Waingankar N. ³, Jia R. ², Galsky M.D. ⁴, Sfakianos J.P. ³</td>
<td>¹Hôpital Européen Georges Pompidou, Dept. of Urology, Paris, France, ²Icahn School of Medicine at Mount Sinai, Institute for Healthcare Delivery Science, Dept. of Population Health Science and Policy, New York, United States of America, ³Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ⁴Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Division of Hematology, Oncology, Dept. of Medicine, New York, United States of America</td>
</tr>
<tr>
<td>608</td>
<td>Conservative management following non-invasive down-staging with neoadjuvant chemotherapy for muscle-invasive bladder cancer patients refusing radical cystectomy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Scientific Programme - EAU19 Barcelona
609

Incidence and impact of histological variants on survival in candidates for radical cystectomy: Results from a multicenter collaboration

By: Moschini M. 1, Zamboni S. 1, Karnes J.R. 2, Roghmann F. 3, Sargos P. 4, Montorsi F. 5, Briganti A. 5, Colombo R. 5, Gallina A. 5, Mattei A. 1, Baumeister P. 1, Rink M. 6, Poyet C. 7, Saba K. 8, Di Trapani E. 9, De Cobelli O. 9, Antonelli A. 10, Simeone C. 10, Boeri L. 2, Soligo M. 11, Simone G. 12, Gallucci M. 12, Aziz A. 13, Xylinas E. 14, Shariat S.F. 15

1Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 
2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 
3Ruhr-University Bochum, Marien Hospital, Dept. of Urology, Herne, Germany, 
4Institut Bergonié, Dept. of Radiation Therapy, Bordeaux, France, 
5Urological Research Institute, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, 
6University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 
7University Hospital Zürich, University of Zürich, Dept. of Urology, Zürich, Switzerland, 
8University Hospital Zürich, University of Zürich, Dept. of Urology, Zürich, Switzerland, 
9European Institute of Oncology, Dept. of Urology, Milan, Italy, 
10Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, 
11Mayo Clinic, Dept. of Urology, Rochester, United States of America, 
12IRCCS, Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 
13University Medical Center Rostock, Dept. of Urology, Rostock, Germany, 
14Bichat Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 
15Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

610

Comparison of different treatment modalities outcomes in clinically node-positive bladder cancer; analysis of a population-based cancer registry.

By: Stanik M. 1, Poprach A. 2, Malúšková D. 3, Zapletalová M. 3, Macík D. 1, Čapák I. 1, Jarkovský J. 3, Lakomý R. 2, Doležel J. 1

1Masaryk Memorial Cancer Institute, Dept. of Urologic Oncology, Brno, Czech Republic, 
2Masaryk Memorial Cancer Institute, Dept. of Comprehensive Cancer Care, Brno, Czech Republic, 
3Masaryk University, Institute of Biostatistics and Analyses, Brno, Czech Republic

612

Global assessment of outcomes of Robot-assisted radical cystectomy with orthotopic neobladder: Trifecta vs pentafecta

By: Simone G., Guaglianone S., Gallucci M., Tuderti G., Anceschi U., Misuraca L., Ferriero M., Brassetti A., Minisola F., Flammia R.S., Mastroianni R.

Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

613

Impact of lymph node dissection in radical cystectomy for bladder cancer: How many vs how far?


Asan Medical Center, Dept. of Urology, Seoul, Korea, South
Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study


1The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Urology, Amsterdam, Netherlands, The, 2Caritas St Joseph Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, 3University of Turku, Dept. of Urology, Turku, Finland, 4Southwestern Medical Center, University of Texas, Dept. of Urology, Dallas, United States of America, 5Erasmus MC, Dept. of Pathology, Rotterdam, Netherlands, The, 6Erasmus MC, Dept. of Urology, Rotterdam, Netherlands, The, 7The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Urology, Amsterdam, Netherlands, The, 8University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada, 9University of Erlangen, Dept. of Pathology, Erlangen, Germany, 10Institut Curie, University of Paris, Dept. of Pathology, Paris, France, 11Caritas St Joseph Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, 12University Health Network, Dept. of Pathology, Toronto, Canada
**Testis cancer: Complex problems - here are the solutions!**

**Poster Session 44**

**Sunday 17 March**
**14:00 - 15:30**

**Location:** Green Area, Room 4

**Chairs:** M. Jewett, Toronto (CA)  
J. Oldenburg, Lørenskog (NO)  
D. Pfister, Cologne (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**615**

**Comparison of testis cancer-specific survival: An analysis of National Cancer Registry Data from the United States, United Kingdom, and Germany**


1 NIHR Biomedical Research Centre, King’s College, MRC Centre for Transplantation, London, United Kingdom, 2 Brigham and Women’s Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 3 University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 4 Pierre et Marie Curie University, Pitié Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France, 5 University Medical Center Goettingen, Dept. of Urology, Goettingen, Germany, 6 Brigham and Women’s Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 7 Dana Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, Massachusetts, United States of America

---

**616**

**Comprehensive analysis of metastatic seminoma germ cell tumors shows divergent expression of immune-related pathways**

By: Nestler T. 1, Haidl F. 1, Wittersheim M. 2, Dalvi P. 2, Paffenhitz P. 1, Wagener-Ryczek S. 2, Pfister D. 1, Hellmich M. 3, Böttner R. 2, Odenathal M. 2, Heidenreich A. 1

1 University Hospital of Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany, 2 University Hospital of Cologne, Institute of Pathology, Cologne, Germany, 3 University of Cologne, Institute of Medical Statistics and Computational Biology, Cologne, Germany

---

**617**

**Change in body composition following systemic chemotherapy in patients with testicular germ cell tumor**


Yamagata University Faculty of Medicine, Dept. of Urology, Yamagata, Japan

---

**618**

**Primary retroperitoneal lymph-node dissection (RPLND) in stage IIA/IIB germ-cell tumours (GCT) of the testis: Is it an effective and safe approach in modern setting?**
619

Template versus bilateral postchemotherapy retroperitoneal lymph node dissection in patients with testicular cancer

University of Düsseldorf, Dept. of Urology, Medical Faculty, Düsseldorf, Germany

620

Independent validation of two models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer

By: Paffenholtz P., Nestler T., Hoier S., Pfister D., Hellmich M., Heidenreich A.
University Hospital Cologne, Dept. of Urology, Cologne, Germany, University of Cologne, Dept. of Medical Statistics and Computational Biology, Cologne, Germany

621

Higher frequency of adjunctive surgery after salvage chemotherapy in patients with testicular cancer

Universitätsklinikum Düsseldorf, Dept. of Urology, Düsseldorf, Germany, Universitätsklinikum Düsseldorf, Dept. of Urology, Duesseldorf, Germany

622

Non-pulmonary visceral metastases are associated with poor survival in postchemotherapy retroperitoneal lymph node dissection (RPLND) for non-seminomatous germ cell tumours (NSGCT) of the testis

By: Dosanjh A., Baldwin S., Evison F., Gallier S., Wallace M., Patel P.
University Hospitals Birmingham NHS Foundation Trust, Health Informatics, Birmingham, United Kingdom, University Hospitals Birmingham NHS Foundation Trust, Dept. of Urology, Birmingham, United Kingdom, University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom

624

Laparoscopic residual mass resection as an alternative to template-based postchemotherapy retroperitoneal lymph node dissection

By: Blok J.M., Meijer R., Van Der Poel H., Bex A., Bosch R., Horenblas S.
University Medical Center Utrecht, Dept. of Oncological and Urology, Utrecht, Netherlands, The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The
Seminomatous germ cell tumors are heterogenic and metastasis can be predicted based on a gene signature of the tumor invasive front

By: Nestler T.¹, Haidl F.¹, Wittersheim M.², Dalvi P.², Paffenholz P.¹, Wagener-Ryczek S.², Pfister D.¹, Hellmich M.³, Böttner R.², Odenthal M.², Heidenreich A.¹
¹University Hospital of Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany, ²University Hospital of Cologne, Institute of Pathology, Cologne, Germany, ³University of Cologne, Institute of Medical Statistics and Computational Biology, Cologne, Germany

Newly identified regulation mechanism in EBV positive seminoma

By: von Brandenstein M.¹, Paffenholz P.¹, Thönnissen J.¹, Salem J.¹, Köditz B.¹, Nestler T.¹, Fries J.W.U.², Göbel H.², Heidenreich A.¹
¹University Hospital of Cologne, Dept. of Urology, Cologne, Germany, ²University Hospital of Cologne, Institute of Pathology, Cologne, Germany

Impact of adjuvant treatment and patient factors on long-term quality of life of testicular cancer survivors

By: Van Hoorn R.¹, Siva S.², Tran B.³, Ngo T.¹, Wong L-M.¹
¹St Vincent's Hospital Melbourne, Dept. of Urology and Surgery, Melbourne, Australia, ²Peter MacCallum Cancer Centre, Dept. of Radiation Oncology, Melbourne, Australia, ³The Royal Melbourne Hospital, Dept. of Medical Oncology, Melbourne, Australia

Non-leydig cell-stromal-tumors of the testis: Systematic literature review and meta-analysis of treatment outcomes in 745 patients

By: Grogg J.¹, Schneider K.¹, Bode P-K.², Wettstein M.S.¹, Eberli D.¹, Sulser T.¹, Beyer J.³, Hermanns T.¹, Fankhauser C.D.¹
¹University Hospital, University of Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital, University of Zurich, Dept. of Pathology of Molecular Pathology, Zurich, Switzerland, ³University Hospital, University of Bern, Dept. of Oncology, Zurich, Switzerland
Social media, ICT and urology; fake news?

**Poster Session 45**

**Sunday 17 March**
14:00 - 15:30

**Location:** Green Area, Room 5

**Chairs:**
- P. Dasgupta, London (GB)
- D. Murphy, Melbourne (AU)
- M.R. Van Balken, Arnhem (NL)
- To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**631**

**Impact of health literacy on decision-making for prostate-specific antigen screening in the United States**

By: Nguyen D-D. ¹, Trinh Q-D. ¹, Tully K. ¹, Krimphove M.J. ¹, Nguyen P. ², Sammon J. ³

¹Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America,
²Brigham and Women's Hospital, Harvard Medical School, Dept. of Radiation Oncology, Boston, Massachusetts, United States of America,
³Maine Medical Center, Division of Urology and Center for Outcomes Research and Evaluation, Portland, Maine, United States of America

---

**632**

* **Social media coverage of scientific articles immediately after publication predicts subsequent citations: #SoMe_Impact Score**

By: Sathianathen N. ¹, Lane R. ¹, Murphy D.G. ², Loeb S. ³, Bakker C. ¹, Lamb A.D. ⁴, Weight C.J. ¹

¹University of Minnesota, Dept. of Urology, Minneapolis, United States of America,
²Peter MacCallum Cancer Centre, Dept. of Surgical Oncology, Melbourne, Australia,
³New York University, Dept. of Urology, New York, United States of America,
⁴University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom

---

**634**

**Prostate Cancer Canada electronic-library for Improved Function (eLIFT): The construction of the platform and initial analysis for patients' satisfaction**

By: Hetou K. ¹, Tangen-Steffins K. ², Nair S. ¹, Siddiqui K. ¹, Chan G. ¹, Leong H. ¹, Leong N. ², Goulart J. ², Chin J.L. ¹

¹University of Western Ontario, Dept. of Urology, London, Canada,
²BC Cancer, Victoria Centre, Dept. of Radiation Oncology, Victoria, Canada

---

**636**

**An interactive application for hospitalized patients providing real-time feedback to caregivers**
637

Informed consent (IC), randomized controlled trial digital vs conventional IC

By: Galve La Hoz V. ¹, Rioja J. ², Salas E. ¹, Enguita L. ¹, Sanz Del Pozo M. ¹, Corbatón D. ¹, Garea C. ¹, Ezquerra S. ¹, Muñoz M. ¹, Cabañuz T. ¹, Gil P. ¹, Gil M.J. ¹

¹University Hospital Miguel Servet, Dept. of Urology, Zaragoza, Spain, ²University Clinic Hospital , Dept. of Urology, Zaragoza, Spain

* 638

The view of patients and urologists on an online decision aid for patients with non-metastatic prostate cancer: A nationwide project with over 6,000 users in two years

By: Huber J. ¹, Valdix J. ¹, Karschuck P. ¹, Ihrig A. ², Hölscher T. ³, Krones T. ⁴, Kessler E. ⁵, Kliesch S. ⁶, Wülfing C. ⁷, Thomas C. ¹, Groeben C. ¹

¹TU Dresden, Dept. of Urology, Dresden, Germany, ²University of Heidelberg, Dept. of General Internal Medicine and Psychosomatic, Heidelberg, Germany, ³TU Dresden, Dept. of Radiation Oncology, Dresden, Germany, ⁴University of Zurich, Dept. of Clinical Ethics, Zurich, Switzerland, ⁵ASD Concepts GmbH&Co. KG, CEO, Reinheim, Germany, ⁶University of Muenster, Centre of Andrology and Reproductive Medicine, Muenster, Germany, ⁷Asklepios Hospital Altona, Dept. of Urology, Hamburg, Germany

639

A smartphone-based mobile health app to address the adverse effects of androgen deprivation therapy in men with prostate cancer

By: Cole A.P. ¹, Sun M. ², Fletcher S.A. ¹, Berry D.L. ³, Nguyen P.L. ⁴, Sweeney C. ², Menon M. ⁵, Kibel A.S. ¹, Trinh Q-D. ¹

¹Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, ²Dana Farber Cancer Institute, Harvard Medical School, Lank Center for Genitourinary Oncology, Boston, United States of America, ³Dana Farber Cancer Institute, Harvard Medical School, Phyllis F Cantor Center for Research in Nursing and Patient Care Services, Boston, United States of America, ⁴Brigham and Women’s Hospital, Harvard Medical School, Dept. of Radiation Oncology, Boston, United States of America, ⁵Vatikutti Urology Institute, Henry Ford Health System, Detroit, United States of America

640

Deep learning model to predict urinary continence after robot-assisted radical prostatectomy

By: Hung A. ¹, Chen J. ¹, Liu Z.Q ², Nguyen J. ¹, Purushotham S. ³, Liu Y. ⁴

¹Keck School of Medicine, University of Southern California, USC Institute of Urology, Center for Robotic Simulation & Education, Los Angeles, United States of America, ²Peking University, School of Electronics Engineering and Computer Science, Beijing, China, ³University of Maryland, Dept. of Information Systems, Baltimore, United States of America, ⁴Viterbi School of Engineering, University of Southern California, Computer Science Department, Los Angeles, United States of America
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>641</td>
<td>Implementation of a ureteric colic phone consult clinic reduces unnecessary outpatient urology consults</td>
<td>Lu J., Ong C.S.H., Tan L.</td>
<td>National University Hospital, Dept. of Urology, Singapore, Singapore</td>
</tr>
<tr>
<td>15:19 - 15:26</td>
<td>Social media in urology; fake news or reality?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:26 - 15:33</td>
<td>Summary</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
How to improve predictions and outcomes of recurrent prostate cancer

Poster Session 46

**Location:** Green Area, Room 10

**Chairs:** G. De Meerleer, Ghent (BE)  
G. Gandaglia, Milan (IT)  
A. Mendoza-Valdes, Mexico City (MX)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

### 643

**Prospective randomized trial of gene expression classifier utility in men at high risk of recurrence following radical prostatectomy (G-MINOR)**

By: Morgan T.¹, Okoth L.¹, Feng F.², Johnson A.¹, Lane B.³, Linsell S.¹, Khurdish G.¹, Montie J.¹, Fishbane N.⁴, Marti T.⁵, Du Plessis M.⁶, Mehra R.⁷, Davicioni E.⁸, Maatman T.⁹, Wojno K.¹⁰, Burks F.¹¹, Rodriguez P.¹², Liu N.¹³, Sarle R.¹⁴, Miller D.¹, Cher M.¹⁵

¹University of Michigan, Michigan Medicine, Dept. of Urology, Ann Arbor, United States of America, ²University of California, Dept. of Radiation Oncology, San Francisco, United States of America, ³Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, United States of America, ⁴GenomeDx Biosciences, Biostatistics, Vancouver, Canada, ⁵GenomeDx Biosciences, Clinical Research, Vancouver, Canada, ⁶GenomeDx Biosciences, , Clinical Research, Vancouver, Canada, ⁷University of Michigan, Michigan Medicine, Dept. of Pathology, Ann Arbor, United States of America, ⁸GenomeDx Biosciences, Vancouver, Canada, ⁹Michigan Urological Clinic, Dept. of Urology, Grand Rapids, United States of America, ¹⁰Comprehensive Urology, Dept. of Pathology, Royal Oak, United States of America, ¹¹Comprehensive Urology, Dept. of Urology, Royal Oak, United States of America, ¹²Urology Associates of Grand Rapids P.C, Dept. of Urology, Grand Rapids, United States of America, ¹³IHA Urology, Dept. of Urology, Ypsilanti, United States of America, ¹⁴Michigan Institute of Urology, Dept. of Urology, Troy, United States of America, ¹⁵Wayne State University, Dept. of Urology, Detroit, United States of America

### 644

**Multi-scale tissue architecture analysis of prostate cancer biopsies: A new imaging tissue biomarker of biochemical recurrence?**

By: Pukl M.¹, Carraro A.², Korbelic J.², Harisson A.², Zhaoyang C.², Palcic B.², Macaulay C.², Guillaud M.², Volavsek M.³

¹GH Celje, Dept. of Urology, Celje, Slovenia, ²British Columbia Cancer Research Centre, Dept. of Integrative Oncology, Vancouver, Canada, ³Faculty of Medicine, University of Ljubljana, Dept. of Pathology, Ljubljana, Slovenia

### 645

**Identifying the optimal definition for early biochemical recurrence after radical prostatectomy: A risk-stratified approach to optimize postoperative follow-up and**
the use of timely salvage therapies

By: Mazzone E.¹, Gandaglia G.¹, Knipper S.², Graefen M.², Gallina A.¹, Tilki D.², Suardi N.¹, Bandini M.¹, Cucchiara V.¹, Stabile A.¹, Dell'oglio P.¹, Fossati N.¹, Montorsi F.¹, Briganti A.¹

¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, URI, Milan, Italy,
²University Hospital Hamburg-Eppendorf, Dept. of Urology, Martini Klinik, Hamburg, Germany

Testosterone replacement therapy prevents disease progression in men undergoing radical prostatectomy

By: Towe M., Huynh L.M., El-Khatib F.M., Yafi F.A., Ahlering T.
University of California, Dept. of Urology, Irvine, Orange, United States of America

Evaluating the impact of lead-time bias on the observed efficacy of early salvage radiation therapy in prostate cancer: A post-hoc analysis of the RTOG 9601 trial

Henry Ford Hospital, Vattikuti Urology Institute, Center for Outcomes Research, Analytics and Evaluation, Detroit, United States of America

What is the best definition of biochemical response to salvage radiation therapy in prostate cancer patients treated for PSA rising after radical prostatectomy? Results from a multi-institutional series

By: Fossati N.¹, Karnes R.J.², Boorjian S.A.², Boeri L.², Bossi A.³, Di Muzio N.⁴, Cozzarini C.⁴, Noris Chiorda B.⁴, Mazzone E.⁵, Gandaglia G.⁵, Barletta F.⁵, Bartkowiak D.⁶, Böhmer D.⁷, Shariat S.⁸, Goldner G.⁹, Battaglia A.¹⁰, Joniau S.¹⁰, Haustermans K.¹¹, De Meerleer G.¹¹, Fonteyne V.¹², Ost P.¹², Van Poppel H.¹⁰, Montorsi F.⁵, Wiegel T.⁶, Briganti A.⁵

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, MN, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, URI, Milan, Italy, ⁶University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁷Charité University Hospital Berlin, Dept. of Radiation Oncology, Berlin, Germany, ⁸Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁹Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ¹⁰University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹¹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹²Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

Impact of primary Gleason pattern on results of early salvage radiotherapy after radical prostatectomy

By: Preisser F.¹, Pompe R.S.², Chun F.K-H.¹, Graefen M.³, Huland H.³, Tilki D.³
¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²University Hospital
Rates and patterns of metastases in patients with node-negative prostate cancer at radical prostatectomy that experience PSA failure: Post-hoc analysis of RTOG 9601 trial data

By: Sood A., Keeley J., Arora S., Dalela D., Jeong W., Rogers C., Peabody J., Menon M., Abdollah F.
Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America

There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy


Tumor control outcomes of salvage cryotherapy for radiorecurrent prostate cancer at median 12 years follow-up

By: Nair S., Peters M., Abed H., Van Der Voort Van Zyp J., Van Son M., Chin J.L.

Long-term functional and oncological outcomes of salvage cryosurgery for locally recurrent prostate cancer following radiotherapy: A 12-year single center analysis

By: Exterkate L., Somford D.M., Vergunst H.
Canisius-Wilhelmina Hospital, Dept. of Urology, Nijmegen, Netherlands

Salvage cryotherapy versus salvage radical prostatectomy for radiorecurrent prostate cancer: Long-term oncologic outcomes
Outcomes of the miltuximab first in human trial and proposed study design for a phase 1 trial 89zr/177lu theranostic trial

By: Campbell D.¹, Sabanathan D.², Gurney H.², Gillatt D.², Trifunovic M.³, Poursoultan P.⁴, Ho Shon K.³, Mackay T.¹, Roach P.⁵, Bailey D.⁵, Walsh B.¹
¹Minomic International Ltd, Macquarie Park, Australia, ²Macquarie University, Faculty of Medicine and Health Sciences, Macquarie Park, Australia, ³Macquarie Medical Imaging, Macquarie Park, Australia, ⁴Macquarie University, Faculty of Medicine and Health Sciences, Macquarie Park, Australia, ⁵Pharmascint, St Leonards, Australia

PSA persistence after radical prostatectomy and its impact on oncologic outcomes

By: Preisser F.¹, Pompe R.S.², Chun F.¹, Graefen M.³, Huland H.³, Tilki D.³
¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³University Hospital Hamburg-Eppendorf, Martini-Klinik, Hamburg, Germany

What are the current indications for salvage radiotherapy

To be confirmed

Summary

To be confirmed
Evaluation for LUTS in clinical practice
Poster Session 47

Location: Green Area, Room 11
Chairs: W. Artibani, Verona (IT)
To be confirmed
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

657 Malnutrition evaluated by the controlling nutritional status (CONUT) score is associated with severe nocturia in males
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Dept. of Urology, Tokyo, Japan

658 Risk factors for the prevalence and cumulative incidence of urinary incontinence during pregnancy and the first year postpartum: A prospective cohort study
By: Chang S-R.
National Taiwan University, College of Medicine, School of Nursing, Taipei, Taiwan

659 Night shift workers have a higher overactive bladder score with an impairment of quality of life: A prospective cohort study
Sapienza University of Rome, Sant’Andrea Hospital, Dept. of Urology, Rome, Italy

661 Urodynamic study for distinguishing multiple system atrophy from Parkinson’s disease
By: Shin J.H. 1, Park K.W. 2, Lee J. 1, An D.H. 1, Lee S. 1, Choo M.S. 1
1Asan Medical Center, Dept. of Urology, Seoul, Korea, South, 2Asan Medical Center, Dept. of Neurology, Seoul, Korea, South

662 Detrusor underactivity: Are different diagnostic criteria often reliable in clinical practice?
By: Rapisarda S. 1, Russo G.I. 1, Lombardo R. 2, De Nunzio C. 2, Scandura C. 1, Carbonaro B. 1, Sica A. 3, Vicentini C. 4, Cimino S. 1, Tubaro A. 1, Morgia G. 1
1University of Catania, Dept. of Urology Section, Dept. of Surgery, Catania, Italy, 2Sant’Andrea Hospital, Sapienza University, Dept. of Urology, Rome, Italy, 3Azienda
663  Caesarean section versus vaginal delivery and the development of urinary incontinence and/or LUTS in premenopausal parous women

By: Michailidou S. 1, Petridou M. 1, Tsapara V. 1, Moysidis K. 2, Apostolidis A. 2
1Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece, 2Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece

664  Categories for severity of the main symptom scores (ICIQ-MLUTS and IPSS) in Male LUTS

By: Ito H. 1, Young G. 2, Lewis A. 2, Blair P. 1, Cotterill N. 1, Abrams P. 1, Lane A. 2, Drake M. 1
1Southmead Hospital, Bristol Urological Institute, Bristol, United Kingdom, 2University of Bristol, Population Health Sciences, Bristol, United Kingdom

665  Impact of 6F dual channel urethral catheter on flow rate during video-urodynamic investigations

University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

666  Development of a novel voided volume measuring device for automated recording of voiding diary

By: Takai S. 1, Matsukawa Y. 1, Hashizume N. 2, Gotoh M. 1
1Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan, 2Shimadzu Corporation, Technology Research Laboratory, Kyoto, Japan

668  A score for screening severe obstructive sleep apnea syndrome in patients referred for nocturia

By: Misrai V. 1, Peyronnet B. 2, Pépin J. 3, Charbonneau H. 4, Pathak A. 5, Attias D. 6
1Clinique Pasteur, Dept. of Urology, Toulouse, France, 2Rennes University, Dept. of Urology, Rennes, France, 3Laboratoire HP2, INSERM U1042, Univ. Grenoble Alpes, Dept. of Pulmonology, Grenoble, France, 4Clinique Pasteur, Dept. of Anesthesiology and intensive care unit, Toulouse, France, 5Clinique Pasteur, Dept. of Cardiovascular Medicine, INSERM U1048, Toulouse, France, 6Clinique Pasteur, Dept. of Pulmonology, Toulouse, France

669  Higher salt intake and non-dipping blood pressure are associated with nocturnal polyuria in patients with lower urinary tract symptoms

Iwate Medical University, Dept. of Urology, Morioka, Japan
<table>
<thead>
<tr>
<th>Session No.</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>670</td>
<td>Relationship between lower urinary tract symptoms and visceral fat mass and psoas major muscle mass in women</td>
<td>Tomohiro M., Miyata Y., Yuno T., Araki K., Nakamura Y., Sagara Y., Ohba K., Sakai H.</td>
<td>Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan</td>
</tr>
<tr>
<td>671</td>
<td>Prospective validation of a novel visual analogue uroflowmetry score (VAUS) in 1000 men with lower urinary tract symptoms (LUTS)</td>
<td>Tiwari R.V., Ng M.Y., Ho S.S.H.</td>
<td>Singapore General Hospital, Dept. of Urology, Singapore, Singapore</td>
</tr>
</tbody>
</table>
Let's have a closer look! Imaging of renal cancer

Poster Session 48

Sunday 17 March
14:00 - 15:30

Location: Green Area, Room 12
Chairs: U. Capitanio, Milan (IT)
A. Kotsar, Tartu (EE)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 672

Differentiation of clear cell and non-clear cell renal cell carcinomas by radiomics features

By: Liu G. ¹, Wu G. ², Li Z. ³
¹Renji Hospital?School of Medicine?Shanghai Jiaotong University, Dept. of Radiology, Shanghai, China, ²Renji Hospital?School of Medicine?Shanghai Jiaotong University, Dept. of Radiology, Shanghai, China, ³Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Dept. of Biomedical and Health Engineering, Shenzhen, China

673

Differentiation of chromophobe renal cell carcinoma and renal oncocytoma with whole-lesion ADC analysis on diffusion-weighted MRI

By: Uchida Y ¹, Yoshida S. ¹, Shimoda H. ¹, Tanaka H. ², Yamamoto K. ³, Sakamoto T. ⁴, Kaneko K. ¹, Kijima T. ¹, Yokoyama M. ¹, Ishioka J. ¹, Matsuoka Y. ¹, Saito K. ¹, Fujii Y. ¹
¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan, ³Tokyo Medical and Dental University, Dept. of Pathology, Tokyo, Japan, ⁴PixSpace Ltd, Dept. of Radiology, Fukuoka, Japan

674

99mTc-sestamibi SPECT/CT for the diagnosis of benign renal oncocytomas and hybrid oncocytic/chromophobe tumors: Combined data from prospective trials and real-world clinical experience

By: Meyer A.R. ¹, Patel H.D. ¹, Javadi M.S. ², Pierorazio P. ¹, Pavlovich C. ¹, Han M. ¹, Rowe S.P. ², Allaf M.E. ¹, Gorin M.A. ¹
¹Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, ²Johns Hopkins University School of Medicine, Dept. of Radiology, Baltimore, United States of America

675

Contrast-enhanced ultrasonography (CEUS) and time/intensity curves for the characterization of small renal masses
**676**

**Contrast-enhanced ultrasound in the diagnosis of renal mass and its concordance with the computerized tomography**

By: Del Pozo Jiménez G. 1, Castillón Vela I. 1, Rengifo Abbad D. 1, Fontanilla Echeveste T. 2, Minaya Bernedo J. 1, Turo Antona J. 1, Carballido Rodríguez J. 1

1 H.U. Puerta de Hierro, Dept. of Urology, Majadahonda (Madrid), Spain, 2 H.U. Puerta de Hierro, Radiodiagnostic Service, Majadahonda (Madrid), Spain

**681**

**Circularity analysis with three-dimensional reconstruction models as predictors of prognosis for clear cell renal cell carcinoma**

By: Zhao X. 1, Sun Z. 1, Jiang B. 1, Kan Y. 1, Zheng J. 2, Guo X. 2, Guo H. 1

1 Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical School, Dept. of Urology, Nanjing, China, 2 Incol Medical Technology Co., Ltd., Dept. of technology, Hangzhou, China

**682**

**Great clinical diagnostic value of (68)Ga-PSMA PET/CT imaging for clear cell renal cell carcinoma**

By: Zhang C. 1, Zhao X. 1, Wang F. 2, Guo H. 1

1 Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, 2 Nanjing First Hospital, Dept. of Nuclear Medicine, Nanjing, China

**683**

**PSMA PET/CT for the primary evaluation of a localized renal mass**

By: Aviv T. 1, Prokocimer Y. 1, Bernstein H. 2, Nadu A. 1, Domachevsky L. 2, Groshar D. 2, Ben Daniel J. 1, Golan S. 1

1 Rabin Medical Center - Beilinson Hospital, Dept. of Urology, Petah Tikva, Israel, 2 Rabin Medical Center - Beilinson Hospital, Dept. of Nuclear Medicine, Petah Tikva, Israel
Expression of prostate-specific membrane antigen in clear cell renal cancer patients: A novel option for metastasis detection

By: Thibaut A. 1, Hölters S. 1, Ohlmann C. 1, Janssen M. 1, Zimpfer A. 2, Bohle R. 2, Ezziddin S. 3, Stöckle M. 1, Junker K. 1

1Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany, 2Saarland University, Institute of Pathology, Homburg, Germany, 3Saarland University, Dept. of Nuclear Medicine, Homburg, Germany
Paediatric urology: Bladder function and posterior urethral valves
Poster Session 49

Location: Green Area, Room 19
Chairs: To be confirmed
J.M. Nijman, Groningen (NL)
S. Tekgül, Sihhiye, Ankara (TR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

686
Analysis of factors influencing operative time of transvesicoscopic ureteral reimplantation
By: Kobayashi K., Johnin K., Tomita K., Murai R., Tsuru T., Yoshida T., Kageyama S., Narita M., Kawauchi A.
Shiga University of Medical Science, Dept. of Urology, Otsu, Japan

687
Medical history of nocturnal enuresis at school age is a risk factor for nocturia in adults: The Nagahama study
1University of Tsukuba Hospital, Dept. of Urology, Ibaraki, Japan, 2National Cancer Center Hospital, Dept. of Urology, Tokyo, Japan, 3Kyoto University Graduate School of Medicine, Center for Genomic Medicine, Kyoto, Japan, 4Kyoto University Graduate School of Medicine, Dept. of Urology, Kyoto, Japan, 5Shizuoka General Hospital, Dept. of Urology, Shizuoka, Japan, 6Hyogo College of Medicine, Dept. of Urology, Hyogo, Japan

688
Clinical utility of a grading scale of urinary incontinence (ENURI) in children with monosymptomatic enuresis
1University and Polytechnic Hospital La Fe Valencia, Dept. of Paediatric Urology, Valencia, Spain, 2University and Polytechnic Hospital La Fe Valencia, Dept. of Reconstructive and Functional Urology (SURF), Valencia, Spain

689
Lower urinary tract dysfunction in children with hypermobility of joints
By: Topuz B., Pekbay Y., Sarikaya S., Acar Z.Z., Irkilata H.C., Dayanc M.M.
1Gulhane Research and Training Hospital, Dept. of Urology, Ankara, Turkey, 2Prof. Dr. Murat Dayanc Private Pediatric Urology Clinic, Dept. of Pediatric Urology, Ankara, Turkey, 3Private Davraz Yasam Hospital, Dept. of Urology, Isparta, Turkey
Usefulness of the BEARS sleep screening tool in the evaluation of sleep disorders in children with monosymptomatic enuresis

By: Sánchez González J.V. 1, March-Villalba J.A. 1, Martínez-Cayuelas L. 2, Conca Baenas M.A. 1, Polo Rodrigo A. 1, Serrano Durbá A. 1, Domínguez Hinarejos C. 1, Boronat Tormo F. 1
1University and Polytechnic Hospital La Fe, Dept. of Pediatric Urology, Valencia, Spain, 2University Hospital San Juan, Dept. of Urology, Alicante, Spain

Relationship between 25-hydroxyvitamin D, vitamin B12, folate and primer nocturnal enuresis (PNE) in five to thirteen year old children: A single center cohort study

By: Keles A. 1, Karakeci A. 2, Onur R. 3
1Istanbul Esenyurt State Hospital, Dept. of Urology, Istanbul, Turkey, 2Fırat University School of Medicine, Dept. of Urology, Elazı̇ğ, Turkey, 3Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey

The effects of pelvic floor muscle rehabilitation (PFMR) on symptoms, voiding and pelvic floor muscle parameters in children with overactive bladder

By: Pekbay Y. 1, Ergin O. 2, Topuz B. 3, Sarıkaya S. 3, Acar Z.Z. 4, Irkilata H.C. 2, Dayanc M.M. 4
1Prof.Dr. Murat Dayanc Pediatric Urology Clinic, Pediatric Urology, Ankara, Turkey, 2Private Davraz Yasam Hospital, Dept. of Urology, Isparta, Turkey, 3Gülhane Research and Training Hospital, Dept. of Urology, Ankara, Turkey, 4Prof.Dr. Murat Dayanc Pediatric Urology Clinic, Dept. of Pediatric Urology, Ankara, Turkey

Influence of pediatric patient’s age in the remission of monosymptomatic enuresis when a therapeutic modality is applied

By: Sánchez González J.V. 1, March-Villalba J.A 2, Conca Baenas M.A 2, Polo Rodrigo A. 2, Serrano Durbá A. 2, Domínguez Hinarejos C. 2, Boronat Tormo F. 2
1University and Polytechnic Hospital La Fe, Dept. of Paediatric Urology, Valencia, Spain, 2University and Polytechnic Hospital La Fe, Dept. of paediatric Urology, Valencia, Spain

Different kinds of posterior urethral valves in boys

By: Sabirzyanova Z. , Pavlov A. , Simonyan G. , Miphtyakhedtinnova O.
Russian scientific center of roentgenradiology, Dept. of Urology, Moscow, Russia

Posterior urethral valves in patients with a urethra appearing normally on VCUG: An approach to secondary radiologic signs

By: Haid B. 1, Thüminger J. 2, De Jong T.P.V.M. 3, Oswald J. 1
1Hospital of the Sisters of Charity, Dept. of Pediatric Urology, Linz, Austria, 2Medical University Graz, Dept. of Pediatric Surgery, Graz, Austria, 3Emma Children's Hospital, University of Amsterdam, Dept. of Pediatric Urology, Utrecht, Netherlands, The Netherlands
698 Management of posterior urethral valve in infants: What is the role of vesicostomy?

By: El-Moghazy H.
Sohag University, Dept. of Urology, Sohag, Egypt

699 Surgical interventions in an adult population of posterior urethral valves: Long term urological outcomes

By: Namdarian B., Wilby D., Dunford C., Connolly J., Wood D.N.
1University College London Hospital, Paediatric Urology and Adolescent Reconstructive Urology, London, United Kingdom, 2University College London Hospital, Dept. of Nephrology, London, United Kingdom
## Non-muscle invasive bladder cancer: Role of markers for diagnosis, prognosis and surveillance

Posters Session 50

| Sunday 17 March  |
| 14:00 - 15:30 |

**Location:** Green Area, Room 20

**Chairs:**
- R. Campi, Florence (IT)
- L.H. Klotz, Toronto (CA)
- H. Mostafid, Surrey (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

### 700

**Role of surgeon experience in the outcome of transurethral resection of bladder tumors**

**By:** Ali MH, Eltobgy A., Ismail I.Y., Ghobeish A.A.
Faculty of Medicine, Suez Canal University, Dept. of Urology, Ismailia, Egypt

### 701

**The impact of a past medical history of upper urinary tract urothelial carcinoma on failure cases of bacillus Calmette–Guérin intravesical instillation therapy**

**By:** Iida K.¹, Naiki T.¹, Nagai T.², Nozaki S.¹, Etani T.¹, Ando R.¹, Akita H.², Okamura T.², Kubota H.³, Kawai N.¹, Yasui T.¹

¹Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, ²Anjo Kosei Hospital, Dept. of Urology, Aichi, Japan, ³Kanian Hospital, Dept. of Urology, Aichi, Japan

### 702

**Up-date of pathological outcome and subjective definition of failure for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: result from Bladder Cancer Italian Active Surveillance (BIAS) project**

Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy

### 703

**Systemic inflammatory markers and oncological outcomes in patients with high-risk non-muscle invasive urothelial bladder cancer**

**By:** Russo G.I.¹, Cantiello F.², Vartolomei M.³, Lucarelli G.⁴, Serretta V.⁵, Morgia G.¹, Damiano R.², De Cobelli O.³, Ferro M.³

¹University of Catania, Dept. of Urology, Catania, Italy, ²University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ³Istituto Europeo di Oncologia (IEO), Dept. of Urology, Milano, Italy, ⁴University of Bari, Dept. of Urology, Bari, Italy, ⁵University of Palermo, Dept. of Urology, Palermo, Italy
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>704</td>
<td>Tumor associated macrophages promote bladder tumor growth through PI3k/AKT signal induced by collagen</td>
<td>Shi Q., Jiakun L., Kun J., Lu Y., Qiang W.</td>
<td>West China Hospital, Dept. of Urology, Institute of Urology, Chengdu, China</td>
</tr>
<tr>
<td>706</td>
<td>Substratification of intermediate-risk non-muscle-invasive bladder cancer based on the prediction of high-risk recurrence: Impact of bladder neck involvement and positive urine cytology</td>
<td>Fukushima H., Toide M., Fukuda S., Moriyama S., Yasuda Y., Uehara S., Kijima T., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Fujii Y.</td>
<td>Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan</td>
</tr>
<tr>
<td>707</td>
<td>Evaluation of non-muscle-invasive bladder cancer recurrence using a mRNA-based urine test (Xpert® Bladder Cancer Monitor) and cytology</td>
<td>Cancel-Tassin G.¹, Ciofu C.², Varinot J.², Audouin M.², Ondet V.², Gaffory C.¹, Roupret M.³, Comperat E.², Cussenot O.²</td>
<td>¹CeRePP, ²Sorbonne Universite, ³ONCOTYPE-URO, AP-HP, ⁴Tenon Hospital, Paris, France, ⁵Sorbonne Universite, ⁶ONCOTYPE-URO, ⁷AP-HP, ⁸Pitie-Salpetriere Hospital, Paris, France</td>
</tr>
<tr>
<td>710</td>
<td>Treatment of high grade non-muscle invasive bladder carcinoma by standard number and dose of intravesical BCG instillations versus reduced number and dose of intravesical BCG instillations. An initial report of the phase III clinical trial ‘NIMBUS’</td>
<td>Grimm M-O.¹, Van Der Heijden A.², Colombel M.³, Muijwijk T.⁴, Martinez-Piñeiro L.⁵, Bjartell A.⁶, Caris C.⁶, Schipper R.⁶, Witjes W.⁶, Babjuk M.⁷, Türkeri L.⁸</td>
<td>¹University Hospital Jena, Dept. of Urology, Jena, Germany, ²Radboud UMC, Dept. of Urology, Nijmegen, Netherlands, The, ³Hôpital Edouard Herriot, Dept. of Urology, Lyon, France, ⁴University Hospital Leuven, Dept. of Urology, Leuven, Belgium, ⁵Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ⁶EAU Research Foundation, Dept. of Clinical Research, Arnhem, Netherlands, The, ⁷Hospital Motol, Charles University, Dept. of Urology, Prague, Czech Republic, ⁸Acibadem University, Dept. of Urology, Istanbul, Turkey</td>
</tr>
<tr>
<td>711</td>
<td>Risk-stratified surveillance and cost effectiveness of follow-up after trans-urethral resection of bladder tumor in patients with primary non-muscle-invasive bladder cancer</td>
<td>Fujita N.¹, Momota M.¹, Tobisawa Y.¹, Yoneyama T.¹, Yamamoto H.¹, Imai A.¹, Hatakeyama S.¹, Ito H.², Yoneyama T.¹, Hashimoto Y.³, Ohyama C.¹</td>
<td>¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, ³Mutsu General Hospital, Dept. of Urology, Mutsu, Japan</td>
</tr>
</tbody>
</table>
# Advanced endourology in the non-standard patients with urolithiasis

**ESU Course 37**

**Sunday 17 March**
**14:30 - 17:30**

**Location:** Green Area, Room 13

**Chair:** G.M. Kamphuis, Amsterdam (NL)

## Aims and objectives of this session

Discuss available literature and practical management options and examples treatment of urolithiasis in ‘non-index’ patients, covering:

- Horse shoe kidney, caliceal diverticula, duplicate urinary system.
- Pregnancy, complex metabolic patients.
- After bladder substitution/ileal conduit/reimplantation.
- In transplant kidneys and spinal malformation.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Introduction</strong> G.M. Kamphuis, Amsterdam (NL)</td>
</tr>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Urolithiasis in urinary system anomalies: Horse shoe kidneys</strong> E. Emiliani, Barcelona (ES)</td>
</tr>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Urolithiasis in urinary system anomalies: Calyceal diverticula stones</strong> S. Doizi, Paris (FR)</td>
</tr>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Urolithiasis in pregnancy</strong> G.M. Kamphuis, Amsterdam (NL)</td>
</tr>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Urolithiasis in urinary system anomalies: After bladder substitution/ ileal conduit/ ureteral reimplantation</strong> E. Emiliani, Barcelona (ES)</td>
</tr>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Medullary sponge kidneys</strong> S. Doizi, Paris (FR)</td>
</tr>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Urolithiasis in transplant kidneys</strong> G.M. Kamphuis, Amsterdam (NL)</td>
</tr>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Urolithiasis in urinary system anomalies: Duplicate urinary system and ectopic kidney</strong> S. Doizi, Paris (FR)</td>
</tr>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Surgical treatment of complex metabolic patients: Brushite and cystine stones</strong> E. Emiliani, Barcelona (ES)</td>
</tr>
<tr>
<td>14:30 - 17:30</td>
<td><strong>Patients with relative contraindications: Spinal malformation / bleeding diathesis</strong> G.M. Kamphuis, Amsterdam (NL)</td>
</tr>
</tbody>
</table>
Aims and objectives of this session
Focal treatment is about eradicating the cancer lesion within the prostate while preserving genitourinary function. This interactive course offers delegates:
- understanding of the rationale for focal treatment and patient selection criteria.
- update on principles, outcome and side effects of focal technologies.
- a thorough discussion of biopsy strategies and imaging in diagnostic work-up and follow-up
- information about existing registries.

As men with prostate cancer are getting younger the side effects of whole gland treatment are getting more important. With several new technologies available a significant development of focal treatment is expected in the coming years.

Selection criteria for FT

Rationale for FT
A. Breda, Barcelona (ES)

Role of imaging
E. Barret, Paris (FR)

Prostate biopsy modalities
A. Govorov, Moscow (RU)

Focal therapy modalities

Treatment modalities
A. Breda, Barcelona (ES)

Energy sources (technical aspects - videos)

HIFU
E. Barret, Paris (FR)

Cryotherapy
A. Govorov, Moscow (RU)

Brachytherapy
A. Govorov, Moscow (RU)

Others (laser ablation, irreversible electroporation, radiofrequency)
E. Barret, Paris (FR)

Follow up
<table>
<thead>
<tr>
<th>Section</th>
<th>Author</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up modalities</td>
<td>A. Breda</td>
<td>Barcelona (ES)</td>
</tr>
<tr>
<td>Oncological and functional outcomes</td>
<td>A. Govorov</td>
<td>Moscow (RU)</td>
</tr>
<tr>
<td>Definition of failure and failure management</td>
<td>E. Barret</td>
<td>Paris (FR)</td>
</tr>
<tr>
<td>Salvage FT</td>
<td>A. Breda</td>
<td>Barcelona (ES)</td>
</tr>
<tr>
<td>Clinical cases</td>
<td>E. Barret</td>
<td>Paris (FR)</td>
</tr>
</tbody>
</table>
How will immunotherapy change the multidisciplinary management of urothelial bladder cancer?

ESU Course 35

Sunday 17 March 14:30 - 17:30

**Location:** Green Area, Room 15

**Chairs:** A. Necchi, Milan (IT)  
J. Bedke, Tübingen (DE)

**Aims and objectives of this session**

Results obtained from large immunotherapy trials paved the way of a revolutionary road in the treatment of locally advanced and metastatic urothelial bladder cancer (UBC).

For clear-cell renal cell carcinoma (RCC), use of immunotherapy combinations (with either other immune checkpoint inhibitors or targeted therapy/antiangiogenic drugs) resulted in a shifting paradigm for the first-line therapy of advanced disease.

For both of these tumors, developments of immunotherapy trials in earlier disease stages are progressing at an impressively quick step. Therefore, as never before, there is a need for updates on the multidisciplinary management of these patients.

In brief, the aims of the course will be the following:

- To provide urologists with the state-of-the-art on the use of immune-checkpoint inhibitors in UBC and RCC.
- To provide urologists with an overview of the ongoing clinical trials throughout the clinical stages, with a special focus on perioperative stages.
- To discuss the optimal clinical management of patients with UBC or RCC receiving immune checkpoint inhibitor treatment, including the management of side effects.

**Background - state-of-the art and ongoing developments**

A. Necchi, Milan (IT)

**Clinical cases discussion**

J. Bedke, Tübingen (DE)

**Immune checkpoint inhibitors in the perioperative setting of urothelial cancer:**

**Immune checkpoint inhibitors and the multidisciplinary management of locally-advanced bladder cancer:**

**Case discussion 1 – optimal approach for cisplatin - ineligible patients**

J. Bedke, Tübingen (DE)

**Background**

A. Necchi, Milan (IT)

**Case discussion 2 – therapeutic sequences for platinum - refractory patients**

A. Necchi, Milan (IT)
Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Case discussion 3 - Management of adverse events: What urologists should know</th>
<th>J. Bedke, Tübingen (DE)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Management of RCC in the perioperative setting:</strong></td>
<td></td>
</tr>
<tr>
<td>Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy</td>
<td>A. Bex, Amsterdam (NL)</td>
</tr>
<tr>
<td>Neoadjuvant and adjuvant immunotherapy developments</td>
<td>J. Bedke, Tübingen (DE)</td>
</tr>
<tr>
<td><strong>Immune checkpoint inhibitors and the multidisciplinary management of locally - advanced renal cell cancer:</strong></td>
<td></td>
</tr>
<tr>
<td>Case discussion 2 – role of tyrosine-kinase inhibitors in advanced RCC</td>
<td>J. Bedke, Tübingen (DE)</td>
</tr>
<tr>
<td>Benchmark of immunotherapy - based results</td>
<td>A. Necchi, Milan (IT)</td>
</tr>
<tr>
<td>Case discussion 3 – development of first-line immune - oncology combinations</td>
<td>A. Bex, Amsterdam (NL)</td>
</tr>
<tr>
<td>Case discussion 1 – combination immunotherapy as first line therapy of advanced RCC</td>
<td>A. Bex, Amsterdam (NL)</td>
</tr>
<tr>
<td><strong>Conclusion</strong></td>
<td>A. Necchi, Milan (IT)</td>
</tr>
</tbody>
</table>
Laparoscopic and robot-assisted laparoscopic radical cystectomy
ESU Course 34

Sunday 17 March
14:30 - 17:30

Location: Green Area, Room 16
Chair: N.P. Wiklund, Stockholm (SE)

Aims and objectives of this session
The course is video based. The steps in the surgical treatment of muscle invasive bladder cancer by conventional laparoscopy and robot-assisted technique will be described. The surgical technique to perform Male and female cystectomy, lymph node dissection, urinary diversion with extracorporeal and intracorporeal technique, conduits as well as orthotopic neobladders, will be shown. Indications, contraindications, outcomes and handling of complications will be discussed.

• The surgical steps in nerve sparing and non-nerve sparing male cystectomy.
• The surgical steps in female cystectomy with and without organ sparing technique.
• The surgical steps in lymph node dissection during cystectomy.
• The technique in urinary diversion, conduit and neobladder, with intra and extracorporeal technique.
• Indications, outcomes and complications after minimally invasive cystectomy.
• The handling of the most common complications after minimally invasive cystectomy.

Laparoscopic cystectomy in males (video-based teaching)

Conventional laparoscopy
J. Rassweiler, Heilbronn (DE)

Robot-assisted technique with nerve sparing technique
C.J. Wijburg, Arnhem (NL)

Laparoscopic cystectomy in Females (video based teaching)

Conventional cystectomy
J. Rassweiler, Heilbronn (DE)

Robot-assisted cystectomy with organ preservation
N.P. Wiklund, Stockholm (SE)

Laparoscopic lymph node dissection (video-based teaching)
J. Rassweiler, Heilbronn (DE)

Laparoscopic urinary diversion (video-based teaching)

Intracorporeal: Bricker
C.J. Wijburg, Arnhem (NL)

Intracorporeal: Neobladder
N.P. Wiklund, Stockholm (SE)
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extracorporeal urinary diversion</td>
<td>J. Rassweiler, Heilbronn (DE)</td>
</tr>
<tr>
<td>Challenge the expert: Controversies in laparoscopic and robotic cystectomy</td>
<td></td>
</tr>
<tr>
<td>Oncological outcomes in laparoscopic cystectomy - Challenger</td>
<td>C.J. Wijburg, Arnhem (NL)</td>
</tr>
<tr>
<td>Oncological outcomes in laparoscopic cystectomy - Pro</td>
<td>N.P. Wiklund, Stockholm (SE)</td>
</tr>
<tr>
<td>Complications and functional outcomes in laparoscopic cystectomy - Challenger</td>
<td>J. Rassweiler, Heilbronn (DE)</td>
</tr>
<tr>
<td>Complications and functional outcomes in laparoscopic cystectomy - Pro</td>
<td>N.P. Wiklund, Stockholm (SE)</td>
</tr>
</tbody>
</table>
Management of BPO: From medical to surgical treatment, including setbacks and operative solutions (SOS)
ESU Course 38

Sunday 17 March
14:30 - 17:30

Location: Green Area, Room 21
Chair: V.A.C. Ramani, Manchester (GB)

Aims and objectives of this session
• To help delegates understand the principles and evidence behind the assessment and medical management of a BPO patient
• To summarise / review the evidence base for electro surgery and lasers for surgical management of BPO
• To help delegates understand the factors that influence the patient's and surgeon's choice of treatment modalities
• Setbacks and Operative Solutions (SOS): Tips and Tricks to improve outcomes and avoid complications

Introduction/scene setting BPO 2019
V.A.C. Ramani, Manchester (GB)

Assessment and medical management
V.A.C. Ramani, Manchester (GB)

Surgical management – Electrosurgery
T.R.W. Herrmann, Hanover (DE)

Surgical management – Lasers and less invasive options
S. Ahyai, Göttingen (DE)

Setbacks and operative solutions / Case presentations
S. Ahyai, Göttingen (DE)
T.R.W. Herrmann, Hanover (DE)
V.A.C. Ramani, Manchester (GB)
Aims and objectives of this session
Recently new imaging technologies have been developed to improve the diagnosis and management of prostate cancer. These are multiparametric MRI, choline PET and new ultrasound based technologies. The course’s aim is to provide:
• An overview on the currently available imaging tools for prostate cancer.
• Practical information about their use.
• A critical assessment of their clinical performance and their limitations.

Introduction and objective of course
J. Walz, Marseille (FR)

Diagnosis of prostate cancer:

Standardization, acquisition and reporting of multiparametric MRI
I.G. Schoots, Rotterdam (NL)

Reading of a prostate MRI and use of MRI for diagnosis of prostate cancer
I.G. Schoots, Rotterdam (NL)

MRI guided biopsy and image fusion (mp MRI and Ultrasound)
J. Walz, Marseille (FR)

What are possible alternatives to multiparametric MRI?
J. Walz, Marseille (FR)

Staging of prostate cancer:

Staging with CT, MRI and bone scintigraphy
P.J.L. De Visschere, Ghent (BE)

MRI in local staging of prostate cancer
P.J.L. De Visschere, Ghent (BE)

Recurrent disease:

Use of PET in the management of prostate cancer (initial staging and recurrence)
J. Walz, Marseille (FR)

MRI in detection of locally recurrent prostate cancer
P.J.L. De Visschere, Ghent (BE)
When to do imaging of the prostate? Case discussion and current practical questions
I.G. Schoots, Rotterdam (NL)
P.J.L. De Visschere, Ghent (BE)
J. Walz, Marseille (FR)

Closure and evaluation
Advanced course on urethral stricture surgery
ESU Course 40

[43x772]Sunday 17 March
14:30 - 17:30

Location: Green Area, Room 23
Chair: R. Inman, Sheffield (GB)

Aims and objectives of this session
The advanced urethral stricture course will cover the assessment and surgical treatment of strictures of the penile, bulbar and posterior urethra. General principles of assessment and follow up, oral mucosa harvest and complications will be reviewed with evidence. Techniques of penile, bulbar and full length urethroplasty will be discussed and compared and cases reviewed with audience participation encouraged. Pelvic fracture urethral injuries will also be discussed together with management techniques. Female urethroplasty will also be discussed and assessed. Prior knowledge of relevant anatomy and basic endoscopic techniques will be helpful to those attending the course.

Introduction
R. Inman, Sheffield (GB)

General principles in urethral stricture surgery and cases
P. Nyirády, Budapest (HU)

Penile urethroplasty and cases
R. Inman, Sheffield (GB)

Bulbar and full length urethroplasty and cases
R. Inman, Sheffield (GB)

Posterior urethroplasty and cases
L. Martínez Piñeiro, Madrid (ES)

Female urethroplasty
R. Inman, Sheffield (GB)
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

---

**Introduction**

C.M. Scoffone, Turin (IT)
P.J.S. Osther, Fredericia (DK)

**PT247**

**Effect of payer status on perioperative outcomes and costs associated with elective therapy for nephroureterolithiasis**

By: Friedlander D.F., Krimphove M.J., Cole A.P., Marchese M., Ortega G., Trinh Q-D.

1Brigham and Women's Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America,
2Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America,
3Brigham and Women's Hospital, Harvard Medical School, Center For Surgery and Public Health, Boston, United States of America

**PT248**

**Development and validation of the prediction nomogram for a stone episode**

By: Hatakeyama S., Imai A., Hamano I., Tanaka T., Yoneyama T., Yamamoto H., Yoneyama T., Hashimoto Y., Nakaji S., Ohyama C.

1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,
2Hirosaki University Graduate School of Medicine, Social Medicine, Hirosaki, Japan

**PT251**

**Measuring hounsfield units in cystinuria: Is it really so hard?**

By: Warren H., Thomas K., Poon D., Srinivasan R., Rottenberg G., Bultitude M., Thomas K.

1Guy’s and St. Thomas’ NHS Foundation Trust, Urology Centre, London, United Kingdom,
2Guy’s and St. Thomas’ NHS Foundation Trust, Dept. of Radiology, London, United Kingdom

**PT252**

**Budget impact analysis to support the decision between replacing reusable flexible ureteroscopes by single use devices and adopting a hybrid strategy for the**
PT254  
**In vitro and in vivo new evidence for flexor vue deflecting endoscopic system use: Optimization of the stone free rate (sfr) after rirs**

By: Saita A.R. 1, Villa L. 2, Paciotti M. 1, Fasulo V. 1, Casale P. 1, Lughezzani G. 1, Buffi N.M. 1, Hurle R. 1, Domanico L. 1, Bevilacqua G. 1, Peschechera R. 1, Lazzeri M. 1, Guazzoni G. 1

1Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, 2San Raffaele Hospital, Dept. of Urology, Rozzano, Italy

PT255  
**Protective effect of lead curtain on radiation exposure to the operator during ureteroscopy**

By: Denis E. 1, Abid N. 2

1CH St Joseph St Luc, Dept. of Urology, Lyon, France, 2Hôpital Edouard Herriot, Dept. of Urology, Lyon, France

PT256  
**China Medical University Hospital – Post Ureteral Lithotripsy Sepsis Evaluation Score (CMUH-PULSE score) is a brand new tool to precise predict postoperative sepsis rate resulting from ureteroscopic lithotripsy (URSL)**

By: Laih C.Y. 1, Lai C.M 2, Hsiao P.J 1, Huang C.P 1, Chou C.L 1, Chang C.H 1

1China Medical University Hospital, Dept. of Urology, Taichung, Taiwan, 2University of California Davis, Dept. of Computer Science, Davis, United States of America

PT257  
**Significance of albumin to globulin ratio as a predictor of febrile urinary tract infection after ureteroscopic lithotripsy**

By: Choi S.H. 1, Ha Y. 1, Kim B.S. 1, Yoo E.S. 1, Chung S.K. 1, Min K. 2, Chung J-W. 2, Lee J.N. 2, Kim H.T. 2, Kim T. 2, Kwon T.G. 2

1Kyungpook National University Hospital, Dept. of Urology, Daegu, Korea, South, 2Kyungpook National University Chilgok Hospital, Dept. of Urology, Daegu, Korea, South

PT258  
**Role of cultural analysis in patients with indwelling ureteral stent submitted to ureteroscopy for stones**

By: Carobbio F. 1, Zamboni S. 1, Lattarulo M. 1, D’aietti D. 1, Cristinelli L. 1, Van Hauwermeiren E. 2, Moroni A. 1, Antonelli A. 1, Simeone C. 1

1Spedali Civili Hospital of Brescia, University of Brescia, Dept. of Urology, Brescia, Italy, 2Spedali Civili Hospital of Brescia, University of Brescia, Dept. of Infectious Diseases, Brescia, Italy
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT259</td>
<td>Prospective evaluation and classification of ureteroscopic findings of impacted calculi</td>
<td>By: Hamamoto S.¹, Sugino T.¹, Taguchi K.¹, Ando R.¹, Inoue T.², Okada S.³, Okada A.¹, Matsuda T.², Yasui T.⁴</td>
<td>Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, Kansai Medical University Medical Center, Dept. of Urology, Osaka, Japan, Gyotoku general Hospital, Dept. of Urology, Chiba, Japan, Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Osaka, Japan</td>
</tr>
<tr>
<td>PT260</td>
<td>Withdrawn</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>PT261</td>
<td>Emergency versus elective ureteroscopy: Retrospective analysis of 4021 cases</td>
<td>By: Malkhasyan V.A.¹, Semenyakin I.V.², Ivanov V.³, Dzhuraeva M.¹, Kasyan G.R.¹, Pushkar D.¹</td>
<td>A.I. Evdokimov Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, City clinical hospital named after S.I. Spasokukotsky, Dept. of Urology, Moscow, Russia, City Clinical Hospital named after S.I. Spasokukotsky, Dept. of Urology, Moscow, Russia</td>
</tr>
<tr>
<td>PT262</td>
<td>Comparison of primary and delayed ureteroscopy for ureteric stones: Prospective Non-Randomised comparative study</td>
<td>By: Aboumarzouk O.M.¹, Pietropaolo A.², Geraghty R.², Whitehurst L.², Kyriakides R.², Somani B.²</td>
<td>NHS Greater Glasgow and Clyde, Dept. of Urology, Glasgow, United Kingdom, University Hospitals Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom</td>
</tr>
<tr>
<td>PT263</td>
<td>Perioperative outcomes of flexible ureterorenoscopy for urolithiasis using the sheathless technique: A comparative study</td>
<td>By: Pradere B.¹, Peyronnet B.², Khene Z.E.², Freton L.², Alimi Q.², Mathieu R.², Manunta A.², Bensalah K.²</td>
<td>CHRU Tours, Dept. of Urology, Tours, France, CHU Rennes, Dept. of Urology, Rennes, France</td>
</tr>
<tr>
<td>PT264</td>
<td>Predicting ureteroscopic lithotripsy outcome by three-dimentional mean stone density</td>
<td>By: Higuchi M., Yamashita S., Takashi I., Satoshi N., Kazuro K., Yasuo K., Isao H. Wakayama medical University, Dept. of Urology, Wakayama, Japan</td>
<td></td>
</tr>
<tr>
<td>PT265</td>
<td>Rates of primary ureterorenoscopy access failure in a multiethnec Asian population</td>
<td>By: Lu J.¹, Khor V.², Loke W.T²</td>
<td></td>
</tr>
</tbody>
</table>
Role of general anesthesia versus general anesthesia with short intraoperative apnea for retrograde intrarenal surgery and for ureteroscopic laser lithotripsy for proximal ureteric stone: A single institution randomized control study

By: Panackal A.¹, Singh M.², Krishana L.², Srinivas R.²
¹Kims Oman Hospital, Dept. of Urology, Muscat, Oman, ²Kims Oman Hospital, Dept. of Anesthesia, Muscat, Oman

The S.T.O.N.E. score: A new assessment tool to predict stone free rates in ureteroscopy

By: Chaker K., Bouzouita A., Gharbi M., Chakroune M., Saadi A., Ayed H., Cherif M., Ben Slama M.R., Derouiche A., Chebil M.
Charles Nicolle Hospital, University of Tunis El Manar, Dept. of Urology, Tunis, Tunisia

When is the best time to assess the stone free rate after laser lithotripsy?

Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

Upper pole renal puncture in supine percutaneous nephrolithotomy – 9 year experience from a single tertiary stone unit

By: Moghul M., Withington J., Goyal A., Kucheria R., Allen D., Ajayi L.
Royal Free Hospital, Dept. of Urology, London, United Kingdom

Evaluation of the surgical outcome SWL, mini-PCNL and RIRS for the management of lower pole stones with a size <2cm stones: A systematic review and meta-analysis

By: Kallidonis P.¹, Kotsiris D.¹, Adamou C.¹, Ntasiotis P.¹, Somani B.², Tailly T.³, Oszoy M.⁴, Liatsikos E.¹
¹University Hospital of Patras, Dept. of Urology, Patras, Greece, ²University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ³Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria

Supine percutaneous nephrolithotomy in the obese patient

By: Moghul M., Withington J., Goyal A., Kucheria R., Allen D., Ajayi L.
Royal Free Hospital, Dept. of Urology, London, United Kingdom

Ureteroscopic assistance contributes to the safer renal puncture during endoscopic combined intrarenal surgery

By: Sugino T.¹, Hamamoto S.¹, Tanaka Y.¹, Unno R.¹, Taguchi K.¹, Ando R.¹,
<table>
<thead>
<tr>
<th>PT273</th>
<th>Should a miniature percutaneous nephrolithotomy be performed in obese patients?</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Burns H., Ahmad N., Nalagatla S.K.</td>
</tr>
<tr>
<td></td>
<td>University Hospital Monklands, Dept. of Urology, Glasgow, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT275</th>
<th>Comparison of the treatment in patients with infectious risk factors: Laparoscopic pyelolithotomy, percutaneous nephrolithotomy or retrograde intrarenal surgery.</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Lu J., Xun Y., Li C., Wang S.</td>
</tr>
<tr>
<td></td>
<td>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT276</th>
<th>Conservative treatment in small renal stones according to EAU recommendations: Long term results of a multicenter study, about 474 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Sallami S., Abou El Makarim S., Ben Atta M.</td>
</tr>
<tr>
<td></td>
<td>Mohamed Tahar Maamouri Teaching Hospital, Dept. of Urology, Nabeul, Tunisia, Oran Teaching Hospital, Dept. of Urology, Oran, Algeria</td>
</tr>
</tbody>
</table>
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

Introduction
A. De La Taille, Créteil (FR)
To be confirmed

PT280
Impact of early dorsal venous complex ligation on early urinary continence recovery after robot-assisted radical prostatectomy: Results of a pre-specified interim analysis of a randomized clinical trial

By: Montorsi F. ¹, Bravi C.A. ², Fallara G. ¹, Rosiello G. ¹, Scarcella S. ¹, D'ambrosio L. ¹, Gallina A. ¹, Scuderi S. ¹, Martini A. ¹, Mirone V. ³, Longo N. ³, Gandaglia G. ¹, Fossati N. ¹, Briganti A. ¹
¹IRCCS San Raffaele Hospital, Division of Oncology, Unit of Urology URI, Milan, Italy,
²IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology URI, Milan, Italy,
³University of Naples Federico II, Dept. of Urology, Naples, Italy

PT281
Sacrifice of accessory pudendal arteries during robot-assisted radical prostatectomy does not impact recovery of urinary continence

By: Matsushita K. ¹, Sandhu J.S. ², Narimoto K. ³, Shimbo M. ³, Endo F. ³, Hattori K. ³, Horie S. ¹
¹Juntendo University, Graduate School of Medicine, Dept. of Urology, Tokyo, Japan,
²Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America,
³St. Lukes International Hospital, Dept. of Urology, Tokyo, Japan

PT282
Defining the indications for pelvic lymph node dissection (PLND) in prostate cancer (PCa) patients within a statewide quality improvement collaborative

By: Abdollah F. ¹, Betrus G. ², Cher M. ³, Dalela D. ¹, Keeley J. ¹, Kim T. ⁴, Lane B. ⁵, Mansour S. ⁶, Montie J. ⁴, Schervish E. ⁷, Sood A. ¹, Swana K. ⁴, Peabody J. ¹, For The Michigan Urological Surgery Improvement Collaborative .. ⁴
¹Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America,
²Urology Associates of Port Huron - McLaren, Dept. of Urology, Port Huron, United States
<table>
<thead>
<tr>
<th>PT283</th>
<th>Risk of inguinal hernia repair after radical prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Ahtinen M. 1, Vironen J. 2, Murtola T. 3</td>
<td></td>
</tr>
<tr>
<td>1Tampere University Hospital, Dept. of Surgery, Tampere, Finland, 2Helsinki University Hospital, Abdominal Center, Helsinki, Finland, 3University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT284</th>
<th>The impact of high initial PSA (≥50 ng/ml) at the time of radical prostatectomy for clinically localized prostate cancer on cancer specific survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Mandel P. 1, Knipper S. 2, Chun F. 1, Steuber T. 2, Huland H. 2, Graefen M. 2, Tilki D. 2</td>
<td></td>
</tr>
<tr>
<td>1University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 2University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT285</th>
<th>Multivisceral surgery in men with locally advanced, symptomatic castration-resistant prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Heidenreich A., Porres D., Karapanos L., Salem J., Pfister D.</td>
<td></td>
</tr>
<tr>
<td>University of Cologne, Dept. of Urology, Cologne, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT286</th>
<th>Very early continence in patients undergoing radical prostatectomy and its influencing factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Theissen L.T., Preisser F., Roos F., Becker A., Chun F., Mandel P.</td>
<td></td>
</tr>
<tr>
<td>University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT287</th>
<th>Long-term outcome following radical prostatectomy; Results from the Göteborg screening trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Arnsrud Godtman R. 1, Hellstrand A. 2, Månsson M. 1, Hugosson J. 1</td>
<td></td>
</tr>
<tr>
<td>1Institute of clinical sciences, Sahlgrenska Academy, University of Göteborg, Dept. of Urology, Göteborg, Sweden, 2Örebro University, Faculty of Medicine, Örebro, Sweden</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT290</th>
<th>Facility-level variation in pelvic lymph node dissection during radical prostatectomy and effect on overall survival in men with clinically localized high-risk prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Krimphove M.J. 1, Friedlander D. 2, Cole A. 2, Lipsitz S. 3, Kluth L.A. 4, Trinh Q-D. 2</td>
<td></td>
</tr>
<tr>
<td>1Universitätsklinikum Frankfurt, Dept. of Urology, Frankfurt, Germany, 2Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America, 3Center for Surgery and Public Health, Brigham and Women's Hospital, Dept. of Surgery, Boston,</td>
<td></td>
</tr>
<tr>
<td>PT291</td>
<td>Does surgical approach have an impact on the development of symptomatic lymphoceles after radical prostatectomy and pelvic lymph node dissection?</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>By:</td>
<td>Tsaur I., Ziewers S., Thomas A., Dotzauer R., Haferkamp A., Thomas C. University Medicine Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT292</th>
<th>The impact of prostate size on the outcomes of Retzius-sparing robotic radical prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Kusuma V.R.M., Pavlakis P., Eden C. The Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT293</th>
<th>New approach to preserve male sexual function after nerve-sparing radical prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Kyzlasov P., Plekhanova O.A., Volodin D.I., Sergeev V.P. State Research Center Medical Biophysical Center FMBA, Dept. of Urology, Moscow, Russia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT294</th>
<th>Intraoperative frozen section significantly reduces positive surgical margin rates and increases frequency of nerve-sparing at radical prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Preisser F.1, Theissen L.T.1, Wild P.2, Köllermann J.2, Chun F.K-H.1, Mandel P.1</td>
</tr>
<tr>
<td></td>
<td>1University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 2University Hospital Frankfurt, Dept. of Pathology, Frankfurt, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT295</th>
<th>Oligometastatic prostate cancer: The importance of a multidisciplinary approach in a high volume robotic center</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Mistretta F.A.1, Conti A.1, Catellani M.1, Serino A.1, Delor M.1, Luzzago S.1, Cozzi G.1, Ferro M.1, Matei D.V.1, Musi G.1, Verri E.2, Jereczek-Fossa B.A.3, De Cobelli O.1</td>
</tr>
<tr>
<td></td>
<td>1European Institute of Oncology - IEO, Dept. of Urology, Milan, Italy, 2European Institute of Oncology - IEO, Dept. of Oncology, Milan, Italy, 3European Institute of Oncology - IEO, Dept. of Radiotherapy, Milan, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT298</th>
<th>Long-term functional outcomes after robotic vs. retropubic radical prostatectomy in routine care: A 6-year follow-up of a large German health services research study</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Huber J.1, Baunacke M.1, Schmidt M-L.1, Thomas C.1, Groeben C.1, Koch R.2, Chun F.3, Weissbach L.4</td>
</tr>
<tr>
<td></td>
<td>1TU Dresden, Dept. of Urology, Dresden, Germany, 2TU Dresden, Dept. of Medical Statistics and Biometry, Dresden, Germany, 3University of Frankfurt, Dept. of Urology, Frankfurt, Germany, 4Health Research for Men gGmbH, gfm, Berlin, Germany</td>
</tr>
<tr>
<td>PT299</td>
<td>Significance of time until PSA recurrence on clinical progression of surgically treated high-risk prostate cancer patients</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>By: Venclovas Z. 1, Stanionis M. 2, Matjosaitytė A.J. 1, Milonas D. 1</td>
<td></td>
</tr>
<tr>
<td>1Lithuanian University of Health Sciences, Dept. of Urology, Kaunas, Lithuania,</td>
<td></td>
</tr>
<tr>
<td>2Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT300</th>
<th>Withdrawn</th>
</tr>
</thead>
<tbody>
<tr>
<td>To be confirmed</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT302</th>
<th>Modern era robotic radical prostatectomy bias toward high volume accomplished surgeons in preeminent journals: Scientometrics</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Moretti T.B.C. 1, Magna L.A. 2, Reis L.O. 3</td>
<td></td>
</tr>
<tr>
<td>1Institute of Urology of Piracicaba, Dept. of Urology, Piracicaba, Brazil,</td>
<td></td>
</tr>
<tr>
<td>2University of Campinas, Dept. of Genetics, Campinas, Brazil,</td>
<td></td>
</tr>
<tr>
<td>3University of Campinas, Dept. of Urology, Campinas, Brazil</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT303</th>
<th>Early and long-term continence is superior after early micturition on day two after robot-assisted radical prostatectomy: A randomized prospective trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Harke N.N. 1, Wagner C. 2, Addali M. 2, Urbanova K. 2, Witt J.H. 2</td>
<td></td>
</tr>
<tr>
<td>1Essen University Hospital, Dept. of Urology, Essen, Germany,</td>
<td></td>
</tr>
<tr>
<td>2PZNW St. Antonius Hospital Gronau, Dept. of Urology, Gronau, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT306</th>
<th>Retzius-sparing vs. non-Retzius-sparing robotic-assisted radical prostatectomies: A comparative analysis of oncological outcomes of over 500 patients at a tertiary referral centre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
ESU/ESFFU Hands-on Training Course in Sacral Neuromodulation
Sponsored by MEDTRONIC

Location: Green Area, Room 7
Chairs: To be confirmed
H. Hashim, Bristol (GB)

Tutors: To be confirmed
E. Chartier-Kastler, Paris (FR)
D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)
S. Musco, Florence (IT)
S. Arlandis Guzman, Valencia (ES)
L. Thomas, Bristol (GB)
P. Van Kerrebroeck, Maastricht (NL)

Aims and objectives of this session
A practical hands-on workshop that will allow the participants to practice on models the different steps of performing sacral neuromodulation including primary percutaneous nerve evaluation, tined lead and battery implantation and programming and also troubleshooting.

• Understand the indications for SNM
• Be able to perform the different steps of the procedure in a standardized format
• Be able to troubleshoot problems with SNM
New developments in robot-assisted prostatectomy

Video Session 09

Sunday 17 March
15:45 - 17:15

Location: Red Area, eURO Auditorium 1
Chairs: R. Gaston, Bordeaux (FR)
        F. Gómez Veiga, Salamanca (ES)
        S. Nathan, London (GB)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V60
Salvage robot-assisted laparoscopic prostatectomy: Does primary treatment make a difference?

By: Önol F.F.1, Bhat S.1, Rogers T.1, Jenson C.1, Roof S.1, Rocco B.2, Patel V.1
1Florida Hospital Global Robotics Institute, Dept. of Urology, Celebration, United States of America, 2University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy

V61
The Bollens’ stitch: A modified technique for robot-assisted radical prostatectomy

1Regina Elena Hospital, Dept. of Urology, Rome, Italy, 2Université Nord de France, St. Phillibert Hospital, Dept. of Urology, Lille, France, 3Tor Vergata Hospital, Dept. of Urology, Rome, Italy, 4San Giovanni Hospital, Dept. of Urology, Rome, Italy, 5Umberto I Hospital, La Sapienza University, Dept. of Urology, Rome, Italy

V63
Initial experience with da Vinci Single Port (SP) robot-assisted radical prostatectomies

By: Agarwal D.K., Sharma V., Viers B., Frank I., Tollefson M., Gettman M.
Mayo Clinic, Dept. of Urology, Rochester, United States of America

V64
Standardized and simplified robot-assisted super-extended pelvic lymph node dissection for prostate cancer: The monoblock technique

By: Würnschimmel C., Grande P., Hyseni A., Moschini M., Baumeister P., Mordasini L., Mattei A.
Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland

V66
Innovations and techniques allowing surgical tailoring in patients with prostatic adenocarcinoma

By: Rocco B.1, Puliatti S.1, Eissa A.2, Elsherbiny A.2, Inzillo R.1, Micali S.1, De Carne C.1, Patel V.3, Bianchi G.1, Sighinolfi M.C.1
1University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, 2Tanta
University, Dept. of Urology, Faculty of Medicine, Tanta, Italy, ³Global Robotic Institute, Dept. of Urology, Orlando, United States of America
Outcomes after radiotherapy and brachytherapy

Poster Session 51

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 2
Chairs: A. Bossi, Villejuif (FR)
G. Morgia, Catania (IT)
C. Surcel, Bucharest (RO)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

715

**Hyprofractionated vs conventionally fractionated radiotherapy for prostate cancer: 7-year outcome from the Dutch HYPRO trial**

By: Wortel R.C., De Vries K., Pos F.J., Oomen-De Hoop E., Heemsbergen W.D., Incrocci L.

1 UMC Utrecht, Dept. of Urology, Utrecht, Netherlands, The
2 Erasmus MC, Dept. of Radiation Oncology, Rotterdam, Netherlands, The

716

**Comparison of self-reported acute urinary incontinence in patients treated with adjuvant or salvage post-prostatectomy intensity modulated-radiotherapy (IMRT)**


1 Ospedale Regionale U.Parini, AUSL Valle d’Aosta, Dept. of Radiotherapy, Aosta, Italy,
2 Ospedale di Ivrea, A.S.L. TO4, Dept. of Radiotherapy, Ivrea, Italy,
3 Istituto di Candiolo-Fondazione del Piemonte per l’Oncologia IRCCS, Dept. of Radiotherapy, Turin, Italy,
4 Istituto Nazionale dei Tumori Regina Elena, Dept. of Radiotherapy, Rome, Italy,
5 Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy,
6 Cliniche Gavazzeni-Humanitas GAV, Dept. of Radiotherapy, Bergamo, Italy,
7 Ospedale degli Infermi, Dept. of Radiotherapy, Biella, Italy,
8 Comprensorio Sanitario di Bolzano, Dept. of Radiotherapy, Bolzano, Italy,
9 Azienda Ospedaliero Universitaria S. Maria della Misericordia, Dept. of Radiotherapy, Udine, Italy,
10 IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy,
11 IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy

717

**Dose-effect relationship for 1-year incontinence after post-prostatectomy intensity modulated radiotherapy (MRT)**

By: Gabriele P., Cante D., Sanguineti G., Munoz F., Avuzzi B., Garibaldi E., Noris Chiorda B., Villa E., Saracino B., Girelli G., Waskiewicz J.M., Magli A.
The efficacy and feasibility of radiation therapy to the primary tumor in patients with metastatic castration resistant prostate cancer

By: Fujita N. 1, Momota M. 1, Tobisawa Y. 1, Yoneyama T. 1, Yamamoto H. 1, Imai A. 1, Hatakeyama S. 1, Ito H. 2, Yoneyama T. 1, Hashimoto Y. 1, Yoshikawa K. 3, Ohyama C. 1

1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, 3Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

External beam radiotherapy (EBRT) compared with EBRT plus HDR brachytherapy boost (EBRT+BRACHY) dose escalation for intermediate- or high-risk prostate cancer: Higher disease control and survival with lower distant metastases and toxicity

By: Guix B. 1, Bartrina J.M. 2, Guix I. 2, Tello J.I. 2, Garcia I. 2, Del Campo J.M. 2, Quinzaños L. 2, Lacorte T.M. 2, Guix T. 2, Ocaña J. 2

IMOR Foundation, Medical Institute for Onco-Radiotherapy, Dept. of Radiation Oncology, Barcelona, Spain

Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

By: Mazzone E. 1, Fossati N. 1, Karnes R.J. 2, Boorjian S.A. 2, Luca B. 2, Bossi A. 3, Di Muzio N. 4, Cozzarini C. 4, Noris Chiorda B. 4, Gandaglia G. 1, Scuderi S. 1, Bartkowiak D. 5, Böhmer D. 6, Shariat S. 7, Goldner G. 8, Battaglia A. 9, Joniau S. 9, Haustermans K. 10, De Meerleer G. 10, Fonteyne V. 11, Ost P. 11, Van Poppel H. 9, Montorsi F. 1, Wiegel T. 5, Briganti A. 1

1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Gustave Roussy
Clinical result of helical tomotherapy for high-risk and very high-risk prostate cancer at single institution

By: Tsukuda F. 1, Horiguchi Y. 2, Ogata A. 1, Sakamoto N. 2, Koga S. 1, Hama Y. 3
1Edogawa Hospital, Transplantation and Regenerative Medicine Center, Dept. of Urology, Tokyo, Japan, 2Edogawa Hospital, Dept. of Urology, Tokyo, Japan, 3Edogawa Hospital, Tokyo Edogawa Cancer Center, Dept. of Radiology, Tokyo, Japan

Comparison of the oncologic outcomes of men with high risk prostate cancer treated with either I-125 or Pd-103 brachytherapy

By: Skouteris V. 1, Stock R. 2, Dounis A. 1, Koutsouveli E. 1, Katsochi D. 1, Kollias G. 1, Skouteris M. 1, Metsinis M. 1, Stone N. 3
1Hygeia Brachytherapy Center, Dept. of Urology, Athens, Greece, 2The Icahn School of Medicine at Mount Sinai, Dept. of Radiation Oncology, New York, United States of America, 3The Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America

Persistent under-utilization of adjuvant radiotherapy in patients with adverse pathological features at radical prostatectomy: A national cancer database (NCDB) analysis

By: Rakic N. 1, Fotouhi A. 2, Baumgarten L. 1, Borchert A. 1, Dalela D. 1, Sood A. 1, Arora S. 1, Menon M. 1, Abdollah F. 1
1Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, 2Wayne State University, School of Medicine, Detroit, United States of America

Identification of differentially expressed genes to predict radioresistant prostate carcinomas

By: Nestler T. 1, Wittersheim M. 2, Hellmich M. 3, Pfister D. 1, Odenthal M. 2, Büttner R. 2, Schäfer S. 2, Heidenreich A. 1
1University Hospital of Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany, 2University Hospital of Cologne, Institute of Pathology, Cologne, Germany, 3University of Cologne, Institute of Medical Statistics and Computational Biology, Cologne, Germany

Biochemical control of a combination of cyclooxygenase-2 inhibitor and 125I-brachytherapy in an open-labeled controlled randomized trial as a secondary endpoint
**Comparison of the morbidity in men with intermediate and high-risk prostate cancer treated with either I-125 or Pd-103 brachytherapy combined with external beam irradiation**

By: Stone N.¹, Skouteris V.², Dounis A.², Koutsouveli E.³, Katsochi D.³, Kollias G.³, Skouteris M.², Metsinis M.², Stock R.⁴

¹The Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ²Hygeia Brachytherapy Center, Dept. of Urology, Athens, Greece, ³Hygeia Brachytherapy Center, Dept. of Radiation Oncology, Athens, Greece, ⁴The Icahn School of Medicine at Mount Sinai, Dept. of Radiation Oncology, New York, United States of America

**High detection rate of colorectal cancer in scheduled serial total colonoscopy screening after radiation therapy for prostate cancer**

By: Nakamura Y., Kageyama Y., Soma T., Aoki Y., Fukui N., Sakai Y.

Saitama Cancer Center, Dept. of Urology, Saitama, Japan

**Is external beam radiotherapy for prostate cancer a risk factor for bladder or rectal cancer?**

By: Mekayten M.¹, Duvdevani M.¹, Yutkin V.¹, Pode D.¹, Hidas G.¹, Landau E.H.¹, Youssef F.¹, Cohn Y.¹, Gielchinsky I.¹, Lorber A.¹, Sapir E.², Meirovitz A.², Gofrit O.N.¹, Wygoda M.²

¹Hadassah Hebrew University Medical Center, Dept. of Urology, Jerusalem, Israel, ²Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel

**Prostate cancer as a risk factor for bladder carcinoma**

By: Rinott Mizrahi G., Friedman B., Boyarsky L., Rani Z., Orlin I., Yasinov F., Fares G., Stein A., Dekel Y.

Carmel Medical Center, Dept. of Urology, Haifa, Israel
**Innovations in the diagnosis and management of upper tract urothelial carcinoma**

**Poster Session 52**

**Sunday 17 March**
**15:45 - 17:15**

**Location:** Green Area, Room 3

**Chairs:**
- F. Audenet, Paris (FR)
- P. Black, Vancouver (CA)
- A. Kolodziej, Wroclaw (PL)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 731

**Parallels between immunohistochemical classification of upper and lower tract urothelial carcinoma using markers of urothelial differentiation**

By: Hayashi T.¹, Sentani K.², Ikeda K.³, Goto K.¹, Oo H.Z.³, Abdi H.⁴, Shinmei S.¹, Inoue S.¹, Teishima J.¹, Yasui W.², Black P.C.³, Matsubara A.¹

¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, ³Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, ⁴University of Ottawa, Dept. of Urology, Ottawa, Canada

732

**The relationship of expression of programmed cell death 1 ligand 1 (PD-L1) in cancer and extent of tumor infiltrating mononuclear cell (TIMC) to clinicopathological factors in upper tract urothelial carcinoma**


Dokkyo Medical University, Dept. of Urology, Mibu, Japan

733

**Can quantitative computed tomography texture analysis be used for evaluating stage and histologic grade of upper tract urothelial carcinoma?**

By: Goujon A.¹, Khene Z.E.¹, Thenault R.¹, El Akri M.¹, Bensalah K.¹, Shariat S.F.², Acosta O.³, De Crevoisier R.⁴, Mathieu R.¹

¹CHU Pontchaillou, Dept. of Urology, Rennes, France, ²Vienna General Hospital, Dept. of Urology, Vienna, Austria, ³Rennes 1 university, LTSI, Inserm U1099, Rennes, France, ⁴Centre Eugene Marquis, Radiotherapy, Rennes, France

734

**Selective cytology in detection of high grade upper urinary tract urothelial cancer: A systematic review and meta-analysis**

By: Pones M.¹, Abufaraj M.¹, Förster B.¹, D’andrea D.¹, Soria F.¹, Qteishat A.², Gandaglia G.³, Briganti A.³, Shariat S.¹

¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Princess Alexandra
Hospital NHS Trust, Dept. of Urology, Harlow, United Kingdom, 3Urological Research Institute IRCCS, Unit of Urology, Division of Oncology, Milan, Italy

736

**Lower urinary pH increases the risk of upper tract urothelial carcinoma development in patients with non-muscle invasive bladder cancer**

By: Ide H., Kikuchi E., Naoya N., Ogihara K., Masuda T., Baba Y., Oya M. Keio University, Dept. of Urology, Tokyo, Japan

737

**Diagnostic value of FDG-positron emission tomography (PET/CT) for lymph node staging in patients with upper tract urothelial carcinoma (UTUC)**


1Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, Netherlands, The, 2Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, 3UZ Leuven, Dept. of Urology, Leuven, Belgium, 4Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 5Moffitt Cancer Center, Dept. of Genitourinary Oncology, Tampa, United States of America, 6Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, 7UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, 8Aarhus University Hospital, Dept. of Nuclear Medicine and PET-Centre, Aarhus, Denmark, 9Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Biometrics, Amsterdam, Netherlands, The, 10Medical University of Vienna, Dept. of Urology, Vienna, Austria, 11Bichat Hospital Paris Descartes University, Dept. of Urology, Paris, France, 12Bichat Hospital Paris Descartes University, Dept. of Urology, Roskilde, Denmark, 13Seoul National University Hospital, Dept. of Urology, Yongon Dong, Korea, South, 14Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, Netherlands, The

738

**Evaluation of sarcopenia in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A study from the young academic urologists urothelial carcinoma group of the European association of urology**


1CHRU Lille, Dept. of Urology, Lille, France, 2CHU Toulouse, Dept. of Urology, Toulouse, France, 3Bichat Claude Bernard Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 4Ruhr-University Bochum, Marien Hospital, Dept. of Urology, Herne, Germany, 5University Medical Center Rostock, Dept. of Urology, Rostock, Germany, 6Cochin Hospital, Paris Descartes University, Dept. of Oncology, Paris, France, 7Institut Bergonié, Dept. of Radiation Therapy, Bordeaux, France, 8University Hospital Zürich, University of Zürich, Dept. of Urology, Zürich, Switzerland, 9Luzerner Kantons spitale, Dept. of Urology, Luzerne, Switzerland, 10University of Bern, Dept. of Urology, Bern, Switzerland, 11Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical
739 NBI versus white light digital flexible ureteroscopy in transitional renal cell carcinoma – An evidence-based, prospective, pathology-blinded comparison

By: Geavlete B., Multescu R., Georgescu D., Moldoveanu C., Ene C., Bulai C., Balan G., Ene A., Geavlete P.
Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania

740 Algorithms predicting ≥pT2 and ≥pT3 upper tract urothelial cancer incorporating diffusion-weighted MRI

By: Koga F., Sakamoto K., Takemura K., Suzuki H., Kataoka M., Ito M., Nakanishi Y., Tobisu K.
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan

741 The American Joint Committee on Cancer prognostic groups for prediction of patients treated with surgery for invasive upper tract urothelial carcinoma

By: Li Z., Li X., Han H., Zhou F., Xiao K.
1 Shenzhen People’s Hospital, Dept. of Urology, Shenzhen, China, 2 The Seventh Affiliated Hospital, Sun Yat-sen University, Dept. of Oncology, Shenzhen, China, 3 Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China

742 Serum cytokeratin 19 fragments: A novel useful postoperative prognostic marker in patients with upper urinary tract urothelial carcinoma

By: Endo Y.E., Kimura G., Akatsuka A., Obayashi K., Sano M., Takeda H., Hayashi T., Kondo Y.
Nippon Medical School Hospital, Dept. of Urology, Tokyo, Japan

743 Adjuvant single-dose upper urinary tract instillation of mitomycin-C after therapeutic ureteroscopy for upper tract urothelial carcinoma: Preliminary results

Fundació Puigvert, Dept. of Urology, Barcelona, Spain
Validation of primary aldosteronism (PA) discrimination score for confirmatory tests of PA

By: Yamamoto H.¹, Hatakeyama S.², Okita K.², Konishi S.², Matsumoto T.², Fujita N.², Suzuki Y.², Yoneyama T.², Imai A.², Yoneyama T.², Hashimoto Y.², Takayasu S.³, Nakaji S.⁴, Ohyama C.²
¹Afghanistan, ²Hirosaki University, Dept. of Urology, Hirosaki, Japan, ³Hirosaki University, Endocrinology and Metabolism, Hirosaki, Japan, ⁴Hirosaki University, Social Medicine, Hirosaki, Japan

Prediction of adrenal pathology in patients with primary aldosteronism

By: Nishimoto K.¹, Hayashi T.², Araki R.³, Seki T.⁴, Yasuda M.⁵, Umakoshi H.⁶, Naruse M.⁶
¹Saitama Medical University, International Medical Center, Dept. of Uro-Oncology, Saitama, Japan, ²Saitama Medical University, International Medical Center, Dept. of Urology, Saitama, Japan, ³Saitama Medical University, International Medical Center, Community Health Science Center, Saitama, Japan, ⁴California University of Science and Medicine, School of Medicine, Dept. of Physiology and Medical Education, San Bernardino, United States of America, ⁵Saitama Medical University, International Medical Center, Dept. of Pathology, Saitama, Japan, ⁶Kyoto Medical Center, Dept. of Endocrinology and Metabolism, Kyoto, Japan

Laparoscopic adrenalectomy: Surgical technique, tips and tricks

By: Del Pozo Jiménez G., Castillón Vela I., Rengifo Abbad D., Turo Antona J., Rodríguez Reina G., Rodríguez Monsalve M., Carballido Rodríguez J. H.U.Puerta de Hierro, Dept. of Urology, Madrid, Spain

Permanent flank bulge after kidney surgery: Patient- and physician-reported outcomes of ten years

By: Kranz J.¹, Wussow F.², Grundl S.¹, Schneidewind L.³, Steffens J.¹
1St.-Antonius Hospital, Dept. of Urology, Eschweiler, Germany, 2Bethlehem Gesundheitszentrum, Dept. of Gynaecology, Stolber, Germany, 3Universitätsmedizin Greifswald, Clinic for Internal Medicine C, Haematology and Oncology, Greifswald, Germany

750

Changes in circulating blood volume measured by pulse dye-densitometry during preoperative management with an α-blocker in patients with pheochromocytoma

By: Miyaji Y. 1, Maeshima K. 2, Kido E. 2, Kawamoto Y. 2, Tsukimori S. 1, Kaifu M. 1, Sanada J. 3, Hara R. 1, Fujii T. 1, Nakatsuka H. 2, Mune T. 3, Nagai A. 1

1Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan, 2Kawasaki Medical School, Dept. of Anesthesiology, Kurashiki, Japan, 3Kawasaki Medical School, Division of Diabetes, Endocrinology and Metabolism, Kurashiki, Japan

752

Impact of multimodal salvage therapy on survival in patients with recurrent adrenocortical carcinoma


Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

753

The safety and efficacy of anatomical retroperitoneoscopic approach vs intra-adipose capsule approach via adrenalectomy


The First Affiliated Hospital Of Dalian Medical University, Dept. of Urology, Dalian, China

754

Comparison of robot-assisted adrenalectomy with traditional laparoscopic adrenalectomy: Perioperative and pathologic outcomes

By: Ji C., Lu Q., Guo H.

Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Nanjing, China

V92

Robotic assisted adrenalectomy for a malignant adrenal tumor

By: Papadoukakis S. 1, Nellas S. 1, Frangou E. 2, Horstmann M. 1

1MKH St. Josefshospital, Dept. of Urology, Krefeld, Germany, 2MKH St. Josefshospital, Dept. of Pathology, Krefeld, Germany
### Surgical aspects of kidney transplantation focusing on robotic laparoscopy

**Poster Session 54**

**Location:** Green Area, Room 5

**Chairs:**
- A. Alcaraz, Barcelona (ES)
- To be confirmed
- To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

#### 755

**Increasing kidneys grafts for transplantation**

By: Musquera M.¹, Sierra Del Rio A.¹, Peri L.¹, Paredes D.², Mercader Barrull C.¹, Pérez M.¹, Esforzado N.³, Sebastià M.C.⁴, Ribal M.J.¹, Revueltas N.³, Alcaraz Asensio A.¹

¹Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain,
²Hospital Clínic de Barcelona, Donation Unit, Barcelona, Spain,
³Hospital Clínic de Barcelona, Renal Transplant Unit, Barcelona, Spain,
⁴Hospital Clínic de Barcelona, Dept. of Radiology, Barcelona, Spain

#### 756

**Effectiveness and harms of using kidneys with small renal tumors from deceased or living donors as a source of renal transplantation: A systematic review**

By: Hevia Palacios V.¹, Hassan Zakri R.², Fraser Taylor C.³, Bruins H.M.⁴, Boissier R.⁵, Lledo E.⁶, Regele H.⁷, Budde K.⁸, Figueiredo A.⁹, Breda A.¹⁰

¹Hospital Universitario Ramón y Cajal, Dept. of Urology and Kidney Transplant, Madrid, Spain,
²Guy’s & St Thomas’ NHS Trust Hospitals, Dept. of Urology and Transplant, London, United Kingdom,
³St Georges NHS Trust Hospitals, Dept. of Urology and Transplant, London, United Kingdom,
⁴Radboudumc, Dept. of Urology, Nijmegen, Netherlands,
⁵La Conception University Hospital, Aix-Marseille University, Dept. of Urology and Transplant, Marseille, France,
⁶Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain,
⁷Clinical Institute of Pathology, Medical University of Vienna, Dept. of Pathology, Vienna, Austria,
⁸Charité Medical University Berlin, Dept. of Nephrology, Berlin, Germany,
⁹Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal,
¹⁰Fundacion Puigvert, Dept. of Urology, Barcelona, Spain

#### *757

**Robotic assisted kidney transplantation: Update from the ERUS series**

By: Musquera Felipe M.¹, Peri L.¹, Ajami T.¹, Breda A.², Territo A.², Campi R.³, Semin S.³, Tugcu V.⁴, Decasestecker K.⁵, Janssen M.⁶, Stockle M.⁶, Fornara P.⁷, Doumerc N.⁸, Alcaraz A.¹

¹Scientific Programme - EAU19 Barcelona
Prospective propensity matched non-randomized comparison between open and robot-assisted kidney transplantation

By: Kumar A., Maheshwari R., Chaturvedi S., Desai P., Gaur P., Rakhu L.R., Qadri S., Banerjee K.
Max Healthcare, Dept. of Urology, Uro-Oncology, Robotics and Renal Transplantation, New Delhi, India

Results of the 50 first cases of robotic assisted kidney transplantation compared to matched-pair open cases

By: Musquera Felip M., Ajami Fardoun T., Peri Cusi L., D’anna M., Izquierdo Reyes L., Diekman F., Alcaraz Asensio A.
1Hospital Clinic de Barcelona, Dept. of Urology, Barcelona, Spain, 2Hospital Clinic de Barcelona, Dept. of Nephrology, Barcelona, Spain

Robotic kidney transplant using renal grafts with multiple renal arteries has outcomes comparable to grafts with single artery

Medanta the Medicity, Dept. of Urology and Robotic Surgery, Gurgaon, India

Robotic kidney transplantation from living and deceased donors in a referral academic centre: Technical nuances and preliminary results

1University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, 2University of Florence, Careggi Hospital, Dept. of Nephrology, Florence, Italy, 3University of Florence, Careggi Hospital, Intensive Care Unit and Regional ECMO Referral Centre, Florence, Italy, 4Fundación Puigvert, University Autonoma of Barcelona, Dept. of Urology, Barcelona, Spain

Robot-assisted kidney transplantation in the obese: Result at 2 years of the first French series

By: Lesourd M., Beauval J-B., Sallusto F., Kamar N., Soulié M., Gamé X., Rischmann P., Roumiguié M., Doumerc N.
1CHU Rangueil Toulouse, Dept. of Urology, Toulouse, France, 2CHU Rangueil Toulouse, Dept. of Nephrology, Toulouse, France
Prospective comparative study on robot-assisted vs open kidney transplantation: Trend to less perioperative inflammatory response and similar functional results

By: Territo A. 1, Subiela J.D. 1, Theil G. 2, Gausa L. 1, Regis F. 1, Boissier R. 3, Nasr El Din M. 2, Fornara P. 2, Gallioli A. 1, Guirado L. 4, Breda A. 1
1 Fundació Puigvert, Autonoma University of Barcelona, Dept. of Urology, Barcelona, Spain, 2 University Hospital Halle, Dept. of Urology, Halle, Germany, 3 Aix-Marseille Université, APHM, Nord Academic Hospital, Dept. of Urology, Marseille, France, 4 Fundació Puigvert, Autonoma University of Barcelona, Dept. of Nephrology, Barcelona, Spain

Sixteen years after the first laparoscopic living donor nephrectomy

By: Musquera M. 1, D’Anna M. 1, Peri L. 1, Ajami T. 1, Ribal M.J. 1, Álvarez-Vijande R. 1, Huguet J. 2, Izquierdo L. 1, Vilaseca A. 1, Martos R. 1, Diekmann F. 3, Alcaraz A. 1
1 Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain, 2 Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 3 Hospital Clínic de Barcelona, Dept. of Nephrology, Barcelona, Spain

Interest of intraoperative heparin therapy during renal transplantation after donor-living nephrectomy

To be confirmed

Magnetic Black-Star® double J stent in kidney transplantation: Is it worthy?

By: Sallusto F. 1, Rischmann P. 1, Prudhomme T. 1, Labadens I. 2, Danet C. 2, Game X. 1, Doumerc N. 1, Huyghe E. 1, Roumigue M. 1, Beauval J.B 1, Delaunay B. 1, Laclergerie F. 1, Benoit T. 1, Thoulouzan M. 1, Gryn A. 1, Roulette P. 1, Binhazza M. 1, Moreau C. 3, Kamar N. 4, Soulie M. 1
1 Rangueil University Hospital, Dept. of Urology, Kidney Transplantation and Andrology, Toulouse, France, 2 Rangueil University Hospital, Dept. of Pharmacology, Toulouse, France, 3 Rangueil University Hospital, Ambulatory Care Nurse Unit, Toulouse, France, 4 Rangueil University Hospital, Dept. of Nephrology, Multiorgan Transplantation and Dialysis, Toulouse, France

Summary

A. Alcaraz, Barcelona (ES)
Imaging-guided approaches for the treatment of recurrent prostate cancer
Poster Session 55

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 10

Chairs: T. Steuber, Hamburg (DE)
J.P. Sweeney, Cork (IE)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

Long-term oncologic outcomes of patients treated with salvage lymph node dissection for nodal recurrence of prostate cancer: Results from a large, multi-institutional series


1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3University of Cologne, Dept. of Urology, Cologne, Germany, 4Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 5University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 6University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Kiel, Germany, 7Heinrich-Heine-University Medical Faculty, Dept. of Urology, Düsseldorf, Germany, 8Medical University of Vienna, Dept. of Urology, Vienna, Austria, 9University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 10University of Southern California, USC Institute of Urology, Los Angeles, United States of America, 11OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium

Mapping of site-specific relapse in patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 or 11C-Choline PET/CT: Impact of postoperative androgen deprivation therapy and radiotherapy

By: Devos G.1, Witters M.1, Raskin Y.1, Everaerts W.1, Van Poppel H.1, Tosco L.2, De Meerleer G.3, Goffin K.4, Joniau S.1

1University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 2Humanitas Gradenigo Hospital, Dept. of Urology, Turin, Italy, 3University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, 4University Hospitals Leuven, Dept. of Nuclear Medicine, Leuven, Belgium
Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis


1Ghent University Hospital, Dept. of Urology, Ghent, Belgium, 2University of Milan, Dept. of Oncology and Hemato-oncology, Milan, Italy, 3Centre Oscar Lambret, Dept. of Radiation Oncology, Lille, France, 4University Hospital Geneva, Dept. of Radiation Oncology, Geneva, Switzerland, 5The Royal Marsden NHS Foundation Trust, Dept. of Radiation Oncology, London, United Kingdom, 6Peter MacCallum Cancer Centre, Dept. of Radiation Oncology, Melbourne, Australia, 7San Raffaele Scientific Institute, Dept. of Radiation Oncology, Milan, Italy, 8Iridium Cancer Network, Dept. of Radiation Oncology, Antwerp, Belgium, 9Hospital de Cruces, Dept. of Radiation Oncology, Barakaldo, Spain, 10Azienda Ospedaliera Santa Maria Di Terni, Dept. of Radiation Oncology, Terni, Italy, 11Azienda Ospedaliera, Universitaria Careggi, Dept. of Radiation Oncology, Florence, Italy, 12Tor Vergata General Hospital, Dept. of Diagnostic imaging, Molecular imaging, Interventional radiology and Radiotherapy, Rome, Italy, 13University and Spedali Civili Hospital, Dept. of Radiation Oncology, Brescia, Italy, 14University Hospital of Modena, Dept. of Oncology and Hematology, Radiotherapy unit, Modena, Italy, 15Ospedale Sacro Cuore-Don calabria, Dept. of Radiation Oncology, Verona, Italy, 16University of Ghent, Dept. of Applied Mathematics, Computer Science and Statistics, Ghent, Belgium, 17Ghent University Hospital, Dept. of Radiotherapy and Experimental Cancer Research, Ghent, Belgium, 18European Institute of Oncology, Dept. of Radiation Oncology, Milan, Italy, 19University of Ghent, Applied Mathematics, Computer Science and Statistics, Ghent, Belgium, 20Ghent University Hospital, Radiotherapy and Experimental Cancer Research, Ghent, Belgium.

Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series


1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3University of Cologne, Dept. of Urology, Cologne, Germany, 4Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 5University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 6University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Kiel, Germany, 7Medical University of Vienna, Dept. of Urology, Vienna, Austria, 8Heinrich-Heine-University Medical Faculty, Dept. of Urology, Düsseldorf, Germany, 9University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 10University of Southern California, USC Institute of Urology, Los Angeles, United States of America, 11OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium, 12University of...
Metastases-yield and PSA-kinetics following salvage lymph node dissection for prostate cancer: A comparison between conventional surgical approach and PSMA-radioguided surgery

By: Knipper S.1, Tilki D.1, Mansholt J.1, Berliner C.2, Bernreuther C.2, Steuber T.1, Maurer T.1, Graefen M.1
1Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, 2University Hospital Hamburg-Eppendorf, Dept. of Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg, Germany

68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy at low PSA values ≤ 0.5 ng/ml

By: Kranzbühler B.1, Müller J.2, Becker A.3, Garcia Schüler H.4, Fankhauser C.1, Guckenberger M.4, Kaufmann P.2, Eberli D.1, Burger I.2
1University Hospital Zürich, Dept. of Urology, Zurich, Switzerland, 2University Hospital Zürich, Dept. of Nuclear Medicine, Zurich, Switzerland, 3University Hospital Zürich, Dept. of Radiology, Zurich, Switzerland, 4University Hospital Zürich, Dept. of Radiation Oncology, Zurich, Switzerland

Comparing the diagnostic accuracy of 68Ga-PSMA and 11C-Choline PET/CT scan according to PSA level: A large multi-institutional analysis with histological verification in patients treated with salvage lymph node dissection for recurrent prostate cancer

1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3University of Cologne, Dept. of Urology, Cologne, Germany, 4Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 5University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 6University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Kiel, Germany, 7Medical University of Vienna, Dept. of Urology, Vienna, Austria, 8Heinrich-Heine-University Medical Faculty, Dept. of Urology, Düsseldorf, Germany,
776

Open and robotic salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: Morbidity and functional outcomes from a large multicenter series


1 San Giovanni Battista Hospital, Dept. of Surgical Sciences, Urology, Turin, Italy, 2 University of Turin, Dept. of Statistics, Turin, Italy, 3 Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, 4 Guy’s Hospital, Dept. of Urology, London, United Kingdom, 5 Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, 6 Bristol NHS Foundation Trust, Dept. of Urology, Bristol, United Kingdom, 7 Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 8 Leuven University Hospitals, Dept. of Urology, Leuven, Belgium, 9 Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, 10 CHU Mondor, Dept. of Urology, Créteil, France, 11 Sorbonne Université, Hôpital Pitié-Salpêtrière, GRC n°5, Oncotype-URO, AP-HP, Paris, France, 12 Institut Jules Bordet, Université Libre de Bruxelles, Dept. of Urology, Bruxelles, Belgium, 13 Mayo Clinic, Dept. of Urology, Rochester, MN, United States of America, 14 OLV Hospital, Dept. of Urology, Aalst, Belgium, 15 Vanderbilt University, Medical Center North, Dept. of Urology, Nashville, TN, United States of America, 16 USC Norris Comprehensive Cancer Center and Hospital, University of Southern California, Dept. of Urology, Los Angeles, CA, United States of America, 17 University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 18 Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Victoria, Australia, 19 The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, TX, United States of America

777

Robotic assisted radical prostatectomy after focal therapy: Oncological and functional outcomes


1 Guys and St Thomas NHS Foundation Trust, Urology Centre, London, United Kingdom, 2 Kings College Hospital, Dept. of Urology, London, United Kingdom, 3 Institut Mutualiste Montsouris, Université Paris-Descartes, Dept. of Urology, Paris, France, 4 University College London Hospitals (UCLH), Dept. of Urology, London, United Kingdom, 5 Imperial College London, Dept. of Urology, London, United Kingdom, 6 Faculty of Medical Sciences, University College London, Dept. of Surgery and Interventional Science, London, United Kingdom

778

Stereotactic reirradiation for local recurrence in the prostatic bed after prostatectomy: Preliminary results
Salvage irreversible electroporation for locally recurrent prostate cancer after radiotherapy – Oncologic and functional outcomes

By: Blazevski A. 1, Scheltema M.J.S. 2, Yuen B. 1, Cusick T. 2, Masand N. 2, Haynes A. 2, Stricker P.D. 1

1St. Vincent's Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, 2Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Sydney, Australia

Salvage robot-assisted laparoscopic prostatectomy: Does primary treatment make a difference?

By: Önlö F.F. 1, Bhat S. 1, Rogers T. 1, Jenson C. 1, Roof S. 1, Rocco B. 2, Patel V. 1

1Florida Hospital Global Robotics Institute, Dept. of Urology, Celebration, United States of America, 2University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy

Laparoscopic salvage lymph node dissection after radical prostatectomy: A feasible technique

By: Gerolimetto C., Sampalmieri M., Proietti F., Molinaro E., Guidotti M., Franco G., Leonardo C.

Policlinico "Umberto I", Dept. of Urology, Rome, Italy
Old and new slings and things for male incontinence

Poster Session 56

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 11

Chairs: To be confirmed
N. Thiruchelvam, Cambridge (GB)
F. Van Der Aa, Leuven (BE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

782

High vs. low volume predicts outcome in males treated with AMS 800: Results from a large mid European cohort study (DOMINO, debates on male incontinence)


1 University Hospital of Muenster, Dept. of Urology and Pediatric Urology, Muenster, Germany, 2 University Medical Center of Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, 3 Ludwig-Maximilians University Hospital, Dept. of Urology, Munich, Germany, 4 University Hospital of Bonn, Dept. of Urology, Pediatric Urology and Neurourology, Bonn, Germany, 5 University Hospital of Bonn, Dept. of Pediatric Urology and Neurourology, Bonn, Germany, 6 Vivantes Hospital Am Urban, Dept. of Urology, Berlin, Germany, 7 Lueneburg Hospital, Dept. of Urology, Lueneburg, Germany, 8 Goettlicher Heiland Hospital of Vienna, Dept. of Urology, Vienna, Austria, 9 Bethel Evangelical Hospital, Dept. of Urology, Bielefeld, Germany, 10 University Hospital of Kiel, Dept. of Urology and Pediatric Urology, Kiel, Germany, 11 Dianconal Hospital of Stuttgart, Dept. of Urology, Stuttgart, Germany, 12 University Hospital of Heidelberg, Dept. of Urology and Pediatric Urology, Heidelberg, Germany, 13 Weinviertel Korneuburg Hospital, Dept. of Urology, Korneuburg, Austria, 14 Westpfalz Medical Center, Dept. of Urology and Pediatric Urology, Kaiserslautern, Germany, 15 Prosper-Hospital, Dept. of Urology and Robotic Surgery, Recklinghausen, Germany, 16 University Hospital of Muenster, Dept. of Urology and Pediatric Urology, Muenster, Germany

783

Robot-assisted bladder neck artificial urinary sphincter implantation in male patients with neurogenic stress urinary incontinence: A multicenter study

By: Encatassamy F. 1, Hascoët J. 2, Brièrre T. 3, Manunta A. 2, Le Normand L. 1, Gamé X. 3, Peyronnet B. 2, Perrouin-Verbe M-A. 1

1 CHU de Nantes, Dept. of Urology, Nantes, France, 2 CHU de Rennes, Dept. of Urology, Rennes, France, 3 CHU de Toulouse, Dept. of Urology, Toulouse, France

784

Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy

By:
**785**

**Urinary male incontinence: Long term follow up with adjustable trans obturatory male sling**

By: **Favro M.**, Marchioro G., Vidali M., Terrone C., Volpe A.

1Maggiore della Carità Hospital, Dept. of Urology, Novara, Italy, 2Maggiore della Carità Hospital, Clinical Chemistry Unit, Novara, Italy, 3Policlinico San Martino Hospital, Dept. of Urology, Genova, Italy

**786**

**Comparing fixed and adjustable male slings for treatment of male stress urinary incontinence**


1University Medical Center of Johannes Gutenberg University, Urology and Pediatric Urology, Mainz, Germany, 2Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 3University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 4St. Bernward Hospital, Dept. of Urology, Hildesheim, Germany, 5University Hospital Bonn, Neuro-Urology/Urology and Pediatric Urology, Bonn, Germany, 6Asklepios Hospital West, Dept. of Urology, Berlin, Germany, 7Helios Hospital Duisburg, Dept. of Urology, Duisburg, Germany, 8Hospital Lüneburg, Dept. of Urology, Lüneburg, Germany, 9Barmherzige Brüder Wien, Dept. of Urology, Wien, Austria, 10St. Barbara Hospital Hamm GmbH, Dept. of Urology, Hamm, Germany, 11Diakonie Hospital Stuttgart, Dept. of Urology, Stuttgart, Germany, 12Evangelic Hospital Bielefeld, Dept. of Urology, Bielefeld, Germany, 13University Hospital Muenster, Dept. of Urology, Münster, Germany, 14University Hospital Kiel, Dept. of Urology, Kiel, Germany, 15Catholic Hospital St. Johann Nepomuk, Dept. of Urology, Erfurt, Germany, 16University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 17Diakonie Hospital Schwäbisch Hall, Dept. of Urology, Schwäbisch Hall, Germany, 18Technical University Munich, Institute of Medical Statistic and Epidemiology, Munich, Germany, 19Hospital Weinviertel Korneuburg, Dept. of Urology, Korneuburg, Austria, 20Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 21University Medical Center of Johannes Gutenberg University, Dept. of Urology, Mainz, Germany

**787**

**Artificial urinary sphincter implantation improves several storage and voiding symptoms in addition to urinary incontinence**


1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2National Cancer Center Hospital East, Dept. of Urology, Kashiwa-city, Japan, 3Tokyo Metropolitan Cancer
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>788</td>
<td>Prospective european registry for patients undergoing surgery for male stress urinary incontinence: An initial report of the registry ‘SATURN’</td>
<td>By: Van Der Aa F. 1, Heesakkers J. 2, Martens F. 2, Thiruchelvam N. 3, Bjartell A. 4, Caris C. 4, Schipper R. 4, Witjes W. 4, Hamid R. 5</td>
<td>University Hospital Leuven, Dept. of Urology, Leuven, Belgium, Radboud UMC, Dept. of Urology, Nijmegen, Netherlands, Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, EAU Research Foundation, Dept. of Clinical Research, Arnhem, Netherlands, Royal National Orthopaedic Hospital, Dept. of Neurourology, London, United Kingdom</td>
</tr>
<tr>
<td>790</td>
<td>The transfixed sub-urethral sling: A safe and effective option for all degrees of post prostatectomy urinary incontinence</td>
<td>By: Inder M.S., Sullivan J.F., Lonergan P.E., Manecksha R.P., Lynch T.H.</td>
<td>St. James's Hospital, Dept. of Urology, Dublin, Ireland</td>
</tr>
<tr>
<td>791</td>
<td>Prospective analysis of continence and complication rates of AMS 800 AUS devices for patients with a history of neurological disease</td>
<td>By: Ludwig T.A., Maurer V.M., Marks P., Rosenbaum C., Vetterlein M., Gild P., Engel O., Fisch M., Dahlem R.</td>
<td>University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany</td>
</tr>
<tr>
<td>792</td>
<td>Refillable artificial urinary sphincter ZSI 375 PF: Spanish multicentre experience</td>
<td>By: Padilla Fernandez B.Y. 1, González-López R. 2, Resel-Folkersma L. 3, Madurga-Patuel B. 4, Garde-García H. 2, Hernández-Hernández D. 1, Lorenzo-Gómez M.F. 5, Concepción-Masip T. 1, Moreno-Sierra J. 3, González-Enguita C. 2, Castro-Díaz D.M. 1</td>
<td>University Hospital of the Canary Islands, Dept. of Urology, San Cristóbal de La Laguna, Spain, Fundación Jiménez Díaz University Hospital, Dept. of Urology, Madrid, Spain, Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, University Hospital Puerta del Mar, Dept. of Urology, Cádiz, Spain, University Hospital of Salamanca, Dept. of Urology, Salamanca, Spain</td>
</tr>
<tr>
<td>793</td>
<td>Very early PFMT with indwelling catheter for post-prostatectomy incontinence, a randomized controlled trial</td>
<td>By: Filocamo M.T., Alladio F., Cordara G., Moiso A., Mondino P., Rossi R., Rosso D., Coppola P.</td>
<td>SS. Annunziata Hospital, Dept. of Urology, Savigliano, Italy</td>
</tr>
</tbody>
</table>
New imaging in urology
Poster Session 57

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 12

Chairs: M. Bertolotto, Trieste (IT)
J. Denstedt, London, Ontario (CA)
M. Ritter, Mannheim (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

795

Split renal function assessment by mathematical analysis of 3D rendering of CT scans

By: Proskura A., Alyaev Y.G., Khokhlachev S.B., Shpot E.V., Fiev D.N., Sorokin N.I. Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

798

Impact of computerized tomography for upper tract imaging and potential role of renal ultrasound in patients presenting with asymptomatic microscopic hematuria

By: Fankhauser C., Waisbrod S., Fierz C., Kranzbühler B., Wettstein M.S., Eberli D., Sulser T., Mostafid H., Hermanns T.

1University of Zurich, Dept. of Urology, Zurich, Switzerland, 2Royal Surrey County Hospital, Dept. of Urology, Surrey, United Kingdom

799

The first real time imaging of hemorrhage after bladder overdistention by wireless capsule endoscopy - Hematuria after release from acute urinary retention

By: Mizuno H., Yamamoto T., Yoko Y., Matsukawa Y., Kamihira O., Gotoh M.

1Komaki City Hospital, Dept. of Urology, Komaki, Japan, 2Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan

800

Deep learning with a convolutional neural network algorithm for automated detection of urinary tract stones using abdominal X-ray image


1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2Tsuchiura Kyodo General Hospital, Dept. of Urology, Tsuchiura, Japan, 3JA Toride Medical Center, Dept. of Urology, Toride, Japan, 4Tokyo Institute of Technology, School of Engineering, Dept. of Information and Communications Engineering, Tokyo, Japan, 5Tokyo Institute of...
The efficacy of CT scan scout film in determining the urinary stones biochemical composition

By: Levi O. 1, Elias S. 2, Bass R. 1, Sidi A.A. 1, Tsivian A. 1, Tavdy E. 1

1The Edith Wolfson Medical Center, The Sackler faculty of Medicine, Dept. of Urologic Surgery, Holon, Israel, 2The Edith Wolfson Medical Center, The Sackler faculty of Medicine, Dept. of Diagnostics Imaging, Holon, Israel

The use of dual energy computed tomograph in the identification of urinary stones in urolithiasis

By: Nazarov T., Komyakov B.K., Rychkov I.V., Lebedev D.G., Tursunov A.I., Trubnikova K.E., Lepekhina A.

North-Western State Medical University, Dept. of Urology, Saint-Petersburg, Russia

The role of bladder wall thickness in the evaluation of detrusor underactivity: Development of a clinical nomogram

By: De Nunzio C. 1, Lombardo R. 1, Carter S. 2, Tema G. 1, Nacchia A. 1, Cancrini F. 1, Sica A. 1, Vicentini C. 3, Tubaro A. 1

1Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, 2London Clinic, Dept. of Urology, London, Italy, 3University of L'Aquila, Surgical Sciences, L'Aquila, Italy

Predicting vital retroperitoneal residual tumors of metastatic testicular tumor patients after chemotherapy using radiomics

By: Nestler T. 1, Baeßler B. 2, Pinto Dos Santos D. 2, Paffenholz P. 1, Pfister D. 1, Maintz D. 2, Heidenreich A. 1

1University Hospital of Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany, 2University Hospital of Cologne, Institute of Diagnostic and Interventional Radiology, Cologne, Germany

Clinical applications of magnetic resonance imaging in urethral strictures: Preliminary report with reference to 3D-volume rendering and 3D-printed models

By: Frankiewicz M. 1, Markiet K. 2, Belka M. 3, Kozak O. 2, Krukowski J. 1, Szurowska E. 2, Matuszewski M. 1

1Medical University of Gdansk, Dept. of Urology, Gdansk, Poland, 2Medical University of Gdansk, Dept. of Radiology, Gdansk, Poland, 3Medical University of Gdansk, Dept. of Pharmaceutical Chemistry, Gdansk, Poland

17:04 - 17:08

Summary

M. Bertolotto, Trieste (IT)
Paediatric urology: The testis and specific problems

Poster Session 58

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 19

Chairs: To be confirmed
Y. Farahat, Dubai (AE)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

808

Clinical usefulness of diagnostic tool to distinguish testicular torsion from torsion of the appendix testis

By: Kodama H. 1, Hatakeyama S. 1, Yamamoto H. 1, Imai A. 1, Yoneyama T. 1, Hashimoto Y. 1, Ito H. 2, Yoshikawa K. 3, Sasaki A. 4, Takahashi S. 5, Ohyama C. 1
1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,
2Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan,
3Mutsu General Hospital, Dept. of Urology, Mutsu, Japan,
4Tsugaru General Hospital, Dept. of Urology, Goshogawara, Japan,
5Aomori City Hospital, Dept. of Urology, Aomori, Japan

809

Testicular migration through the inguinal canal: Analysis in 208 human fetuses

State University of Rio de Janeiro, Urogenital Research Unit, Rio de Janeiro, Brazil

810

Shear wave elastography evaluation of the testis in Prader-Willi syndrome

By: Matsuyama S., Matsui F., Yazawa K., Matsumoto F.
Osaka Women’s and Children’s Hospital, Dept. of Urology, Osaka, Japan

811

Testicular sparing surgery for testicular masses in the paediatric population: Current review of practice

By: Radford A. 1, Haid B. 2, Spinoit A. 3, Silay M.S. 4, Banuelos B. 5, Powis M. 6, Lakshminarayanan B. 6
1Leeds Children's Hospital, EAU Young Academic Urologists Paediatric Urology Group, Dept. of Paediatric Urology, Leeds, United Kingdom,
2Hospital of the Sisters of Charity, EAU Young Academic Urologists Paediatric Urology Group, Dept. of Paediatric Urology, Linz, Austria,
3Ghent University Hospital, EAU Young Academic Urologists, Paediatric Urology Group, Dept. of Urology, Ghent, Belgium,
4Istanbul Medeniyet University, EAU Young Academic Urologists, Paediatric Urology Group, Dept. of Urology, Istanbul, Turkey,
5Charité University Clinic, EAU Young Academic Urologists, Paediatric Urology Group, Dept. of Urology, Berlin, Germany,
6Leeds Children's Hospital, British Association of...
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>812</td>
<td>Is the Koff procedure with low spermatic vessel ligation the optimal choice for testes at the inner inguinal ring with long-looping vas?</td>
<td>By: Harms M., Haid B., Becker T., Oswald J.</td>
<td>Ordensklinikum Linz, Barmherzige Schwestern, Dept. of Pediatric Urology, Linz, Austria</td>
</tr>
<tr>
<td>814</td>
<td>Novel technique for laparoscopic orchiopexy: New route production safely method to scrotum</td>
<td>By: Naito Y., Ajiki J., Yamada Y., Shiraishi T., Fujihara A., Matsubara H., Suzuki K., Hongo F., Ukimura O.</td>
<td>Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan</td>
</tr>
<tr>
<td>816</td>
<td>Testicular atrophy after orchiopexy for congenital undescended testis: Outcomes of testicular survival by different primary locations and ages at orchiopexy</td>
<td>By: Tseng C-S., Kuo M-C., Huang K-H., Huang C-Y., Pu Y-S., Chang H-C., Chiang I-N.</td>
<td>National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan</td>
</tr>
<tr>
<td>821</td>
<td>Robot-assisted extravesical ureteral reimplantation (REVUR) for bilateral vesico-ureteral reflux in children: Results of a multicentric international survey</td>
<td>By: Esposito C., Masieri L., Steyaert H., Escolino M., Cerulo M., Cini C., Venturini S., S. Lendvay T.</td>
<td>1University of Naples Federico II, Dept. of Pediatric Surgery, Naples, Italy, 2University of Florence, Meyer Children's Hospital, Dept. of Urology, Florence, Italy, 3Université Libre de Bruxelles(ULB), Dept. of Pediatric Surgery, Brussels, Belgium, 4Seattle Children's Hospital, Dept. of Pediatric Surgery, Seattle, United States of America</td>
</tr>
<tr>
<td>822</td>
<td>Low-dose antibiotic prophylaxis has no significant impact on the stability of the intestinal microbiome in children with urogenital tract malformations under 1 year of age</td>
<td>By: Strasser C., Spindelböck W., Kashofer K., Oswald J., Haid B.</td>
<td>1Kepleruniversitätsklinikum, Dept. of Urology and Andrology, Linz, Austria, 2Medical University Graz, Dept. of Internal Medicine, Division of Gastroenterology and Hepatology, Graz, Austria, 3Medical University of Graz, Institute of Pathology, Graz, Austria, 4Hospital of the Sisters of Charity, Dept. of Paediatric Urology, Linz, Austria</td>
</tr>
</tbody>
</table>
The impact of education and surgeon burnout on quality of care and service provision
Poster Session 59

Sunday 17 March 15:45 - 17:15
Location: Green Area, Room 20
Chairs: T. Bach, Hamburg (DE)
To be confirmed
K. Dimitropoulos, Aberdeen (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

823
To what extent statistical findings in randomized controlled trials are facts? The fragility index in urological oncology literature

By: Chertin L., Zisman A., Haifler M.
Shamir (Assaf Harofeh) Medical Center, Dept. of Urology, Zerifin, Israel

825
Satisfaction with surgical training and confidence in performing surgical procedures among European urology residents

By: Carrion D.M.1, Rodriguez Socarras M.2, Mantica G.2, Esperto F.3, Duijvesz D.4, Vasquez J.L.5, Gozen A.6, Veneziano D.7, Palou J.8, Gomez Rivas J.1
1La Paz University Hospital, Dept. of Urology, Madrid, Spain, 2San Raffaele-Turro Hospital, San Raffaele University, Dept. of Urology, Milan, Italy, 3Humanitas Gavazzeni, Dept. of Urology, Bergamo, Italy, 4Erasmus Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, 5Herlev and Gentofte Hospital, Dept. of Urology, Herlev, Denmark, 6SLK-Kliniken, University of Heidelberg, Dept. of Urology, Heilbronn, Germany, 7Grande Ospedale Metropolitano, Dept. of Urology, Reggio Calabria, Italy, 8Fundacio Puigvert, University of Barcelona, Dept. of Urology, Barcelona, Spain

826
Simulation in urological training and education (SIMULATE): A randomised controlled clinical and educational trial to determine the effect of structured surgical simulation training

1King’s College London, MRC Centre for Transplantation, London, United Kingdom, 2Hokkaido University Hospital, Dept. of Urology, Sapporo, Japan, 3SLK-Kliniken, University of Heidelberg, Dept. of Urology, Heilbronn, Germany, 4University of Bern, Dept. of Urology, Bern, Switzerland, 5Sindelfingen-Bo?blingen Medical Centre, University of
Academic and scientific activity of European urology residents during their training


1 La Paz University Hospital, Dept. of Urology, Madrid, Spain, 2 San Raffaele-Turro Hospital, San Raffaele University, Dept. of Urology, Milan, Italy, 3 San Raffaele-Turro Hospital, San Raffaele University, Dept. of Urology, Milan, Spain, 4 Humanitas Gavazzeni, Dept. of Urology, Bergamo, Italy, 5 Ulm University Medical Center, Dept. of Urology, Ulm, Germany, 6 Herlev and Gentofte Hospital, Dept. of Urology, Herlev, Denmark, 7 Fundacio Puigvert, University of Barcelona, Dept. of Urology, Barcelona, Spain

Outcomes of European basic laparoscopic urological skills (EBLUS) exams: Results from European School of Urology (ESU) over 6 years (2013-2018)


1 University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, 2 University Hospital Gasthuisberg, Dept. of Urology, Leuven, Belgium, 3 SLK Klinikum Heilbronn, Dept. of Urology, Heilbronn, Germany, 4 University of Athens, Dept. of Urology, Athens, Greece, 5 St. Antonius-Hospital, Dept. of Urology, Gronau, Germany, 6 University Hospital Leicester, Dept. of Urology, Leicester, United Kingdom, 7 Erasme Hospital, Dept. of Urology, Brussels, Belgium, 8 Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 9 AG Savvas Anticancer Hospital, Dept. of Urology, Athens, Greece, 10 Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, 11 University Hospital Motol, Dept. of Urology, Prague, Czech Republic, 12 Azienda Ospedaliero-Universitaria di Careggi, Dept. of Urology, Florence, Italy, 13 Ospedale San Raffaele-Turro, Dept. of Urology, Milan, Italy, 14 Grande Ospedale Metropolitano, Dept. of Urology, Calabria, Italy

Depression and suicidal thoughts in U.S. urology residents: A national survey study

By: Marchalik D., Rodriguez A., Alger J., Lynch J., Padmore J., Krasnow R.

1 MedStar Georgetown University Hospital, Dept. of Urology, Washington, United States of America, 2 Georgetown University School of Medicine, Dept. of Urology, Washington, United States of America, 3 MedStar Health, Dept. of Physician Wellbeing, Washington, United States of America
Definition of a structured training curriculum for robot-assisted radical cystectomy: A Delphi-consensus study led by the ERUS Educational Board


Onze Lieve Vrouw Hospital, Orsi Academy, Dept. of Urology, Aalst, Belgium, Azienda Ospedaliero, Universitàtaria Pisana, Dept. of Urology, Pisa, Italy, Urological Research Institute, IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium, Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, Fundació Puigvert, Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, Royal Liverpool University Hospital, Dept. of Urology, Liverpool, United Kingdom, Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, Ankara Yildirim Beyazit University, Dept. of Urology, Ankara, Turkey, Aarhus University Hospital, Dept. of Clinical Medicine, Dept. of Urology, Aarhus, Denmark, University of Southern California Institute of Urology & Catherine and Joseph Aresty, Dept. of Urology, Los Angeles, United States of America, Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, Azienda Ospedaliera Universitaria Integrata, University of Verona, Dept. of Urology, Verona, Italy, Eberhard Karls University, Dept. of Urology, Tübingen, Germany, University College London Hospital, Dept. of Urology, London, United Kingdom, MRC Centre for Transplantation, NIHR Biomedical Research Centre, Guy's Hospital, King's College, Dept. of Urology, London, United Kingdom, Robotic Surgery, Rijnstate Hospital, Dept. of Urology, Arnhem, Netherlands, University of Southern California Institute of Urology & Catherine and Joseph Aresty, Dept. of Urology, Los Angeles, United States of America, Orsi Academy, Dept. of Urology, Aalst, Belgium

Simulation-based teaching of prostate biopsies: Predictive validity of a prostate biopsy simulator

By: Fiard G., Selmi S-Y., Maigron M., Promayon E., Descotes J-L., Troccaz J.

Grenoble University Hospital, Dept. of Urology and Kidney Transplant, Grenoble, France, TIMC-IMAG Laboratory, Dept. of GMCAO, Grenoble, France, Université Grenoble Alpes, Faculty of Medicine, Grenoble, France

Informed consent: What risks are material to patients?

By: McCauley N., Manson-Bahr D., Lane T., Clark C.

Lister Hospital Stevenage, East and North Herts Trust, Dept. of Urology, Stevenage, United Kingdom

Trainee burnout in the united states and europe: A multi-national comparative study

By: Marchalik D., Talso M., Goldman C., Carvalho F., Esperto F., Pradere B.
How does burnout affect patient outcome?
To be confirmed
**Aims and objectives of this session**

This session aims to debate on some controversial topics in the field of prostate cancer in a novel, interactive way. Each speaker will expose his or her view on the subject and then will be challenged by a multi-disciplinary jury composed by key figures involved in the clinical decision-making process of prostate cancer. Finally, the role of mp-MRI as a possible triage test before first biopsy will be discussed in terms of utility and cost-effectiveness. The session also includes the AUA lecture on prostate cancer.

**08:00 - 09:45**

**Controversies in the management of prostate cancer: The jury is out**

**08:00 - 09:45**

**Members of the jury:**

- **Jury member** Urologist from YAU (Young Academic Urologists)
  R.C.N. Van Den Bergh, Nieuwegein (NL)
- **Jury member** Geriatrician
  A. Wagg, Edmonton (CA)
- **Jury member** Psychologist
  L. Bellardita, Milano (IT)
- **Jury member** Radiation oncologist
  A. Bossi, Villejuif (FR)
- **Jury member** Urologist
  C. Stief, Munich (DE)

**08:00 - 08:05**

**Case presentation** Screening in a 73-year old but fit man

**08:05 - 08:20**

**Questions/challenges from 3 members of the jury**

- C. Stief, Munich (DE)
- A. Wagg, Edmonton (CA)
- L. Bellardita, Milano (IT)

**08:20 - 08:35**

**Rebuttal from presenter**

To be confirmed

**08:35 - 08:40**

**Case presentation** Active surveillance in Gleason 3+4 but negative MRI

A. Rannikko, Helsinki (FI)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:40 - 08:55</td>
<td>Questions/challenges from 3 members of the jury</td>
</tr>
<tr>
<td></td>
<td>R.C.N. Van Den Bergh, Nieuwegein (NL)</td>
</tr>
<tr>
<td></td>
<td>A. Wagg, Edmonton (CA)</td>
</tr>
<tr>
<td></td>
<td>L. Bellardita, Milano (IT)</td>
</tr>
<tr>
<td>08:55 - 09:10</td>
<td>Rebuttal from presenter</td>
</tr>
<tr>
<td></td>
<td>A. Rannikko, Helsinki (FI)</td>
</tr>
<tr>
<td>09:10 - 09:15</td>
<td>Case presentation Local treatment in metastatic prostate cancer</td>
</tr>
<tr>
<td></td>
<td>M. Graefen, Hamburg (DE)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>Questions/challenges from 3 members of the jury</td>
</tr>
<tr>
<td></td>
<td>C. Stief, Munich (DE)</td>
</tr>
<tr>
<td></td>
<td>R.C.N. Van Den Bergh, Nieuwegein (NL)</td>
</tr>
<tr>
<td></td>
<td>A. Bossi, Villejuif (FR)</td>
</tr>
<tr>
<td>09:30 - 09:45</td>
<td>Rebuttal from presenter</td>
</tr>
<tr>
<td></td>
<td>M. Graefen, Hamburg (DE)</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td>Recent advances in prostate cancer: Real game changers?</td>
</tr>
<tr>
<td>09:45 - 09:55</td>
<td>Pre-biopsy MRI for all patients: Effective and sustainable?</td>
</tr>
<tr>
<td></td>
<td>M. Emberton, London (GB)</td>
</tr>
<tr>
<td>09:55 - 10:00</td>
<td>The EAU guidelines view</td>
</tr>
<tr>
<td></td>
<td>P. Cornford, Liverpool (GB)</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>American Urological Association (AUA) lecture Patient-reported outcomes after prostate cancer therapy: How good are we doing?</td>
</tr>
<tr>
<td></td>
<td>S. Chang, Nashville (US)</td>
</tr>
<tr>
<td>10:15 - 10:20</td>
<td>PIONEER – The European network of excellence for Big Data in prostate cancer</td>
</tr>
<tr>
<td></td>
<td>J. N'Dow, Aberdeen (GB)</td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>The EAU and European Health: The ERN eUROGEN programme</td>
</tr>
<tr>
<td></td>
<td>C.R. Chapple, Sheffield (GB)</td>
</tr>
</tbody>
</table>
The role of the urologist in sexual and fertility issues of cancer survivorship

Plenary 6

Monday 18 March
08:00 - 10:15

**Location:** Red Area, eURO Auditorium 2

**Chairs:**
M. Albersen, Leuven (BE)
J.O.R. Sønksen, Herlev (DK)

**Aims and objectives of this session**
As more men achieve long-term survival after urogenital cancers, sexual dysfunction and infertility have increasingly been recognized as negative consequences that impact quality of life in cancer survivors. The surgeries we perform as urologists, including prostatectomy, retroperitoneal lymph node dissection and penile surgery can have profound and direct effects on sexual wellbeing and fertility. Furthermore, systemic therapies including chemotherapy and hormonal manipulation have been strongly associated to reductions in sexual function and sperm count. In this session, we will discuss these devastating side effects and provide guidance on how to deal with these issues in the daily practice.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 08:00 - 08:30| Case-based debate Hypogonadal prostate cancer patient following treatment with curative intent
**Moderator:** E.C. Serefoglu, Istanbul (TR) |
| 08:00 - 08:05| Case presentation                                                                  |
**E.C. Serefoglu, Istanbul (TR)** |
| 08:05 - 08:15| Pro: Patient is definitely a candidate for TRT
**J.P. Mulhall, New York (US)** |
| 08:15 - 08:25| Con: I would be reluctant to give this man TRT
**B. Tombal, Brussels (BE)** |
| 08:25 - 08:30| Rebuttal and summary                                                               |
| 08:30 - 08:45| Hypogonadism following childhood and testis cancer treatments: An underestimated issue?
**A. Giwercman, Malmö (SE)** |
| 08:45 - 09:00| Pre- and postpubertal fertility preservation in men facing cancer?                  |
**C.F.S. Jensen, Herlev (DK)** |
| 09:00 - 09:15| Neglected sexual side-effects of radical prostatectomy and pelvic radiotherapy     |
**P.A.S. Vendeira, Matosinhos (PT)** |
| 09:15 - 09:30| Has penile rehabilitation following prostatectomy proven useful?                    |
**G. Gandaglia, Milan (IT)** |
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:30 - 09:45 | **Guidelines snapshot** Sexual function and organ preservation in penile cancer  
B.E. Ayres, London (GB) |
| 09:45 - 10:00 | **Challenges in penile implant surgery following pelvic cancer treatment (fibrosis, reservoir placement)**  
I. Moncada, Madrid (ES) |
| 10:00 - 10:15 | **Confederación Americana de Urología (CAU) lecture** Sexual function preservation in robotic urology?  
R. Coelho, Sao Paulo (BR) |
Aims and objectives of this session
During the course recent practice changing alterations in the guidelines will be discussed. Based on the clinical recommendations the highlights of the guidelines one prostate, renal and bladder cancer as changed in the 2019 updates will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

Introduction
H.G. Van Der Poel, Amsterdam (NL)

Update renal cancer: Localized
A. Volpe, Novara (IT)

Discussion

Update renal cancer: Metastasized
A. Volpe, Novara (IT)

Discussion

Update bladder cancer: Non-muscle invasive
J.L. Domínguez Escrig, Valencia (ES)

Discussion

Update bladder cancer: Muscle invasive
J.L. Domínguez Escrig, Valencia (ES)

Discussion

Update prostate cancer: Localized
H.G. Van Der Poel, Amsterdam (NL)

Discussion
Update prostate cancer: Metastasized
H.G. Van Der Poel, Amsterdam (NL)

Discussion
Aims and objectives of this session

Ultrasound is the basic imaging tool of the urologist and almost all urologists are using ultrasound in daily practice. Despite this, training and teaching of urological ultrasound is not provided in a satisfactory manner. The aim of the course is to provide the technical basics and standards for the use of ultrasound in urology. After the course the delegate should know the ideal settings for reliable and informative urological ultrasound as well as the normal and pathological findings.

- Covering urological organs: kidney, ureter, bladder, testis and penis.
- Standard patient positioning.
- Best choice of transducers and settings.
- Standard operating procedures (SOP).
- Normal, benign and malignant pathologic findings.
- Interventional and intraoperative ultrasound.

Technical basics and new technologies
T. Loch, Flensburg (DE)

Standardisation, tuning, acquisition and reporting of ultrasound exams
M. Ritter, Mannheim (DE)

Ultrasound of the kidney and ureter
M. Ritter, Mannheim (DE)

Ultrasound of the bladder
T. Loch, Flensburg (DE)

Ultrasound of the testis
T. Loch, Flensburg (DE)

Ultrasound of the penis
M. Ritter, Mannheim (DE)
### Aims and objectives of this session

This course gives practical information about prolapse management by urologists. From anatomy to mesh implant, the recent revival of native tissue repairs and the management of complications. Also laparoscopic and robotic approaches will be evaluated.

### Case 1: What can go wrong in the female pelvic floor support

**Evaluation of female pelvic floor and basic anatomical concepts**
E. Kocjancic, Chicago (US)

**Imaging**
G.R. Kasyan, Moscow (RU)

**POP classifications and its clinical usefulness**
H. Hashim, Bristol (GB)

### Case 2: Anterior prolapse

**Site specific repair**
G.R. Kasyan, Moscow (RU)

**Use of biological and synthetic meshes**
E. Kocjancic, Chicago (US)

**Use of pessaries**
H. Hashim, Bristol (GB)

### Case 3: Vaginal vault prolapse

**Vaginal approach**
E. Kocjancic, Chicago (US)

**Open colposacropexy**
H. Hashim, Bristol (GB)

**Laparoscopic and robotic colposacropexy**
G.R. Kasyan, Moscow (RU)

### Case 4: POP and urinary incontinence
<table>
<thead>
<tr>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Functional evaluation</td>
<td>H. Hashim, Bristol (GB)</td>
</tr>
<tr>
<td>Stress incontinence and POP</td>
<td>G.R. Kasyan, Moscow (RU)</td>
</tr>
<tr>
<td>Urgency incontinence and POP</td>
<td>E. Kocjancic, Chicago (US)</td>
</tr>
<tr>
<td>Case 5: Complications of POP surgery</td>
<td></td>
</tr>
<tr>
<td>Interactive discussion on different clinical scenarios</td>
<td>G.R. Kasyan, Moscow (RU)</td>
</tr>
<tr>
<td></td>
<td>E. Kocjancic, Chicago (US)</td>
</tr>
<tr>
<td></td>
<td>H. Hashim, Bristol (GB)</td>
</tr>
<tr>
<td>Questions and answers</td>
<td></td>
</tr>
</tbody>
</table>
The infertile couple - Urological aspects
ESU Course 41

Monday 18 March
08:30 - 11:30

Location: Green Area, Room 16
Chair: W. Aulitzky, Vienna (AT)

Aims and objectives of this session
This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility. In terms of therapy, this course will provide updated information on evidence based data and will discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation. We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

Diagnostic work-up, medical treatment
A. Salonia, Milan (IT)

Pathophysiology, diagnosis and treatment of varicocele
W. Aulitzky, Vienna (AT)

Microsurgical refertilisation
W. Aulitzky, Vienna (AT)

Sperm retrieval techniques and genetic aspects of IVF/ICSI
A. Salonia, Milan (IT)
Aims and objectives of this session

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions.
• To learn about equipment.
• To learn about technique and indications.
• To learn how to use an Holmium Laser.
• To learn tips and tricks for special circumstances.

Welcome message and introduction of the course
O. Traxer, Paris (FR)

Instrumentation: Endoscopes
O. Traxer, Paris (FR)

Instrumentation: Laser and lithotripsy devices
M. Grasso, New York (US)

Instrumentation: Disposable (wires, retrieving devices, UAS, irrigation devices and others)
P.J.S. Oster, Fredericia (DK)

Technique: Stones
O. Traxer, Paris (FR)

Technique: Urothelial tumours and strictures
M. Grasso, New York (US)

Tips and tricks and special circumstances
O. Traxer, Paris (FR)

Indications (guidelines) and clinical cases
P.J.S. Oster, Fredericia (DK)

Conclusions
O. Traxer, Paris (FR)
### Nerve-sparing cystectomy and orthotopic bladder substitution - Surgical tricks and management of complications

**ESU Course 46**

**Location:** Green Area, Room 22

**Chair:** A. Stenzl, Tübingen (DE)

#### Aims and objectives of this session

This course has over many years dealt with the technique of urethra- and nerve-sparing cystectomy and subsequent orthotopic bladder substitution in male and female patients. It will deal with indications, technique, possible complications and their prevention. Urologists with a vast experience in cystectomy and urinary diversion will present technical tips using videoclips, results in the literature as well as own data.

- Technique of nerve-sparing cystectomy.
- Optimization of sphincter preservation for optimal continence results.
- Technical tips and tricks in orthotropic neobladder surgery.
- What to observe in male and female patients.

#### Preoperative investigations and selection of patients for orthotopic bladder substitution

J.E. Gschwend, Munich (DE)

#### Arguments for nerve-sparing cystectomy with orthotopic bladder substitution

A. Stenzl, Tübingen (DE)

#### How to do a nerve-sparing cystectomy in male patients

H. Abol-Enein, Mansoura (EG)

#### Surgical tricks to avoid complications with orthotopic bladder substitution

J.E. Gschwend, Munich (DE)

#### Video on how to obtain good functional results in female patients

A. Stenzl, Tübingen (DE)

#### Tips and Tricks: Male/female orthotopic urinary diversion

H. Abol-Enein, Mansoura (EG)

#### How to treat complications during follow-up

J.E. Gschwend, Munich (DE)
Aims and objectives of this session
An effective communicator needs to be flexible, energetic and enthusiastic. Making a presentation puts you on public display. An audience not only listens to your ideas, it also responds to the way you use your voice and your body. You need more than a well written presentation to make an impact: you will also need to deliver it in a lively, flexible and interesting way.

In this course we deliver tips and tricks for inspiring, invoking energy, confidence and safety in your presentation style. The course will be performed in TED format, with no podium available and itinerant talks in front of the slides.

At the end of this course, participants should be able to:
• Understand how Guidelines recommendations are formulated.
• Highlight the changes and the gaps of the different Guidelines discussed at the course.
• Be familiar with the strength of the evidence of the current Guidelines.
• Apply knowledge gained in this course to develop an evidence-based practice in the management of patients.

Introduction
D. Veneziano, Reggio Calabria (IT)
J. Gómez Rivas, Madrid (ES)

How to deliver an effective talk. Verbal language
J. Gómez Rivas, Madrid (ES)

Non-verbal language. Tips and tricks
J. Gómez Rivas, Madrid (ES)

TED talks: How to structure a successful presentation
D. Veneziano, Reggio Calabria (IT)

Optimizing your presentations with the latest software and hardware
D. Veneziano, Reggio Calabria (IT)

How to present the results of your research
G.E. Cacciamani, Verona (IT)

Mastering the stage. The expert opinion
M.J. Ribal, Barcelona (ES)

Closing remarks
| HOT 25
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ESU/ESUT/ESUI Hands-on Training in Prostate MRI reading for urologists</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Location:</strong></td>
<td>Green Area, Room 9</td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td>To be confirmed</td>
</tr>
<tr>
<td><strong>Tutor:</strong></td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
Latest and hot news in medical treatment in onco-urology

Thematic 11

Monday 18 March
10:30 - 12:00

Location: Red Area, eURO Auditorium 1

Chairs: F. Montorsi, Milan (IT)
To be confirmed

Aims and objectives of this session
Several new, potentially practice-changing data are released annually in the field of genito-urinary cancers. These studies involve not only Urologists but also Medical Oncologists and Radiation Therapists, highlighting the true multidisciplinary approach beyond the treatment of these tumours. This session aims to update the audience about the results of the new trials presented at the major international meetings in 2018 and early 2019 using a novel, multidisciplinary format.

10:30 - 12:00
Conclusions from recent oncology meetings regarding:

Moderators: To be confirmed
To be confirmed

10:30 - 10:45
Hormone-naive prostate cancer
P.L. Nguyen, Boston (US)

10:45 - 11:00
Castration-resistant prostate cancer
C.P. Evans, Sacramento (US)

11:00 - 11:15
Urothelial cancer
T. Powles, London (GB)

11:15 - 11:30
Renal cell carcinoma
A.S. Merseburger, Lübeck (DE)

11:30 - 11:45
Testis and penile cancer
J. Oldenburg, Lørenskog (NO)

11:45 - 12:00
Society for Urologic Oncology (SUO) lecture Targeting the adaptive molecular landscape of advanced prostate cancer
M. Gleave, Vancouver (CA)
**Semi-live surgery: Cystectomy and urinary diversion**

**Location:** Red Area, eURO Auditorium 2

**Discussants:**
- P. Albers, Düsseldorf (DE)
- M. Gallucci, Rome (IT)
- N.P. Wiklund, Stockholm (SE)

**Aims and objectives of this session**
Cystectomy and urinary diversion is one of the most difficult procedures in uro-oncological surgery. This session will present tips and tricks in robotic and open procedures including to deal with complications of the approaches. Videos will be presented and discussed by the surgeon and a distinguished panel.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 11:00</td>
<td><strong>Tips and tricks in robotic cystectomy</strong></td>
</tr>
<tr>
<td>10:30 - 10:33</td>
<td>Discussant showing the technique</td>
</tr>
<tr>
<td>10:30 - 10:33</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>Surgical video presentation <strong>Tips and tricks in robotic cystectomy</strong></td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>S. Siemer, Homburg (DE)</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Questioned by discussants</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td><strong>Intra- versus extracorporal conduit (robotic)</strong></td>
</tr>
<tr>
<td>11:00 - 11:03</td>
<td>Discussant showing the technique</td>
</tr>
<tr>
<td>11:00 - 11:03</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Surgical video presentation <strong>Intra- versus extracorporal conduit (robotic)</strong></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>A.E. Canda, Istanbul (TR)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Questioned by discussants</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td><strong>Different types of uretero-ileal anastomosis (open and robotic)</strong></td>
</tr>
<tr>
<td>11:30 - 11:33</td>
<td>Discussant showing the technique</td>
</tr>
<tr>
<td>11:30 - 11:33</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Surgical video presentation <strong>Different types of uretero-ileal anastomosis (open and robotic)</strong></td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>G. Niegisch, Düsseldorf (DE)</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Questioned by discussants</td>
</tr>
</tbody>
</table>
## Stress urinary incontinence in women: Tape troubleshooting

### Aims and objectives of this session
Artificial mid-urethral sling is the most common surgery performed throughout the world to correct female stress urinary incontinence. Albeit considered a simple surgery, the failure to perform it adequately may cause complications and prevent the cure legitimated expected by patients. More recently, a movement against the use of artificial meshes for the treatment of pelvic organ prolapse invaded the field of stress urinary incontinence bewildering patients and caregivers. A clarification of these issues will constitute the main objective of the session.

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Complications by sling type: Are all synthetic slings equal?</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Urethral and bladder erosion</td>
<td>M. Tutolo, Milan (IT)</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Pain after tape placement</td>
<td>F.M.J. Martens, Nijmegen (NL)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Voiding dysfunction: If and when to do a release?</td>
<td>A.K. Nambiar, Newcastle upon Tyne (GB)</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>The legal minefield of tape surgery</td>
<td>B. Leigh, London (GB)</td>
</tr>
<tr>
<td>11:45 - 11:53</td>
<td>Late breaking session TBC</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
**Let's reduce the harm of surgery!**  
**Thematic 13**

**Monday 18 March**  
**10:30 - 12:00**

**Location:** Green Area, Room 3

**Chairs:**  
F.C. Burkhard, Bern (CH)  
J.W. Collins, Stockholm (SE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:30 - 10:45 | **The principles and the rationale of enhanced recovery ’around’ surgery (ERAS)**  
J.W.F. Catto, Sheffield (GB) |
| 10:45 - 10:50 | **Case presentation** The ERAS patient case                                                |
| 10:50 - 11:00 | **The evaluation by the geriatrician**  
S. O’Hanlon, Reading (GB) |
| 11:00 - 11:10 | **The need for prehabilitation**  
N. Fleshner, Toronto (CA) |
| 11:10 - 11:20 | **What can the anaesthesiologist do?**  
To be confirmed |
| 11:20 - 11:30 | **What needs to be done by the urologist?**  
J.W. Collins, Stockholm (SE) |
| 11:30 - 11:40 | **The role of the nursing staff/patient manager**  
B. Thoft Jensen, Aarhus (DK) |
| 11:40 - 12:00 | **Discussion** Who is the target patient?  
**Panel:**  
To be confirmed  
To be confirmed  
N. Fleshner, Toronto (CA)  
To be confirmed  
S. O’Hanlon, Reading (GB)  
B. Thoft Jensen, Aarhus (DK) |
### From everyday clinical practice to curiosities - management of hot topics in infectious disease

**Thematic 14**

**Monday 18 March**

**10:30 - 12:00**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:48</td>
<td>Case <strong>Treatment of urogenital tuberculosis - chemotherapy, surgery or a combined approach?</strong></td>
</tr>
<tr>
<td>10:30 - 10:40</td>
<td>Case presentation E. Kulchavenya, Novosibirsk (RU)</td>
</tr>
<tr>
<td>10:40 - 10:48</td>
<td>Discussion</td>
</tr>
<tr>
<td>10:48 - 11:03</td>
<td>Case <strong>Recurrent urinary tract infection - a standardised diagnostic work-up</strong></td>
</tr>
<tr>
<td>11:03 - 11:13</td>
<td>Case presentation V. Mouraviev, Davenport (US)</td>
</tr>
<tr>
<td>11:13 - 11:21</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:21 - 11:39</td>
<td>Case <strong>Optimal antimicrobial use in endoscopic stone surgery</strong></td>
</tr>
<tr>
<td>11:21 - 11:31</td>
<td>Case presentation To be confirmed</td>
</tr>
<tr>
<td>11:31 - 11:39</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:39 - 11:54</td>
<td>Antimicrobial treatment in the hospital setting - indication, route of administration, duration and choice of antimicrobials</td>
</tr>
<tr>
<td>11:54 - 12:00</td>
<td>Concluding remarks G. Bonkat, Basel (CH)</td>
</tr>
</tbody>
</table>

**Location:** Green Area, Room 4

**Chairs:**
- G. Bonkat, Basel (CH)
- F.M.E. Wagenlehner, Giessen (DE)

**Aims and objectives of this session**

This session shows the broad scope of urogenital infections, every urologist is faced. From tuberculosis, which is a WHO high priority infection to antimicrobial resistance and antimicrobial stewardship strategies will be covered, highlighting the urgent Needs to cope with infectious Problems, are addressed in this session.
Aims and objectives of this session
Stone treatment today means minimally-invasive surgery. However, minimally-invasive doesn’t mean complication-free surgery. It is mandatory to select the right treatment modality for the right patient to avoid complications. If they occur, urologists should have a plan to deal with them.

10:30 - 10:45  Anticoagulation and stone treatment - what is possible?
K. Ghani, Ann Arbor (US)

10:45 - 11:00  Spinal, regional, sedation, general anesthesia: Which is best for whom and when?
S. Sabaté, Barcelona (ES)

11:00 - 11:22  Debate  Ureteral access sheaths: Yes or no?
Moderator: G. Giusti, Milan (IT)

11:00 - 11:05  Introduction
G. Giusti, Milan (IT)

11:05 - 11:12  Yes
P. Kallidonis, Patras (GR)

11:12 - 11:19  No
V.M.J. De Coninck, Paris (FR)

11:19 - 11:22  Rebuttal

11:22 - 12:00  Case presentations  Complication prevention in stone surgery

11:22 - 11:27  Case presentation
B. Turna, İzmir (TR)

11:27 - 12:00
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 11:05</td>
<td><strong>Case presentation and techniques</strong> Severe oligospermia</td>
</tr>
<tr>
<td>10:30 - 10:37</td>
<td><strong>Case presentation</strong></td>
</tr>
<tr>
<td></td>
<td>M.M. Fode, Herlev (DK)</td>
</tr>
<tr>
<td>10:37 - 10:44</td>
<td><strong>Technique</strong> Ejaculated sperm: Don’t touch the testis</td>
</tr>
<tr>
<td></td>
<td>Z. Kopa, Budapest (HU)</td>
</tr>
<tr>
<td>10:44 - 10:51</td>
<td><strong>Technique</strong> Epididymal sperm is the way to go</td>
</tr>
<tr>
<td></td>
<td>T. Diemer, Giessen (DE)</td>
</tr>
<tr>
<td>10:51 - 10:58</td>
<td><strong>Technique</strong> Testicular sperm is the best option</td>
</tr>
<tr>
<td></td>
<td>N. Sofikitis, Ioannina (GR)</td>
</tr>
<tr>
<td>10:58 - 11:05</td>
<td><strong>Summary</strong></td>
</tr>
<tr>
<td></td>
<td>M.M. Fode, Herlev (DK)</td>
</tr>
<tr>
<td>11:05 - 11:20</td>
<td><strong>Fertility-sparing surgery in testis cancer</strong></td>
</tr>
<tr>
<td></td>
<td>M. Dinkelman-Smit, Rotterdam (NL)</td>
</tr>
<tr>
<td>11:20 - 11:45</td>
<td><strong>OAT case: Administration of antioxidants in men with oligoasthenospermia: Is it for the benefit of the male?</strong></td>
</tr>
<tr>
<td>11:20 - 11:25</td>
<td><strong>Case presentation</strong></td>
</tr>
<tr>
<td></td>
<td>P. Capogrosso, Milan (IT)</td>
</tr>
<tr>
<td>11:25 - 11:32</td>
<td><strong>Pro</strong> If it doesn't help, it doesn't hurt</td>
</tr>
<tr>
<td></td>
<td>S.S. Minhas, London (GB)</td>
</tr>
<tr>
<td>11:32 - 11:39</td>
<td><strong>Con</strong> Potentially dangerous for sperm-fertilising capacity</td>
</tr>
<tr>
<td></td>
<td>S. Çayan, Mersin (TR)</td>
</tr>
<tr>
<td>11:39 - 11:45</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>P. Capogrosso, Milan (IT)</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td><strong>Genetic factors involved in male fertility: Are we testing enough?</strong></td>
</tr>
<tr>
<td></td>
<td>S. Viville, Strasbourg (FR)</td>
</tr>
</tbody>
</table>
Upper Tract Urothelial Cancer (UTUC)
Thematic 17

**Monday 18 March**
**10:30 - 12:00**

**Location:** Green Area, Room 11  
**Chairs:** P. Gontero, Turin (IT)  
J. Palou, Barcelona (ES)

**Aims and objectives of this session**
Radical nephro-ureterectomy (RNU) is still considered the standard treatment of patients with localised Upper Tract Urothelial Cancer (UTUC). However, RNU has a significant morbidity and alters renal function. Kidney-sparing procedures (KSP) have been proposed to preserve renal function while providing similar oncologic results in selected patients. The purpose of this session is to discuss all new findings in UTUC: Risk stratification, preoperative workup, lymphadenectomy template and the role for systemic treatment.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Troubleshooting challenges in diagnostics</td>
<td>P. Black, Vancouver (CA)</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Radical nephro-ureterectomy: How radical to go?</td>
<td>T. Seisen, Boston (US)</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Technical video masterclass</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Robotic lower end</td>
<td>B.J. Challacombe, London (GB)</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Nephron-sparing approaches</td>
<td>A. Breda, Barcelona (ES)</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>A rational approach to systemic treatment of UTUC</td>
<td>S. Sridhar, Toronto (CA)</td>
<td></td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Lynch syndrome: The tip of the iceberg</td>
<td>A.R. Zlotta, Toronto (CA)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 10:30 - 10:45| **Cancer risk in end-stage renal disease and after renal transplantation: What to consider?**  
O. Rodríguez Faba, Barcelona (ES) |
| 10:45 - 11:00| **Non-muscle invasive urothelial cancer after renal transplantation: Treatment, outcome and follow-up**  
R. Boissier, Marseille (FR) |
| 11:00 - 11:15| **How to deal with tumours in the transplant and native kidneys**  
M. Musquera Felip, Barcelona (ES) |
| 11:15 - 11:50| **Case-based debate**  
Localised prostate cancer in kidney transplant recipients (1 low risk, 1 intermediate risk case) |
| 11:15 - 11:20| **Case presentation**  
E. Lledó García, Madrid (ES) |
| 11:20 - 11:30| **Radical prostatectomy**  
To be confirmed |
| 11:30 - 11:40| **External beam radiation**  
To be confirmed |
| 11:40 - 11:50| **Focal therapy**  
M. Schostak, Magdeburg (DE) |
| 11:50 - 12:00| **Associated abstract presentation**  
To be confirmed |
How to successfully run a urology office in Europe

Aims and objectives of this session
Providing good medical care on the basis of scientific knowledge and making rational decisions are cornerstones of a successful urologic office, amended by a patient-centred approach and an appropriate organizational infrastructure of the office.

In this session different aspects of the optimal infrastructure are presented by office urologists: Established conjunctions to GPs, other specialties, and clinics are of core importance for a successful management of sick patients. Public communication to the patients, offering them the specialist’s help, and using new media, often misunderstood as merely a marketing tool, are important especially in unclear and complex situations. This communication has recently been regulated (and complicated) by the European Data Protection Law: the relevance in daily practice and how to implement it in our offices will be discussed. Science in office and scientific collaboration of offices and clinics are achieved in clinical studies, this will be discussed from an office urologist’s point of view.

The shape of office urology in Europe is not uniform and differs from country to country: office urologists will give you information about the characteristics in their country.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:35</td>
<td>Welcome and introduction: Office urology in Europe</td>
</tr>
<tr>
<td></td>
<td>H. Haas, Heppenheim (DE)</td>
</tr>
<tr>
<td>10:35 - 10:50</td>
<td>The new European data protection law (GDPR): Practical implications in daily practice</td>
</tr>
<tr>
<td></td>
<td>S.M. Haensel, Rotterdam (NL)</td>
</tr>
<tr>
<td>10:50 - 11:05</td>
<td>How to market your urology practice ethically and economically</td>
</tr>
<tr>
<td></td>
<td>A. Zachariou, Volos (GR)</td>
</tr>
<tr>
<td>11:05 - 11:20</td>
<td>Social media in office urology</td>
</tr>
<tr>
<td></td>
<td>S. Czarniecki, Warsaw (PL)</td>
</tr>
<tr>
<td>11:20 - 11:35</td>
<td>Networking in urologic office</td>
</tr>
<tr>
<td></td>
<td>H. Brenneis, Pirmasens (DE)</td>
</tr>
<tr>
<td>11:35 - 11:50</td>
<td>Cooperation with clinical studies (phase III/IV studies)</td>
</tr>
<tr>
<td></td>
<td>A. Dobrowolski, Myslowice (PL)</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>Future of office urology in Europe and closing remarks</td>
</tr>
<tr>
<td></td>
<td>S.M. Haensel, Rotterdam (NL)</td>
</tr>
</tbody>
</table>
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

**PT307**  
**Essential research priorities in renal cancer: A modified Delphi consensus statement**

By: Rossi S.¹, Blick C.², Handforth C.³, Brown J.³, Stewart G.¹  
¹University of Cambridge, Dept. of Urology, Cambridge, United Kingdom, ²Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, ³Weston Park Hospital and the University of Sheffield, Academic Unit of Clinical Oncology and Cancer Clinical Trials Unit, Sheffield, United Kingdom

**PT308**  
**Development of modified IMDC model for metastatic renal cell carcinoma patients**

By: Shirotake S.¹, Kaneko G.¹, Nishimoto K.¹, Tanaka N.², Ito K.³, Kosaka T.², Oya M.², Oyama M.¹  
¹Saitama Medical University International Medical Center, Dept. of Uro-Oncology, Saitama, Japan, ²Keio University School of Medicine, Dept. of Urology, Tokyo, Japan, ³National Defense Medical College, Dept. of Urology, Saitama, Japan

**PT309**  
**Prognostic value of metabolic conditions in patients with synchronous metastatic renal cell carcinoma**

By: Yuk H.D.¹, Yu J.H.¹, Cho D.Y.¹, Sung L.H.¹, Chung J.Y.¹, Oh J.J.², Lee S.C.², Hong S.K.², Lee S.E.², Byun S-S.², Kim Y.J.³, Hwang E.C.⁴, Kang S.H.⁵, Hong S-H.⁶, Chung J.S.⁷, Kwon T.G.⁸, Kwak C.⁹, Kim H.H.⁹, Lee H.M.²  
¹Inje University Sanggye Paik Hospital, Dept. of Urology, Seoul, Korea, South, ²Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, Korea, South, ³Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, Korea, South, ⁴Chonnam National University Hwasun Hospital, Dept. of Urology, Hwasun, Korea,
PT310

**Early flare-response of C-reactive protein is associated with tumor shrinkage in patients with metastatic renal cell carcinoma treated with nivolumab**

By: Fukuda S. 1, Saito K. 1, Yasuda Y. 1, Soma T. 2, Toide M. 1, Fukushima H. 1, Moriyama S. 1, Uehara S. 1, Fukui N. 2, Kijima T. 1, Yoshida S. 1, Yokoyama M. 1, Ishioka J. 1, Matsuoka Y. 1, Kageyama Y. 2, Fujii Y. 1

1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2Saitama Cancer Center, Dept. of Urology, Saitama, Japan

PT312

**Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients**

By: Numakura K. 1, Fujiyama N. 2, Takahashi M. 1, Igarashi R. 1, Nara T. 1, Chiba S. 1, Kanda S. 1, Saito M. 1, Narita S. 1, Inoue T. 1, Habuchi T. 1

1Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, 2Akita University Hospital, Center for Kidney Disease and Renal Transplantation, Akita, Japan

PT313

**Influence of genetic polymorphisms of vascular endothelial related genes on clinical outcome of axitinib in patients with metastatic renal cell carcinoma**


Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan

PT314

**Cost analysis of different sequential treatment regimens for metastatic renal cell carcinoma in China**

By: Guohai S.

Shanghai Cancer Center, Dept. of Urology, Shanghai, China

PT317

**The peripheral blood inflammatory markers may predict response to nivolumab for advanced renal cell carcinoma**


Iwate Medical University, Dept. of Urology, Iwate-ken, Japan

PT320

**The impact of perioperative blood transfusion on oncologic outcomes in patients with non-metastatic renal cell carcinoma treated with surgery**

By: Kim H.S. 1, Kim J.H. 1, Yoon H.S. 1, Lee H.W. 1, Lee J.W. 1, Bae J. 1, Kwak C. 2, Ku J.H. 2, Kim H.H. 2
<table>
<thead>
<tr>
<th>PT322</th>
<th>The contribution of demographic, access and treatment-related factors on racial disparities in bladder cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Cole A.P. 1, Krimphove M.J. 1, Fletcher S.A. 1, Lipsitz S. 2, Gild P. 3, Preston M. 4, Menon M. 5, Kibel A. 1, Trinh Q-D. 1</td>
</tr>
<tr>
<td>1Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 2Brigham and Women's Hospital, Harvard Medical School, Division of Internal Medicine and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 3University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 4Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery, Boston, Massachusetts, United States of America, 5Vatikutti Urology Institute, Henry Ford Health System, Detroit, Michigan, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT323</th>
<th>Impact of frailty on treatment modality selection in patients with muscle-invasive bladder cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Hatakeyama S. 1, Yamamoto H. 1, Imai A. 1, Yoneyama T. 1, Hashimoto Y. 1, Koie T. 2, Ohyama C. 1</td>
</tr>
<tr>
<td>1Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Gifu University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT325</th>
<th>Pathologic downstaging after neoadjuvant cisplatin-based combination chemotherapy in immunohistochemistry-defined molecular subtypes of bladder cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Sjodahl G. 1, Abrahamsson J. 1, Holmsten K. 2, Eriksson P. 3, Lövgren K. 3, Lindh C. 4, Ullén A. 2, Liedberg F. 1</td>
</tr>
<tr>
<td>1Lund University, Division of Urological Research, Department of Translational Medicine., Malmö, Sweden, 2Karolinska Institutet, Theme Cancer, Patient Area Pelvic Cancer, Karolinska Hospital and Department of Oncology-Pathology, Stockholm, Sweden, 3Lund University, Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden, 4Karolinska University Hospital, Dept. of Pathology and Cytology, Stockholm, Sweden</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT326</th>
<th>The impact of insurance status on outcomes for bladder cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Fletcher S.A. 1, Cole A.P. 1, Krimphove M.J. 1, Lu C. 2, Berg S. 1, Lipsitz S.R. 3, Trinh Q-D. 1</td>
</tr>
<tr>
<td>1Brigham and Women's Hospital, Harvard Medical School, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, 2Harvard TH Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America, 3Brigham and Women's Hospital, Harvard Medical School, Dept. of General Internal Medicine and Center for Surgery and Public Health, Boston, United States of America</td>
<td></td>
</tr>
</tbody>
</table>
Concomitant carcinoma in situ at radical cystectomy: Survival, recurrence and follow-up implications

ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy

Neutrophil to lymphocyte ratio (NLR) as a predictor of outcomes in patients with urothelial carcinoma (UC) treated with immune checkpoint inhibitors (ICI)

1Guy's and St. Thomas' Nhs Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, 2King's College London, Dept. of Translational Oncology and Urology Team (TOUR), London, United Kingdom, 3Guy's and St. Thomas' Nhs Foundation Trust, Dept of Urology, London, United Kingdom

Bladder-sparing radiotherapy with vinorelbine in localized muscle-invasive bladder cancer: A valid option for cisplatin-unfit patients?

1Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, 2Medical University Innsbruck, Medical Statistics, Informatics and Health Economics, Innsbruck, Austria, 3Medical University Innsbruck, Therapeutic Radiology and Oncology, Innsbruck, Austria

Response to Vinflunine treatment correlates with survival outcomes in patients with advanced or metastatic urothelial carcinoma after platinum failure – Analyses from the German, prospective, multicenter real-life study JONAS

By: Hegele A., De Geeter P., Goebell P.J., Matz U., Rosé C., Villanova G.
1Philips University, Dept. of Urology and Pediatric Urology, Marburg, Germany, 2Kassel Hospital, Dept. of Urology, Kassel, Germany, 3Friedrich-Alexander University, Dept. of Urology, Erlangen, Germany, 4Medical Urologic Practice, Doebeln, Germany, 5Pierre Fabre Pharma GmbH, Medical Department, Freiburg, Germany, 6Pierre Fabre Médicament, Medical Department, Boulogne-Billancourt, France

Impact of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy (TMT) for muscle-invasive bladder cancer

1University of Toronto, Dept. of Surgery, Toronto, Canada, 2Mount Sinai Hospital, Dept. of Urology, Toronto, Canada, 3University Health Network, Dept. of Urology, Toronto, Canada, 4University Health Network, Dept. of Radiology, Toronto, Canada
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

**Introduction**

To be confirmed
M. Burger, Regensburg (DE)

**PT333**

**EVOLVE: Designing a model of meaningful patient involvement in guideline development**

By: Bjorkqvist J.E. ¹, MacLennan S. ¹, Giles R.H. ², Comford P. ³, MacLennan S.J. ⁴

¹Academic Urology Unit, University of Aberdeen, Aberdeen, United Kingdom,
²Regenerative Medicine Centre Utrecht, University Medical Centre Utrecht, Dept. of Nephrology and Hypertension, Utrecht, Netherlands, The, ³Royal Liverpool University Hospitals Trust, Dept. of Urology, Liverpool, United Kingdom, ⁴Urological Cancer Charity, Foresterhill Health Centre, Aberdeen, United Kingdom
Aims and objectives of this session
This novel course will give a state of the art update on the variety of penile diseases that Urologists will encounter in everyday clinical practice. The faculty consists of a group of internationally renowned experts in this field. A spectrum of pathologies can affect the penis including benign disorders to cancers. There will be particular focus on interactive case based discussions highlighting the pitfalls and controversies in management of penile diseases;

- The aetiology, diagnosis and medical management of the common penile diseases including inflammatory conditions of the penis.
- The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis.
- The medical and surgical management of Peyronie’s disease.
- The course will also deal with the surgical management of these diseases including the surgical indications and surgical techniques used in penile reconstructive surgery.
- The management of penile carcinoma including the aetiology, techniques/outcome of organ sparing surgery and surgical management of advanced disease including lymphadenectomy will be discussed.

Peyronie’s disease
S.S. Minhas, London (GB)

Penile dermatology for the urologist
C. Bunker, London (GB)

Surgical management of penile diseases
S.S. Minhas, London (GB)

HPV, premalignant lesions and penile cancer
S.S. Minhas, London (GB)

Management of penile cancer and lymph nodes
C. Protzel, Schwerin (DE)
### Percutaneous nephrolithotripsy (PCNL)

**ESU Course 50**

**Monday 18 March**
**12:00 - 15:00**

**Location:** Green Area, Room 14

**Chair:** E. Liatsikos, Patras (GR)

#### Aims and objectives of this session

Aim of this course is to describe in detail the surgical techniques of all available treatment options in percutaneous surgery of renal stones. In addition, to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on their prevention and proper management.

**Objectives**

- Describe the basic percutaneous nephrolithotripsy techniques.
- Provide tips to improve the efficacy of the operation.
- Provide evidence on the comparison of percutaneous with ureteroscopic and extracorporeal treatment options; Which approach for which stone.
- Describe associate complications including their management.

#### Guidelines on stone treatment

T. Knoll, Sindelfingen (DE)

#### PCNL instrumentation – Suite organisation, wires, dilators and lithotriptors

C.M. Scoffone, Turin (IT)

#### From Skin to Stone: Step-by-Step access using only fluoroscopy (Prone position)

E. Liatsikos, Patras (GR)

#### From Skin to Stone: Step-by-Step access using US and fluoroscopy (Supine position)

C.M. Scoffone, Turin (IT)

#### MiniPerc- Indications, equipment and technique

T. Knoll, Sindelfingen (DE)

#### Tips and tricks in PCNL

E. Liatsikos, Patras (GR)

#### Round table: Complications of PCNL: Diagnosis, management, prevention

E. Liatsikos, Patras (GR)
T. Knoll, Sindelfingen (DE)
C.M. Scoffone, Turin (IT)
Aims and objectives of this session
This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained on a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well.
Don’t miss this course, a must for all robotic surgeons!:
• Video based step-by-step approach.
• Standard techniques.
• Complex cases.
• Troubleshooting and complication management.
• Technical innovations: What’s new in robotics?

Introduction
A. Mottrie, Aalst (BE)

Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery
B.J. Challacombe, London (GB)

Robotic pyeloplasty: Multichannel or single technique
N. Buffi, Milan (IT)

Renal surgery: Nephrectomy and nephroureterectomy: How I do it
B.J. Challacombe, London (GB)

Partial nephrectomy I: Step 1: Isolation of renal hilum; Step 2: Mobilisation of the kidney; Step 3: Clamping of renal pedicle: Different techniques
N. Buffi, Milan (IT)

Partial nephrectomy II: Step 4: Different tumour resection techniques
A. Mottrie, Aalst (BE)

Partial nephrectomy III: Step 5: Different renorraphy techniques
B.J. Challacombe, London (GB)

Partial nephrectomy IV: Special & difficult indications
A. Mottrie, Aalst (BE)

Partial nephrectomy V: Complication management and new tools
A. Mottrie, Aalst (BE)
Wrap up and conclusions
B.J. Challacombe, London (GB)
Aims and objectives of this session
• To review:
  - mechanisms of continence in men.
  - mechanisms of post surgical incontinence in men.
• To analyse symptoms and to indicate conservative treatment.
• To be able to select one surgical treatment, referring to literature and guidelines.
• To learn about long term follow-up of each surgical technique and to be able to deliver the best and objective information to patients.

Introduction
E. Chartier-Kastler, Paris (FR)

Aetiology
F. Van Der Aa, Leuven (BE)

Workout of post-surgical incontinence
E. Chartier-Kastler, Paris (FR)

Conservative treatment for post-surgical incontinence
F. Van Der Aa, Leuven (BE)

Postsurgical LUTS
F. Van Der Aa, Leuven (BE)

Surgical treatment for post-surgical incontinence
E. Chartier-Kastler, Paris (FR)
Aims and objectives of this session
Having attended the course, the attendee should:
• Understand the basic physical principles referable to urodynamics.
• Be able to assess the quality of a urodynamic trace.
• Recognise common artefacts and know how to correct them.
• Know the indications for urodynamic studies in men, women and neurological patients.

Urodynamics: Philosophy, scientific basis and technique
P. Abrams, Bristol (GB)

Urodynamics in neurourology
J.L.H.R. Bosch, Berkel en Rodenrijs (NL)

Urodynamics in female urology
P. Abrams, Bristol (GB)

Urodynamics in men
J.L.H.R. Bosch, Berkel en Rodenrijs (NL)
Advanced course on upper tract laparoscopy: Kidney, UPJ, ureter and stones
ESU Course 53

Location: Green Area, Room 22
Chair: G. Janetschek, Salzburg (AT)

Aims and objectives of this session
Surgery of the kidney by means of laparoscopy is standard of care, and has replaced open surgery to a great extent.
Approach: Transperitoneal, retroperitoneoscopy, posterior, direct through the mesentery of the colon. Each approach has specific advantages also depending on the procedure to be performed.
Procedures: Ablative, reconstruction, stone surgery.
Presentation: Power-point, interactive, videos, tips and tricks, complications.

• For surgery of the kidney, the daVinci robot is often an overkill. Also it is not available everywhere. Therefore standard laparoscopy is still of importance and should be mastered by every endoscopic surgeon.
• Choice of the perfect approach makes the respective surgery easier and safer.
• Standard laparoscopy is greatly facilitated by 3D vision.
• When mastering both laparoscopic surgical skills as well as the surgical concept of the respective procedure complications can either be avoided or managed appropriately.

Approach: Transperitoneal, retroperitoneoscopy
G. Janetschek, Salzburg (AT)

Kidney: Nephrectomy, management of cysts
A. Alcaraz, Barcelona (ES)

Ureter: Nephroureterectomy, end-to-end anastomosis, replacement
H. Baumert, Paris (FR)

Pyeloplasty: Indication – techniques – problems
H. Baumert, Paris (FR)

Stone surgery
A. Alcaraz, Barcelona (ES)

Complication management
G. Janetschek, Salzburg (AT)

Questions, tips and tricks
A. Alcaraz, Barcelona (ES)
H. Baumert, Paris (FR)
G. Janetschek, Salzburg (AT)
Office management of male sexual dysfunction
ESU Course 54

Aims and objectives of this session
The course is aimed at providing practical advice on how to diagnose and treat a patient with Premature ejaculation or ED. It will allow
• An up-to-date understanding of the aetiology of ED and EP.
• An adequate work up enabling an individually adopted regimen.
• Currently available treatment options as topical and oral drugs, testosterone and devices.
• Post-prostatectomy ED with various approaches.

Introduction
C. Stief, Munich (DE)

Diagnostics - What is necessary?
I. Eardley, Leeds (GB)

Testosterone replacement
C. Stief, Munich (DE)

Oral therapy for ED
I. Eardley, Leeds (GB)

Therapy of ED when pills fail
D.J. Ralph, London (GB)

Medical therapy for premature ejaculation
I. Eardley, Leeds (GB)

Surgical topics: Penile implants, priapism, Peyronie's
D.J. Ralph, London (GB)

What to do after radical prostatectomy?
C. Stief, Munich (DE)
Advancements in benign prostatic hyperplasia treatment and prostate biopsy

Video Session 10

Monday 18 March
12:15 - 13:45

Location: Red Area, eURO Auditorium 1

Chairs: J-N.L. Cornu, Rouen (FR)
        F. Gomez Sancha, Madrid (ES)
        T.R.W. Herrmann, Frauenfeld (CH)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V67

First 3D holmium laser enucleation of the prostate (3D-HoLEP)

By: Sanchez Macias J. 1, Franco M. 1, Pardo A. 2, Camacho Rovira D. 1, Calaf O. 3, Mercader C. 1, Alcaraz A. 1

1Hospital Clinic, Dept. of Urology, Barcelona, Spain, 2Laseralia, C.E.O., Barcelona, Spain, 3hospital Germans Trias, Dept. of Urology, Badalona, Spain

V68

Urethra and ejaculation preserving robot-assisted simple prostatectomy: Near infrared fluorescence imaging-guided Madigan technique

By: Simone G., Misuraca L., Anceschi U., Minisola F., Ferriero M., Guaglianone S., Tuderti G., Gallucci M.

Regina Elena National Cancer Institute, Dept.of Urology, Rome, Italy

V69

Transurethral bipolar-plasmakinetic endoscopic enucleation of prostate exceeding 200g: Tips ans tricks with 24 cases results

By: Zou Z., Liang C.

The First Affiliated Hospital of Anhui Medical University, Dept. of Urology, Heifei, China

V70

Holmium laser enucleation of the prostate: Tips and tricks to reduce incontinence

By: Maheshwari P. 1, Chaurasia A. 1, Okwi N. 2, Mukasa N.V. 3

1Fortis Hospital Mulund, Dept. of Urology, Mumbai, India, 2Busitema University, Dept. of Surgery, Faculty of Health Sciences, Busetima, Uganda, 3Mulago National Hospital, Dept. of Surgery, Kampala, Uganda

V71

Endoscopic enucleation of the prostate: A step by step approach

By: Enikeev D., Rapoport L., Taratkin M., Glybochko P.

Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

V72

Freehand MRI/US cognitive fusion transperineal biopsy of the prostate in local anesthesia: A video demonstration
By: Shahin O.¹, Kwiatkowski M. ², Wyler S. ²
¹Uromerian.ch, Praxis an der Merian Iselin Klinik, Basel, Switzerland, ²Kantonsspital Aarau, Dept. of Urology, Aarau, Switzerland

V73

Local Anaesthetic Transperineal Prostate (LATP) biopsy using the precision point access system: A step-by-step video

By: Campbell A. ¹, Omer A.E. ¹, Popert R. ², Lamb A. ¹
¹University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, ²Guys Hospital, Dept. of Urology, London, United Kingdom
**Minimising the risk of treatment in candidates for cystectomy**

**Poster Session 60**

**Monday 18 March**  
**12:15 - 13:45**

**Location:** Red Area, eURO Auditorium 2

**Chairs:** J. Cresswell, Middlesbrough (GB)  
To be confirmed  
P. Zehnder, Sursee (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**835**

**The role of cutaneous ureterostomy diversion: A multicenter analysis**

By: Laura I. ¹, Lombardo R. ², Tema G. ², Cancrini F. ², Lotrecchiano G. ³, Minervini A. ⁴, Simone G. ⁵, Cindolo L. ⁶, D’orta C. ⁶, Ajami T. ¹, Antonelli A. ⁷, Castellani D. ⁸, Alcaraz A. ¹, De Nunzio C. ²

¹Hospital Clinic of Barcelona, Urology, Dept. of Urology, Barcelona, Spain, ²Sapienza University of Rome, Sant'Andrea, Dept. of Urology, Rome, Italy, ³AORN “Rummo” Hospital, Dept. of Urology, Benevento, Italy, ⁴University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ⁵IFO, Istituto Nazionale Tumori Regina Elena Hospital, Dept. of Urology, Rome, Italy, ⁶San Pio da Pietralcina Hospital, Dept. of Urology, Vasto, Italy, ⁷Spedali Civili di Brescia Hospital, Dept. of Urology, Brescia, Italy, ⁸INRCA Hospital, Dept. of Urology, Ancona, Italy

---

**836**

**Utility of serum markers in the assessment of perioperative and postoperative morbidity and mortality after radical cystectomy for muscle invasive bladder cancer**

By: Claps F., Pavan N., Rizzo M., Boltri M., Migliozzi F., Liguori G., Trombetta C.

Urology Clinic, Dept. of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy

---

**839**

**Long term survival after radical cystectomy with respect to centralisation: Outcomes from 1110 patients treated at a single high-volume centre**

By: Pang K.H.¹, Novara G.H.², Din O.S.³, Morgan S.L.⁴, Noon A.P.⁵, Catto J.W.F.¹, Rosario D.J.¹

¹University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, ²University of Padova, Dept. of Surgery, Oncology and Gastroenterology, Padova, Italy, ³Sheffield Teaching Hospitals NHS Foundation Trust, Cancer Research Centre, Sheffield, United Kingdom, ⁴Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Histopathology, Sheffield, United Kingdom, ⁵Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Sheffield, United Kingdom

---

**840**

**Tetra-modality bladder sparing therapy can be a viable treatment option for muscle-invasive bladder cancer patients with sarcopenia**
842

Association between antiplatelet or anticoagulant therapy and perioperative morbidity in patients undergoing radical cystectomy for urinary bladder cancer

By: Vetterlein M.W., Gild P., Bradtke M., Klemm J., Janisch F., Soave A., Dahlem R., Fisch M., Rink M.
University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

843

Comparative effectiveness of robotic assisted and open radical cystectomy in contemporary cohorts of bladder cancer patients: An international multicenter collaboration

By: Zamboni S.¹, Soria F.², Mathieu R.², Xylinas E.³, Tan W.S.⁴, Kelly J.D.⁴, Simone G.⁵, Gallucci M.⁵, Meraney A.⁶, Konety B.⁷, Antonelli A.⁸, Simeone C.⁸, Baumeister P.¹, Mattei A.¹, Montorsi F.⁹, Briganti A.⁹, Rink M.¹⁰, Aziz A.¹¹, Karakiewicz P.I.¹², Rouprêt M.¹³, Scherr D.S.¹⁴, Ploussard G.¹⁵, Sooriakumaran P.¹⁶, Shariat S.F.², Moschini M.¹⁷
¹Luzerner KantonsSpital, Dept. of Urology, Lucerne, Switzerland, ²Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria, ³Bichat Hospital, Paris Descartes University, Dept. of Urology, Paris, France, ⁴Division of Surgery and Intervention Science, University College London, University College London Hospital, Dept. of Urology, London, United Kingdom, ⁵IRCCS, Regina Elena National Cancer Institute, Dept. of Urology, Roma, Italy, ⁶Hartford Healthcare Medical Group, Urology Division, Hartford, United States of America, ⁷University of Minnesota, Dept. of Urology, Minneapolis, United States of America, ⁸Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, ⁹Urological Research Institute, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ¹⁰University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ¹¹University Medical Center Rostock, Dept. of Urology, Rostock, Germany, ¹²University of Montreal Health Centre, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, ¹³Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Dept. of Urology, Paris, France, ¹⁴Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA, Dept. of Urology, New York, United States of America, ¹⁵La Croix du Sud, Dept. of Urology, Toulouse, France, ¹⁶University College London Hospital NHS Foundation Trust, Dept. of Uro-Oncology, London, United Kingdom, ¹⁷Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

844

Optimizing outcomes reporting after robot-assisted radical cystectomy: External validation of the USC-Pentafecta

Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy
Clinical recurrence after radical cystectomy for bladder cancer, defining optimal surveillance after surgery

By: Moschini M. 1, Zamboni S. 1, Karnes J.R. 2, Montorsi F. 3, Briganti A. 3, Colombo R. 3, Gallina A. 3, Mattei A. 1, Baumeister P. 1, Di Trapani E. 4, De Cobelli O. 4, Musi G. 4, Antonelli A. 5, Simeone C. 5, Boeri L. 2, Solmi M. 2, Simone G. 6, Gallucci M. 6, Aziz A. 7, Xylinas E. 8, Shariat S.F. 9

1Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Urological Research Institute, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, 4European Institute of Oncology, Dept. of Urology, Milan, Italy, 5Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, 6IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 7University Medical Center Rostock, Dept. of Urology, Rostock, Germany, 8Bichat Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 9Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

The impact of acute kidney injury on renal impairment and cardiovascular disease in patients with muscle invasive bladder cancer treated with radical cystectomy

By: Fujita N. 1, Momota M. 1, Tobisawa Y. 1, Yoneyama T. 1, Yamamoto H. 1, Imai A. 1, Hatakeyama S. 1, Ito H. 2, Yoneyama T. 1, Hashimoto Y. 1, Yoshikawa K. 3, Ohyama C. 1

1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, 3Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

ERAS concepts in the perioperative management of patients undergoing radical cystectomy for bladder cancer: Long-term-follow up and oncological outcome of a prospective randomized study

By: Ziegelmüller B.K., Jokisch F., Buchner A., Kretschmer A., Schulz G., Stief C.G., Karl A.
Großhadern Clinics, LMU, Dept. of Urology, Munich, Germany

Feasibility of endoluminal partial cystectomy for urothelial cancer: First results from an animal hybrid model

By: Aufderklamm S. 1, Kruck S. 2, Hoffmans T. 1, Aicher W.K. 1, Hennenlotter J. 1, Scharpf M. 3, Stenzl A. 1, Amend B. 1

1Eberhard Karls University, Dept. of Urology, Tübingen, Germany, 2Helios Klinikum Pforzheim, Dept. of Urology, Pforzheim, Germany, 3Eberhard Karls University, Dept. of Pathology, Tübingen, Germany
**Novel compounds in prostate cancer therapies**

*Poster Session 61*

**Monday 18 March**
**12:15 - 13:45**

**Location:** Green Area, Room 1

**Chairs:** To be confirmed
C.P. Evans, Sacramento (US)
C. Thomas, Dresden (DE)

**Aims and objectives of this session**
Recently, novel therapies which interfere with DNA repair have been introduced in prostate cancer. This could be a basis for a more personalized approach in prostate cancer therapy. In addition, innovative approaches with oncolytic viruses in preclinical therapy will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**850**

**Novel mechanism of bone metastasis mediated by exosomes derived from metastatic prostate cancer**

By: **Urabe F.**, Kosaka N., Yamamoto Y., Kimura T., Egawa S., Ochiya T.

1National Cancer Center Research Institute, Division of Molecular and Cellular Medicine, Tokyo, Japan,
2The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan

---

**851**

**KIFC1 inhibitor CW069 induces apoptosis and reverses resistance to docetaxel in prostate cancer**

By: **Sekino Y.**, Koike Y., Sakamoto N., Shiota M., Shigematsu Y., Sentani K., Oue N., Teishima J., Yasui W., Matsubara A.

1Hiroshima University Graduate School of Biomedical and Health Sciences, Dept. of Urology, Hiroshima, Japan,
2Hiroshima University Graduate School of Biomedical and Health Sciences, Dept. of Molecular Pathology, Hiroshima, Japan,
3Kyushu University, Dept. of Urology, Fukuoka, Japan

---

**852**

**Iron induces ferroptosis and synergizes with anti-androgen therapy in prostate cancer pre-clinical models**

By: **Campanella A.**, Bordini J., Morisi F., Elia A.R., Cucchiara V., Bellone M., Camaschella C., Briganti A.

1Vita-Salute San Raffaele University, Dept. of Experimental Oncology, Milan, Italy,
2IRCCS Ospedale San Raffaele, Dept. of Genetics and Cell Biology, Milan, Italy,
3IRCCS Ospedale San Raffaele, Dept. of Immunology, Transplantation and Infectious Diseases, Milan, Italy,
4IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Dept. of Experimental Oncology/Unit of Urology, URI, Milan, Italy
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
</table>
| 853  | A novel three-dimensional cell culture model based on the composite dacron/collagen scaffold for prostate cancer | By: Hu M.¹, Liu X.², Li C.², Ding Q.¹, Wang L.², Jiang H.¹  
¹Huashan Hospital, Fudan University, Dept. of Urology, Shanghai, China, ²Donghua University, Key Laboratory of Textile Science and Technology of Ministry of Education and College of Textiles, Shanghai, China |                                                                                        |
| *854 | Establishment of an androgen-sensitive patient derived xenograft model of prostate cancer         | By: Karkampouna S.¹, Grosjean J.¹, Klima I.¹, Genitsch V.², Sboner A.³, K. Y. Ng C.⁴, De Filippo M.R.⁵, Piscuoglio S.⁵, Spahn M.⁶, Rubin M.A.¹, Thalmann G.N.⁷, Kruithof-De Julio M.¹  
¹University of Bern, Dept. of BioMedical Research, Bern, Switzerland, ²University of Bern, Institute of Pathology, Bern, Switzerland, ³Institute for Computational Biomedicine, Dept. of Pathology and Laboratory Medicine, Bern, Switzerland, ⁴University of Basel, Dept. of Biomedicine, Basel, Switzerland, ⁵University of Basel, Institute of Pathology, Basel, Switzerland, ⁶Centre for Urology Hirslanden Clinic, Dept. of Urology, Zurich, Switzerland, ⁷University Hospital of Bern, Dept. of Urology, Bern, Switzerland |                                                                                        |
| 856  | Cripto blockade reduces prostate cancer reactivity to microenvironment and metastatic potential    | By: La Manna F.¹, Staender L.¹, Gray P.C.², Zoni E.¹, Karkampouna S.¹, Thalmann G.N.³, Kruithof-De Julio M.¹  
¹University of Bern, Dept. of BioMedical Research, Bern, Switzerland, ²The Salk Institute for Biological Studies, Clayton Foundation Laboratories for Peptide Biology, San Diego, United States of America, ³University Hospital of Bern, Dept. of Urology, Bern, Switzerland |                                                                                        |
| 857  | Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells | By: Iwamoto H., Izumi K., Kadono Y., Mizokami A.  
Kanazawa University Graduate School of Medical Science, Dept. of Integrative Cancer Therapy and Urology, Kanazawa, Japan |                                                                                        |
| 858  | Anti-tumor effect of oncolytic reovirus in castration resistance prostate cancer: In vitro and in vivo analysis | By: Han J.H.¹, Kim Y.², Kim B.M.², Choi S.Y.¹, Lim B.¹, Kyung Y.S.¹, You D.², Kim C-S.²  
¹Asan Medical Center, Dept. of Urology, Seoul, Korea, South, ²Asan Medical Center, Dept. of Urology, Seoul, Korea, South |                                                                                        |
| 859  | Niclosamide exerts anticancer activity via inhibition of FOXM1-mediated DNA damage response in castration resistant prostate cancer | |                                                                                        |
By: Park Y.H., Jung A.R., Kim G.E., Kim M.Y., Ha U-S., Hong S., Kim S.W., Lee J.Y. The Catholic University of Korea Seoul St. Mary's Hospital, Dept. of Urology, Seoul, Korea, South

* 861

Overcoming ABCB1-mediated olaparib resistance in advanced prostate cancer

By: Gao A., Lombard A., Liu C., Lou W., Armstrong C., Dall M., Evans C. University of California Davis, Dept. of Urology, Sacramento, United States of America

862

Impact of CT guided high-dose prostate irradiation on rodent gland regeneration

By: Zahalka A.H.,1 Brodin P.,2 Maryanovich M.,1 Watts K.L.,3 Guha C.,2 Frenette P.S.4

1Albert Einstein College of Medicine, Dept. of Cell Biology, New York City, United States of America, 2Albert Einstein College of Medicine, Dept. of Radiation Oncology, New York City, United States of America, 3Montefiore Medical Center, Dept. of Urology, New York City, United States of America, 4Albert Einstein College of Medicine, Dept. of Stem Cell and Regenerative Medicine, New York City, United States of America
Indications and oncological outcomes of the use of neoadjuvant targeted therapy in patients with localized kidney cancer

By: Voylenko O., Stakhovskyi O., Kononenko O., Pikul M., Semko S., Vitruk I., Stakhovsky E.
National Cancer Institute, Dept. of Plastic and Reconstructive Oncourology, Kiev, Ukraine

Who is dying after nephrectomy for cancer? Study of risk factors and causes of death after analyzing morbidity and mortality reviews (UroCCR-33 study)

By: Fontenil A., Bigot PB, Bensalah KB, Mejean AM, Soulié MS, Bernhard J.C.B, Salomon L.S, Charles T.C, Azzouzi AR, Larre S.L
1CHU Angers, Dept. of Urology, Angers, France, 2CHU Rennes, Dept. of Urology, Rennes, France, 3Hôpital Georges Pompidou, Dept. of Urology, Paris, France, 4CHU Toulouse, Dept. of Urology, Toulouse, France, 5CHU Bordeaux, Dept. of Urology, Bordeaux, France, 6CHU Henri Mondor, Dept. of Urology, Paris, France, 7CHU Poitiers, Dept. of Urology, Poitiers, France, 8CHU Reims, Dept. of Urology, Reims, France

A retrospective national database review analysing post-operative mortality of renal surgery in Australia

By: Brien M., Maddern G.J., Catterwell R.
1The Queen Elizabeth Hospital, Dept. of Surgery, Adelaide, Australia, 2The Queen Elizabeth Hospital, Dept. of Urology, Adelaide, Australia

Should stage III renal cell carcinoma with pN1 be classified as stage IV of the American Joint Committee on Cancer classification? A RECUR external validation

1Lund University, Dept. of Clinical Sciences Lund, Lund, Sweden, 2Haukeland University Hospital and University of Bergen, Dept. of Urology and Dept. of Clinical Medicine,
Impact of sex on prognosis of non-metastatic clear cell renal cell carcinoma patients undergoing curative surgery: An inverse probability of treatment weighting analysis

By: Fukushima H.¹, Saito K.¹, Yasuda Y.¹, Tanabe K.¹, Toide M.¹, Fukuda S.¹, Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Patil D.², Cotta B.³, Patel S.³, Master V.², Derweesh I.³, Fujii Y.¹
¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ³University of California San Diego, Dept. of Urology, San Diego, United States of America

External validation of the updated Leibovich prognostic models for prediction of oncologic outcomes in clear cell and papillary renal cell carcinoma

Singapore General Hospital, Dept. of Urology, Singapore, Singapore

Testing the external validity of CARMENA trial comparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma

By: Arora S.¹, Sood A.¹, Dalela D.¹, Patel A.¹, Keeley J.¹, Trinh Q-D.², Audrey F.³, Prokopiv U.³, Rakic N.³, Rogers C.¹, Menon M.¹, Abdollah F.¹
¹Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, ²Brigham and Women’s hospital, Dept. of Urological Surgery and Center for Surgery and Public Health, Boston, United States of America, ³Wayne State University School of Medicine, Medical School, Detroit, United States of America

Trends in the treatment of renal cell carcinoma metastases in the era of targeted therapies – a population based analysis in Germany

By: Meyer C.P.¹, Groeben C.², Koch R.², Rink M.¹, Huber J.²
¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany,
Systematic review of the role of pancreatic metastatectomy in metastatic renal cell carcinoma (mRCC)

By: Rodger F., Nair R., Holroyd D.

1Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, 2Guys and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom
Work-up and evaluation for LUTS before and after surgery
Poster Session 63

Monday 18 March 12:15 - 13:45

Location: Green Area, Room 3
Chairs: D.J.M.K. De Ridder, Leuven (BE)
K. Kobashi, Seattle (US)
T. Tarcan, Istanbul (TR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

878
ICS educational module: Cough stress test in the evaluation of female urinary incontinence: Introducing the ICS-Uniform cough stress test
By: Guralnick M.L.1, Fritel X.2, Tarcan T.3, Espuna-Pons M.4, Rosier P.F.W.5
1Medical College of Wisconsin, Dept. of Urology, Milwaukee, United States of America,
2Universite de Poitiers, Dept. of Medicine and Pharmacy, Poitiers, France,
3Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey,
4University of Barcelona, ICGON, Barcelona, Spain,
5University Medical Center Utrecht, Dept. of Urology, Utrecht, Netherlands,

879
Comparison of longitudinal health-related quality of life outcomes between the anterior and posterior surgical approach to robot-assisted radical prostatectomy
Okayama University Graduate School of Medicine, Dept. of Urology, Okayama, Japan

880
Urinary incontinence with no obvious reason at 1 month after robot-assisted radical prostatectomy strongly predicts delayed continence recovery: The longitudinal survey of questionnaires
1Jichi Medical University, Dept. of Urology, Tochigi, Japan,
2The University of Tokyo, Graduate School of Medicine, Dept. of Continence Medicine, Tokyo, Japan,
3Kyorin University, Dept. of Urology, Tokyo, Japan,
4The University of Tokyo, Graduate School of Medicine, Dept. of Rehabilitation, Tokyo, Japan,
5The University of Tokyo, Graduate School of Medicine, Dept. of Urology, Tokyo, Japan,
6The University of Tokyo, Graduate School of Medicine, Dept. of Gerontological Nursing/ Wound Care Management, Tokyo, Japan,
7Teikyo University School of Medicine, Dept. of Urology, Tokyo, Japan,
8Japan Red Cross Hospital, Dept. of Urology, Tokyo, Japan
A prospective analysis of the effects of nerve-sparing robot-assisted radical prostatectomy on lower urinary tract symptoms

Tottori University Faculty of Medicine, Dept. of Urology, Yonago, Japan

Risk of prolapse and urinary complications in adult spina bifida patients with neurogenic acontractile detrusor using clean intermittent catheterization versus Valsalva voiding

1CHU Pontchaillou, Dept. of Urology, Rennes, France, 2CHU Pontchaillou, Spina Bifida Reference Center, Rennes, France, 3CHU Rangueil, Dept. of Urology, Toulouse, France

Sarcopenia patients are clinically dissatisfied with postoperative urinary function compared with non-sarcopenia patients in robot-assisted radical prostatectomy

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan

Predictive factors for post-prostatectomy incontinence based on urodynamic evaluation

By: Majima T., Takai S., Oowaki T., Fujita T., Yasuhito F., Yoshihisa M., Masashi K., Tokunori Y., Momokazu G.
Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan

Nocturnal polyuria in males with LUTS: Prevalence and association with nocturia, IPSS and uroflowmetry

1A.O.U.I. Verona, Dept. of Urology, Verona, Italy, 2AULSS 9 Mater Salutis Hospital, Dept. of Urology, Legnago, Italy

Prospective comparative investigation of telephone follow-up in female urology

By: Balzarro M., Rubilotta E., Trabacchin N., Bassi S., Mancini V., Cerruto M.A., Illiano E., Costantini E., Artibani W.
1A.O.U.I. Verona, Dept. of Urology, Verona, Italy, 2University of Foggia, Dept. of Urology and Renal Transplantation, Foggia, Italy, 3Clinic Santa Maria Hospital, University of Perugia, Dept. of Andrology and Urogynecology, Terni, Italy
888  
Pubis-rectum length and early recovery of continence after robot-assisted laparoscopic prostatectomy  
By: Kiuchi H. , Sekii Y. , Inagaki Y. , Ueda N. , Takezawa K. , Fukuhara S. , Fujita K. , Uemura M. , Imamura R. , Nonomura N.  
Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan  

889  
Preoperative functional ultrasound imaging of the pelvic floor: Correlation with early continence outcomes post radical prostatectomy  
By: van Diepen D.C. , Chan L. , Thanigasalam R. , Leslie S. , Andre L. , Sved P. , Vasilaras A. , Tse V. , Mitterdorfer A.  
1Institute of Academic Surgery - Royal Prince Alfred & Concord Repatriation General Hospital, Dept. of Urology, Sydney, Australia, 2Concord Repatriation General Hospital, Dept. of Urology, Sydney, Australia, 3Royal Prince Alfred Hospital, Dept. of Urology, Sydney, Australia  

890  
Comparing pad use per day versus ICIQ-SF for the assessment of continence following radical prostatectomy  
1Clinica Universidad de Navarra & Hospital Universitari Son Espases, Dept. of Urology, Pamplona & Palma de Mallorca, Spain, 2Macquarie University, Dept. of Mathematics and Statistics, Sidney, Australia, 3Clinica Universidad de Navarra, Dept. of Urology, Pamplona, Spain, 4The University of Sydney, Westmead Hospital, Dept. of Urology, Sidney, Australia, 5University of Melbourne & Clinical Research Institute, Westmead Private Physiotherapy Services, Dept. of Physiotherapy, Sidney, Australia  

891  
The relationship between predominant symptom in mixed urinary incontinence and video-urodynamic findings in women – are the proposed updated NICE 2018 guidelines reasonable?  
University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom
Advances and challenges in the treatment of castration resistant prostate cancer
Poster Session 64

Monday 18 March
12:15 - 13:45

Location: Green Area, Room 4
Chairs: R. Azhar, Jeddah (SA)
        R.J. Van Soest, Rotterdam (NL)
        A. Zarkar, ()

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

893

Risk of dementia following androgen deprivation therapy for treatment of prostate cancer

By: Tully K. 1, Krasnova A. 2, Epstein M. 3, Marchese M. 1, Dickerman B. 4, Cole A.P. 1, Lipsitz S. 5, Nguyen P. 6, Kibel A. 1, Choueiri T. 7, Basaria S. 8, Mucci L. 4, Sun M. 7, Trinh Q-D. 1

1Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 2Columbia Mailman School of Public Health, Columbia Mailman School of Public Health, New York, New York, United States of America, 3SUNY Downstate Medical Center, SUNY Downstate Medical Center, New York, New York, United States of America, 4Harvard TH Chan School of Public Health, Dept. of Epidemiology, Boston, Massachusetts, United States of America, 5Brigham and Women's Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 6Brigham and Women's Hospital, Harvard Medical School, Dept. of Radiation Oncology, Boston, Massachusetts, United States of America, 7Dana Farber Cancer Institute, Harvard Medical School, Lank Center for Genitourinary Oncology, Boston, Massachusetts, United States of America, 8Brigham and Women's Hospital, Harvard Medical School, Research Program in Men's Health: Aging and Metabolism, Boston, Massachusetts, United States of America

894

Correlation of androgen deprivation therapy with cognitive dysfunction in patients with prostate cancer: A nationwide population-based study using the National Health Insurance Service database

By: Tae B.S. 1, Jeon B.J. 1, Choi H. 1, Bae J.H. 1, Park J.Y. 1, Jun C. 2, Lee J.G. 3

1Korea University Ansan Hospital, Dep. of Urology, Ansan, Korea, South, 2Korea University Anam Hospital, Dept. of Urology, Seoul, Korea, South, 3Korea University Anam Hospital, Dep. of Urology, Seoul, Korea, South

895

Disease burden and bone health in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO non-
interventional study

By: Poeppel T.D. 1, M?llers M. 2, Assa E. 3, Kalinovsky J. 4, Benson A. 5, Selinski I. 3
1University of Duisburg-Essen and German Cancer Consortium (DKTK), partner site University Hospital Essen, Dept. of Nuclear Medicine, Essen, Germany,
2Knappschaftskrankenhaus Dortmund, Dept. of Nuclear Medicine, Dortmund, Germany,
3Helios Dr. Horst-Schmidt-Kliniken, Institute of Nuclear Medicine, Wiesbaden, Germany,
4Bayer Consumer Care AG, Medical Affairs – Oncology, Basel, Switzerland,
5Bayer HealthCare, Medical Affairs – Statistics, Whippany, United States of America

896

Overall adverse events in patients treated with Radium223 for metastatic castration resistant prostate cancer: Registry study and analysis of real life data from EudraVigilance

Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy

897

Circulating tumour cells in patients with metastatic castration resistant prostate cancer under treatment with cabazitaxel - A prospective biomarker study from the Hellenic Oncology Research Group

Hellenic Oncology Research Group, Dept. of Medical Oncology, Athens, Greece

* 898

Next generation sequencing (NGS) in metastatic castration resistant prostate cancer (mCRPC) to identify targets for individualized treatment – Is it feasible in daily routine?

By: Heidenreich A., Nestler T., Paffenholz P., Büttner R., Pfister D.
University of Cologne, Dept. of Urology, Cologne, Germany

900

Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Long-term overall survival and safety analyses of the phase 3 PREVAIL study

By: Armstrong A. 1, Tombal B. 2, Saad F. 3, Parli T. 4, Phung D. 5, Beer T.M. 6
1Duke University, Dept. of Medicine and Surgery, Durham, United States of America,
2Clinique Universitaires Saint-Luc, Dept. of Urology, Brussels, Belgium,
3University of Montreal Hospital Center, Dept. of Urologic Oncology, Montreal, Canada,
4Pfizer Inc., Clinical Development, San Francisco, United States of America,
5Astellas Pharma Inc., Dept. of Biostatistics, Leiden, Netherlands, The,
6OHSU Knight Cancer Institute, Oregon Health & Science University, Dept. of Hematology-Medical Oncology, Portland, United States of America

901

Performance of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer men: A head to head comparison based on a 2014-2017 French population-based study
902

Open-label, phase I, dose escalation study to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E (GEN0101) in castration-resistant prostate cancer patients

By: Fujita K.¹, Nakai Y.¹, Kato D.¹, Kawashima A.¹, Ujike T.¹, Nagahara A.¹, Uemura M.¹, Imamura R.¹, Okihara K.², Ukimura O.², Kaneda Y.³, Nonomura N.¹
¹Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan, ²Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, ³Osaka University Graduate School of Medicine, Division of Gene Therapy Science, Suita, Japan

903

Age influence on adverse events in patients treated with abiraterone plus prednisone, enzalutamide and radium-223 for metastatic castration resistant prostate cancer: Analysis of real life data from Eudra Vigilance database.

Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy

904

Late administration of luteinizing hormone-releasing hormone agonists, the impact on testosterone (T) suppression, and frequency of T and PSA testing in prostate cancer in the real-world

By: Crawford E.D.C.¹, Boldt-Houle D.², Concepcion R.³, Atkinson S.²
¹University of Colorado, Dept. of Urology, Aurora, United States of America, ²Tolmar Pharmaceuticals, Inc., Dept. of Medical Affairs, Lincolnshire, United States of America, ³Integra Connect, Dept. of Urologic Clinical, West Palm Beach, United States of America

905

Switching from GnRH agonists to antagonists for castration-resistant prostate cancer as a second-line hormonal therapy: A multicenter prospective study

By: Sugimura R.¹, Kawahara T.¹, Yokomizo Y.², Ohtake S.², Kuroda S.¹, Taku M.¹, Ito H.¹, Izumi K.¹, Miyoshi Y.¹, Yao M.², Miyamoto H.³, Uemura H.¹
¹Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Dept. of Urology, Yokohama, Japan, ³University of Rochester, Dept. of Surgical Pathology and Laboratory Medicine, Rochester, United States of America

13:34 - 13:41

The advances in the treatment of CRPC
R.J. Van Soest, Rotterdam (NL)
Alternative approaches to the small renal mass
Poster Session 65

Monday 18 March
12:15 - 13:45

Location: Green Area, Room 5
Chairs: A. Bex, Amsterdam (NL)
M.C. Mir Maresma, Barcelona (ES)
D. Pushkar, Moscow (RU)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

906
A novel trifecta to simplify the assessment of perioperative outcomes after robot assisted partial nephrectomy for cT1 renal masses: Results of a multicenter series

By: Brassetti A., Anceschi U., Tuderti G., Anceschi S., Ferriero M.C., Brassetti A., Mastroianni R., Flammia R.S., Gallucci M., Simone G.
Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

907
Strict trifecta and pentafecta rates in laparoscopic partial nephrectomy: A single centre retrospective study

Hospital Universitario Virgen de la Victoria, Dept. of Urology, Malaga, Spain

908
Mid-term oncologic and functional outcomes of endoscopic robot-assisted simple enucleation for renal tumors: Results from a tertiary referral centre

University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy

* 909
Pre- or peri-ablative biopsies: A comparison of different diagnostic strategies in small renal masses treated with ablation

By: Widdershoven C.V. 1, Aarts B.M. 1, Van Heerik A. 2, Zondervan P.J. 2, Klompenhouwer E.G. 1, Lagerveld B.L. 3, Bex A 1
1Antoni van Leeuwenhoek, Dept. of Urology, Amsterdam, Netherlands, The, 
2Amsterdam UMC, Dept. of Urology, Amsterdam, Netherlands, The, 
3OLVG, Dept. of Urology, Amsterdam, Netherlands, The
**Active surveillance vs. nephron sparing surgery for small renal mass in very elderly patients: A competing risk analysis**


1 Fundacion Instituto Valenciano Oncologia, Dept. of Urology, Valencia, Spain, 2 SSS Annunziata Hospital, Dept. of Urology, Chieti, Italy, 3 University of Trieste, Dept. of Urology, Trieste, Italy, 4 Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, 5 Urological Research Institute, IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 6 Kidney Center, Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan, 7 UCSD, Dept. of Urology, San Diego, United States of America, 8 Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, 9 Urological Science Institute, Yonsei University College of Medicine, Dept. of Urology, Seoul, Korea, South, 10 Technical University of Munich, Dept. of Urology, Munich, Germany, 11 ORSI Academy and Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium, 12 University of Grenoble, Dept. of Urology, Grenoble, France, 13 Fundacio Puigvert, Dept. of Urology, Barcelona, Spain, 14 School of Medicine, University of Turin-San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, 15 James Buchanan Brady Urological Institute and Johns Hopkins Medicine, Dept. of Urology, Baltimore, United States of America, 16 Glickman Urological and Kidney Cancer Center; Cleveland Clinic Foundation, Dept. of Urology, Cleveland, United States of America, 17 KULeuven, Dept. of Urology, Leuven, Belgium, 18 VCU Medical Center, Dept. of Urology, Richmond, United States of America

**Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A retrospective cohort study**

By: Tan W.S. 1, Trinh Q-D. 2, Hayn M. 3, Marchese M. 2, Lipsitz S. 4, Nabi J. 2, Kilbridge K. 5, Kibel A. 2, Sun M. 5, Chang S. 2, Sammon J. 3

1 Imperial College Healthcare, Dept. of Urology, London, United Kingdom, 2 Brigham and Women’s Hospital, Dept. of Urology, Boston, United States of America, 3 Maine Medical Center, Dept. of Urology, Portland, United States of America, 4 Brigham and Women’s Hospital, Center for Surgery and Public Health, Boston, United States of America, 5 Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, United States of America

**Cryoablation vs partial nephrectomy for T1a renal cell carcinoma: A comparison of survival benefit stratified by tumour size**

By: Liao X., Qiu S., Bao Y., Yang L., Wei Q.

West China Hospital, Sichuan University, Dept. of Urology, Institute of Urology, Chengdu, China

**Is cryoablation an effective treatment for trifecta outcomes in small renal masses? Long-term results from a multicenter cryotherapy registry**

By: Silvestri T. 1, Piasentin A. 1, Barbati G. 2, Gregorio C. 3, De Concilio B. 4, Celia A. 4, Cicero C. 5, Bertolotto M. 6, Stacul F. 6, Cova M.A. 6, Botli M. 1, Rizzo M. 1, Liguori
Cryoablation versus partial nephrectomy for clinical T1b renal cell carcinoma: Comparison of survival outcomes in a matched cohort

By: Zheng X.N., Yang L., Wei Q.
West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China
920 Transcriptome-wide analysis of Peyronie’s disease plaques using RNA sequencing uncovers targetable signalling pathways for medical therapy

By: Milenkovic U. 1, Janky R. 2, Hatzichristodoulou G. 3, Van Renterghem K. 4, Cellek S. 5, Bivalacqua T.J 6, De Ridder D. 1, Albersen M. 1
1KU Leuven, Dept. of Development and Regeneration, Faculty of Medicine, Leuven, Belgium, 2KU Leuven, VIB Nucleomics Core, Leuven, Belgium, 3Julius-Maximilians-University of Würzburg, Dept. of Urology and Pediatric Urology, Wurzburg, Germany, 4University of Hasselt, Faculty of Medicine, Hasselt, Belgium, 5Anglia Ruskin University, Faculty of Health, Education, Medicine and Social Care, Chelmsford, United Kingdom, 6Johns Hopkins School of Medicine, James Buchanan Brady Urological Institute and Dept. of Urology, Baltimore, United States of America

922 Low intensity shockwave therapy (LiST) may promote angiogenesis and alter α1/α2 adrenergic receptors ratio with decrease in sympathetic activity in the erectile tissue of naturally aged rats

By: Sokolakis I. 1, Dimitriadis F. 2, Psalla D. 3, Kalyvianakis D. 2, Hatzichristou D. 2
1Julius-Maximillian University Medical Centre of Wuerzbrug, Dept. of Urology and Paediatric Urology, Wuerzburg, Germany, 2Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, 3Aristotle University of Thessaloniki, Faculty of Veterinary Medicine, Laboratory of Pathology, Thessaloniki, Greece

923 Contribution of Orai channels to contraction of rat and human corpus cavernosum increases with aging

By: Garcia Rojo E. 1, Angulo J. 2, García-Gómez B. 1, Justo Quintas J. 1, Santos-Pérez de la Blanca R. 1, Medina-Polo J. 3, Romero Otero J. 1
1Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, 2Hospital Universitario Ramón y Cajal, Dept. of Histology and Histopathology Research, Madrid, Spain, 3al Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain

924 Simvastatin and the rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie’s disease-derived fibroblasts via inhibition of YAP/TAZ
nuclear translocation

By: Milenkovic U. 1, Ilg M.M. 2, Zuccato C. 3, Ramazani Y. 4, De Ridder D. 1, Albersen M. 1

1KU Leuven, Dept. of Development and Regeneration, Faculty of Medicine, Leuven, Belgium, 2Anglia Ruskin University, Faculty of Medical Sciences, Chelmsford, United Kingdom, 3University of Padua, Faculty of Medicine and Surgery, Padua, Italy, 4KU Leuven, Dept. of Pediatric Nephrology and Growth and Regeneration, Leuven, Belgium

927 Receptors and sensory nerve pathways of the penis: A three dimensional computer assisted anatomical dissection (3DCAAD)

By: Flochlay M. 1, Diallo D. 2, Bessede T. 2, Prudhomme M. 3, Costa P. 1, Kharlamov E. 4, Mitrokhin V. 5, Aleksandrov B. 6, Droupy S. 1

1CHU de Nîmes, Dept. of Urology Andrology, Nîmes, France, 2University Paris XI, Lab of experimental surgery, Le Kremlin Bicêtre, France, 3CHU de Nîmes, Lab of surgical anatomy, Nîmes, France, 4University of Oslo, Dept. of Computer science, Oslo, Norway, 5Russian National Research Medical University, Fundamental and Applied Physiology, Moscow, Russia, 6Rostagroexport ltd, Dept. of Research, Moscow, Russia

928 Adipose-derived stem cells (ASCs) combined with control-released DF-PEG/GCS hydrogel scaffold restore the erectile function in a diabetes rat model

By: Lu M., Xiao D.D., Ti Y.R., Zou L., Yan H., Lu M.

Shanghai Renji Hospital, Dept. of Urology and Andrology, Shanghai, China

929 Effects of exosomes from adipose-derived stem cells on recovery of erectile function in a bilateral cavernous nerve injury rat model


Seoul St. Mary's Hospital, The Catholic University of Korea, Dept. of Urology, Seoul, Korea, South

930 Human induced pluripotent stem cell-derived testosterone-producing Leydig cells ameliorate serum testosterone level in rats

By: Takaki I. 1, Masato F. 2, Takashi A. 3

1Kobe University, Dept. of Urology, Kobe, Japan, 2Kobe University, Dept. of Urology, Kobe, Afghanistan, 3Kobe University, Dept. of iPS cell Aplications, Kobe, Japan

931 Testosterone associated relaxation of human corpus cavernosum of patients with erectile dysfunction: Are non genomic pathways involved?

By: Soebadi M.A. 1, Van Den Broeck T. 2, Raets L. 3, Brone B. 4, Van Renterghem K. 2

1Laboratory of Experimental Urology, Dept. of Development and Regeneration, Leuven, Belgium, 2Jessa Hospital, Dept. of Urology, Hasselt, Belgium, 3University of Hasselt, Dept. of Urology, Hasselt, Belgium, 4University of Hasselt, Dept. of Biomedical Research Institute, Hasselt, Belgium
Loss-of-function mutation in FGFR1 gene as a cause of idiopathic hypogonadotrophic hypogonadism

By: Wang D., Niu Y., Chen Y., Liu J.
Tongji Hospital, Dept. of Urology, Wuhan, China

Can we cure erectile dysfunction?
To be confirmed
Reconstructive aspects of the upper urinary tract and bladder
Poster Session 67

Monday 18 March
12:15 - 13:45

Location: Green Area, Room 11
Chairs: Y. Abu-Ghanem, Ramat Gan (IL)
E.L. Koldewijn, ()
A. Vaze, Mumbai (IN)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

933

The long-term effect of bladder augmentation on renal function

University College London Hospitals NHS Foundation Trust, Dept. of Reconstructive Urology, London, United Kingdom

934

Extraperitoneal robotic YV-plasty for recurrent bladder neck contracture

By: Brachlow J.F., John H., Padevit C., Horton K.
Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

935

Mitrofanoff continent urinary diversion: Better life comfort in spite of surgical complications

Habib Bourguiba Hospital, Dept. of Urology, Sfax, Tunisia

936

Long-term outcomes of Mitrofanoff channel formation in adults

By: O'Connor E.¹, Malde S.², Raja L.¹, Foley C.L.³, Taylor C.J.², Wood D.N.¹, Ockrim J.L.¹, Greenwell T.J.¹
¹University College Hospital at Westmoreland Street, Dept. of Urology, London, United Kingdom, ²Guy's and St Thomas's Hospital Trust, Dept. of Urology, London, United Kingdom, ³Lister Hospital, Dept. of Urology, Stevenage, United Kingdom

938

Transvesicle laparoendoscopic single-site surgery for repair of vesicovaginal fistula with a homemade single-port device: Experience in 42 patients

Sun Yat-sen memorial hospital, Dept. of Urology, Guangzhou, China

939

Retrosigmoid ileal conduit with no transposition of the left ureter reduces the risk of ureteroileal anastomotic strictures after radical cystectomy: Mid-term follow-up
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>940</td>
<td>The long-term results of ureteral reimplantation by different antireflux techniques: Analysis of the trifecta, functional, anatomic, and surgical outcomes</td>
<td>By: Tseng C-S., Wong S-M., Kuo M-C., Chow P-M., Huang C-Y., Pu Y-S., Chang H-C.</td>
<td>National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan</td>
</tr>
<tr>
<td>941</td>
<td>Autophagy is needed during the differentiation of adipose derived stem cells to functional smooth muscle cells for use in bladder engineering</td>
<td>By: Salemi S., Haralampieva-Mohr D., Kranzbühler B., Mortezavi A., Sulser T., Eberli D.</td>
<td>University Hospital Zürich, Dept. of Urology, Zürich, Switzerland</td>
</tr>
<tr>
<td>944</td>
<td>Image based 3D reconstruction of the bladder using structure-from-motion – Proof of principle in a phantom model</td>
<td>By: Ujwala P., Pentek Q., Hein S., Miernik A., Reiterer A.</td>
<td>INATECH, University of Freiburg, Dept. of Sustainable Systems Engineering, Freiburg, Germany, Medical Center, University of Freiburg, Dept. of Urology, Division of Urotechnology, Freiburg, Germany</td>
</tr>
</tbody>
</table>
History of urology

Poster Session 68

Monday 18 March
12:15 - 13:45

Location: Green Area, Room 12

Chairs: L.A. Fariña-Pérez, Vigo (ES)
To be confirmed
P. Van Kerrebroeck, Maastricht (NL)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

956

Urology in modern/contemporary music, literature and art

By: Månsson K.G.W., Skånes Universitetssjukhus, Dept. of Urology, Malmö, Sweden

949

Urological disease as a basis for miracles in the canonization process of the Roman Catholic church

By: Touma N. 1, Duffin J. 2
1Queen's University, Dept. of Urology, Kingston, Canada, 2Queen's University, Dept. of History and Medicine, Kingston, Canada

950

Hypersexuality: An important urological problem and cause of death in the French Valois kings

By: Van Kerrebroeck P., Maastricht University Medical Center, Dept. of Urology, Maastricht, Netherlands, The

951

Medical illustration in the work 'urogenital' pathology and 'morphology and function of vesico-prostato-urethral musculature' by the spanish urologist Salvador Gil Vernet

By: Gil-Vernet Sedo J.M., Teknon Medical Center, Dept. of Urology, Barcelona, Spain

952

Francis Seymour Kidd (1878–1934): Urologist and co-founder of British Journal of Urology (BJU)

By: Lee X.W.J., Grice P., Goddard J.
Leicester General Hospital, Dept. of Urology, Leicester, United Kingdom

954

Gonorrhoea! What the Dickens?

By: Goddard J.C. 1, Cambridge N. 2
1University of Leicester Hospitals NHS Trust, Dept. of Urology, Leicester, United...
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>955</td>
<td>Urology in Persia: From Avicenna’s canon of medicine to modern urology in today’s Iran</td>
<td>Rahnama’i M.S. ¹, Hajebrahiimi S. ², Tavakoli F. ², Van Kerrebroeck Ph.E.V. ³, Kajbafzadeh A. ⁴</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Uniklinik RWTH Aachen, Dept. of Urology, Aachen, Germany, ²Research Center for Evidence Based Medicine (RCEBM), Tabriz University of Medical Sciences, Dept. of Urology, Tabriz, Iran, ³Maastricht University, Dept. of Urology, Maastricht, Netherlands, The, ⁴Pediatric Urology and Regenerative Medicine Research Center, Children’s Hospital Medical Center, Tehran University of Medical Sciences, Dept. of Urology, Tehran, Iran</td>
</tr>
<tr>
<td>957</td>
<td>Male genitalia votives to Gods giving specific disease information during Ancient Ages</td>
<td>Guner E., Seker K.G., Sam E. University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Dept. of Urology, Istambul, Turkey</td>
</tr>
<tr>
<td>958</td>
<td>Giorgio Nicolich, father of urology in Trieste</td>
<td>Boschian R. ¹, Ponte E. ², Pavan N. ¹, Rizzo M. ¹, Rebez G. ¹, Liguori G. ¹, Trombetta C. ¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹University of Trieste, Dept. of Urology, Trieste, Italy, ²University of Trieste, Dept. of Medical History, Trieste, Italy</td>
</tr>
<tr>
<td>959</td>
<td>De Gironcoli Franco 1982 Gorizia – 1979 Vienna, Urologist, “Visionnaire” and Poet</td>
<td>Fandella A. Casa di Cura Rizzola, Dept. of Urology, San Donà di Piave Ve, Italy</td>
</tr>
<tr>
<td>961</td>
<td>The double lithotome caché</td>
<td>Álvarez-Vijande R., D’Anna M., Costa-Grau M. Hospital Clínic of Barcelona, Dept. of Urology, Barcelona, Spain</td>
</tr>
</tbody>
</table>
Ablative surgery for BPO relief: Lasers on prime time

Poster Session 69

Monday 18 March 12:15 - 13:45

Location: Green Area, Room 20

Chairs: M. Rieken, Zürich (CH)
        G.Y. Robert, Bordeaux (FR)
        To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

962

Photoselective vaporization of the prostate: Evaluation of conflicts of interest and industrial sponsorship stratified by favorability of the study outcome

By: Wettstein M.S.¹, Pazhepurackel C.¹, Neumann A.S.¹, Woon D.T.S.², Herrera-Caceres J.O.², Poyet C.¹, Sulser T.¹, Kulkarni G.S.², Hermanns T.¹

¹University Hospital of Zurich, Dept. of Urology, Zurich, Switzerland, ²Princess Margaret Cancer Centre, University Health Network, Division of Urology, Dept. of Surgery, Toronto, Canada

963

Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate: Results of the UNBLOCS randomized controlled trial

By: Hashim H.¹, Lane A.², Worthington J.², Noble S.², Brooks S.², Cotterill N.³, Page T.⁴, Swami S.⁵, Abrams P.¹

¹North Bristol NHS Trust, Bristol Urological Institute, Bristol, United Kingdom, ²University of Bristol, School of Social and Community Medicine, Bristol, United Kingdom, ³Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, ⁴The Newcastle upon Tyne Hospitals NHS Foundation Trust, Dept. of Urology, Newcastle, United Kingdom, ⁵NHS Grampian, Academic Urology Unit, Aberdeen, United Kingdom

964

Postoperative complications after holmium laser enucleation of the prostate in a high volume center with more than 15 years of experience

By: Capogrosso P.¹, Pozzi E.², Abbate C.¹, Chierigo F.², Schifano N.¹, Zuabi R.², Belladelli F.², Cazzaniga W.¹, Ventimiglia E.¹, Matloob R.¹, Scattoni V.¹, Dehò F.¹, Mirone V.³, Gaboardi F.⁴, Salonia A.¹, Montorsi F.¹

¹IRCCS Ospedale San Raffaele, Unit of Urology, URI, Milan, Italy, ²Università Vita-Salute San Raffaele, Unit of Urology, URI, Milan, Italy, ³Department of Neurosciences, Sciences of Reproduction and Odontostomatologia, Urology Unit, University of Naples “Federico II”, Dept. of Urology, Naples, Italy, ⁴IRCCS Ospedale San Raffaele Turro, Unit of Urology, Milan, Italy

965

Major acute cardiovascular events after transurethral prostate surgery: A population-based analysis
966 Complications after surgery for benign prostatic enlargement and medication use: A population-based cohort study in Ontario, Canada

By: Matta R. 1, Labossiere J.R.H. 2, Wallis C.J.D. 1, Hird A.E. 1, Kulkarni G.S. 1, Kodama R.T. 1, Carr L.K. 1, Radomski S.B. 1, Herschorn S. 1, Nam R.K. 1
1 University of Toronto, Dept. of Urology, Toronto, Canada, 2 University of Alberta, Dept. of Urology, Edmonton, Canada

967 Relationship between recovery of urinary continence after holmium laser enucleation of the prostate (HoLEP) and preoperative membranous urethral length on magnetic resonance imaging

By: Zhang F., Liu K., Xiao C., Ma L.
Peking University, Dept. of Urology, Beijing, China

968 Outcomes of holmium laser enucleation of the prostate in acute-on-chronic urinary retention with high residual volumes

By: Guest K., Whiting D., Penev B., Smith T., Cynk M.
Maidstone Hospital, Dept. of Urology, Maidstone, United Kingdom

969 Influence of the median lobe on the results at 4 years of the prostate vaporization by GreenLight laser®

By: Vanalderwerelt V., Grevez T., Pradère B., Faivre D’arcier B., Bruyère F.
CHRU of Tours, Dept. of Urology, Tours, France


Comparing transurethral endoscopic enucleation of the prostate using 980nm diode laser vs. bipolar-plasmakinetic: Dual-centre, noninferiority, randomized controlled trial with 2-year follow-up results

By: Zou Z.¹, Xu A.², Chen B.², Chen J.³, Duan C.⁴, Gao Y.², Wang Y.⁵, Zheng S.², Liu C.², Liang C.¹

¹The First Affiliated Hospital of Anhui Medical University, Dept. of Urology, Hefei, China, ²Zhujiang Hospital of Southern Medical University, Dept. of Urology, Guangzhou, China, ³The Second Affiliate Hospital of Shantou University Medical College, Dept. of Urology, Shantou, China, ⁴Southern Medical University, Dept. of Biostatistics, School of Public Health, Guangzhou, China, ⁵Ludwig-Maximilians University, Dept. of Urology, Munich, Germany

Effect of preoperative urethral dilatation during HoLEP on preventing urethral stricture: Randomized controlled study

By: Shin Y.S., Park J.K.
Chonbuk National University Medical School, Dept. of Urology, Jeonju, Korea, South

Withdrawn
To be confirmed

Comparison of perioperative course and short term outcome of aquablation, laser enucleation, greenlight vaporisation and TUR-P

By: Bach T.¹, Wuelfing C.², Anheuser P.³, Tauber S.³, Brunken C.⁴, Gross A.J.⁵
¹Asklepios Hospital Harburg, Dept. of Urology, Hamburg, Germany, ²Asklepios Hospital Altona, Dept. of Urology, Hamburg, Germany, ³Asklepios Hospital Wandsbek, Dept. of Urology, Hamburg, Germany, ⁴Asklepios Westklinikum, Dept. of Urology, Hamburg, Germany, ⁵Asklepios Hospital Barmbek, Dept. of Urology, Hamburg, Germany

Thulium vapoenucleation of the prostate versus holmium laser enucleation of the prostate: A prospective randomized trial with 24-month follow-up
Impact of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: A lesson from five-year serial follow-up data

By: Kim S-E. ¹, Hwang Y.C. ¹, Yoo S. ², Chun S.J. ³, Park J. ², Cho S.Y. ², Cho M.C. ², Son H. ², Jeong H. ², Oh S-J. ¹, Kim S.W. ¹, Paick J-S. ⁴
¹Seoul National University Hospital, Dept. of Urology, Seoul, Korea, South, ²Boramae Medical Center, Dept. of Urology, Seoul, Korea, South, ³Gwangju Veterms Hospital, Dept. of Urology, Gwangju, Korea, South, ⁴Mediplex Sejong Hospital, Dept. of Urology, Incheon, Korea, South
Mini invasive approaches for upper tract urothelial cancer treatment
Expert-Guided Poster Tour 14

**Location:** Green Area, Room A (Expert-Guided Poster Tours)

**Chairs:** To be confirmed
S. Shariat, Vienna (AT)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

---

**Introduction**
S. Shariat, Vienna (AT)
To be confirmed

---

**PT352**
Withdrawn
To be confirmed

**PT353**
Upper tract urothelial carcinoma and paired intravesical recurrences: Are they clonally related?

By: van Doeveren T.¹, Van Leenders A.G.J.L.H.², Dinjens W.N.M.², Van De Werken H.J.G.³, Van Leeuwen P.J.⁴, Van Riet J.³, Boormans J.L.¹

¹Erasmus MC, University Medical Center Rotterdam, Dept. of Urology, Rotterdam, Netherlands, The
²Erasmus MC, University Medical Center, Dept. of Pathology, Rotterdam, Netherlands, The
³Erasmus MC, University Medical Center, Cancer Computational Biology Center, Rotterdam, Netherlands, The
⁴Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The

**PT355**
Comparison of oncological and perioperative outcomes of open, laparoscopic, and robotic nephroureterectomy approaches in patients with non-metastatic upper-tract urothelial carcinoma

By: Kim H.J.¹, Kim T.², Song S.H.¹, Lee H.M.¹, Kwon O.S.³, Oh J.J.¹, Lee S.E.¹, Hong S.K.², Byun S.S.¹

¹Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, Korea, South
²Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, Korea, South
³Hallym University Kangnam Sacred Heart Hospital, Dept. of Urology, Seoul, Korea, South

**PT356**
Do laparoscopic or open approach distal ureter for bladder cuff during RNU impact: Oncological impact outcomes?
PT357

Lymph node dissection for patients with invasive upper tract urothelial carcinoma managed by radical nephroureterectomy

By: Li Z. 1, Li X. 2, Zhou F. 3, Xiao K. 1, Han H. 3, Zhang X. 1, Fang J. 1, Guo J. 1

1Shenzhen People’s Hospital, Dept. of Urology, Shenzhen, China, 2The Seventh Affiliated Hospital?Sun Yat-sen University, Dept. of Oncology, Shenzhen, China, 3Sun Yat-sen University Cancer Cente, Dept. of Urology, GuangZhou, China

PT358

The impact of histological variants on survival in in upper urinary tract urothelial carcinoma patients treated with nephroureterectomy: A multicenter collaboration

By: Zamboni S. 1, Foerster B. 2, Abufaraj M. 2, Seisen T. 3, Roupret M. 3, De La Taille A. 4, Peyronnet B. 5, Bensalah K. 6, Wirth M.P. 7, Novotny V. 7, Soria F. 8, Chlosta P. 9, Antonelli A. 10, Simeone C. 10, Baumeister P. 1, Mattei A. 1, Montorsi F. 11, Simone G. 12, Gallucci M. 12, Matsumoto K. 13, Karakiewicz P.I. 14, Briganti A. 11, Xylinas E. 15, Shariat S.F. 2, Moschini M. 2

1Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 2Vienna General Hospital, Medical University of Vienna, Dept. of Urology, Vienna, Austria, 3Pitié-Salpêtrière Hospital, Assistance-Publique Hôpitaux de Paris; Pierre et Marie Curie Medical School, University Paris 6, Academic Dept. of Urology, Paris, France, 4Centre Hospitalier Universitaire Mondor Assistance Publique des Hôpitaux de Paris, INSERM U955Eq07, Dept. of Urology, Paris, France, 5Hospit Pontchaillou, CHU Rennes, Dept. of Urology, Rennes, France, 6Rennes University Hospital (France), 2 rue Henri Le Guillou, Rennes, France, 35000, Dept. of Urology, Rennes, France, 7University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, 8Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria, Dept. of Urology and Andrology, Vienna, Austria, 9Jagiellonian University, Dept. of Urology, Krakow, Poland, 10Spedali Civili Hospital of Brescia, University of Brescia, Dept. of Urology, Brescia, Italy, 11Urological Research Institute, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, 12Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 13Kitasato University School of Medicine, Dept. of Urology, Kanagawa, Japan, 14University of Montreal, Dept. of Urology, Montreal, Canada, 15Bichat Hospital, Paris Descartes University, Dept. of Urology, Paris, France

PT359

Psoas major muscle volume predicts the prognosis of patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy


Tokai University, Dept. of Urology, Isehara, Japan
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT360</td>
<td><strong>The crucial role of ureteroscopy in the diagnostic/therapeutic pathway of upper tract urothelial carcinoma</strong></td>
<td>Gallioli A. 1, Breda A. 1, Boissier R. 1, Territo A. 1, Gaya J.M. 1, Martínez M.J. 2, Gavrilov P. 1, Mercadé A. 1, Regis F. 1, Palou Redorta J. 1</td>
<td>Fundació Puigvert, Dept. of Urology, Barcelona, Spain, Fundació Puigvert, Dept. of Radiology, Barcelona, Spain</td>
</tr>
<tr>
<td>PT362</td>
<td><strong>Are urine cytology, retrograde pyelography, and ureteroscopy still routinely required for all patients with upper tract urothelial cancer in the modern era of cross-sectional imaging?</strong></td>
<td>Elawdy M. 1, Osman Y. 1, Taha D.E. 1, Abd El-Hamid M. 2, Abouelkheir R. 3, Elsaeed E. 1</td>
<td>Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt, Urology and Nephrology Center, Mansoura University, Dept. of Pathology, Mansoura, Egypt, Urology and Nephrology Center, Mansoura University, Dept. of Radiology, Mansoura, Egypt</td>
</tr>
<tr>
<td>PT363</td>
<td><strong>Laparoscopic/robotic nephroureterectomy comparing intra-corporeal versus open extra-vesical bladder cuff excision</strong></td>
<td>Kuo W-T, Lin J, Yu C, Tsai C.M</td>
<td>Kaohsiung Veteran General Hospital, Dept. of Urology, Kaohsiung, Taiwan</td>
</tr>
<tr>
<td>PT365</td>
<td><strong>Developing a prediction model for disease-free survival from upper urinary tract urothelial carcinoma in the Korean population: A retrospective multicenter study</strong></td>
<td>Kim S.H. 1, Song M.K. 2, Hong B. 3, Kang S.H. 4, Jeong B.C. 5, Ku J.H. 6, Seo H.K. 7</td>
<td>Center for Prostate Cancer, National Cancer Center, Dept. of Urology, Goyang-si, Korea, South, Research institute and National Cancer Center, Biometrics Research Branch, Goyang-si, Korea, South, Asan Medical Center, Dept. of Urology, Seoul, Korea, South, Korea University Anam Hospital, Korea University College of Medicine, Dept. of Urology, Seoul, Korea, South, Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, Korea, South, Seoul National University Hospital, Dept. of Urology, Seoul, Korea, South, Center for Prostate Cancer, Hospital Biomarker Branch, Research Institute, National Cancer Center, Dept. of Urology, Goyang, Korea, South</td>
</tr>
<tr>
<td>PT366</td>
<td><strong>The impact of preoperative blood-based inflammation markers and tumor size on oncologic outcomes in patients with upper tract urothelial carcinoma</strong></td>
<td>Jan H-C., Hu C-Y., Yang W-H., Ou C-H.</td>
<td>National Cheng-Kung University Hospital, Dept. of Urology, Tainan, Taiwan</td>
</tr>
<tr>
<td>PT367</td>
<td><strong>Accurate clinical T3 staging by a computed tomography scoring system is an independent preoperative predictor of survival in patients with urothelial carcinoma of the ureter</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PT368

**Obesity-specific effect of sex on prognosis of upper tract urothelial carcinoma patients undergoing radical nephroureterectomy: A Japanese multicenter study**

By: Fukushima H. 1, Saito K. 1, Yasuda Y. 1, Uehara S. 1, Kijima T. 1, Yoshida S. 1, Yokoyama M. 1, Ishioka J. 1, Matsuoka Y. 1, Kihara K. 1, Koga F. 2, Okuno T. 3, Arisawa C. 4, Kamata S. 5, Nagahama K. 6, Masuda H. 7, Yonese J. 8, Kogeyama Y. 9, Noro A. 10, Tsuji T. 11, Morimoto S. 12, Fujii Y. 1

1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, 3Toride Medical Center, Dept. of Urology, Ibaraki, Japan, 4Tobu Chiiki Hospital, Dept. of Urology, Tokyo, Japan, 5Soka Municipal Hospital, Dept. of Urology, Soka, Japan, 6National Center for Global Health and Medicine, Konodai Hospital, Dept. of Urology, Chiba, Japan, 7National Cancer Center Hospital East, Dept. of Urology, Chiba, Japan, 8Canter Institute Hospital of Japanese Foundation for Cancer Research, Dept. of Urology, Tokyo, Japan, 9Saitama Cancer Center, Dept. of Urology, Saitama, Japan, 10Saitama Red Cross Hospital, Dept. of Urology, Saitama, Japan, 11Tokyo Metropolitan Otsuka Hospital, Dept. of Urology, Tokyo, Japan, 12Tsuchiura Kyodo General Hospital, Dept. of Urology, Ibaraki, Japan

PT370

**Can we predict the histopathologic grade of upper tract urothelial carcinoma based on the ureteroscopic appearance?**

By: Freund J.E. 1, Legemate J.D. 1, Baard J. 1, Saeb-Parsy K. 2, Wiseman O. 2, Doizi S. 3, Emiliani E. 4, Breda A. 4, Boodt B-J. 5, Van Haarst E.P. 6, Leeflagh M.M.G. 7, Kamphuis G.M. 1

1Amsterdam UMC, University of Amsterdam, Dept. of Urology, Amsterdam, Netherlands, 2Cambridge University, Cambridge Hospitals NHS Trust, Dept. of Urology, Cambridge, United Kingdom, 3Hôpital Tenon, Sorbonne Université, Dept. of Urology, Paris, France, 4Fundacion Puigvert, University Autonoma de Barcelona, Dept. of Urology, Barcelona, Spain, 5Flevoziekenhuis, Dept. of Urology, Almere, Netherlands, The, 6OLVG, Dept. of Urology, Amsterdam, Netherlands, The, 7Amsterdam UMC, University of Amsterdam, Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam, Netherlands, The

PT372

**Retrograde pyelography before radical nephroureterectomy for upper urinary tract urothelial carcinoma aggravates intravesical tumor recurrence**

By: Ko Y.H., Choi J.Y., Song P.H., Moon K.H., Jung H.C.

Yeungnam University, Dept. of Urology, Daegu, Korea, South
Local treatment of prostate cancer
Expert-Guided Poster Tour 15

Monday 18 March
13:30 - 15:30

Location: Green Area, Room B (Expert-Guided Poster Tours)
Chairs: To be confirmed
        A. Lamb, Oxford (GB)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The posters will be on display for 30 minutes before the start of the session. During the Poster Tour, two experts acting as moderators, will ask questions to the poster presenters.

---

**Introduction**
To be confirmed
A. Lamb, Oxford (GB)

**PT373**
The effect of US Preventive Services Task Force’s screening recommendation on trifecta and pentafecta outcomes in robot-assisted laparoscopic prostatectomy based on analysis of a single-surgeon series

By: Bhat K.R.S., Onol F., Rogers T., Jenson C., Patel V.
Global Robotic Institute, Dept. of Urology, Celebration, United States of America

**PT374**
The changing face of surgically treated low-risk prostate cancer (PCa): A national cancer database (NCDB) analysis

1Wayne State University, School of Medicine, Detroit, United States of America, 2Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, 3Harvard Medical School, Dept. of Surgery, Boston, United States of America

**PT376**
The EORTC quality of life questionnaire predicts long-term overall survival in patients treated with robotic assisted radical prostatectomy: Analysis of a large single center cohort

1Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, 2Sapienza University of Rome, ICOT Latina Hospital, Dept. of Urology, Latina, Italy, 3St. Antonius Hospital, Dept. of Urology, Paediatric Urology and Urological Oncology, Gronau, Germany
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT377</td>
<td>Long-term survival rates of localized prostate cancer patients treated by radical prostatectomy are significantly better than predicted life expectancy of the general population</td>
<td>Sakai Y.S., Soma T., Nakamura Y., Aoki Y., Fukui N., Kageyama Y.</td>
<td>Saitama Cancer Center, Dept. of Urology, Ina, Japan</td>
</tr>
<tr>
<td>PT379</td>
<td>Gleason grade grouping: The significance of primary Gleason 5 in patients with Gleason grade group 5</td>
<td>Tilki D., Preisser F., Huland H., Graefen M., Chun F., Mandel P.</td>
<td>University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany</td>
</tr>
<tr>
<td>PT380</td>
<td>Development of a procedure-specific classification system for reporting postoperative complications in prostate cancer patients undergoing robot-assisted radical prostatectomy</td>
<td>Gandaglia G., Barletta F., Robesti D., Pellegrino A., Cannoletta D., Stabile A., Martini A., Cucchiara V., Galosi A.B, Bertini R., Colombo R., Suardi N., Gallina A., Fossati N., Montorsi F., Briganti A.</td>
<td>IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, University Hospital &quot;Ospedali Riuniti&quot;, Unit of Urology, Milan, Italy</td>
</tr>
<tr>
<td>PT381</td>
<td>Opioid use before and after radical prostatectomy: Nationwide population-based study</td>
<td>Cazzaniga W., Loeb S., Garmo H., Robinson D., Stattin P.</td>
<td>IRCCS Ospedale San Raffaele, Uppsala University, Division of Experimental Oncology, Unit of Urology URI, Milan, Italy, New York University and Manhattan Veterans Affairs Medical Center, Dept. of Urology and Population Health, New York, United States of America, Regional Cancer Centre Uppsala Orebro, Uppsala University Hospital, Regional Cancer Centre, Uppsala, Sweden, Ryhov Hospital, Dept. of Urology, Jonköping, Sweden, Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden</td>
</tr>
<tr>
<td>PT382</td>
<td>Fewer days of workplace absenteeism with robotic radical prostatectomy compared to open radical prostatectomy</td>
<td>Pucheril D.T., Chen X., Krimphove M.J., Tully K.H., Fletcher S.A., Dasgupta P., Trinh Q-D.</td>
<td>Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom</td>
</tr>
<tr>
<td>PT383</td>
<td>Hot or cold: No difference in long-term potency between touch-cautery and athermic suture-ligation in control of pedicle during robot-assisted radical prostatectomy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PT384

A novel nomogram to predict lymph node invasion among patients with clinically localized prostate cancer based on clinical and mpMRI parameters: The importance of ECE score. Results from a single center series

By: Di Trapani E.¹, Catellani M.¹, Musi G.¹, Ferro M.¹, Bianchi R.¹, Cozzi G.¹, Alessi S.², Luzzago S.¹, Cordina G.¹, Mistretta F.A.¹, Conti A.¹, Matei D.V.¹, Petralia G.², De Cobelli O.¹

¹IEO, European Institute of Oncology IRCCS, Dept. of Urology, Milan, Italy; ²IEO, European Institute of Oncology IRCCS, Dept. of Radiology, Milan, Italy

PT386

Impact of focal versus whole-gland therapy for prostate cancer in sexual function and urinary continence

By: Borges R.C.¹, Tourinho-Barbosa R.R.¹, Collura-Merlier S.¹, Muttin F.¹, Constantin D.S.¹, Bakavicius A.¹, Barret E.¹, Rozet F.¹, Carneiro A.², Cathala N.¹, Prapotnich D.¹, Mombet A.¹, Sanchez-Salas R.¹, Cathelineau X.¹

¹Institut Mutualiste Montsouris, Dept. of Urology, Paris, France; ²Hospital Israelita Albert Einstein, Dept. of Urology, Sao Paulo, Brazil

PT387

Higher free testosterone predicts faster potency recovery after robot assisted radical prostatectomy

By: El-Khatib F.M.¹, Huynh L., Towe M., Yafi F., Ahlering T.

University of California, Irvine, Dept. of Urology, Orange, United States of America

PT388

Long-term outcomes and patterns of recurrence in patients with clinical lymphadenopathies undergoing radical prostatectomy as part of a multimodal treatment

By: Gandaglia G.¹, Karnes R.J.², Devos G.³, Battaglia A.³, Muijwijk T.³, Soligo M.², Evaraerts W.³, Boeri L.², Robesti D.¹, Bianchi M.¹, Pellegrino A.¹, Rizzo A.¹, Fossati N.¹, Moschini M.², Joniaux S.³, Montorsi F.¹, Briganti A.¹

¹IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, URI, Milan, Italy; ²Mayo Clinic, Dept. of Urology, Rochester, MN, United States of America; ³University Hospitals Leuven, Dept. of Urology, Leuven, Belgium

PT389

Extended lymph node dissection is associated with improved overall survival in patients with very high-risk prostate cancer: A national cancer database analysis

By: Sood A., Keeley J., Arora S., Dalela D., Jeong W., Rogers C., Peabody J., Menon M., Abdollah F.

Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America

PT390

TRoMbone: Testing radical prostatectomy in men with oligo metastatic prostate cancer that has spread to the bone - A randomized controlled feasibility trial
By: Sooriakumaran P. 1, Rajan P. 1, Al Kadhi O. 1, Kelly J. 1, Aning J. 2, Soomro N. 2, Bryant R. 3, Lamb A. 3, Cathcart P. 4, Elhage O. 4, Eden C. 5, Ahmad I. 6, Leung H. 6, Nathan S. 1, Hamdy F. 3
1University College London Hospital, Dept. of Uro-Oncology, London, United Kingdom, 2Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, 3Oxford University Hospital, Dept. of Urology, Oxford, United Kingdom, 4Guy's Hospital, Dept. of Urology, London, United Kingdom, 5Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, 6Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom

PT391
Impact of timing on radiation therapy adverse events following radical prostatectomy, an analysis of the RTOG 9601 cohort

By: Baumgarten L.C 1, Borchert A. 1, Delela D. 1, Sood A. 1, Arora S. 1, Keeley J. 1, Trinh Q. 2, Rogers C.G. 1, Peabody J.O 1, Menon M. 1, Abdollah F. 1
1Henry Ford Hospital, Health System, Dept. of Urology, Detroit, United States of America, 2Harvard Medical School, Dept. of Urology, Boston, United States of America

PT392
Barriers to selective referral of genitourinary cancers to high- vs. low-volume hospitals

By: Berg S. 1, Daniel P. 1, Sahraoui A. 1, Tan W.S. 2, Krimphove M.J. 1, Marchese M. 1, Lipsitz S.R. 3, Noldus J. 4, Kibel A.S. 1, Trinh Q-D. 1
1Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 2University College London, Division of Surgery and Interventional Science, Dept. of Urology, London, United Kingdom, 3Brigham and Women's Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 4Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and NeuroUrology, Herne, Germany

PT393
Retzius sparing robotic assisted radical prostatectomy: Beyond the learning curve - "Warts 'n all"

Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom

PT395
Hormone therapy for prostate cancer increases the risk of new-onset hypertension: A nationwide propensity score-matched four-year longitudinal cohort study

By: Tseng S., Shiaojin S., Wen-Jeng W., Ching-Chia C., Jhen-Hao J.
Kaohsiung Medical University Hospital, Dept. of Urology, Kaohsiung City, Taiwan

PT396
The impact of initial PSA <100 ng/mL on prognosis in patients with metastatic hormone naïve prostate cancer (mHNPC)

By: Suzuki Y. 1, Hatakeyama S. 1, Yamamoto H. 1, Imai A. 1, Yoneyama T. 1, Hashimoto Y. 1, Koie T. 2, Ohyama C. 1
Androgen deprivation treatment (ADT) in the contemporary management of prostate cancer: Real life practice patterns vs. guidelines

By: Mitropoulos D.¹, Chliosta P.², Häggman M.³, Ström T.⁴, Markussis V.⁵

¹National and Kapodistrian University of Athens Medical School, Dept. of Urology, Athens, Greece, ²Jagiellonian University, Dept. of Urology, Krakow, Poland, ³Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden, ⁴Ipsen Sweden, Medical Department, Stockholm, Sweden, ⁵Ipsen Greece, Medical Department, Athens, Greece
Management of complex urethral strictures

Video Session 11

Monday 18 March
14:00 - 15:30

Location: Red Area, eURO Auditorium 1

Chairs: S. Kulkarni, Pune (IN)
L. Martínez Piñeiro, Madrid (ES)
To be confirmed

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V74
Withdrawn
To be confirmed

V75
Oral grafts for urethral augmentation. Step-by-step harvesting technique from inner cheek and sublingual area

Marques de Valdecilla University Hospital, Dept. of Urology, Santander, Spain

V76
Bulbo-membranous urethroplasty with "BAES-flap": A description of the surgical technique

By: Gil-Vernet A., Céspedes M., Ropero J., Díaz F.
Parc Sanitari Sant Joan de Déu, Dept. of Urology, Barcelona, Spain,
Hospital Universitari Vall d’Hebron, Dept. of Urology, Barcelona, Spain

V79
Augmented non-transected anastomotic urethroplasty (Kodama’s operation)

By: Kotov S.V.
Pirogov Russian National Research Medical University, Dept. of Urology and Andrology, Moscow, Russia

V80
Transperineal prerectal approach for the treatment of posterior urethral stricture after radical prostatectomy

By: Vitarelli A., Divenuto L., Vulpi M., Ditonno P.
University of Bari "Aldo Moro", Urology and Andrology Unit, Department of Emergency and Organ Transplantation, Bari, Italy,
University of Bari, Urology and Andrology Unit, Department of Emergency and Organ Transplantation, Bari, Italy

V81
Ventral inlay and dorsal onlay buccal grating for long segment nearly obliterative to obliterative bulbar urethral strictures

By: Chawla A.K., Kapadia A., Odougar A., Hegde P., Binmohammed Z.
Kasturba Medical College, Manipal University, Dept. of Urology and Renal Transplant, Manipal, India
Reducing complications and improving outcomes in cystectomy
Poster Session 70

Monday 18 March
14:00 - 15:30

Location: Red Area, eURO Auditorium 2
Chairs: B. Ali-El-Dein, Mansoura (EG)
A. Noon, Sheffield (GB)
G.N. Thalmann, Berne (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

977 Understanding risk factors associated with early unplanned reoperation after radical cystectomy and urinary diversion
By: Laymon M., Ghobrial F.K., Hashem A., Abol-Enein H., Shaaban A., Mosbah A.
Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

978 Modified Wallace anastomosis reduces ureteroenteric stricture rates – Prospective randomised study of ureteroenteric stricture rates after ileal conduit urinary diversion
Clinical centre of Montenegro, Dept. of Urology, Podgorica, Montenegro

979 The impending need of a new disease specific comorbidity index for bladder cancer patients candidate to robot-assisted radical cystectomy
By: Lambert E.1, Dell’oglio P.2, Vollemaere J.1, Uvin P.1, Goossens M.1, Van Der Jeugt J.1, Devos G.1, De Grote R.1, Turri F.1, Larcher A.3, Collins J.4, Schatteman P.1, De Naeyer G.1, D’hondt F.1, Mottrie A.2
1Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium, 2Onze Lieve Vrouw Hospital, Orsi Academy, Dept. of Urology, Aalst, Belgium, 3Urological Research Institute, IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 4Orsi Academy, Dept. of Urology, Aalst, Belgium

982 Impact of neoadjuvant pembrolizumab on intra and peri-operative complications after radical cystectomy: A comparison with both standard chemotherapy and no adjuvant treatment
By: Zaffuto E.1, Moschini M.2, Burgio G.1, Scuderi S.1, Barletta F.1, Nocera L.1, Mirone V.3, Salonia A.1, Colombo R.1, Montorsi F.1, Briganti A.1, Necchi A.4, Gallina A.1
1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 2Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 3University Federico II, Dept. of Urology, Naples, Italy, 4Fondazione IRCCS Istituto Nazionale Tumori, Division of Oncology, Unit of Urology, Milan, Italy
983  
Phase 1 clinical trial to evaluate the use of a tissue engineered neo-urinary conduit using adipose derived smooth muscle cells after radical cystectomy  
By: Bivalacqua T. 1, Steinberg G. 2, Smith N. 2, Joice G. 1, Sopko N. 1, Lerner S. 3, Bochner B. 4, Lee C. 5, Rivera E. 6, Jain D. 6, Bertram T. 6, Schoenberg M. 7  
1Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, 2University of Chicago, Dept. of Urology, Chicago, United States of America, 3Baylor College of Medicine, Dept. of Urology, Houston, United States of America, 4Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 5Ohio State University, Dept. of Urology, Columbus, United States of America, 6Tengion Regenerative Medicine, Dept. of Urology, Winston-Salem, United States of America, 7Albert Einstein School of Medicine, Dept. of Urology, Bronx, United States of America

984  
Comprehensive assessment of time-to-event data of perioperative short-term complications following radical cystectomy  
University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

986  
Randomized controlled trial to compare the length of stay, perioperative outcomes and complications in patients undergoing radical cystectomy with and without the enhanced recovery after surgery (eras) protocol in a tertiary care centre in India  
By: Nayak B. 1, Bansal D 1, Singh P. 1, Seth A. 1, Nayyar R. 1, Ramachandran R. 2  
1All India Institute of Medical Sciences, New Delhi, Dept. of Urology, New Delhi, India, 2All India Institute of Medical Sciences, New Delhi, Dept. of Anaesthesia, New Delhi, India

987  
Prospective randomized comparison of quality of life and sexual function between ileal neobladder versus sigmoid neobladder reconstruction following nerve sparing, vas sparing, seminal vesicle sparing and partial prostate sparing radical cystectomy  
By: Singh V., Sinha R.J., Aggarwal A.J., Pandey S.  
King George's Medical University, Dept. of Urology, Lucknow, India

988  
Patients with perioperative complications presented a higher risk of cancer specific mortality after radical cystectomy: A two year multicentre Italian real-life analysis  
By: De Nunzio C. 1, Cindolo L. 2, Simone G. 3, Lombardo R. 1, Tema G. 1, Leonardo C. 4, Rocco B. 5, Seri S. 6, Schips L. 2, Alvarez-Maestro M. 7, Antonelli A. 8, Bove P. 9, Celia A. 10, Cancrini F. 1, Ceruti C. 11, Crivellaro S. 12, Falsaperla M. 13, Frea B. 12, Gallucci M. 3, Lo Treccchiano G. 14, Minervini A. 6, Porreca A. 15, Zaramella S. 16, Tubaro A. 1  
1Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, 2Padre Pio Da Pietralcina Hospital, Dept. of Urology, Vasto, Italy, 3Istituto Tumori Regina Elena, Dept. of Urology, Rome, Italy, 4Sapienza University of Rome, Umberto Primo Hospital, Dept. of Urology, Rome, Italy, 5Policlinico Di Milano, Dept. of Urology, Milan,
Period-specific mean annual hospital volume of radical cystectomy is associated with outcome and perioperative quality of care in Sweden – A nation-wide population based study

By: Liedberg F.¹, Hagberg O.², Aljabery F.³, Gårdmark T.⁴, Hosseini A.⁵, Jahnson S.³, Jancke G.³, Malmström P-U.⁶, Sherif A.⁷, Ströck V.⁸, Häggström C.⁶, Holmberg L.⁶

1Institution of Translational Medicine, Lund University, Dept. of Urology, Lund, Sweden, 2Institution of Translational Medicine, Lund University, Dept. of Urology, Lund, Sweden, 3Linköping University, Dept. of Clinical and Experimental Medicine, Linköping, Sweden, 4Karolinska Institute, Danderyd Hospital, Dept. of Clinical Sciences, Stockholm, Sweden, 5Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, 6Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, 7Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, 8Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Gothenburg, Sweden

A competing risk analysis of survival after radical cystectomy for bladder cancer patients: The impact of age at the time of surgery

By: Moschini M.¹, Martini A.¹, Zamboni S.², Mattei A.², Baumeister P.², Dell’oglio P.¹, Zaffuto E.¹, Burgio G.¹, Shariat S.F.³, Salonia A.¹, Montorsi F.¹, Briganti A.¹, Colombo R.¹, Gallina A.¹

1IRCCS Ospedale San Raffaele; URI, Dept. of Urology, Division of Oncology, Milan, Italy, 2Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 3Medical University of Vienna, Dept. of Urology, Vienna, Austria
Preclinical therapies in prostate cancer and strategies to overcome resistance
Poster Session 71

Monday 18 March
14:00 - 15:30

Location: Green Area, Room 1
Chairs: To be confirmed
To be confirmed
C. Robson, Newcastle upon Tyne (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

992
An intratumoural cytotoxic immunotherapy approach to target prostate cancer in a syngeneic murine model
By: Papaevangelou E.¹, Smolarek D.¹, Elhage O.¹, Smith R.A.², Dasgupta P.¹, Galustian C.¹
¹King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom, ²King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom

993 *
Development and characterization of novel AKR1C3 inhibitors: Therapeutic potential for castration-resistant prostate cancer
By: Fujimoto N.¹, Endo S.², Oguri H.², Toyooka N.³, Matsunaga T.², Ikari A.², Tomisaki I.¹, Nakayama T.⁴
¹University of Occupational and Environmental Health, Dept. of Urology, Kitakyushu, Japan, ²Gifu Pharmaceutical University, Laboratory of Biochemistry, Gifu, Japan, ³University of Toyama, Graduate School of Innovative Life Science, Toyama, Japan, ⁴University of Occupational and Environmental Health, Dept. of Pathology, Kitakyushu, Japan

996
Novel selective lysine specific demethylase 1 inhibitors effectively impair castration resistant prostate cancer growth
By: Etani T.¹, Naiki T.¹, Nagai T.¹, Nozaki S.¹, Iida K.¹, Ando R.¹, Kawai N.¹, Tozawa K.¹, Suzuki T.², Yasui T.¹
¹Nagoya city university, Dept. of Nephro-urology, Nagoya, Japan, ²Kyoto Prefectural University of Medicine, Dept. of Chemistry, Kyoto, Japan

998
Potential therapeutic role of the combination of biguanides and statins in prostate cancer: Association with alterations in key genes and miRNAs levels
By: Herrero-Aguayo V.¹, Jiménez-Vacas J.M.¹, Saéz-Martínez P.¹, Gómez-Gómez E.
2, León-González A.J. 1, Montero-Hidalgo A.J. 1, Requena-Tapia M.J. 3, Castaño J.P. 1, Gahete M.D. 1, Luque R.M. 1

1Maimonides Institute of Biomedical Research of Cordoba, Dept. of Cell Biology, Physiology and Immunology, University of Cordoba, Reina Sofia University Hospital, CIBER Physiopathology of Obesity and Nutrition, Cordoba, Spain, 2Maimonides Institute of Biomedical Research of Cordoba, Dept. of Cell Biology, Physiology and Immunology, University of Cordoba, Urology Service of Reina Sofia University Hospital, CIBER Physiopathology of Obesity and Nutrition, Cordoba, Spain, 3Maimonides Institute of Biomedical Research of Cordoba, Urology Service of Reina Sofia University Hospital, Cordoba, Spain

**999**

Identification of a novel therapeutic target for castration-resistant prostate cancer by proteomic analysis of serum extracellular vesicles

By: Yu I., Koh Y., Matsushita M., Nakano K., Hayashi Y., Wong C., Yamamoto Y., Kato T., Kawashima A., Ujike T., Nagahara A., Fukuhara S., Fujita K., Kiuchi H., Uemura M., Imamura R., Nonomura N. Graduate School of Medicine, Osaka University, Dept. of Urology, Osaka, Japan

**1000**

Carboxylesterase - TRAIL expressing human adipose stem cells inhibit tumor growth in castration resistant prostate cancer bearing mice with less toxicity

By: Song Y.S. 1, Oh E.J. 1, Lee S.H. 2, Song E.S. 3, Kim J.H. 1, Doo S.W. 1, Yang W.J. 1, Yun J.H. 1, Lee S.J. 4

1 Soonchunhyang University College of Medicine, Dept. of Urology, Seoul, Korea, South, 2 Soonchunhyang University College of Medicine, Medical Research Institute, Seoul, Korea, South, 3 Gwangjin-Gu Health Center, Medical Treatment Division, Seoul, Korea, South, 4 Kyunghee University Hospital, Dept. of Urology, Seoul, Korea, South

**1001**

Investigation of gene therapy for prostate cancer by the JC virus-like particles delivering a PSA promoter driven-suicide gene

By: Shen C-H. 1, Jou Y-C. 1, Lai W-H. 1, Lin M-C. 1, Chang D. 2

1 Chiayi Christian Hospital, Dept. of Urology, Chiayi, Taiwan, 2 National Chung Cheng University, Institute of Molecular Biology, Chiayi, Taiwan

**1002**

Overcoming enzalutamide-resistance by inhibition of the transcription factor Stat5b in prostate cancer

By: Erb H. 1, Bodenbender J. 2, Diehl T. 2, Tsauer I. 2, Jüngel E. 2, Gleave M. 3, Haferkamp A. 2, Culig Z. 4, Thomas C. 1

1 University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, 2 University of Mainz, Dept. of Urology, Mainz, Germany, 3 University of British Columbia, The Vancouver Prostate Centre, Vancouver, Canada, 4 University of Innsbruck, Dept. of Urology, Innsbruck, Austria

**1004**

CDK8/CDK19 inhibition as a new therapeutic option for advanced prostate cancer

By: Hupe M.C. 1, Offermann A. 2, Becker F. 2, Joerg V. 2, Vogel W. 2, Braegelmann J.
VERU-111, a novel oral inhibitor of α and β tubulin, inhibits tumor growth in the human castration-resistant AR variant prostate cancer (PCa) model 22Rv1

By: Getzenberg R. ¹, Markowski M.M. ², Eisenberger M.A. ², Steiner M.S. ³, Antonarakis E.S. ²
¹Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, Florida, United States of America, ²Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States of America, ³Veru Inc, Veru, Miami, Florida, United States of America
### ERAS; what really makes a difference

**Poster Session 72**

**Monday 18 March 14:00 - 15:30**

**Location:** Green Area, Room 2  
**Chairs:** S. Daneshmand, Los Angeles (US)  
W. Kochakarn, Bangkok (TH)  
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1006</td>
<td>Evaluation of enhanced mobilisation with individual goal-setting and self-monitoring after abdominal surgery due to cancer</td>
<td>Porserud A.¹, Aly M.², Nygren-Bonnier M.³, Hagströmer M.³</td>
<td>¹Karolinska University Hospital, Dept. of Physiotherapy, Stockholm, Sweden, ²Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, ³Karolinska Institutet, Dept. of Physiotherapy, Stockholm, Sweden</td>
</tr>
<tr>
<td>1007</td>
<td>Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis</td>
<td>Nazzani S.¹, Clementi M.C.², Stubinski R.², Bandini M.³, Marchioni M.⁴, Preisser F.⁵, Carmignani L.⁶, Karakiewicz P.⁵</td>
<td>¹IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ²IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ⁴SS Annunziata Hospital, Dept. of Urology, Chieti, Italy, ⁵CHUM, Cancer Prognostics and Health Outcome Unit, Montreal, Canada, ⁶IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy</td>
</tr>
<tr>
<td>1008</td>
<td>Effects of enhanced recovery after surgery protocols of postoperative ileus and bowel obstruction in patients undergoing radical cystectomy</td>
<td>Fujiwara R., Numao N., Komai Y., Ogawa M., Inatsu H., Ishikawa Y., Yasuoka S., Yuasa T., Yamamoto S., Fukui I., Yonese J.</td>
<td>Cancer Institute Hospital, Japanese Foundation for Cancer Research, Dept. of Genitourinary Oncology, Tokyo, Japan</td>
</tr>
<tr>
<td>1009</td>
<td>Alvimopan is associated with a reduction in length of stay and hospital costs for patients undergoing radical cystectomy</td>
<td>Huang T.H.¹, Mossanen M.¹, Preston M.¹, Chung B.I.², Huang W.J.³, Chang S.L.¹</td>
<td>¹Brigham and Women’s Hospital, Dept. of Surgery, Boston, United States of America, ²University of California, San Francisco, ³Yale University, ⁴Brigham and Women’s Hospital, Boston, USA</td>
</tr>
</tbody>
</table>
1010  
**Evaluation of patient satisfaction managed in a enhanced recovery after surgery program (ERAS) using the validated questionnaire EVAN-G**

By: Fakhfakh S. 1, Pouliquen C. 2, Walz J. 1, Brun C. 2, Tourret M. 2, Fauchard M. 2, Mokart D. 3, Cini E. 4, Bouant S. 5, Massacrier S. 5, Pignot G. 1

1Institut Paoli Calmettes , Dept. of Onco Urology, Marseille, France, 2Institut Paoli Calmettes , Dept. of Anesthesiology, Marseille, France, 3Institut Paoli Calmettes, Dept. of Anesthesiology, Marseille, France, 4Institut Paoli Calmettes, Dept. of Onco Urology ERAS, Marseille, France, 5Institut Paoli Calmettes , Dept. of Onco Urology ERAS Nurse, Marseille, France

1011  
**Patient blood management applied to radical cystectomy in "enhanced recovery after surgery" era: Preliminary results**


1Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Dept. of Urology, Milan, Italy, 2Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico Department of Clinical Sciences and Community Health, University of Milan, Dept. of Urology, Milan, Italy, 3Rare Diseases Center, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico Department of Clinical Sciences and Community Health, University of Milan, Dept. of Medicine, Milan, Italy

1012  
**Intensified and standardized digital communication with your cystectomy patients potentially is a simple and effective way to decrease readmission rates**

By: Zehnder P., Moltzahn F., Zehnder J-L., Hasler D., Flückiger D., Birkhäuser F.D. Hirslanden Klinik St. Anna, Dept. of Urology, Lucerne, Switzerland

1014  
**Outcomes of “Chennai” enhanced recovery protocol after major urological surgery**

By: Ragavan N., Dholakia K., Karthik V.C., Ramesh M., Baskaran J. Apollo Hospital, Dept. of Urology, Chennai, India

1015  
**ERAS® protocol improves cancer-specific and overall survival after elective radical cystectomy: A retrospective cohort study**

By: Crettenand F. 1, M’baye O. 1, Jichlinski P. 1, Martel P. 1, Dartiguenave F. 1, Blanc C. 2, Rouvé J.D. 2, Valerio M. 1, Cerantola Y. 1, Luca I. 1

1University Hospital-CHUV, Dept. of Urology, Lausanne, Switzerland, 2University Hospital-CHUV, Dept. of Anesthesiology, Lausanne, Switzerland

1016  
**Enhanced recovery after nephrectomy: Conception, implementation and outcomes in a high volume specialist centre**
Pain control after laparoscopic partial nephrectomy (LPN): Comparison of transversus abdominis plane block (TAP block) versus wound infiltration

By: Taha T., Sionov B.V., Tiberiu E., Rosenberg P., Stein A., Sidi A.A., Tsivian A.
1The E. Wolfson Medical Center, Dept. of Urologic Surgery, Holon, Israel, 2The E. Wolfson Medical Center, Dept. of Anesthesiology, Holon, Israel

The impact of Enhanced Recovery After Surgery protocol on postoperative pain management in the era of opioid crisis: The post-chemotherapy open RPLND paradigm

By: Dimitropoulos K., Pisters L.L., Karatzas A., Vaiopoulos C., Papandreou C., Daliani D., Zachos I., Gravas S., Tzortzis V.
1Aberdeen Royal Infirmary, NHS Grampian, Dept. of Urology, Aberdeen, United Kingdom, 2MD Anderson Cancer Centre, Dept. of Urology, Houston, United States of America, 3University Hospital of Larissa, Dept. of Urology, Larissa, Greece, 4Papageorgiou Hospital, Dept. of Medical Oncology, Thessaloniki, Greece, 5Euroclinic, Dept. of Medical Oncology, Athens, Greece, 6Afghanistan

Identifying factors which prolong length of stay following open retroperitoneal lymph node dissection

The Royal Marsden Hospital, Dept. of Urology, London, United Kingdom

Summary
To be confirmed
POP and SUI: Treatment options and long term outcomes

**Poster Session 73**

**Monday 18 March**
**14:00 - 15:30**

**Location:** Green Area, Room 3

**Chairs:** To be confirmed

To be confirmed

D. Waltregny, Liège (BE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1020 Pelvic floor muscle training improves sexual distress in women with stress urinary incontinence

By: Zachariou A. ¹, Papakosta S. ², Filiponi M. ², Dimitriadis F. ³, Skouros S. ¹,
Tsounapi P. ⁴, Takenaka A. ⁴, Sofikitis N. ¹

¹University of Ioannina, Dept. of Urology, Ioannina, Greece, ²Rehabilitation Centre EF PRATTEIN, Dept. of Physical Medicine and Rehabilitation, Volos, Greece, ³Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, ⁴Tottori University, Dept. of Urology, Yonago, Japan

1021 A prospective parallel cohort, multi-center study of the Solyx™ single incision sling system vs. the Obtryx™ II sling system for the treatment of women with stress urinary incontinence: Patient-reported outcomes at 3 years

By: White A.B. ¹, Eilber K.S. ², Anger J.T. ², Kahn B.S. ³, Schaffer J.I. ⁴

¹University of Texas, Dell Medical School, Dept. of Women’s Health, Austin, United States of America, ²Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America, ³Scripps Clinic, Dept. of Obstetrics and Gynecology, San Diego, United States of America, ⁴University of Texas Southwestern Medical Center, Dept. of Obstetrics and Gynecology, Dallas, United States of America

1022 Effects of the REMEEX system® in female patients with intrinsic sphincteric deficiency and recurrent urinary incontinence: 10-year outcomes

By: Song P.H. ¹, Min G.E. ², Choi J.Y. ¹, Ko Y.H. ¹, Moon K.H. ¹, Jung H.C. ¹

¹College of Medicine, Yeungnam University, Dept. of Urology, Daegu, Korea, South, ²Kyung Hee University College of Medicine, Kyung Hee University Hospital at Gangdong, Dept. of Urology, Seoul, Korea, South

1023 Comparison of open and robot-assisted artificial urinary sphincter implantation in female patients with stress urinary incontinence: A multicenter study

By: Peyronnet B. ¹, Tricard T. ², Capon G. ³, Belas O. ⁴, Manunta A. ⁵, Hascouet J. ⁵, Freton L. ⁵, Goujon A. ⁵, Belas M. ⁴, Calves J. ⁶, Cardot V. ⁷, Vidart A. ⁸, Delreux A. ⁹,
Scientific Programme - EAU19 Barcelona

Dubois F. 9, Robert G. 3, Haab F. 10, Peyrat L. 11, Cornu J.N. 12, Grise P. 12, Descazeaud A. 13, Fournier G. 14
1University of Rennes, Dept. of Urology, Rennes, France, 2Strasbourg University Hospital, Dept. of Urology, Strasbourg, France, 3Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, 4Pole Sante Sud, Dept. of Urology, Le Mans, France, 5Rennes University Hospital, Dept. of Urology, Rennes, France, 6Brest University Hospital, Dept. of Urology, Brest, France, 7Pitié Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, 8Foch Hospital, Dept. of Urology, Suresnes, France, 9Saint Grégoire Private Hospital, Dept. of Urology, Rennes, France, 10Groupe hospitalier Diaconess Croix Saint Simon, Dept. of Urology, Paris, France, 11Tenon University Hospital, Dept. of Urology, Paris, France, 12Rouen University Hospital, Dept. of Urology, Rouen, France, 13Limoges University Hospital, Dept. of Urology, Limoges, France, 14Brest University Hospital, Dept. of Urology, Brest, France

V05 Robot-assisted implantation of artificial urinary sphincter in women: A standardized surgical technique

By: Peyronnet B. 1, Capon G. 2, Belas O. 3, Manunata A. 1, Cardot V. 4, Dubois F. 5, Hascoet J. 1, Vidart A. 6, Game X. 7, Descazeaud A. 8, Fournier G. 9
1Rennes University Hospital, Dept. of Urology, Rennes, France, 2Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, 3Pole Santé Sud, Dept. of Urology, Le Mans, France, 4Pitié Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, 5Saint Grégoire Private Hospital, Dept. of Urology, Rennes, France, 6Foch Hospital, Dept. of Urology, Suresnes, France, 7Toulouse University Hospital, Dept. of Urology, Toulouse, France, 8Limoges University Hospital, Dept. of Urology, Limoges, France, 9Brest University Hospital, Dept. of Urology, Brest, France

1024 Long-term outcomes of female stress incontinence surgery: A real-world study

By: Ravindra P., Henry M., Bazo A., Parkinson R.
Nottingham University Hospitals NHS Trust, Dept. of Urology, Nottingham, United Kingdom

1025 Efficacy and safety of minislings for the treatment of female stress urinary incontinence in a cohort with a median follow-up of 10 years

By: Manso M., Botelho F., Silva C., Cruz F.
Centro Hospitalar São João, Dept. of Urology, Porto, Portugal

1026 Outcomes of open artificial urinary sphincter in female patients with stress urinary incontinence after a follow-up of 10 years

By: Tricard T., Jochum F., Saussine C.
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg, Dept. of Urology, Strasbourg, France

1027 Tension-free vaginal tape: Over 10 years follow-up

By: Illiano E. 1, Natale F. 2, Marchesi A. 3, Costantini E. 1
1Andrological and Urogynecological Clinic, Santa Maria Hospital Terni, University of Perugia, Dept. of Surgery and Biomedical Sciences, Terni, Italy, 2San Carlo di Nancy hospital, Dept. of Urology, Rome, Italy, 3Andrological and Urogynecological Clinic, Santa Maria Hospital Terni, University of Perugia, Dept. of surgery and biomedical sciences, Terni, Italy

1028 Success and satisfaction of tension-free vaginal tape surgery in females with stress urinary incontinence: Results at 17 years of follow-up

By: Kim H.W. 1, Shin D.G. 1, Yoon C.S. 2, Cho W.Y. 4, Min K.S. 5, Oh T.H. 6, Lee W. 7, Lee J.Z. 1
1Pusan National University Hospital, Dept. of Urology, Busan, Korea, South, 2BHS Hans-eo Hospital, Dept. of Urology, Busan, Korea, South, 3Kosin University College of Medicine, Dept. of Urology, Busan, Korea, South, 4Dong-A University Hospital, Dept. of Urology, Busan, Korea, South, 5Inje University Busan Paik Hospital, Dept. of Urology, Busan, Korea, South, 6Samsung Changwon Hospital, Dept. of Urology, Changwon, Korea, South, 7Ulsan-jeil Hospital, Dept. of Urology, Ulsan, Korea, South

1029 A multicenter randomized trial comparing robot-assisted versus pure laparoscopic sacrocolpopexy for pelvic organ prolapse

By: Wagner L. 1, Douvier S. 2, Ruffion A. 3, Saussine C. 4, Soustelle L. 1, Rigaud J. 5, Meurette G. 6, Chartier-Kastler E. 7, Vidart A. 8, Manunta A. 9, Vincens E. 10, Dorez M. 11, Melanie C. 12, Hoepffner J.L 13, Bouvier S. 14, Costa P. 1, Droupy S. 1
1CHU de Nîmes, Dept. of Urology, Nîmes, France, 2CHU de Dijon, Dept. of Gynecology, Dijon, France, 3CHU de Lyon, Dept. of Urology, Lyon, France, 4CHU de Strasbourg, Dept. of Urology, Strasbourg, France, 5CHU de Nantes, Dept. of Urology, Nantes, France, 6CHU de Nantes, Dept. of Gynecology, Nantes, France, 7CHU Pitié Salpêtrière, Dept. of Urology, Paris, France, 8Hôpital Foch, Dept. of Urology, Surennes, France, 9CHU de Rennes, Dept. of Urology, Rennes, France, 10Hôpital des Diaconesses, Dept. of Urology, Paris, France, 11CHU de Nice, Dept. of Gynaecology, Nice, France, 12CHU de Montpellier, Dept. of Gynaecology, Montpellier, France, 13Clinique Saint-Augustin, Dept. of Urology, Bordeaux, France, 14CHU de Nîmes, Dept. of Methodology, Nîmes, France

1030 Surgical and long-term postoperative outcomes of minimally invasive mesh sacrocolpopexy: A high-volume center experience

By: Morselli S., Di Maida F., Mari A., Di Camillo M., Verrienti P., Campi R., Sforza S., Viola L., Rivetti A., Corti F., Masieri L., Siena G., Li Marzi V., Serni S., Minervini A. University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy

1031 Transvaginal mesh repair for pelvic organ prolapse surgery improve patient's quality of life at long term follow up

By: Morselli S., Li Marzi V., Spatafora P., Zaccaro C., Di Camillo M., Frizzi J., Milanesi M., Masieri L., Tosto A., Serni S. University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy
Management of urethrocutaneous fistulae complicating sacral and perineal pressure ulcer in neuro-urological patients: A national multicenter study from the French-speaking Neurourology Study Group (GENULF)

By: Gambachidze D.¹, Lefèvre C.², Chartier-Kastler E.¹, Perrouin Verbe M-A.³, Kerdraon J.⁴, Egon G.⁵, Even A.⁶, Denys P.⁶, Castel-Lacanal E.⁷, Gamé X.⁸, Ruffion A.⁹, Hascoet J.¹⁰, Peyronnet B.¹⁰, Chaussard H.¹¹, Lo Verde K.¹², Karsenty G.¹², Phé V.¹

¹Médecine Sorbonne Université, Dept. of Urology, Paris, France, ²CHU Nantes, Dept. of Physical Medicine and Rehabilitation, Nantes, France, ³CHU de Nantes, Dept. of Urology, Nantes, France, ⁴Kerpape Hospital, Dept. of Physical Medicine and Rehabilitation, Ploemeur, France, ⁵Rehabilitation Centre of L’Arche, Dept. of Physical Medicine and Rehabilitation, Saint-Saturnin, France, ⁶Raymond Poincaré Academic Hospital, Dept. of Physical Medicine and Rehabilitation, Garches, France, ⁷CHU Rangueil, Dept. of Physical Medicine and Rehabilitation, Toulouse, France, ⁸CHU Rangueil, Dept. of Urology, Toulouse, France, ⁹Lyon Sud Hospital, Lyon University Hospital, Dept. of Urology, Lyon, France, ¹⁰CHU Rennes, Dept. of Urology, Rennes, France, ¹¹Raymond Poincaré Academic Hospital, Dept. of Orthopaedic Surgery, Garches, France, ¹²APHM, Hôpital de la Conception, Aix Marseille Université, Dept. of Urology, Marseille, France
**The evolving field of hormone-sensitive prostate cancer**

*Poster Session 74*

**Monday 18 March 14:00 - 15:30**

**Location:** Green Area, Room 4

**Chairs:** To be confirmed

A. Morgans, Chicago (US)

B. Ralla, Berlin (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1033

**The role of abiraterone acetate plus prednisone/prednisolone in high- and low-risk metastatic hormone sensitive prostate cancer**


1 The Christie GenitoUrinary Research Group, Dept. of Surgery, The Christie Hospital, Manchester, United Kingdom, 2 Institute of Cancer and Genomic Studies, Dept. of Oncology, Birmingham, United Kingdom, 3 Academic Urology Unit, Dept. of Medical Oncology, London, United Kingdom, 4 Medical Research Council, Clinical Trials Unit, London, United Kingdom, 5 University College London Cancer Institute, Dept. of Oncology, London, United Kingdom, 6 Guys and St Thomas NHS Foundation trust, Dept. of Medical Oncology, London, United Kingdom, 7 St James University Hospital, Dept. of Urology, Leeds, United Kingdom, 8 Beatson West of Scotland Cancer Centre, Dept. of Medical Oncology, Glasgow, United Kingdom, 9 University of Wolverhampton, Faculty of Education, Health and Wellbeing, Wolverhampton, United Kingdom, 10 Cardiff University, Division of Cancer and Genetics, Cardiff, United Kingdom, 11 University Hospital Birmingham NHS Foundation Trust, Dept. of Radiology, Birmingham, United Kingdom

1034

**Survival in men with de novo metastatic prostate cancer before and after the introduction of chemotherapy for advanced prostate cancer: A nationwide, population-based study**

By: Westerberg M. 1, Franck Lissbrant I. 2, Damber J.E. 2, Robinson D. 3, Garmo H. 4, Stattin P. 4

1 Uppsala University, Dept. of Mathematics, Uppsala, Sweden, 2 Institute of Clinical Sciences, Sahlgrenska Academy at University of Göteborg, Dept. of Oncology, Göteborg, Sweden, 3 Ryhov Hospital, Dept. of Urology, Jönköping, Sweden, 4 Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1036</td>
<td>Inpatient morbidity and cost of cytoreductive radical prostatectomy in the United States</td>
<td>Arora S.¹, Sood A.¹, Dalela D.¹, Keeley J.¹, Rakic N.², Prokopiv U.², Fotouhi A.², Peabody J.O.², Mani M.¹, Abdollah F.¹</td>
<td>Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, ²Wayne State University School of Medicine, Medical School, Detroit, United States of America</td>
</tr>
<tr>
<td>1037</td>
<td>Neoadjuvant apalutamide (arn-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (near)–initial results of a phase ii trial</td>
<td>Aslim E.J.¹, Yang X.¹, Ngo N-T.², Khor L.Y.², Chen K.¹, Chong T.W.¹, Yuen J.S.P.¹, Tay K.J.¹, Ho H.S.S.¹, Lee L.S.¹</td>
<td>¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²Singapore General Hospital, Dept. of Pathology, Singapore, Singapore</td>
</tr>
<tr>
<td>1040</td>
<td>Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study</td>
<td>Peltomaa A.I.P.¹, Talala K.², Taari K.³, Tammela T.L.J.⁴, Auvinen A.⁵, Murtola T.¹</td>
<td>¹University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland, ²Finnish Cancer Registry, Dept. of Cancer Statistics, Helsinki, Finland, ³Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁴Tampere University Hospital, Dept. of Urology, Tampere, Finland, ⁵University of Tampere, Faculty of Social Sciences, Tampere, Finland</td>
</tr>
<tr>
<td>1041</td>
<td>Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin-releasing hormone (GnRH) agonist for prostate cancer: Final analysis of the EQUINOXE study</td>
<td>Droupy S.¹, Colson M.², Pello-Leprince-Ringuet N.³, Perrot V.³, Descazeaud A.⁴</td>
<td>¹CHU de Nimes, Dept. of Urology, Nimes, France, ²CHU de Marseille, Dept. of Sexology, Marseille, France, ³Ipsen Pharma, Dept. of Urology, Boulogne-Billancourt, France, ⁴CHU de Limoges, Dept. of Urology, Limoges, France</td>
</tr>
<tr>
<td>1042</td>
<td>Radium 223 therapy in symptomatic metastatic castrate resistant prostate cancer - quality of life matters: Real-world outcomes from a single UK centre</td>
<td>Jiang X.Y.¹, Atkinson S.², Cumming S.¹, Burns A.³, Pearson R.A.¹, Frew J.¹, Azzabi A.¹, Mcmenemin R.¹, Pedley I.¹</td>
<td>¹Northern Centre for Cancer Care, Dept. of Clinical Oncology, Newcastle upon Tyne, United Kingdom, ²Northern Centre for Cancer Care, Dept. of Nuclear Medicine, Newcastle upon Tyne, United Kingdom, ³Northern Centre for Cancer Care, Dept. of Radiotherapy Information Technology, Newcastle upon Tyne, United Kingdom</td>
</tr>
<tr>
<td>1043</td>
<td>Initial patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
*1044

**Identifying the optimal postoperative strategies for clinically node positive patients treated with radical prostatectomy and extended pelvic lymph node dissection: Is androgen deprivation therapy always mandatory?**

By: Gandaglia G.¹, Karnes R.J.², Devos G.³, Battaglia A.³, Mulwijk T.³, Soligo M.², Evaraerts W.³, Boeri L.², Robesti D.¹, Cannoletta D.¹, Zaffuto E.¹, Scuderi S.¹, Barletta F.¹, Karakiewicz P.I.⁴, Fossati N.¹, Moschini M.², Joniau S.³, Montorsi F.¹, Briganti A.¹

¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology URI, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester (MN), United States of America, ³University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁴University of Montreal Health Center, Montreal, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada

15:17 - 15:24

**Contemporary management of hormone sensitive prostate cancer**

A. Morgans, Chicago (US)
Outcomes of partial nephrectomy: Kidney function and beyond

Poster Session 75

Monday 18 March
14:00 - 15:30

Location: Green Area, Room 5
Chairs: A. Antonelli, Brescia (IT)
P.L. Chlosta, Cracow (PL)
M. Oya, Tokyo (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1048
CT measurement of intraparenchymal tumor volume as predictor of renal function after robotic partial nephrectomy
Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy

1049
Development and validation of a novel scoring index CART (C-reactive protein, age, race, tumor size) to predict renal functional decline post partial nephrectomy
1UC San Diego Health, Dept. of Urology, La Jolla, United States of America, 2Emory University School of Medicine, Dept. of Urology, Emory, United States of America, 3Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

1051
Robotic partial nephrectomy in solitary kidneys: Impact of ischemia on trifecta outcomes
1Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2Glickman Urological and Kidney Institute, Cleveland Clinic, Dept. of Urology, Cleveland, United States of America

1052
Biomarkers in express-diagnosing of acute kidney injury among patients with the localized kidney cancer after partial nephrectomy under warm ischemia
By: Dimitriadis S. , Kit O. , Frantsiyantz E. , Velichko A. , Rozenko D. , Faenson A. , Filatova E. , Goncharov S.
1Rostov Research Institute of Oncology, Dept. of Oncourology, Rostov-on-Don, Russia, 2Rostov Research Institute of Oncology, Administration Department, Rostov-on-Don,
Scientific Programme - EAU19 Barcelona

Russia, \textsuperscript{3}Rostov Research Institute of Oncology, Research lab, Rostov-on-Don, Russia, \textsuperscript{4}Rostov Research Institute of Oncology, ICU Department, Rostov-on-Don, Russia

1053

\textbf{Robot-assisted partial nephrectomy is associated with early recovery of renal function: Comparison of open, laparoscopic, and robot-assisted partial nephrectomy using diethylene triamine penta-acetic acid (DTPA) renal scintigraphy}

Asan Medical Center, Dept. of Urology, Seoul, Korea, South

1055

\textbf{Comparison of overall survival between the life expectancy and the estimated outcome in patients who underwent radical nephrectomy or partial nephrectomy for renal cell carcinoma}

By: Tanaka N., Nakai Y., Miyake M., Inoue T., Anai S., Fujimoto K.
Nara Medical University, Dept. of Urology, Kashihara, Japan

\* 1056

\textbf{Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals}

By: Tan W.S., \textsuperscript{1}Berg S., \textsuperscript{2}Cole A., \textsuperscript{2}Krimphove M., \textsuperscript{2}Marchese M., \textsuperscript{2}Lipsitz S., \textsuperscript{3}Nabi J., \textsuperscript{2}Sammon J., \textsuperscript{4}Choueiri T., \textsuperscript{5}Kibel A., \textsuperscript{2}Sun M., \textsuperscript{5}Chang S., \textsuperscript{2}Trinh Q-D.
\textsuperscript{1}Imperial College Healthcare, Dept. of Urology, London, United Kingdom, \textsuperscript{2}Brigham and Women’s Hospital, Dept. of Urology, Boston, United States of America, \textsuperscript{3}Brigham and Women’s Hospital, Center for Surgery and Public Health, Boston, United States of America, \textsuperscript{4}Maine Medical Center, Dept. of Urology, Boston, United States of America, \textsuperscript{5}Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, United States of America

1057

\textbf{Comparison of long-term functional outcomes after radical nephrectomy and nephron-sparing surgery}

By: Semko S., Pikul M., Voylenko O., Stakhovskyi O., Kononenko O., Vitruk I., Stakhovsky E.
National Cancer Institute, Dept. of Plastic and Reconstructive Oncology, Kiev, Ukraine

1058

\textbf{The influence of robot-assisted nephron sparing surgery on blood pressure of patients with hypertension: The preliminary results}

By: Wang X., Zhao X., Guo H.
Drum Tower Hospital, Dept. of Urology, Nanjing, China
Diagnostic advancements and medical therapy in male sexual dysfunction and hypogonadism
Poster Session 76

Monday 18 March
14:00 - 15:30

Location: Green Area, Room 10
Chairs: M.M. Fode, Herlev (DK)
J.I. Martinez Salamanca, Madrid (ES)
E.C. Serefoglu, Istanbul (TR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1061
A new method of quantitatively measuring penile erection hardness in erectile dysfunction patients: Real-time ultrasonic shear wave elastography
By: Yang L.¹, Ruan L.², He D.¹
¹The First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xian, China,
²The First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Ultrasonography, Xian, China

1063
The impact of aortic calcification on severe erectile dysfunction in patients with end stage renal disease
By: Fujita N.¹, Momota M.¹, Tobisawa Y.¹, Yoneyama T.¹, Yamamoto H.¹, Imai A.¹
¹Hiroasaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,
²Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

1064
Differences in provider-led sexual health counseling practices for male versus female radical cystectomy patients
By: Gupta N.¹, Kucirka L.², Semerjian A.³, Bivalacqua T.¹
¹Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America,
²Johns Hopkins University School of Medicine, Dept. of Gynecology and Obstetrics, Baltimore, United States of America,
³St. Joseph Mercy Hospital, Dept. of Urology, Ypsilanti, United States of America

1065
Pelvic muscle floor rehabilitation in lifelong premature ejaculation: 48 months follow-up outcomes
By: Pastore A.L.¹, Maruccia S.², Casellato S.², Al Salhi Y.¹, Fuschi A.¹, Martoccia A.¹, Capone L.¹, Illiano E.³, Velotti G.¹, Costantini E.³, Carbone A.¹
¹Sapienza University of Rome, Faculty of Pharmacy and Medicine, Dept. of Urology,
**1066**

**Current step-wise EAU recommendations for hypogonadism screening in erectile dysfunction are not cost-effective**

By: Ribeiro Morgado L.A. , Moura M.L., Dinis P. , Silva C.

1Centro Hospitalar São João, Dept. of Urology, Porto, Portugal, 2Faculdade de Medicina da Universidade do Porto, Dept. of Urology, Porto, Portugal

**1067**

**Testosterone replacement therapy improves potency recovery following robot assisted radical prostatectomy**

By: El-Khatib F.M., Huynh L., Towe M., Yafi F., Ahlering T.

1University of California, Irvine, Chao Family Comprehensive Cancer Center, Irvine, United States of America, 2University of California, Irvine, Dept. of Urology, Irvine, United States of America

**1069**

**The effect of testosterone replacement therapy on sexual dysfunction and quality of life in adult men with opioid-induced androgen dysfunction: A systematic review**

By: Birch B., Kunitsyna M.

University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

**1070**

**Comparison for subgroups of patients with LOH symptoms based on endocrinological findings - Normal vs compensated normal, and primary hypogonadism vs secondary hypogonadism**

By: Ishikawa K., Soejima M., Yoshiyama A., Nagashima Y., Hiramatsu I., Uesaka Y., Nozaki T., Ogishima T., Shirai M., Kobayashi K., Horie S., Tsujimura A.

1Juntendo University Urayasu Hospital, Dept. of Urology, Chiba, Japan, 2Men’s Health Clinic Tokyo, Dept. of Urology, Tokyo, Japan, 3Juntendo University, Graduate School of Medicine, Dept. of Urology, Tokyo, Japan

**1071**

**Serum PSA as a predictor of symptomatic hypogonadism particularly in relation to psychological symptoms**

By: Matsushita K., Tsujimura A., Horie S.

Juntendo University, Dept. of Urology, Tokyo, Japan

**1072**

**The relationship between depressive symptoms and erectile dysfunction across different ages: Which patients deserve more clinical attention?**


1IRCCS Ospedale San Raffaele, Dept. Urology, Urological research institute (URI), Milan,
Molecular classification of urothelial tumors and implications for clinical practice
Poster Session 77

Location: Green Area, Room 11

Chairs: To be confirmed
A. Necchi, Milan (IT)
A. Vlahou, Athens (GR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1074

FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?


1 Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept of Surgical Oncology, Urology, Amsterdam, Netherlands, The, 2 Caritas St Joseph Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, 3 University of Turku, Dept. of Urology, Turku, Finland, 4 CNIO, Dept. of Genetic Molecular Epidemiology and Cancer Biology, Madrid, Spain, 5 Erasmus MC, Dept. of Pathology, Rotterdam, Netherlands, The, 6 Erasmus MC, Dept. of Urology, Rotterdam, Netherlands, The, 7 Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Medical Oncology, Amsterdam, Netherlands, The, 8 University of Erlangen, Dept. of Pathology, Erlangen, Germany, 9 University Health Network, Dept. of Urology, Toronto, Canada, 10 Institut Curie, Dept. of Pathology, Paris, France, 11 University Health Network, Dept. of Pathology, Toronto, Canada

1075

Comprehensive genomic analysis of upper urinary tract urothelial carcinoma

By: Fujii Y. 1, Sato Y. 1, Suzuki H. 2, Tetsuchi Y. 2, Yoshida K. 2, Shiraishi Y. 3, Kawai T. 1, Nakagawa T. 1, Nishimatsu H. 4, Okaneya T. 5, Sanada M. 6, Makishima H. 2, Miyano S. 3, Ogawa S. 2, Kume H. 1

1 The University of Tokyo Hospital, Dept. of Urology, Tokyo, Japan, 2 Graduate School of Medicine, Kyoto University, Dept. of Pathology and Tumor Biology, Kyoto, Japan, 3 Institute of Medical Science The University of Tokyo, Laboratory of DNA information Analysis, Human Genome Center, Tokyo, Japan, 4 The Fraternity Memorial Hospital, Dept.
**Scientific Programme - EAU19 Barcelona**

of Urology, Tokyo, Japan, Toranomon Hospital, Dept. of Urology, Tokyo, Japan, Clinical Research Center, Nagoya Medical Center, Dept. of Advanced Diagnosis, Nagoya, Japan

*1076*

**Assessment of TERT mutations in urinary sediment DNA by NGS and ddPCR for bladder cancer detection – A comparison**

By: Stoeckel F. 1, Salomo K. 1, Stasik S. 2, Thiede C. 2, Menschikowski M. 3, Heberling U. 1, Wirth M.P. 1, Füssel S. 1

1University Hospital, Technische Universität Dresden, Dept. of Urology, Dresden, Germany, 2University Hospital, Technische Universität Dresden, Medical Department I, Dresden, Germany, 3University Hospital, Technische Universität Dresden, Institute of Clinical Chemistry and Laboratory Medicine, Dresden, Germany

1077

**Circulating tumor cells are a strong predictor of cancer specific survival in high risk nonmuscle invasive bladder cancer: Final analysis of a prospective observational study**

By: Busetto G.M. 1, Raimondi C. 2, Gazzaniga P. 2, Del Giudice F. 1, De Berardinis E. 1

1Sapienza Rome University Policlinico Umberto I, Dept. of Urology, Rome, Italy, 2Sapienza Rome University Policlinico Umberto I, Molecular Medicine, Rome, Italy

*1078*

**Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes**


1University Hospital, Friedrich-Alexander Universität Erlangen-Nürnberg, Dept. of Gynaecology and Obstetrics, Erlangen, Germany, 2University Hospital, Friedrich-Alexander Universität Erlangen-Nürnberg, Institute of Pathology, Erlangen, Germany, 3The George Washington University School of Medicine and Health Sciences, Dept. of Microbiology, Immunology and Tropical Medicine, Washington, DC, United States of America, 4University Hospital, Friedrich-Alexander Universität Erlangen-Nürnberg, Dept. of Urology and Paediatric Urology, Erlangen, Germany, 5Stratifyer Molecular Pathology, Cologne, Germany, 6University Hospital, University of Regensburg, Dept. of Urology, Regensburg, Germany, 7Ruprecht-Karls-Universität Heidelberg, Dept. of Urology, Medical Faculty, Mannheim, Germany, 8University Hospital, University of Ulm, Dept. of Urology, Ulm, Germany, 9TU Munich, Institute of Pathology, Munich, Germany

1079

**10-immune related gene expression panel to predict the overall survival and tumor recurrence in patient with muscle-invasive bladder cancer**

By: Zhu Y., Zhang J., Gu C., Zhu Y., Ye D.

Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

1080

**High levels of heat-shock factor 1 (HSF1) are associated with poor prognosis in muscle-invasive bladder cancer patients treated with chemoradiation-based bladder sparing protocol**


1081  Impact of RAGE gene polymorphisms on urothelial cell carcinoma clinicopathologic characteristics and long term survival

By: Sheng-Chun H. 1, Wang S-S. 1, Li J-R. 1, Chen C-S. 1, Chang L.W. 1, Yang C-K. 1, Chiu K-Y. 1, Cheng C-L. 1, Ou Y-C. 2, Ho H-C. 1, Yang S-F. 3
1 Taichung Veteran General Hospital, Dept. of Surgery, Taichung, Taiwan, 2 Tung's Taichung MetroHarbor Hospital, Dept. of Urology, Taichung, Taiwan, 3 Chung Shan Medical University, Institute of Medicine, Taichung, Taiwan

1082  Urinary microbiota — a potential biomarker and therapeutic target for bladder cancer

By: Bi H. 1, Tian Y. 2, Huang Y. 1, Zhang Y. 2
1 Peking University Third Hospital, Dept. of Urology, Beijing, China, 2 Beijing Ditan Hospital, Institute of Infectious Diseases, Beijing, China

1083  EGFR cell expression during adjuvant treatment after transurethral resection for non-muscle invasive bladder cancer

By: Di Maida F. 1, Mari A. 1, Scalici Gesolfo C. 2, Cangemi A. 3, Allegro R. 4, Tellini R. 1, Russo A. 3, Carini M. 1, Minervini A. 1, Serretta V. 2
1 University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, 2 University of Palermo, Dept. of Urology, Palermo, Italy, 3 University of Palermo, Dept. of Oncology, Palermo, Italy, 4 University of Palermo, Dept. of Statistics, Palermo, Italy

1084  Long noncoding RNA LNMAT2 promotes bladder cancer metastasis by CCL5-dependent macrophage recruitment

By: Chen C. 1, Jian H. 1, Wang H. 1, Xu C. 1, Yue Z. 2, Tianxin L. 1
1 Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China, 2 Sun Yat-Sen University, Dept. of Tumor Intervention, Guangzhou, China

15:19 - 15:24  Summary
To be confirmed
**Understanding approaches to ureteric obstruction**

**Poster Session 78**

**Monday 18 March**

**14:00 - 15:30**

**Location:** Green Area, Room 12

**Chairs:** To be confirmed

M. Bultitude, London (GB)

S.K. Lildal, Arhus N (DK)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

1085

**Surgical approaches for treatment of ureteropelvic junction obstruction – A systematic review and network meta-analysis**

By: **Uhlig A.**¹, **Uhlig J.**², **Trojan L.**¹, **Hinterthaner M.**³, **Emmert A.**⁴, **Strauss A.**¹

¹University Medical Center Goettingen, Dept. of Urology, Goettingen, Germany,

²University Medical Center Goettingen, Dept. of Diagnostic and Interventional Radiology, Goettingen, Germany,

³University Medical Center Goettingen, Dept. of Thoracic and Cardiovascular Surgery, Goettingen, Germany,

⁴University Medical Center Goettingen, Thoracic and Cardiovascular Surgery, Goettingen, Germany

1088

**Is the ureteral length associated with the patient’s size?**

By: **Mansouri A.**¹, **Thanwerdas J.**¹, **Malavaud B.**²

¹Hôpital Jean ROUGIER, Dept. of Urology, CAHORS, France,

²CHU Rangueil, Dept. of Urology, Toulouse, France

1090

**Long term outcome of balloon dilatation of benign ureteric strictures**

By: **Yam W.L.**¹, **Ng K.S.**², **Teo J.K.**¹, **Ng F.C.**¹

¹Changi General Hospital, Dept. of Urology, Singapore, Singapore,

²Changi General Hospital, Dept. of Radiology, Singapore, Singapore

1091

**Endourological management of benign ureteral stricture: Less is more?**

By: **Colicchia M.**, **Beltrami P.**, **Soligo M.**, **Bettin L.**, **Zattoni F.**, **Iafrate M.**, **Dal Moro F.**, **Zattoni F.**

University of Padua, Dept. of Urology, Padua, Italy

1092

**Management of long ureteral stenosis: Alternatives to indwelling ureteral stents**

By: **Roux S.**¹, **Pettenati C.**², **Dariane C.**², **Sbizzera M.**³, **Dominique I.**⁴, **Matillon X.**⁵, **Toinet T.**⁶, **Neuzillet Y.**⁷, **Bessède T.**⁸, **Drouin S.**⁹, **Nouaille A.**¹⁰, **Champy C.**¹¹, **Timsit M.O.**², **Méjean A.**²

¹Hôpital Européen Georges-Pompidoul, AP-HP, University of Paris Descartes, Dept. of
1093
Interest of the pigtail suture stent in preventing the irritative signs of the lower urinary tract

By: Mrabti M.¹, Tetou M.¹, El Harech Y.¹, Bouaiti E.², Ameur A.¹, Alami M.¹
¹Military Hospital Mohammed V, Dept. of Urology, Rabat, Morocco, ²Military Hospital Mohammed V, Dept. of Epidemiology, Rabat, Morocco

1095
Rational renographic approach for the evaluation of uretero-ileal stenosis

By: Recupero S.M.¹, Ragonese M.¹, Pinto F.¹, Racioppi M.¹, Sacco E.¹, Palermo G.¹, Tartaglione G.², Bassi P.¹, Foschi N.¹
¹Catholic University Medical School and Academic Hospital Fondazione A.Gemelli - IRCSS, Dept. of Urology, Nephrology and Kidney Transplantation, Rome, Italy, ²Cristo Re Hospital, Dept. of Nuclear medicine, Rome, Italy

1097
Minimally invasive treatment for complex urinary tract endometriosis. Results from a high-volume referral center at a median follow up of 47 months

By: Mari A.¹, Di Maida F.¹, Tellini R.¹, Sforza S.¹, Campi R.¹, Rivetti A.¹, Mattei A.², Tuccio A.¹, Siena G.¹, Masieri L.¹, Carini M.¹, Minervini A.¹
¹University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ²University of Florence, Careggi Hospital, Dept. of Gynecology and Obstetrics, Florence, Italy

1099
Comparative assessment of laparoendoscopic single-site surgery to conventional laparoscopy in management of upper urinary tract pathologies

By: Ghaith A.F.¹, Abdel-Karim A.², Abdel Raheem A.¹, Hagras A.¹, El-Tatawy H.¹, Micali S.³, Elashry O.¹
¹Tanta University Hospital, Dept. of Urology, Tanta, Egypt, ²Alexandria University Hospital, Dept. of Urology, Alexandria, Egypt, ³University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy
Minimally-invasive surgical therapies for BPO: Results and indications

Poster Session 79

Monday 18 March
14:00 - 15:30

Location: Green Area, Room 20

Chairs: P.A. Geavlete, Bucharest (RO)
S. Madersbacher, Vienna (AT)
M. Speakman, Taunton (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1100
Rezūm steam ablation therapy for benign prostatic hyperplasia: Initial results from the United Kingdom

By: Johnston M.1, Shah T.2, Emara A.1, Gehring T.1, Farmer T.1, Nedas T.G.1, Rajkumar G.1, Mcfarlane A.2, Winkler M.2, El-Husseiny T.2, Ahmed H.U.2, Hindley R.G.1

1Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke, United Kingdom, 2Imperial College London, Dept. of Urology, London, United Kingdom

1101
Evaluation of outcome of transurethral needle ablation (TUNA) for treating symptomatic BPH: A 10-year experience

By: Haroun H., El-Tatawy H., Soliman M.G., Ragab M., Tawfik A., Sabaa M.
Tanta University, Faculty of Medicine, Dept. of Urology, Tanta, Egypt

1102
The prostatic urethral lift (Urolift) versus the convection water vapor ablation (Rezūm) for minimally invasive treatment of BPH: A comparison of improvements and durability in 3-year clinical outcomes

By: Shepherd S.1, Hossein S.1, Chuhtai B.2, Elterman D.1

1Toronto Western Hospital - University Health Network, Dept. of Surgery, Division of Urology, Toronto, Canada, 2Weill Cornell Medicine, Dept. of Urology, New York City, United States of America

1104
Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: 12 month results of a clinical trial

By: Giral Villalta P.J.1, Aguilar Guevara J.F.1, López Ubillos G.1, Lacarra Fernández S.1, Zabalo San Juan A.1, Asiain Urmeneta M.1, Meza Huaman A.M.1, Sazatniel Escuer M.1, Insauti Gorbae I.2, Saez De Ocair Garcia A.2, Solchaga Alvarez S.2, Napal Lecumberri S.1, Cebranil Lostal J.L.1, Losada Alvarez I.1

1Complejo Hospitalario de Navarra, Dept. of Urology, Pamplona, Spain, 2Complejo Hospitalario de Navarra, Dept. of Interventional Radiology, Pamplona, Spain
Retrograde ejaculation after holmium laser enucleation of the prostate (HOLEP) – evaluation of patient bother and impact on sexual function using validated questionnaires

By: Gild P.¹, Pompe R.¹, Vetterlein M.W.¹, Maurer V.¹, Marks P.¹, Lukas L.¹, Ihab D.¹, Ernst T.¹, Dahlem R.¹, Fisch M.¹, Reiss P.¹, Rink M.¹, Meyer C.P.¹, Becker A.²

¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Frankfurt University Hospital and University Medical Center Hamburg-Eppendorf, Dept. of Urology, Frankfurt, Germany

Predictors of index bladder outlet obstruction procedure care setting and its impact on perioperative outcomes and costs

By: Tully K.¹, Friedlander D.², Krimphove M.³, Noldus J.⁴, Trinh Q-D.²

¹Marien Hospital Herne, Dept. of Urology, Herne, Germany, ²Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America, ³University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany, ⁴Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany

Relief of lower urinary tract symptoms after MRI-guided transurethral ultrasound ablation (TULSA): Subgroup analyses in patients with symptoms of benign prostatic hyperplasia

By: Elterman D.¹, Hatiboglu G.², Hetou K.³, Staruch R.⁴, Burtynyk M.⁴, Relle J.⁵, Shepherd S.⁶, Chin J.⁷

¹Toronto Western Hospital - University Health Network, Dept. of Surgery, Division of Urology, Toronto, Canada, ²University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ³Western University, London Health Sciences Centre, Division of Urology, Ontario, London, Canada, ⁴Profound Medical, Medical Affairs, Mississauga, Ontario, Canada, ⁵Beaumont Health System, Dept. of Urology, Royal Oak, Michigan, United States of America, ⁶Toronto Western Hospital - University Health Network, Dept. of Surgery, Division of Urology, Toronto, Canada, ⁷Western University, London Health Sciences Centre, Division of Urology, Ontario, London, Canada

Ejaculatory hood sparing vs. standard GreenLightTM Laser photoselective vaporization of the prostate: Sexual and urodynamic assessment through randomized controlled trial

By: Abolazm A.E., Elshal A.M., El-Hefnawy A.S., Laymon M., Shehab El-Din A.B. Mansoura Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

Pulling the foley: Can the prostatic urethral lift be used in men with catheter dependent urinary retention?

By: McMahon G.C.M.¹, Panuganti S.¹, Wilson M.¹, Thaker T.¹, Mueller T.²

¹Rowan University, Dept. of Urology, Stratford, United States of America, ²New Jersey Urology, Dept. of Urology, Voorhees, United States of America
<table>
<thead>
<tr>
<th>Time</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:23 - 15:30</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
# How to proceed with hematuria

**ESU Course 55**

**Location:** Green Area, Room 13  
**Chair:** S. Boorjian, Rochester (US)

## Aims and objectives of this session

Hematuria is one of the most common indications for urologic evaluation, and is recognized as a sign of potentially important illness. Therefore, knowledge of the differential diagnosis, principles of evaluation, and strategies for management of hematuria is critical. This course is designed for the practicing urologist, to provide a guidelines-based and case-oriented approach to the evaluation and management of hematuria.

After attending the course, participants will:
- Understand guideline recommendations for initial evaluation of asymptomatic microscopic hematuria.
- Describe existing data regarding hematuria screening.
- Recognize intravesical treatment regimens and associated side effect profiles for hemorrhagic cystitis.
- Create strategies for treating refractory hemorrhagic cystitis, upper urinary tract, and prostate-related bleeding.

## Course introduction and background to hematuria

S. Boorjian, Rochester (US)

## Review of microscopic hematuria

H. Mostafid, Surrey (GB)

## AUA guidelines (and beyond) on microscopic hematuria

S. Boorjian, Rochester (US)

## Cases and questions focusing on microhematuria

S. Boorjian, Rochester (US)  
H. Mostafid, Surrey (GB)

## Evaluation and management of gross hematuria and hemorrhagic cystitis

S. Boorjian, Rochester (US)  
H. Mostafid, Surrey (GB)

## Prostate/Urethral/Upper urinary tract bleeding

H. Mostafid, Surrey (GB)

## Cases and questions focusing on gross hematuria

S. Boorjian, Rochester (US)  
H. Mostafid, Surrey (GB)
<table>
<thead>
<tr>
<th>Video Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>V83</td>
<td>Surgical treatment of Peyronie's disease with buccal mucosa graft</td>
<td>Kotov S.V., Usufov A.G. Pirogov Russian National Research Medical University, Dept. of Urology and Andrology, Moscow, Russia</td>
</tr>
<tr>
<td>V84</td>
<td>Robotic sigmoid vaginoplasty: A feasible single stage minimally invasive alternative</td>
<td>Khandekar A., Pandey S., Abraham B., Mohammad A.I. Kokilaben Dhirubhai Ambani Hospital, Dept. of Urology, Mumbai, India</td>
</tr>
<tr>
<td>V85</td>
<td>From pubis to phallus: A complete demonstration of the three stages of radial artery forearm phalloplasty formation</td>
<td>Chiriacò G., Blecher G.A., Christopher A.N., Ralph D.J. University College London Hospital (UCLH), Dept. of Andrology, London, United Kingdom</td>
</tr>
<tr>
<td>V86</td>
<td>Gender affirming surgery: Vaginoplasty and clitoroplasty with modified penoscrotal flap technique</td>
<td>Trombetta C., Migliozzi F., Rizzo M., Bucci S., Perin C., Boltri M., Claps F., Liguori G. ASUITS, Faculty of Medicine and Surgery, Dept. of Urology, Trieste, Italia, Italy</td>
</tr>
</tbody>
</table>
Advancing the outcome of advanced and metastatic bladder cancer
Poster Session 80

Monday 18 March
15:45 - 17:15

Location: Red Area, eURO Auditorium 2
Chairs: C. Beisland, Bergen (NO)
Y. Loriot, Villejuif (FR)
P. Patel, Edgbaston, Birmingham (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1114
The role of surgery and peri-operative systemic therapy
To be confirmed

1114
Do urologists take the better slice of cake in muscle-invasive bladder cancer (MIBC)?

By: Dosanjh A.1, Mintz H.P.2, Mytton J.L.1, Gallier S.1, James N.D.3, Patel P.3
1University Hospitals Birmingham NHS Foundation Trust, Dept. of Health Informatics, Birmingham, United Kingdom, 2University of Warwick, Warwick Medical School, Coventry, United Kingdom, 3University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom

1115
Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histological subtype matter?

By: Berg S.1, D’andrea D.2, Vetterlein M.W.3, Cole A.P.1, Fletcher S.A.1, Krimphove M.J.1, Marchese M.1, Lipsitz S.R.4, Sonpavde G.5, Noldus J.6, Shariat S.F.2, Kibel A.S.1, Trinh Q-D.1, Mossanen M.1
1Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, 2Medical University of Vienna, Dept. of Urology, Vienna, Austria, 3University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 4Brigham and Women's Hospital, Harvard Medical School, Division of Internal Medicine and Center for Surgery and Public Health, Boston, United States of America, 5Dana Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America, 6Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and NeuroUrology, Herne, Germany

1116
Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup
1117

Combining DNA-repair gene mutations and molecular subtyping for more accurate prediction of outcome after neoadjuvant chemotherapy for bladder cancer

By: Batista Da Costa J. ¹, Seiler R. ², Ikeda K. ¹, Zhou J. ¹, Winters B. ³, Gibb E. ⁴, Volik S. ¹, Wright J. ³, Sommerland M. ⁵, Douglas J. ⁵, Collins C. ¹, Black P. ¹
¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²University of Bern, Dept. of Urology, Bern, Switzerland, ³University of Washington School of Medicine, Dept. of Urology, Seattle, United States of America, ⁴GenomeDX Biosciences, Dept. of R&D, Vancouver, Canada, ⁵University Hospital of Southampton, Dept. of Urology, Southampton, United Kingdom

1118

Meta-analysis of prospective trials for bladder preserving tri-modal therapy in patients with muscle invasive bladder cancer

By: Inamoto T. ¹, Ibuki N. ¹, Komura K. ¹, Juri H. ², Yamamoto K. ², Yamamoto K. ², Narumi Y. ², Azuma H. ¹
¹Osaka Medical College, Dept. of Urology, Takatsuki, Japan, ²Osaka Medical College, Dept. of Radiology, Takatsuki, Japan

* 1119

FIERCE-21: Phase 2 study of Vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUCC)

By: Necchi A. ¹, Castellano D. ², Mellado B. ³, Pang S.T. ⁴, Urun Y. ⁵, Park S.H. ⁶
Validation of the COBRA nomogram for the prediction of cancer specific survival in patients with bladder cancer treated with radical cystectomy


1 Sant'Andrea Hospital- "Sapienza" University, Dept. of Urology, Rome, Italy, 2 Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 3 University of Southern California, Dept. of Urology, Los Angeles, United States of America, 4 Mansoura University, Dept. of Urology, Mansoura, Egypt, 5 Sant'Andrea Hospital-, Dept. of Urology, Rome, Italy, 6 Umberto I- "Sapienza" University, Dept. of Urology, Rome, Italy

Surgical outcome of pre-operative atezolizumab before radical cystectomy for muscle-invasive urothelial carcinoma of the bladder

By: Szabados B. 1, Duran I. 2, Crabb S.J. 3, Van Der Heijden M.S. 4, Font Pous A. 5, Gravis G. 6, Anido Herranz U. 7, Protheroe A. 8, Ravaud A. 9, Maillet D. 10, Mendez-Vidal M.J. 11, Suárez C. 12, Linch M.D. 13, Prendergast A. 1, Mousa K. 1, Castellano D.E. 14, Powles T. 1, Rodriguez-Vida A. 15

1 Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, 2 Hospital Universitario Marqués de Valdecilla, Dept. of Medical Oncology, Santander, Spain, 3 University of Southampton, Southampton Clinical Trials Unit, Southampton, United Kingdom, 4 Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, Netherlands, The, 5 Hospital Universitari Germans Trias i Pujol (HUGTIP), Institut Català d’Oncologia, Badalona, Spain, 6 Institut Paoli-Calmettes, Dept. of Medical Oncology, Marseille, France, 7 Hospital Clinico Universitario, Dept. of Medical Oncology, Santiago De Compostela, Spain, 8 Churchill Hospital, Dept. of Medical Oncology, Oxford, United Kingdom, 9 Hôpital Saint-André, Dept. of Medical Oncology, Bordeaux, France, 10 Hosp Lyon SUD, Dept. of Medical Oncology, Lyon, France, 11 Reina Sofia University Hospital, Dept. of Medical Oncology, Cordoba, Spain, 12 Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain, 13 Royal Marsden Hospital, Dept. of Medical Oncology, London, United Kingdom, 14 Hospital Universitario, Dept. of Medical Oncology, Madrid, Spain, 15 Hospital Del Mar, Dept. of Medical Oncology, Barcelona, Spain

* 1122

First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (Pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC)
Antihypertensive drugs and risk of bladder cancer death in Finland

By: Santala E.E.¹, Kotsar A.², Tammela T.L.J.¹, Murtola T.¹
¹University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland, ²Tartu University Hospital, Dept. of Urology, Tartu, Estonia

Identification of stromal macrophage infiltration predict overall survival and recurrence-free survival in patients with muscle invasive bladder cancer

By: Zhu Y., Zhang J., Gu C., Zhu Y., Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Current role of systemic therapy
To be confirmed
PSA and prostate cancer screening: What is new in 2019?
Poster Session 81

Location: Green Area, Room 1

Chairs: F. Abdollah, West Bloomfield (US)
S. Carlsson, New York (US)
G.T. Sung, Busan (KR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1126
Prostate-specific antigen (PSA) levels in men 60 to 70 years of age predict aggressive prostate cancer in the PLCO cancer screening trial: Implications for risk-stratified screening

By: Berger A. ¹, Aden-Buie G. ², Kibel A.S. ¹, Mucci L.A. ³, Penney K. ³, Wilson K. ³, Gerke T. ², Preston M. ¹
¹Brigham and Women's Hospital/Harvard University, Dept. of Surgery, Urology, Boston, United States of America, ²Moffit Cancer Center, Dept. of Surgery, Urology, Tampa, United States of America, ³Harvard Channing School of Public Health, Dept. of Epidemiology, Boston, United States of America

1127
Inappropriate PSA Testing - can it be stopped?

By: Hatem E., Green J.S.A., Hughes-Hallett A.
Whipps Cross University Hospital, Dept. of Urology, London, United Kingdom

1128
Socioeconomic patterns of first-time PSA testing in general practice

By: Benzon Larsen S. ¹, Lerche C.S. ¹, Andersen I. ², Thygesen L.C. ³, Andersen K.K. ⁴, Duun-Henriksen A.K. ⁵, Johansen C. ⁶, Røder M.A. ¹, Dalton S.O. ⁶, Brasso K. ¹
¹Copenhagen University Hospital, Copenhagen Prostate Cancer Center, Copenhagen, Denmark, ²Copenhagen University, Dept. of Public Health, Copenhagen, Denmark, ³University of Southern Denmark, National Institute of Public Health, Copenhagen, Denmark, ⁴Danish Cancer Society Research Center, Statistics and Pharmaco-Epidemiology, Copenhagen, Denmark, ⁵Danish Cancer Society Research Center, Statistics and Pharmacoepidemiology, Copenhagen, Denmark, ⁶Danish Cancer Society Research Center, Survivorship, Copenhagen, Denmark

1129
The relation between baseline PSA, cancer detection and PC death, long-term data from ERSPC

By: Roobol M. ¹, Remmers S. ¹, Hugosson J. ², Carlsson S.V. ³, Auvinen A. ⁴, Tammela T.L.J. ⁵, Denis L.J. ⁶, Nelen V. ⁷, Villers A. ⁸, Rebillard X. ⁹, Kwiatkowski M. ¹⁰, Recker F. ¹⁰, Zappa M. ¹¹, Puliti D. ¹¹, Paez A. ¹², Lujan M. ¹³, Bangma C.H. ¹
PSA-testing as a part of mandated health check-ups and risk of prostate cancer: Nationwide, population-based case control study of firefighters

By: Cazzaniga W. 1, Gauffin O. 2, Johansson E. 2, Robinson D. 3, Stattin P. 4
1 University Vita-Salute San Raffaele, Dept. of Urology, Milan, Italy,
2 Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden,
3 Ryhov Hospital, Dept. of Urology, Jönköping, Sweden,
4 Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau)

By: Gstrein L. 1, Mortezavi A. 1, Millan C. 1, Wyler S. 2, Grobholz R. 3, Huber A. 4, Manka L. 5, Sulser T. 1, Recker F. 2, Eberli D. 1, Kwiatkowski M. 2
1 University Hospital Zurich, Dept. of Urology, Zurich, Switzerland,
2 Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland,
3 Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland,
4 Cantonal Hospital Aarau, Laboratory Medicine, Aarau, Switzerland,
5 Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany

The effect of common diabetes medications on PSA levels in men without prostate cancer

By: Binti Abd Jalal N. 1, Garmo H. 1, Nordstrom T. 2, Aly M. 2, Eklund M. 2, Aldofsson J. 3, Van Hemelrijck M. 1, Beckmann K. 1
1 Kings College London, School of Cancer and Pharmaceutical Studies, London, United Kingdom,
2 Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden,
3 Karolinska Institute, CLINTEC-Department, Stockholm, Sweden

Effects of antihypertensive drug use on prostate cancer-specific survival in Finnish men

By: Siltari A. 1, Murtola T. 2, Talala K. 3, Taari K. 4, Tammela T. 1, Auvinen A. 5
1 University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland,
2 University of Tampere, Tampere University Hospital, Faculty of Medicine and Life Sciences, Department of Urology, Tampere, Finland,
3 Finnish Cancer Registry, Finnish Cancer Registry, Helsinki, Finland,
4 University of Helsinki, Helsinki University Hospital,
1134

Association of common medication with prostate-specific antigen level in 45-year-old German men: Results of the PROBASE trial

By: Herkommer K. ¹, Meissner V.H. ¹, Ertlav Z. ¹, Kron M. ², Schulwitz H. ¹, Albers P. ³, Arsov C. ³, Kućzyk M. ⁴, Imkamp F. ⁴, Hohenfellner M. ⁵, Hadaschik B. ⁵, Gschwend J.E. ¹

¹Klinikum Rechts der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, ²University of Ulm, Institute of Epidemiology and Medical Biometry, Ulm, Germany, ³Universitätsklinikum Düsseldorf, Heinrich-Heine-University, Dept. of Urology, Düsseldorf, Germany, ⁴Hannover Medical School, Clinic for Urology and Urologic Oncology, Hannover, Germany, ⁵Universitätsklinikum Heidelberg, Ruprecht-Karls-University, Dept. of Urology, Heidelberg, Germany

1135

A population-based randomized trial of early detection of clinically significant prostate cancer (ProScreen): Pilot phase results

By: Rannikko A. ¹, Kilpeläinen T. ¹, Matikainen M. ¹, Kenttämies A. ², Petas A. ¹, Santti H. ¹, Mirtti T. ³, Rinta-Kiikka I. ⁴, Kujala P. ⁵, Taari K. ¹, Natunen K. ⁶, Lilja H. ⁷, Tammela T. ⁸, Auvinen A. ⁶

¹University of Helsinki and HUS Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ²University of Helsinki and HUS Helsinki University Hospital, Dept. of Radiology, Helsinki, Finland, ³University of Helsinki and HUS Helsinki University Hospital, Dept. of Pathology, Helsinki, Finland, ⁴Tampere University Hospital and University of Tampere, Dept. of Radiology, Tampere, Finland, ⁵Tampere University Hospital and University of Tampere, Fimlab laboratories, Dept. of Pathology, Tampere, Finland, ⁶University of Tampere, Faculty of Social Sciences, Tampere, Finland, ⁷Memorial Sloan Kettering Cancer Center, Dept. of Laboratory Medicine and Medicine, New York, United States of America, ⁸Tampere University Hospital and University of Tampere, Dept. of Urology, Tampere, Finland

1136

Impact of a changing population structure and clustering of cancer in prostate cancer patients depending on a first-degree family-history

By: Herkommer K. ¹, Bittner R. ¹, Meissner V.H. ¹, Kron M. ², Schiele S. ¹, Schulwitz H. ¹, Gschwend J.E. ¹

¹Klinikum rechts der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, ²University of Ulm, Institute of Epidemiology and Medical Biometry, Ulm, Germany

1139

Multi-parametric prostate MRI as a screening test among male BRCA carriers

By: Margel D. ¹, Sela S. ¹, Tamir S. ², Kedar I. ³, Ber Y. ¹, Kedar D. ¹, Nadu A. ¹, Baniel J. ¹

¹Rabin Medical Center, Dept. of Urology, Peath-Tikva, Israel, ²Rabin Medical Center, Dept. of Imaging, Peath-Tikva, Israel, ³Rabin Medical Center, The Rafael Recanati Genetic Institute, Peath-Tikva, Israel
Improving management and outcomes of urological emergencies

Poster Session 82

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 2
Chairs: N. Kitrey, Ramat Gan (IL)
L. Martínez Piñeiro, Madrid (ES)
S.V. Yrastorza, Quezon City (PH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1141

Testicular torsion and atmospheric temperature: Is there any relationship?

By: Mokadem S. , Chakroun M. , Essid M.A. , Bouzouita A. , Ayed H. , Cherif M. , Ben Slama R. , Derouiche A. , Chebil M.
Hôpital Charles Nicolle, Dept. of Urology, Tunis, Tunisia

1142

Neutrophil-lymphocyte ratio predicts organ salvage in testicular torsion with marginal diagnostic delay

By: Ko Y.H. , Choi J.Y. , Song P.H. , Moon K.H. , Jung H.C.
Yeungnam University, Dept. of Urology, Daegu, Korea, South

1143

Orchidopexy for testicular torsion: A systematic review of surgical technique

1North Wales Clinical Research Centre, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Dept. of Urology, Wrexham, United Kingdom, 2BURST Research Collaborative, Dept. of Urology, London, United Kingdom, 3Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Sheffield, United Kingdom, 4Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, 5Royal Free Hospital, Dept. of Urology, London, United Kingdom, 6Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, 7University of Aberdeen, Academic Urology Group, Aberdeen, United Kingdom, 8Charing Cross Hospital, Imperial College Healthcare NHS Trust, Imperial Prostate, Department of Surgery and Cancer, Imperial College London, London, United Kingdom, 9University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, 10University of Cambridge, Dept. of Surgery Academic Urology Group, Cambridge, United Kingdom, 11Manchester Royal Infirmary, Manchester University Hospitals NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, 12University College London, Division of Surgery and Interventional Science, London, United Kingdom
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1145</td>
<td>Ameliorative effect of ozone therapy on testicular ischemia-reperfusion injury in rats</td>
<td>Sancak E.B. 1, Demirci E.D 2. 1Canakkale Onsekiz Mart University, Dept. of Urology, Faculty of Medicine, Canakkale, Turkey, 2Yozgat City Hospital, Dept. of Urology, Yozgat, Turkey</td>
</tr>
<tr>
<td>1148</td>
<td>Results of surgical treatment of radiation induced hemorrhagic cystitis</td>
<td>Oliveira Marinho A.C., Simões P., Figueiredo A. Hospital and University Center of Coimbra, Urology and Renal Transplantation, Coimbra, Portugal</td>
</tr>
<tr>
<td>1149</td>
<td>Incidence and predictive factors of pseudo-aneurysms after renal trauma: Results of TRAUMAFUF, a national multicentric study</td>
<td>Pradere B. 1, Freton L. 2, Bergerat S. 3, Olivier J. 4, Matillon X. 5, Dominique I. 5, Panayotopoulos P. 6, Lebacle C. 7, Chebbi A. 8, Rizk J. 9, Szlaba N. 10, Sabourin L. 11, Betari R. 12, Madec F.X. 13, Patard P.M. 14, Dariane C. 15, Fiard G. 16, Peyronnet B. 2. 1CHRU Tours, Dept. of Urology, Tours, France, 2CHU Rennes, Dept. of Urology, Rennes, France, 3CHU Strasbourg, Dept. of Urology, Strasbourg, France, 4CHRU Lille, Dept. of Urology, Lille, France, 5CHU Lyon, Dept. of Urology, Lyon, France, 6CHU Angers, Dept. of Urology, Angers, France, 7Hopital Kremlin Bicetre, Dept. of Urology, Paris, France, 8CHU Rouen, Dept. of Urology, Rouen, France, 9CHRU Lille, Dept. of Urology, Lille, France, 10CHU Caen, Dept. of Urology, Caen, France, 11CHU Clermont Ferrand, Dept. of Urology, Clermont Ferrand, France, 12CHU Amiens, Dept. of Urology, Amiens, France, 13CHU Nantes, Dept. of Urology, Nantes, France, 14CHU toulouse, Dept. of Urology, Toulouse, France, 15Hopital Pompidou, Dept. of Urology, Paris, France, 16CHU grenoble, Dept. of Urology, Grenoble, France</td>
</tr>
<tr>
<td>1150</td>
<td>A 15 year retrospective analysis of renal trauma in a tertiary South Australian hospital</td>
<td>Herath M., Catterwell R. Royal Adelaide Hospital, Dept. of Surgery, Adelaide, Australia</td>
</tr>
<tr>
<td>*1151</td>
<td>Risk factors for death after renal trauma: Results of the French multicenter study TRAUMAFUF</td>
<td>Lebacle C. 1, Ruggiero M. 1, Hutin M. 2, Freton L. 3, Olivier J. 4, Dominique I. 5</td>
</tr>
</tbody>
</table>
The role of magnetic resonance imaging for the diagnosis of penile fracture in real life emergency settings – Comparative analysis with intraoperative findings

By: Sokolakis I.¹, Schubert T.¹, Oelschlaeger M.¹, Krebs M.¹, Gschwend J.², Holzapfel K.³, Kuebler H.¹, Gakis G.¹, Hatzichristodoulou G.¹

¹Julius-Maximillian University Medical Centre of Wuerzburg, Dept. of Urology and Paediatric Urology, Würzburg, Germany, ²Technical University of Munich, Klinikum rechts der Isar, Dept. of Urology, Munich, Germany, ³Landshut-Achdorf Hospital, Institute of Radiology, Landshut, Germany
**Urology in the elderly**
*Poster Session 83*

**Monday 18 March**
**15:45 - 17:15**

**Location:** Green Area, Room 3

**Chairs:**
- T. Antunes Lopes, Porto (PT)
- S. Arlandis Guzman, Valencia (ES)
- To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**1153**

*The impact of frailty gap on prognosis in patients with urological cancers: A comparison of community-dwelling population*

By: Soma O. ¹, Hatakeyama S. ¹, Yamamoto H. ¹, Imai A. ¹, Yoneyama T. ¹, Hashimoto Y. ¹, Koie T. ², Ohyama C. ³

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,
²Gifu University School of Medicine, Dept. of Urology, Gifu, Japan

**1154**

*Pre-operative risk assessment by ASA score and modified Frailty Index (mFI) in oncological and non oncological urological surgery*

By: Serretta V. ¹, Muffoletto F. ¹, Tulone G. ¹, Dioguardi S. ¹, Guzzardo C. ¹, Bileci S. ¹, Baiamonte D. ¹, Giannone S. ¹, Sanfilippo C. ², Scalici Gesolfo C. ³, Simonato A. ¹

¹University of Palermo, Section of Urology, Dept. of Surgical, Oncological and Oral Sciences, Palermo, Italy,
²GSTU Foundation, Statistics, Palermo, Italy,
³Paolo Borsellino Hospital, Dept. of Urology, Marsala, Italy

**1155**

*Improved prognosis for old-aged patients with metastatic renal cell carcinoma after targeted therapy*

By: Teishima J. ¹, Mita K. ², Shigeta M. ³, Hasegawa Y. ⁴, Kadonishi Y. ⁵, Inoue S. ¹, Hayashi T. ¹, Matsubara A. ¹

¹Hiroshima University, Dept. of Urology, Hiroshima, Japan,
²Hiroshima City Asa Citizens Hospital, Dept. of Urology, Hiroshima, Japan,
³Kure Medical Center and Chugoku Cancer Center, Dept. of Urology, Kure, Japan,
⁴Fukuyama Medical Center, Dept. of Urology, Fukuyama, Japan,
⁵Onomichi General Hospital, Dept. of Urology, Onomichi, Japan

**1156**

*Non-muscle invasive urothelial bladder cancer (NMIBC) in very elderly patients: What does affect overall survival (OS)? Clinical outcomes in a retrospective analysis*

By: Di Cosmo G., Verzotti E., Pavan N., Silvestri T., Boschian R., Liguori G.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1157</td>
<td>Comparison of outcomes between standard and palliative management for high grade non-muscle invasive bladder cancer in patients older than 85 years</td>
<td>Carrión Puig A., Diaz F., Raventos C., Lozano F., Miret E., Cuadras M., Morote J.</td>
<td>Hospital Vall Hebron, Dept. of Urology, Barcelona, Spain</td>
</tr>
<tr>
<td>1158</td>
<td>Too old for a prostate biopsy?</td>
<td>Mendes Carvalho J., Nunes P., Lima J., Caetano R., Tavares-Da-Silva E.</td>
<td>Coimbra University Hospital Center, Dept. of Urology and Renal Transplantation, Coimbra, Portugal, Coimbra University Hospital Center, Dept. of Pathology, Coimbra, Portugal</td>
</tr>
<tr>
<td>1159</td>
<td>Perioperative parameters and prognosis analysis of patients aged 80 years old or older treated with radical prostatectomy for prostate cancer</td>
<td>Zhang F., Huang Y., Ma L.</td>
<td>Peking University Third Hospital, Dept. of Urology, Beijing, China</td>
</tr>
<tr>
<td>1160</td>
<td>The role of G8 screening tool in the assessment of surgical outcome of elderly patients (≥75 y.o.) with high-risk prostate cancer: A pilot study</td>
<td>Matsushita K., Sandhu J.S., Horie S., Endo F., Shimbo M., Narimoto K., Hattori K.</td>
<td>Juntendo University, Dept. of Urology, Tokyo, Japan, Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America, St. Lukes International Hospital, Dept. of Urology, Tokyo, Japan</td>
</tr>
<tr>
<td>1162</td>
<td>The impact of fall on nocturia and frailty in community-dwelling individuals</td>
<td>Hatakeyama S., Imai A., Yamamoto H., Matsumoto T., Soma O., Yoneyama T., Hashimoto Y., Nakaji S., Ohyama C.</td>
<td>Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, Hirosaki University School of Medicine, Social Medicine, Hirosaki, Japan</td>
</tr>
<tr>
<td>1163</td>
<td>Benign prostatic hyperplasia increases the risk of Parkinson’s disease: A population-based study</td>
<td>Chan J.K-S., Shih H.J., Huang C.J.</td>
<td>Wan Fang Hospital, Dept. of Urology, Taipei, Taiwan, Wan Fang Hospital, Dept. of Anesthesiology, Taipei, Taiwan</td>
</tr>
<tr>
<td>1165</td>
<td>Effect of mirabegron on cognitive function in elderly patients with overactive bladder: Results from a phase 4 placebo-controlled study (PILLAR)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Strategies to safely treat OAB in the elderly based on comorbidity, comedication and risks of serious adverse events

By: Martens F.M.J., De Wall L.L., Heesakkers J.P.F.A.
Radboudumc, Dept. of Urology, Nijmegen, Netherlands, The
Survivorship in prostate cancer: It’s all about patients

Location: Green Area, Room 4
Chairs: To be confirmed
To be confirmed
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1168 Utilization of psychiatric resources prior to genitourinary (GU) cancer diagnosis: Implications for survival outcomes

By: Klaassen Z.¹, Wallis C.², Goldberg H.², Chandrasekar T.³, Sayyid R.¹, Williams S.⁴, Moses K.⁵, Terris M.¹, Nam R.⁶, Kurdyak P.⁷, Kulkarni G.²
¹Medical College of Georgia at Augusta University; Georgia Cancer Center, Surgery, Division of Urology, Augusta, United States of America, ²University of Toronto, Princess Margaret Cancer Centre, Surgery, Division of Urology, Toronto, Canada, ³Thomas Jefferson University Hospital, Dept. of Urology, Philadelphia, United States of America, ⁴University of Texas Medical Branch, Surgery, Division of Urology, Galveston, United States of America, ⁵Vanderbilt University, Dept. of Urology, Nashville, United States of America, ⁶Sunnybrook Hospital, Surgery, Division of Urology, Toronto, Canada, ⁷Centre for Addiction and Mental Health, Dept. of Psychiatry, Toronto, Canada

1169 Evaluating the prognostic value of radical prostatectomy and radiation therapy on survival of patients with neuroendocrine prostate cancer: A retrospective study based on SEER database

By: Yang B., Cao X., Yang G., Guo Y., Mao S., Yao X.
Shanghai Tenth People’s Hospital, Dept. of Urology, Shanghai, China

1170 Psychological and functional impact of different primary treatments for prostate cancer: A comparative prospective analysis

By: Maggi M., Salciccia S., Gentilucci A., Sciarra A.
University Sapienza, Dept. of Urological Sciences, Rome, Italy

1171 The hazard of depression after radical prostatectomy – A nationwide registry-based study

By: Friberg A.S.¹, Brasso K.², Andersen E.W.³, Helgstrand J.T.², Röder M.A.², Johansen C.¹, Dalton S.O.⁴
¹Rigshospitalet, Copenhagen University Hospital, Dept. of Oncology, Copenhagen, Denmark, ²Rigshospitalet, Copenhagen University Hospital, Copenhagen Prostate
Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study

By: Knipper S.¹, Preisser F.², Mazzone E.³, Mistretta F.A.³, Palumbo C.³, Tian Z.³, Briganti A.⁴, Shariat S.F.⁵, Saad F.³, Tilki D.¹, Graefen M.¹, Karakiewicz P.³
¹Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ²University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ³Danish Cancer Society Research Center, Dept. of Statistics and Pharmaco-epidemiology, Copenhagen, Denmark, ⁴Danish Cancer Society Research Center, Survivorship, Copenhagen, Denmark

Impact of putative chemopreventative agents on prostate cancer diagnosis

By: Goldberg H.¹, Mohsin F.², Klaassen Z.¹, Chandrasekar T.¹, Wallis C.J.D.¹, Herrera Caceres J.O.¹, Ahmed A.¹, Woon D.¹, Alibhai S.³, Berlin A.⁴, Sasaki R.⁵, Hamilton R.J.¹, Kulkarni G.S.¹, Fleshner N.¹
¹University Health Network, University of Toronto, Dept. of Surgical Oncology, Urology Division, Toronto, Canada, ²University of Toronto, Dalla Lana School of Public Health, Toronto, Canada, ³Princess Margaret Cancer Center, University of Toronto, Dept. of Geriatric Oncology, Toronto, Canada, ⁴University Health Network, University of Toronto, Dept. of Radiation Oncology, Toronto, Canada, ⁵Institute for Clinical Evaluative Sciences, ICES Central - Cancer Research Program, Toronto, Canada

Decision regret after radical prostatectomy is no matter of surgical approach: A 6-year follow-up of a large German collective from routine care

By: Baunacke M.¹, Schmidt M.-L.¹, Groeben C.¹, Thomas C.¹, Koch R.², Chun F.³, Weissbach L.⁴, Huber J.¹
¹TU Dresden, Dept. of Urology, Dresden, Germany, ²TU Dresden, Dept. of Medical Statistics and Biometry, Dresden, Germany, ³Goethe-University Hospital, Dept. of Urology, Frankfurt/Main, Germany, ⁴Health Research for Men GmbH, gfm, Berlin, Germany

Impact of preoperative pelvic floor muscles strength and endurance on urinary incontinence after radical prostatectomy

By: Milonas D.¹, Venclovas Z.¹, Siupsinskas L.², Zachovajevas P.³, Zachovajevas P.³, Zachovajeviene B.⁴
¹Lithuanian University of Health Sciences, Medical Academy, Dept. of Urology, Kaunas, Lithuania, ²Lithuanian University of Health Sciences, Medical Academy, Institute of Sport, Kaunas, Lithuania, ³Lithuanian Sport University, Dept. of Rehabilitation and Applied Biology, Kaunas, Lithuania, ⁴Lithuanian university of Health Sciences, Institute of Sport, Kaunas, Lithuania
5 and 10-years follow up of radical prostatectomy with pelvic lymphadenectomy: A cancer-specific survival analysis on a 1274 prostate cancer cohort


1University of Modena & Reggio Emilia, Dept. of Urology, Modena, Italy, 2Faculty of Medicine, Tanta University, Dept. of Urology, Tanta, Egypt, 3University of Brescia, Data Methods and Systems Statistical Laboratory, Brescia, Italy, 4Azienda Ospedaliera Universitaria di Modena, Dept. of Oncology, Modena, Italy, 5AUSL, Dept. of Urology, Carpi, Italy, 6Ospedale di Sassuolo, Dept. of Urology, Modena, Italy, 7University of Modena & Reggio Emilia, Dept. of Pathology, Modena, Italy, 8Global Robotic institute, Dept. of Urology, Orlando, United States of America

Longitudinal QoL in patients with high versus low-intermediate risk prostate cancer treated by RALP: A multicentre study

By: Devlies W., De Coster G., Van Damme N., Roumeguère T., Quackels T., Van Cleynenbreugel B., Dekuypier P., Ameye F., Everaerts W., Joniau S.

1KU Leuven, University of Leuven, Dept. of Urology, Leuven, Belgium, 2Belgian Cancer Registry, Belgian Cancer Registry, Brussels, Belgium, 3Université Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, 4Maria Middelares Hospital, Dept. of Urology, Ghent, Belgium
Tips and tricks in partial nephrectomy
Poster Session 85

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 5
Chairs: V. Matveev, Moscow (RU)
F. Porpiglia, Turin (IT)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1182
Robot-assisted laparoscopic partial nephrectomy in selective ischemia versus conventional laparoscopic partial nephrectomy in total ischemia: Functional and surgical outcomes of a prospective randomised controlled trial

By: Würnschimmel C. 1, Di Pierro G.B. 1, Grande P. 1, Baumeister P. 1, Roth M. 2, Moschini M. 1, Mattei A. 1
1 Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 2 Luzerner Kantonsspital, Dept. of Radiology, Lucerne, Switzerland

1184
Trifecta outcomes of off-clamp versus on-clamp robot assisted partial nephrectomy: Nephrometry adjusted analysis from ROSULA database

By: Brassetti A. 1, Bertolo R. 2, Tuderti G. 1, Bindayi A. 3, Garisto J. 2, Anceschi U. 1, Guaglianone S. 1, Ferriero M. 1, Simone G. 1
1 Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2 Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, 3 UC San Diego Health System, Dept. of Urology, La Jolla, United States of America

1187
Clinical outcome and characteristics of 41 patients underwent selective artery embolization for postoperative bleeding following 2076 partial nephrectomy

By: Chung J.Y. 1, Almujalhem A. 1, Raheem A. 2, Kim J. 1, Chang K. 3, Kim J.H. 1, Hong S.J. 1, Chung B.H. 4, Choi Y.D. 1, Rha K.H. 1
1 Yonsei University College of Medicine, Urological Science Institute, Dept. of Urology, Seoul, Korea, South, 2 Tanta University College of Medicine, Dept. of Urology, Tanta, Egypt, 3 Yonsei University Wonju College of Medicine, Dept. of Urology, Wonju, Korea, South, 4 Gangnam Severance Hospital, Yonsei University College of Medicine, Dept. of Urology, Seoul, Korea, South

1188
Impact of learning curve on perioperative outcomes of off-clamp minimally invasive partial nephrectomy: Propensity score matched comparison of outcomes between training versus expert series

By: Tuderti G., Ferriero M., Anceschi U., Mastroianni R., Flammia R.S., Brassetti A.
Learning curves of 500 robot-assisted partial nephrectomies: The bed-side assistant counts

By: Zeuschner P. 1, Saar M. 1, Meyer I. 1, Wagenpfeil G. 2, Stöckle M. 1, Siemer S. 1, Janssen M. 1

1Saarland University, Dept.of Urology and Pediatric Urology, Hamburg, Germany, 2Saarland University, Dept.of Medical Biometry, Epidemiology and Informatics, Hamburg, Germany

Virtual planning of organ-preserving laparoscopic surgery in patients with localized kidney cancer

By: Sirota E., Alyaev Y.G., Rapoport L.M., Bezrukov E.A.
Institute for urology and reproductive health, Sechenov University, Dept. of Urology, Moscow, Russia

The volume of the functional renal parenchyma as objective indicator for the resection of RCC: Results from high volume center

By: Voylenko O., Semko S., Vitruk I., Stakhovskyi O., Kononenko O., Pikul M., Stakhovsky E.
National Cancer Institute, Dept. of Plastic and Reconstructive OncoUrology, Kyiv, Ukraine

Impact of resection techniques on perioperative and early functional outcomes after partial nephrectomy for localized renal masses: Results from a prospective, multicentre study (SIB Project)


1Careggi Hospital, University of Florence, Dept. of Urology, Florence, Italy, 2University of Florence, Dept. of Urology, Florence, Italy, 3Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, Michigan, United States of America, 4European Institute of Oncology, University of Milan, Dept. of Urology, Milan, Italy, 5Southmead Hospital, Bristol Urological Institute, Bristol, United Kingdom, 6Technical University of Munich, University Hospital Klinikum Rechts Der Isar, Dept. of Urology, Munich, Germany, 7University of Brescia, Dept. of Urology, Brescia, Italy, 8Fundacio Puigvert, Uro-oncology Unit, Barcelona, Spain, 9Radboud University Nijmegen Medical Centre, Dept. of Urology, Nijmegen, Netherlands, The, 10Addenbrooke’s Hospital, Dept. of Urology, Cambridge, United Kingdom, 11ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, 12Hacettepe University, School of Medicine, Dept. of Urology, Ankara, Turkey, 13Dirkapı Yıldırım Beyazıt Training and Research Hospital, Dept. of Urology, Ankara, Turkey, 14Graz Medical University, Dept. of Urology, Graz, Austria, 15University Vita-Salute San Raffaele, Scientific Institute Hospital San Raffaele, Dept. of Urology, Milan, Italy
Feasibility of omitting outer (cortical) renorrhaphy during robotic partial nephrectomy - A multi-institutional analysis

By: Arora S. 1, Bronkema C. 2, Porter J.R. 3, Mottrie A. 4, Menon M. 1, Rogers C.G. 1, Jeong W. 1, Dasgupta P. 5, Rha K.H. 6, Ahiwat R.K. 7, Capitanio U. 8, Yuvaraja T.B. 9, Rawal S. 10, Moon D.A. 11, Sivaramakrishnan A. 12, Maes K.K. 13, Porpiglia F. 14, Gautam G. 15, Turkeri L. 16, Bhandari M. 1, Abdollah F. 1

1Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, 2Wayne State University School of Medicine, Medical School, Detroit, United States of America, 3Swedish Medical Center, Dept. of Urology, Seattle, United States of America, 4OLV Vattikuti Robotic Surgery Institute, Dept. of Urology, Melle, Belgium, 5MRC Centre for Transplantation, King's Collge, Dept. of Urology, London, United Kingdom, 6Yonsei University Health System, Dept. of Urology, Seoul, Korea, South, 7Medanta Kidney and Urology Institute, Dept. of Urology, Gurgaon, India, 8San Raffaele Hospital, Urology Clinic, Milan, Italy, 9Kokilaben Dhirubhai Ambani Hospital, Dept. of Urology, Mumbai, India, 10Rajiv Gandhi Cancer Institute and Research Center, Dept. of Urology, Delhi, India, 11Peter MacCallum Cancer Center, Dept. of Urology, Melbourne, Australia, 12Apollo Hospital, Dept. of Urology, Chennai, India, 13Hospital Da Luz, Center for Robotic and Minimally Invasive Surgery, Luz Saude, Portugal, 14San Luigi Gonzaga University Hospital, Dept. of Urology, Torino, Italy, 15Max Institute of Cancer Care, Dept. of Surgical Oncology, New Delhi, India, 16Acibadem Hospitals Group, Dept. of Urology, Istanbul, Turkey

Cellular analysis of the intra-cystic fluid after partial or radical nephrectomy for Bosniak III-IV cystic renal lesions

By: Anract J. 1, Dariane C. 1, Soutif A. 1, Verkarre V 2, Pettenati C. 1, Wiedemann L. 1, Rembeyo G. 1, Le Guilchett T. 1, Hurel S. 1, Mandron E. 1, Fontaine E. 1, Correas J.M. 3, Mejean A. 1, Timsit M.O. 1

1Hopital European Georges Pompidou, Dept. of Urology, Paris, France, 2Hopital European Georges Pompidou, Dept. of Pathology, Paris, France, 3Hopital Necker, Dept. of Radiology, Paris, France

Multi-photon microscopy for characterization of renal cell carcinoma pseudocapsule: Implications for tumour enucleation

By: Tan Y.Q. 1, Tay W.K. 1, Ooi L.Y. 2, Teo Z.C.R. 3, Tiong H.Y. 1

1National University Health System, Dept. of Urology, Singapore, Singapore, 2National University Health System, Dept. of Pathology, Singapore, Singapore, 3National University Health System, Division of Nephrology, Dept. of Medicine, Singapore, Singapore
Peyronie’s disease, priapism and shockwave therapy in andrology

Poster Session 86

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 10
Chairs: I. Gruenwald, Haifa (IL)
To be confirmed
A. Muneer, London (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1199

Treatment related outcomes for patients with atypical Peyronie’s disease

By: El-Khatib F.M., Osman M.M., Towe M., Huynh L.M., Yafi F.
University of California, Irvine, Dept. of Urology, Orange, United States of America

1202

The repair of abnormalities in the penile suspensory ligament

By: Ralph O., Shroff N., Blecher G., Anfonso M., Christopher N., Ralph D.J.
UCLH, Dept. of Urology, Chesham, United Kingdom

1203

Penile implant surgery does not reduce penile size; A prospective study of 122 patients followed up for two years

By: Habous M.E. 1, Giona S. 2, Abdelwahab O. 3, Binsaleh S. 4, Mulhall J. 5, Muir G. 6, Ralph D. 7
1 Elaj Medical Center, Dept. of Urology, Jeddah, Saudi Arabia, 2 Frimley Park Hospital, Dept. of Urology, Camberley, United Kingdom, 3 Benha University, Dept. of Urology, Benha, Egypt, 4 King Saud University, Dept. of Urology, Riyadh, Saudi Arabia, 5 MSKCC, Dept. of Sexual medicine and Infertility, New York, United States of America, 6 King’s College Hospital, Dept. of Urology, London, United Kingdom, 7 St Peter institute, UCLH, Dept. of Andrology, London, United Kingdom

1204

Satisfaction with inflatable penile prosthesis in patients with history of ischemic priapism

By: Hawksworth D.J., Koomson A.B., Burnett A.L.
Johns Hopkins University School of Medicine, Brady Urological Institute, Baltimore, United States of America

1206

oMtFSFI: operated male to female sexual function index. Development and validation of the first questionnaire to assess sexual function after male to female gender reassignment surgery
* 1208

**Effectiveness and safety of Platelet rich Plasma (PrP) cavernosal injections plus external shock wave treatment for penile erectile dysfunction: First results from a prospective, randomized, controlled, interventional study**

By: **Ruffo A.** ¹, Franco M. ², Illiano E. ³, Stanojevic N. ⁴

¹Ospedale Santa Maria delle Grazie, Dept. of Urology, Naples, Italy, ²Hospital Clinic, Dept. of Urology, Barcelona, Spain, ³Santa Maria Hospital, Andrological and Urogynecological Clinic, Terni, Italy, ⁴Sava-Perovic Foundation, Center for Genitourinary Reconstructive Surgery, Belgrade, Serbia

1209

**Linear focus low-intensity extracorporeal shockwave therapy in the treatment of erectile dysfunction: A multi-center, double-blinded, prospective, randomized, placebo-controlled study**

By: **Yang L.**, Chen X., He D.
The First Affiliated Hospital of Xian Jiaotong University, Dept. of Urology, Xian, China

**17:08 - 17:10**

**Can we treat all Peyronie's disease without surgery?**

A. Muneer, London (GB)
Understanding the origins of urothelial tumours

Poster Session 87

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 11
Chairs: To be confirmed
To be confirmed
R. Seiler, Liebefeld (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1211

Long noncoding RNA DANCR facilitates metastasis and proliferation in bladder cancer cells by activating IL-11-STAT3 signaling

By: Xu C., Ziyue C., Ruihui X., Ming H., Jingtong Z., Qianghua Z., Jian H., Tianxin L.
Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

1213

Tumor microenvironment enhances autologous mesenchymal stem cells carrying telomerase-dependent adenoviruses for metastatic cancers

By: Hu C-Y. 1, Shiau A-L. 2, Wu C-L. 3, Shieh G-S. 4
1 National Cheng-Kung University Hospital, Dept. of Urology, Tainan, Taiwan,
2 National Cheng Kung University Medical College, Dept. of Microbiology and Immunology, Tainan, Taiwan,
3 National Cheng Kung University Medical College, Dept. of Biochemistry and Molecular Biology, Tainan, Taiwan,
4 Tainan Hospital, Dept. of Urology, Tainan, Taiwan

1215

Molecular characterization of N-methyl-N-nitrosourea-induced bladder urothelial tumor in rats

1 Hyogo Prefectural Nishinomiya Hospital, Dept. of Urology, Nishinomiya, Japan,
2 The Johns Hopkins University School of Medicine, Dept. of Pathology, Baltimore, United States of America,
3 The Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America

1217

Identification of neoantigen candidates in bladder cancer reveals negative correlation between antigen-specific immunoreactivity and inflammation

1 Xinhua hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shang, Afghanistan,
2 Xinhua hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China,
3 Shanghai Institute, Shanghai Jiaotong University
The expression of ANGPTL2 on tumor vessels predicts outcome in invasive bladder cancer after radical cystectomy

By: Poyet C.¹, Buser L.², Wild P.², Saba K.¹, Sulser T.¹, Detmar M.³, Roudnicky F.³

¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital Zurich, Dept. of Pathology, Zurich, Switzerland, ³ETH Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland

Possible molecular targeted therapy for invasive bladder cancer: Sonic hedgehog signaling inhibitor, cyclopamine

By: Shigemura K.¹, Kitagawa K.², Nishimoto K.², Yamada N.², Sung S.³, Chen K.⁴, Huang C.⁵, Chiang Y.⁴, Liu M.⁴, Fujisawa M.¹

¹Kobe University, Dept. of Urology, Kobe, Japan, ²Kobe University, Health Science, Kobe, Japan, ³Taipei Medical University, Ph.D. Program for Translational Medicine, Taipei, Taiwan, ⁴Taipei Medical University, Dept. of Urology, Taipei, Taiwan, ⁵Taipei Medical University, Dept of. Pediatrics, Taipei, Taiwan

Loss of CHEK2 is associated with risk of progression and worse progression-free survival in pT1 urothelial carcinoma of the bladder

By: Spachmann P.J.¹, Azzolina V.¹, Weber F.², Evert M.², Denzinger S.¹, Burger M.¹, Otto W.¹, Breyer J.¹

¹University of Regensburg, Caritas St. Josef Medical Center, Dept. of Urology, Regensburg, Germany, ²University of Regensburg, Institute of Pathology, Regensburg, Germany

Beta-Arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer

By: Hennig M.J.P.¹, Kallifatidis G.², Smith D.², Morera D.², Kuczyk M.³, Kramer M.¹, Merseburger A.¹, Lokeshwar B.², Lokeshwar V.²

¹University of Lübeck, Dept. of Urology, Lübeck, Germany, ²Augusta University, Dept. of Biochemistry and Molecular Biology, Augusta, United States of America, ³Hannover Medical School, Dept. of Urology, Hannover, Germany

Potential new treatment for patients with bladder cancer with a high risk of progression to invasive disease

By: Van Der Pluijm G.¹, Van Der Horst G.¹, Van De Merbel A.¹, Ruigrok E.¹, Van Der Mark M.H.¹, Ploeg E.¹, Jäättela M.², Kruithof-De Julio M.³, Uhm J.¹, Pelger R.C.M.¹, Bangma C.H.⁴, Boormans J.⁴, Zwarthoff E.C.⁵

¹Scientific Programme - EAU19 Barcelona
New biomarkers of bladder cancer in liquid biopsies

By: Do Rosário Fernandes F.J., Flores J., Horvatovich P., Lodeiro C., Martinez J.L., Santos H., Calais F., Pinheiro L.

1Centro Hospitalar de Lisboa Central, Dept. of Urology, Lisboa, Portugal, 2Faculty of Sciences and Technology, BIOSCOPE Research Group, Lisboa, Portugal, 3Faculty of Science and Engineering, Dept. of Analytical Biochemistry Group, Groningen, Netherlands, The
Improving outcomes of renal transplantation
Poster Session 88

Monday 18 March 15:45 - 17:15

Location: Green Area, Room 12
Chairs: O. Hakenberg, Rostock (DE)
        J.D. Olsburgh, London (GB)
        C. Terrone, Turin (IT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1226 Donation after controlled circulatory death, type III. Experience and results over 4 years in a single institution, HUGTIP

By: Castillo C.1, Areal Calama J.1, Perez Mir M.2, Buisan Rueda O.1, Gonzalez Satue C.1
1Hospital Universitari Germans Trias i Pujol, Dept. of Urology, Badalona, Spain,
2Hospital Universitari Germans Trias i Pujol, Dept. of Nefrology, Badalona, Spain

1227 Maastricht III kidneys: Does donor age influence DGF or graft survival?

By: Fernandez-Concha Schwalb J.1, Etcheverry B.1, Riera L.1, Fiol M.1, Bonet X.1, Suárez J.F.1, Bestard O.2, Vigués F.1
1Bellvitge University Hospital, Dept. of Urology, Barcelona, Spain,
2Bellvitge University Hospital, Dept. of Nephrology, Barcelona, Spain

1228 Kidneys received from living donors over 70 years of age: Are those feasible as the grafts?

Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan

1229 Management of end-stage renal disease patients diagnosed with active surveillance-eligible prostate cancer during pre-transplantation work-up: A decision analysis

By: Bieri U.1, Hübel K.2, Seeger H.2, Kulkarni G.S.3, Sulser T.1, Hermanns T.1, Wettstein M.S.1
1University Hospital Zurich, Dept. of Urology, Zurich, Switzerland,
2University Hospital Zurich, Dept. of Nephrology, Zurich, Switzerland,
3Princess Margaret Cancer Centre, University Health Network, Division of Urology, Dept. of Surgery, Toronto, Canada

1230 Incidence, management and clinical outcomes of prostate cancer in kidney transplant recipients
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1231</td>
<td>Body fat area as a predictive marker of new-onset diabetes mellitus after kidney transplantation</td>
<td>By: Taoka R., Abe Y., Naito H., Miyauchi Y., Matsuoka Y., Tajima M., Kato T., Tsunemori H., Ueda N., Sugimoto M., Kakehi Y. Kagawa University, Dept. of Urology, Kagawa, Japan</td>
</tr>
<tr>
<td>1232</td>
<td>The level of QOL improves slower in preemptive kidney transplantation than the one in non-preemptive kidney transplantation</td>
<td>By: Mitsui Y., Araki M., Ariyoshi Y., Maruyama Y., Sadahira T., Wada K., Edamura K., Kobayashi Y., Watanabe M., Watanabe T., Nasu Y. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan</td>
</tr>
<tr>
<td>1233</td>
<td>A novel, specific RIPK1 inhibitor reduces necroptosis and provides significant benefit in ischemic kidney injury in mice</td>
<td>By: Gallagher K.M., Beal A., Finger J., Hughes J., Ross J., Marson L., Bertin J., Ferenbach D., Boulter L., Laird A., Leung S., Wigmore S., Harrison E. 1University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom, 2GlaxoSmithKline, Pattern Recognition Receptor DPU, Collegeville, United States of America, 3University of Edinburgh, MRC Institute of genetics and molecular medicine, Edinburgh, United Kingdom, 4Western General Hospital Edinburgh, Dept. of Urology, Edinburgh, United Kingdom, 5University of Edinburgh, Centre for Medical Informatics, Usher Institute, Edinburgh, United Kingdom</td>
</tr>
<tr>
<td>1234</td>
<td>Tissue-resident memory CD8+ T cells in the kidney – Implications for renal transplantation</td>
<td>By: Friedersdorff F., Dornieden T., Sattler A., Bergmann Y., Ruhm A., Schlomm T., Kotsch K. 1Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, 2Charité Universitätsmedizin Berlin, Dept. of Surgery, Berlin, Germany</td>
</tr>
<tr>
<td>1235</td>
<td>Genetic predisposition with regards to the role of MMPs in Allograft Rejections following renal transplantation</td>
<td>By: Srivastava A., Prasad N., Bhatt M. 1SGPGIMS, Dept. of Urology and Renal Transplantation, Lucknow, India, 2SGPGIMS, Dept. of Nephrology, Lucknow, India</td>
</tr>
<tr>
<td>1236</td>
<td>Early application of mTOR inhibitors reduce vascular inflammatory response after ischemia-reperfusion injury</td>
<td>By: Wenzel M., Haffer H., Werner I., Richter M., Chun F., Beiras-Fernandez A.</td>
</tr>
</tbody>
</table>
Longitudinal serum N-glycan profiling predict biopsy-proven graft rejection after a living donor kidney transplantation

By: Soma O.¹, Hatakeyama S.¹, Yoneyama T.¹, Noro D.¹, Tobisawa Y.¹, Hashimoto Y.¹, Koie T.², Sasaki H.³, Saito M.⁴, Harada H.⁵, Chikaraishi T.³, Ishida H.⁶, Tanabe K.⁶, Satoh S.⁴, Ohyama C.¹

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Gifu University School of Medicine, Dept. of Urology, Gifu, Japan, ³St. Marianna University of Medicine, Dept. of Urology, Kawasaki, Japan, ⁴Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁵Sapporo City General Hospital, Dept. of Kidney Transplant Surgery, Sapporo, Japan, ⁶Tokyo-Woman’s Medical University, Dept. of Urology, Tokyo, Japan

13:34 - 13:38
Summary
J.D. Olsburgh, London (GB)

13:38 - 13:45
Summary
J.D. Olsburgh, London (GB)
What is the optimal treatment for patients with male LUTS?

Plenary 7

Tuesday 19 March
08:00 - 13:25

Location: Red Area, eURO Auditorium 1

Chairs: C.R. Chapple, Sheffield (GB)
        A. Stenzl, Tübingen (DE)

Aims and objectives of this session
There is a wide variety of options for treatment of male LUTS. In this session game changing studies will be presented and discussed. In addition various new interventional techniques will be compared to established ones with the help of ease based discussions.
The second part of this sessions is reserved for a summing up of the entire meeting: top experts will give an overview of the best contributions of the 2019 meeting and their impact in the upcoming years.

08:00 - 08:15 Medical treatment
C. Gratzke, Munich (DE)

08:15 - 08:40 Game changer Study: Upstream

08:15 - 08:30 Study presentation
M. Drake, Bristol (GB)

08:30 - 08:40 Discussant
S. Gravas, Larissa (GR)

08:40 - 08:55 When is the best time for intervention?
F. Fusco, Naples (IT)

08:55 - 09:10 Société Internationale d’Urologie (SIU) lecture Balancing cost, efficacy and intervention in BPH
D. Bolton, Heidelberg (AU)

09:10 - 09:25 Introduction of new techniques in the treatment of BPH: Faith, truth or fake news?
To be confirmed

09:25 - 09:50 Case 1 Standard patient eligible for surgery: 60 kg, 60 grams and 60 years old
Moderators: J-N.L. Cornu, Rouen (FR)
            J.P.F.A. Heesakkers, Nijmegen (NL)

09:25 - 09:30 Case presentation
J-N.L. Cornu, Rouen (FR)

09:30 - 09:35 1. TURP (mono and bipolar)
S. Madersbacher, Vienna (AT)
## Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:35 - 09:40 | 2. Vaporisation  
A. Elshal, Mansoura (EG) |
| 09:40 - 09:45 | 3. Enucleation  
G.Y. Robert, Bordeaux (FR) |
| 09:45 - 09:50 | 4. Aquablation  
T. Bach, Hamburg (DE) |
| 09:50 - 10:15 | **Case 2**  
**Same patient with strong wish to preserve ejaculation**  
*Moderators:*  
J-N.L. Cornu, Rouen (FR)  
J.P.F.A. Heesakkers, Nijmegen (NL) |
| 09:50 - 09:55 | **Case presentation**  
J.P.F.A. Heesakkers, Nijmegen (NL) |
| 09:55 - 10:00 | 1. Apex-sparing surgery (TUR, GLL)  
S. Doizi, Paris (FR) |
| 10:00 - 10:05 | 2. Rezūm  
L. Wagrell, Stockholm (SE) |
| 10:05 - 10:10 | 3. Urolift / TIND  
C. Gratzke, Munich (DE) |
| 10:10 - 10:15 | 4. PAE  
D. Abt, St. Gallen (CH) |
| 10:15 - 10:35 | **Case 3**  
**Big prostate 150 gram**  
*Moderators:*  
J-N.L. Cornu, Rouen (FR)  
J.P.F.A. Heesakkers, Nijmegen (NL) |
| 10:15 - 10:20 | **Case presentation**  
J-N.L. Cornu, Rouen (FR) |
| 10:20 - 10:25 | 1. Holep  
C.M. Scoffone, Turin (IT) |
| 10:25 - 10:30 | 2. Laparoscopic or robotic adenomectomy  
H. John, Winterthur (CH) |
| 10:30 - 10:35 | 3. Open simple prostatectomy  
A. Elshal, Mansoura (EG) |
| 10:35 - 11:00 | **Case 4**  
**75 years old, 4 stents on clopidogrel, cannot stop. Prostate 70 gram, retention**  
*Moderators:*  
J-N.L. Cornu, Rouen (FR)  
J.P.F.A. Heesakkers, Nijmegen (NL) |
| 10:35 - 10:40 | **Case presentation**  
J.P.F.A. Heesakkers, Nijmegen (NL) |
| 10:40 - 10:45 | 1. Turp?  
S. Madersbacher, Vienna (AT) |
## Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 10:50</td>
<td>2. Laserablation</td>
<td>C. Llorente, Madrid (ES)</td>
</tr>
<tr>
<td>10:50 - 10:55</td>
<td>3. PAE</td>
<td>D. Abt, St. Gallen (CH)</td>
</tr>
<tr>
<td>10:55 - 11:00</td>
<td>4. Rezūm</td>
<td>L. Wagrell, Stockholm (SE)</td>
</tr>
<tr>
<td>11:00 - 11:10</td>
<td>Lessons learned</td>
<td>C.R. Chapple, Sheffield (GB)</td>
</tr>
<tr>
<td>11:25 - 13:25</td>
<td>Souvenir sessions</td>
<td></td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td>Urolithiasis and endourology</td>
<td>T. Knoll, Sindelfingen (DE)</td>
</tr>
<tr>
<td>11:45 - 11:55</td>
<td>Renal cancer and transplantation</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>11:55 - 12:05</td>
<td>Prostate cancer: Early detection and screening</td>
<td>C.H. Bangma, Rotterdam (NL)</td>
</tr>
<tr>
<td>12:05 - 12:15</td>
<td>Prostate cancer: Localised and advanced disease</td>
<td>A. Briganti, Milan (IT)</td>
</tr>
<tr>
<td>12:15 - 12:25</td>
<td>Systemic therapy in Genitourinary (GU) cancer</td>
<td>M. De Santis, Berlin (DE)</td>
</tr>
<tr>
<td>12:25 - 12:35</td>
<td>Urothelial cancer</td>
<td>M. Rouprêt, Paris (FR)</td>
</tr>
<tr>
<td>12:35 - 12:45</td>
<td>Functional urology</td>
<td>J.P.F.A. Heesakkers, Nijmegen (NL)</td>
</tr>
<tr>
<td>12:45 - 12:55</td>
<td>Imaging in urology</td>
<td>A. Villers, Lille (FR)</td>
</tr>
<tr>
<td>12:55 - 13:05</td>
<td>Basic science</td>
<td>Z. Culig, Innsbruck (AT)</td>
</tr>
<tr>
<td>13:05 - 13:15</td>
<td>Paediatric urology and rare diseases</td>
<td>W.F.J. Feitz, Nijmegen (NL)</td>
</tr>
</tbody>
</table>